
<html lang="en"     class="pb-page"  data-request-id="034edf2c-b5d3-4478-9df6-d47404e51c4c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2016.59.issue-16;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.6b00915;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph" /></meta><meta name="dc.Creator" content="Nicholas A.  Meanwell" /></meta><meta name="dc.Description" content="The development of direct-acting antiviral agents that can cure a chronic hepatitis C virus (HCV) infection after 8–12 weeks of daily, well-tolerated therapy has revolutionized the treatment of thi..." /></meta><meta name="Description" content="The development of direct-acting antiviral agents that can cure a chronic hepatitis C virus (HCV) infection after 8–12 weeks of daily, well-tolerated therapy has revolutionized the treatment of thi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 8, 2016" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00915" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00915" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00915" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00915" /></link>
        
    
    

<title>2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00915" /></meta><meta property="og:title" content="2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0059.jpeg" /></meta><meta property="og:description" content="The development of direct-acting antiviral agents that can cure a chronic hepatitis C virus (HCV) infection after 8–12 weeks of daily, well-tolerated therapy has revolutionized the treatment of this insidious disease. In this article, three of Bristol-Myers Squibb’s HCV programs are summarized, each of which produced a clinical candidate: the NS3 protease inhibitor asunaprevir (64), marketed as Sunvepra, the NS5A replication complex inhibitor daclatasvir (117), marketed as Daklinza, and the allosteric NS5B polymerase inhibitor beclabuvir (142), which is in late stage clinical studies. A clinical study with 64 and 117 established for the first time that a chronic HCV infection could be cured by treatment with direct-acting antiviral agents alone in the absence of interferon. The development of small molecule HCV therapeutics, designed by medicinal chemists, has been hailed as “the arc of a medical triumph” but may equally well be described as “the arc of a medicinal chemistry triumph”." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00915"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00915">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00915&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00915&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00915&amp;href=/doi/10.1021/acs.jmedchem.6b00915" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 16</span><span class="cit-fg-pageRange">, 7311-7351</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/16" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.5b01349" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph<a class="ref internalNav" href="#titlefnt" aria-label=""></a></span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicholas+A.++Meanwell">Nicholas A. Meanwell</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Department of Discovery Chemistry, Bristol-Myers Squibb Research & Development, Wallingford, Connecticut 06492, United States</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#034d6a606b6c6f62702d4e66626d74666f6f43616e702d606c6e"><span class="__cf_email__" data-cfemail="0f41666c6760636e7c21426a6e61786a63634f6d627c216c6062">[email protected]</span></a>. Phone: 203-677-6679. Fax: 203-677-7704.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00915&amp;href=/doi/10.1021%2Facs.jmedchem.6b00915" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 16</span><span class="cit-pageRange">, 7311–7351</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 8, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>18 June 2016</li><li><span class="item_label"><b>Published</b> online</span>8 August 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 August 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00915" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00915</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7311%26pageCount%3D41%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DNicholas%2BA.%2BMeanwell%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D16%26contentID%3Dacs.jmedchem.6b00915%26title%3D2015%2BPhilip%2BS.%2BPortoghese%2BMedicinal%2BChemistry%2BLectureship.%2BCuring%2BHepatitis%2BC%2BVirus%2BInfection%2Bwith%2BDirect-Acting%2BAntiviral%2BAgents%253A%2BThe%2BArc%2Bof%2Ba%2BMedicinal%2BChemistry%2BTriumph%26numPages%3D41%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7351%26publicationDate%3DAugust%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00915"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2389</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">27</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00915" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Nicholas&quot;,&quot;last_name&quot;:&quot;A. Meanwell&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;16&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;7311-7351&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00915&quot;},&quot;abstract&quot;:&quot;The development of direct-acting antiviral agents that can cure a chronic hepatitis C virus (HCV) infection after 8–12 weeks of daily, well-tolerated therapy has revolutionized the treatment of this insidious disease. In this article, three of Bristol-Myers Squibb’s HCV programs are summarized, each of which produced a clinical candidate: the NS3 protease inhibitor asunaprevir (64), marketed as Sunvepra, the NS5A replication complex inhibitor daclatasvir (117), marketed as Daklinza, and the allosteric NS5B polymerase inhibitor beclabuvir (142), which is in late stage clinical studies. A clinical study with 64 and 117 established for the first time that a chronic HCV infection could be cured by treatment with direct-acting antiviral agents alone in the absence of interferon. The development of small molecule HCV therapeutics, designed by medicinal chemists, has been hailed as “the arc of a medical triumph” but may equally well be described as “the arc of a medicinal chemistry triumph”.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00915&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00915" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00915&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00915" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00915&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00915" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00915&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00915&amp;href=/doi/10.1021/acs.jmedchem.6b00915" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00915" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00915" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00915%26sid%3Dliteratum%253Aachs%26pmid%3D27501244%26genre%3Darticle%26aulast%3DMeanwell%26date%3D2016%26atitle%3D2015%2BPhilip%2BS.%2BPortoghese%2BMedicinal%2BChemistry%2BLectureship.%2BCuring%2BHepatitis%2BC%2BVirus%2BInfection%2Bwith%2BDirect-Acting%2BAntiviral%2BAgents%253A%2BThe%2BArc%2Bof%2Ba%2BMedicinal%2BChemistry%2BTriumph%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D16%26spage%3D7311%26epage%3D7351%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291430" title="Infectious diseases">Infectious diseases</a>,</li><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292016" title="Therapeutics">Therapeutics</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/16" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/jmcmar.2016.59.issue-16/20160825/jmcmar.2016.59.issue-16.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0059.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The development of direct-acting antiviral agents that can cure a chronic hepatitis C virus (HCV) infection after 8–12 weeks of daily, well-tolerated therapy has revolutionized the treatment of this insidious disease. In this article, three of Bristol-Myers Squibb’s HCV programs are summarized, each of which produced a clinical candidate: the NS3 protease inhibitor asunaprevir (<b>64</b>), marketed as Sunvepra, the NS5A replication complex inhibitor daclatasvir (<b>117</b>), marketed as Daklinza, and the allosteric NS5B polymerase inhibitor beclabuvir (<b>142</b>), which is in late stage clinical studies. A clinical study with <b>64</b> and <b>117</b> established for the first time that a chronic HCV infection could be cured by treatment with direct-acting antiviral agents alone in the absence of interferon. The development of small molecule HCV therapeutics, designed by medicinal chemists, has been hailed as “the arc of a medical triumph” but may equally well be described as “the arc of a medicinal chemistry triumph”.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77420" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77420" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Over the past century, small molecule therapeutic agents have contributed significantly to the reduction in mortality and morbidity that has translated into a positive effect on human health and longevity.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Of particular note are those individuals who are infected with human immunodeficiency virus 1 (HIV-1) and hepatitis B virus (HBV), pathogens that establish chronic infections with the former incurable based on available drugs and the current understanding of latency, while curing the latter remains a significant challenge.<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3-5)</a> For HIV-1 infection, contemporary combinations of antiretroviral therapeutics have transformed the prospects of those infected from the fate of certain death in the 1980s and early 1990s to that of a manageable, chronic infection compatible with a near normal life span when therapy is initiated before damage is inflicted on the immune system, although the long-term effect of living with HIV-1 is not without its morbidities as we are learning more about the manifestations of the infection.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> For HBV, although viral replication can effectively be controlled by nucleos(t)ide-based inhibitors, persistent protein production from the covalently closed circular viral DNA appears to prevent a sterilizing cure.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Having established how to effectively control HIV-1 and HBV replication in vivo, attention is now being directed toward developing approaches to cure these chronic infections, a significant challenge, particularly for HIV-1 infection where a copy of the viral DNA is integrated into the host cell chromosome.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> A third problematic chronic viral infection that was recognized in the early 1970s as non-A, non-B hepatitis is the result of a virus that remained anonymous until 1989 when Michael Houghton, Daniel Bradley, and colleagues isolated a cDNA clone of what was designated as hepatitis C virus (HCV) after amplifying viral RNA isolated from an infected patient using the polymerase chain reaction.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10-12)</a> The virus was classified as a member of the flavivirus family, and the information encoded in the RNA genome was quickly deciphered into three structural (E1, E2, and capsid) and seven nonstructural (NS) proteins that included the p7 ion channel protein (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> Within the HCV NS proteins it was determined that the virus encoded for two proteases (the NS2 metalloprotease and the NS3 serine protease), while the viral RNA-dependent RNA polymerase (RdRp) was associated with the NS5B protein.<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15-17)</a> It was subsequently demonstrated that the NS4A protein was a cofactor for the NS3 protease and that the NS3 protein comprised the protease in the 181-residue amino terminus while the carboxy terminus was associated with helicase activity.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> The 447-residue protein encoded by NS5A, although critical for viral replication in vivo, was viewed as enigmatic in nature, with no known enzymatic activity and little information about its function that could be gleaned from an analysis of its amino acid sequence.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Although these studies provided a very basic understanding of the virus, the lack of cell culture systems that supported viral replication significantly hampered progress toward understanding the virus lifecycle in more detail and its inevitably complex modulation of the host cell environment.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> While this problem would take almost a decade to solve, early drug discovery efforts by necessity focused on the NS3 protease and NS5B RdRp, since these were considered the most tractable targets based on a basic understanding of their function, role in viral replication, and the ability to biochemically recapitulate enzymatic activity in vitro.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> Importantly, since HCV replication occurs in the cytosolic compartment and the replicative intermediates do not involve a reverse transcription step to afford a viral DNA, HCV is a curable infection, unlike HIV-1 and HBV, with chronicity a function of effective control of the host immune response by the virus.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Genetic organization of HCV that comprises 5′- and 3′-untranslated regions and encodes for structural and nonstructural proteins with the sites of cleavage of the polypeptide depicted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The complexity of HCV was ultimately revealed when it was determined to be comprised of seven major genotypes and 67 subtypes that demonstrated differential worldwide distribution, with genotype-1 (GT-1) the most prevalent in the United States, Japan, and Europe.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> HCV is most commonly transmitted by percutaneous exposure to infected blood and establishes a chronic infection in the majority of subjects exposed to the virus, exerting a slowly progressing burden on the liver over a period of 20–30 years. Over this extended period, the virus inflicts severe damage to the liver, causing cirrhosis, hepatocellular carcinoma, and end stage liver disease, while the early stages of infection are largely asymptomatic such that most are unaware of their infection.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">The discovery and characterization of HCV coupled with its prevalence, worldwide distribution, and associated morbidity and mortality stimulated a significant effort within the pharmaceutical industry to identify and develop specific, direct-acting inhibitors that would have the potential to be effective therapeutic agents to treat the disease. At Bristol-Myers Squibb, our initial drug discovery efforts were focused on developing and implementing HCV NS3 protease inhibition assays for use in high throughput screening (HTS) campaigns. In addition, in parallel we probed for inhibitors of bovine viral diarrhea virus (BVDV) using a cell-based screen in the anticipation that since this was the closest phylogenetic relative of HCV, leads discovered in this fashion might provide a productive avenue into the identification of HCV inhibitors. However, analogous to the experiences of others, our HTS campaigns failed to identify structural matter that could be optimized into potent inhibitors of NS3 protease. In contrast, cell-based BVDV screening identified the substituted benzimidazole-2-one derivative <b>1</b> as an inhibitor of replication, EC<sub>50</sub> ≈ 2.2 μM, for which resistance mapped to a single Glu291Gly mutation in the viral polymerase. However, the inhibitory activity observed with <b>1</b> could not be detected in a BVDV polymerase biochemical assay, only in a membrane-based assay, severely compromising this strategic approach as an entree into HCV inhibitors which was conducted several years before the advent of cell-based HCV replication systems.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0030.gif" alt="" id="fx1" /></img></div><div class="NLM_p last">In the absence of screening leads, we designed and synthesized prospective libraries of potential NS3 inhibitors that took advantage of known peptidic and nonpeptidic mechanism-based serine protease inhibitor chemotypes. This approach was also unsuccessful in identifying lead HCV NS3 inhibitors, although the saccharin derivative <b>2</b> emerged from this work as a potent, mechanism-based inhibitor of human mast cell tryptase that is notable for its lack of a basic moiety capable of being recognized by the S1 subsite of this enzyme.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> A more productive approach was the result of a collaboration with Axys Pharmaceuticals that sought to identify inhibitors of NS3 by building upon their original observation that serine protease inhibitors based on a bis-benzimidazolemethane motif create a binding site for Zn <sup>2+</sup> when appropriately juxtaposed with the catalytic histidine and serine side chains (His57 and Ser139 in HCV NS3 protease).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The recruitment of Zn<sup>2+</sup> ion to a serine protease/inhibitor complex with appropriately deployed functionality leads to enhanced potency by stabilization of the complex. A screening campaign using this technology identified <b>3</b> as a lead inhibitor of NS3/NS4A activity that exhibited a <i>K</i><sub>i</sub> of 200 nM in the presence of Zn<sup>2+</sup> ion.<a onclick="showRef(event, 'cit31a'); return false;" href="javascript:void(0);" class="ref cit31a">(31a)</a> In the presence of EDTA, which sequesters the Zn<sup>2+</sup>, the <i>K</i><sub>i</sub> increased to 167 μM providing a measure of the stabilizing effect conferred by metal coordination. However, despite this seemingly promising start, further probing of this inhibitor class failed to identify suitable replacements for the 2-amino-3-phosphonopropanoic acid moiety that might facilitate membrane permeability.<a onclick="showRef(event, 'cit31b'); return false;" href="javascript:void(0);" class="ref cit31b">(31b)</a> Rather, polyacidic compounds exemplified by the poly-2-amino-3-phosphonopropanoic acid derivative <b>4</b>, which displayed <i>K</i><sub>i</sub> values of 27 nM and 1 μM in the presence and absence of Zn<sup>2+</sup> ion, respectively, emerged as the only more potent inhibitors. However, these compounds did not offer a clear line of sight to more druglike molecules and, as a consequence, this approach had to be abandoned.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0031.gif" alt="" id="fx2" /></img></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">2 Discovery of the HCV NS3 Protease Inhibitor Asunaprevir</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24154" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24154" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">An extensive series of biochemical studies conducted at both academic and industrial laboratories led to a deeper understanding of the function and activity of the HCV NS3/4A protease that illuminated fundamental aspects associated with substrate specificity, the choreography of viral protein cleavage, and its role in viral homeostasis.<a onclick="showRef(event, 'ref23 ref32'); return false;" href="javascript:void(0);" class="ref ref23 ref32">(23, 32)</a> The solid state structure of the NS3/4A complex was solved by two groups simultaneously, revealing the full extent of the challenge that this protein presented as an antiviral drug target, with its extended, shallow, and featureless substrate binding groove that lacked the kind of invaginations more commonly associated with mammalian serine proteases.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> While this architecture provided an explanation for the failure to identify lead inhibitors from screening campaigns, an important discovery to emerge from the biochemical studies was that the HCV NS3/4A protease was subject to product inhibition.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> This observation led to the characterization of the hexapeptide <b>5</b> as a potent inhibitor of the NS3 enzyme with a <i>K</i><sub>i</sub> value of 600 nM.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The extended, polyacidic nature of this peptidic inhibitor, which echoes elements of the discoveries that we had made with the bis-benzimidazolemethane derivatives <b>3</b> and <b>4</b> described above, provided a significant challenge for optimization into druglike molecules. Structure–activity relationship (SAR) studies were unable to identify noncharged replacements for all of the carboxylic acid Cα side chains with something more amenable to optimization into cell permeable inhibitors. Some progress was made when it was demonstrated that the P2 glutamate could be replaced by a cyclohexylmethyl glycine while a CF<sub>2</sub>H moiety was identified as an effective isostere of the P1 cysteine thiol, the value of which is exemplified by comparing the activities if the homologous series of inhibitors <b>6</b>–<b>8</b>.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35, 36)</a> Further refinement identified the keto acid <b>9</b> as a smaller, slow-binding, mechanism-based inhibitor of HCV NS3 protease activity that relied upon the electrophilicity of the keto carbonyl to react at its <i>si</i>-face with the catalytic hydroxyl of Ser139, forming a covalently bound, tetrahedral intermediate that was observed in a cocrystal structure. While the X-ray structure confirmed the isosteric relationship between the CF<sub>2</sub>H and SH moieties, <b>9</b> displayed only modest inhibitory potency in biochemical assays with a <i>K</i><sub>i</sub> of 17 μM and a <i>K</i><sub>i</sub>* of 27 nM.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Nevertheless, the α-keto acid moiety was incorporated into telaprevir (<b>10</b>) and boceprevir (<b>11</b>), the first NS3 protease inhibitors to be approved by the United States (U.S.) Food and Drug Administration (FDA) in 2011 for use as add-on therapy to pegylated interferon-α (PEG-IFN-α) and ribavirin (<b>12</b>), the dual drug combination that by that time had been developed as the standard of care (SOC) for treating HCV infection.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38, 39)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0032.gif" alt="" id="fx3" /></img></div><div class="NLM_p">An important breakthrough in HCV NS3 inhibitor design occurred with the description of ciluprevir (<b>13</b>, BILN-2061), a macrocyclic tripeptidic acid derivative that was profiled as a potent enzyme inhibitor in vitro and that demonstrated rapid antiviral activity following administration to HCV-infected subjects.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40, 41)</a> Oral dosing of a solution of <b>13</b> (200 mg) in PEG 400 and ethanol twice daily for 2 days to eight HCV GT-1-infected subjects produced a 2–3 log<sub>10</sub> IU mL<sup>–1</sup> decline in viremia in all patients, with most subjects achieving undetectable levels of HCV RNA by 48 h following the first dose.<a onclick="showRef(event, 'cit40a'); return false;" href="javascript:void(0);" class="ref cit40a">(40a)</a> The design of <b>13</b> was the result of an extensive medicinal chemistry campaign that originated with the hexapeptide <b>14</b>, a poorly potent enzyme inhibitor, IC<sub>50</sub> = 150 μM, that was optimized by a careful and systematic examination of the effect of structural modifications introduced at the each of the P1, P2, P3, and P4 residues.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40, 41)</a> The tetrapeptide derivative <b>15</b>, IC<sub>50</sub> = 3.5 μM, incorporated a cyclopropyl glycine at P1 that was associated with a 3-fold increase in potency when compared to a norvaline-containing progenitor. However, it was the large, lipophilic naphthyl moiety attached to C-4 of the P2 proline residue that was the critical SAR breakthrough, providing a 380-fold enhancement in potency when introduced into <b>14</b>.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> This discovery, combined with additional optimization guided by X-ray and NMR structure analyses, allowed truncation to a tripeptide-based inhibitor that was further preorganized into the bound conformation via a macrocyclization, arrived at by covalently linking the P1 and P3 moieties that are proximal in the cocrystal structure of acyclic inhibitors bound to the enzyme.<a onclick="showRef(event, 'ref40 ref42'); return false;" href="javascript:void(0);" class="ref ref40 ref42">(40, 42)</a> The result of these studies was the design of <b>16</b> as a potent NS3 enzyme inhibitor, IC<sub>50</sub> = 11 nM, that set the stage for further optimization to give <b>13</b> which was 3-fold more potent than <b>16</b>, IC<sub>50</sub> = 3.0 nM, highly active in a replicon assay, EC<sub>50</sub> = 1.2 nM, and bioavailable in rats following oral dosing, with <i>F</i> = 42%.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0033.gif" alt="" id="fx4" /></img></div><div class="NLM_p">We were intrigued by this chemotype when it was originally disclosed and were able to quickly confirm the intrinsic enzyme inhibitory activity of the prototype molecule <b>17</b> toward a GT-1a enzyme, IC<sub>50</sub> = 54 nM, and we also found that the compound was active in our newly developed GT-1b replicon assay with an EC<sub>50</sub> value of 550 nM (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).<a onclick="showRef(event, 'ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref43 ref44 ref45">(43-45)</a> The profile of <b>17</b> and its compact tripeptidic structure compared to <b>5</b> provided a suitable vehicle with which to explore the concept of designing inhibitors capable of projecting functionality into the small but well-defined S1′ pocket of the enzyme that is contiguous with the oxyanion hole. This general approach to serine protease inhibitor design had been examined previously in the context of mechanism-based inhibitors of the mammalian enzyme chymotrypsin that relied upon an electrophilic ketone warhead to interact covalently with the catalytic serine hydroxyl.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> The methyl acylsulfonamide <b>18</b> was the first representation of the concept to be prepared, a compound that exhibited potency in both the biochemical and cell-based assays that was comparable to the progenitor carboxylic acid <b>17</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The next phase of the structure–activity survey focused on the systematic optimization of the methyl substituent of the acylsulfonamide element of <b>18</b>, studies that were guided by computer models of the drug–inhibitor complex. The result of this survey was a very clear inflection point with the cyclopropyl derivative <b>21</b> which expressed potent inhibitory activity in both in vitro assays, with an EC<sub>50</sub> value in the GT-1b replicon of 4 nM, a value that met our target criteria of <10 nM for a potential clinical candidate. The SARs compiled in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> reflect the unique size and shape demands of the S1′ pocket of the NS3 protease with, notably, the simple opening of the cyclopropyl ring to an isopropyl moiety (<b>20</b>), formally the addition of two hydrogen atoms, resulting in a 20-fold reduction in potency. Quite remarkably, this modification was less well tolerated than the ring expanded cyclobutyl analogue <b>22</b> while the phenyl analogue <b>25</b> is an order of magnitude more potent than the cyclohexyl derivative <b>24</b>, providing an interesting example of the advantage of unsaturation in this particular context and some sense of the plasticity of the S1′ pcoket.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47, 48)</a> The advantage offered by the cyclopropyl acylsulfonamide discovered with <b>21</b>, which typically confers 10- to 100-fold enhanced potency dependent upon context, was readily understood from a cocrystal structure of compounds synthesized later in the program with the protease which revealed the key drug target interactions depicted in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The acidity of the acylsulfonamide moiety is such that deprotonation readily occurs, allowing the nitrogen atom to form a salt bridge with His57, one of the three catalytic residues of the enzyme. The carbonyl moiety projects into the oxyanion hole, accepting a H-bond from the backbone NH of Gly137, while both oxygen atoms of the sulfone moiety engage the NS3 protein by accepting H-bonds, one from the backbone NH of Gly137, which is bifurcated, and the other from the backbone NH of Ser139, the catalytic residue. This spatial arrangement provides a geometry that is optimal to project the cyclopropyl ring into the well-defined, small hydrophobic S1′ pocket of the enzyme.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Key drug–target interactions between the acylsulfonamide moiety of <b>21</b> and the NS3 protease protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. HCV NS3 Inhibitory Activity and GT-1b Replicon Inhibition Associated with the Tripeptide Carboxylic Acid <b>17</b> and Acylsulfonamide Derivatives <b>18</b>–<b>25</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0018.gif" alt="" id="fx28" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0019.gif" alt="" id="fx29" /></img><div></div></div><div class="NLM_p">The unique advantages offered by the cyclopropyl acylsulfonamide led to it being adopted as the carboxy terminus element for subsequent studies, and this moiety is now established as a privileged structural element in NS3 protease inhibitor design, present in all marketed drugs and those compounds in late stage clinical development that target this mechanism (vide infra).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> In order to facilitate analogue synthesis, a convenient and practical synthetic approach to access cyclopropanesulfonamide (<b>32</b>) and the 1-substituted homologues <b>33</b> was required. The procedure summarized in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> was developed that started from the commercially available <b>26</b> and relied upon a dianion-mediated intramolecular alkylation to effect ring closure, with the sulfonamide nitrogen atom protected with either a <i>tert</i>-butyl (<b>27</b>) or <i>tert</i>-butoxycarbonyl (<i>t</i>-Boc, <b>29</b>) moiety.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> This process afforded <b>30</b> and <b>31</b>, respectively, and deprotection of each was readily effected under acidic conditions to give <b>32</b> while dianion formation from <b>30</b> or <b>31</b> provided access to the α-substituted derivatives <b>33</b> after alkylation and protecting group removal.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0015.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparative Procedure for Cyclopropanesulfonamide (<b>32</b>) and 1-Subsituted Cyclopropanesulfonamide Derivatives <b>33</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With these developments in hand, attention was directed toward understanding the structural parameters of these tripeptide-based inhibitors that would facilitate oral delivery. In the absence of convenient animal models of HCV infection, the strategy that we adopted was to demonstrate plasma and liver exposure in preclinical species following oral dosing as a means of estimating human exposure and predicting clinical dosing regimens. This approach, which was implemented prior to the first clinical observations with small molecule direct-acting antiviral agents (DAAs), anticipated that a small phase 1b clinical study conducted in HCV-infected patients would provide a rapid assessment of the efficacy and therapeutic potential of a candidate molecule, a strategy that was ultimately vindicated. The pharmacokinetic properties of <b>21</b> were poor in both the rat and dog with low exposure observed after oral dosing; clearance was high and the plasma half-life was short in both species although the exposure, particularly in the liver, was superior to the corresponding carboxylic acid analogue <b>17</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). However, <b>21</b> exhibited good metabolic stability in vitro with a <i>t</i><sub>1/2</sub> of 162 and 170 min in rat and dog liver microsomes (LM), respectively. Moreover, in the rat <b>21</b> demonstrated a hepatotropic disposition with higher levels of the drug in the liver compared to plasma at both 4 and 8 h after oral dosing, demonstrating that the drug could be delivered to the target organ with some facility but also suggesting the potential for the involvement of transporters in liver uptake. In order to expedite in vivo profiling of new analogues, test compounds were dosed intraduodenally to surgically prepared rats with plasma levels monitored for 4 h after dosing while liver concentrations were determined at the termination of the experiment. This dosing protocol facilitated compound evaluation in vivo, of importance because at this early stage of the effort a broad-based survey of SARs was conducted, with an initial emphasis on identifying the H-bond donors and acceptors that were important for drug target interactions while simultaneously probing approaches to reduce molecular weight and optimize oral exposure. Modeling studies suggested the importance of each of the NH and C═O moieties of the tripeptide backbone which were predicted to interact with complementary H-bond acceptors and donors in the enzyme, hypotheses confirmed by X-ray cocrystallographic analyses, while the P1 vinyl and P3 <i>tert</i>-butyl substituents and the Boc moiety at P4 engaged the enzyme through close van der Waals contact with their respective subpockets.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Truncation of either the P1 or P3 moieties led to significant reductions in potency in both the biochemical and cell-based assays, while replacement of the terminal <i>tert</i>-butoxycarbonyl element with a methoxycarbonyl moiety largely preserved potency, but this compound exhibited a poor PK profile in the rat in vivo screen. These results directed attention toward the P2* quinoline element which was found to show some tolerance toward structural manipulation without severely compromising antiviral activity, attributed to the potency enhancing effects of the cyclopropyl acylsulfonamide moiety. This line of enquiry proved to be both insightful and productive with respect to solving the drug delivery challenge. Reducing the molecular weight of <b>21</b> by removing the 2-phenyl substituent from the P2* quinoline heterocycle afforded <b>34</b>, which was associated with a 5-fold reduction of antiviral potency while the PK profile was also eroded compared to the progenitor. A critical breakthrough toward solving the problem of poor oral bioavailability came with the evaluation of the isomeric isoquinoline-substituted compounds <b>35</b> and <b>36</b> of which the former offered potency equivalent to <b>21</b> while <b>36</b> exhibited a marginal advantage over <b>34</b>. However, the exposure of both <b>35</b> and <b>36</b> following oral administration to rats was significantly improved over their matched quinoline isomers, with the plasma AUC and liver levels of <b>35</b> being 14-fold and 9-fold higher than for the same dose of <b>21</b>, while for <b>36</b> the exposure advantage over <b>34</b> amounted to a remarkable 693-fold in plasma and 104-fold in liver, both measured at the end of a 4 h rat experiment (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Both of these compounds fall outside the physicochemical metrics that have been proposed to predict oral absorption, and the differences in performance in vivo are not reflected in any of the efficiency factors that have been advocated for assessing compound quality, with only the cLogP and cLogD values of <b>34</b> and <b>36</b> diverging, presumably a function of differences in basicity, dipole moments, and relative exposure of the heterocycle nitrogen atom (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51, 52)</a> This observation extended to the matched pair of chloro-substituted compounds <b>37</b> and <b>38</b> where the in vivo advantage for the latter over the former was 56-fold in the liver at 4 h postdosing and over 1000-fold with respect to the plasma AUC. A similar advantageous PK profile was subsequently noted for the isoquinoline <b>40</b> which exhibited a 36-fold higher plasma AUC over 4 h in rats compared to the quinolone isomer <b>39</b> while the liver levels were improved by 4.75-fold.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Biological Activity and PK Parameters Associated with the Quinoline- and Isoquinoline-Based HCV NS3 Inhibitors <b>17</b>, <b>21</b>, and <b>34</b>–<b>36</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0020.gif" alt="" id="fx30" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0021.gif" alt="" id="fx31" /></img><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Physicochemical Properties Associated with the NS3 Protease Inhibitors <b>34</b> and <b>36</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>34</b></th><th class="colsep0 rowsep0" align="center"><b>36</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MW</td><td class="colsep0 rowsep0" align="left">713.84</td><td class="colsep0 rowsep0" align="left">713.84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HAC</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rotatable bonds</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HBAs/HBDs</td><td class="colsep0 rowsep0" align="left">14/3</td><td class="colsep0 rowsep0" align="left">14/3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cLogP</td><td class="colsep0 rowsep0" align="left">3.56</td><td class="colsep0 rowsep0" align="left">4.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cLogP (pH = 7)</td><td class="colsep0 rowsep0" align="left">1.66</td><td class="colsep0 rowsep0" align="left">2.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PSA, Å<sup>2</sup></td><td class="colsep0 rowsep0" align="left">191</td><td class="colsep0 rowsep0" align="left">191</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">All physicochemical data values are abstracted from SciFinder and calculated using Advanced Chemical Development (ADC)/Laboratories) software, version 11.02.</p></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0034.gif" alt="" id="fx5" /></img><div class="NLM_p">The SARs and structure–PK relationships surrounding <b>36</b> and the associated in vivo profiling revealed some sensitivity to small variations (data summarized in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). The 6-ethoxy homologue <b>41</b> expressed similar antiviral properties to the progenitor, but the in vivo exposure in the rat was ∼5-fold lower while the 6-F (<b>42</b>), 6-Cl (<b>43</b>), and 6-<i>tert</i>-butyl (<b>44</b>) analogues were markedly less potent in vitro. These results were interpreted in the context of the interaction of the phenyl portion of the isoquinoline ring with Arg155 in a π–cation type of interaction that would be favored by electron donating groups, while the poor activity associated with <b>44</b> was attributed to unfavorable steric interactions between the inhibitor and the enzyme. The 6-cyano derivative <b>45</b> profiled as an outlier, with the potent enzyme inhibition observed with this molecule considered to be a function of the electronegative tip of the substituent engaging the protonated guanidine moiety of Arg155. The poor potency associated with <b>46</b> was attributed to combination of steric and electronic effects that result in a distortion of the amide functionality from planarity with the heterocycle ring. The 4-methoxy and 5-methoxy analogues <b>47</b> and <b>48</b> respectively exhibited potent enzyme inhibitory activity, although the replicon potency for these compounds was lower than for <b>36</b>, and <b>47</b> also demonstrated poor plasma and liver exposure after oral dosing. The combination of 4,6-dimethoxy substitution in <b>49</b> was associated with excellent in vitro potency but the rat PK was poor, a profile similar to that of both the isomeric isoquinoline <b>50</b> and the homologous quinazoline <b>51</b>. Saturation of the P1 vinyl moiety afforded <b>52</b> which combined reduced replicon potency with poorer PK when compared to <b>36</b>, while the profile of the carboxylic acid <b>53</b> confirmed the positive effects of the acyl sulfonamide on both potency, particularly in the replicon, and PK properties in vivo.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro and in Vivo Profiling of <b>41</b>–<b>53</b>, Analogues of <b>36</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0022.gif" alt="" id="fx32" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0023.gif" alt="" id="fx33" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn2"><div class="footnote" id="t4fn2"><sup>Table a</sup><p class="last">Full PK experiment. BLD = below limit of detection.</p></div></div><div></div></div><div class="NLM_p">While the substitution pattern of the isoquinoline moiety was being explored, the properties of <b>36</b> (BMS-605339) were examined in more detail, with the PK profile in three preclinical species summarized in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>. The oral bioavailability was higher in the dog than the rat, while the poor PK in the cynomolgus monkey was readily explained by its low metabolic stability in monkey LM and high first-pass extraction.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Compound <b>36</b> was profiled in mdr1a-deficient mice where lower clearance and a smaller volume of distribution were observed along with a longer <i>t</i><sub>1/2</sub> and higher serum and liver AUC values when compared to the PK parameters in control FVB animals following iv dosing. After oral administration, the bioavailability of <b>36</b> was ∼8-fold higher in the mdr1a-deficient animals compared to the wild type species, indicative of P-gp involvement in intestinal absorption, while the lower clearance in these mice also suggested P-gp involvement in elimination. The liver levels in the rat and dog measured at 24 h following an oral dose were higher than in plasma, with a 140-fold advantage in the rat after 15 mpk and a 64-fold difference in the dog after 14 mpk, with drug concentrations in the liver well in excess of the replicon EC<sub>50</sub> values for GT-1 virus.<a onclick="showRef(event, 'ref45 ref54'); return false;" href="javascript:void(0);" class="ref ref45 ref54">(45, 54)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Preclinical PK Parameters for <b>36</b> in the Rat, Dog, and Cynomolgus Monkey<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">dose (mpk, po/iv)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">rat (20/10)</th><th class="colsep0 rowsep0" align="center">dog (3/1)</th><th class="colsep0 rowsep0" align="center">cynomolgus monkey (3/1)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po <i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">51</td><td class="colsep0 rowsep0" align="left"><1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po AUC (μM·h)</td><td class="colsep0 rowsep0" align="left">14.1</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">4.4</td><td class="colsep0 rowsep0" align="left">17.6</td><td class="colsep0 rowsep0" align="left">17.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">4.4</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">24 h liver and plasma levels after po dosing (dose)</td><td class="colsep0 rowsep0" align="left">liver: 733 nM</td><td class="colsep0 rowsep0" align="left">liver: 384 nM</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma: 5 nM</td><td class="colsep0 rowsep0" align="left">plasma: 6 nM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(15 mpk)</td><td class="colsep0 rowsep0" align="left">(14 mpk)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LM <i>t</i><sub>1/2</sub> (min)</td><td class="colsep0 rowsep0" align="left">126</td><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">5.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">ND = not determined.</p></div></div></div><div class="NLM_p">On the basis of in vitro potency in the less sensitive GT-1a replicon (EC<sub>50</sub> = 8 nM), a liver level of drug that was 10-fold higher was set as the threshold target to be maintained over a 24 h period in humans in order to predict efficacy. This estimate was combined with a conservative 30-fold liver/plasma ratio to project that a trough plasma level of 2.7 ng/mL in humans would be an adequate target exposure. The preclinical PK properties and toxicological profiling of <b>36</b> were supportive of advancing the compound into phase I clinical trials where the initial evaluation was in a single ascending dose (SAD) study conducted in normal healthy volunteers (NHVs) at doses of 10, 30, 60, and 120 mg.<a onclick="showRef(event, 'ref45 ref54'); return false;" href="javascript:void(0);" class="ref ref45 ref54">(45, 54)</a> Plasma exposure of <b>36</b> increased with dose with the <i>C</i><sub>max</sub> observed at 1.5 h after drug administration, indicative of relatively rapid absorption, while the terminal half-life was 4–8 h, with drug still detectable in plasma 24 h after dosing. These data set the stage for a phase 1b clinical study in HCV-infected patients where doses of 10, 60, and 120 mg were selected for evaluation, with the results presented in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> A reduction in viremia was observed following all three doses, with the magnitude of the effect increasing with dose. The single 120 mg dose of <b>36</b> was associated with a mean 1.8 log<sub>10</sub> IU/mL fall in viral load measured at 12 h postdosing, with viremia returning to the original set point several days later. While these results were broadly comparable to the effects observed with the macrocyclic tripeptide carboxylic acid <b>13</b> and validated the assumptions made based on preclinical profiling, two subjects, one a NHV and the other infected with HCV, experienced electrocardiographic changes following the administration of a 120 mg dose of <b>36</b>. Mild bradycardia, PR-interval prolongation, and junctional rhythm disturbances were observed in these two subjects that, while asymptomatic in presentation, were considered to present a significant safety risk in a broader patient population. The onset of these effects occurred 4.5 h after dosing of <b>36</b> and persisted for as long as 18.5 h, a profile that led to the decision to terminate further clinical development of the compound.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Mean reduction in plasma viral RNA following the administration of single oral doses of <b>36</b> to HCV-infected subjects. Figure reproduced with permission from  <cite>Journal of Medicinal Chemistry</cite> (<span class="NLM_year">2014</span>, <em>57</em>, 1708–1729).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Copyright 2014 American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Cardiovascular (CV) effects that were qualitatively similar to those observed in the clinical trial associated with <b>36</b> had been observed in both rabbits and dogs but at appreciably higher plasma exposures, indicating that humans were considerably more sensitive than preclinical species. This observation necessitated the implementation of a modified screening paradigm that would incorporate a CV assessment early in the evaluation tier in order to identify compounds with a safer profile.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The <i>C</i><sub>max</sub> values of <b>36</b> in the two subjects that experienced electrocardiogram changes were 113 nM (NHV) and 206 nM (HCV-infected subject), while it was estimated that the plasma concentration of drug in telemeterized dogs experiencing similar effects was 12 μM (dose = 15 mpk b.i.d.), 60- to 100-fold higher. The differences in the observation of CV effects could not be explained by protein binding, since the extent of association was similar in assays conducted using human and dog plasma as measured by equilibrium dialysis (dog = 98.2%, human = 99.1%). Studies conducted in anesthetized rabbits revealed a similar CV profile, with effects observed at total plasma exposure of between 1.65 and 27 μM, while the concentration of drug in cardiac tissue at the end of the experiment was 250 nM. Since profiling of <b>36</b> in a suite of CV-related receptor and ion channel assays failed to identify a specific biochemical basis for the observed effects, the screening plan that was adopted relied upon a Langendorff rabbit isolated heart preparation to evaluate candidate compounds. Escalating doses of <b>36</b> were perfused at a high concentration in Krebs–Henseleit solution in the absence of plasma proteins onto a beating rabbit heart, an experiment that revealed a mild decrease in heart rate (HR) and a moderate increase in sinoatrial node recovery time (SNRT) compared to the vehicle control, with no detectable effect on atrioventricular conduction time, QRS interval, or coronary flow (<a class="ref internalNav" href="#fig4" aria-label="Figure 04">Figure 04</a>).</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effects of <b>36</b> on heart rate and sinoatrial node recovery time in a rabbit Langendorff heart preparation. Reproduced with permission from  <cite>Journal of Medicinal Chemistry</cite> (<span class="NLM_year">2014</span>, <em>57</em>, 1730–1752).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Copyright 2014 American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Since the Langendorff isolated heart assay is complex in both nature and implementation and does not lend itself to high or even moderate throughput screening, the decision was made to screen compounds at a single test concentration of 10 μM perfused for 20 min.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The initial screening set that was selected was designed to illuminate fundamental aspects of the structure of <b>36</b> that were associated with CV effects, with the results summarized in <a class="ref internalNav" href="#tbl6" aria-label="Table 06">Table 06</a>, where data for <b>36</b> are included for comparison. The role of the acylsulfonamide moiety was probed by evaluating the carboxylic acid analogue <b>53</b> which exerted cardiovascular effects that although milder than for <b>36</b> gave confidence that this was not a specific source of the problem (<a class="ref internalNav" href="#tbl6" aria-label="Table 06">Table 06</a>). Modifications at P3 and P4, compounds <b>54</b> and <b>55</b>, also failed to abrogate changes in HR and SNRT as did the major structural changes introduced at P2* in the context of <b>56</b> and <b>57</b>. These data indicated that solving the CV issue would require considerable finesse, and attention was redirected toward probing the effects of subtle structural changes within the context of isoquinoline-based derivatives, since this moiety afforded good PK properties. While the unsubstituted compound <b>58</b> profiled analogously to <b>36</b>, the 5-methoxy derivative <b>59</b> demonstrated only mild CV effects in the Langendorff heart preparation, providing the first indication that the cardiac effects were sensitive to the pattern of substitution of the P2* isoquinoline heterocycle (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). However, this compound lacked the targeted potency (EC<sub>50</sub> < 10 nM) in the GT-1b replicon screen. The 4 methoxy isomer <b>60</b> also demonstrated only modest effects on HR and SNRT, a result that was confirmed in an experiment where monitoring was extended out to 60 min. In contrast, the 4,6-dimethoxy analogue <b>61</b> presented a more severe CV profile, although both the intrinsic protease and replicon inhibitory potency associated with this compound were high. This result, along with other structure–function data from the Langendorff heart assay, implicated the C-6 methoxy moiety as a structural element contributing to the CV effects. Since a substituent in the phenyl portion of the isoquinoline ring had favorable effects on potency, the three chloro-substituted derivatives <b>62</b>–<b>64</b> were prepared and evaluated. All three compounds demonstrated potent replicon inhibition. While <b>64</b> was associated with significant CV effects, the effects of the C-6 chloro compound <b>63</b> were milder, while the C-7 chloro analogue <b>64</b> was benign in the Langendorff heart model, a favorable profile confirmed when the evaluation was conducted over 60 min of monitoring (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). A series of close analogues of <b>64</b> that probed the effects of modification of the methoxy and halogen isoquinoline substituents as well as the P1 vinyl and P4 moieties confirmed the unique antiviral, PK, and CV properties of this molecule which is now recognized as asunaprevir (BMS-650032).<a onclick="showRef(event, 'ref55 ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref55 ref56 ref57">(55-57)</a></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Preliminary Series of HCV NS3 Inhibitors Screened in the Rabbit Langendorff Heart Assay<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0024.gif" alt="" id="fx34" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0025.gif" alt="" id="fx36" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">The asterisk (∗) indicates compounds tested at a concentration of 10 μM with 20 min of monitoring of cardiac function.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Effects of Structural Variation of P2* on Potency and CV Effects in the Rabbit Langendorff Heart Preparation</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0026.gif" alt="" id="fx37" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0027.gif" alt="" id="fx38" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>Table a</sup><p class="last">Compounds tested at a concentration of 10 μM with 20 min of monitoring of cardiac function.</p></div><div class="footnote" id="t7fn2"><sup>Table b</sup><p class="last">Compounds monitored for 60 min.</p></div></div><div></div></div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Overlay of the cardiac effects of <b>36</b> and <b>64</b> perfused at a concentration of 10 μM for 60 min. Reproduced with permission from  <cite>Journal of Medicinal Chemistry</cite> (<span class="NLM_year">2014</span>, <em>57</em>, 1730–1752).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Copyright 2014 American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The antiviral and PK profiling data that qualified <b>64</b> for nomination as a clinical candidate are summarized in <a class="ref internalNav" href="#tbl8" aria-label="Table 08">Table 08</a>, revealing a potent inhibitor of NS3 proteases isolated from GT-1a, GT-1b, GT-4a, GT-5a, and GT-6a viruses, while GT-2a, GT-2b, and GT-3a proteases are 10- to 200-fold less sensitive.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56, 57)</a> This profile is reflected in replicon inhibitory activity where GT-1a, GT-1b, and GT-4a replication is half-maximally reduced at concentrations ranging from 1.2 to 4.0 nM while GT-2a and GT-3a replicons require much higher concentrations to observe a similar antiviral effect.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The preclinical PK profile of <b>64</b> exhibited some differences from <b>36</b>, particularly in the rat where clearance was several-fold higher, which resulted in a 10-fold lower plasma exposure and almost 2-fold higher liver levels determined at 24 h postdose (<a class="ref internalNav" href="#tbl8" aria-label="Table 08">Table 08</a>).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> This profile was consistent with the observation that uptake of <b>64</b> into hepatocytes was, in part, mediated by an active transport process. The PK profile of <b>64</b> in dogs was similar to <b>36</b>, with 61% oral bioavailability, while the plasma exposure and oral bioavailability in the cynomolgus monkey, although low, were higher than for <b>36</b>. In both of these species, liver levels were considerably higher than in plasma measured at 24 h after a single dose, reflecting the more hepatotropic disposition observed in the rat.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Antiviral and Preclinical PK Profile of <b>64</b><a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="3" align="center">Antiviral Properties</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1a</td><td class="colsep0 rowsep0" align="left">0.70</td><td class="colsep0 rowsep0" align="left">4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1b</td><td class="colsep0 rowsep0" align="left">0.30</td><td class="colsep0 rowsep0" align="left">1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-2a</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">230</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-2b</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-3a</td><td class="colsep0 rowsep0" align="left">320</td><td class="colsep0 rowsep0" align="left">1162</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-4a</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-5a</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-6a</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="5" align="center">Pharmacokinetic Profiling</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">dose (mpk, po/iv)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">mouse (5/2)</th><th class="colsep0 rowsep0" align="center">rat (15/5)</th><th class="colsep0 rowsep0" align="center">dog (3/1)</th><th class="colsep0 rowsep0" align="center">cynomolgus monkey (3/1)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po <i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">61</td><td class="colsep0 rowsep0" align="left">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po AUC (μM·h)</td><td class="colsep0 rowsep0" align="left">0.54</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">0.41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">57.3</td><td class="colsep0 rowsep0" align="left">38</td><td class="colsep0 rowsep0" align="left">18.7</td><td class="colsep0 rowsep0" align="left">18.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">4.6</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">24 h liver concn after po dosing (dose, mpk)</td><td class="colsep0 rowsep0" align="left">710 nM (5)</td><td class="colsep0 rowsep0" align="left">1200 nM (15)</td><td class="colsep0 rowsep0" align="left">2500 nM (6)</td><td class="colsep0 rowsep0" align="left">440 nM (10)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">24 h plasma concn after po dosing (dose, mpk)</td><td class="colsep0 rowsep0" align="left">BLQ (5)</td><td class="colsep0 rowsep0" align="left">40 nM (15)</td><td class="colsep0 rowsep0" align="left">6 nM (6)</td><td class="colsep0 rowsep0" align="left">BLQ (10)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver/plasma ratio at 24 h</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">300</td><td class="colsep0 rowsep0" align="left">410</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">BLQ = below level of quantification. ND = not determined.</p></div></div></div><div class="NLM_p">The successful resolution of the problematic CV effects associated with <b>36</b> relies upon a remarkably subtle change in structure. The only difference in the constitutional formulas between <b>36</b> and <b>64</b> is the addition of a single chlorine atom that is configured in the context of an altered substitution pattern of the P2* isoquinoline heterocycle. Nevertheless, the manifestation of these subtle structural changes on both the CV effects and PK profile within the context of a molecule with a molecular weight of 748 is quite remarkable, with only marginal differences between the more common physicochemical descriptors used to assess compound quality.<a onclick="showRef(event, 'cit52b'); return false;" href="javascript:void(0);" class="ref cit52b">(52b)</a></div><div class="NLM_p">Compound <b>64</b> was advanced into clinical trials following a pathway similar to that established for <b>36</b> with a SAD study conducted in HCV-infected patients after establishing PK parameters and tolerability in NHVs.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Notably and gratifyingly, no significant CV changes were observed following single oral doses ranging from 10 to 1200 mg as determined by a detailed ECG analyses, validating the use of the rabbit Langendorff isolated heart assay to assess the CV liabilities of preclinical compounds. In HCV-infected subjects, the mean maximum decline in plasma viremia was 0.28, 0.64, 2.26, and 2.87 log<sub>10</sub> IU/mL following doses of 10, 50, 200, and 600 mg, respectively, as summarized in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>. In a multiple ascending dose study in which <b>64</b> was administered to HCV-infected subjects at doses of 200, 400, and 600 mg b.i.d. for 3 days, the mean maximal reductions in viral load were 3.09, 3.57, and 2.84 log<sub>10</sub> IU/mL, respectively.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The antiviral effects observed with <b>64</b> in HCV-infected subjects was considered encouraging, and further development of the compound was pursued (vide infra).</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Mean maximum change in viremia associated with escalating doses of <b>64</b> administered to HCV-infected subjects in a SAD clinical study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">3 NS5A Replication Complex Inhibitors: Discovery of Daclatasvir</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50658" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50658" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">While the discovery of the NS3 protease inhibitors <b>36</b> and <b>64</b> have their roots in a program relying upon structure-based drug design, the identification of lead NS5A replication complex inhibitors (RCIs) was the result of the contrasting and completely orthogonal strategy associated with phenotypic screening.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Phenotypic screening has proven to be a useful and effective approach for the discovery of anti-infective agents, and there is renewed interest in this strategy in a broader context for discovering lead inhibitors with unanticipated modes of action promoted, in part, by the design and application of new tools to facilitate the identification of targets. The development of subgenomic HCV replicons allowed the implementation of a screen of the Bristol-Myers Squibb corporate compound collection, initially conducted against a library of 200 000 compounds but subsequently extended to a total of over 1 million molecules.<a onclick="showRef(event, 'ref24 ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref24 ref60 ref61 ref62">(24, 60-62)</a> Upon the basis of the experience of screening for BVDV inhibitors as a surrogate of HCV, this virus was adopted as a stringent counterscreen, with test wells seeded with both the HCV and BVDV replicons, each isolated in the same Huh-7 cell background. The extent of HCV replication inhibition was assessed by presenting a substrate of the NS3 protease to lysed cell preparations while the BVDV replicon incorporated luciferase as a conveniently assessed bioluminescent reporter. The final piece of data abstracted from this screen determined cell viability via alamarBlue (resazurin) staining which evaluates mitochondrial health. Compounds exhibiting antiviral activity toward the HCV replicon in this screen that either inhibited BVDV replication or were cytotoxic at concentrations within 10-fold of that for HCV inhibition were discarded, a rigorous approach that distilled the compounds surveyed to a single molecule, the iminothiazolidinone <b>65</b> (<a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a>).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> This compound had been prepared as part of a purely prospective library, and while iminothiazolidinone derivatives were well represented in the literature, they are typically C-5-benzylidine derivatives that are readily prepared by a Knoevenagel condensation between the C-5 unsubstituted parent and an aldehyde.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> The unique C-5-phenyl substituent in <b>65</b> would turn out to be of significance for the interesting discoveries that lay ahead as this chemotype was adopted and explored in more depth. The in vitro antiviral properties of <b>65</b> are summarized in <a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a> and met the targeted selectivity criteria with respect to BVDV inhibition, with antiviral specificity confirmed by profiling in respiratory syncytial virus (RSV), human rhinovirus (HRV), and HIV-1 cell culture assays where the compound was essentially inactive.<a onclick="showRef(event, 'ref62 ref64'); return false;" href="javascript:void(0);" class="ref ref62 ref64">(62, 64)</a> The absence of inhibitory effects in HCV NS3 protease and polymerase biochemical assays suggested that <b>65</b> was acting via a novel mode of action in the replicon, a hypothesis confirmed by the generation of resistant replicons which mapped sensitivity to mutations in the amino terminus domain (domain I) of the HCV NS5A phosphoprotein. More specifically, the resistant phenotype was mapped to a Tyr93His mutation or a dual Leu31Val/Gln54Leu combination in NS5A, both of which conferred at least 10-fold reduced inhibitory sensitivity.<a onclick="showRef(event, 'ref62 ref64'); return false;" href="javascript:void(0);" class="ref ref62 ref64">(62, 64)</a> At the time that <b>65</b> was discovered, the function of NS5A and its role in virus replication was poorly understood, although it had been defined as essential for replication in vivo and there were several lines of evidence suggesting that NS5A was a mediator of the response of infection to the antiviral effects of IFN-α in vivo.<a onclick="showRef(event, 'ref65 ref66 ref67 ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref65 ref66 ref67 ref68 ref69">(65-69)</a> The NS5A protein does not express any enzymatic activity, and despite considerable study over the past 15 years, its specific functions in the viral life cycle remain complex and enigmatic to this day.<a onclick="showRef(event, 'ref66 ref69'); return false;" href="javascript:void(0);" class="ref ref66 ref69">(66, 69)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0035.gif" alt="" id="fx6" /></img></div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. In Vitro Antiviral Profile of the HCV GT-1b Replicon Inhibitor <b>65</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">CC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1b HCV replicon</td><td class="colsep0 rowsep0" align="left">0.57</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BVDV replicon</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BVDV virus</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">>150</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HIV-1</td><td class="colsep0 rowsep0" align="left">41</td><td class="colsep0 rowsep0" align="left">41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HRV</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RSV</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">23</td></tr></tbody></table></div></div><div class="NLM_p">The antiviral profile of <b>65</b> was appealing, and structure–activity studies were embarked upon that focused initially on surveying the effects of changes to the three main elements: the furan heterocycle, the fluorophenyl ring attached to the thiazolidinone heterocycle, and the Cbz-protected alanine moiety, with a synopsis of the results compiled in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Modifications to the thiazolidinone heterocycle substituents demonstrated an excellent tolerance toward structural manipulation, with a good dynamic range of potency observed in which more polar replacements for both the furan (<b>66</b>–<b>68</b>) and fluorophenyl (<b>69</b>–<b>71</b>) elements improved the potency of the prototype <b>65</b>, while more lipophilic moieties typically led to reduced antiviral activity. However, the most informative SARs were gleaned from modifications of the alanine element where inversion of the absolute configuration of the amino acid led to a ∼200-fold erosion of potency (<b>72</b>) while simplification to the glycine homologue <b>73</b> was associated with a 10-fold loss in antiviral effect. Of the other amino acids studied, only the proline derivative <b>74</b> was found to be compatible with significant replicon inhibition and this compound offered 5-fold enhanced potency compared to <b>65</b>. The antiviral potency of <b>74</b> was also dependent upon the absolute configuration, since the antipode <b>75</b> was 50-fold less active. Manipulation of the carboxybenzyl group revealed that the isosteric phenethyl analogue <b>76</b> was marginally weaker in the replicon while abbreviation to the phenylacetic derivative <b>77</b> led to an almost 100-fold increase in potency, SARs that were fully recapitulated in the proline series, as exemplified by the analogues <b>78</b> and <b>79</b>.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structure and replicon EC<sub>50</sub> values for <b>65</b> and a select set of analogues that define fundamental aspects of the SARs of the screening lead.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While these results were encouraging, as studies with the thiazolidinone chemotype continued, it became apparent that <b>65</b> was chemically unstable in some solvents and also in the replicon assay medium. This phenomenon was originally detected as compound degradation when a solution of <b>65</b> in DMSO that had been stored at room temperature for several days was analyzed prior to evaluation in a biochemical assay. A subsequent preparative experiment resulted in the isolation of the thiohydantoin derivative <b>80</b> as the major degradation product. This was confirmed with a careful and detailed analysis of the more potent analogue <b>77</b> which, although stable in the solid state or as a solution in MeOH or CH<sub>3</sub>CN, degraded in DMSO to afford <b>81</b> along with the thiourea <b>82</b>. More remarkable was the observation that although <b>77</b> suffered complete degradation when incubated in replicon medium for 3 days, there was no apparent loss in antiviral potency when this solution was presented to the replicon cells and activity remained sensitive to the Tyr93His mutation.<a onclick="showRef(event, 'cit70b ref71'); return false;" href="javascript:void(0);" class="ref cit70b ref71">(70b, 71)</a> Since there were no additional products evident in the initial high performance liquid chromatography (HPLC) analysis of material that had been incubated in replicon medium, speculation focused on the presence of minor but highly active degradation products, since neither <b>81</b> nor <b>82</b> demonstrated significant antiviral activity in the GT-1b replicon. In an effort to understand the degradation pathway more completely, <b>77</b> was incubated in replicon medium at a concentration of 5 μM for 48 h before being extracted with CH<sub>3</sub>CN and subjected to a HPLC biogram analysis. Biogram methodology, which was developed to analyze natural product extracts, combines semipreparative HPLC separation techniques, automated compound handling and distribution, high throughput biological screening, and informatics tools to develop a graphical report in which bioactivity is overlaid with HPLC retention time.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> The initial analysis surveyed 80 HPLC fractions that were collected and concentrated to allow evaluation of the residue in the GT-1b replicon. The results of this experiment were that HCV inhibitory was found to be associated with fractions eluting from the reversed phase HPLC column after both parent <b>77</b> and the known degradation products <b>81</b> and <b>82</b>. However, the active fractions were not associated with a distinct and readily detectable UV peak in the HPLC trace, and where the bioactivity assay identified active material, the UV trace was comparable to baseline, suggestive of small amounts of potently active material. At this point, a preparative experiment was conducted that required the development of practically important enrichment procedures prior to HPLC analysis in order to isolate the active components from the replicon medium.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> This process comprised extracting the complex medium matrix with CH<sub>3</sub>CN and centrifuging the organic phase which was then frozen at −20 °C to promote separation of the aqueous phase. The unfrozen CH<sub>3</sub>CN layer was recovered and further refined using a CHCl<sub>3</sub>–MeOH–H<sub>2</sub>O partitioning step and then concentrated and the residue fractionated by HPLC, guided by antiviral assessment in both wild-type and Tyr93His resistant GT-1b HCV replicons. This process resulted in the identification of two active components that were isolated in sufficient quantity to allow their detailed characterization by <sup>1</sup>H and <sup>13</sup>C NMR spectroscopy. These fractions, which were designated as peak 4 and peak 6 in the HPLC trace, exhibited potent antiviral activity in the GT-1b replicon with EC<sub>50</sub> values of 43 and 0.6 nM, respectively. The <sup>1</sup>H NMR spectral data acquired for the compound designated as peak 4 indicated preservation of all of the major structural elements of <b>77</b> with the exception of the C-5 methine proton which was absent while the <sup>13</sup>C NMR resonance for the C-5 carbon atom was deshielded relative to <b>77</b>, shifted from δ 51.4 to δ 70.2. Both of the peak 4 and peak 6 compounds were found to be high molecular weight species with the mass determined to be 1139.3379 Da (MH<sup>+</sup>) by high resolution analysis, a value that is just 2 mass units less than double that of <b>77</b>. Moreover, the peak 4 and peak 6 components were determined to be structurally related when heating of a sample of the peak 6 material in CD<sub>3</sub>CN at 55 °C in order to homogenize the amide resonances in the <sup>1</sup>H NMR spectrum resulted in its conversion to the peak 4 component. These data and collective observations led to the suggestion that the two components were symmetrical dimers represented generically by <b>83</b> that were derived from <b>77</b> by dimerization across C-5 of the thiazolidinone ring, with the peak 4 component the thermodynamically more stable diastereomer.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> The mechanistic interpretation of these observations is summarized in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> and envisages hydrogen atom abstraction from C-5 of the thiazolidinone ring as the activating step, a process presumed to be mediated by molecular oxygen which in the ground state is a diradical species. The C-5 radical <b>84</b> that is generated by this process is stabilized in a captodative fashion by the phenyl ring, sulfur atom, and carbonyl substituents.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> The combination of <b>84</b> with molecular oxygen would produce the hydroperoxide <b>85</b> that may be subject to reduction in (by) DMSO to afford the corresponding C-5 alcohol which would be anticipated to ring-open to the ketoamide <b>86</b> and reclose to give the more stable thiohydantoin <b>81</b>. In aqueous media, the α-ketoamide <b>86</b> would be susceptible to hydrolytic degradation to provide the thiourea <b>82</b> and, presumably, the α-ketoacid <b>87</b>, which was not isolated. The stability of the radical species <b>84</b> presumably allows adequate time for radical combination in assay media to give the dimeric species <b>83</b>, possibly facilitated by aggregation of the parent compound <b>77</b> under aqueous conditions.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Evidence that the C-5 hydrogen atoms of <b>77</b> and <b>79</b> are capable of participating in radical-based chemistry was obtained by heating these compounds with Mn(OAc)<sub>3</sub> and Cu(OAc)<sub>2</sub> in AcOH at 80 °C, reaction conditions that have been shown to promote the oxidation of radicals to cations that can then be trapped by the solvent.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> In this particular case, the acetates represented by <b>88</b> were produced which upon methanolysis afforded the substituted thiohydantoin derivative <b>81</b> and its proline homologue (structure not shown).<a onclick="showRef(event, 'cit70b'); return false;" href="javascript:void(0);" class="ref cit70b">(70b)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0036.gif" alt="" id="fx7" /></img></div><figure id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0016.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Chemical Degradation Pathways Associated with the Thiazolidinone Derivative <b>77</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The potency associated with the two putative diastereomeric dimers represented by <b>83</b> and their sensitivity to the Tyr93His mutation in HCV NS5A suggested that these compounds retained the antiviral phenotype of the screening hit <b>65</b> and its analogues <b>77</b> and <b>79</b>, a profile that encouraged continued interest in the chemotype. On the basis of the observations that the antiviral activity of <b>65</b> was highly sensitive to small structural changes to the alanine moiety while variation of the thiazolidinone ring N-substituents was associated with more nebulous SARs, it was hypothesized that the NS5A-inhibiting pharmacophore in <b>83</b> was defined by the embedded bibenzyl element and that the remainder of the thiazolidinone ring and its substituents were superfluous for antiviral activity.<a onclick="showRef(event, 'cit70b'); return false;" href="javascript:void(0);" class="ref cit70b">(70b)</a> This scenario envisioned the thiazolidinone ring acting as a scaffolding element to convene a symmetrical molecule in the cell culture assay, a pharmacophore concept that was readily and straightforwardly tested by preparing <b>89</b> which incorporates the proline cap moiety. This compound exhibited an EC<sub>50</sub> value of 30 nM in the GT-1b replicon, but its synthetic precursor, the conformationally less mobile stilbene <b>90</b>, was a considerably more interesting and compelling inhibitor based on its picomolar antiviral potency, EC<sub>50</sub> = 0.086 nM in the GT-1b replicon, an advantage of more than 300-fold over <b>89</b>.<a onclick="showRef(event, 'cit70b ref71'); return false;" href="javascript:void(0);" class="ref cit70b ref71">(70b, 71)</a> The antiviral activity of <b>90</b> remained sensitive to the NS5A Tyr93His mutation with the EC<sub>50</sub> value shifting to 4 μM in this replicon, and the compound was inactive in the BVDV counterscreen. Collectively, these data indicated that we had finessed an important NS5A-inhibiting pharmacophore expressed in the dimeric species <b>83</b> that was cryptically expressed by <b>79</b> in cell culture. At this juncture of the project, the dimeric species represented by <b>89</b> and <b>90</b> became the primary focus of further study.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0037.gif" alt="" id="fx8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0038.gif" alt="" id="fx9" /></img></div><div class="NLM_p">While the high level of antiviral potency associated with stilbene <b>90</b> was attractive, this compound presented three problems that were considered to be of significance in further optimization. From the perspective of chemical structure, the stilbene olefin was subject to configurational instability via cis–trans isomerism, observed in studies with analogues of <b>90</b>, while the embedded aniline moiety was of concern because of the potential for release in vivo by protease- or esterase-mediated cleavage of the proline amide bond.<a onclick="showRef(event, 'ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref76 ref77">(76, 77)</a> Anilines are potentially mutagenic and genotoxic after metabolic activation, arousing considerable anxiety around this potential safety issue.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> While it was anticipated that these issues could be addressed by a series of structure–activity studies, the discovery of <b>89</b> and <b>90</b> coincided with the development of a GT-1a replicon where both compounds were determined to be essentially inactive, with EC<sub>50</sub> values of >10 μM. This was considered to be a significant problem, since a compound with selectivity for HCV GT-1b would be of limited value as a therapeutic agent based on demographic analyses that revealed the worldwide prevalence and importance of GT-1a infections.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Nevertheless, against the backdrop of the unique mechanism of the chemotype, a broad-based approach to structural exploration was implemented that focused on further defining the NS5A-inhibiting pharmacophore while, where possible, integrating structural modifications that were designed to address the inherent chemical liabilities described above. The oral delivery of the symmetrical chemotype was also of some concern given the relatively high molecular weight (640), cLogP (6.2) and rotatable bond count (10), but this was allayed to some extent by studies with the cyclopropylmethyl amide <b>91</b>, a potent HCV GT-1b inhibitor, which displayed 64% oral bioavailability in the rat. However, it was the GT-1a inhibition that would ultimately prove to be the most challenging problem to solve and the endeavor that ultimately succeeded in resolving this issue required considerable experimentation and persistence.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0039.gif" alt="" id="fx10" /></img></div><div class="NLM_p">While a wide range of derivatives and analogues of <b>90</b> that explored structural variation of the proline, phenylacetic acid, and olefin moieties were prepared and profiled for antiviral activity, none provided a clear seam of coherent and tractable SARs with respect to GT-1a inhibition.<a onclick="showRef(event, 'ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref79 ref80">(79, 80)</a> Representative examples of molecules with measurable GT-1a inhibition are provided by the oxazole <b>92</b>, which was unique within a series of olefin replacements, while the substituted proline analogue <b>93</b> and the ortho-substituted benzoic acid <b>94</b> were the only compounds within a series of stilbene derivatives to demonstrate detectable GT-1a inhibition.<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81, 82)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0040.gif" alt="" id="fx11" /></img></div><div class="NLM_p">The critical breakthrough came with the synthesis and evaluation of the isoquinoline-1-carboxamide <b>95</b> that, although demonstrating only modest antiviral activity in replicons, proved to be a bona fide lead inhibitor of GT-1a HCV replication.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> For example, the 3,5-disubstituted homologue <b>96</b> was 20-fold more potent in the GT-1a replicon, although this was accompanied by a more modest increase in GT-1b inhibitory activity. While additional studies that explored the substitution pattern of the isoquinoline heterocycle in more detail expanded the SARs associated with this moiety, it was a more radical structural surgery in which the isoquinoline ring was deconstructed to give the α-keto amide <b>97</b> that proved to be the most informative modification (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). The amide element of the α-keto amide <b>97</b> was designed to preserve the H-bond accepting function of the isoquinoline ring N atom of prototype compound <b>95</b> while introducing the potential for both conformational relaxation and, by manipulation of the keto moiety, the incorporation of substituents that explored new vectors.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> The addition of mandelic acid caps to the core pyrrolidine rings afforded the diastereomeric alcohols <b>98</b> and <b>99</b> that exhibited discordant antiviral activity, with the (<i>R</i>)-isomer <b>98</b> 190-fold more potent than the (<i>S</i>)-analogue <b>99</b> toward the GT-1b replicon, although the GT-1a replicon was far less discriminatory (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). More interestingly, the antiviral activities associated with the methyl carbinols <b>100</b> and <b>101</b> were similarly discordant but potency was resolved in a complementary fashion with respect to the absolute configuration since the (<i>S</i>)-isomer <b>101</b> was more potent than the (<i>R</i>)-isomer <b>100</b>, particularly toward the GT-1a replicon where the values were titrated.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Antiviral activity of the series of stilbene-based proline amide HCV NS5A RCIs <b>97</b>–<b>101</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While this survey of the cap elements was being conducted, structural changes to the core had continued to be explored in parallel, which facilitated the hybridization of several of the key discoveries and concepts with SAR developments that emerged from modifications to the cap elements.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Replacement of the olefin moiety of the stilbene <b>90</b> with an alkyne was designed to address the cis–trans isomerism problem, and although the antiviral profile of <b>102</b> was poorly balanced with potent GT-1b but low GT-1a inhibition, substitution of the phenylacetic acid cap was restorative (<a class="ref internalNav" href="#tbl10" aria-label="Table 10">Table 10</a>). The (<i>R</i>)-dimethylamino derivative <b>103</b> demonstrated potent and more balanced antiviral properties, while the (<i>S</i>)-isomer <b>104</b> was considerably less impressive as an inhibitor of GT-1a replication. The (<i>R</i>)-NHCO<sub>2</sub>CH<sub>3</sub> analogue <b>105</b> performed similarly to <b>103</b>, leading to the suggestion that a H-bond donor in the cap element was an important pharmacophoric element, particularly for GT-1a inhibition, and fulfilled in <b>103</b> by the protonated form of the dimethylamine functionality. This hypothesis was supported by the lesser antiviral activity associated with the morpholine derivative <b>106</b> compared to what is presumed to be the (<i>R</i>)-<i>N</i>-methylpiperazine <b>107</b> where the potency differences were attributed to their likely divergent protonation states at physiological pH.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. SARs Associated with 1,2-Diphenylethyne-Based HCV NS5A RCIs <b>102</b>–<b>107</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0028.gif" alt="" id="fx39" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0029.gif" alt="" id="fx40" /></img><div></div></div><div class="NLM_p">The potent antiviral activity associated with <b>103</b> and <b>105</b> provided a structural basis from which to explore functional alternatives to the anilide moiety that were designed to abrogate the potential for the in vivo release of an aniline derivative.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Both the NH and carbonyl oxygen atom of the anilide moiety were considered to be of importance for antiviral activity based on the extant SARs, and it was recognized that both of these structural elements could be preserved in a benzimidazole heterocycle. However, this motif alters the topology of the vectors between the core and the terminal cap elements, providing a potential explanation for the weaker GT-1a inhibition observed with both <b>108</b> and <b>109</b> when compared to their anilide analogues. In order to restore the topological relationship between the cap elements and the core, additional structural adjustments were given consideration. Recognition that the linearity associated with the 1,2-diphenyl alkyne core of <b>103</b> and <b>105</b> could be reproduced by a biphenyl system led to this scaffolding element being explored, but its deployment required a compensatory structural adjustment based on the appreciation that this modification would shorten the spatial relationship between the two cap elements. This topology problem was addressed by dismantling the fused ring system of the heterocycle in a process of deannelation, which identified an imidazole–phenyl–phenyl–imidazole motif as a potential core on which to deploy the cap elements, a design process delineated in <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0041.gif" alt="" id="fx12" /></img></div><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0009.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structural evolution of the 1,2-diphenyl alkyne core of NS5A inhibitors to that of an imidazole–4,4′-biphenyl–imidazole motif.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This concept was reduced to practice in the context of the phenylglycine derivatives <b>110</b> and <b>111</b>, both of which expressed potent and balanced antiviral activity in the GT-1a and GT-1b replicons.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> However, these compounds could not be progressed further because of an absence of plasma and liver exposure following oral administration to rats. The approach adopted to address this deficiency focused on assessing the effect of reducing the molecular weight of the molecule by abridging the aromatic rings of the phenylglycine moieties to simpler and more sp<sup>3</sup> carbon atom-rich isopropyl substituents. Implementation of this concept led to the synthesis of the bis-<span class="smallcaps smallerCapital">d</span>-valine derivative <b>112</b>, but this compound suffered from a dramatic 44 000-fold decline in potency toward the GT-1a virus, although GT-1b inhibition was affected to a much lesser extent (29-fold). Further probing of this SAR observation revealed that manipulation of just a single phenylglycine to smaller structural elements resulted in significant declines in GT-1a inhibition, with values ranging from 400 to 11 000-fold.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Although this result was somewhat perplexing and markedly disappointing, the two representative compounds <b>113</b> and <b>114</b> were nevertheless advanced into PK studies in an effort to substantiate the validity of the proposed strategy. Both compounds exhibited poor oral bioavailability in the rat but were somewhat improved in the mouse and considerably better in the dog, where the fraction of the dose reaching the systemic circulation was 60% for <b>113</b> and 45% for <b>114</b>. Despite the poor oral bioavailability of <b>114</b> in rats (6.8%), an oral dose of 5 mg/kg delivered liver levels of 116 nM measured at 24 h postdose, with 26-fold lower levels in plasma at this time point. Collectively, these data were viewed from the positive perspective of providing support for the strategy of reducing molecular weight in order to improve oral exposure.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0042.gif" alt="" id="fx13" /></img></div><div class="NLM_p">With these results in hand, further attention was focused on modifying the cap moieties where the effort was directed toward identifying compounds that combined high antiviral potency with diminutive C-α substituents. While considerable experimentation was devoted to the exploration of analogues and homologues of <b>113</b> and <b>114</b>, it was the synthesis and evaluation of the unsymmetrical derivative <b>115</b>, in which one of the cap elements of <b>114</b> has been exchanged for an <i>N</i>-methoxycarbonyl-<span class="smallcaps smallerCapital">l</span>-alanine moiety, that provided the seminal and unanticipated insight. Compound <b>115</b> demonstrated subnamomolar EC<sub>50</sub> values in the HCV genotype replicons, and potent antiviral activity was preserved in the fully symmetrical homologue <b>116</b> that incorporated the natural amino acid at each cap. Homologation of <span class="smallcaps smallerCapital">l</span>-Ala to <span class="smallcaps smallerCapital">l</span>-Val afforded <b>117</b> (BMS-790052), the molecule that would eventually be identified as daclatasvir, which is 5- to 10-fold more potent than the alanine progenitor.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> The SARs surrounding the amino acid nitrogen and C-α substituents were quickly and systematically explored, guided, in part, by established insights, and the most promising inhibitors were profiled in PK studies. This initiative identified <b>117</b> and the unsymmetrical compound <b>118</b> as the leading contenders for nomination to advance into IND-enabling toxicology studies, and the antiviral properties and PK profiles of these two compounds are compiled in <a class="ref internalNav" href="#tbl11" aria-label="Tables 11">Tables 11</a> and <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a>, respectively. The antiviral data reveal that both compounds exhibit potent activity toward all of the genotype replicons and hybrid replicons tested with comparable EC<sub>50</sub> values, with the exception of GT-3a virus where <b>118</b> is an order of magnitude more potent than <b>117</b>. The PK profiles show some differences, with the plasma exposure (AUC and concentration at 24 h) of <b>118</b> lower than that for <b>117</b>, although the liver levels of both compounds in the rat were high. The unsymmetrical <b>118</b> exhibited a more hepatotropic profile than <b>117</b> based on the ratio of the 24 h drug levels, while the oral bioavailability of <b>117</b> was higher across the species than <b>118</b>. In an effort to further differentiate the compounds, both were assessed in a 4-day toxicological study conducted in mice where both were well tolerated, but the analysis of plasma, liver, and heart levels revealed a 2-fold accumulation of <b>118</b> at all doses over the 4 days of study while the tissue levels of <b>117</b> were similar on days 1 and 4, an observation that led to the selection of <b>117</b> for advancement.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0043.gif" alt="" id="fx14" /></img></div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Antiviral and Preclinical PK Profile of <b>117</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="2" align="center">Antiviral Activity</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">replicon</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (pM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1a</td><td class="colsep0 rowsep0" align="left">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1b</td><td class="colsep0 rowsep0" align="left">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-2a (JFH)</td><td class="colsep0 rowsep0" align="left">71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-2a (JFH)<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">103</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-3a<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">146</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-4a<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-5a<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">33</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="4" align="center">Pharmacokinetic Profile after Oral Dosing<a class="ref internalNav" href="#t11fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">species (dose, mpk)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">rat (5)</th><th class="colsep0 rowsep0" align="center">dog (2.3)</th><th class="colsep0 rowsep0" align="center">cynomolgus monkey (2.8)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (μM·h)</td><td class="colsep0 rowsep0" align="left">4.8</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">1.93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma concn (nM) at 24 h</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">6.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver concn (nM) at 24 h</td><td class="colsep0 rowsep0" align="left">103</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">108</td><td class="colsep0 rowsep0" align="left">38</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup>a</sup><p class="last">Data from hybrid replicons.</p></div><div class="footnote" id="t11fn2"><sup>b</sup><p class="last">ND = not determined.</p></div></div></div><div class="NLM_table-wrap" id="tbl12"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 12. Antiviral and Preclinical PK Profile of <b>118</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="2" align="center">Antiviral Activity</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">replicon</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (pM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1a</td><td class="colsep0 rowsep0" align="left">36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1b</td><td class="colsep0 rowsep0" align="left">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-2a (JFH)</td><td class="colsep0 rowsep0" align="left">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-3a<a class="ref internalNav" href="#t12fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-4a<a class="ref internalNav" href="#t12fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-5a<a class="ref internalNav" href="#t12fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">21</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="4" align="center">Pharmacokinetic Profile after Oral Dosing<a class="ref internalNav" href="#t12fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">species (dose, mpk)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">rat (5)</th><th class="colsep0 rowsep0" align="center">dog (3.5)</th><th class="colsep0 rowsep0" align="center">cynomolgus monkey (3.0)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (μM·h)</td><td class="colsep0 rowsep0" align="left">0.165</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">0.497</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma concn (nM) at 24 h</td><td class="colsep0 rowsep0" align="left">BD</td><td class="colsep0 rowsep0" align="left">9.0</td><td class="colsep0 rowsep0" align="left">4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver concn (nM) at 24 h</td><td class="colsep0 rowsep0" align="left">178</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">3.6</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="left">20.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t12fn1"><div class="footnote" id="t12fn1"><sup>a</sup><p class="last">Data from hybrid replicons.</p></div><div class="footnote" id="t12fn2"><sup>b</sup><p class="last">BD = below the level of detection. ND = not determined.</p></div></div></div><div class="NLM_p">While addressing the GT-1a inhibition had proven to be a significant challenge, the solution that was ultimately devised encompassed all of the genotypes that were available for testing in replicons or hybrid replicons at the time of compound nomination. As <b>117</b> was advancing toward clinical studies, an infectious GT-2a virus was developed that was found to be sensitive to the compound with an EC<sub>50</sub> value of 28 pM, potency comparable to that recorded in the GT-2a hybrid replicon.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> This result provided additional confidence in the potential of a first-in-class molecule that targeted a protein with no known enzymatic activity and imprecisely and poorly defined functions in the viral lifecycle. That the chemotype represented by <b>117</b> bound to the NS5A protein was established in studies with the biotinylated probe <b>119</b> which was synthesized and evaluated in replicons along with the analogue in which both prolines were of the unnatural <span class="smallcaps smallerCapital">d</span>-configuration. The chemical probe <b>119</b> inhibited replication of the GT-1b replicon with an EC<sub>50</sub> value of 33 nM, antiviral activity that was sensitive to the Tyr93His mutation, EC<sub>50</sub> > 10 μM, while the analogue with the unnatural <span class="smallcaps smallerCapital">d</span>-proline moieties was inactive, EC<sub>50</sub> > 10 μM. The initial pull-down experiments that were conducted with <b>119</b> followed a design in which the probe was incubated with GT-1b replicon cell lysates before the mixture was passed over a streptavidin column, separated by SDS–polyacrylamide gel electrophoresis and then probed with an antibody specific for HCV NS5A. However, this protocol failed to isolate significant amounts of viral protein and the experiment was redesigned such that <b>119</b> was incubated in the GT-1b replicon for 18 h before the cells were lysed, passed over the streptavidin column, separated by SDS–polyacrylamide gel electrophoresis, and then probed with antibodies. This experiment pulled down the HCV NS5A protein but neither NS3 nor NS5B could be detected by antibody probes, while the inactive <span class="smallcaps smallerCapital">d</span>-proline-based diastereomer failed to pull down any viral proteins. More recent studies have demonstrated the binding of <b>117</b> and structurally related inhibitors to the NS5A protein using complementary experimental techniques.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0044.gif" alt="" id="fx15" /></img></div><div class="NLM_p">An X-ray crystal structure of a portion of the amino terminus (domain 1) of HCV NS5A was published 3 years after the discovery of the stilbene inhibitor chemotype and revealed a dimeric species in which the geometry of the protein interface created a U-shaped surface rich in basic amino acids, suggested to be an RNA binding domain.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> This solid state structure complemented the palindromic topology that we had discovered with <b>83</b>, <b>89</b>, and <b>90</b> and which is retained in <b>117</b>, and the location of resistance mutations suggested a binding site located between the NS5A protein and the membrane, with the compounds spanning the dimer interface to engage both protein monomers.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Subsequent X-ray structures of NS5A have confirmed the preferred shape of the protein but identified alternate dimer interfaces that anticipate an oligomeric species. This concept provides a potential explanation for calculations that suggest that at the EC<sub>50</sub> concentration in replicons, the molecular ratio of NS5A to <b>117</b> in cells is approximately 47 000 which translates to 1 molecule of <b>117</b> for 23 500 dimers of NS5A.<a onclick="showRef(event, 'ref90 ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref90 ref91 ref92">(90-92)</a> In addition, the RNA binding properties of NS5A have been confirmed and the dimeric association of the protein has been shown to be important for viral replication in replicons.<a onclick="showRef(event, 'ref88 ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref88 ref93 ref94">(88, 93, 94)</a></div><div class="NLM_p">Phase 1 clinical trials with <b>117</b> began with a randomized, double-blind SAD study conducted in NHVs which revealed dose-related increases in plasma exposure of the drug which was administered over the dose range of 1–200 mg as an oral solution.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The drug was well tolerated, with concentrations in plasma measured at 24 h postdose and beyond above the protein binding-adjusted EC<sub>90</sub> value determined in the less sensitive GT-1a replicon at all doses tested, reflecting a long plasma half-life, data that collectively predicted the potential for once daily (q.d.) dosing. On the basis of these results, doses of 1, 10, and 100 mg were selected for proof-of-concept studies which were conducted in HCV GT-1-infected subjects. Plasma exposure values of the drug in these individuals were comparable to those in the NHVs given the same dose, with concentrations of <b>117</b> at 24 h determined to be more than 10-fold above the GT-1a protein binding-adjusted EC<sub>90</sub> value. At the lowest 1 mg dose, plasma viremia declined significantly and rapidly over 24 h following drug administration, with a mean maximal reduction of 1.8 log<sub>10</sub> IU/mL, while the 10 and 100 mg doses were associated with more profound mean maximal declines in viral load of 3.2 and 3.6 log<sub>10</sub> IU/mL, respectively, with the latter occurring at 48 h postdose (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> One of the subjects receiving the 100 mg dose achieved a viral load that was below the assay detection limit and that persisted for the entire 144 h follow-up period. The rate at which viral load declined following dosing with <b>117</b> was considerably faster than had been observed with NS3 protease and NS5B RdRp inhibitors. This was subsequently attributed to an inhibitory effect of <b>117</b> on virus assembly that resulted in an immediate interruption of virion production, a property of the molecule that could not have been anticipated based on replicon studies where effects on virion assembly are not assessed.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Several biochemical studies have identified a role for the NS5A protein in virion assembly, but the mapping studies conducted to date have implicated domain III, the carboxy terminus domain of the protein, as the critical protein element.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a></div><figure id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0010.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Mean maximal reductions in viral load following oral administration of <b>117</b> to HCV-infected subjects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">4 Discovery of the Allosteric HCV NS5B Polymerase Inhibitor Beclabuvir</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26764" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26764" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The third mechanistic approach to controlling HCV replication that we explored was a program focused on inhibitors of the NS5B RdRp. This initiative was developed in parallel with inhibitors of HCV NS3 protease and the NS5A replication complex as part of a vision that anticipated combination clinical therapy. Studies of NS5B inhibitors began with <b>120</b> and <b>121</b>, prototypes of benzimidazole carboxylate-based allosteric inhibitors and an indole amide series reported in the literature, that exhibited modest antiviral activity in the GT-1b replicon with EC<sub>50</sub> values of 400 and 100 nM, respectively.<a onclick="showRef(event, 'ref97 ref98'); return false;" href="javascript:void(0);" class="ref ref97 ref98">(97, 98)</a> However, both compounds were of high MW (664 and 589 Da, respectively), lipophilic in nature (cLogP = 6.7 and 6.3, respectively) and incorporated high sp<sup>2</sup> atom content, data that in a retrospective analysis translated into poor LLE values of −0.27 for <b>120</b> and 0.74 for <b>121</b>, based on the replicon data. The pharmacophore inherent to these molecules was reduced to its simplest representation in the context of indole carboxylic acid <b>122</b> which, although demonstrating modest potency in the GT-1b replicon, represented an improvement when viewed through the lens of physicochemical properties. This compound was active in a NS5B enzyme biochemical assay, IC<sub>50</sub> = 120 nM, and was of considerably lower molecular weight with a reduced burden of sp<sup>2</sup> carbon atom count. Conformational constraint was explored by linking the indole N-substituent to the ortho position of the 2-phenyl ring, a concept evaluated initially with the simple alkyl chain incorporated in <b>123</b>, which resulted in a modest enhancement of antiviral potency. Both activity and physicochemical properties were further improved by the introduction of a polar amide moiety into the bridging element which afforded <b>124</b> in the initial iteration, a functionality that simultaneously provided an opportunity to explore new vectors of structural modification. The in vitro criteria set for compound progression for this series were identical to those established for NS3 and NS5A inhibitors with target EC<sub>50</sub> values of <10 nM in the GT-1a and GT-1b replicons. This criterion was met for GT-1b inhibition with the cinnamic acid derivative <b>125</b>, but this compound exhibited poor oral exposure in rats with a measured <i>F</i> value of just 3%.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> The absence of a correlation between antiviral potency and the dihedral angle that defines the relationship between the indole and 2-phenyl rings was interpreted as suggestive of a specific interaction between the bridging elements and the NS5B enzyme. This concept was explored by an X-ray cocrystallographic structure of <b>125</b> bound to the GT-1b NS5B enzyme that helped to guide further structural modification and refine models of drug–target association. The NS5B enzyme adopts the typical shape of RNA polymerases, metaphorically that of a right hand in which the active site is located in the palm region and the fingers element binds to the thumb domain in a process that closes the enzyme around the template and primer to initiate RNA polymerization.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> In the X-ray structure, the indole derivative <b>125</b> bound to one part of an extended groove in the thumb domain, preventing association with elements of the fingers domain and thereby inhibiting the initiation of RNA synthesis. The cyclohexyl moiety of <b>125</b>, which had been established to be an essential component of the pharmacophore, occupied a small lipophilic pocket in the enzyme that is filled by an element of the fingers domain when the enzyme adopts its active conformation. The 2-phenyl ring occupied a small hydrophobic cleft, with a dihedral angle of ∼46° with respect to the core heterocycle, while the indole C-6 amide moiety established a H-bond with Arg503 and the terminal carboxylic acid interacted with Arg503.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Interestingly, the amide moiety in the bridging element projected away from the thumb domain and made no specific contacts with the enzyme, although elements of the finger domain that may productively interact with this moiety in a complex were disordered in the structure.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0045.gif" alt="" id="fx16" /></img></div><div class="NLM_p">While the PK profile in of <b>125</b> in the rat was poor, the oral exposure of the simpler prototype <b>124</b> was higher, although the exposure was far from that targeted in a potential clinical candidate due to the combination of high clearance (35 mL min<sup>–1</sup> kg<sup>–1</sup>) and modest bioavailability (<i>F</i> = 17%). Nevertheless, this molecule became the basis for further structural optimization which initially established that a phenyl ring at C-2 of the indole was the preferred substituent.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> A modification to the bridging tether that proved to be the most productive was translocation of the amide moiety from an endocyclic disposition to one in which it was exocyclic to the fused ring. However, synthetic access to this ring system was problematic, with the olefin metathesis ring closure from <b>126</b> depicted in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> typically affording poor yields of <b>127</b>.<a onclick="showRef(event, 'ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref101 ref102">(101, 102)</a> A synthetic approach that relied upon a tandem Michael addition/Wadsworth–Emmons reaction to effect ring construction was devised that was based on exposing the indole aldehyde <b>128</b>, which existed predominantly in the hemiaminal form depicted in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, to methyl 2-(dimethoxyphosphoryl)acrylate (<b>129</b>) in the presence of Cs<sub>2</sub>CO<sub>3</sub>, a procedure that afforded the unsaturated diester <b>127</b> directly in 96% overall yield.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> The bridgehead ester moiety could be hydrolyzed selectively to afford <b>130</b> in 97% yield, while the use of a <i>tert</i>-butyl ester at C-6 of the indole allowed selective unmasking of this moiety under acidic conditions while preserving the bridge-based ester. This synthetic protocol provided ready access to differentially substituted analogues and significantly expedited SAR studies.</div><figure id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0017.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Approach Developed To Access 6-Carboalkoxy-13-cycloalkyl-5<i>H</i>-indolo[2,1-<i>a</i>][2]benzazepine-10-carboxylic Acid Derivatives</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the saturated series derived from <b>127</b> and <b>130</b>, the morpholine amide <b>131</b> exhibited good potency in the GT-1b replicon while the unsaturated congener <b>132</b> was 2-fold weaker but with balanced inhibition of GT-1a and GT-1b virus replication. However, the PK profile of <b>131</b> in the rat was poor, with oral bioavailability determined to be just 4% despite good permeability in a PAMPA assay and high metabolic stability in human LM in vitro. The poor PK performance was attributed to facile acyl glucuronide formation in vivo, precipitating a study of carboxylic acid replacements that would confer resistance to this metabolic pathway. The (<i>N</i>,<i>N</i>-dimethylsulfamoyl)amide <b>133</b> provided improved antiviral activity that was further enhanced by the introduction of a 4-MeO substituent to the phenyl ring (<b>134</b>). Compound <b>133</b> was 30% orally bioavailable in the rat at a dose of 5 mpk, delivering liver levels of 24 μM determined at 4 h postdose in a snapshot PK experiment. However, <b>133</b> exhibited poor aqueous solubility (<1 μg/mL), and in vitro profiling in liability assays revealed the burden of PXR activation with an IC<sub>50</sub> of 440 nM, activity that predicted a potential for drug–drug interactions.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> This was of concern for a molecule anticipated to be used in combination therapy and was addressed by substitution of the morpholine ring α to the oxygen atoms from which <b>135</b> emerged as a benchmark compound with potent and balanced GT-1a and GT-1b inhibition, a PXR IC<sub>50</sub> value of >10 μM and high liver levels of 33 μM in rats measured at 4 h after an oral dose of 10 mg/kg. In parallel with these studies, modification of the olefin in the bridge had been examined with a view to optimizing drug–target interactions and abrogating any potential problem with the unsaturated amide acting as a Michael acceptor. Cyclopropanation of <b>133</b> afforded the two enantiomers <b>136</b> and <b>137</b>, of which the (<i>R</i>,<i>S</i>)-antipode <b>137</b> was found to be 6- to 10-fold more potent than (<i>S</i>,<i>R</i>)-isomer <b>136</b>.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> The cyclopropane structural motif was adopted for the remainder of the studies with this chemotype, advantageous in the context of a hybrid of the morpholine and phenyl substitution pattern which afforded <b>138</b> as a compound with replicon inhibitory potency that met criteria for progression. However, PXR transactivation remained problematic with <b>138</b> despite the incorporation of the morpholino 3-methyl substituents that had been discovered with <b>135</b>.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0046.gif" alt="" id="fx17" /></img></div><div class="NLM_p">SARs for PXR activation to this point had indicated that adding polar substituents proximal to the morpholine oxygen atom was beneficial, and the next phase of study focused on surveying more polar morpholine mimetics. While some progress was made with modifying the morpholine ring, it was replacement of this heterocycle with a piperazine that provided a productive path forward. The piperazine element combined polarity at a region of the pharmacophore that was beneficial for reducing PXR activation with a solubilizing element that concomitantly addressed the persistent problem of poor solubility with these BCS class 2 compounds. The trimethyl piperazinamide <b>139</b> exhibited an encouraging PK profile, with oral bioavailability of 17% and liver levels of 7.5 μM measured 4 h after a 10 mg/kg dose to rats, no PXR activation issue (EC<sub>50</sub> > 50 μM), and higher solubility (34 μg/mL as amorphous material). The final steps toward the identification of beclabuvir (<b>142</b>, BMS-791325) explored the introduction of a bridging element in the piperazine ring which identified differences in potency and, most notably, PK properties based on its relative location with respect to the core indole heterocycle. Installation of an ethylene bridge distal to the indole core, as represented by the racemic mixture <b>140</b>, was associated with lower antiviral potency compared to its racemic isomer <b>141</b>. The PK profiles of <b>140</b> and <b>141</b> in the rat differed more markedly, with iv clearance of the former measured as 20.6 mg mL<sup>–1</sup> kg<sup>–1</sup> while liver levels were 0.7 μM 4 h after a 10 mg/kg dose. In contrast, the iv clearance for <b>141</b> was much lower at 7.2 mg mL<sup>–1</sup> kg<sup>–1</sup> and a 10 mg/kg oral dose delivered liver levels at 4 h of 55.4 μM. Resolution of <b>141</b> identified <b>142</b> as the eutomer that displayed EC<sub>50</sub> values of 3 and 6 nM for GT-1a and GT-1b inhibition, respectively, while the distomer displayed EC<sub>50</sub> values of 208 and 200 nM toward GT-1a and GT-1b replicons, respectively.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0047.gif" alt="" id="fx18" /></img></div><div class="NLM_p">The in vitro profiling data for <b>142</b> that are compiled in <a class="ref internalNav" href="#tbl13" aria-label="Table 13">Table 13</a> reveal a compound with potent inhibitory activity toward HCV NS5B enzymes and replicons derived from GT-1, GT-3, GT-4, GT-5, and GT-6 while representative GT-2 enzymes and replicons are less sensitive.<a onclick="showRef(event, 'ref101 ref104 ref105 ref106'); return false;" href="javascript:void(0);" class="ref ref101 ref104 ref105 ref106">(101, 104-106)</a> Mechanistic studies indicated that <b>142</b> is a time-dependent, noncompetitive inhibitor of the polymerase that interferes with initiation of replication, with resistance mapping to a Pro495Leu mutation located in the thumb domain and a Leu30Ser change located in the Δ1 loop of the fingers domain.<a onclick="showRef(event, 'ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref106 ref107">(106, 107)</a> A two-step binding mechanism was determined from biochemical and biophysical experiments, with the Pro495Leu mutation modulating the kinetics of the second binding step such that the dissociation rate of the compound is faster than for wild type enzyme. In contrast, <b>142</b> bound several-fold faster to the Leu30Ser resistant enzyme, but the forward and reverse processes to form the final complex were found to be equivalent.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></div><div class="NLM_table-wrap" id="tbl13"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 13. In Vitro Profiling Data for <b>142</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">HCV NS5B enzyme assay</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center">result</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1a</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">HCV GT-1a replicon</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 3 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1b</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">HCV GT-1b replicon</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 6 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-2a JFH-1</td><td class="colsep0 rowsep0" align="left">165</td><td class="colsep0 rowsep0" align="left">HCV GT-2a JFH-1 replicon</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 87 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-2b</td><td class="colsep0 rowsep0" align="left">164</td><td class="colsep0 rowsep0" align="left">40% human serum effect</td><td class="colsep0 rowsep0" align="left"><5-fold</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-3a</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">BVDV replicon</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> > 14 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-4a</td><td class="colsep0 rowsep0" align="left">19.9</td><td class="colsep0 rowsep0" align="left">poliovirus, rhinovirus, coronavirus, coxsackie virus, HIV-1, influenza virus</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> > 14 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-5a</td><td class="colsep0 rowsep0" align="left">4.8</td><td class="colsep0 rowsep0" align="left">cytotoxicity (7 cell lines)</td><td class="colsep0 rowsep0" align="left">EC<sub>50</sub> = 14–30 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-6a</td><td class="colsep0 rowsep0" align="left">61.6</td><td class="colsep0 rowsep0" align="left">mammalian polymerases α, β, γ</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> > 25 μM</td></tr></tbody></table></div></div><div class="NLM_p">Additional preclinical profiling established the aqueous solubility of <b>142</b> to be >1.6 mg/mL at pH = 2.2 and pH = 7.8, but this was reduced considerably at pH 6.5 (∼0.02 mg/mL), reflecting the amphoteric nature of the molecule which has p<i>K</i><sub>a</sub> values of 4.6 and 6.8. Protein binding was found to be 98.8% for human and 97.8–98.7% for the other species tested, and while permeability across an artificial membrane was high, efflux was observed in Caco-2 cells, an indication that <b>142</b> was a P-gp substrate although it was not an inhibitor. Demethylation of the sulfamide moiety of <b>142</b> was observed in LM, and the compound was determined to be a substrate of CYP 3A4, forming <b>143</b> (BMS-794712), a compound with antiviral activity comparable to <b>142</b> but which exhibited poor oral bioavailability in preclinical species thereby precluding consideration of this metabolite as a potential clinical candidate.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0048.gif" alt="" id="fx19" /></img></div><div class="NLM_p">In phase 1 clinical trials, single doses of 100, 300, 600, and 900 mg of <b>142</b> were administered to IFN-α-naive and -experienced, HCV GT-1-infected subjects following a double blind, placebo-controlled study design that was conducted after a standard SAD evaluation in NHVs to assess PK and establish tolerability.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Plasma concentrations of <b>143</b> increased in a dose-related fashion and were maximal between 2 and 4 h postdose, with plasma levels at 24 h exceeding the protein-binding-adjusted EC<sub>90</sub> value in the GT-1 replicon. The exposure profile of the metabolite <b>143</b> was similar to <b>142</b>, but the plasma AUC was ∼22% of that of the parent drug. In general, <b>142</b> was well tolerated in these studies with no serious adverse events or discontinuations noted and plasma viral load declined by 1.30–2.78 log<sub>10</sub> IU/mL, with the higher doses associated with improved efficacy (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>). These results were sufficient to encourage further clinical study of the compound (vide infra).</div><figure id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0011.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Mean maximal reductions in viral load following oral administration of <b>142</b> to HCV-infected subjects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">5 Clinical Trials with Direct-Acting HCV Inhibitors and the Development of Highly Effective and Curative Combination Therapies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01724" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01724" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The initial clinical trials with direct-acting HCV inhibitors typically established efficacy after a single dose of drug or following several days of dosing as monotherapy and were followed by combination studies with PEG-IFN-α and <b>12</b>. The NS3 protease inhibitor <b>13</b> was the first HCV DAA to demonstrate a clinical effect on viral load following oral dosing, results that were reported in 2002 (<a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>). NM-283 (<b>144</b>), administered as its C-3′ valine ester prodrug valopicitabine (<b>145</b>), and nesbuvir (HCV-796, <b>146</b>) established proof-of-concept for active site nucleoside analogue and allosteric NS5B RdRp inhibitors in 2004 and 2006, respectively, while daclatasvir (<b>117</b>) was the pioneering NS5A inhibitor, with efficacy in HCV-infected subjects disclosed in 2008 (<a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>). While <b>13</b> was abandoned without progressing further because of preclinical cardiotoxicity, <b>145</b> and <b>146</b> were advanced into phase 2 clinical trials where they were evaluated in conjunction with PEG IFN-α and <b>12</b>.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> However, while both compounds augmented the effects of PEG IFN-α and <b>12</b> on viral load, both were abandoned because of toxicity issues (gastrointestinal toxicity for <b>145</b> and hepatotoxicity for <b>146</b>) that were observed several weeks into a phase 2 combination study. Despite their shortcomings, these compounds provided important insights into the development of HCV DAAs and helped to define a path to approval for the first small molecules <b>10</b> and <b>11</b> which were licensed in the spring of 2011 as add-on therapy to PEG IFN-α and <b>12</b>.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> The addition of either of these drugs to a backbone of PEG IFN-α and <b>12</b> improved SVR response rates significantly, but these regimens still required 24–48 weeks of therapy; both DAAs were administered on a t.i.d. schedule, and both were associated with additional side effects that added to the considerable burden imposed by the SOC backbone.<a onclick="showRef(event, 'ref113 ref114 ref115'); return false;" href="javascript:void(0);" class="ref ref113 ref114 ref115">(113-115)</a> Ultimately, the marketing of both <b>10</b> and <b>11</b> in the U.S. was abandoned by their sponsors late in 2014 due to the combination of lower efficacy in a real world setting than had been observed in clinical trials and a poor side effect profile (<b>10</b> acquired a black box warning for problems associated with severe rash), a decision that reflected a response to the rapidly changing availability of HCV DAA therapeutic agents with improved antiviral and side effect profiles.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> What, however, was not abundantly clear at the time that these early clinical trials were conducted was whether PEG IFN-α and/or <b>12</b> would remain as an important component of SOC and whether shorter durations of therapy would be effective at producing a SVR.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0049.gif" alt="" id="fx20" /></img></div><figure id="fig12" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0012.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Historical timelines for key events in the development of HCV DAAs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The anticipation of the need for combinations of DAAs for effective HCV therapy was confirmed with early clinical trials, notably in studies with <b>10</b> where resistance emerged within 2 weeks of starting treatment.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Despite its markedly increased potency and efficacy, resistance also proved to be problematic with <b>117</b> when viral rebound was observed in a 14-day monotherapy study, with GT-1a virus evolving resistance more rapidly than GT-1b virus.<a onclick="showRef(event, 'ref110 ref119'); return false;" href="javascript:void(0);" class="ref ref110 ref119">(110, 119)</a> This is a function of the underlying viral genetic constitution where only a single base pair change is typically required for GT-1a virus to encode for an alternative amino acid in contrast to the two base pair changes that are necessary for GT-1b virus.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> This result clearly indicated a need for combination therapy, and two phase 3 clinical trials of <b>117</b> with PEG IFN-α and <b>12</b> were embarked upon where it was demonstrated that the therapeutic regimen could be shortened to 24 weeks of treatment with equivalent or improved efficacy as measured by SVR<sub>24</sub> and without the burden of additional side effects.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> In a similar clinical protocol conducted in treatment-naive GT-1 and GT-4 infected subjects in which <b>64</b> (200 mg b.i.d.) was combined with PEG IFN-α and <b>12</b>, 24 weeks of therapy were associated with SVR<sub>24</sub> rates of 64% and 89% compared to 44% and 43% in the placebo groups, respectively.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> However, compounds <b>64</b> and <b>117</b> had entered clinical trials in a contemporaneous fashion with safety and efficacy data obtained in parallel, a circumstance that presented a unique opportunity to conduct a small phase 2 clinical trial of the dual combination therapy.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> This study was not the first clinical trial of a combination of DAAs, since the NS3 inhibitor danoprevir (<b>147</b>) and the nucleoside-based NS5B inhibitor mericitabine (<b>148</b>), a bis-valine ester prodrug, had been administered to noncirrhotic subjects chronically infected with HCV GT-1.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> However, this clinical study relied upon a protocol of 13 days of dosing with the dual DAA combination followed by a day of drug washout and then 46 weeks of therapy with PEG IFN-α and <b>12</b> and was thus not designed to assess the full potential of an interferon-free DAA regimen.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> In contrast, the study of the combination of <b>64</b> and <b>117</b> was specifically designed to evaluate the full potential of the two drugs in a cohort of 21 GT-1-infected null responders, a difficult-to-treat patient population who had failed to respond to therapy with PEG IFN-α and <b>12</b>.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Most of the patients (19 of 21, 90%) selected for the study of the combination of <b>64</b> and <b>117</b> were determined to have an unfavorable IL28B CT or TT genotype that had been established as being predictive of a lack of response to PEG IFN-α rather than the CC genotype that predicts sensitvity.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> The 21 patients were randomized into two groups, designated A and B, with A receiving <b>64</b> (600 mg q.d.) and <b>117</b> (60 mg b.i.d.) while group B received the two DAAs administered on the same dosing regimen in combination with PEG IFN-α and <b>12</b>, with both arms scheduled to examine the outcome of 24 weeks of combination therapy. The cohort receiving the quadruple therapeutic regimen achieved 100% SVR<sub>12</sub>, and 90% achieved SVR<sub>24</sub>, with one patient experiencing detectable but not quantifiable HCV RNA at week 24 postdosing, although this subject was determined to have undetectable viral RNA 35 days later (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>a).<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> In the dual DAA arm, 36% (4 of 11) of the subjects achieved SVR<sub>12</sub> and all four continued to be free of detectable virus when assessed at 24 weeks after the final dose of the two drugs (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>b). This cohort comprised nine subjects infected with GT-1a virus and two infected with GT-1b of which both GT-1b- and two of the GT-1a-infected subjects were cured of infection. The nine treatment failures were determined to have developed resistance mutations in both the NS3 and NS5A genes, with mutations in the latter including Gln30Arg, Leu31Met or Leu31Val, and Tyr93Cys or Tyr93Asn. Resistance variants in the NS3 protease gene included Arg155Lys and Glu168Ala/Glu/Thr/Val/Tyr, and the single patient in group A who suffered viral relapse in the 12 weeks after drug dosing ended was determined to have the NS3 protease resistance variant Arg155Lys preexisting at baseline and present at the time of viral relapse, while the NS5A resistance variant Gln30Glu was observed only at relapse.<a onclick="showRef(event, 'cit123a'); return false;" href="javascript:void(0);" class="ref cit123a">(123a)</a> The potential for the emergence of resistance in response to HCV DAA therapy has been elegantly explained by a series of studies that have analyzed viral replication rates and half-life in vivo in conjunction with estimates of the rate at which errors are incorporated by the viral polymerase.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> It has been estimated that in an HCV-infected subject, 10<sup>12</sup> virions are produced each day, a replication rate that is 10- to 100-fold higher than that determined for HIV-1, with polymerase error rates estimated at 0.1 per genome synthesized (<a class="ref internalNav" href="#tbl14" aria-label="Table 14">Table 14</a>). This analysis predicts that while 91% of virions will be faithfully reproduced, 9% of the virions produced each day will harbor at least one mutation, with the breakdown anticipating that 87 billion particles will be assembled carrying a single mutation, while 4.2 billion viruses will incorporate two mutations and 130 million virions will be produced with three base pair changes. Since the HCV genomic RNA comprises just over 10 000 bases, the consequence of this analysis is that all single and dual mutations pre-exist and DAA monotherapy will simply and rapidly select for resistant virus.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0050.gif" alt="" id="fx21" /></img></div><figure id="fig13" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0013.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. SVR<sub>12</sub> and SVR<sub>24</sub> rates following 24 weeks of therapy with drug regimens containing <b>64</b> and <b>117</b>. (a) Percentage of patients achieving undetectable HCV RNA in response to the combination of <b>64</b>, <b>117</b>, PEG IFN-α, and <b>12</b> administered to GT-1-infected subjects for 24 weeks. (b) Percentage of patients achieving undetectable HCV RNA in response to the dual combination of the HCV DAAs <b>64</b> and <b>117</b> administered to GT-1-infected subjects for 24 weeks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl14"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 14. Estimated HCV Replication Rates and Predicted Rates of the Production of Mutated Viruses</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="2" align="center">HIV1 and HCV Replication Rates: Virions Produced per Day</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HIV-1</td><td class="colsep0 rowsep0" align="left">10<sup>10</sup> to 10<sup>11</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCV</td><td class="colsep0 rowsep0" align="left">10<sup>12</sup></td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="3" align="center">Daily Production of HCV Mutant Viruses Based on an Error Rate of 0.1 per RNA Synthesized</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no. mutations</th><th class="colsep0 rowsep0" align="center">%</th><th class="colsep0 rowsep0" align="center">virions/day</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="left">910 × 10<sup>9</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">8.7</td><td class="colsep0 rowsep0" align="left">87 × 10<sup>9</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">0.42</td><td class="colsep0 rowsep0" align="left">4.2 × 10<sup>9</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">0.013</td><td class="colsep0 rowsep0" align="left">0.13 × 10<sup>9</sup></td></tr></tbody></table></div></div><div class="NLM_p">Despite the modest clinical success with the dual combination study with <b>64</b> and <b>117</b>, this result was hailed as “a watershed moment in the annals of HCV therapy” because the study demonstrated for the first time that a chronic HCV infection could be cured in the absence of interferon therapy.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> This result set the stage for what would ultimately become an extensive series of clinical trials conducted by multiple pharmaceutical houses examining combinations of DAAs acting by orthogonal mechanisms. These studies defined curative regimens and durations for a broad range of HCV-infected populations, including those with and without liver cirrhosis, those co-infected with HIV-1, those infected with genotypes beyond GT-1, and individuals experiencing reinfection after a liver transplant.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a></div><div class="NLM_p">An expansion of the study of the dual combination of <b>64</b> and <b>117</b> confirmed the results observed with the sentinel cohort in GT-1b-infected subjects and set the stage for development of these two drugs in Japan where this viral subtype is predominant.<a onclick="showRef(event, 'ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref129 ref130">(129, 130)</a> The Pharmaceuticals and Medical Devices Agency (PMDA) granted approval for marketing the combination of <b>64</b> and <b>117</b> in Japan as Daklinza and Sunvepra, respectively, on July 4, 2014, the first HCV DAA combination to be approved worldwide.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> The two-drug combination was studied in two phase 3 clinical trials, one conducted in Japan and the second conducted worldwide, that demonstrated efficacy in a broad range of patient populations, including those naive and nonresponsive to PEG IFNα and <b>12</b> therapy and those either intolerant of or ineligible for this regimen, with a subset of cirrhotic patients included in each trial.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> When administered at doses of 100 mg b.i.d. of <b>64</b> and 60 mg q.d. of <b>117</b> for 24 weeks, the SVR<sub>12</sub> rates in the Japanese study were 81% in nonresponders and 87% in intolerant/ineligible subjects while in the global study SVR<sub>12</sub> rates in these patient populations were 90% and 82%, respectively. In these trials, it was determined that a Tyr93His polymorphism in the NS5A gene was predictive of the clinical outcome, with the probability of achieving SVR declining from 95% to 45% if this mutation pre-existed at baseline.</div><div class="NLM_p">In order to broaden the scope of therapy to include the more difficult to treat GT-1a virus, a fixed dose combination of <b>64</b> (200 mg), <b>117</b> (30 mg), and <b>142</b> (75 mg) was developed to be administered clinically as a b.i.d. regimen to treat GT-1 HCV infection in treatment-naive and treatment-experienced subjects that encompasses those with or without liver cirrhosis.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> In these studies, SVR<sub>12</sub> rates following 12 weeks of therapy were 87–93% dependent upon patient background and the inclusion or exclusion of <b>12</b> as part of the therapeutic regimen, with cure rates in GT-1a-infected subjects somewhat lower than for GT-1b.<a onclick="showRef(event, 'ref132 ref133'); return false;" href="javascript:void(0);" class="ref ref132 ref133">(132, 133)</a></div><div class="NLM_p">Regimens that include <b>117</b> have been used to successfully treat recurrent HCV infection following liver transplantation, with the first example of an SVR reported for the drug in combination with PEG-IFN-α and <b>12</b> therapy for 24 weeks.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> However, it was a study of <b>117</b> in combination with the nucleoside-based HCV NS5B inhibitor sofosbuvir (<b>149</b>), both administered orally daily for 24 weeks, that provided the first example of achieving a SVR in the post-liver-transplant setting using an interferon-free regimen.<a onclick="showRef(event, 'cit134b'); return false;" href="javascript:void(0);" class="ref cit134b">(134b)</a> The patient, who was infected with GT-1b HCV and had plasma RNA levels of 12 × 10<sup>6</sup> IU/mL, had been refractory to therapy with the combination of PEG-IFN-α and <b>12</b>, but the dual combination of <b>117</b> and <b>149</b> resulted in viral RNA being undetectable in plasma 9 months after completing therapy. Combinations of <b>117</b> with the NS3 protease inhibitors <b>64</b> or simeprevir (<b>150</b>), the latter in conjunction with <b>12</b>, have also been found to cure infection following liver transplantation.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0051.gif" alt="" id="fx22" /></img></div><div class="NLM_p">The combination of <b>117</b> and <b>149</b> has been shown to be an effective therapy for the treatment of naive and experienced subjects infected with GT-1 HCV and those co-infected with HIV-1.<a onclick="showRef(event, 'ref135 ref136'); return false;" href="javascript:void(0);" class="ref ref135 ref136">(135, 136)</a> On July 24, 2015, the FDA licensed <b>117</b> for the treatment of HCV GT-3 infection when used in combination with <b>149</b> based on results from the ALLY-3 phase 3 clinical trial, with expansion to include GT-1 infections announced on February 9, 2016. In a phase II clinical trial conducted in GT-1b-infected subjects who were naive to therapy or who had experienced a null response, the combination of <b>117</b> and <b>150</b> with and without <b>12</b> for 12 or 24 weeks was associated with SVR<sub>12</sub> rates ranging from 69.6% to 95%.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a></div><div class="NLM_p">The first fixed dose combination of DAAs to be licensed by the U.S. FDA was a regimen containing <b>149</b> (400 mg) and the NS5A RCI ledipasvir (<b>151</b>, 90 mg) that was approved on October 10, 2014, based on a series of phase 3 clinical trials conducted in HCV-infected subjects with a range of clinical backgrounds.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> This combination, which is well-tolerated and offers the convenience of once daily dosing, is marketed as Harvoni and is associated with cure rates in excess of 90% in the majority of patient populations, as summarized in <a class="ref internalNav" href="#tbl15" aria-label="Table 15">Table 15</a>.<a onclick="showRef(event, 'ref138 ref139'); return false;" href="javascript:void(0);" class="ref ref138 ref139">(138, 139)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0052.gif" alt="" id="fx23" /></img></div><div class="NLM_table-wrap" id="tbl15"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 15. Synopsis of the Clinical Results Observed with Harvoni, a Fixed Dose Combination of <b>149</b> and <b>151</b>, in GT-1 Infected Patients</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">patient population</th><th class="colsep0 rowsep0" align="center">phase</th><th class="colsep0 rowsep0" align="center">status</th><th class="colsep0 rowsep0" align="center">therapy duration (week)</th><th class="colsep0 rowsep0" align="center">SVR<sub>12</sub> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">naive</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">noncirrhotic <10<sup>6</sup> IU/mL RNA</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">93–95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">naive</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">noncirrhotic</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">naive</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">cirrhotic</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">experienced</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">noncirrhotic</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">93–94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">experienced</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">cirrhotic</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HIV co-infected</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">antiretroviral (ARV) naive</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">100</td></tr></tbody></table></div></div><div class="NLM_p">The approval of Harvoni was closely followed by the licensing of Viekira Pak which occurred on December 19, 2015.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Viekira Pak combines the HCV NS3 protease inhibitor paritaprevir (<b>152</b>, 75 mg), the HCV NS5A RCI ombitasvir (<b>153</b>, 12.5 mg), and the CYP 3A4 inhibitor ritonavir (<b>154</b>, 50 mg) to reduce the rate of metabolism of <b>152</b>) in a fixed dose tablet administered on a q.d. schedule that is co-packaged with tablets of the allosteric HCV NS5B inhibitor dasabuvir (<b>155</b>, 250 mg) which is taken twice daily for 12 weeks for the treatment of GT-1b infection. The treatment of GT-1a infection requires the addition of <b>12</b> for 12 weeks of therapy in the absence of cirrhosis which extends to 24 weeks for those with this clinical background. A synopsis of the clinical efficacy of Viekira Pak is compiled in <a class="ref internalNav" href="#tbl16" aria-label="Table 16">Table 16</a>, with cure rates of 89% or higher, while the regimen has also been shown to be effective in treating HCV infections occurring following a liver transplant.<a onclick="showRef(event, 'ref141 ref142'); return false;" href="javascript:void(0);" class="ref ref141 ref142">(141, 142)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0053.gif" alt="" id="fx24" /></img></div><div class="NLM_table-wrap" id="tbl16"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 16. Synopsis of Clinical Results with Viekira Pak, a Fixed Dose Combination of <b>152</b>, <b>153</b>, and <b>154</b> Co-Packaged with <b>155</b>, Administered with or without <b>12</b> Depending on the Clinical Background of the Patient Population</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">patient population</th><th class="colsep0 rowsep0" align="center">phase</th><th class="colsep0 rowsep0" align="center">GT, status</th><th class="colsep0 rowsep0" align="center">therapeutic regimen and duration</th><th class="colsep0 rowsep0" align="center">SVR<sub>12</sub> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">treatment-naive</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">GT-1a, noncirrhotic</td><td class="colsep0 rowsep0" align="left">12 weeks with <b>12</b></td><td class="colsep0 rowsep0" align="left">96</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">GT-1b, noncirrhotic</td><td class="colsep0 rowsep0" align="left">12 weeks</td><td class="colsep0 rowsep0" align="left">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">treatment-experienced</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">GT-1b, noncirrhotic</td><td class="colsep0 rowsep0" align="left">12 weeks</td><td class="colsep0 rowsep0" align="left">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">treatment-naive and -experienced</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">GT-1a, cirrhotic</td><td class="colsep0 rowsep0" align="left">12 weeks with <b>12</b></td><td class="colsep0 rowsep0" align="left">89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">GT-1a, cirrhotic</td><td class="colsep0 rowsep0" align="left">24 weeks with <b>12</b></td><td class="colsep0 rowsep0" align="left">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">GT-1b, cirrhotic</td><td class="colsep0 rowsep0" align="left">12 weeks with <b>12</b></td><td class="colsep0 rowsep0" align="left">99</td></tr></tbody></table></div></div><div class="NLM_p">The third DAA combination to be licensed for marketing by the U.S. FDA was Zepatier, a once-daily fixed dose combination of the NS3 protease inhibitor grazoprevir (<b>156</b>, 100 mg) and the NS5A RCI elbasvir (<b>157</b>, 50 mg) which was approved by the FDA on January 28, 2016.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> The results of the pivotal clinical trials are summarized in <a class="ref internalNav" href="#tbl17" aria-label="Table 17">Table 17</a> which highlights cure rates above 90% in all patient populations tested.<a onclick="showRef(event, 'ref144 ref145'); return false;" href="javascript:void(0);" class="ref ref144 ref145">(144, 145)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0054.gif" alt="" id="fx25" /></img></div><div class="NLM_table-wrap" id="tbl17"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 17. Synopsis of Clinical Results with Zepatier, a Once Daily Fixed Dose Combination of <b>156</b> and <b>157</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">patient population</th><th class="colsep0 rowsep0" align="center">clinical phase</th><th class="colsep0 rowsep0" align="center">GT</th><th class="colsep0 rowsep0" align="center">therapeutic regimen and duration</th><th class="colsep0 rowsep0" align="center">SVR<sub>12</sub> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">naive, no baseline NS5A polymorphism</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">GT-1a</td><td class="colsep0 rowsep0" align="left">12 weeks</td><td class="colsep0 rowsep0" align="left">92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">naive</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">GT-1b</td><td class="colsep0 rowsep0" align="left">12 weeks</td><td class="colsep0 rowsep0" align="left">98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">experienced, no baseline NS5A polymorphism</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">GT-1a</td><td class="colsep0 rowsep0" align="left">12 weeks</td><td class="colsep0 rowsep0" align="left">90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">experienced</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">GT-1b</td><td class="colsep0 rowsep0" align="left">12 weeks</td><td class="colsep0 rowsep0" align="left">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">experienced, including a protease inhibitor</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">GT-1a or GT-1b</td><td class="colsep0 rowsep0" align="left">12 weeks with <b>12</b></td><td class="colsep0 rowsep0" align="left">96</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">naive, HIV</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">GT-1</td><td class="colsep0 rowsep0" align="left">12 weeks</td><td class="colsep0 rowsep0" align="left">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">experienced, HIV</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">GT-1</td><td class="colsep0 rowsep0" align="left">12 weeks</td><td class="colsep0 rowsep0" align="left">97</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">naive/experienced</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">GT-4</td><td class="colsep0 rowsep0" align="left">16 weeks with <b>12</b></td><td class="colsep0 rowsep0" align="left">97</td></tr></tbody></table></div></div><div class="NLM_p">The NDA for the FDC of <b>149</b> (400 mg) with the NS5A RCI velpatasvir (<b>158</b>, 100 mg), which is to be marketed as Epclusa, was filed with the U.S. FDA on October 28, 2015, based on data from four phase 3 clinical trials with approval occurring on June 28, 2016.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Three of the studies evaluated the drug combination in the treatment of GT-1 to GT-6 HCV infections in over 1000 patients without cirrhosis or with compensated cirrhosis of which 98% achieved an SVR<sub>12</sub> after 12 weeks of therapy. In the fourth trial, which was conducted in more than 250 subjects infected with GT-1 to GT-6 HCV who had decompensated cirrhosis, 12 weeks of Epclusa therapy in conjunction with <b>12</b> resulted in 94% of the patients achieving SVR<sub>12</sub> which compared to SVR<sub>12</sub> rates of 83% and 86% for the arms receiving 12 and 24 weeks of Epclusa therapy alone, respectively.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0055.gif" alt="" id="fx26" /></img></div><div class="NLM_p">Another drug combination with pan-genotype HCV inhibition that has advanced into phase 3 clinical trials is the combination of the NS3 protease inhibitor glecaprevir (<b>159</b>) and the NS5A RCI pibrentasvir (<b>160</b>) both of which were evaluated as monotherapy for 3 days in GT-1 HCV-infected subjects who then completed a 12-week course of Viekira Pak in combination with <b>12</b>.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Oral administration of <b>159</b> once daily for 3 days at doses ranging from 100 to 700 mg was associated with mean maximal reductions in viral load of approximately 4 log<sub>10</sub> IU/mL, with <b>160</b> similarly effective at doses of 40, 120, and 400 mg but not 15 mg.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0056.gif" alt="" id="fx27" /></img></div><div class="NLM_p">The pan-genotype NS3 protease inhibitor voxilaprevir (<b>161</b>) demonstrated a potent antiviral effect with ≥3 log<sub>10</sub> IU/mL decline in HCV RNA following three daily oral doses of 100 mg to subjects infected with GT-1a, GT-1b, GT-2, GT-3, or GT-4 HCV.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> This compound has been evaluated in a phase 2 clinical trial where the drug was administered at a daily dose of 100 mg daily along with a fixed dose combination of <b>149</b> (400 mg) and <b>158</b> (100 mg) to 161 treatment-naive or treatment-experienced GT-1- and GT-3-infected subjects.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> The study design evaluated treatment durations of 4 and 6 weeks in treatment-naive subjects without cirrhosis, 6 weeks in treatment-naive subjects with cirrhosis, 6 or 8 weeks in treatment-experienced patients with or without cirrhosis, with the results compiled in <a class="ref internalNav" href="#tbl18" aria-label="Table 18">Table 18</a>.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> The results hold promise for the use of shorter durations of therapy, and the combination is currently being assessed in phase 3 clinical studies.</div><div class="NLM_table-wrap" id="tbl18"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 18. Results of a Phase 2 Clinical Trial of Fixed Dose Combination of <b>149</b> (400 mg) and <b>158</b> (100 mg) Administered with <b>161</b> (100 mg) in Subjects Infected with HCV GT-1 and GT-3</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">genotype</th><th class="colsep0 rowsep0" align="center">patient background</th><th class="colsep0 rowsep0" align="center"><i>n</i></th><th class="colsep0 rowsep0" align="center">duration of therapy (week)</th><th class="colsep0 rowsep0" align="center">SVR<sub>12</sub> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1</td><td class="colsep0 rowsep0" rowspan="2" align="left">treatment-naive, no cirrhosis</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1</td><td class="colsep0 rowsep0" rowspan="2" align="left">treatment-naive, with cirrhosis</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">87</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-3</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1</td><td class="colsep0 rowsep0" rowspan="2" align="left">treatment-experienced (failed an all oral regimen of 2 or more DAAs)</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-3</td><td class="colsep0 rowsep0" align="left">treatment-experienced (failed PEG-IFN-α/<b>12</b>) with cirrhosis</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-1</td><td class="colsep0 rowsep0" align="left">treatment-experienced (failed protease inhibitor-based triple therapy)</td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GT-3</td><td class="colsep0 rowsep0" align="left">treatment-experienced (failed an all oral regimen of 2 or more DAAs)</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">100</td></tr></tbody></table></div></div><div class="NLM_p">The successful development of DAAs that cure chronic HCV infection after short therapeutic regimens of orally active drug combinations that are generally well-tolerated is the result of significant effort, commitment, and tenacity on the part of the pharmaceutical industry which has endured a considerable level of candidate attrition.<a onclick="showRef(event, 'ref150 ref151 ref152 ref153'); return false;" href="javascript:void(0);" class="ref ref150 ref151 ref152 ref153">(150-153)</a> It has been estimated that between 1995 and 2014, 712 unique HCV drugs were evaluated in clinical trials of which just 10 DAAs had been approved worldwide by the end of 2014 in addition to interferon alfacon-1, PEG IFN-α 2a, PEG IFN-α 2b, and <b>12</b>.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> While the approval of the combination of <b>156</b> and <b>157</b> in January 2016 and the combination of <b>149</b> and <b>158</b> in June 2016 have added to the total of marketed DAAs, the overall results still reflect a success rate of ∼2%, about half of an industry average that encompasses all therapeutic areas and modalities.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> The reasons subtending HCV drug candidate failure during development covered the spectrum of causes of compound attrition and included issues associated with poor efficacy, preclinical toxicology, clinical safety, inadequate PK properties, and commercial decisions.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> The abandonment of candidates for commercial decisions reflected the challenges associated with responding to a rapidly evolving clinical landscape that occurred as a myriad of drug combinations were evaluated and their fuller efficacy and side effect profiles were revealed.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> The initial focus of the pharmaceutical industry had been to provide drugs to treat GT-1 infections that were recalcitrant to the combination of PEG IFN-α and <b>12</b>, since many of the other HCV genotypes could be successfully treated with this therapeutic combination. However, as drug candidates with activity toward all genotypes emerged, the targeted profile evolved rapidly toward developing powerful, pan-genotype inhibitor combinations that could be formulated as fixed doses suitable for convenient once-daily oral delivery and that hold promise for 6–8 weeks of curative therapy in uncomplicated clinical backgrounds (<a class="ref internalNav" href="#fig12" aria-label="Figures 12">Figures 12</a> and <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>).<a onclick="showRef(event, 'ref155 ref156 ref157 ref158'); return false;" href="javascript:void(0);" class="ref ref155 ref156 ref157 ref158">(155-158)</a> In the absence of effective therapy, HCV infection was viewed as the equivalent of a ticking time bomb with respect to the incidence of hepatocellular carcinoma and end stage liver failure anticipated in the U.S. based on an analysis of the epidemic in Japan, which is believed to precede that in the U.S. by approximately 30 years.<a onclick="showRef(event, 'ref159 ref160 ref161'); return false;" href="javascript:void(0);" class="ref ref159 ref160 ref161">(159-161)</a> A similar burden is anticipated for European countries, although there is a significant variation in estimates of the global prevalence of HCV infection.<a onclick="showRef(event, 'ref161 ref162'); return false;" href="javascript:void(0);" class="ref ref161 ref162">(161, 162)</a> It was estimated that by 2007 the number of deaths per annum in the U.S. caused by HCV had surpassed those attributed to HIV-1, with 15 106 deaths believed to be a consequence of HCV infection compared to 12 734 for HIV-1 infection.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> By 2013, HCV was believed to be responsible for more deaths than all other nationally notifiable infectious conditions combined.<a onclick="showRef(event, 'cit160b'); return false;" href="javascript:void(0);" class="ref cit160b">(160b)</a> These statistics led to the prediction that in the absence of effective therapy, morbidity and mortality from HCV infection in the U.S. would continue to rise, with the peak estimated to occur between 2030 and 2035 when there would be 38 600 cases of end-stage liver disease in the peak year, leading to 3200 referrals for liver transplantation and 36 100 deaths.<a onclick="showRef(event, 'cit160c'); return false;" href="javascript:void(0);" class="ref cit160c">(160c)</a> With the advent of effective curative therapies, there is the potential to significantly alter this scenario; indeed, the complete eradication of HCV infection in the U.S. has been contemplated.<a onclick="showRef(event, 'ref163 ref164'); return false;" href="javascript:void(0);" class="ref ref163 ref164">(163, 164)</a> However, the eradication of HCV will require significant effort, particularly with respect to screening in order to identify the considerable number of subjects who are infected but who are ignorant of their status.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a></div><figure id="fig14" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0014.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Evolution of HCV therapy and associated cure rates for GT-1 infection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">6 Epilogue</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47713" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47713" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In 2008, several questions were posed about the future of HCV therapy at a time when DAAs were in early clinical development and their full potential to cure HCV infection was unrealized.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> From contemplation of improved interferons and combinations with DAAs that were expected to improve SVR, the questions that were posed included the following: Will treatment duration be reduced? Will immune stimulation be required? Will combinations of DAAs be sufficient to produce SVR? Will <b>12</b> remain an essential component of therapy?<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> These questions have largely been answered with the approval of small molecule DAA combinations that are curative in the absence of interferon therapy over relatively short durations, although with currently approved agents <b>12</b> remains a component for some clinical backdrops despite the enigma surrounding its precise mechanism of action.<a onclick="showRef(event, 'ref115 ref165 ref166'); return false;" href="javascript:void(0);" class="ref ref115 ref165 ref166">(115, 165, 166)</a> The state of contemporary HCV therapy has been eloquently captured in a quote from Dr. Douglas Dieterich, who is the Director of Outpatient Liver Disease Treatment at Mount Sinai Hospital in New York City and who has cleared an HCV infection acquired as the result of a needle stick: “People are coming in who never wanted to be treated before. When I started in 1989, I used to have a 3% cure rate. Now I have a 3% failure rate.”<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> The development of a cure for chronic HCV infection with small molecules has taken 25 years since the discovery of the virus and has been described as “the arc of a medical triumph”.<a onclick="showRef(event, 'ref168 ref169'); return false;" href="javascript:void(0);" class="ref ref168 ref169">(168, 169)</a> The drugs that are providing HCV cures are all small molecules designed, synthesized, and optimized by creative, committed, and insightful medicinal chemists who have demonstrated the kind of persistence and tenacity that is required to conduct successful contemporary drug discovery campaigns where compound failure and problem solving are daily challenges. Indeed, the pharmaceutical industry has dealt with considerable compound attrition in clinical trials, suggesting that the successful outcome may be equally well described as “the arc of a medicinal chemistry triumph”.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00915" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51782" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51782" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicholas A. Meanwell</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Chemistry, Bristol-Myers Squibb Research & Development, Wallingford, Connecticut 06492, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#743a1d171c1b1815075a3911151a03111818341619075a171b19"><span class="__cf_email__" data-cfemail="d19fb8b2b9bebdb0a2ff9cb4b0bfa6b4bdbd91b3bca2ffb2bebc">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The author declares no competing financial interest.<br /></br><p class="inlineNote">This Award Address was presented at the 250th National Meeting and Exposition of the American Chemical Society in Boston, MA, on Tuesday, August 18, 2015; Abstract MEDI-294.</p></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Biography</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11831" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11831" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Nicholas A. Meanwell</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=BIO-d126e4801-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Nicholas A. Meanwell</b> received his Ph.D. degree from the University of Sheffield and conducted postdoctoral studies at Wayne State University before joining Bristol-Myers Squibb in 1982. He has been associated with the discovery of BMY-433771, an inhibitor of respiratory syncytial virus fusion, the HIV-1 attachment inhibitor prodrug fostemsavir, the HIV-1 maturation inhibitor BMS-955176, and the HCV inhibitors asunaprevir (NS3, Sunvepra), daclatasvir (NS5A, Daklinza), and beclabuvir (NS5B). He was elected to the Connecticut Academy of Science and Engineering in February of 2014, is the co-recipient of a 2014 PhRMA Research and Hope Award for Biopharmaceutical Industry Research, is the recipient of the 2015 Philip S. Portoghese Medicinal Chemistry Lectureship Award, and was inducted into the ACS Division of Medicinal Chemistry Hall of Fame in 2015.</p></figure></div><div class="ack" id="ACK-d126e4806-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77074" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77074" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">I express gratitude to all of my co-workers at Bristol-Myers Squibb and beyond that I have had the good fortune to collaborate with on the many antiviral programs that have been conducted over the past 25 years as we committed to discovering and developing direct-acting antiviral agents designed to treat insidious diseases like HCV, HIV-1, and respiratory syncytial virus infections. These individuals have demonstrated the kind of creativity and commitment that is required to deliver candidates in modern drug discovery, and their insights and contributions have added significantly to the field of antiviral inhibitor drug discovery and development. Moreover, they have distinguished themselves by their collaborative spirit and commitment to teamwork in pursuit of the common goal of identifying high quality, innovative candidate drugs. The names of many of them, particularly those that contributed to the discovery of the HCV inhibitors described in this article, are captured in the publications that are cited in the list of references. I would specifically like to recognize the chemistry leads on the three HCV programs summarized here: Dr. Paul M. Scola (NS3 protease), Drs. Lawrence B. Snyder, Lawrence G. Hamann, and Makonen Belema (NS5A replication complex inhibitors), and Drs. John F. Kadow and Robert G. Gentles (NS5B polymerase) for their leadership and collaborative spirit and collegiality. I also thank Dr. Ramkumar Rajamani for providing the graphics associated with inhibitor binding to NS3 protease and Drs. Makonen Belema and John F. Kadow for their constructive review of the manuscript. I also want to recognize the significant benefit of the excellent mentorship that I have enjoyed at the various stages of my career: Dr. D. Neville Jones (Ph.D. supervisor), Professor Carl R. Johnson (postdoctoral fellowship supervisor), and Drs. J. J. Kim Wright, Graham Johnson, Carl P. Decicco, Joel C. Barrish, and Percy H. Carter (supervisors at Bristol-Myers Squibb), individuals who have provided the kind of support, guidance, and insight that are essential for both intellectual and personal growth and success regardless of the endeavor. It is a tremendous honor to be selected as the Philip S. Portoghese Medicinal Chemistry Lectureship Awardee for 2015 and I thank both the <i>Journal of Medicinal Chemistry</i> and the ACS Division of Medicinal Chemistry for the personal and professional recognition as well as the illumination that this brings to our work in the field antiviral drug discovery.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i31" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i31"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i32" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i32"> Abbreviations Used</h2><tr><td class="NLM_term">ARV</td><td class="NLM_def"><p class="first last">antiretroviral</p></td></tr><tr><td class="NLM_term">b.i.d.</td><td class="NLM_def"><p class="first last">bis in die (twice daily dosing)</p></td></tr><tr><td class="NLM_term">BVDV</td><td class="NLM_def"><p class="first last">bovine viral diarrheal virus</p></td></tr><tr><td class="NLM_term">CV</td><td class="NLM_def"><p class="first last">cardiovascular</p></td></tr><tr><td class="NLM_term">DAA</td><td class="NLM_def"><p class="first last">direct-acting antiviral agent</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">GT</td><td class="NLM_def"><p class="first last">genotype</p></td></tr><tr><td class="NLM_term">HBV</td><td class="NLM_def"><p class="first last">hepatitis B virus</p></td></tr><tr><td class="NLM_term">HCV</td><td class="NLM_def"><p class="first last">hepatitis C virus</p></td></tr><tr><td class="NLM_term">HIV-1</td><td class="NLM_def"><p class="first last">human immunodeficiency virus 1</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high performance liquid chromatography</p></td></tr><tr><td class="NLM_term">HR</td><td class="NLM_def"><p class="first last">heart rate</p></td></tr><tr><td class="NLM_term">HRV</td><td class="NLM_def"><p class="first last">human rhinovirus</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high throughput screening</p></td></tr><tr><td class="NLM_term">LM</td><td class="NLM_def"><p class="first last">liver microsomes</p></td></tr><tr><td class="NLM_term">NS</td><td class="NLM_def"><p class="first last">nonstructural</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">RCI</td><td class="NLM_def"><p class="first last">replication complex inhibitor</p></td></tr><tr><td class="NLM_term">RdRp</td><td class="NLM_def"><p class="first last">RNA-dependent RNA polymerase</p></td></tr><tr><td class="NLM_term">RSV</td><td class="NLM_def"><p class="first last">respiratory syncytial virus</p></td></tr><tr><td class="NLM_term">SAD</td><td class="NLM_def"><p class="first last">single ascending dose</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SOC</td><td class="NLM_def"><p class="first last">standard of care</p></td></tr><tr><td class="NLM_term">SNRT</td><td class="NLM_def"><p class="first last">sinoatrial node recovery time</p></td></tr><tr><td class="NLM_term">U.S.</td><td class="NLM_def"><p class="first last">United States</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56020" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56020" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 169 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Lichtenberg, F. R.</span><span> </span><span class="NLM_article-title">Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000–2009</span> <span class="citation_source-journal">Health Policy Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span><span class="refDoi"> DOI: 10.1016/j.hlpt.2013.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.hlpt.2013.09.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=36-58&author=F.+R.+Lichtenberg&title=Pharmaceutical+innovation+and+longevity+growth+in+30+developing+and+high-income+countries%2C+2000%E2%80%932009&doi=10.1016%2Fj.hlpt.2013.09.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.hlpt.2013.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hlpt.2013.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DLichtenberg%26aufirst%3DF.%2BR.%26atitle%3DPharmaceutical%2520innovation%2520and%2520longevity%2520growth%2520in%252030%2520developing%2520and%2520high-income%2520countries%252C%25202000%25E2%2580%25932009%26jtitle%3DHealth%2520Policy%2520Technol.%26date%3D2014%26volume%3D3%26spage%3D36%26epage%3D58%26doi%3D10.1016%2Fj.hlpt.2013.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Meanwell, N. A.; Olson, R. E.; Cheng, P. T.</span><span> </span><span class="NLM_article-title">The practice of medicinal chemistry and its contributions to therapy</span>. In  <span class="citation_source-book">2015 Medicinal Chemistry Reviews</span>; <span class="NLM_publisher-name">Medicinal Chemistry Division of the ACS</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">50</span>, pp  <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=359-393&author=N.+A.+Meanwell&author=R.+E.+Olson&author=P.+T.+Cheng&title=2015+Medicinal+Chemistry+Reviews"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DThe%2520practice%2520of%2520medicinal%2520chemistry%2520and%2520its%2520contributions%2520to%2520therapy%26btitle%3D2015%2520Medicinal%2520Chemistry%2520Reviews%26pub%3DMedicinal%2520Chemistry%2520Division%2520of%2520the%2520ACS%26date%3D2015%26volume%3D50%26spage%3D359%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Lichtenberg, F. R.</span><span> </span><span class="NLM_article-title">The effect of new drug approvals on HIV mortality in the US, 1987–1998</span> <span class="citation_source-journal">Economics Human Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span><span class="refDoi"> DOI: 10.1016/S1570-677X(02)00031-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS1570-677X%2802%2900031-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=15463977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BD2cvpsF2nsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2003&pages=259-266&author=F.+R.+Lichtenberg&title=The+effect+of+new+drug+approvals+on+HIV+mortality+in+the+US%2C+1987%E2%80%931998&doi=10.1016%2FS1570-677X%2802%2900031-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of new drug approvals on HIV mortality in the US, 1987-1998</span></div><div class="casAuthors">Lichtenberg Frank R</div><div class="citationInfo"><span class="NLM_cas:title">Economics and human biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">259-66</span>
        ISSN:<span class="NLM_cas:issn">1570-677X</span>.
    </div><div class="casAbstract">After increasing steadily from 1987 to 1995, the number of US deaths caused by human immunodeficiency virus (HIV) declined sharply from 1995 to 1998.  We analyse aggregate data to consider the hypothesis that this decline was due to a rapid increase in the number of drugs available to treat HIV.  The evidence suggests that new drugs played a key role in the post-1995 decline in HIV mortality.  The annual number of HIV deaths is estimated to have been reduced by over 6000, on average, by an additional HIV drug approval.  The social return to HIV drug innovation appears to be extremely large.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUogft9D3NgO2mnZh2OgS0fW6udTcc2eZQkqTqymqLwbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cvpsF2nsA%253D%253D&md5=413dd70908820061629010d9b69415db</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1570-677X%2802%2900031-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1570-677X%252802%252900031-X%26sid%3Dliteratum%253Aachs%26aulast%3DLichtenberg%26aufirst%3DF.%2BR.%26atitle%3DThe%2520effect%2520of%2520new%2520drug%2520approvals%2520on%2520HIV%2520mortality%2520in%2520the%2520US%252C%25201987%25E2%2580%25931998%26jtitle%3DEconomics%2520Human%2520Biol.%26date%3D2003%26volume%3D1%26spage%3D259%26epage%3D266%26doi%3D10.1016%2FS1570-677X%2802%2900031-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Maartens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celum, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewin, S. R.</span><span> </span><span class="NLM_article-title">HIV infection: epidemiology, pathogenesis, treatment, and prevention</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">384</span><span class="NLM_x">, </span> <span class="NLM_fpage">258</span><span class="NLM_x">–</span> <span class="NLM_lpage">271</span><span class="refDoi"> DOI: 10.1016/S0140-6736(14)60164-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0140-6736%2814%2960164-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24907868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC2cfgt1amuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2014&pages=258-271&author=G.+Maartensauthor=C.+Celumauthor=S.+R.+Lewin&title=HIV+infection%3A+epidemiology%2C+pathogenesis%2C+treatment%2C+and+prevention&doi=10.1016%2FS0140-6736%2814%2960164-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">HIV infection: epidemiology, pathogenesis, treatment, and prevention</span></div><div class="casAuthors">Maartens Gary; Celum Connie; Lewin Sharon R</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">384</span>
        (<span class="NLM_cas:issue">9939</span>),
    <span class="NLM_cas:pages">258-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">HIV prevalence is increasing worldwide because people on antiretroviral therapy are living longer, although new infections decreased from 3.3 million in 2002, to 2.3 million in 2012.  Global AIDS-related deaths peaked at 2.3 million in 2005, and decreased to 1.6 million by 2012.  An estimated 9.7 million people in low-income and middle-income countries had started antiretroviral therapy by 2012.  New insights into the mechanisms of latent infection and the importance of reservoirs of infection might eventually lead to a cure.  The role of immune activation in the pathogenesis of non-AIDS clinical events (major causes of morbidity and mortality in people on antiretroviral therapy) is receiving increased recognition.  Breakthroughs in the prevention of HIV important to public health include male medical circumcision, antiretrovirals to prevent mother-to-child transmission, antiretroviral therapy in people with HIV to prevent transmission, and antiretrovirals for pre-exposure prophylaxis.  Research into other prevention interventions, notably vaccines and vaginal microbicides, is in progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfcH_dOE8ahDDnmmyUf5qOfW6udTcc2eZQkqTqymqLwbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfgt1amuw%253D%253D&md5=1ef5b9d6369e3a5865a8d0eaa4757345</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2960164-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252960164-1%26sid%3Dliteratum%253Aachs%26aulast%3DMaartens%26aufirst%3DG.%26aulast%3DCelum%26aufirst%3DC.%26aulast%3DLewin%26aufirst%3DS.%2BR.%26atitle%3DHIV%2520infection%253A%2520epidemiology%252C%2520pathogenesis%252C%2520treatment%252C%2520and%2520prevention%26jtitle%3DLancet%26date%3D2014%26volume%3D384%26spage%3D258%26epage%3D271%26doi%3D10.1016%2FS0140-6736%2814%2960164-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Deeks, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewin, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havlir, D. V.</span><span> </span><span class="NLM_article-title">The end of AIDS: HIV infection as a chronic disease</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">382</span><span class="NLM_x">, </span> <span class="NLM_fpage">1525</span><span class="NLM_x">–</span> <span class="NLM_lpage">1533</span><span class="refDoi"> DOI: 10.1016/S0140-6736(13)61809-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0140-6736%2813%2961809-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2013&pages=1525-1533&author=S.+G.+Deeksauthor=S.+R.+Lewinauthor=D.+V.+Havlir&title=The+end+of+AIDS%3A+HIV+infection+as+a+chronic+disease&doi=10.1016%2FS0140-6736%2813%2961809-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2813%2961809-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252813%252961809-7%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DS.%2BG.%26aulast%3DLewin%26aufirst%3DS.%2BR.%26aulast%3DHavlir%26aufirst%3DD.%2BV.%26atitle%3DThe%2520end%2520of%2520AIDS%253A%2520HIV%2520infection%2520as%2520a%2520chronic%2520disease%26jtitle%3DLancet%26date%3D2013%26volume%3D382%26spage%3D1525%26epage%3D1533%26doi%3D10.1016%2FS0140-6736%2813%2961809-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Günthard, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aberg, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eron, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoy, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telenti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glesby, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saag, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volberding, P. A.</span><span> </span><span class="NLM_article-title">International Antiviral Society-USA Panel. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">410</span><span class="NLM_x">–</span> <span class="NLM_lpage">425</span><span class="refDoi"> DOI: 10.1001/jama.2014.8722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1001%2Fjama.2014.8722" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2014&pages=410-425&author=H.+F.+G%C3%BCnthardauthor=J.+A.+Abergauthor=J.+J.+Eronauthor=J.+F.+Hoyauthor=A.+Telentiauthor=C.+A.+Bensonauthor=D.+M.+Burgerauthor=P.+Cahnauthor=J.+E.+Gallantauthor=M.+J.+Glesbyauthor=P.+Reissauthor=M.+S.+Saagauthor=D.+L.+Thomasauthor=D.+M.+Jacobsenauthor=P.+A.+Volberding&title=International+Antiviral+Society-USA+Panel.+Antiretroviral+treatment+of+adult+HIV+infection%3A+2014+recommendations+of+the+International+Antiviral+Society-USA+Panel&doi=10.1001%2Fjama.2014.8722"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1001%2Fjama.2014.8722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2014.8722%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnthard%26aufirst%3DH.%2BF.%26aulast%3DAberg%26aufirst%3DJ.%2BA.%26aulast%3DEron%26aufirst%3DJ.%2BJ.%26aulast%3DHoy%26aufirst%3DJ.%2BF.%26aulast%3DTelenti%26aufirst%3DA.%26aulast%3DBenson%26aufirst%3DC.%2BA.%26aulast%3DBurger%26aufirst%3DD.%2BM.%26aulast%3DCahn%26aufirst%3DP.%26aulast%3DGallant%26aufirst%3DJ.%2BE.%26aulast%3DGlesby%26aufirst%3DM.%2BJ.%26aulast%3DReiss%26aufirst%3DP.%26aulast%3DSaag%26aufirst%3DM.%2BS.%26aulast%3DThomas%26aufirst%3DD.%2BL.%26aulast%3DJacobsen%26aufirst%3DD.%2BM.%26aulast%3DVolberding%26aufirst%3DP.%2BA.%26atitle%3DInternational%2520Antiviral%2520Society-USA%2520Panel.%2520Antiretroviral%2520treatment%2520of%2520adult%2520HIV%2520infection%253A%25202014%2520recommendations%2520of%2520the%2520International%2520Antiviral%2520Society-USA%2520Panel%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2014%26volume%3D312%26spage%3D410%26epage%3D425%26doi%3D10.1001%2Fjama.2014.8722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dienstag, J. L.</span><span> </span><span class="NLM_article-title">Hepatitis B virus infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">359</span><span class="NLM_x">, </span> <span class="NLM_fpage">1486</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span><span class="refDoi"> DOI: 10.1056/NEJMra0801644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMra0801644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=18832247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFOru7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2008&pages=1486-1500&author=J.+L.+Dienstag&title=Hepatitis+B+virus+infection&doi=10.1056%2FNEJMra0801644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B virus infection</span></div><div class="casAuthors">Dienstag, Jules L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1486-1500</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review with refs. on drug therapy of chronic hepatitis B, its co-infection with HIV viral infection, mono- and combination therapy and overcoming antiviral resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5ybm-V9V7urVg90H21EOLACvtfcHk0ljK17W3bU9x6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFOru7bL&md5=e4ca2dbdb0fa268fa483eb7b77cf4643</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0801644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0801644%26sid%3Dliteratum%253Aachs%26aulast%3DDienstag%26aufirst%3DJ.%2BL.%26atitle%3DHepatitis%2520B%2520virus%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D359%26spage%3D1486%26epage%3D1500%26doi%3D10.1056%2FNEJMra0801644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tang, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yau, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span> </span><span class="NLM_article-title">Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">6262</span><span class="NLM_x">–</span> <span class="NLM_lpage">6278</span><span class="refDoi"> DOI: 10.3748/wjg.v20.i20.6262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.3748%2Fwjg.v20.i20.6262" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=6262-6278&author=C.-M.+Tangauthor=T.+O.+Yauauthor=J.+Yu&title=Management+of+chronic+hepatitis+B+infection%3A+current+treatment+guidelines%2C+challenges%2C+and+new+developments&doi=10.3748%2Fwjg.v20.i20.6262"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v20.i20.6262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v20.i20.6262%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DC.-M.%26aulast%3DYau%26aufirst%3DT.%2BO.%26aulast%3DYu%26aufirst%3DJ.%26atitle%3DManagement%2520of%2520chronic%2520hepatitis%2520B%2520infection%253A%2520current%2520treatment%2520guidelines%252C%2520challenges%252C%2520and%2520new%2520developments%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2014%26volume%3D20%26spage%3D6262%26epage%3D6278%26doi%3D10.3748%2Fwjg.v20.i20.6262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selwyn, P. A.</span><span> </span><span class="NLM_article-title">Complications of HIV infection: a systems-based approach</span> <span class="citation_source-journal">Am. Fam. Physician</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">406</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2011&pages=395-406&author=C.+Chuauthor=P.+A.+Selwyn&title=Complications+of+HIV+infection%3A+a+systems-based+approach"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DC.%26aulast%3DSelwyn%26aufirst%3DP.%2BA.%26atitle%3DComplications%2520of%2520HIV%2520infection%253A%2520a%2520systems-based%2520approach%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2011%26volume%3D83%26spage%3D395%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rockstroh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guaraldi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deray, G.</span><span> </span><span class="NLM_article-title">HIV and the body: a review of multidisciplinary management</span> <span class="citation_source-journal">HIV Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.1111/j.1468-1293.2010.00859.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fj.1468-1293.2010.00859.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1-8&issue=Suppl.+2&author=J.+Rockstrohauthor=G.+Guaraldiauthor=G.+Deray&title=HIV+and+the+body%3A+a+review+of+multidisciplinary+management&doi=10.1111%2Fj.1468-1293.2010.00859.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1111%2Fj.1468-1293.2010.00859.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1468-1293.2010.00859.x%26sid%3Dliteratum%253Aachs%26aulast%3DRockstroh%26aufirst%3DJ.%26aulast%3DGuaraldi%26aufirst%3DG.%26aulast%3DDeray%26aufirst%3DG.%26atitle%3DHIV%2520and%2520the%2520body%253A%2520a%2520review%2520of%2520multidisciplinary%2520management%26jtitle%3DHIV%2520Med.%26date%3D2010%26volume%3D11%26issue%3DSuppl.%25202%26spage%3D1%26epage%3D8%26doi%3D10.1111%2Fj.1468-1293.2010.00859.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Brown, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glesby, M. J.</span><span> </span><span class="NLM_article-title">Management of the metabolic effects of HIV and HIV drugs</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1038/nrendo.2011.151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrendo.2011.151" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=11-21&author=T.+T.+Brownauthor=M.+J.+Glesby&title=Management+of+the+metabolic+effects+of+HIV+and+HIV+drugs&doi=10.1038%2Fnrendo.2011.151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2011.151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2011.151%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DT.%2BT.%26aulast%3DGlesby%26aufirst%3DM.%2BJ.%26atitle%3DManagement%2520of%2520the%2520metabolic%2520effects%2520of%2520HIV%2520and%2520HIV%2520drugs%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2011%26volume%3D8%26spage%3D11%26epage%3D21%26doi%3D10.1038%2Fnrendo.2011.151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Kitahata, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gange, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merriman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saag, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justice, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deeks, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eron, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rourke, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosch, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterling, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Napravnik, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rachlis, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calzavara, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horberg, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverberg, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebo, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goedert, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Rompaey, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crane, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKaig, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, R. D.</span><span> </span><span class="NLM_article-title">NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">360</span><span class="NLM_x">, </span> <span class="NLM_fpage">1815</span><span class="NLM_x">–</span> <span class="NLM_lpage">1826</span><span class="refDoi"> DOI: 10.1056/NEJMoa0807252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa0807252" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=1815-1826&author=M.+M.+Kitahataauthor=S.+J.+Gangeauthor=A.+G.+Abrahamauthor=B.+Merrimanauthor=M.+S.+Saagauthor=A.+C.+Justiceauthor=R.+S.+Hoggauthor=S.+G.+Deeksauthor=J.+J.+Eronauthor=J.+T.+Brooksauthor=S.+B.+Rourkeauthor=M.+J.+Gillauthor=R.+J.+Boschauthor=J.+N.+Martinauthor=M.+B.+Kleinauthor=L.+P.+Jacobsonauthor=B.+Rodriguezauthor=T.+R.+Sterlingauthor=G.+D.+Kirkauthor=S.+Napravnikauthor=A.+R.+Rachlisauthor=L.+M.+Calzavaraauthor=M.+A.+Horbergauthor=M.+J.+Silverbergauthor=K.+A.+Geboauthor=J.+J.+Goedertauthor=C.+A.+Bensonauthor=A.+C.+Collierauthor=S.+E.+Van+Rompaeyauthor=H.+M.+Craneauthor=R.+G.+McKaigauthor=B.+Lauauthor=A.+M.+Freemanauthor=R.+D.+Moore&title=NA-ACCORD+Investigators.+Effect+of+early+versus+deferred+antiretroviral+therapy+for+HIV+on+survival&doi=10.1056%2FNEJMoa0807252"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0807252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0807252%26sid%3Dliteratum%253Aachs%26aulast%3DKitahata%26aufirst%3DM.%2BM.%26aulast%3DGange%26aufirst%3DS.%2BJ.%26aulast%3DAbraham%26aufirst%3DA.%2BG.%26aulast%3DMerriman%26aufirst%3DB.%26aulast%3DSaag%26aufirst%3DM.%2BS.%26aulast%3DJustice%26aufirst%3DA.%2BC.%26aulast%3DHogg%26aufirst%3DR.%2BS.%26aulast%3DDeeks%26aufirst%3DS.%2BG.%26aulast%3DEron%26aufirst%3DJ.%2BJ.%26aulast%3DBrooks%26aufirst%3DJ.%2BT.%26aulast%3DRourke%26aufirst%3DS.%2BB.%26aulast%3DGill%26aufirst%3DM.%2BJ.%26aulast%3DBosch%26aufirst%3DR.%2BJ.%26aulast%3DMartin%26aufirst%3DJ.%2BN.%26aulast%3DKlein%26aufirst%3DM.%2BB.%26aulast%3DJacobson%26aufirst%3DL.%2BP.%26aulast%3DRodriguez%26aufirst%3DB.%26aulast%3DSterling%26aufirst%3DT.%2BR.%26aulast%3DKirk%26aufirst%3DG.%2BD.%26aulast%3DNapravnik%26aufirst%3DS.%26aulast%3DRachlis%26aufirst%3DA.%2BR.%26aulast%3DCalzavara%26aufirst%3DL.%2BM.%26aulast%3DHorberg%26aufirst%3DM.%2BA.%26aulast%3DSilverberg%26aufirst%3DM.%2BJ.%26aulast%3DGebo%26aufirst%3DK.%2BA.%26aulast%3DGoedert%26aufirst%3DJ.%2BJ.%26aulast%3DBenson%26aufirst%3DC.%2BA.%26aulast%3DCollier%26aufirst%3DA.%2BC.%26aulast%3DVan%2BRompaey%26aufirst%3DS.%2BE.%26aulast%3DCrane%26aufirst%3DH.%2BM.%26aulast%3DMcKaig%26aufirst%3DR.%2BG.%26aulast%3DLau%26aufirst%3DB.%26aulast%3DFreeman%26aufirst%3DA.%2BM.%26aulast%3DMoore%26aufirst%3DR.%2BD.%26atitle%3DNA-ACCORD%2520Investigators.%2520Effect%2520of%2520early%2520versus%2520deferred%2520antiretroviral%2520therapy%2520for%2520HIV%2520on%2520survival%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D1815%26epage%3D1826%26doi%3D10.1056%2FNEJMoa0807252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ahmed, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eltayebi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyrrell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barakat, K.</span><span> </span><span class="NLM_article-title">Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">548</span><span class="NLM_x">–</span> <span class="NLM_lpage">561</span><span class="refDoi"> DOI: 10.1016/j.drudis.2015.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.drudis.2015.01.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=548-561&author=M.+Ahmedauthor=F.+Wangauthor=A.+Levinauthor=C.+Leauthor=Y.+Eltayebiauthor=M.+Houghtonauthor=L.+Tyrrellauthor=K.+Barakat&title=Targeting+the+Achilles+heel+of+the+hepatitis+B+virus%3A+a+review+of+current+treatments+against+covalently+closed+circular+DNA&doi=10.1016%2Fj.drudis.2015.01.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DAhmed%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLevin%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DC.%26aulast%3DEltayebi%26aufirst%3DY.%26aulast%3DHoughton%26aufirst%3DM.%26aulast%3DTyrrell%26aufirst%3DL.%26aulast%3DBarakat%26aufirst%3DK.%26atitle%3DTargeting%2520the%2520Achilles%2520heel%2520of%2520the%2520hepatitis%2520B%2520virus%253A%2520a%2520review%2520of%2520current%2520treatments%2520against%2520covalently%2520closed%2520circular%2520DNA%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D548%26epage%3D561%26doi%3D10.1016%2Fj.drudis.2015.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lucifora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protzer, U.</span><span> </span><span class="NLM_article-title">Attacking hepatitis B virus cccDNA-the holy grail to hepatitis B cure</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x"> (</span><span class="NLM_issue">1 Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">S41</span><span class="NLM_x">–</span> <span class="NLM_lpage">S48</span><span class="refDoi"> DOI: 10.1016/j.jhep.2016.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2016.02.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=S41-S48&issue=1+Suppl.&author=J.+Luciforaauthor=U.+Protzer&title=Attacking+hepatitis+B+virus+cccDNA-the+holy+grail+to+hepatitis+B+cure&doi=10.1016%2Fj.jhep.2016.02.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2016.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2016.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DProtzer%26aufirst%3DU.%26atitle%3DAttacking%2520hepatitis%2520B%2520virus%2520cccDNA-the%2520holy%2520grail%2520to%2520hepatitis%2520B%2520cure%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D64%26issue%3D1%2520Suppl%26spage%3DS41%26epage%3DS48%26doi%3D10.1016%2Fj.jhep.2016.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Levrero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollicino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belloni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raimondo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandri, M.</span><span> </span><span class="NLM_article-title">Control of cccDNA function in hepatitis B virus infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">592</span><span class="refDoi"> DOI: 10.1016/j.jhep.2009.05.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2009.05.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=19616338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFyhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2009&pages=581-592&author=M.+Levreroauthor=T.+Pollicinoauthor=J.+Petersenauthor=L.+Belloniauthor=G.+Raimondoauthor=M.+Dandri&title=Control+of+cccDNA+function+in+hepatitis+B+virus+infection&doi=10.1016%2Fj.jhep.2009.05.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Control of cccDNA function in hepatitis B virus infection</span></div><div class="casAuthors">Levrero, Massimo; Pollicino, Teresa; Petersen, Jorg; Belloni, Laura; Raimondo, Giovanni; Dandri, Maura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">581-592</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The template of hepatitis B virus (HBV) transcription, the covalently closed circular DNA (cccDNA), plays a key role in the life cycle of the virus and permits the persistence of infection.  Novel mol. techniques have opened new possibilities to investigate the organization and the activity of the cccDNA minichromosome in vivo, and recent advances have started to shed light on the complexity of the mechanisms controlling cccDNA function.  Nuclear cccDNA accumulates in hepatocyte nuclei as a stable minichromosome organized by histone and non-histone viral and cellular proteins.  Identification of the mol. mechanisms regulating cccDNA stability and its transcriptional activity at the RNA, DNA and epigenetic levels in the course of chronic hepatitis B (CH-B) infection may reveal new potential therapeutic targets for anti-HBV drugs and hence assist in the design of strategies aimed at silencing and eventually depleting the cccDNA reservoir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo04ONkDq_te7Vg90H21EOLACvtfcHk0lgA_B4ppmKinA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFyhs7k%253D&md5=365616a92ba84ddc3cf7835162d3d900</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2009.05.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2009.05.022%26sid%3Dliteratum%253Aachs%26aulast%3DLevrero%26aufirst%3DM.%26aulast%3DPollicino%26aufirst%3DT.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DBelloni%26aufirst%3DL.%26aulast%3DRaimondo%26aufirst%3DG.%26aulast%3DDandri%26aufirst%3DM.%26atitle%3DControl%2520of%2520cccDNA%2520function%2520in%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2009%26volume%3D51%26spage%3D581%26epage%3D592%26doi%3D10.1016%2Fj.jhep.2009.05.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Rehermann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nascimbeni, M.</span><span> </span><span class="NLM_article-title">Immunology of hepatitis B virus and hepatitis C virus infection</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span><span class="refDoi"> DOI: 10.1038/nri1573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnri1573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=15738952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslSju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=215-229&author=B.+Rehermannauthor=M.+Nascimbeni&title=Immunology+of+hepatitis+B+virus+and+hepatitis+C+virus+infection&doi=10.1038%2Fnri1573"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7dR"><div class="casContent"><span class="casTitleNuber">7d</span><div class="casTitle"><span class="NLM_cas:atitle">Immunology of hepatitis B virus and hepatitis C virus infection</span></div><div class="casAuthors">Rehermann, Barbara; Nascimbeni, Michelina</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-229</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  More than 500 million people worldwide are persistently infected with the hepatitis B virus (HBV) and/or hepatitis C virus (HCV) and are at risk of developing chronic liver disease, cirrhosis and hepatocellular carcinoma.  Despite many common features in the pathogenesis of HBV- and HCV-related liver disease, these viruses markedly differ in their virol. properties and in their immune escape and survival strategies.  This review assesses recent advances in our understanding of viral hepatitis, contrasts mechanisms of virus-host interaction in acute hepatitis B and hepatitis C, and outlines areas for future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK_aXbF6__BLVg90H21EOLACvtfcHk0lh-milSs7SGMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslSju7k%253D&md5=d9ceed9473106d0f31fade725d16c1a6</span></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=10.1038%2Fnri1573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1573%26sid%3Dliteratum%253Aachs%26aulast%3DRehermann%26aufirst%3DB.%26aulast%3DNascimbeni%26aufirst%3DM.%26atitle%3DImmunology%2520of%2520hepatitis%2520B%2520virus%2520and%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2005%26volume%3D5%26spage%3D215%26epage%3D229%26doi%3D10.1038%2Fnri1573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dahabieh, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battivelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdin, E.</span><span> </span><span class="NLM_article-title">Understanding HIV latency: the road to an HIV cure</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span><span class="refDoi"> DOI: 10.1146/annurev-med-092112-152941</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1146%2Fannurev-med-092112-152941" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2015&pages=407-421&author=M.+S.+Dahabiehauthor=E.+Battivelliauthor=E.+Verdin&title=Understanding+HIV+latency%3A+the+road+to+an+HIV+cure&doi=10.1146%2Fannurev-med-092112-152941"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-092112-152941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-092112-152941%26sid%3Dliteratum%253Aachs%26aulast%3DDahabieh%26aufirst%3DM.%2BS.%26aulast%3DBattivelli%26aufirst%3DE.%26aulast%3DVerdin%26aufirst%3DE.%26atitle%3DUnderstanding%2520HIV%2520latency%253A%2520the%2520road%2520to%2520an%2520HIV%2520cure%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2015%26volume%3D66%26spage%3D407%26epage%3D421%26doi%3D10.1146%2Fannurev-med-092112-152941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Passaes, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sáez-Cirión, A.</span><span> </span><span class="NLM_article-title">HIV cure research: advances and prospects</span> <span class="citation_source-journal">Virology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">454–455</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span><span class="refDoi"> DOI: 10.1016/j.virol.2014.02.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.virol.2014.02.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=454%E2%80%93455&publication_year=2014&pages=340-352&author=C.+P.+Passaesauthor=A.+S%C3%A1ez-Ciri%C3%B3n&title=HIV+cure+research%3A+advances+and+prospects&doi=10.1016%2Fj.virol.2014.02.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2014.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2014.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DPassaes%26aufirst%3DC.%2BP.%26aulast%3DS%25C3%25A1ez-Ciri%25C3%25B3n%26aufirst%3DA.%26atitle%3DHIV%2520cure%2520research%253A%2520advances%2520and%2520prospects%26jtitle%3DVirology%26date%3D2014%26volume%3D454%25E2%2580%2593455%26spage%3D340%26epage%3D352%26doi%3D10.1016%2Fj.virol.2014.02.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Spivak, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planelles, V.</span><span> </span><span class="NLM_article-title">HIV-1 eradication: early trials (and tribulations)</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1016/j.molmed.2015.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.molmed.2015.11.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=10-27&author=A.+M.+Spivakauthor=V.+Planelles&title=HIV-1+eradication%3A+early+trials+%28and+tribulations%29&doi=10.1016%2Fj.molmed.2015.11.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2015.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2015.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DSpivak%26aufirst%3DA.%2BM.%26aulast%3DPlanelles%26aufirst%3DV.%26atitle%3DHIV-1%2520eradication%253A%2520early%2520trials%2520%2528and%2520tribulations%2529%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2016%26volume%3D22%26spage%3D10%26epage%3D27%26doi%3D10.1016%2Fj.molmed.2015.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lucifora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepo, C.</span><span> </span><span class="NLM_article-title">Hepatitis: after HCV cure, HBV cure?</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">376</span><span class="NLM_x">–</span> <span class="NLM_lpage">378</span><span class="refDoi"> DOI: 10.1038/nrgastro.2015.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrgastro.2015.103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=376-378&author=J.+Luciforaauthor=C.+Trepo&title=Hepatitis%3A+after+HCV+cure%2C+HBV+cure%3F&doi=10.1038%2Fnrgastro.2015.103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2015.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2015.103%26sid%3Dliteratum%253Aachs%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DTrepo%26aufirst%3DC.%26atitle%3DHepatitis%253A%2520after%2520HCV%2520cure%252C%2520HBV%2520cure%253F%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2015%26volume%3D12%26spage%3D376%26epage%3D378%26doi%3D10.1038%2Fnrgastro.2015.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Revill, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testoni, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locarnini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoulim, F.</span><span> </span><span class="NLM_article-title">Global strategies are required to cure and eliminate HBV infection</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span><span class="refDoi"> DOI: 10.1038/nrgastro.2016.7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrgastro.2016.7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=239-248&author=P.+Revillauthor=B.+Testoniauthor=S.+Locarniniauthor=F.+Zoulim&title=Global+strategies+are+required+to+cure+and+eliminate+HBV+infection&doi=10.1038%2Fnrgastro.2016.7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2016.7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2016.7%26sid%3Dliteratum%253Aachs%26aulast%3DRevill%26aufirst%3DP.%26aulast%3DTestoni%26aufirst%3DB.%26aulast%3DLocarnini%26aufirst%3DS.%26aulast%3DZoulim%26aufirst%3DF.%26atitle%3DGlobal%2520strategies%2520are%2520required%2520to%2520cure%2520and%2520eliminate%2520HBV%2520infection%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2016%26volume%3D13%26spage%3D239%26epage%3D248%26doi%3D10.1038%2Fnrgastro.2016.7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Zeisel, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucifora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sureau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levrero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knolle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benkirane, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durantel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Autran, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosset, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strick-Marchand, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trépo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrat, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacombe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schinazi, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barré-Sinoussi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delfraissy, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoulim, F.</span><span> </span><span class="NLM_article-title">Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">1314</span><span class="NLM_x">–</span> <span class="NLM_lpage">1326</span><span class="refDoi"> DOI: 10.1136/gutjnl-2014-308943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1136%2Fgutjnl-2014-308943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25670809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVCrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=1314-1326&author=M.+B.+Zeiselauthor=J.+Luciforaauthor=W.+S.+Masonauthor=C.+Sureauauthor=J.+Beckauthor=M.+Levreroauthor=M.+Kannauthor=P.+A.+Knolleauthor=M.+Benkiraneauthor=D.+Durantelauthor=M.+L.+Michelauthor=B.+Autranauthor=F.+L.+Cossetauthor=H.+Strick-Marchandauthor=C.+Tr%C3%A9poauthor=J.+H.+Kaoauthor=F.+Carratauthor=K.+Lacombeauthor=R.+F.+Schinaziauthor=F.+Barr%C3%A9-Sinoussiauthor=J.+F.+Delfraissyauthor=F.+Zoulim&title=Towards+an+HBV+cure%3A+state-of-the-art+and+unresolved+questions%2D%2Dreport+of+the+ANRS+workshop+on+HBV+cure&doi=10.1136%2Fgutjnl-2014-308943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure</span></div><div class="casAuthors">Zeisel, Mirjam B.; Lucifora, Julie; Mason, William S.; Sureau, Camille; Beck, Jurgen; Levrero, Massimo; Kann, Michael; Knolle, Percy A.; Benkirane, Monsef; Durantel, David; Michel, Marie-Louise; Autran, Brigitte; Cosset, Francois-Loic; Strick-Marchand, Helene; Trepo, Christian; Kao, Jia-Horng; Carrat, Fabrice; Lacombe, Karine; Schinazi, Raymond F.; Barre-Sinoussi, Francoise; Delfraissy, Jean-Francois; Zoulim, Fabien</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1314-1326</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma.  Although HBV infection can be efficiently prevented by vaccination, and treatments are available, to date there is no reliable cure for the >240 million individuals that are chronically infected worldwide.  Current treatments can only achieve viral suppression, and lifelong therapy is needed in the majority of infected persons.  In the framework of the French National Agency for Research on AIDS and Viral Hepatitis 'HBV Cure' program, a scientific workshop was held in Paris in June 2014 to define the state-ofthe- art and unanswered questions regarding HBV pathobiol., and to develop a concerted strategy towards an HBV cure.  This review summarizes our current understanding of HBV host-interactions leading to viral persistence, as well as the roadblocks to be overcome to ultimately address unmet medical needs in the treatment of chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq3d3BmB6kC7Vg90H21EOLACvtfcHk0lilUViRwcyVug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVCrt7g%253D&md5=3fb4876ea829381ac9fbf8f9f3deeda7</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2014-308943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2014-308943%26sid%3Dliteratum%253Aachs%26aulast%3DZeisel%26aufirst%3DM.%2BB.%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DMason%26aufirst%3DW.%2BS.%26aulast%3DSureau%26aufirst%3DC.%26aulast%3DBeck%26aufirst%3DJ.%26aulast%3DLevrero%26aufirst%3DM.%26aulast%3DKann%26aufirst%3DM.%26aulast%3DKnolle%26aufirst%3DP.%2BA.%26aulast%3DBenkirane%26aufirst%3DM.%26aulast%3DDurantel%26aufirst%3DD.%26aulast%3DMichel%26aufirst%3DM.%2BL.%26aulast%3DAutran%26aufirst%3DB.%26aulast%3DCosset%26aufirst%3DF.%2BL.%26aulast%3DStrick-Marchand%26aufirst%3DH.%26aulast%3DTr%25C3%25A9po%26aufirst%3DC.%26aulast%3DKao%26aufirst%3DJ.%2BH.%26aulast%3DCarrat%26aufirst%3DF.%26aulast%3DLacombe%26aufirst%3DK.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DBarr%25C3%25A9-Sinoussi%26aufirst%3DF.%26aulast%3DDelfraissy%26aufirst%3DJ.%2BF.%26aulast%3DZoulim%26aufirst%3DF.%26atitle%3DTowards%2520an%2520HBV%2520cure%253A%2520state-of-the-art%2520and%2520unresolved%2520questions--report%2520of%2520the%2520ANRS%2520workshop%2520on%2520HBV%2520cure%26jtitle%3DGut%26date%3D2015%26volume%3D64%26spage%3D1314%26epage%3D1326%26doi%3D10.1136%2Fgutjnl-2014-308943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Nassal, M.</span><span> </span><span class="NLM_article-title">HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">1972</span><span class="NLM_x">–</span> <span class="NLM_lpage">1984</span><span class="refDoi"> DOI: 10.1136/gutjnl-2015-309809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1136%2Fgutjnl-2015-309809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26048673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvVSrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=1972-1984&author=M.+Nassal&title=HBV+cccDNA%3A+viral+persistence+reservoir+and+key+obstacle+for+a+cure+of+chronic+hepatitis+B&doi=10.1136%2Fgutjnl-2015-309809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9dR"><div class="casContent"><span class="casTitleNuber">9d</span><div class="casTitle"><span class="NLM_cas:atitle">HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B</span></div><div class="casAuthors">Nassal, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1972-1984</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">At least 250 million people worldwide are chronically infected with HBV, a small hepatotropic DNA virus that replicates through reverse transcription.  Chronic infection greatly increases the risk for terminal liver disease.  Current therapies rarely achieve a cure due to the refractory nature of an intracellular viral replication intermediate termed covalently closed circular (ccc) DNA.  Upon infection, cccDNA is generated as a plasmid-like episome in the host cell nucleus from the protein-linked relaxed circular (RC) DNA genome in incoming virions.  Its fundamental role is that as template for all viral RNAs, and in consequence new virions.  Biosynthesis of RC-DNA by reverse transcription of the viral pregenomic RNA is now understood in considerable detail, yet conversion of RC-DNA to cccDNA is still obscure, foremostly due to the lack of feasible, cccDNA-dependent assay systems.  Conceptual and recent exptl. data link cccDNA formation to cellular DNA repair, which is increasingly appreciated as a crit. interface between cells and viruses.  Together with new in vitro HBV infection systems, based on the identification of the bile acid transporter sodium taurocholate cotransporting polypeptide as an HBV entry receptor, this offers novel opportunities to decipher, and eventually interfere with, formation of the HBV persistence reservoir.  After a brief overview of the role of cccDNA in the HBV infectious cycle, this review aims to summarize current knowledge on cccDNA mol. biol., to highlight the exptl. restrictions that have hitherto hampered faster progress and to discuss cccDNA as target for new, potentially curative therapies of chronic hepatitis B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQaHzOzO1JXLVg90H21EOLACvtfcHk0lil9coX_gEhTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvVSrsbg%253D&md5=7cbbbccef38636fd9bbcae0a9b869bc9</span></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2015-309809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2015-309809%26sid%3Dliteratum%253Aachs%26aulast%3DNassal%26aufirst%3DM.%26atitle%3DHBV%2520cccDNA%253A%2520viral%2520persistence%2520reservoir%2520and%2520key%2520obstacle%2520for%2520a%2520cure%2520of%2520chronic%2520hepatitis%2520B%26jtitle%3DGut%26date%3D2015%26volume%3D64%26spage%3D1972%26epage%3D1984%26doi%3D10.1136%2Fgutjnl-2015-309809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Dusheiko, G.</span><span> </span><span class="NLM_article-title">Towards the elimination and eradication of hepatitis B</span> <span class="citation_source-journal">J. Virus Eradication</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=4-12&author=G.+Dusheiko&title=Towards+the+elimination+and+eradication+of+hepatitis+B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDusheiko%26aufirst%3DG.%26atitle%3DTowards%2520the%2520elimination%2520and%2520eradication%2520of%2520hepatitis%2520B%26jtitle%3DJ.%2520Virus%2520Eradication%26date%3D2015%26volume%3D1%26spage%3D4%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Zoulim, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durantel, D.</span><span> </span><span class="NLM_article-title">Antiviral therapies and prospects for a cure of chronic hepatitis B</span> <span class="citation_source-journal">Cold Spring Harbor Perspect. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">a021501</span><span class="refDoi"> DOI: 10.1101/cshperspect.a021501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1101%2Fcshperspect.a021501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25833942" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=a021501&author=F.+Zoulimauthor=D.+Durantel&title=Antiviral+therapies+and+prospects+for+a+cure+of+chronic+hepatitis+B&doi=10.1101%2Fcshperspect.a021501"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9f&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a021501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a021501%26sid%3Dliteratum%253Aachs%26aulast%3DZoulim%26aufirst%3DF.%26aulast%3DDurantel%26aufirst%3DD.%26atitle%3DAntiviral%2520therapies%2520and%2520prospects%2520for%2520a%2520cure%2520of%2520chronic%2520hepatitis%2520B%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2015%26volume%3D5%26spage%3Da021501%26doi%3D10.1101%2Fcshperspect.a021501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Choo, Q. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overby, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, M.</span><span> </span><span class="NLM_article-title">Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">244</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span><span class="refDoi"> DOI: 10.1126/science.2523562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1126%2Fscience.2523562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=2523562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaL1MXit1Khtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=1989&pages=359-362&author=Q.+L.+Chooauthor=G.+Kuoauthor=A.+J.+Weinerauthor=L.+R.+Overbyauthor=D.+W.+Bradleyauthor=M.+Houghton&title=Isolation+of+a+cDNA+clone+derived+from+a+blood-borne+non-A%2C+non-B+viral+hepatitis+genome&doi=10.1126%2Fscience.2523562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome</span></div><div class="casAuthors">Choo, Qui Lim; Kuo, George; Weiner, Amy J.; Overby, Lacy R.; Bradley, Daniel W.; Houghton, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">4902</span>),
    <span class="NLM_cas:pages">359-62</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A random-primed cDNA library was constructed from plasma contg. the uncharacterized non-A, non-B hepatitis (NANBH) agent and screened with serum from a patient diagnosed with NANBH.  A cDNA clone was isolated that was shown to encode an antigen assocd. specifically with NANBH infections.  This clone is not derived from host DNA but from an RNA mol. present in NANBH infections that consists of ≥10,000 nucleotides, and that is pos.-stranded with respect to the encoded NANBH antigen.  These data indicate that this clone is derived from the genome of the NANBH agent and are consistent with the agent being similar to the togaviridae or flaviviridae.  This mol. approach should be of great value in the isolation and characterization of other unidentified infectious agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqorpVFx7nEkrVg90H21EOLACvtfcHk0lil9coX_gEhTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXit1Khtrk%253D&md5=25161cf212790856dd29d3aaf78f20b8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscience.2523562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2523562%26sid%3Dliteratum%253Aachs%26aulast%3DChoo%26aufirst%3DQ.%2BL.%26aulast%3DKuo%26aufirst%3DG.%26aulast%3DWeiner%26aufirst%3DA.%2BJ.%26aulast%3DOverby%26aufirst%3DL.%2BR.%26aulast%3DBradley%26aufirst%3DD.%2BW.%26aulast%3DHoughton%26aufirst%3DM.%26atitle%3DIsolation%2520of%2520a%2520cDNA%2520clone%2520derived%2520from%2520a%2520blood-borne%2520non-A%252C%2520non-B%2520viral%2520hepatitis%2520genome%26jtitle%3DScience%26date%3D1989%26volume%3D244%26spage%3D359%26epage%3D362%26doi%3D10.1126%2Fscience.2523562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Trepo, C.</span><span> </span><span class="NLM_article-title">A brief history of hepatitis milestones</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span><span class="refDoi"> DOI: 10.1111/liv.12409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fliv.12409" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=29-37&issue=Suppl.+1&author=C.+Trepo&title=A+brief+history+of+hepatitis+milestones&doi=10.1111%2Fliv.12409"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fliv.12409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fliv.12409%26sid%3Dliteratum%253Aachs%26aulast%3DTrepo%26aufirst%3DC.%26atitle%3DA%2520brief%2520history%2520of%2520hepatitis%2520milestones%26jtitle%3DLiver%2520Int.%26date%3D2014%26volume%3D34%26issue%3DSuppl.%25201%26spage%3D29%26epage%3D37%26doi%3D10.1111%2Fliv.12409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Houghton, M.</span><span> </span><span class="NLM_article-title">Discovery of the hepatitis C virus</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">82</span><span class="NLM_x">–</span> <span class="NLM_lpage">88</span><span class="refDoi"> DOI: 10.1111/j.1478-3231.2008.01925.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fj.1478-3231.2008.01925.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=82-88&author=M.+Houghton&title=Discovery+of+the+hepatitis+C+virus&doi=10.1111%2Fj.1478-3231.2008.01925.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1111%2Fj.1478-3231.2008.01925.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1478-3231.2008.01925.x%26sid%3Dliteratum%253Aachs%26aulast%3DHoughton%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DLiver%2520Int.%26date%3D2009%26volume%3D29%26spage%3D82%26epage%3D88%26doi%3D10.1111%2Fj.1478-3231.2008.01925.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Houghton, M.</span><span> </span><span class="NLM_article-title">The long and winding road leading to the identification of the hepatitis C virus</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">939</span><span class="NLM_x">–</span> <span class="NLM_lpage">948</span><span class="refDoi"> DOI: 10.1016/j.jhep.2009.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2009.08.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2009&pages=939-948&author=M.+Houghton&title=The+long+and+winding+road+leading+to+the+identification+of+the+hepatitis+C+virus&doi=10.1016%2Fj.jhep.2009.08.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2009.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2009.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DHoughton%26aufirst%3DM.%26atitle%3DThe%2520long%2520and%2520winding%2520road%2520leading%2520to%2520the%2520identification%2520of%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Hepatol.%26date%3D2009%26volume%3D51%26spage%3D939%26epage%3D948%26doi%3D10.1016%2Fj.jhep.2009.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Choo, Q. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallegos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coit, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina-Selby, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, M.</span><span> </span><span class="NLM_article-title">Genetic organization and diversity of the hepatitis C virus</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">2451</span><span class="NLM_x">–</span> <span class="NLM_lpage">2455</span><span class="refDoi"> DOI: 10.1073/pnas.88.6.2451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1073%2Fpnas.88.6.2451" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=2451-2455&author=Q.+L.+Chooauthor=K.+H.+Richmanauthor=J.+H.+Hanauthor=K.+Bergerauthor=C.+Leeauthor=C.+Dongauthor=C.+Gallegosauthor=D.+Coitauthor=R.+Medina-Selbyauthor=P.+J.+Barrauthor=A.+J.+Weinerauthor=D.+W.+Bradleyauthor=G.+Kuoauthor=M.+Houghton&title=Genetic+organization+and+diversity+of+the+hepatitis+C+virus&doi=10.1073%2Fpnas.88.6.2451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.88.6.2451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.88.6.2451%26sid%3Dliteratum%253Aachs%26aulast%3DChoo%26aufirst%3DQ.%2BL.%26aulast%3DRichman%26aufirst%3DK.%2BH.%26aulast%3DHan%26aufirst%3DJ.%2BH.%26aulast%3DBerger%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DGallegos%26aufirst%3DC.%26aulast%3DCoit%26aufirst%3DD.%26aulast%3DMedina-Selby%26aufirst%3DR.%26aulast%3DBarr%26aufirst%3DP.%2BJ.%26aulast%3DWeiner%26aufirst%3DA.%2BJ.%26aulast%3DBradley%26aufirst%3DD.%2BW.%26aulast%3DKuo%26aufirst%3DG.%26aulast%3DHoughton%26aufirst%3DM.%26atitle%3DGenetic%2520organization%2520and%2520diversity%2520of%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1991%26volume%3D88%26spage%3D2451%26epage%3D2455%26doi%3D10.1073%2Fpnas.88.6.2451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Kato, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hijikata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ootsuyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkoshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimotohno, K.</span><span> </span><span class="NLM_article-title">Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">9524</span><span class="NLM_x">–</span> <span class="NLM_lpage">9528</span><span class="refDoi"> DOI: 10.1073/pnas.87.24.9524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1073%2Fpnas.87.24.9524" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1990&pages=9524-9528&author=N.+Katoauthor=M.+Hijikataauthor=Y.+Ootsuyamaauthor=M.+Nakagawaauthor=S.+Ohkoshiauthor=T.+Sugimuraauthor=K.+Shimotohno&title=Molecular+cloning+of+the+human+hepatitis+C+virus+genome+from+Japanese+patients+with+non-A%2C+non-B+hepatitis&doi=10.1073%2Fpnas.87.24.9524"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.87.24.9524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.87.24.9524%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DN.%26aulast%3DHijikata%26aufirst%3DM.%26aulast%3DOotsuyama%26aufirst%3DY.%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DOhkoshi%26aufirst%3DS.%26aulast%3DSugimura%26aufirst%3DT.%26aulast%3DShimotohno%26aufirst%3DK.%26atitle%3DMolecular%2520cloning%2520of%2520the%2520human%2520hepatitis%2520C%2520virus%2520genome%2520from%2520Japanese%2520patients%2520with%2520non-A%252C%2520non-B%2520hepatitis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1990%26volume%3D87%26spage%3D9524%26epage%3D9528%26doi%3D10.1073%2Fpnas.87.24.9524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Grakoui, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCourt, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wychowski, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinstone, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">2832</span><span class="NLM_x">–</span> <span class="NLM_lpage">2843</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FJVI.67.5.2832-2843.1993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=8386278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK3sXktVClsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1993&pages=2832-2843&author=A.+Grakouiauthor=D.+W.+McCourtauthor=C.+Wychowskiauthor=S.+M.+Feinstoneauthor=C.+M.+Rice&title=Characterization+of+the+hepatitis+C+virus-encoded+serine+proteinase%3A+determination+of+proteinase-dependent+polyprotein+cleavage+sites"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the hepatitis C virus-encoded serine proteinase: Determination of proteinase-dependent polyprotein cleavage sites</span></div><div class="casAuthors">Grakoui, Arash; McCourt, David W.; Wychowski, Czeslaw; Feinstone, Stephen M.; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2832-43</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">Processing of the hepatitis C virus (HCV) H strain polyprotein yields at least nine distinct cleavage products: NH2-C-E1-E2- NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH.  Site-directed mutagenesis and transient expression analyses were used to study the role of a putative serine proteinase domain, located in the N-terminal one-third of the NS3 protein, in proteolytic processing of HCV polyproteins.  All four cleavages which occur C terminal to the proteinase domain (3/4A, 4A/4B, 4B/5A, and 5A/5B) were abolished by substitution of alanine for either of two predicted residues (His-1083 and Ser-1165) in the proteinase catalytic triad.  However, such substitutions have no observable effect on cleavages in the structural region or at the 2/3 site.  Deletion analyses suggest that the structural and NS2 regions of the polyprotein are not required for the HCV NS3 proteinase activity.  NS3 proteinase-dependent cleavage sites were localized by N-terminal sequence anal. of NS4a, NS4B, NS5A, and NS5B.  Sequence comparison of the residues flanking these cleavage sites for all sequenced HCV strains reveals conserved residues which may play a role in detg. HCV NS3 proteinase substrate specificity.  These features include an acidic residue (Asp or Glu) at the P6 position, a Cys or Thr residue at the P1 position, and a Ser or Ala residue at the P1' position.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoXwT-StOiG7Vg90H21EOLACvtfcHk0lg-MFBqyNHdiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktVClsrY%253D&md5=c80cee9b19dfba43766fb0026d566d1d</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1128%2FJVI.67.5.2832-2843.1993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.67.5.2832-2843.1993%26sid%3Dliteratum%253Aachs%26aulast%3DGrakoui%26aufirst%3DA.%26aulast%3DMcCourt%26aufirst%3DD.%2BW.%26aulast%3DWychowski%26aufirst%3DC.%26aulast%3DFeinstone%26aufirst%3DS.%2BM.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DCharacterization%2520of%2520the%2520hepatitis%2520C%2520virus-encoded%2520serine%2520proteinase%253A%2520determination%2520of%2520proteinase-dependent%2520polyprotein%2520cleavage%2520sites%26jtitle%3DJ.%2520Virol.%26date%3D1993%26volume%3D67%26spage%3D2832%26epage%3D2843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahlborn-Laake, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mous, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, H.</span><span> </span><span class="NLM_article-title">Nonstructural protein 3 of the hepatitis C virus encodes a serine type proteinase required for cleavage at the NS3/4 and NS4/5 junctions</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">3835</span><span class="NLM_x">–</span> <span class="NLM_lpage">3844</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1993&pages=3835-3844&author=R.+Bartenschlagerauthor=R.+Ahlborn-Laakeauthor=J.+Mousauthor=H.+Jacobsen&title=Nonstructural+protein+3+of+the+hepatitis+C+virus+encodes+a+serine+type+proteinase+required+for+cleavage+at+the+NS3%2F4+and+NS4%2F5+junctions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBartenschlager%26aufirst%3DR.%26aulast%3DAhlborn-Laake%26aufirst%3DR.%26aulast%3DMous%26aufirst%3DJ.%26aulast%3DJacobsen%26aufirst%3DH.%26atitle%3DNonstructural%2520protein%25203%2520of%2520the%2520hepatitis%2520C%2520virus%2520encodes%2520a%2520serine%2520type%2520proteinase%2520required%2520for%2520cleavage%2520at%2520the%2520NS3%252F4%2520and%2520NS4%252F5%2520junctions%26jtitle%3DJ.%2520Virol.%26date%3D1993%26volume%3D67%26spage%3D3835%26epage%3D3844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Eckart, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selby, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masiarz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, Q. L.</span><span> </span><span class="NLM_article-title">The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">406</span><span class="refDoi"> DOI: 10.1006/bbrc.1993.1429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1006%2Fbbrc.1993.1429" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=1993&pages=399-406&author=M.+R.+Eckartauthor=M.+Selbyauthor=F.+Masiarzauthor=C.+Leeauthor=K.+Bergerauthor=K.+Crawfordauthor=C.+Kuoauthor=G.+Kuoauthor=M.+Houghtonauthor=Q.+L.+Choo&title=The+hepatitis+C+virus+encodes+a+serine+protease+involved+in+processing+of+the+putative+nonstructural+proteins+from+the+viral+polyprotein+precursor&doi=10.1006%2Fbbrc.1993.1429"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1993.1429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1993.1429%26sid%3Dliteratum%253Aachs%26aulast%3DEckart%26aufirst%3DM.%2BR.%26aulast%3DSelby%26aufirst%3DM.%26aulast%3DMasiarz%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DBerger%26aufirst%3DK.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DKuo%26aufirst%3DC.%26aulast%3DKuo%26aufirst%3DG.%26aulast%3DHoughton%26aufirst%3DM.%26aulast%3DChoo%26aufirst%3DQ.%2BL.%26atitle%3DThe%2520hepatitis%2520C%2520virus%2520encodes%2520a%2520serine%2520protease%2520involved%2520in%2520processing%2520of%2520the%2520putative%2520nonstructural%2520proteins%2520from%2520the%2520viral%2520polyprotein%2520precursor%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1993%26volume%3D192%26spage%3D399%26epage%3D406%26doi%3D10.1006%2Fbbrc.1993.1429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Hijikata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizushima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakiuchi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimotohno, K.</span><span> </span><span class="NLM_article-title">Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4665</span><span class="NLM_x">–</span> <span class="NLM_lpage">4675</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=8392606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK3sXlsFChsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1993&pages=4665-4675&author=M.+Hijikataauthor=H.+Mizushimaauthor=T.+Akagiauthor=S.+Moriauthor=N.+Kakiuchiauthor=N.+Katoauthor=T.+Tanakaauthor=K.+Kimuraauthor=K.+Shimotohno&title=Two+distinct+proteinase+activities+required+for+the+processing+of+a+putative+nonstructural+precursor+protein+of+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus</span></div><div class="casAuthors">Hijikata, Makoto; Mizushima, Hiroto; Akagi, Tsuyoshi; Mori, Shigehisa; Kakiuchi, Nobuko; Kato, Nobuyuki; Tanaka, Torahiko; Kimura, Koichi; Shimotohno, Kunitada</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4665-75</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">Gene products of hepatitis C virus (HCV), a possible major causative agent of posttransfusion non-A, non-B hepatitis, are considered to be produced from a precursor polyprotein via proteolytic processing mediated by either host cell or viral proteinases.  The presence of HCV serine proteinase has been proposed from analyses of amino acid sequence homol.  To examine the processing mechanism of the HCV precursor polyprotein, the amino-terminal region of the putative nonstructural protein region of the HCV genome, contg. the serine proteinase motif, was expressed and analyzed by using an in vitro transcription/translation system and a transient expression system in cultured cells.  Two distinct proteinase activities which function in the prodn. of a 70-kDa protein (p70) from the precursor polyprotein were detected.  One of these proteinase activities, which cleaved the C-terminal side of p70, required the presence of the serine proteinase motif, which is located in the N-terminal region of p70.  This suggested that the predicted HCV serine proteinase was functional.  The other activity, which was responsible for the cleavage of the N-terminal side of p70, required the expression of the region upstream and downstream of that cleavage site, including the p70 serine proteinase domain.  From the results of pulse-chase anal., using proteinase inhibitors coupled with a point mutation anal., the latter activity was proposed to be a novel zinc-dependent metalloproteinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZzbnHoEE0Q7Vg90H21EOLACvtfcHk0liQRrPpiYUWBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsFChsLk%253D&md5=aef2e23cfd63d9841d5161b53ef4af34</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHijikata%26aufirst%3DM.%26aulast%3DMizushima%26aufirst%3DH.%26aulast%3DAkagi%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DS.%26aulast%3DKakiuchi%26aufirst%3DN.%26aulast%3DKato%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DShimotohno%26aufirst%3DK.%26atitle%3DTwo%2520distinct%2520proteinase%2520activities%2520required%2520for%2520the%2520processing%2520of%2520a%2520putative%2520nonstructural%2520precursor%2520protein%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Virol.%26date%3D1993%26volume%3D67%26spage%3D4665%26epage%3D4675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Körner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herian, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">8416</span><span class="NLM_x">–</span> <span class="NLM_lpage">8428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=9343198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK2sXmvV2hs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1997&pages=8416-8428&author=V.+Lohmannauthor=F.+K%C3%B6rnerauthor=U.+Herianauthor=R.+Bartenschlager&title=Biochemical+properties+of+hepatitis+C+virus+NS5B+RNA-dependent+RNA+polymerase+and+identification+of+amino+acid+sequence+motifs+essential+for+enzymatic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymic activity</span></div><div class="casAuthors">Lohmann, Volker; Korner, Frank; Herian, Ulrike; Bartenschlager, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">8416-8428</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The NS5B protein of the hepatitis C virus (HCV) is an RNA-dependent RNA polymerase (RdRp) (S.-E. Behrens, L. Tomei, and R. De Francesco, EMBO J. 15:12-22, 1996) that is assumed to be required for replication of the viral genome.  To further study the biochem. and structural properties of this enzyme, an NS5B-hexahistidine fusion protein was expressed with recombinant baculoviruses in insect cells and purified to near homogeneity.  The enzyme was found to have a primer-dependent RdRp activity that was able to copy a complete in vitro-transcribed HCV genome in the absence of addnl. viral or cellular factors.  Filter binding assays and competition expts. showed that the purified enzyme binds RNA with no clear preference for HCV 3'-end sequences.  Binding to homopolymeric RNAs was also examd., and the following order of specificity was obsd.: poly(U) > poly(G) > poly(A) > poly(C).  An inverse order was found for the RdRp activity, which used poly(C) most efficiently as a template but was inactive on poly(U) and poly(G), suggesting that a high binding affinity between polymerase and template interferes with processivity.  By using a mutational anal., four amino acid sequence motifs crucial for RdRp activity were identified.  While most substitutions of conserved residues within these motifs severely reduced the enzymic activities, a single substitution in motif D which enhanced the RdRp activity by about 50% was found.  Deletion studies indicate that amino acid residues at the very termini, in particular the amino terminus, are important for RdRp activity but not for RNA binding.  Finally, we found a terminal transferase activity assocd. with the purified enzyme.  However, this activity was also detected with NS5B proteins with an inactive RdRp, with an NS4B protein purified in the same way, and with wild-type baculovirus, suggesting that it is not an inherent activity of NS5B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdCeTDzvlRArVg90H21EOLACvtfcHk0liQRrPpiYUWBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvV2hs7s%253D&md5=98640d185270f0b331db0fa0624865cd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DK%25C3%25B6rner%26aufirst%3DF.%26aulast%3DHerian%26aufirst%3DU.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DBiochemical%2520properties%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA-dependent%2520RNA%2520polymerase%2520and%2520identification%2520of%2520amino%2520acid%2520sequence%2520motifs%2520essential%2520for%2520enzymatic%2520activity%26jtitle%3DJ.%2520Virol.%26date%3D1997%26volume%3D71%26spage%3D8416%26epage%3D8428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">4373</span><span class="NLM_x">–</span> <span class="NLM_lpage">4380</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=7769699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK2MXmt1agsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1995&pages=4373-4380&author=C.+Linauthor=J.+A.+Thomsonauthor=C.+M.+Rice&title=A+central+region+in+the+hepatitis+C+virus+NS4A+protein+allows+formation+of+an+active+NS3-NS4A+serine+proteinase+complex+in+vivo+and+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro</span></div><div class="casAuthors">Lin, Chao; Thomson, John A.; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4373-80</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A virus-encoded serine proteinase mediates four site-specific cleavages in the hepatitis C virus polyprotein.  In addn. to the catalytic domain, which is located in the N-terminal one-third of nonstructural protein NS3, the 54-residue NS4A protein is required for cleavage at some but not all sites.  Here, the authors provide evidence for a non-ionic detergent-stable interaction between NS4A and the NS3 serine proteinase domain and demonstrate that the central region of NS4A plays a key role in NS4A-dependent processing.  Hydrophobic residues, in particular Ile-29, were shown to be important for NS4A activity, and a synthetic peptide, spanning NS4A residues 22 to 34, could substitute for intact NS4A in a cell-free trans cleavage assay.  Furthermore, NS4A mutations, which abolished or inhibited processing, correlated with destabilization of the NS3-NS4A complex.  These results suggest that a stable interaction exists between the central region of NS4A and the NS3 catalytic domain which is required for NS4A-dependent processing.  Since NS4A is required for processing at certain serine proteinase-dependent cleavage sites, this interaction may represent a new target for development of antiviral compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMCmcNIeRxo7Vg90H21EOLACvtfcHk0lixSXuj62rNsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmt1agsrg%253D&md5=2b8f528b4ac4bcee3033adf6b100243d</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.%26aulast%3DThomson%26aufirst%3DJ.%2BA.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DA%2520central%2520region%2520in%2520the%2520hepatitis%2520C%2520virus%2520NS4A%2520protein%2520allows%2520formation%2520of%2520an%2520active%2520NS3-NS4A%2520serine%2520proteinase%2520complex%2520in%2520vivo%2520and%2520in%2520vitro%26jtitle%3DJ.%2520Virol.%26date%3D1995%26volume%3D69%26spage%3D4373%26epage%3D4380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Landro, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raybuck, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luong, Y. P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Malley, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harebeson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgenstern, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livingston, D. J.</span><span> </span><span class="NLM_article-title">Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect <i>via</i> kinetic analysis and inhibitor mapping</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">9340</span><span class="NLM_x">–</span> <span class="NLM_lpage">9348</span><span class="refDoi"> DOI: 10.1021/bi963054n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi963054n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=9340-9348&author=J.+A.+Landroauthor=S.+A.+Raybuckauthor=Y.+P.+C.+Luongauthor=E.+T.+O%E2%80%99Malleyauthor=S.+L.+Harebesonauthor=K.+A.+Morgensternauthor=G.+Raoauthor=D.+J.+Livingston&title=Mechanistic+role+of+an+NS4A+peptide+cofactor+with+the+truncated+NS3+protease+of+hepatitis+C+virus%3A+elucidation+of+the+NS4A+stimulatory+effect+via+kinetic+analysis+and+inhibitor+mapping&doi=10.1021%2Fbi963054n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1021%2Fbi963054n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi963054n%26sid%3Dliteratum%253Aachs%26aulast%3DLandro%26aufirst%3DJ.%2BA.%26aulast%3DRaybuck%26aufirst%3DS.%2BA.%26aulast%3DLuong%26aufirst%3DY.%2BP.%2BC.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DE.%2BT.%26aulast%3DHarebeson%26aufirst%3DS.%2BL.%26aulast%3DMorgenstern%26aufirst%3DK.%2BA.%26aulast%3DRao%26aufirst%3DG.%26aulast%3DLivingston%26aufirst%3DD.%2BJ.%26atitle%3DMechanistic%2520role%2520of%2520an%2520NS4A%2520peptide%2520cofactor%2520with%2520the%2520truncated%2520NS3%2520protease%2520of%2520hepatitis%2520C%2520virus%253A%2520elucidation%2520of%2520the%2520NS4A%2520stimulatory%2520effect%2520via%2520kinetic%2520analysis%2520and%2520inhibitor%2520mapping%26jtitle%3DBiochemistry%26date%3D1997%26volume%3D36%26spage%3D9340%26epage%3D9348%26doi%3D10.1021%2Fbi963054n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Suzich, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer-Hill, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrener, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grakoui, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinstone, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collett, M. S.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS3 protein polynucleotide stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">6152</span><span class="NLM_x">–</span> <span class="NLM_lpage">6158</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1993&pages=6152-6158&author=J.+A.+Suzichauthor=J.+K.+Tamuraauthor=F.+Palmer-Hillauthor=P.+Warrenerauthor=A.+Grakouiauthor=C.+M.+Riceauthor=S.+M.+Feinstoneauthor=M.+S.+Collett&title=Hepatitis+C+virus+NS3+protein+polynucleotide+stimulated+nucleoside+triphosphatase+and+comparison+with+the+related+pestivirus+and+flavivirus+enzymes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSuzich%26aufirst%3DJ.%2BA.%26aulast%3DTamura%26aufirst%3DJ.%2BK.%26aulast%3DPalmer-Hill%26aufirst%3DF.%26aulast%3DWarrener%26aufirst%3DP.%26aulast%3DGrakoui%26aufirst%3DA.%26aulast%3DRice%26aufirst%3DC.%2BM.%26aulast%3DFeinstone%26aufirst%3DS.%2BM.%26aulast%3DCollett%26aufirst%3DM.%2BS.%26atitle%3DHepatitis%2520C%2520virus%2520NS3%2520protein%2520polynucleotide%2520stimulated%2520nucleoside%2520triphosphatase%2520and%2520comparison%2520with%2520the%2520related%2520pestivirus%2520and%2520flavivirus%2520enzymes%26jtitle%3DJ.%2520Virol.%26date%3D1993%26volume%3D67%26spage%3D6152%26epage%3D6158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Kolykhalov, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihalik, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinstone, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′-nontranslated region are essential for virus replication <i>in vivo</i></span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">2046</span><span class="NLM_x">–</span> <span class="NLM_lpage">2051</span><span class="refDoi"> DOI: 10.1128/JVI.74.4.2046-2051.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FJVI.74.4.2046-2051.2000" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2000&pages=2046-2051&author=A.+A.+Kolykhalovauthor=K.+Mihalikauthor=S.+M.+Feinstoneauthor=C.+M.+Rice&title=Hepatitis+C+virus-encoded+enzymatic+activities+and+conserved+RNA+elements+in+the+3%E2%80%B2-nontranslated+region+are+essential+for+virus+replication+in+vivo&doi=10.1128%2FJVI.74.4.2046-2051.2000"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1128%2FJVI.74.4.2046-2051.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.74.4.2046-2051.2000%26sid%3Dliteratum%253Aachs%26aulast%3DKolykhalov%26aufirst%3DA.%2BA.%26aulast%3DMihalik%26aufirst%3DK.%26aulast%3DFeinstone%26aufirst%3DS.%2BM.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DHepatitis%2520C%2520virus-encoded%2520enzymatic%2520activities%2520and%2520conserved%2520RNA%2520elements%2520in%2520the%25203%25E2%2580%25B2-nontranslated%2520region%2520are%2520essential%2520for%2520virus%2520replication%2520in%2520vivo%26jtitle%3DJ.%2520Virol.%26date%3D2000%26volume%3D74%26spage%3D2046%26epage%3D2051%26doi%3D10.1128%2FJVI.74.4.2046-2051.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Hepatitis C virus replicons: potential role for drug development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">911</span><span class="NLM_x">–</span> <span class="NLM_lpage">916</span><span class="refDoi"> DOI: 10.1038/nrd942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrd942" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=911-916&author=R.+Bartenschlager&title=Hepatitis+C+virus+replicons%3A+potential+role+for+drug+development&doi=10.1038%2Fnrd942"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1038%2Fnrd942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd942%26sid%3Dliteratum%253Aachs%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DHepatitis%2520C%2520virus%2520replicons%253A%2520potential%2520role%2520for%2520drug%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D911%26epage%3D916%26doi%3D10.1038%2Fnrd942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">The hepatitis C virus replicon system: from basic research to clinical application</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">216</span><span class="refDoi"> DOI: 10.1016/j.jhep.2005.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2005.05.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2005&pages=210-216&author=R.+Bartenschlager&title=The+hepatitis+C+virus+replicon+system%3A+from+basic+research+to+clinical+application&doi=10.1016%2Fj.jhep.2005.05.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2005.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2005.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DThe%2520hepatitis%2520C%2520virus%2520replicon%2520system%253A%2520from%2520basic%2520research%2520to%2520clinical%2520application%26jtitle%3DJ.%2520Hepatol.%26date%3D2005%26volume%3D43%26spage%3D210%26epage%3D216%26doi%3D10.1016%2Fj.jhep.2005.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">On the history of hepatitis C virus cell culture systems</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1627</span><span class="NLM_x">–</span> <span class="NLM_lpage">1642</span><span class="refDoi"> DOI: 10.1021/jm401401n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401401n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ylsrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1627-1642&author=V.+Lohmannauthor=R.+Bartenschlager&title=On+the+history+of+hepatitis+C+virus+cell+culture+systems&doi=10.1021%2Fjm401401n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21cR"><div class="casContent"><span class="casTitleNuber">21c</span><div class="casTitle"><span class="NLM_cas:atitle">On the History of Hepatitis C Virus Cell Culture Systems</span></div><div class="casAuthors">Lohmann, Volker; Bartenschlager, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1627-1642</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  HCV infections are a major global health burden.  After the identification of the virus in 1989, insights into viral replication and drug development have long been hampered by the lack of efficient cell culture models.  Their establishment was an important prerequisite for the development of selective antivirals.  This review describes the initial difficulties to achieve HCV replication in cell culture, finally leading to the establishment of subgenomic replicons and the infectious virus model (HCVcc).  The review further summarizes the current state of HCV cell culture systems with respect to available virus isolates, engineered genomes, and cell types allowing efficient HCV propagation.  Finally, we comment on how these cell culture models contributed to the development of directly acting antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYlObUbN-_cLVg90H21EOLACvtfcHk0ljKlTBGUpEhqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ylsrnP&md5=09643efac2375d3c08c5d40e515a697f</span></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=10.1021%2Fjm401401n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401401n%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DOn%2520the%2520history%2520of%2520hepatitis%2520C%2520virus%2520cell%2520culture%2520systems%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1627%26epage%3D1642%26doi%3D10.1021%2Fjm401401n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Morikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lange, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gouttenoire, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meylan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brass, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moradpour, D.</span><span> </span><span class="NLM_article-title">Nonstructural protein 3–4A: the Swiss army knife of hepatitis C virus</span> <span class="citation_source-journal">J. Viral. Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span><span class="refDoi"> DOI: 10.1111/j.1365-2893.2011.01451.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fj.1365-2893.2011.01451.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=305-315&author=K.+Morikawaauthor=C.+M.+Langeauthor=J.+Gouttenoireauthor=E.+Meylanauthor=V.+Brassauthor=F.+Peninauthor=D.+Moradpour&title=Nonstructural+protein+3%E2%80%934A%3A+the+Swiss+army+knife+of+hepatitis+C+virus&doi=10.1111%2Fj.1365-2893.2011.01451.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2893.2011.01451.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2893.2011.01451.x%26sid%3Dliteratum%253Aachs%26aulast%3DMorikawa%26aufirst%3DK.%26aulast%3DLange%26aufirst%3DC.%2BM.%26aulast%3DGouttenoire%26aufirst%3DJ.%26aulast%3DMeylan%26aufirst%3DE.%26aulast%3DBrass%26aufirst%3DV.%26aulast%3DPenin%26aufirst%3DF.%26aulast%3DMoradpour%26aufirst%3DD.%26atitle%3DNonstructural%2520protein%25203%25E2%2580%25934A%253A%2520the%2520Swiss%2520army%2520knife%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Viral.%2520Hepatitis%26date%3D2011%26volume%3D18%26spage%3D305%26epage%3D315%26doi%3D10.1111%2Fj.1365-2893.2011.01451.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Raney, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moustafa, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span> </span><span class="NLM_article-title">Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">22725</span><span class="NLM_x">–</span> <span class="NLM_lpage">22731</span><span class="refDoi"> DOI: 10.1074/jbc.R110.125294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1074%2Fjbc.R110.125294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=20457607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFenu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=22725-22731&author=K.+D.+Raneyauthor=S.+D.+Sharmaauthor=I.+M.+Moustafaauthor=C.+E.+Cameron&title=Hepatitis+C+virus+non-structural+protein+3+%28HCV+NS3%29%3A+a+multifunctional+antiviral+target&doi=10.1074%2Fjbc.R110.125294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C Virus Non-structural Protein 3 (HCV NS3): A Multifunctional Antiviral Target</span></div><div class="casAuthors">Raney, Kevin D.; Sharma, Suresh D.; Moustafa, Ibrahim M.; Cameron, Craig E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">22725-22731</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus non-structural protein 3 contains a serine protease and an RNA helicase.  Protease cleaves the genome-encoded polyprotein and inactivates cellular proteins required for innate immunity.  Protease has emerged as an important target for the development of antiviral therapeutics, but drug resistance has turned out to be an obstacle in the clinic.  Helicase is required for both genome replication and virus assembly.  Mechanistic and structural studies of helicase have hurled this enzyme into a prominent position in the field of helicase enzymol.  Nevertheless, studies of helicase as an antiviral target remain in their infancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI9DvVa0U07rVg90H21EOLACvtfcHk0ljKlTBGUpEhqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFenu70%253D&md5=0e7a635cf9517099ca66d4d1aaa4bfe0</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R110.125294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R110.125294%26sid%3Dliteratum%253Aachs%26aulast%3DRaney%26aufirst%3DK.%2BD.%26aulast%3DSharma%26aufirst%3DS.%2BD.%26aulast%3DMoustafa%26aufirst%3DI.%2BM.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26atitle%3DHepatitis%2520C%2520virus%2520non-structural%2520protein%25203%2520%2528HCV%2520NS3%2529%253A%2520a%2520multifunctional%2520antiviral%2520target%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D22725%26epage%3D22731%26doi%3D10.1074%2Fjbc.R110.125294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Behrens, S.-E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span> </span><span class="NLM_article-title">Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1996&pages=12-22&author=S.-E.+Behrensauthor=L.+Tomeiauthor=R.+De+Francesco&title=Identification+and+properties+of+the+RNA-dependent+RNA+polymerase+of+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBehrens%26aufirst%3DS.-E.%26aulast%3DTomei%26aufirst%3DL.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26atitle%3DIdentification%2520and%2520properties%2520of%2520the%2520RNA-dependent%2520RNA%2520polymerase%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DEMBO%2520J.%26date%3D1996%26volume%3D15%26spage%3D12%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Körner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus</span> <span class="citation_source-journal">Virology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">249</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.1006/viro.1998.9311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1006%2Fviro.1998.9311" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=249&publication_year=1998&pages=108-118&author=V.+Lohmannauthor=A.+Roosauthor=F.+K%C3%B6rnerauthor=J.+O.+Kochauthor=R.+Bartenschlager&title=Biochemical+and+kinetic+analyses+of+NS5B+RNA-dependent+RNA+polymerase+of+the+hepatitis+C+virus&doi=10.1006%2Fviro.1998.9311"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1006%2Fviro.1998.9311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fviro.1998.9311%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DRoos%26aufirst%3DA.%26aulast%3DK%25C3%25B6rner%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DJ.%2BO.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DBiochemical%2520and%2520kinetic%2520analyses%2520of%2520NS5B%2520RNA-dependent%2520RNA%2520polymerase%2520of%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DVirology%26date%3D1998%26volume%3D249%26spage%3D108%26epage%3D118%26doi%3D10.1006%2Fviro.1998.9311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sofia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosley, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, B. S.</span><span> </span><span class="NLM_article-title">Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2481</span><span class="NLM_x">–</span> <span class="NLM_lpage">2531</span><span class="refDoi"> DOI: 10.1021/jm201384j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201384j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1aqu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2481-2531&author=M.+J.+Sofiaauthor=W.+Changauthor=P.+A.+Furmanauthor=R.+T.+Mosleyauthor=B.+S.+Ross&title=Nucleoside%2C+nucleotide%2C+and+non-nucleoside+inhibitors+of+hepatitis+C+virus+NS5B+RNA-dependent+RNA-polymerase&doi=10.1021%2Fjm201384j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23cR"><div class="casContent"><span class="casTitleNuber">23c</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase</span></div><div class="casAuthors">Sofia, Michael J.; Chang, Wonsuk; Furman, Phillip A.; Mosley, Ralph T.; Ross, Bruce S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2481-2531</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This is a Perspectives review and does not require an abstr.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWh0maPUC6grVg90H21EOLACvtfcHk0libAcADFLtqzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1aqu7rF&md5=3236ff10d16104b1a39d77f04774ac77</span></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=10.1021%2Fjm201384j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201384j%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26atitle%3DNucleoside%252C%2520nucleotide%252C%2520and%2520non-nucleoside%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA-dependent%2520RNA-polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2481%26epage%3D2531%26doi%3D10.1021%2Fjm201384j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wieland, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chisari, F. V.</span><span> </span><span class="NLM_article-title">Stealth and cunning: hepatitis B and hepatitis C viruses</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">9369</span><span class="NLM_x">–</span> <span class="NLM_lpage">9380</span><span class="refDoi"> DOI: 10.1128/JVI.79.15.9369-9380.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FJVI.79.15.9369-9380.2005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=9369-9380&author=S.+F.+Wielandauthor=F.+V.+Chisari&title=Stealth+and+cunning%3A+hepatitis+B+and+hepatitis+C+viruses&doi=10.1128%2FJVI.79.15.9369-9380.2005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.15.9369-9380.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.15.9369-9380.2005%26sid%3Dliteratum%253Aachs%26aulast%3DWieland%26aufirst%3DS.%2BF.%26aulast%3DChisari%26aufirst%3DF.%2BV.%26atitle%3DStealth%2520and%2520cunning%253A%2520hepatitis%2520B%2520and%2520hepatitis%2520C%2520viruses%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D9369%26epage%3D9380%26doi%3D10.1128%2FJVI.79.15.9369-9380.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Guidotti, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chisari, F. V.</span><span> </span><span class="NLM_article-title">Immunobiology and pathogenesis of viral hepatitis</span> <span class="citation_source-journal">Annu. Rev. Pathol.: Mech. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1146/annurev.pathol.1.110304.100230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1146%2Fannurev.pathol.1.110304.100230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=18039107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD28XktVOitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=23-61&author=L.+G.+Guidottiauthor=F.+V.+Chisari&title=Immunobiology+and+pathogenesis+of+viral+hepatitis&doi=10.1146%2Fannurev.pathol.1.110304.100230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Immunobiology and pathogenesis of viral hepatitis</span></div><div class="casAuthors">Guidotti, Luca G.; Chisari, Francis V.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pathology: Mechanisms of Disease</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23-61</span>CODEN:
                <span class="NLM_cas:coden">ARPMCU</span>;
        ISSN:<span class="NLM_cas:issn">1553-4006</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Among the many viruses that are known to infect the human liver, hepatitis B virus (HBV) and hepatitis C virus (HCV) are unique because of their prodigious capacity to cause persistent infection, cirrhosis, and liver cancer.  HBV and HCV are noncytopathic viruses and, thus, immunol. mediated events play an important role in the pathogenesis and outcome of these infections.  The adaptive immune response mediates virtually all of the liver disease assocd. with viral hepatitis.  However, it is becoming increasingly clear that antigen-nonspecific inflammatory cells exacerbate cytotoxic T lymphocyte (CTL)-induced immunopathol. and that platelets enhance the accumulation of CTLs in the liver.  Chronic hepatitis is characterized by an inefficient T cell response unable to completely clear HBV or HCV from the liver, which consequently sustains continuous cycles of low-level cell destruction.  Over long periods of time, recurrent immune-mediated liver damage contributes to the development of cirrhosis and hepatocellular carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eRjyvjhbi7Vg90H21EOLACvtfcHk0libAcADFLtqzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktVOitb4%253D&md5=c740de97e8b1d52a3e3f9e3e7be3bd89</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pathol.1.110304.100230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pathol.1.110304.100230%26sid%3Dliteratum%253Aachs%26aulast%3DGuidotti%26aufirst%3DL.%2BG.%26aulast%3DChisari%26aufirst%3DF.%2BV.%26atitle%3DImmunobiology%2520and%2520pathogenesis%2520of%2520viral%2520hepatitis%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2006%26volume%3D1%26spage%3D23%26epage%3D61%26doi%3D10.1146%2Fannurev.pathol.1.110304.100230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rehermann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nascimbeni, M.</span><span> </span><span class="NLM_article-title">Immunology of hepatitis B virus and hepatitis C virus infection</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span><span class="refDoi"> DOI: 10.1038/nri1573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnri1573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=15738952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslSju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=215-229&author=B.+Rehermannauthor=M.+Nascimbeni&title=Immunology+of+hepatitis+B+virus+and+hepatitis+C+virus+infection&doi=10.1038%2Fnri1573"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24cR"><div class="casContent"><span class="casTitleNuber">24c</span><div class="casTitle"><span class="NLM_cas:atitle">Immunology of hepatitis B virus and hepatitis C virus infection</span></div><div class="casAuthors">Rehermann, Barbara; Nascimbeni, Michelina</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-229</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  More than 500 million people worldwide are persistently infected with the hepatitis B virus (HBV) and/or hepatitis C virus (HCV) and are at risk of developing chronic liver disease, cirrhosis and hepatocellular carcinoma.  Despite many common features in the pathogenesis of HBV- and HCV-related liver disease, these viruses markedly differ in their virol. properties and in their immune escape and survival strategies.  This review assesses recent advances in our understanding of viral hepatitis, contrasts mechanisms of virus-host interaction in acute hepatitis B and hepatitis C, and outlines areas for future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK_aXbF6__BLVg90H21EOLACvtfcHk0lihO2RgndoOGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslSju7k%253D&md5=d9ceed9473106d0f31fade725d16c1a6</span></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=10.1038%2Fnri1573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1573%26sid%3Dliteratum%253Aachs%26aulast%3DRehermann%26aufirst%3DB.%26aulast%3DNascimbeni%26aufirst%3DM.%26atitle%3DImmunology%2520of%2520hepatitis%2520B%2520virus%2520and%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2005%26volume%3D5%26spage%3D215%26epage%3D229%26doi%3D10.1038%2Fnri1573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Sklan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charuworn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J. S.</span><span> </span><span class="NLM_article-title">Mechanisms of HCV survival in the host</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1038/nrgastro.2009.32</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrgastro.2009.32" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=217-227&author=E.+H.+Sklanauthor=P.+Charuwornauthor=P.+S.+Pangauthor=J.+S.+Glenn&title=Mechanisms+of+HCV+survival+in+the+host&doi=10.1038%2Fnrgastro.2009.32"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24d&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2009.32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2009.32%26sid%3Dliteratum%253Aachs%26aulast%3DSklan%26aufirst%3DE.%2BH.%26aulast%3DCharuworn%26aufirst%3DP.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DGlenn%26aufirst%3DJ.%2BS.%26atitle%3DMechanisms%2520of%2520HCV%2520survival%2520in%2520the%2520host%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2009%26volume%3D6%26spage%3D217%26epage%3D227%26doi%3D10.1038%2Fnrgastro.2009.32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Horner, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, M.,  Jr.</span><span> </span><span class="NLM_article-title">Regulation of hepatic innate immunity by hepatitis C virus</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">888</span><span class="refDoi"> DOI: 10.1038/nm.3253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnm.3253" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=879-888&author=S.+M.+Hornerauthor=M.+Gale&title=Regulation+of+hepatic+innate+immunity+by+hepatitis+C+virus&doi=10.1038%2Fnm.3253"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24e&amp;dbid=16384&amp;doi=10.1038%2Fnm.3253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3253%26sid%3Dliteratum%253Aachs%26aulast%3DHorner%26aufirst%3DS.%2BM.%26aulast%3DGale%26aufirst%3DM.%26atitle%3DRegulation%2520of%2520hepatic%2520innate%2520immunity%2520by%2520hepatitis%2520C%2520virus%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D879%26epage%3D888%26doi%3D10.1038%2Fnm.3253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Horner, S. M.</span><span> </span><span class="NLM_article-title">Activation and evasion of antiviral innate immunity by hepatitis C virus</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">426</span><span class="NLM_x">, </span> <span class="NLM_fpage">1198</span><span class="NLM_x">–</span> <span class="NLM_lpage">1209</span><span class="refDoi"> DOI: 10.1016/j.jmb.2013.10.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jmb.2013.10.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2014&pages=1198-1209&author=S.+M.+Horner&title=Activation+and+evasion+of+antiviral+innate+immunity+by+hepatitis+C+virus&doi=10.1016%2Fj.jmb.2013.10.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24f&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2013.10.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2013.10.032%26sid%3Dliteratum%253Aachs%26aulast%3DHorner%26aufirst%3DS.%2BM.%26atitle%3DActivation%2520and%2520evasion%2520of%2520antiviral%2520innate%2520immunity%2520by%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D426%26spage%3D1198%26epage%3D1209%26doi%3D10.1016%2Fj.jmb.2013.10.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Smith, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuiken, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muerhoff, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stapleton, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmonds, P.</span><span> </span><span class="NLM_article-title">Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">318</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span><span class="refDoi"> DOI: 10.1002/hep.26744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.26744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24115039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FktFWnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=318-327&author=D.+B.+Smithauthor=J.+Bukhauthor=C.+Kuikenauthor=A.+S.+Muerhoffauthor=C.+M.+Riceauthor=J.+T.+Stapletonauthor=P.+Simmonds&title=Expanded+classification+of+hepatitis+C+virus+into+7+genotypes+and+67+subtypes%3A+updated+criteria+and+genotype+assignment+web+resource&doi=10.1002%2Fhep.26744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource</span></div><div class="casAuthors">Smith Donald B; Bukh Jens; Kuiken Carla; Muerhoff A Scott; Rice Charles M; Stapleton Jack T; Simmonds Peter</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Baltimore, Md.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">318-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  The 2005 consensus proposal for the classification of hepatitis C virus (HCV) presented an agreed and uniform nomenclature for HCV variants and the criteria for their assignment into genotypes and subtypes.  Since its publication, the available dataset of HCV sequences has vastly expanded through advancement in nucleotide sequencing technologies and an increasing focus on the role of HCV genetic variation in disease and treatment outcomes.  The current study represents a major update to the previous consensus HCV classification, incorporating additional sequence information derived from over 1,300 (near-)complete genome sequences of HCV available on public databases in May 2013.  Analysis resolved several nomenclature conflicts between genotype designations and using consensus criteria created a classification of HCV into seven confirmed genotypes and 67 subtypes.  There are 21 additional complete coding region sequences of unassigned subtype.  The study additionally describes the development of a Web resource hosted by the International Committee for Taxonomy of Viruses (ICTV) that maintains and regularly updates tables of reference isolates, accession numbers, and annotated alignments (http://talk.ictvonline.org/links/hcv/hcv-classification.htm).  The Flaviviridae Study Group urges those who need to check or propose new genotypes or subtypes of HCV to contact the Study Group in advance of publication to avoid nomenclature conflicts appearing in the literature.  While the criteria for assigning genotypes and subtypes remain unchanged from previous consensus proposals, changes are proposed in the assignment of provisional subtypes, subtype numbering beyond "w," and the nomenclature of intergenotypic recombinant.  CONCLUSION:  This study represents an important reference point for the consensus classification of HCV variants that will be of value to researchers working in clinical and basic science fields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgofAQo7eS9BWfpMXQLRstfW6udTcc2eZBWY4-KLGyirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FktFWnsg%253D%253D&md5=b0bfea063822f132a1204a8973081876</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1002%2Fhep.26744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26744%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BB.%26aulast%3DBukh%26aufirst%3DJ.%26aulast%3DKuiken%26aufirst%3DC.%26aulast%3DMuerhoff%26aufirst%3DA.%2BS.%26aulast%3DRice%26aufirst%3DC.%2BM.%26aulast%3DStapleton%26aufirst%3DJ.%2BT.%26aulast%3DSimmonds%26aufirst%3DP.%26atitle%3DExpanded%2520classification%2520of%2520hepatitis%2520C%2520virus%2520into%25207%2520genotypes%2520and%252067%2520subtypes%253A%2520updated%2520criteria%2520and%2520genotype%2520assignment%2520web%2520resource%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26spage%3D318%26epage%3D327%26doi%3D10.1002%2Fhep.26744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Messina, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaxman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pybus, O. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, E.</span><span> </span><span class="NLM_article-title">Global distribution and prevalence of hepatitis C virus genotypes</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span><span class="refDoi"> DOI: 10.1002/hep.27259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.27259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25069599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC2cbms1CgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=77-87&author=J.+P.+Messinaauthor=I.+Humphreysauthor=A.+Flaxmanauthor=A.+Brownauthor=G.+S.+Cookeauthor=O.+G.+Pybusauthor=E.+Barnes&title=Global+distribution+and+prevalence+of+hepatitis+C+virus+genotypes&doi=10.1002%2Fhep.27259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Global distribution and prevalence of hepatitis C virus genotypes</span></div><div class="casAuthors">Messina Jane P; Humphreys Isla; Flaxman Abraham; Brown Anthony; Cooke Graham S; Pybus Oliver G; Barnes Eleanor</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Baltimore, Md.)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-87</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Hepatitis C virus (HCV) exhibits high genetic diversity, characterized by regional variations in genotype prevalence.  This poses a challenge to the improved development of vaccines and pan-genotypic treatments, which require the consideration of global trends in HCV genotype prevalence.  Here we provide the first comprehensive survey of these trends.  To approximate national HCV genotype prevalence, studies published between 1989 and 2013 reporting HCV genotypes are reviewed and combined with overall HCV prevalence estimates from the Global Burden of Disease (GBD) project.  We also generate regional and global genotype prevalence estimates, inferring data for countries lacking genotype information.  We include 1,217 studies in our analysis, representing 117 countries and 90% of the global population.  We calculate that HCV genotype 1 is the most prevalent worldwide, comprising 83.4 million cases (46.2% of all HCV cases), approximately one-third of which are in East Asia.  Genotype 3 is the next most prevalent globally (54.3 million, 30.1%); genotypes 2, 4, and 6 are responsible for a total 22.8% of all cases; genotype 5 comprises the remaining <1%.  While genotypes 1 and 3 dominate in most countries irrespective of economic status, the largest proportions of genotypes 4 and 5 are in lower-income countries.  CONCLUSION:  Although genotype 1 is most common worldwide, nongenotype 1 HCV cases--which are less well served by advances in vaccine and drug development--still comprise over half of all HCV cases.  Relative genotype proportions are needed to inform healthcare models, which must be geographically tailored to specific countries or regions in order to improve access to new treatments.  Genotype surveillance data are needed from many countries to improve estimates of unmet need.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2Xg9XEOxbiuQ4Pl9hzjQhfW6udTcc2eaqwt2Mf-eiJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbms1CgtA%253D%253D&md5=4ad9cc1d6592acffdc485d0baccfe939</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1002%2Fhep.27259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27259%26sid%3Dliteratum%253Aachs%26aulast%3DMessina%26aufirst%3DJ.%2BP.%26aulast%3DHumphreys%26aufirst%3DI.%26aulast%3DFlaxman%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DCooke%26aufirst%3DG.%2BS.%26aulast%3DPybus%26aufirst%3DO.%2BG.%26aulast%3DBarnes%26aufirst%3DE.%26atitle%3DGlobal%2520distribution%2520and%2520prevalence%2520of%2520hepatitis%2520C%2520virus%2520genotypes%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D77%26epage%3D87%26doi%3D10.1002%2Fhep.27259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Alberti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacoin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morais, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefevre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abogunrin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iheanacho, I.</span><span> </span><span class="NLM_article-title">A literature review of the distribution of hepatitis C virus genotypes across Europe</span> <span class="citation_source-journal">J. Med. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1002/jmv.24573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fjmv.24573" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=A.+Albertiauthor=L.+Lacoinauthor=E.+Moraisauthor=C.+Lefevreauthor=S.+Abogunrinauthor=I.+Iheanacho&title=A+literature+review+of+the+distribution+of+hepatitis+C+virus+genotypes+across+Europe&doi=10.1002%2Fjmv.24573"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=10.1002%2Fjmv.24573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjmv.24573%26sid%3Dliteratum%253Aachs%26aulast%3DAlberti%26aufirst%3DA.%26aulast%3DLacoin%26aufirst%3DL.%26aulast%3DMorais%26aufirst%3DE.%26aulast%3DLefevre%26aufirst%3DC.%26aulast%3DAbogunrin%26aufirst%3DS.%26aulast%3DIheanacho%26aufirst%3DI.%26atitle%3DA%2520literature%2520review%2520of%2520the%2520distribution%2520of%2520hepatitis%2520C%2520virus%2520genotypes%2520across%2520Europe%26jtitle%3DJ.%2520Med.%2520Virol.%26date%3D2016%26doi%3D10.1002%2Fjmv.24573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pawlotsky, J. M.</span><span> </span><span class="NLM_article-title">Pathophysiology of hepatitis C virus infection and related liver disease</span> <span class="citation_source-journal">Trends Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span><span class="refDoi"> DOI: 10.1016/j.tim.2003.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.tim.2003.12.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=96-102&author=J.+M.+Pawlotsky&title=Pathophysiology+of+hepatitis+C+virus+infection+and+related+liver+disease&doi=10.1016%2Fj.tim.2003.12.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2003.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2003.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.%2BM.%26atitle%3DPathophysiology%2520of%2520hepatitis%2520C%2520virus%2520infection%2520and%2520related%2520liver%2520disease%26jtitle%3DTrends%2520Microbiol.%26date%3D2004%26volume%3D12%26spage%3D96%26epage%3D102%26doi%3D10.1016%2Fj.tim.2003.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">McCombs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonnu-Mihara, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saab, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">L’italien, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juday, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Y.</span><span> </span><span class="NLM_article-title">The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry</span> <span class="citation_source-journal">JAMA Int. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">174</span><span class="NLM_x">, </span> <span class="NLM_fpage">204</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span><span class="refDoi"> DOI: 10.1001/jamainternmed.2013.12505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1001%2Fjamainternmed.2013.12505" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2014&pages=204-212&author=J.+McCombsauthor=T.+Matsudaauthor=I.+Tonnu-Miharaauthor=S.+Saabauthor=P.+Hinesauthor=G.+L%E2%80%99italienauthor=T.+Judayauthor=Y.+Yuan&title=The+risk+of+long-term+morbidity+and+mortality+in+patients+with+chronic+hepatitis+C%3A+results+from+an+analysis+of+data+from+a+Department+of+Veterans+Affairs+Clinical+Registry&doi=10.1001%2Fjamainternmed.2013.12505"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1001%2Fjamainternmed.2013.12505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamainternmed.2013.12505%26sid%3Dliteratum%253Aachs%26aulast%3DMcCombs%26aufirst%3DJ.%26aulast%3DMatsuda%26aufirst%3DT.%26aulast%3DTonnu-Mihara%26aufirst%3DI.%26aulast%3DSaab%26aufirst%3DS.%26aulast%3DHines%26aufirst%3DP.%26aulast%3DL%25E2%2580%2599italien%26aufirst%3DG.%26aulast%3DJuday%26aufirst%3DT.%26aulast%3DYuan%26aufirst%3DY.%26atitle%3DThe%2520risk%2520of%2520long-term%2520morbidity%2520and%2520mortality%2520in%2520patients%2520with%2520chronic%2520hepatitis%2520C%253A%2520results%2520from%2520an%2520analysis%2520of%2520data%2520from%2520a%2520Department%2520of%2520Veterans%2520Affairs%2520Clinical%2520Registry%26jtitle%3DJAMA%2520Int.%2520Med.%26date%3D2014%26volume%3D174%26spage%3D204%26epage%3D212%26doi%3D10.1001%2Fjamainternmed.2013.12505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Alter, H. J.</span><span> </span><span class="NLM_article-title">HCV natural history: the retrospective and prospective in perspective</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">550</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span><span class="refDoi"> DOI: 10.1016/j.jhep.2005.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2005.07.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2005&pages=550-552&author=H.+J.+Alter&title=HCV+natural+history%3A+the+retrospective+and+prospective+in+perspective&doi=10.1016%2Fj.jhep.2005.07.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26c&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2005.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2005.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DAlter%26aufirst%3DH.%2BJ.%26atitle%3DHCV%2520natural%2520history%253A%2520the%2520retrospective%2520and%2520prospective%2520in%2520perspective%26jtitle%3DJ.%2520Hepatol.%26date%3D2005%26volume%3D43%26spage%3D550%26epage%3D552%26doi%3D10.1016%2Fj.jhep.2005.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Thursz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontanet, A.</span><span> </span><span class="NLM_article-title">HCV transmission in industrialized countries and resource-constrained areas</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1038/nrgastro.2013.179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrgastro.2013.179" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=28-35&author=M.+Thurszauthor=A.+Fontanet&title=HCV+transmission+in+industrialized+countries+and+resource-constrained+areas&doi=10.1038%2Fnrgastro.2013.179"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26d&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2013.179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2013.179%26sid%3Dliteratum%253Aachs%26aulast%3DThursz%26aufirst%3DM.%26aulast%3DFontanet%26aufirst%3DA.%26atitle%3DHCV%2520transmission%2520in%2520industrialized%2520countries%2520and%2520resource-constrained%2520areas%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2014%26volume%3D11%26spage%3D28%26epage%3D35%26doi%3D10.1038%2Fnrgastro.2013.179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Racela, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Specific inhibition of bovine viral diarrhea virus replicase</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">6753</span><span class="NLM_x">–</span> <span class="NLM_lpage">6760</span><span class="refDoi"> DOI: 10.1128/JVI.77.12.6753-6760.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FJVI.77.12.6753-6760.2003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2003&pages=6753-6760&author=J.-H.+Sunauthor=J.+A.+Lemmauthor=D.+R.+O%E2%80%99Boyleauthor=J.+Racelaauthor=R.+Colonnoauthor=M.+Gao&title=Specific+inhibition+of+bovine+viral+diarrhea+virus+replicase&doi=10.1128%2FJVI.77.12.6753-6760.2003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1128%2FJVI.77.12.6753-6760.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.77.12.6753-6760.2003%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DRacela%26aufirst%3DJ.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DSpecific%2520inhibition%2520of%2520bovine%2520viral%2520diarrhea%2520virus%2520replicase%26jtitle%3DJ.%2520Virol.%26date%3D2003%26volume%3D77%26spage%3D6753%26epage%3D6760%26doi%3D10.1128%2FJVI.77.12.6753-6760.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Groutas, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkataraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epp, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houser-Archield, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClenahan, J. J.</span><span> </span><span class="NLM_article-title">Potential mechanism-based inhibitors of proteolytic enzymes</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)80445-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0960-894X%2801%2980445-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1992&pages=175-180&author=W.+C.+Groutasauthor=M.+J.+Brubakerauthor=R.+Venkataramanauthor=J.+B.+Eppauthor=N.+Houser-Archieldauthor=L.+S.+Chongauthor=J.+J.+McClenahan&title=Potential+mechanism-based+inhibitors+of+proteolytic+enzymes&doi=10.1016%2FS0960-894X%2801%2980445-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2980445-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252980445-5%26sid%3Dliteratum%253Aachs%26aulast%3DGroutas%26aufirst%3DW.%2BC.%26aulast%3DBrubaker%26aufirst%3DM.%2BJ.%26aulast%3DVenkataraman%26aufirst%3DR.%26aulast%3DEpp%26aufirst%3DJ.%2BB.%26aulast%3DHouser-Archield%26aufirst%3DN.%26aulast%3DChong%26aufirst%3DL.%2BS.%26aulast%3DMcClenahan%26aufirst%3DJ.%2BJ.%26atitle%3DPotential%2520mechanism-based%2520inhibitors%2520of%2520proteolytic%2520enzymes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1992%26volume%3D2%26spage%3D175%26epage%3D180%26doi%3D10.1016%2FS0960-894X%2801%2980445-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hlasta, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boaz, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Court, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franke, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mura, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunlap, R. A.</span><span> </span><span class="NLM_article-title">Benzisothiazolone class of potent, selective mechanism-based inhibitors of human leukocyte elastase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1801</span><span class="NLM_x">–</span> <span class="NLM_lpage">1806</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)80374-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0960-894X%2801%2980374-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1994&pages=1801-1806&author=D.+J.+Hlastaauthor=M.+R.+Bellauthor=N.+W.+Boazauthor=J.+J.+Courtauthor=R.+C.+Desaiauthor=C.+A.+Frankeauthor=A.+J.+Muraauthor=C.+Subramanyamauthor=R.+A.+Dunlap&title=Benzisothiazolone+class+of+potent%2C+selective+mechanism-based+inhibitors+of+human+leukocyte+elastase&doi=10.1016%2FS0960-894X%2801%2980374-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2980374-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252980374-7%26sid%3Dliteratum%253Aachs%26aulast%3DHlasta%26aufirst%3DD.%2BJ.%26aulast%3DBell%26aufirst%3DM.%2BR.%26aulast%3DBoaz%26aufirst%3DN.%2BW.%26aulast%3DCourt%26aufirst%3DJ.%2BJ.%26aulast%3DDesai%26aufirst%3DR.%2BC.%26aulast%3DFranke%26aufirst%3DC.%2BA.%26aulast%3DMura%26aufirst%3DA.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DDunlap%26aufirst%3DR.%2BA.%26atitle%3DBenzisothiazolone%2520class%2520of%2520potent%252C%2520selective%2520mechanism-based%2520inhibitors%2520of%2520human%2520leukocyte%2520elastase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1994%26volume%3D4%26spage%3D1801%26epage%3D1806%26doi%3D10.1016%2FS0960-894X%2801%2980374-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hlasta, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Court, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cundy, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maycock, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span> </span><span class="NLM_article-title">The design of potent and stable benzisothiazolone inhibitors of human leukocyte elastase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1016/0960-894X(95)00030-W</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2F0960-894X%2895%2900030-W" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1995&pages=331-336&author=D.+J.+Hlastaauthor=M.+R.+Bellauthor=J.+J.+Courtauthor=K.+C.+Cundyauthor=R.+C.+Desaiauthor=E.+W.+Fergusonauthor=R.+J.+Gordonauthor=V.+Kumarauthor=A.+L.+Maycockauthor=C.+Subramanyam&title=The+design+of+potent+and+stable+benzisothiazolone+inhibitors+of+human+leukocyte+elastase&doi=10.1016%2F0960-894X%2895%2900030-W"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28c&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2895%2900030-W&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252895%252900030-W%26sid%3Dliteratum%253Aachs%26aulast%3DHlasta%26aufirst%3DD.%2BJ.%26aulast%3DBell%26aufirst%3DM.%2BR.%26aulast%3DCourt%26aufirst%3DJ.%2BJ.%26aulast%3DCundy%26aufirst%3DK.%2BC.%26aulast%3DDesai%26aufirst%3DR.%2BC.%26aulast%3DFerguson%26aufirst%3DE.%2BW.%26aulast%3DGordon%26aufirst%3DR.%2BJ.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DMaycock%26aufirst%3DA.%2BL.%26aulast%3DSubramanyam%26aufirst%3DC.%26atitle%3DThe%2520design%2520of%2520potent%2520and%2520stable%2520benzisothiazolone%2520inhibitors%2520of%2520human%2520leukocyte%2520elastase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1995%26volume%3D5%26spage%3D331%26epage%3D336%26doi%3D10.1016%2F0960-894X%2895%2900030-W" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Groutas, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkataraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epp, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houser-Archield, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoidal, J. R.</span><span> </span><span class="NLM_article-title">Amino acid-derived phthalimide and saccharin derivatives as inhibitors of human leukocyte elastase, cathepsin G and proteinase 3</span> <span class="citation_source-journal">Arch. Biochem. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1006/abbi.1996.0350</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1006%2Fabbi.1996.0350" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=1996&pages=335-340&author=W.+C.+Groutasauthor=L.+S.+Chongauthor=R.+Venkataramanauthor=R.+Kuangauthor=J.+B.+Eppauthor=N.+Houser-Archieldauthor=H.+Huangauthor=J.+R.+Hoidal&title=Amino+acid-derived+phthalimide+and+saccharin+derivatives+as+inhibitors+of+human+leukocyte+elastase%2C+cathepsin+G+and+proteinase+3&doi=10.1006%2Fabbi.1996.0350"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28d&amp;dbid=16384&amp;doi=10.1006%2Fabbi.1996.0350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabbi.1996.0350%26sid%3Dliteratum%253Aachs%26aulast%3DGroutas%26aufirst%3DW.%2BC.%26aulast%3DChong%26aufirst%3DL.%2BS.%26aulast%3DVenkataraman%26aufirst%3DR.%26aulast%3DKuang%26aufirst%3DR.%26aulast%3DEpp%26aufirst%3DJ.%2BB.%26aulast%3DHouser-Archield%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHoidal%26aufirst%3DJ.%2BR.%26atitle%3DAmino%2520acid-derived%2520phthalimide%2520and%2520saccharin%2520derivatives%2520as%2520inhibitors%2520of%2520human%2520leukocyte%2520elastase%252C%2520cathepsin%2520G%2520and%2520proteinase%25203%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D1996%26volume%3D332%26spage%3D335%26epage%3D340%26doi%3D10.1006%2Fabbi.1996.0350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yeung, K.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span> </span><span class="NLM_article-title">A facile construction of 4-hydroxymethylbenzisothiazolone-1,1-dioxide</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1483</span><span class="NLM_x">–</span> <span class="NLM_lpage">1486</span><span class="refDoi"> DOI: 10.1016/S0040-4039(98)00011-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0040-4039%2898%2900011-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=1483-1486&author=K.-S.+Yeungauthor=N.+A.+Meanwellauthor=Y.+Liauthor=Q.+Gao&title=A+facile+construction+of+4-hydroxymethylbenzisothiazolone-1%2C1-dioxide&doi=10.1016%2FS0040-4039%2898%2900011-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2898%2900011-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252898%252900011-2%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DK.-S.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DQ.%26atitle%3DA%2520facile%2520construction%2520of%25204-hydroxymethylbenzisothiazolone-1%252C1-dioxide%26jtitle%3DTetrahedron%2520Lett.%26date%3D1998%26volume%3D39%26spage%3D1483%26epage%3D1486%26doi%3D10.1016%2FS0040-4039%2898%2900011-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit29b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Yeung, K.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">A synthesis of 4-thiomethylbenzisothiazolone-1,1-dioxide using HDPT</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">5309</span><span class="NLM_x">–</span> <span class="NLM_lpage">5312</span><span class="refDoi"> DOI: 10.1016/S0040-4039(98)01074-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0040-4039%2898%2901074-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=5309-5312&author=K.-S.+Yeungauthor=N.+A.+Meanwell&title=A+synthesis+of+4-thiomethylbenzisothiazolone-1%2C1-dioxide+using+HDPT&doi=10.1016%2FS0040-4039%2898%2901074-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2898%2901074-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252898%252901074-0%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DK.-S.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DA%2520synthesis%2520of%25204-thiomethylbenzisothiazolone-1%252C1-dioxide%2520using%2520HDPT%26jtitle%3DTetrahedron%2520Lett.%26date%3D1998%26volume%3D39%26spage%3D5309%26epage%3D5312%26doi%3D10.1016%2FS0040-4039%2898%2901074-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit29c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulgeze, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisacchi, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, D. G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiler, S. M.</span><span> </span><span class="NLM_article-title">1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">4854</span><span class="NLM_x">–</span> <span class="NLM_lpage">4860</span><span class="refDoi"> DOI: 10.1021/jm9804580</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9804580" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=4854-4860&author=K.+D.+Combrinkauthor=H.+B.+Gulgezeauthor=N.+A.+Meanwellauthor=B.+C.+Pearceauthor=P.+Zulanauthor=G.+S.+Bisacchiauthor=D.+G.+M.+Robertsauthor=P.+Stanleyauthor=S.+M.+Seiler&title=1%2C2-Benzisothiazol-3-one+1%2C1-dioxide+inhibitors+of+human+mast+cell+tryptase&doi=10.1021%2Fjm9804580"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29c&amp;dbid=16384&amp;doi=10.1021%2Fjm9804580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9804580%26sid%3Dliteratum%253Aachs%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DGulgeze%26aufirst%3DH.%2BB.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DPearce%26aufirst%3DB.%2BC.%26aulast%3DZulan%26aufirst%3DP.%26aulast%3DBisacchi%26aufirst%3DG.%2BS.%26aulast%3DRoberts%26aufirst%3DD.%2BG.%2BM.%26aulast%3DStanley%26aufirst%3DP.%26aulast%3DSeiler%26aufirst%3DS.%2BM.%26atitle%3D1%252C2-Benzisothiazol-3-one%25201%252C1-dioxide%2520inhibitors%2520of%2520human%2520mast%2520cell%2520tryptase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D4854%26epage%3D4860%26doi%3D10.1021%2Fjm9804580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Katz, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finer-Moore, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroud, R. M.</span><span> </span><span class="NLM_article-title">Design of potent selective zinc-mediated serine protease inhibitors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">391</span><span class="NLM_x">, </span> <span class="NLM_fpage">608</span><span class="NLM_x">–</span> <span class="NLM_lpage">612</span><span class="refDoi"> DOI: 10.1038/35422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2F35422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=9468142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK1cXhtVSrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=1998&pages=608-612&author=B.+A.+Katzauthor=J.+M.+Clarkauthor=J.+S.+Finer-Mooreauthor=T.+E.+Jenkinsauthor=C.+R.+Johnsonauthor=M.+J.+Rossauthor=C.+Luongauthor=W.+R.+Mooreauthor=R.+M.+Stroud&title=Design+of+potent+selective+zinc-mediated+serine+protease+inhibitors&doi=10.1038%2F35422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30aR"><div class="casContent"><span class="casTitleNuber">30a</span><div class="casTitle"><span class="NLM_cas:atitle">Design of potent selective zinc-mediated serine protease inhibitors</span></div><div class="casAuthors">Katz, Bradley A.; Clark, James M.; Finer-Moore, Janet S.; Jenkins, Thomas E.; Johnson, Charles R.; Ross, Michael J.; Luong, Christine; Moore, William R.; Stroud, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">6667</span>),
    <span class="NLM_cas:pages">608-612</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Many serine proteases are targets for therapeutic intervention because they often play key roles in disease.  Small mol. inhibitors of serine proteases with high affinity are esp. interesting as they could be used as scaffolds from which to develop drugs selective for protease targets.  One such inhibitor is bis(5-amidino-2-benzimidazolyl)methane (BABIM), standing out as the best inhibitor of trypsin (by a factor of over 100) in over 60 relatively closely related analogs.  By probing the structural basis of inhibition, the authors discovered, using crystallog. methods, a new mode of high-affinity binding in which a Zn2+ ion is tetrahedrally coordinated between two chelating nitrogens of BABIM and two active site residues, His 57 and Ser 195, Zn2+, at sub-physiol. levels, enhances inhibition by over 103-fold.  The distinct Zn2+ coordination geometry implies a strong dependence of affinity on substituents.  This unique structural paradigm has enabled development of potent, highly selective, Zn2+-dependent inhibitors of several therapeutically important serine proteases, using a physiol. ubiquitous metal ion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8qw3xlj3NJ7Vg90H21EOLACvtfcHk0lhxq7uMHwDjgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtVSrtrY%253D&md5=091ffd477397892356b7a5384f3cc5fa</span></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=10.1038%2F35422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35422%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DB.%2BA.%26aulast%3DClark%26aufirst%3DJ.%2BM.%26aulast%3DFiner-Moore%26aufirst%3DJ.%2BS.%26aulast%3DJenkins%26aufirst%3DT.%2BE.%26aulast%3DJohnson%26aufirst%3DC.%2BR.%26aulast%3DRoss%26aufirst%3DM.%2BJ.%26aulast%3DLuong%26aufirst%3DC.%26aulast%3DMoore%26aufirst%3DW.%2BR.%26aulast%3DStroud%26aufirst%3DR.%2BM.%26atitle%3DDesign%2520of%2520potent%2520selective%2520zinc-mediated%2520serine%2520protease%2520inhibitors%26jtitle%3DNature%26date%3D1998%26volume%3D391%26spage%3D608%26epage%3D612%26doi%3D10.1038%2F35422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit30b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Katz, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luong, C.</span><span> </span><span class="NLM_article-title">Recruiting Zn<sup>2+</sup> to mediate potent, specific inhibition of serine proteases</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">292</span><span class="NLM_x">, </span> <span class="NLM_fpage">669</span><span class="NLM_x">–</span> <span class="NLM_lpage">684</span><span class="refDoi"> DOI: 10.1006/jmbi.1999.3071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1006%2Fjmbi.1999.3071" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=1999&pages=669-684&author=B.+A.+Katzauthor=C.+Luong&title=Recruiting+Zn2%2B+to+mediate+potent%2C+specific+inhibition+of+serine+proteases&doi=10.1006%2Fjmbi.1999.3071"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1999.3071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1999.3071%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DB.%2BA.%26aulast%3DLuong%26aufirst%3DC.%26atitle%3DRecruiting%2520Zn2%252B%2520to%2520mediate%2520potent%252C%2520specific%2520inhibition%2520of%2520serine%2520proteases%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1999%26volume%3D292%26spage%3D669%26epage%3D684%26doi%3D10.1006%2Fjmbi.1999.3071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit30c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Janc, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warne, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elrod, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, W. R.</span><span> </span><span class="NLM_article-title">A novel approach to serine protease inhibition: kinetic characterization of inhibitors whose potencies and selectivities are dramatically enhanced by zinc(II)</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">4792</span><span class="NLM_x">–</span> <span class="NLM_lpage">4800</span><span class="refDoi"> DOI: 10.1021/bi992182j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi992182j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=4792-4800&author=J.+W.+Jancauthor=J.+M.+Clarkauthor=R.+L.+Warneauthor=K.+C.+Elrodauthor=B.+A.+Katzauthor=W.+R.+Moore&title=A+novel+approach+to+serine+protease+inhibition%3A+kinetic+characterization+of+inhibitors+whose+potencies+and+selectivities+are+dramatically+enhanced+by+zinc%28II%29&doi=10.1021%2Fbi992182j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30c&amp;dbid=16384&amp;doi=10.1021%2Fbi992182j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi992182j%26sid%3Dliteratum%253Aachs%26aulast%3DJanc%26aufirst%3DJ.%2BW.%26aulast%3DClark%26aufirst%3DJ.%2BM.%26aulast%3DWarne%26aufirst%3DR.%2BL.%26aulast%3DElrod%26aufirst%3DK.%2BC.%26aulast%3DKatz%26aufirst%3DB.%2BA.%26aulast%3DMoore%26aufirst%3DW.%2BR.%26atitle%3DA%2520novel%2520approach%2520to%2520serine%2520protease%2520inhibition%253A%2520kinetic%2520characterization%2520of%2520inhibitors%2520whose%2520potencies%2520and%2520selectivities%2520are%2520dramatically%2520enhanced%2520by%2520zinc%2528II%2529%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D4792%26epage%3D4800%26doi%3D10.1021%2Fbi992182j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yeung, K.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janc, J. W.</span><span> </span><span class="NLM_article-title">Structure-activity relationship studies of a bisbenzimidazole-based, Zn<sup>2+</sup>-dependent inhibitor of HCV NS3 serine protease</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2355</span><span class="NLM_x">–</span> <span class="NLM_lpage">2359</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00457-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0960-894X%2801%2900457-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=2355-2359&author=K.-S.+Yeungauthor=N.+A.+Meanwellauthor=Z.+Qiuauthor=D.+Hernandezauthor=S.+Zhangauthor=F.+McPheeauthor=S.+Weinheimerauthor=J.+M.+Clarkauthor=J.+W.+Janc&title=Structure-activity+relationship+studies+of+a+bisbenzimidazole-based%2C+Zn2%2B-dependent+inhibitor+of+HCV+NS3+serine+protease&doi=10.1016%2FS0960-894X%2801%2900457-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900457-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900457-7%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DK.-S.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DWeinheimer%26aufirst%3DS.%26aulast%3DClark%26aufirst%3DJ.%2BM.%26aulast%3DJanc%26aufirst%3DJ.%2BW.%26atitle%3DStructure-activity%2520relationship%2520studies%2520of%2520a%2520bisbenzimidazole-based%252C%2520Zn2%252B-dependent%2520inhibitor%2520of%2520HCV%2520NS3%2520serine%2520protease%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D2355%26epage%3D2359%26doi%3D10.1016%2FS0960-894X%2801%2900457-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sperandio, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangloff, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litvak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hataye, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elrod, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janc, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, K.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staab, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, J. R.</span><span> </span><span class="NLM_article-title">Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">3129</span><span class="NLM_x">–</span> <span class="NLM_lpage">3133</span><span class="refDoi"> DOI: 10.1016/S0960-894X(02)00680-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0960-894X%2802%2900680-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=3129-3133&author=D.+Sperandioauthor=A.+R.+Gangloffauthor=J.+Litvakauthor=R.+Goldsmithauthor=J.+M.+Hatayeauthor=V.+R.+Wangauthor=E.+J.+Sheltonauthor=K.+Elrodauthor=J.+W.+Jancauthor=J.+M.+Clarkauthor=K.+Riceauthor=S.+Weinheimerauthor=K.-S.+Yeungauthor=N.+A.+Meanwellauthor=D.+Hernandezauthor=A.+J.+Staabauthor=B.+L.+Venablesauthor=J.+R.+Spencer&title=Highly+potent+non-peptidic+inhibitors+of+the+HCV+NS3%2FNS4A+serine+protease&doi=10.1016%2FS0960-894X%2802%2900680-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900680-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900680-7%26sid%3Dliteratum%253Aachs%26aulast%3DSperandio%26aufirst%3DD.%26aulast%3DGangloff%26aufirst%3DA.%2BR.%26aulast%3DLitvak%26aufirst%3DJ.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DHataye%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DV.%2BR.%26aulast%3DShelton%26aufirst%3DE.%2BJ.%26aulast%3DElrod%26aufirst%3DK.%26aulast%3DJanc%26aufirst%3DJ.%2BW.%26aulast%3DClark%26aufirst%3DJ.%2BM.%26aulast%3DRice%26aufirst%3DK.%26aulast%3DWeinheimer%26aufirst%3DS.%26aulast%3DYeung%26aufirst%3DK.-S.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DStaab%26aufirst%3DA.%2BJ.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DSpencer%26aufirst%3DJ.%2BR.%26atitle%3DHighly%2520potent%2520non-peptidic%2520inhibitors%2520of%2520the%2520HCV%2520NS3%252FNS4A%2520serine%2520protease%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D3129%26epage%3D3133%26doi%3D10.1016%2FS0960-894X%2802%2900680-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Steinkühler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span> </span><span class="NLM_article-title"><i>In vitro</i> activity of hepatitis C virus protease NS3 purified from recombinant baculovirus-infected Sf9 cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">6367</span><span class="NLM_x">–</span> <span class="NLM_lpage">6373</span><span class="refDoi"> DOI: 10.1074/jbc.271.11.6367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1074%2Fjbc.271.11.6367" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=6367-6373&author=C.+Steink%C3%BChlerauthor=L.+Tomeiauthor=R.+De+Francesco&title=In+vitro+activity+of+hepatitis+C+virus+protease+NS3+purified+from+recombinant+baculovirus-infected+Sf9+cells&doi=10.1074%2Fjbc.271.11.6367"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.11.6367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.11.6367%26sid%3Dliteratum%253Aachs%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DTomei%26aufirst%3DL.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26atitle%3DIn%2520vitro%2520activity%2520of%2520hepatitis%2520C%2520virus%2520protease%2520NS3%2520purified%2520from%2520recombinant%2520baculovirus-infected%2520Sf9%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D6367%26epage%3D6373%26doi%3D10.1074%2Fjbc.271.11.6367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windsor, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNemar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, H. V.</span><span> </span><span class="NLM_article-title">Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">6208</span><span class="NLM_x">–</span> <span class="NLM_lpage">6213</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1997&pages=6208-6213&author=R.+Zhangauthor=J.+Durkinauthor=W.+T.+Windsorauthor=C.+McNemarauthor=L.+Ramanathanauthor=H.+V.+Le&title=Probing+the+substrate+specificity+of+hepatitis+C+virus+NS3+serine+protease+by+using+synthetic+peptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DDurkin%26aufirst%3DJ.%26aulast%3DWindsor%26aufirst%3DW.%2BT.%26aulast%3DMcNemar%26aufirst%3DC.%26aulast%3DRamanathan%26aufirst%3DL.%26aulast%3DLe%26aufirst%3DH.%2BV.%26atitle%3DProbing%2520the%2520substrate%2520specificity%2520of%2520hepatitis%2520C%2520virus%2520NS3%2520serine%2520protease%2520by%2520using%2520synthetic%2520peptides%26jtitle%3DJ.%2520Virol.%26date%3D1997%26volume%3D71%26spage%3D6208%26epage%3D6213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Urbani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tramontano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinkühler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessi, A.</span><span> </span><span class="NLM_article-title">Substrate specificity of the hepatitis C virus serine protease NS3</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">9204</span><span class="NLM_x">–</span> <span class="NLM_lpage">9209</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=9204-9209&author=A.+Urbaniauthor=E.+Bianchiauthor=F.+Narjesauthor=A.+Tramontanoauthor=R.+De+Francescoauthor=C.+Steink%C3%BChlerauthor=A.+Pessi&title=Substrate+specificity+of+the+hepatitis+C+virus+serine+protease+NS3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUrbani%26aufirst%3DA.%26aulast%3DBianchi%26aufirst%3DE.%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DTramontano%26aufirst%3DA.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DPessi%26aufirst%3DA.%26atitle%3DSubstrate%2520specificity%2520of%2520the%2520hepatitis%2520C%2520virus%2520serine%2520protease%2520NS3%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D9204%26epage%3D9209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Love, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parge, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickersham, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habuka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moomaw, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomska, Z.</span><span> </span><span class="NLM_article-title">The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)81350-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0092-8674%2800%2981350-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=8861916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK28XmsVGhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1996&pages=331-342&author=R.+A.+Loveauthor=H.+E.+Pargeauthor=J.+A.+Wickershamauthor=Z.+Hostomskyauthor=N.+Habukaauthor=E.+W.+Moomawauthor=T.+Adachiauthor=Z.+Hostomska&title=The+crystal+structure+of+hepatitis+C+virus+NS3+proteinase+reveals+a+trypsin-like+fold+and+a+structural+zinc+binding+site&doi=10.1016%2FS0092-8674%2800%2981350-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site</span></div><div class="casAuthors">Love, Robert A.; parge, Hans E.; Wickersham, John A.; Hostomsky, Zdenek; Habuka, Noriyuki; Moomaw, Ellen W.; Adachi, Tsuyoshi; Hostomska, Zuzana</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">331-342</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">During replication of hepatitis C virus (HCV), the final steps of polyprotein processing are performed by a viral proteinase located in the N-terminal 1/3 of nonstructural protein 3 (NS3).  Here, the structure of NS3 proteinase (I) from HCV BK strain was detd. by x-ray crystallog. at 2.4 Å resoln.  I folded as a trypsin-like proteinase with 2 β-barrels and a catalytic triad of His-57, Asp-81, Ser-139.  The I structure had a substrate-binding site consistent with the cleavage specificity of the enzyme.  Novel features included a structural Zn-binding site and a long N-terminus that interacted with neighboring mols. by binding to a hydrophobic surface patch.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokLfJmy4sb-7Vg90H21EOLACvtfcHk0lhzEEMSNG5tsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVGhsb0%253D&md5=1dbf21ea1276378b47b809971969d895</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981350-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981350-1%26sid%3Dliteratum%253Aachs%26aulast%3DLove%26aufirst%3DR.%2BA.%26aulast%3DParge%26aufirst%3DH.%2BE.%26aulast%3DWickersham%26aufirst%3DJ.%2BA.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DMoomaw%26aufirst%3DE.%2BW.%26aulast%3DAdachi%26aufirst%3DT.%26aulast%3DHostomska%26aufirst%3DZ.%26atitle%3DThe%2520crystal%2520structure%2520of%2520hepatitis%2520C%2520virus%2520NS3%2520proteinase%2520reveals%2520a%2520trypsin-like%2520fold%2520and%2520a%2520structural%2520zinc%2520binding%2520site%26jtitle%3DCell%26date%3D1996%26volume%3D87%26spage%3D331%26epage%3D342%26doi%3D10.1016%2FS0092-8674%2800%2981350-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgenstern, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landro, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markland, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepre, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Malley, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbeson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murcko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, J. A.</span><span> </span><span class="NLM_article-title">Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">343</span><span class="NLM_x">–</span> <span class="NLM_lpage">355</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)81351-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0092-8674%2800%2981351-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=8861917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK28XmsVGhsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1996&pages=343-355&author=J.+L.+Kimauthor=K.+A.+Morgensternauthor=C.+Linauthor=T.+Foxauthor=M.+D.+Dwyerauthor=J.+A.+Landroauthor=S.+P.+Chambersauthor=W.+Marklandauthor=C.+A.+Lepreauthor=E.+T.+O%E2%80%99Malleyauthor=S.+L.+Harbesonauthor=C.+M.+Riceauthor=M.+A.+Murckoauthor=P.+R.+Caronauthor=J.+A.+Thomson&title=Crystal+structure+of+the+hepatitis+C+virus+NS3+protease+domain+complexed+with+a+synthetic+NS4A+cofactor+peptide&doi=10.1016%2FS0092-8674%2800%2981351-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide</span></div><div class="casAuthors">Kim, J. L.; Morgenstern, K. A.; Lin, C.; Fox, T.; Dwyer, M. D.; Landro, J. A.; Chambers, S. P.; Markland, W.; Lepre, C. A.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">343-355</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">An estd. 1% of the global human population is infected by hepatitis C viruses (HCVs), and there are no broadly effective treatments for the debilitating progression of chronic hepatitis C.  A serine protease located within the HCV NS3 protein processes the viral polyprotein at four specific sites and is considered essential for replication.  Thus, it emerges as an attractive target for drug design.  We report here the 2.5 Å resoln. X-ray crystal structure of the NS3 protease domain complexed with a synthetic NS4A activator peptide.  The protease has a chymotrypsin-like fold and features a tetrahedrally coordinated metal ion distal to the active site.  The NS4A peptide intercalates within a β sheet of the enzyme core.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX5CClA0eyj7Vg90H21EOLACvtfcHk0lgt1kn7OLgAYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVGhsbo%253D&md5=c6bdc0d069608e019fee3960c76df429</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981351-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981351-3%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DMorgenstern%26aufirst%3DK.%2BA.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DFox%26aufirst%3DT.%26aulast%3DDwyer%26aufirst%3DM.%2BD.%26aulast%3DLandro%26aufirst%3DJ.%2BA.%26aulast%3DChambers%26aufirst%3DS.%2BP.%26aulast%3DMarkland%26aufirst%3DW.%26aulast%3DLepre%26aufirst%3DC.%2BA.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DE.%2BT.%26aulast%3DHarbeson%26aufirst%3DS.%2BL.%26aulast%3DRice%26aufirst%3DC.%2BM.%26aulast%3DMurcko%26aufirst%3DM.%2BA.%26aulast%3DCaron%26aufirst%3DP.%2BR.%26aulast%3DThomson%26aufirst%3DJ.%2BA.%26atitle%3DCrystal%2520structure%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520domain%2520complexed%2520with%2520a%2520synthetic%2520NS4A%2520cofactor%2520peptide%26jtitle%3DCell%26date%3D1996%26volume%3D87%26spage%3D343%26epage%3D355%26doi%3D10.1016%2FS0092-8674%2800%2981351-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laplante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurice, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibeault, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span> </span><span class="NLM_article-title">Peptide-based inhibitors of the hepatitis C virus serine protease</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1713</span><span class="NLM_x">–</span> <span class="NLM_lpage">1718</span><span class="refDoi"> DOI: 10.1016/S0960-894X(98)00299-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0960-894X%2898%2900299-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=1713-1718&author=M.+Llin%C3%A0s-Brunetauthor=M.+Baileyauthor=G.+Fazalauthor=S.+Gouletauthor=T.+Halmosauthor=S.+Laplanteauthor=R.+Mauriceauthor=M.+Poirierauthor=M.-A.+Poupartauthor=D.+Thibeaultauthor=D.+Wernicauthor=D.+Lamarre&title=Peptide-based+inhibitors+of+the+hepatitis+C+virus+serine+protease&doi=10.1016%2FS0960-894X%2898%2900299-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900299-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900299-6%26sid%3Dliteratum%253Aachs%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DFazal%26aufirst%3DG.%26aulast%3DGoulet%26aufirst%3DS.%26aulast%3DHalmos%26aufirst%3DT.%26aulast%3DLaplante%26aufirst%3DS.%26aulast%3DMaurice%26aufirst%3DR.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DPoupart%26aufirst%3DM.-A.%26aulast%3DThibeault%26aufirst%3DD.%26aulast%3DWernic%26aufirst%3DD.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DPeptide-based%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520serine%2520protease%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D1713%26epage%3D1718%26doi%3D10.1016%2FS0960-894X%2898%2900299-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit34b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Steinkühler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biasiol, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortese, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span> </span><span class="NLM_article-title">Product inhibition of the hepatitis C virus NS3 protease</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">8899</span><span class="NLM_x">–</span> <span class="NLM_lpage">8905</span><span class="refDoi"> DOI: 10.1021/bi980313v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi980313v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=8899-8905&author=C.+Steink%C3%BChlerauthor=G.+Biasiolauthor=M.+Brunettiauthor=A.+Urbaniauthor=U.+Kochauthor=R.+Corteseauthor=A.+Pessiauthor=R.+De+Francesco&title=Product+inhibition+of+the+hepatitis+C+virus+NS3+protease&doi=10.1021%2Fbi980313v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.1021%2Fbi980313v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi980313v%26sid%3Dliteratum%253Aachs%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DBiasiol%26aufirst%3DG.%26aulast%3DBrunetti%26aufirst%3DM.%26aulast%3DUrbani%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DCortese%26aufirst%3DR.%26aulast%3DPessi%26aufirst%3DA.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26atitle%3DProduct%2520inhibition%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D8899%26epage%3D8905%26doi%3D10.1021%2Fbi980313v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit34c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ingallinella, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taliani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingenito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortese, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinkühler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessi, A.</span><span> </span><span class="NLM_article-title">Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">8906</span><span class="NLM_x">–</span> <span class="NLM_lpage">8914</span><span class="refDoi"> DOI: 10.1021/bi980314n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi980314n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK1cXjsFeiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=8906-8914&author=P.+Ingallinellaauthor=S.+Altamuraauthor=E.+Bianchiauthor=M.+Talianiauthor=R.+Ingenitoauthor=R.+Corteseauthor=R.+De+Francescoauthor=C.+Steink%C3%BChlerauthor=A.+Pessi&title=Potent+peptide+inhibitors+of+human+hepatitis+C+virus+NS3+protease+are+obtained+by+optimizing+the+cleavage+products&doi=10.1021%2Fbi980314n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34cR"><div class="casContent"><span class="casTitleNuber">34c</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage Products</span></div><div class="casAuthors">Ingallinella, Paolo; Altamura, Sergio; Bianchi, Elisabetta; Taliani, Marina; Ingenito, Raffaele; Cortese, Riccardo; De Francesco, Raffaele; Steinkuehler, Christian; Pessi, Antonello</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">8906-8914</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the absence of a broadly effective cure for hepatitis caused by hepatitis C virus (HCV), much effort is currently devoted to the search for inhibitors of the virally encoded protease NS3.  This chymotrypsin-like serine protease is required for the maturation of the viral polyprotein, cleaving it at the NS3-NS4A, NS4A-NS4B, NS4B-NS5A, and NS5A-NS5B sites.  In the course of our studies on the substrate specificity of NS3, the authors found that the products of cleavage corresponding to the P6-P1 region of the substrates act as competitive inhibitors of the enzyme, with IC50s ranging from 360 to 1 μM.  A detailed study of product inhibition by the natural NS3 substrates is described in the preceding paper [Steinkuhler, C., et al. (1997) Biochem. 37].  Here the authors report the results of a study of the structure-activity relationship of the NS3 product inhibitors, which suggest that the mode of binding of the P region-derived products is similar to the ground-state binding of the corresponding substrates, with addnl. binding energy provided by the C-terminal carboxylate.  Optimal binding requires a dual anchor: an "acid anchor" at the N terminus and a "P1 anchor" at the C-terminal part of the mol.  The authors have then optimized the sequence of the product inhibitors by using single mutations and combinatorial peptide libraries based on the most potent natural product, Ac-Asp-Glu-Met-Glu-Glu-Cys-OH (Ki = 0.6 μM), derived from cleavage at the NS4A-NS4B junction.  By sequentially optimizing positions P2, P4, P3, and P5, the authors obtained several nanomolar inhibitors of the enzyme.  These compds. are useful both as a starting point for the development of peptidomimetic drugs and as structural probes for investigating the substrate binding site of NS3 by modeling, NMR, and crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4KmZ8PDEEKrVg90H21EOLACvtfcHk0ljf_ihEYKB2hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjsFeiu70%253D&md5=d6ad2b6766249fc695c3e91167bbdc1b</span></div><a href="/servlet/linkout?suffix=cit34c&amp;dbid=16384&amp;doi=10.1021%2Fbi980314n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi980314n%26sid%3Dliteratum%253Aachs%26aulast%3DIngallinella%26aufirst%3DP.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DBianchi%26aufirst%3DE.%26aulast%3DTaliani%26aufirst%3DM.%26aulast%3DIngenito%26aufirst%3DR.%26aulast%3DCortese%26aufirst%3DR.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DPessi%26aufirst%3DA.%26atitle%3DPotent%2520peptide%2520inhibitors%2520of%2520human%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520are%2520obtained%2520by%2520optimizing%2520the%2520cleavage%2520products%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D8906%26epage%3D8914%26doi%3D10.1021%2Fbi980314n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Narjes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colarusso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinkühler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matassa, V. G.</span><span> </span><span class="NLM_article-title">A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">701</span><span class="NLM_x">–</span> <span class="NLM_lpage">704</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00842-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0960-894X%2801%2900842-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=11844705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtFKqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=701-704&author=F.+Narjesauthor=K.+F.+Koehlerauthor=U.+Kochauthor=B.+Gerlachauthor=S.+Colarussoauthor=C.+Steink%C3%BChlerauthor=M.+Brunettiauthor=S.+Altamuraauthor=R.+De+Francescoauthor=V.+G.+Matassa&title=A+designed+P1+cysteine+mimetic+for+covalent+and+non-covalent+inhibitors+of+HCV+NS3+protease&doi=10.1016%2FS0960-894X%2801%2900842-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35aR"><div class="casContent"><span class="casTitleNuber">35a</span><div class="casTitle"><span class="NLM_cas:atitle">A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease</span></div><div class="casAuthors">Narjes, Frank; Koehler, Konrad F.; Koch, Uwe; Gerlach, Benjamin; Colarusso, Stefania; Steinkuhler, Christian; Brunetti, Mirko; Altamura, Sergio; De Francesco, Raffaele; Matassa, Victor G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">701-704</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The difluoromethyl group was designed by computational chem. methods as a mimetic of the canonical P1 cysteine thiol for inhibitors of the hepatitis C virus NS3 protease.  This modification led to the development of competitive, non-covalent inhibitor AcAspGlu-NHCH(CHPH2)CO-Glu-NHCH(CH2C6H11)CONHCH(CH2CHF2)R (I, R = CHO) Ki 30 nM and reversible covalent inhibitors (I, R = CO2H) Ki 0.5 nM; and (I, R = COCO2H) Ki* 10 pM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVoMg5xhUdXbVg90H21EOLACvtfcHk0ljN7mwxAZKbsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtFKqur8%253D&md5=3797b78c5827e4db42a7170844d0c0cb</span></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900842-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900842-3%26sid%3Dliteratum%253Aachs%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DKoehler%26aufirst%3DK.%2BF.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DGerlach%26aufirst%3DB.%26aulast%3DColarusso%26aufirst%3DS.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DBrunetti%26aufirst%3DM.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DMatassa%26aufirst%3DV.%2BG.%26atitle%3DA%2520designed%2520P1%2520cysteine%2520mimetic%2520for%2520covalent%2520and%2520non-covalent%2520inhibitors%2520of%2520HCV%2520NS3%2520protease%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D701%26epage%3D704%26doi%3D10.1016%2FS0960-894X%2801%2900842-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Erickson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLoughlin, J. I.</span><span> </span><span class="NLM_article-title">Hydrogen bond donor properties of the difluoromethyl group</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1626</span><span class="NLM_x">–</span> <span class="NLM_lpage">1631</span><span class="refDoi"> DOI: 10.1021/jo00111a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00111a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK2MXktleksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1995&pages=1626-1631&author=J.+A.+Ericksonauthor=J.+I.+McLoughlin&title=Hydrogen+bond+donor+properties+of+the+difluoromethyl+group&doi=10.1021%2Fjo00111a021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35bR"><div class="casContent"><span class="casTitleNuber">35b</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrogen Bond Donor Properties of the Difluoromethyl Group</span></div><div class="casAuthors">Erickson, Jon A.; McLoughlin, Jim I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1626-31</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A theor. and exptl. study of the existence and the properties of the difluoromethyl group acting as a hydrogen bond donor has been carried out.  An intramol. CF2H...O:C interaction was examd. using semiempirical MO calcns. of both a non-hydrogen-bonded and hydrogen-bonded conformation of a CF2H-substituted pyrazolecarboxamide fungicide.  Results revealed a short H...O contact, a significant energy stabilization, and a lowering in the IR spectrum of 22 cm-1.  The exptl. IR spectrum of this mol. gave two carbonyl stretching frequencies, one lower by 18 cm-1, very similar to the calcd. no.  Low-temp. NMR results are also consistent with a geometry having the possibility of an intramol. CF2H...O:C hydrogen bond.  The hydrogen bond in this system may be related to the enhanced biol. activity of the CF2H compd. over its CF3 counterpart.  In addn., ab initio MO methods were employed to examine inter- and intramol. hydrogen-bonding models of the difluoromethyl group.  The results showed that the CF2H...O:C interaction has a binding energy of ∼1.0 kcal mol-1 and a H...O distance of ∼2.4 Å.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV4ifnttVlabVg90H21EOLACvtfcHk0lhuEzWunNoXjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXktleksrY%253D&md5=efa305f99bfa66ac92aa3b72942289b4</span></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=10.1021%2Fjo00111a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00111a021%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DJ.%2BA.%26aulast%3DMcLoughlin%26aufirst%3DJ.%2BI.%26atitle%3DHydrogen%2520bond%2520donor%2520properties%2520of%2520the%2520difluoromethyl%2520group%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1995%26volume%3D60%26spage%3D1626%26epage%3D1631%26doi%3D10.1021%2Fjo00111a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Synopsis of some recent tactical application of bioisosteres in drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2529</span><span class="NLM_x">–</span> <span class="NLM_lpage">2591</span><span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+some+recent+tactical+application+of+bioisosteres+in+drug+design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0liFyUHP1WEjIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520some%2520recent%2520tactical%2520application%2520of%2520bioisosteres%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Narjes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colarusso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biasiol, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fattori, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francesco, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matassa, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinkühler, C.</span><span> </span><span class="NLM_article-title">α-Ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1849</span><span class="NLM_x">–</span> <span class="NLM_lpage">1861</span><span class="refDoi"> DOI: 10.1021/bi9924260</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi9924260" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=1849-1861&author=F.+Narjesauthor=M.+Brunettiauthor=S.+Colarussoauthor=B.+Gerlachauthor=U.+Kochauthor=G.+Biasiolauthor=D.+Fattoriauthor=R.+D.+Francescoauthor=V.+G.+Matassaauthor=C.+Steink%C3%BChler&title=%CE%B1-Ketoacids+are+potent+slow+binding+inhibitors+of+the+hepatitis+C+virus+NS3+protease&doi=10.1021%2Fbi9924260"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=10.1021%2Fbi9924260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi9924260%26sid%3Dliteratum%253Aachs%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DBrunetti%26aufirst%3DM.%26aulast%3DColarusso%26aufirst%3DS.%26aulast%3DGerlach%26aufirst%3DB.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DBiasiol%26aufirst%3DG.%26aulast%3DFattori%26aufirst%3DD.%26aulast%3DFrancesco%26aufirst%3DR.%2BD.%26aulast%3DMatassa%26aufirst%3DV.%2BG.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26atitle%3D%25CE%25B1-Ketoacids%2520are%2520potent%2520slow%2520binding%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D1849%26epage%3D1861%26doi%3D10.1021%2Fbi9924260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Di Marco, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colarusso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matassa, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sollazzo, M.</span><span> </span><span class="NLM_article-title">Inhibition of the hepatitis C virus NS3/4A protease: the crystal structures of two protease-inhibitor complexes</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">275</span><span class="NLM_x">, </span> <span class="NLM_fpage">7152</span><span class="NLM_x">–</span> <span class="NLM_lpage">7157</span><span class="refDoi"> DOI: 10.1074/jbc.275.10.7152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1074%2Fjbc.275.10.7152" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=7152-7157&author=S.+Di+Marcoauthor=M.+Rizziauthor=C.+Volpariauthor=M.+A.+Walshauthor=F.+Narjesauthor=S.+Colarussoauthor=R.+De+Francescoauthor=V.+G.+Matassaauthor=M.+Sollazzo&title=Inhibition+of+the+hepatitis+C+virus+NS3%2F4A+protease%3A+the+crystal+structures+of+two+protease-inhibitor+complexes&doi=10.1074%2Fjbc.275.10.7152"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.275.10.7152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.275.10.7152%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMarco%26aufirst%3DS.%26aulast%3DRizzi%26aufirst%3DM.%26aulast%3DVolpari%26aufirst%3DC.%26aulast%3DWalsh%26aufirst%3DM.%2BA.%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DColarusso%26aufirst%3DS.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DMatassa%26aufirst%3DV.%2BG.%26aulast%3DSollazzo%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%252F4A%2520protease%253A%2520the%2520crystal%2520structures%2520of%2520two%2520protease-inhibitor%2520complexes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D7152%26epage%3D7157%26doi%3D10.1074%2Fjbc.275.10.7152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perni, R. B.</span><span> </span><span class="NLM_article-title">Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3–4A serine protease</span> <span class="citation_source-journal">Infect. Disord.: Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span><span class="refDoi"> DOI: 10.2174/187152606776056706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.2174%2F187152606776056706" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=3-16&author=C.+Linauthor=A.+D.+Kwongauthor=R.+B.+Perni&title=Discovery+and+development+of+VX-950%2C+a+novel%2C+covalent%2C+and+reversible+inhibitor+of+hepatitis+C+virus+NS3%E2%80%934A+serine+protease&doi=10.2174%2F187152606776056706"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=10.2174%2F187152606776056706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152606776056706%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.%26aulast%3DKwong%26aufirst%3DA.%2BD.%26aulast%3DPerni%26aufirst%3DR.%2BB.%26atitle%3DDiscovery%2520and%2520development%2520of%2520VX-950%252C%2520a%2520novel%252C%2520covalent%252C%2520and%2520reversible%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520NS3%25E2%2580%25934A%2520serine%2520protease%26jtitle%3DInfect.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2006%26volume%3D6%26spage%3D3%26epage%3D16%26doi%3D10.2174%2F187152606776056706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit38b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kwong, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, P.</span><span> </span><span class="NLM_article-title">Discovery and development of telaprevir: an NS3–4A protease inhibitor for treating genotype 1 chronic hepatitis C virus</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">1003</span><span class="refDoi"> DOI: 10.1038/nbt.2020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnbt.2020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=22068541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVCntLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=993-1003&author=A.+D.+Kwongauthor=R.+S.+Kauffmanauthor=P.+Hurterauthor=P.+Mueller&title=Discovery+and+development+of+telaprevir%3A+an+NS3%E2%80%934A+protease+inhibitor+for+treating+genotype+1+chronic+hepatitis+C+virus&doi=10.1038%2Fnbt.2020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38bR"><div class="casContent"><span class="casTitleNuber">38b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus</span></div><div class="casAuthors">Kwong, Ann D.; Kauffman, Robert S.; Hurter, Patricia; Mueller, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">993-1003</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Infection with hepatitis C virus (HCV) is a major medical problem with over 170 million people infected worldwide.  Substantial morbidity and mortality are assocd. with hepatic manifestations (cirrhosis and hepatocellular carcinoma), which develop with increasing frequency in people infected with HCV for more than 20 years.  Less well known is the burden of HCV disease assocd. with extrahepatic manifestations (diabetes, B-cell proliferative disorders, depression, cognitive disorders, arthritis and Sjoegren's syndrome).  For patients infected with genotype 1 HCV, treatment with polyethylene glycol decorated interferon (peginterferon) α and ribavirin (PR) is assocd. with a low (40-50%) success rate, substantial treatment-limiting side effects and a long (48-wk) duration of treatment.  In the past 15 years, major scientific advances have enabled the development of new classes of HCV therapy, the direct-acting antiviral agents, also known as specifically targeted antiviral therapy for hepatitis C (STAT-C).  In combination with PR, the HCV NS3-4A protease inhibitor telaprevir has recently been approved for treatment of genotype 1 chronic HCV in the United States, Canada, European Union and Japan.  Compared with PR, telaprevir combination therapy offers significantly improved viral cure rates and the possibility of shortened treatment duration for diverse patient populations.  Developers of innovative drugs have to blaze a new path with few validated sign posts to guide the way.  Indeed, telaprevir's development was once put on hold because of its performance in a std. IC50 assay.  Data from new hypotheses and novel expts. were required to justify further investment and reduce risk that the drug might fail in the clinic.  In addn., the poor drug-like properties of telaprevir were a formidable hurdle, which the manufg. and formulation teams had to overcome to make the drug.  Finally, novel clin. trial designs were developed to improve efficacy and shorten treatment in parallel instead of sequentially.  Lessons learned from the development of telaprevir suggest that makers of innovative medicines cannot rely solely on traditional drug discovery metrics, but must develop innovative, scientifically guided pathways for success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodUEHshXTAvbVg90H21EOLACvtfcHk0lhxGqo7GdmSIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVCntLvJ&md5=952966419a2e72107550d0a63c337ae4</span></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2020%26sid%3Dliteratum%253Aachs%26aulast%3DKwong%26aufirst%3DA.%2BD.%26aulast%3DKauffman%26aufirst%3DR.%2BS.%26aulast%3DHurter%26aufirst%3DP.%26aulast%3DMueller%26aufirst%3DP.%26atitle%3DDiscovery%2520and%2520development%2520of%2520telaprevir%253A%2520an%2520NS3%25E2%2580%25934A%2520protease%2520inhibitor%2520for%2520treating%2520genotype%25201%2520chronic%2520hepatitis%2520C%2520virus%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D993%26epage%3D1003%26doi%3D10.1038%2Fnbt.2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, N.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piwinski, J. J.</span><span> </span><span class="NLM_article-title">Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">50</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span><span class="refDoi"> DOI: 10.1021/ar700109k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar700109k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlCgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=50-59&author=F.+G.+Njorogeauthor=K.+X.+Chenauthor=N.-Y.+Shihauthor=J.+J.+Piwinski&title=Challenges+in+modern+drug+discovery%3A+a+case+study+of+boceprevir%2C+an+HCV+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Far700109k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges in Modern Drug Discovery: A Case Study of Boceprevir, an HCV Protease Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Njoroge, F. George; Chen, Kevin X.; Shih, Neng-Yang; Piwinski, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-59</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  More than 170 million people worldwide are affected by the hepatitis C virus (HCV).  The disease has been described as a "silent epidemic" and "a serious global health crisis".  HCV infection is a leading cause of chronic liver disease such as cirrhosis, carcinoma, or liver failure.  The current pegylated interferon and ribavirin combination therapy is effective in only 50% of patients.  Its moderate efficacy and apparent side effects underscore the need for safer and more effective treatments.  The nonstructural NS3 protease of the virus plays a vital role in the replication of the HCV virus.  The development of small mol. inhibitors of NS3 protease as antiviral agents has been intensively pursued as a viable strategy to eradicate HCV infection.  However, it is a daunting task.  The protease has a shallow and solvent-exposed substrate binding region, and the inhibitor binding energy is mainly derived from weak lipophilic and electrostatic interactions.  Moreover, lack of a robust in vitro cell culture system and the absence of a convenient small animal model have hampered the assessment of both in vitro and in vivo efficacy of any antiviral compds.  Despite the tremendous challenges, with access to a recently developed cell-based replicon system, major progress has been made toward a more effective small mol. HCV drug.  In our HCV program, facing no leads from our screening effort, a structure-based drug design approach was carried out.  An α-ketoamide-type electrofile was designed to trap the serine hydroxyl of the protease.  Early ketoamide inhibitors mimicked the structures of the peptide substrates.  With the aid of X-ray structures, we successfully truncated the undecapeptide lead that had a mol. wt. of 1265 Da stepwise to a tripeptide with a mol. wt. of 500 Da.  In an attempt to depeptidize the inhibitors, various strategies such as hydrazine urea replacement of amide bonds and P2 to P4 and P1 to P3 macrocyclizations were examd.  Further optimization of the tripeptide inhibitors led to the identification of the best moieties for each site: primary ketoamide at P', cyclobutylalanine at P1, gem-dimethylcyclopropylproline at P2, tert-leucine at P3, and tert-Bu urea as capping agent.  The combination of these led to the discovery of compd. 8 (SCH 503034, boceprevir), our clin. candidate.  It is a potent inhibitor in both enzyme assay (Ki* = 14 nM) and cell-based replicon assay (EC90 = 0.35 μM).  It is highly selective (2200×) against human neutrophil elastase (HNE).  Boceprevir is well tolerated in humans and demonstrated antiviral activity in phase I clin. trials.  It is currently in phase II trials.  This Account details the complexity and challenges encountered in the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouDZPm8xBmjrVg90H21EOLACvtfcHk0ljl6M5wI68dQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlCgsw%253D%253D&md5=98c07ae0d013b72c6f06a06655ba8d82</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1021%2Far700109k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far700109k%26sid%3Dliteratum%253Aachs%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26aulast%3DChen%26aufirst%3DK.%2BX.%26aulast%3DShih%26aufirst%3DN.-Y.%26aulast%3DPiwinski%26aufirst%3DJ.%2BJ.%26atitle%3DChallenges%2520in%2520modern%2520drug%2520discovery%253A%2520a%2520case%2520study%2520of%2520boceprevir%252C%2520an%2520HCV%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D50%26epage%3D59%26doi%3D10.1021%2Far700109k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit39b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Venkatraman, S.</span><span> </span><span class="NLM_article-title">Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">289</span><span class="refDoi"> DOI: 10.1016/j.tips.2012.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.tips.2012.03.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=289-289&author=S.+Venkatraman&title=Discovery+of+boceprevir%2C+a+direct-acting+NS3%2F4A+protease+inhibitor+for+treatment+of+chronic+hepatitis+C+infections&doi=10.1016%2Fj.tips.2012.03.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2012.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2012.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatraman%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520boceprevir%252C%2520a%2520direct-acting%2520NS3%252F4A%2520protease%2520inhibitor%2520for%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520infections%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D289%26epage%3D289%26doi%3D10.1016%2Fj.tips.2012.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit39c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Venkatraman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogen, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arasappan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jao, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parekh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santhanam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vibulbhan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butkiewicz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pichardo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baroudy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malcolm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prongay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madison, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broske, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brisson, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prelusky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korfmacher, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogdanowich-Knipp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlovsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saksena, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganguly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piwinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girijavallabhan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span> </span><span class="NLM_article-title">Discovery of (1<i>R</i>,5<i>S</i>)-<i>N</i>-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(<i>S</i>)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(<i>S</i>)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6074</span><span class="NLM_x">–</span> <span class="NLM_lpage">6086</span><span class="refDoi"> DOI: 10.1021/jm060325b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060325b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlOlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6074-6086&author=S.+Venkatramanauthor=S.+L.+Bogenauthor=A.+Arasappanauthor=F.+Bennettauthor=K.+Chenauthor=E.+Jaoauthor=Y.-T.+Liuauthor=R.+Loveyauthor=S.+Hendrataauthor=Y.+Huangauthor=W.+Panauthor=T.+Parekhauthor=P.+Pintoauthor=V.+Popovauthor=R.+Pikeauthor=S.+Ruanauthor=B.+Santhanamauthor=B.+Vibulbhanauthor=W.+Wuauthor=W.+Yangauthor=J.+Kongauthor=X.+Liangauthor=J.+Wongauthor=R.+Liuauthor=N.+Butkiewiczauthor=R.+Chaseauthor=A.+Hartauthor=S.+Agrawalauthor=P.+Ingravalloauthor=J.+Pichardoauthor=R.+Kongauthor=B.+Baroudyauthor=B.+Malcolmauthor=Z.+Guoauthor=A.+Prongayauthor=V.+Madisonauthor=L.+Broskeauthor=X.+Cuiauthor=K.-C.+Chengauthor=Y.+Hsiehauthor=J.-M.+Brissonauthor=D.+Preluskyauthor=W.+Korfmacherauthor=R.+Whiteauthor=S.+Bogdanowich-Knippauthor=A.+Pavlovskyauthor=P.+Bradleyauthor=A.+K.+Saksenaauthor=A.+Gangulyauthor=J.+Piwinskiauthor=V.+Girijavallabhanauthor=F.+G.+Njoroge&title=Discovery+of+%281R%2C5S%29-N-%5B3-amino-1-%28cyclobutylmethyl%29-2%2C3-dioxopropyl%5D-3-%5B2%28S%29-%5B%5B%5B%281%2C1-dimethylethyl%29amino%5Dcarbonyl%5Damino%5D-3%2C3-dimethyl-1-oxobutyl%5D-6%2C6-dimethyl-3-azabicyclo%5B3.1.0%5Dhexan-2%28S%29-carboxamide+%28SCH+503034%29%2C+a+selective%2C+potent%2C+orally+bioavailable+hepatitis+C+virus+NS3+protease+inhibitor%3A+a+potential+therapeutic+agent+for+the+treatment+of+hepatitis+C+infection&doi=10.1021%2Fjm060325b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39cR"><div class="casContent"><span class="casTitleNuber">39c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection</span></div><div class="casAuthors">Venkatraman, Srikanth; Bogen, Stephane L.; Arasappan, Ashok; Bennett, Frank; Chen, Kevin; Jao, Edwin; Liu, Yi-Tsung; Lovey, Raymond; Hendrata, Siska; Huang, Yuhua; Pan, Weidong; Parekh, Tejal; Pinto, Patrick; Popov, Veljko; Pike, Russel; Ruan, Sumei; Santhanam, Bama; Vibulbhan, Bancha; Wu, Wanli; Yang, Weiying; Kong, Jianshe; Liang, Xiang; Wong, Jesse; Liu, Rong; Butkiewicz, Nancy; Chase, Robert; Hart, Andrea; Agrawal, Sony; Ingravallo, Paul; Pichardo, John; Kong, Rong; Baroudy, Bahige; Malcolm, Bruce; Guo, Zhuyan; Prongay, Andrew; Madison, Vincent; Broske, Lisa; Cui, Xiaoming; Cheng, Kuo-Chi; Hsieh, Tony Y.; Brisson, Jean-Marc; Prelusky, Danial; Korfmacher, Walter; White, Ronald; Bogdanowich-Knipp, Susan; Pavlovsky, Anastasia; Bradley, Prudence; Saksena, Anil K.; Ganguly, Ashit; Piwinski, John; Girijavallabhan, Viyyoor; Njoroge, F. George</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6074-6086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide.  Currently the only therapeutic regimens are s.c. interferon-α or polyethylene glycol (PEG)-interferon-α alone or in combination with oral ribavirin.  Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virol. response.  Herein, the SAR leading to the discovery of SCH 503034 (I), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clin. trials in human beings for the treatment of hepatitis C viral infections is described.  X-ray structure of I complexed with the NS3 protease and biol. data are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjAR2KjtnJV7Vg90H21EOLACvtfcHk0lhKZqKkgc12iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlOlsLg%253D&md5=e48b2e2d3eb19f7f28aaa76f96d03414</span></div><a href="/servlet/linkout?suffix=cit39c&amp;dbid=16384&amp;doi=10.1021%2Fjm060325b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060325b%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DBogen%26aufirst%3DS.%2BL.%26aulast%3DArasappan%26aufirst%3DA.%26aulast%3DBennett%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DJao%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DY.-T.%26aulast%3DLovey%26aufirst%3DR.%26aulast%3DHendrata%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DParekh%26aufirst%3DT.%26aulast%3DPinto%26aufirst%3DP.%26aulast%3DPopov%26aufirst%3DV.%26aulast%3DPike%26aufirst%3DR.%26aulast%3DRuan%26aufirst%3DS.%26aulast%3DSanthanam%26aufirst%3DB.%26aulast%3DVibulbhan%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DButkiewicz%26aufirst%3DN.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DHart%26aufirst%3DA.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DPichardo%26aufirst%3DJ.%26aulast%3DKong%26aufirst%3DR.%26aulast%3DBaroudy%26aufirst%3DB.%26aulast%3DMalcolm%26aufirst%3DB.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DProngay%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DBroske%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DK.-C.%26aulast%3DHsieh%26aufirst%3DY.%26aulast%3DBrisson%26aufirst%3DJ.-M.%26aulast%3DPrelusky%26aufirst%3DD.%26aulast%3DKorfmacher%26aufirst%3DW.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DBogdanowich-Knipp%26aufirst%3DS.%26aulast%3DPavlovsky%26aufirst%3DA.%26aulast%3DBradley%26aufirst%3DP.%26aulast%3DSaksena%26aufirst%3DA.%2BK.%26aulast%3DGanguly%26aufirst%3DA.%26aulast%3DPiwinski%26aufirst%3DJ.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DDiscovery%2520of%2520%25281R%252C5S%2529-N-%255B3-amino-1-%2528cyclobutylmethyl%2529-2%252C3-dioxopropyl%255D-3-%255B2%2528S%2529-%255B%255B%255B%25281%252C1-dimethylethyl%2529amino%255Dcarbonyl%255Damino%255D-3%252C3-dimethyl-1-oxobutyl%255D-6%252C6-dimethyl-3-azabicyclo%255B3.1.0%255Dhexan-2%2528S%2529-carboxamide%2520%2528SCH%2520503034%2529%252C%2520a%2520selective%252C%2520potent%252C%2520orally%2520bioavailable%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitor%253A%2520a%2520potential%2520therapeutic%2520agent%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6074%26epage%3D6086%26doi%3D10.1021%2Fjm060325b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lamarre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bös, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faucher, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagace, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rancourt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sentjens, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St George, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simoneau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibeault, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weldon, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span> </span><span class="NLM_article-title">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">426</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span><span class="refDoi"> DOI: 10.1038/nature02099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnature02099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=14578911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2003&pages=186-189&author=D.+Lamarreauthor=P.+C.+Andersonauthor=M.+Baileyauthor=P.+Beaulieuauthor=G.+Bolgerauthor=P.+Bonneauauthor=M.+B%C3%B6sauthor=D.+R.+Cameronauthor=M.+Cartierauthor=M.+G.+Cordingleyauthor=A.+M.+Faucherauthor=N.+Goudreauauthor=S.+H.+Kawaiauthor=G.+Kukoljauthor=L.+Lagaceauthor=S.+R.+LaPlanteauthor=H.+Narjesauthor=M.+A.+Poupartauthor=J.+Rancourtauthor=R.+E.+Sentjensauthor=R.+St+Georgeauthor=B.+Simoneauauthor=G.+Steinmannauthor=D.+Thibeaultauthor=Y.+S.+Tsantrizosauthor=S.+M.+Weldonauthor=C.+L.+Yongauthor=M.+Llin%C3%A0s-Brunet&title=An+NS3+protease+inhibitor+with+antiviral+effects+in+humans+infected+with+hepatitis+C+virus&doi=10.1038%2Fnature02099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40aR"><div class="casContent"><span class="casTitleNuber">40a</span><div class="casTitle"><span class="NLM_cas:atitle">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span></div><div class="casAuthors">Lamarre, Daniel; Anderson, Paul C.; Bailey, Murray; Beaulieu, Pierre; Bolger, Gordon; Bonneau, Pierre; Boes, Michael; Cameron, Dale R.; Cartier, Mireille; Cordingley, Michael G.; Faucher, Anne-Marie; Goudreau, Nathalie; Kawai, Stephen H.; Kukolj, George; Lagace, Lisette; LaPlante, Steven R.; Narjes, Hans; Poupart, Marc-Andre; Rancourt, Jean; Sentjens, Roel E.; St. George, Roger; Simoneau, Bruno; Steinmann, Gerhard; Thibeault, Diane; Tsantrizos, Youla S.; Weldon, Steven M.; Yong, Chan-Loi; Llinas-Brunet, Montse</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">6963</span>),
    <span class="NLM_cas:pages">186-189</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide with more than 170 million infected individuals at risk of developing significant morbidity and mortality.  Current interferon-based therapies are suboptimal esp. in patients infected with HCV genotype 1, and they are poorly tolerated, highlighting the unmet medical need for new therapeutics.  The HCV-encoded NS3 protease is essential for viral replication and has long been considered an attractive target for therapeutic intervention in HCV-infected patients.  Here we identify a class of specific and potent NS3 protease inhibitors and report the evaluation of BILN 2061, a small mol. inhibitor biol. available through oral ingestion and the first of its class in human trials.  Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive redn. of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor.  Our results further illustrate the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPnVapDO21RLVg90H21EOLACvtfcHk0libwSmGjZCk8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D&md5=36db818d5af257d3ebeef1a061ca68cb</span></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=10.1038%2Fnature02099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02099%26sid%3Dliteratum%253Aachs%26aulast%3DLamarre%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DP.%2BC.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DBeaulieu%26aufirst%3DP.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DB%25C3%25B6s%26aufirst%3DM.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DCartier%26aufirst%3DM.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26aulast%3DFaucher%26aufirst%3DA.%2BM.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DKawai%26aufirst%3DS.%2BH.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLagace%26aufirst%3DL.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DNarjes%26aufirst%3DH.%26aulast%3DPoupart%26aufirst%3DM.%2BA.%26aulast%3DRancourt%26aufirst%3DJ.%26aulast%3DSentjens%26aufirst%3DR.%2BE.%26aulast%3DSt%2BGeorge%26aufirst%3DR.%26aulast%3DSimoneau%26aufirst%3DB.%26aulast%3DSteinmann%26aufirst%3DG.%26aulast%3DThibeault%26aufirst%3DD.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DWeldon%26aufirst%3DS.%2BM.%26aulast%3DYong%26aufirst%3DC.%2BL.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26atitle%3DAn%2520NS3%2520protease%2520inhibitor%2520with%2520antiviral%2520effects%2520in%2520humans%2520infected%2520with%2520hepatitis%2520C%2520virus%26jtitle%3DNature%26date%3D2003%26volume%3D426%26spage%3D186%26epage%3D189%26doi%3D10.1038%2Fnature02099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit40b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faucher, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorys, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grand-Maître, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapeyre-Paquette, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liard, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhéaume, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span> </span><span class="NLM_article-title">Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1605</span><span class="NLM_x">–</span> <span class="NLM_lpage">1608</span><span class="refDoi"> DOI: 10.1021/jm0342414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0342414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1ylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1605-1608&author=M.+Llin%C3%A0s-Brunetauthor=M.+D.+Baileyauthor=G.+Bolgerauthor=C.+Brochuauthor=A.-M.+Faucherauthor=J.+M.+Ferlandauthor=M.+Garneauauthor=E.+Ghiroauthor=V.+Gorysauthor=C.+Grand-Ma%C3%AEtreauthor=T.+Halmosauthor=N.+Lapeyre-Paquetteauthor=F.+Liardauthor=M.+Poirierauthor=M.+Rh%C3%A9aumeauthor=Y.+S.+Tsantrizosauthor=D.+Lamarre&title=Structure-activity+study+on+a+novel+series+of+macrocyclic+inhibitors+of+the+hepatitis+C+virus+NS3+protease+leading+to+the+discovery+of+BILN+2061&doi=10.1021%2Fjm0342414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40bR"><div class="casContent"><span class="casTitleNuber">40b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061</span></div><div class="casAuthors">Llinas-Brunet, Montse; Bailey, Murray D.; Bolger, Gordon; Brochu, Christian; Faucher, Anne-Marie; Ferland, Jean Marie; Garneau, Michel; Ghiro, Elise; Gorys, Vida; Grand-Maitre, Chantal; Halmos, Ted; Lapeyre-Paquette, Nicole; Liard, Francine; Poirier, Martin; Rheaume, Manon; Tsantrizos, Youla S.; Lamarre, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1605-1608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">From the discovery of competitive hexapeptide inhibitors, potent and selective HCV NS3 protease macrocyclic inhibitors have been identified.  Structure-activity relationship studies were performed focusing on optimizing the N-terminal carbamate and the arom. substituent on the (4R)-hydroxyproline moiety.  Inhibitors meeting the potency criteria in the cell-based assay and with improved oral bioavailability in rats were identified.  BILN 2061 was selected as the best compd., the first NS3 protease inhibitor reported with antiviral activity in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_KmuWcS2jSrVg90H21EOLACvtfcHk0lghPDqR4fIm8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1ylsLo%253D&md5=d4d8116d2a688e4088e94be617fc396b</span></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=10.1021%2Fjm0342414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0342414%26sid%3Dliteratum%253Aachs%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DM.%2BD.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DFaucher%26aufirst%3DA.-M.%26aulast%3DFerland%26aufirst%3DJ.%2BM.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DGhiro%26aufirst%3DE.%26aulast%3DGorys%26aufirst%3DV.%26aulast%3DGrand-Ma%25C3%25AEtre%26aufirst%3DC.%26aulast%3DHalmos%26aufirst%3DT.%26aulast%3DLapeyre-Paquette%26aufirst%3DN.%26aulast%3DLiard%26aufirst%3DF.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DRh%25C3%25A9aume%26aufirst%3DM.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DStructure-activity%2520study%2520on%2520a%2520novel%2520series%2520of%2520macrocyclic%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520leading%2520to%2520the%2520discovery%2520of%2520BILN%25202061%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1605%26epage%3D1608%26doi%3D10.1021%2Fjm0342414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit40c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span> </span><span class="NLM_article-title">The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061 - from the NMR tube to the clinic</span> <span class="citation_source-journal">Biopolymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">323</span><span class="refDoi"> DOI: 10.1002/bip.20127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fbip.20127" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=309-323&author=Y.+S.+Tsantrizos&title=The+design+of+a+potent+inhibitor+of+the+hepatitis+C+virus+NS3+protease%3A+BILN+2061+-+from+the+NMR+tube+to+the+clinic&doi=10.1002%2Fbip.20127"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40c&amp;dbid=16384&amp;doi=10.1002%2Fbip.20127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.20127%26sid%3Dliteratum%253Aachs%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26atitle%3DThe%2520design%2520of%2520a%2520potent%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%253A%2520BILN%25202061%2520-%2520from%2520the%2520NMR%2520tube%2520to%2520the%2520clinic%26jtitle%3DBiopolymers%26date%3D2004%26volume%3D76%26spage%3D309%26epage%3D323%26doi%3D10.1002%2Fbip.20127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit40d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Tsantrizos, Y.</span><span> </span><span class="NLM_article-title">Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1252</span><span class="NLM_x">–</span> <span class="NLM_lpage">1263</span><span class="refDoi"> DOI: 10.1021/ar8000519</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar8000519" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=1252-1263&author=Y.+Tsantrizos&title=Peptidomimetic+therapeutic+agents+targeting+the+protease+enzyme+of+the+human+immunodeficiency+virus+and+hepatitis+C+virus&doi=10.1021%2Far8000519"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40d&amp;dbid=16384&amp;doi=10.1021%2Far8000519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far8000519%26sid%3Dliteratum%253Aachs%26aulast%3DTsantrizos%26aufirst%3DY.%26atitle%3DPeptidomimetic%2520therapeutic%2520agents%2520targeting%2520the%2520protease%2520enzyme%2520of%2520the%2520human%2520immunodeficiency%2520virus%2520and%2520hepatitis%2520C%2520virus%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D1252%26epage%3D1263%26doi%3D10.1021%2Far8000519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit40e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span> </span><span class="NLM_article-title">Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1356</span><span class="NLM_x">–</span> <span class="NLM_lpage">1360</span><span class="refDoi"> DOI: 10.1002/anie.200390347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fanie.200390347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlygsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=1356-1360&author=Y.+S.+Tsantrizosauthor=G.+Bolgerauthor=P.+Bonneauauthor=D.+R.+Cameronauthor=N.+Goudreauauthor=G.+Kukoljauthor=S.+R.+LaPlanteauthor=M.+Llin%C3%A0s-Brunetauthor=H.+Narauthor=D.+Lamarre&title=Macrocyclic+inhibitors+of+the+NS3+protease+as+potential+therapeutic+agents+of+hepatitis+C+virus+infection&doi=10.1002%2Fanie.200390347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40eR"><div class="casContent"><span class="casTitleNuber">40e</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection</span></div><div class="casAuthors">Tsantrizos, Youla S.; Bolger, Gordon; Bonneau, Pierre; Cameron, Dale R.; Goudreau, Nathalie; Kukolj, George; LaPlante, Steven R.; Llinas-Brunet, Montse; Nar, Herbert; Lamarre, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1356-1360</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A novel class of selective inhibitors of the hepatitis C virus NS3 protease, an enzyme which is essential for viral replication in vivo, was developed.  The inhibitors are based on the structure-activity relationship between a substrate-based peptidomimetic ligand and the HCV NS3 serine protease.  The designed HCV inhibitor and its satd. analogs are the first inhibitors of the NS3 protease which inhibit HCV RNA replication in the cell-based replicon assay.  In addn., they are orally absorbed and stable to metabolic breakdown.  Thus, these compds. show many of the desirable properties of a druglike archetype and could lead t a clin. useful antiviral agent for the treatment of hepatitis C viral infections in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCij3shP5tmLVg90H21EOLACvtfcHk0lhFF-cuR0W8mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlygsrc%253D&md5=e0a3c98ee0096bfc3d058bf0b92b81c3</span></div><a href="/servlet/linkout?suffix=cit40e&amp;dbid=16384&amp;doi=10.1002%2Fanie.200390347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200390347%26sid%3Dliteratum%253Aachs%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DMacrocyclic%2520inhibitors%2520of%2520the%2520NS3%2520protease%2520as%2520potential%2520therapeutic%2520agents%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D1356%26epage%3D1360%26doi%3D10.1002%2Fanie.200390347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorys, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurice, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rancourt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibeault, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span> </span><span class="NLM_article-title">Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2267</span><span class="NLM_x">–</span> <span class="NLM_lpage">2270</span><span class="refDoi"> DOI: 10.1016/S0960-894X(00)00465-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0960-894X%2800%2900465-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=11055335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntF2lu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=2267-2270&author=M.+Llin%C3%A0s-Brunetauthor=M.+Baileyauthor=G.+Fazalauthor=E.+Ghiroauthor=V.+Gorysauthor=S.+Gouletauthor=T.+Halmosauthor=R.+Mauriceauthor=M.+Poirierauthor=M.+A.+Poupartauthor=J.+Rancourtauthor=D.+Thibeaultauthor=D.+Wernicauthor=D.+Lamarre&title=Highly+potent+and+selective+peptide-based+inhibitors+of+the+hepatitis+C+virus+serine+protease%3A+towards+smaller+inhibitors&doi=10.1016%2FS0960-894X%2800%2900465-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors</span></div><div class="casAuthors">Llinas-Brunet, M.; Bailey, M.; Fazal, G.; Ghiro, E.; Gorys, V.; Goulet, S.; Halmos, T.; Maurice, R.; Poirier, M.; Poupart, M.-A.; Rancourt, J.; Thibeault, D.; Wernic, D.; Lamarre, D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2267-2270</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Structure-activity studies on a hexapeptide N-terminal cleavage product of a dodecamer substrate led to the identification of very potent and highly specific inhibitors of the HCV NS3 protease/NS4A cofactor peptide complex.  The largest increase in potency was accomplished by the introduction of a (4R)-naphthalen-1-yl-4-methoxy substituent to the P2 proline.  N-Terminal truncation resulted in tetrapeptides contg. a C-terminal carboxylic acid, which exhibited low micromolar activity against the HCV serine protease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJanVq8aCK0LVg90H21EOLACvtfcHk0lhIlm8KfqPyuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntF2lu70%253D&md5=e5c3a87c7242007d27e161c5472dc245</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900465-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900465-0%26sid%3Dliteratum%253Aachs%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DFazal%26aufirst%3DG.%26aulast%3DGhiro%26aufirst%3DE.%26aulast%3DGorys%26aufirst%3DV.%26aulast%3DGoulet%26aufirst%3DS.%26aulast%3DHalmos%26aufirst%3DT.%26aulast%3DMaurice%26aufirst%3DR.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DPoupart%26aufirst%3DM.%2BA.%26aulast%3DRancourt%26aufirst%3DJ.%26aulast%3DThibeault%26aufirst%3DD.%26aulast%3DWernic%26aufirst%3DD.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DHighly%2520potent%2520and%2520selective%2520peptide-based%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520serine%2520protease%253A%2520towards%2520smaller%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D2267%26epage%3D2270%26doi%3D10.1016%2FS0960-894X%2800%2900465-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubry, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurice, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibeault, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span> </span><span class="NLM_article-title">Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">18618</span><span class="NLM_x">–</span> <span class="NLM_lpage">18624</span><span class="refDoi"> DOI: 10.1074/jbc.274.26.18618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1074%2Fjbc.274.26.18618" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=18618-18624&author=S.+R.+LaPlanteauthor=D.+R.+Cameronauthor=N.+Aubryauthor=S.+Lefebvreauthor=G.+Kukoljauthor=R.+Mauriceauthor=D.+Thibeaultauthor=D.+Lamarreauthor=M.+Llin%C3%A0s-Brunet&title=Solution+structure+of+substrate-based+ligands+when+bound+to+hepatitis+C+virus+NS3+protease+domain&doi=10.1074%2Fjbc.274.26.18618"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42a&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.26.18618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.26.18618%26sid%3Dliteratum%253Aachs%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DAubry%26aufirst%3DN.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DMaurice%26aufirst%3DR.%26aulast%3DThibeault%26aufirst%3DD.%26aulast%3DLamarre%26aufirst%3DD.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26atitle%3DSolution%2520structure%2520of%2520substrate-based%2520ligands%2520when%2520bound%2520to%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D18618%26epage%3D18624%26doi%3D10.1074%2Fjbc.274.26.18618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit42b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubry, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Déziel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, P.</span><span> </span><span class="NLM_article-title">Transferred <sup>13</sup>C <i>T</i><sub>1</sub> relaxation at natural isotopic abundance: a practical method for determining site-specific changes in ligand flexibility upon binding to a macromolecule</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">12530</span><span class="NLM_x">–</span> <span class="NLM_lpage">12535</span><span class="refDoi"> DOI: 10.1021/ja0017817</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0017817" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2000&pages=12530-12535&author=S.+R.+LaPlanteauthor=N.+Aubryauthor=R.+D%C3%A9zielauthor=F.+Niauthor=P.+Xu&title=Transferred+13C+T1+relaxation+at+natural+isotopic+abundance%3A+a+practical+method+for+determining+site-specific+changes+in+ligand+flexibility+upon+binding+to+a+macromolecule&doi=10.1021%2Fja0017817"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42b&amp;dbid=16384&amp;doi=10.1021%2Fja0017817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0017817%26sid%3Dliteratum%253Aachs%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DAubry%26aufirst%3DN.%26aulast%3DD%25C3%25A9ziel%26aufirst%3DR.%26aulast%3DNi%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DP.%26atitle%3DTransferred%252013C%2520T1%2520relaxation%2520at%2520natural%2520isotopic%2520abundance%253A%2520a%2520practical%2520method%2520for%2520determining%2520site-specific%2520changes%2520in%2520ligand%2520flexibility%2520upon%2520binding%2520to%2520a%2520macromolecule%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2000%26volume%3D122%26spage%3D12530%26epage%3D12535%26doi%3D10.1021%2Fja0017817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit42c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakalian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubry, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S. H.</span><span> </span><span class="NLM_article-title">Ligand bioactive conformation plays a critical role in the design of drugs that target the hepatitis C Virus NS3 protease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1777</span><span class="NLM_x">–</span> <span class="NLM_lpage">1789</span><span class="refDoi"> DOI: 10.1021/jm401338c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401338c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Cktb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1777-1789&author=S.+R.+LaPlanteauthor=H.+Narauthor=C.+T.+Lemkeauthor=A.+Jakalianauthor=N.+Aubryauthor=S.+H.+Kawai&title=Ligand+bioactive+conformation+plays+a+critical+role+in+the+design+of+drugs+that+target+the+hepatitis+C+Virus+NS3+protease&doi=10.1021%2Fjm401338c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42cR"><div class="casContent"><span class="casTitleNuber">42c</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand Bioactive Conformation Plays a Critical Role in the Design of Drugs That Target the Hepatitis C Virus NS3 Protease</span></div><div class="casAuthors">LaPlante, Steven R.; Nar, Herbert; Lemke, Christopher T.; Jakalian, Araz; Aubry, Norman; Kawai, Stephen H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1777-1789</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A ligand-focused strategy employed NMR, X-ray, modeling, and medicinal chem. to expose the crit. role that bioactive conformation played in the design of a variety of drugs that target the HCV protease.  The bioactive conformation (bound states) were detd. for key inhibitors identified along our drug discovery pathway from the hit to clin. compds.  All adopt similar bioactive conformations for the common core derived from the hit peptide DDIVPC.  A carefully designed SAR anal., based on the advanced inhibitor 1 in which the P1 to P3 side chains and the N-terminal Boc were sequentially truncated, revealed a correlation between affinity and the relative predominance of the bioactive conformation in the free state.  Interestingly, synergistic conformation effects on potency were also noted.  Comparisons with clin. and recently marketed drugs from the pharmaceutical industry showed that all have the same core and similar bioactive conformations.  This suggested that the variety of appendages discovered for these compds. also properly satisfy the bioactive conformation requirements and allowed for a large variety of HCV protease drug candidates to be designed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFi-4R4F9wwbVg90H21EOLACvtfcHk0lhxbwHU5SjLFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Cktb7P&md5=2ccb36504903255ba012223529318a69</span></div><a href="/servlet/linkout?suffix=cit42c&amp;dbid=16384&amp;doi=10.1021%2Fjm401338c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401338c%26sid%3Dliteratum%253Aachs%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DLemke%26aufirst%3DC.%2BT.%26aulast%3DJakalian%26aufirst%3DA.%26aulast%3DAubry%26aufirst%3DN.%26aulast%3DKawai%26aufirst%3DS.%2BH.%26atitle%3DLigand%2520bioactive%2520conformation%2520plays%2520a%2520critical%2520role%2520in%2520the%2520design%2520of%2520drugs%2520that%2520target%2520the%2520hepatitis%2520C%2520Virus%2520NS3%2520protease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1777%26epage%3D1789%26doi%3D10.1021%2Fjm401338c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Llinas-Brunet, M.; Bailey, M. D.; Cameron, D.; Faucher, A.-M; Ghiro, E.; Goudreau, N.; Halmos, T.; Poupart, M.-A.; Rancourt, J.; Tsantrizos, Y. S.; Wernic, D. M.; Simoneau, B.</span><span> </span><span class="NLM_article-title">Preparation of hepatitis C inhibitory tripeptides</span>. World Patent Application WO 2000/0009543, February 24,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=M.+Llinas-Brunet&author=M.+D.+Bailey&author=D.+Cameron&author=A.-M+Faucher&author=E.+Ghiro&author=N.+Goudreau&author=T.+Halmos&author=M.-A.+Poupart&author=J.+Rancourt&author=Y.+S.+Tsantrizos&author=D.+M.+Wernic&author=B.+Simoneau&title=Preparation+of+hepatitis+C+inhibitory+tripeptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLlinas-Brunet%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520hepatitis%2520C%2520inhibitory%2520tripeptides%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit43b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Llinas-Brunet, M.; Bailey, M.; Cameron, D.; Ghiro, E.; Goudreau, N.; Poupart, M.-A.; Rancourt, J.; Tsantrizos, Y. S.</span><span> </span><span class="NLM_article-title">Hepatitis C inhibitor peptides</span>. World Patent Application WO 2000/0009558, February 24,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=M.+Llinas-Brunet&author=M.+Bailey&author=D.+Cameron&author=E.+Ghiro&author=N.+Goudreau&author=M.-A.+Poupart&author=J.+Rancourt&author=Y.+S.+Tsantrizos&title=Hepatitis+C+inhibitor+peptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLlinas-Brunet%26aufirst%3DM.%26atitle%3DHepatitis%2520C%2520inhibitor%2520peptides%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Campbell, J. A.; Good, A.</span><span> </span><span class="NLM_article-title">Hepatitis C tripeptide inhibitors</span>. World Patent Application WO 2002/060926, August 8,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=J.+A.+Campbell&author=A.+Good&title=Hepatitis+C+tripeptide+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DJ.%2BA.%26atitle%3DHepatitis%2520C%2520tripeptide%2520inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Scola, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sit, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocuzza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilder, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuring, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesenberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span> </span><span class="NLM_article-title">Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1708</span><span class="NLM_x">–</span> <span class="NLM_lpage">1729</span><span class="refDoi"> DOI: 10.1021/jm401840s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401840s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVaqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1708-1729&author=P.+M.+Scolaauthor=A.+X.+Wangauthor=A.+C.+Goodauthor=L.-Q.+Sunauthor=K.+D.+Combrinkauthor=J.+A.+Campbellauthor=J.+Chenauthor=Y.+Tuauthor=N.+Sinauthor=B.+L.+Venablesauthor=S.-Y.+Sitauthor=Y.+Chenauthor=A.+Cocuzzaauthor=D.+M.+Bilderauthor=S.+D%E2%80%99Andreaauthor=B.+Zhengauthor=P.+Hewawasamauthor=M.+Dingauthor=J.+Thuringauthor=J.+Liauthor=D.+Hernandezauthor=F.+Yuauthor=P.+Falkauthor=G.+Zhaiauthor=A.+K.+Sheafferauthor=C.+Chenauthor=M.+S.+Leeauthor=D.+Barryauthor=J.+O.+Knipeauthor=W.+Liauthor=Y.-H.+Hanauthor=S.+Jenkinsauthor=C.+Gesenbergauthor=Q.+Gaoauthor=M.+W.+Sinzauthor=K.+S.+Santoneauthor=T.+Zvyagaauthor=R.+Rajamaniauthor=H.+E.+Kleiauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=E.+Hughesauthor=C.+Chienauthor=S.+Adamsauthor=P.+C.+Levesqueauthor=D.+Liauthor=J.+Zhuauthor=N.+A.+Meanwellauthor=F.+McPhee&title=Discovery+and+early+clinical+evaluation+of+BMS-605339%2C+a+potent+and+orally+efficacious+tripeptidic+acylsulfonamide+NS3+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Fjm401840s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Scola, Paul M.; Wang, Alan Xiangdong; Good, Andrew C.; Sun, Li-Qiang; Combrink, Keith D.; Campbell, Jeffrey A.; Chen, Jie; Tu, Yong; Sin, Ny; Venables, Brian L.; Sit, Sing-Yuen; Chen, Yan; Cocuzza, Anthony; Bilder, Donna M.; D'Andrea, Stanley; Zheng, Barbara; Hewawasam, Piyasena; Ding, Min; Thuring, Jan; Li, Jianqing; Hernandez, Dennis; Yu, Fei; Falk, Paul; Zhai, Guangzhi; Sheaffer, Amy K.; Chen, Chaoqun; Lee, Min S.; Barry, Diana; Knipe, Jay O.; Li, Wenying; Han, Yong-Hae; Jenkins, Susan; Gesenberg, Christoph; Gao, Qi; Sinz, Michael W.; Santone, Kenneth S.; Zvyaga, Tatyana; Rajamani, Ramkumar; Klei, Herbert E.; Colonno, Richard J.; Grasela, Dennis M.; Hughes, Eric; Chien, Caly; Adams, Stephen; Levesque, Paul C.; Li, Danshi; Zhu, Jialong; Meanwell, Nicholas A.; McPhee, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1708-1729</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of BMS-605339 (35), a tripeptidic inhibitor of the NS3/4A enzyme, is described.  This compd. incorporates a cyclopropylacylsulfonamide moiety that was designed to improve the potency of carboxylic acid prototypes through the introduction of favorable nonbonding interactions within the S1' site of the protease.  The identification of 35 was enabled through the optimization and balance of crit. properties including potency and pharmacokinetics (PK).  This was achieved through modulation of the P2* subsite of the inhibitor which identified the isoquinoline ring system as a key template for improving PK properties with further optimization achieved through functionalization.  A methoxy moiety at the C6 position of this isoquinoline ring system proved to be optimal with respect to potency and PK, thus providing the clin. compd. 35 which demonstrated antiviral activity in HCV-infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJmlq7vS_NcLVg90H21EOLACvtfcHk0lgiCoerYOT8cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVaqsL4%253D&md5=cac18d2020ecf9d3ac1a8e1237e0ea7c</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm401840s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401840s%26sid%3Dliteratum%253Aachs%26aulast%3DScola%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DA.%2BX.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DCampbell%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DSit%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCocuzza%26aufirst%3DA.%26aulast%3DBilder%26aufirst%3DD.%2BM.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DThuring%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DY.-H.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DGesenberg%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DRajamani%26aufirst%3DR.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DMcPhee%26aufirst%3DF.%26atitle%3DDiscovery%2520and%2520early%2520clinical%2520evaluation%2520of%2520BMS-605339%252C%2520a%2520potent%2520and%2520orally%2520efficacious%2520tripeptidic%2520acylsulfonamide%2520NS3%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1708%26epage%3D1729%26doi%3D10.1021%2Fjm401840s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Imperiali, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abeles, R. H.</span><span> </span><span class="NLM_article-title">Extended binding inhibitors of chymotrypsin that interact with leaving group subsites S1′–S3′</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">4474</span><span class="NLM_x">–</span> <span class="NLM_lpage">4477</span><span class="refDoi"> DOI: 10.1021/bi00388a044</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00388a044" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1987&pages=4474-4477&author=B.+Imperialiauthor=R.+H.+Abeles&title=Extended+binding+inhibitors+of+chymotrypsin+that+interact+with+leaving+group+subsites+S1%E2%80%B2%E2%80%93S3%E2%80%B2&doi=10.1021%2Fbi00388a044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fbi00388a044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00388a044%26sid%3Dliteratum%253Aachs%26aulast%3DImperiali%26aufirst%3DB.%26aulast%3DAbeles%26aufirst%3DR.%2BH.%26atitle%3DExtended%2520binding%2520inhibitors%2520of%2520chymotrypsin%2520that%2520interact%2520with%2520leaving%2520group%2520subsites%2520S1%25E2%2580%25B2%25E2%2580%2593S3%25E2%2580%25B2%26jtitle%3DBiochemistry%26date%3D1987%26volume%3D26%26spage%3D4474%26epage%3D4477%26doi%3D10.1021%2Fbi00388a044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Johansson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poliakov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Åkerblom, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiklund, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeberg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winiwarter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danielson, U. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallberg, A.</span><span> </span><span class="NLM_article-title">Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-length NS3 (protease-helicase/NTPase) - a comparative study of different C-terminals</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2551</span><span class="NLM_x">–</span> <span class="NLM_lpage">2568</span><span class="refDoi"> DOI: 10.1016/S0968-0896(03)00179-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0968-0896%2803%2900179-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=2551-2568&author=A.+Johanssonauthor=A.+Poliakovauthor=E.+%C3%85kerblomauthor=K.+Wiklundauthor=G.+Lindebergauthor=S.+Winiwarterauthor=U.+H.+Danielsonauthor=B.+Samuelssonauthor=A.+Hallberg&title=Acyl+sulfonamides+as+potent+protease+inhibitors+of+the+hepatitis+C+virus+full-length+NS3+%28protease-helicase%2FNTPase%29+-+a+comparative+study+of+different+C-terminals&doi=10.1016%2FS0968-0896%2803%2900179-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2803%2900179-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252803%252900179-2%26sid%3Dliteratum%253Aachs%26aulast%3DJohansson%26aufirst%3DA.%26aulast%3DPoliakov%26aufirst%3DA.%26aulast%3D%25C3%2585kerblom%26aufirst%3DE.%26aulast%3DWiklund%26aufirst%3DK.%26aulast%3DLindeberg%26aufirst%3DG.%26aulast%3DWiniwarter%26aufirst%3DS.%26aulast%3DDanielson%26aufirst%3DU.%2BH.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DHallberg%26aufirst%3DA.%26atitle%3DAcyl%2520sulfonamides%2520as%2520potent%2520protease%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520full-length%2520NS3%2520%2528protease-helicase%252FNTPase%2529%2520-%2520a%2520comparative%2520study%2520of%2520different%2520C-terminals%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D2551%26epage%3D2568%26doi%3D10.1016%2FS0968-0896%2803%2900179-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit47b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Oertqvist, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aakerblom, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gossas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabnis, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeberg, G.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1448</span><span class="NLM_x">–</span> <span class="NLM_lpage">1474</span><span class="refDoi"> DOI: 10.1016/j.bmc.2006.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmc.2006.11.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=1448-1474&author=P.+Oertqvistauthor=S.+D.+Petersonauthor=E.+Aakerblomauthor=T.+Gossasauthor=Y.+A.+Sabnisauthor=R.+Franssonauthor=G.+Lindeberg&title=Phenylglycine+as+a+novel+P2+scaffold+in+hepatitis+C+virus+NS3+protease+inhibitors&doi=10.1016%2Fj.bmc.2006.11.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DOertqvist%26aufirst%3DP.%26aulast%3DPeterson%26aufirst%3DS.%2BD.%26aulast%3DAakerblom%26aufirst%3DE.%26aulast%3DGossas%26aufirst%3DT.%26aulast%3DSabnis%26aufirst%3DY.%2BA.%26aulast%3DFransson%26aufirst%3DR.%26aulast%3DLindeberg%26aufirst%3DG.%26atitle%3DPhenylglycine%2520as%2520a%2520novel%2520P2%2520scaffold%2520in%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D1448%26epage%3D1474%26doi%3D10.1016%2Fj.bmc.2006.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit47c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lampa, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafsson, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alogheli, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akerblom, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeberg, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artursson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danielson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandstrom, A.</span><span> </span><span class="NLM_article-title">Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2–P1′ Region</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">254</span><span class="refDoi"> DOI: 10.1021/ml400217r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400217r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=249-254&author=A.+K.+Lampaauthor=S.+M.+Bergmanauthor=S.+S.+Gustafssonauthor=H.+Alogheliauthor=E.+B.+Akerblomauthor=G.+G.+Lindebergauthor=R.+M.+Svenssonauthor=P.+Arturssonauthor=H.+Danielsonauthor=A.+Karlenauthor=A.+Sandstrom&title=Novel+Peptidomimetic+Hepatitis+C+Virus+NS3%2F4A+Protease+Inhibitors+Spanning+the+P2%E2%80%93P1%E2%80%B2+Region&doi=10.1021%2Fml400217r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47c&amp;dbid=16384&amp;doi=10.1021%2Fml400217r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400217r%26sid%3Dliteratum%253Aachs%26aulast%3DLampa%26aufirst%3DA.%2BK.%26aulast%3DBergman%26aufirst%3DS.%2BM.%26aulast%3DGustafsson%26aufirst%3DS.%2BS.%26aulast%3DAlogheli%26aufirst%3DH.%26aulast%3DAkerblom%26aufirst%3DE.%2BB.%26aulast%3DLindeberg%26aufirst%3DG.%2BG.%26aulast%3DSvensson%26aufirst%3DR.%2BM.%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DDanielson%26aufirst%3DH.%26aulast%3DKarlen%26aufirst%3DA.%26aulast%3DSandstrom%26aufirst%3DA.%26atitle%3DNovel%2520Peptidomimetic%2520Hepatitis%2520C%2520Virus%2520NS3%252F4A%2520Protease%2520Inhibitors%2520Spanning%2520the%2520P2%25E2%2580%2593P1%25E2%2580%25B2%2520Region%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D249%26epage%3D254%26doi%3D10.1021%2Fml400217r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit47d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Roenn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gossas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabnis, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daoud, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aakerblom, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danielson, U. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandstroem, A.</span><span> </span><span class="NLM_article-title">Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">4057</span><span class="NLM_x">–</span> <span class="NLM_lpage">4068</span><span class="refDoi"> DOI: 10.1016/j.bmc.2007.03.089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmc.2007.03.089" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=4057-4068&author=R.+Roennauthor=T.+Gossasauthor=Y.+A.+Sabnisauthor=H.+Daoudauthor=E.+Aakerblomauthor=U.+H.+Danielsonauthor=A.+Sandstroem&title=Evaluation+of+a+diverse+set+of+potential+P1+carboxylic+acid+bioisosteres+in+hepatitis+C+virus+NS3+protease+inhibitors&doi=10.1016%2Fj.bmc.2007.03.089"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.03.089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.03.089%26sid%3Dliteratum%253Aachs%26aulast%3DRoenn%26aufirst%3DR.%26aulast%3DGossas%26aufirst%3DT.%26aulast%3DSabnis%26aufirst%3DY.%2BA.%26aulast%3DDaoud%26aufirst%3DH.%26aulast%3DAakerblom%26aufirst%3DE.%26aulast%3DDanielson%26aufirst%3DU.%2BH.%26aulast%3DSandstroem%26aufirst%3DA.%26atitle%3DEvaluation%2520of%2520a%2520diverse%2520set%2520of%2520potential%2520P1%2520carboxylic%2520acid%2520bioisosteres%2520in%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D4057%26epage%3D4068%26doi%3D10.1016%2Fj.bmc.2007.03.089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Gunaydin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartberger, M. B.</span><span> </span><span class="NLM_article-title">Stacking with no planarity?</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">344</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00099</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00099" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=341-344&author=H.+Gunaydinauthor=M.+B.+Bartberger&title=Stacking+with+no+planarity%3F&doi=10.1021%2Facsmedchemlett.6b00099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00099%26sid%3Dliteratum%253Aachs%26aulast%3DGunaydin%26aufirst%3DH.%26aulast%3DBartberger%26aufirst%3DM.%2BB.%26atitle%3DStacking%2520with%2520no%2520planarity%253F%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D341%26epage%3D344%26doi%3D10.1021%2Facsmedchemlett.6b00099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">De Clercq, E.</span><span> </span><span class="NLM_article-title">Current race in the development of DAAs (direct-acting antivirals) against HCV</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">452</span><span class="refDoi"> DOI: 10.1016/j.bcp.2014.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bcp.2014.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24735613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslGmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2014&pages=441-452&author=E.+De+Clercq&title=Current+race+in+the+development+of+DAAs+%28direct-acting+antivirals%29+against+HCV&doi=10.1016%2Fj.bcp.2014.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Current race in the development of DAAs (direct-acting antivirals) against HCV</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, narlaprevir and simeprevir, in addn. to those that are already developed [telaprevir (Incivek) and boceprevir (Victrelis)], (ii) NS5A protein inhibitors: ABT-267, daclatasvir, ledipasvir, ACH-2928, ACH-3102, PPI-668, AZD-7295, MK-8742, and GSK 2336805; (iii) NS5B (nucleoside-type) polymerase inhibitors: sofosbuvir (now approved by the FDA since 6 Dec. 2013), GS-0938, mericitabine, VX-135, ALS 2158 and TMC 649128; (iv) NS5B (non-nucleoside-type) polymerase inhibitors: VX-222, ABT-072, ABT-333, deleobuvir, tegobuvir, setrobuvir, VCH-916, VCH-759, BMS-791325 and TMC-647055.  Future drug combinations will likely exist of two or more DAAs belonging to any of the 4 categories, with the aim to achieve (i) pan-genotypic hepatitis C virus (HCV) activity, (ii) little or no risk for resistance; (iii) short duration (i.e. 12 wk) of treatment, and (iv) a sustained viral response (SVR) and definite cure of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpohrsiqE5QLVg90H21EOLACvtfcHk0lgAOqLcx2-k_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslGmsrY%253D&md5=9259fadafae600a93b2703bbe95a47ec</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2014.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2014.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DCurrent%2520race%2520in%2520the%2520development%2520of%2520DAAs%2520%2528direct-acting%2520antivirals%2529%2520against%2520HCV%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2014%26volume%3D89%26spage%3D441%26epage%3D452%26doi%3D10.1016%2Fj.bcp.2014.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P. M.</span><span> </span><span class="NLM_article-title">A facile synthesis of 1-substituted cyclopropylsulfonamides</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_fpage">725</span><span class="NLM_x">–</span> <span class="NLM_lpage">728</span><span class="refDoi"> DOI: 10.1055/s-2006-933130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1055%2Fs-2006-933130" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=725-728&author=J.+Liauthor=D.+Smithauthor=H.+S.+Wongauthor=J.+A.+Campbellauthor=N.+A.+Meanwellauthor=P.+M.+Scola&title=A+facile+synthesis+of+1-substituted+cyclopropylsulfonamides&doi=10.1055%2Fs-2006-933130"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1055%2Fs-2006-933130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2006-933130%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DH.%2BS.%26aulast%3DCampbell%26aufirst%3DJ.%2BA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DScola%26aufirst%3DP.%2BM.%26atitle%3DA%2520facile%2520synthesis%2520of%25201-substituted%2520cyclopropylsulfonamides%26jtitle%3DSynlett%26date%3D2006%26spage%3D725%26epage%3D728%26doi%3D10.1055%2Fs-2006-933130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Navia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P. R.</span><span> </span><span class="NLM_article-title">Design principles for orally bioavailable drugs</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span><span class="refDoi"> DOI: 10.1016/1359-6446(96)10020-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2F1359-6446%2896%2910020-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK28XlvVajurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1996&pages=179-189&author=M.+Naviaauthor=P.+R.+Chaturvedi&title=Design+principles+for+orally+bioavailable+drugs&doi=10.1016%2F1359-6446%2896%2910020-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51aR"><div class="casContent"><span class="casTitleNuber">51a</span><div class="casTitle"><span class="NLM_cas:atitle">Design principles for orally bioavailable drugs</span></div><div class="casAuthors">Navia, Manuel A.; Chaturvedi, Pravin R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">179-189</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 57 refs.  Compd. design is the hallmark of modern pharmaceutical research and development.  Unfortunately, comprehensive and reliable guidelines for the introduction of favorable bioavailability properties into designed compds. remain elusive.  Here, the authors discuss the limited set of design principles that address the problem of bioavailability, based on a retrospective anal. of orally bioavailable drugs.  The roles of partition coeff., mol. wt., carrier-mediated transport and conformational flexibility are evaluated.  These properties are discussed as guiding principles only, and cannot be considered all-encompassing determinants of oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomGbb2CkH99bVg90H21EOLACvtfcHk0li0lNiWrGKNkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlvVajurk%253D&md5=76cf28a4da6132c71427edc45c916717</span></div><a href="/servlet/linkout?suffix=cit51a&amp;dbid=16384&amp;doi=10.1016%2F1359-6446%2896%2910020-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F1359-6446%252896%252910020-9%26sid%3Dliteratum%253Aachs%26aulast%3DNavia%26aufirst%3DM.%26aulast%3DChaturvedi%26aufirst%3DP.%2BR.%26atitle%3DDesign%2520principles%2520for%2520orally%2520bioavailable%2520drugs%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D1996%26volume%3D1%26spage%3D179%26epage%3D189%26doi%3D10.1016%2F1359-6446%2896%2910020-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit51b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lipinski, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominy, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, P. J.</span><span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51bR"><div class="casContent"><span class="casTitleNuber">51b</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0ljhYqHFDbk4dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit51b&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit51c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Egan, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merz, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, J. J.</span><span> </span><span class="NLM_article-title">Prediction of drug absorption using multivariate statistics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3867</span><span class="NLM_x">–</span> <span class="NLM_lpage">3877</span><span class="refDoi"> DOI: 10.1021/jm000292e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000292e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3867-3877&author=W.+J.+Eganauthor=K.+M.+Merzauthor=J.+J.+Baldwin&title=Prediction+of+drug+absorption+using+multivariate+statistics&doi=10.1021%2Fjm000292e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51cR"><div class="casContent"><span class="casTitleNuber">51c</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Drug Absorption Using Multivariate Statistics</span></div><div class="casAuthors">Egan, William J.; Merz, Kenneth M. Jr.; Baldwin, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3867-3877</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Literature data on compds. both well- and poorly-absorbed in humans were used to build a statistical pattern recognition model of passive intestinal absorption.  Robust outlier detection was utilized to analyze the well-absorbed compds., some of which were intermingled with the poorly-absorbed compds. in the model space.  Outliers were identified as being actively transported.  The descriptors chosen for inclusion in the model were PSA and AlogP98, based on consideration of the phys. processes involved in membrane permeability and the interrelationships and redundancies between available descriptors.  These descriptors are quite straightforward for a medicinal chemist to interpret, enhancing the utility of the model.  Mol. wt., while often used in passive absorption models, was shown to be superfluous, as it is already a component of both PSA and AlogP98.  Extensive validation of the model on hundreds of known orally delivered drugs, "drug-like" mols., and Pharmacopeia, Inc. compds., which had been assayed for Caco-2 cell permeability, demonstrated a good rate of successful predictions (74-92%, depending on the dataset and exact criterion used).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbZF9e_GNz8LVg90H21EOLACvtfcHk0lhOUvPjgx8w9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitLk%253D&md5=44f909ad1fd6187840921e7f07497b4e</span></div><a href="/servlet/linkout?suffix=cit51c&amp;dbid=16384&amp;doi=10.1021%2Fjm000292e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000292e%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DW.%2BJ.%26aulast%3DMerz%26aufirst%3DK.%2BM.%26aulast%3DBaldwin%26aufirst%3DJ.%2BJ.%26atitle%3DPrediction%2520of%2520drug%2520absorption%2520using%2520multivariate%2520statistics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3867%26epage%3D3877%26doi%3D10.1021%2Fjm000292e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit51d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Daina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoete, V.</span><span> </span><span class="NLM_article-title">A BOILED-egg to predict gastrointestinal absorption and brain penetration of small molecules</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">–</span> <span class="NLM_lpage">1121</span><span class="refDoi"> DOI: 10.1002/cmdc.201600182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fcmdc.201600182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=27218427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1117-1121&author=A.+Dainaauthor=V.+Zoete&title=A+BOILED-egg+to+predict+gastrointestinal+absorption+and+brain+penetration+of+small+molecules&doi=10.1002%2Fcmdc.201600182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51dR"><div class="casContent"><span class="casTitleNuber">51d</span><div class="casTitle"><span class="NLM_cas:atitle">A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules</span></div><div class="casAuthors">Daina, Antoine; Zoete, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1117-1121</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Apart from efficacy and toxicity, many drug development failures are imputable to poor pharmacokinetics and bioavailability.  Gastrointestinal absorption and brain access are two pharmacokinetic behaviors crucial to est. at various stages of the drug discovery processes.  To this end, the Brain Or IntestinaL Estd. permeation method (BOILED-Egg) is proposed as an accurate predictive model that works by computing the lipophilicity and polarity of small mols.  Concomitant predictions for both brain and intestinal permeation are obtained from the same two physicochem. descriptors and straightforwardly translated into mol. design, owing to the speed, accuracy, conceptual simplicity and clear graphical output of the model.  The BOILED-Egg can be applied in a variety of settings, from the filtering of chem. libraries at the early steps of drug discovery, to the evaluation of drug candidates for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr3-QrxWyZcbVg90H21EOLACvtfcHk0ljRWu6DHJrPWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWit78%253D&md5=2cf19e6fe089ef1c0d8f38f0fdb528cc</span></div><a href="/servlet/linkout?suffix=cit51d&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600182%26sid%3Dliteratum%253Aachs%26aulast%3DDaina%26aufirst%3DA.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DA%2520BOILED-egg%2520to%2520predict%2520gastrointestinal%2520absorption%2520and%2520brain%2520penetration%2520of%2520small%2520molecules%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1117%26epage%3D1121%26doi%3D10.1002%2Fcmdc.201600182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1420</span><span class="NLM_x">–</span> <span class="NLM_lpage">1456</span><span class="refDoi"> DOI: 10.1021/tx200211v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200211v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlCitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1420-1456&author=N.+A.+Meanwell&title=Improving+drug+candidates+by+design%3A+a+focus+on+physicochemical+properties+as+a+means+of+improving+compound+disposition+and+safety&doi=10.1021%2Ftx200211v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52aR"><div class="casContent"><span class="casTitleNuber">52a</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1420-1456</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of small mol. drug candidates from the discovery phase to a marketed product continues to be a challenging enterprise with very low success rates that have fostered the perception of poor productivity by the pharmaceutical industry.  Although there have been significant advances in preclin. profiling that have improved compd. triaging and altered the underlying reasons for compd. attrition, the failure rates have not appreciably changed.  As part of an effort to more deeply understand the reasons for candidate failure, there has been considerable interest in analyzing the physicochem. properties of marketed drugs for the purpose of comparing with drugs in discovery and development as a means capturing recent trends in drug design.  The scenario that has emerged is one in which contemporary drug discovery is thought to be focused too heavily on advancing candidates with profiles that are most easily satisfied by mols. with increased mol. wt. and higher overall lipophilicity.  The preponderance of mols. expressing these properties is frequently a function of increased arom. ring count when compared with that of the drugs launched in the latter half of the 20th century and may reflect a preoccupation with maximizing target affinity rather than taking a more holistic approach to drug design.  These attributes not only present challenges for formulation and absorption but also may influence the manifestation of toxicity during development.  By providing some definition around the optimal physicochem. properties assocd. with marketed drugs, guidelines for drug design have been developed that are based largely on calcd. parameters and which may readily be applied by medicinal chemists as an aid to understanding candidate quality.  The physicochem. properties of a mol. that are consistent with the potential for good oral absorption were initially defined by Lipinski, with addnl. insights allowing further refinement, while deeper analyses have explored the correlation with metabolic stability and toxicity.  These insights have been augmented by careful analyses of physicochem. aspects of drug-target interactions, with thermodn. profiling indicating that the signature of best-in-class drugs is a dependence on enthalpy to drive binding energetics rather than entropy, which is dependent on lipophilicity.  Optimization of the entropic contribution to the binding energy of a ligand to its target is generally much easier than refining the enthalpic element.  Consequently, in the absence of a fundamental understanding of the thermodn. complexion of an interaction, the design of mols. with increased lipophilicity becomes almost inevitable.  The application of ligand efficiency, a measure of affinity per heavy atom, group efficiency, which assesses affinity in the context of structural changes, and lipophilic ligand efficiency, which relates potency to lipophilicity, offer less sophisticated but practically useful anal. algorithms to assess the quality of drug-target interactions.  These parameters are readily calcd. and can be applied to lead optimization programs in a fashion that helps to maximize potency while minimizing the kind of lipophilic burden that has been dubbed "mol. obesity".  Several recently described lead optimization campaigns provide illustrative, informative, and productive examples of the effect of paying close attention to carefully controlling physicochem. properties by monitoring ligand efficiency and lipophilic ligand efficiency.  However, to be successful during the lead optimization phase, drug candidate identification programs will need to adopt a holistic approach that integrates multiple parameters, many of which will have unique dependencies on both the drug target and the specific chemotype under prosecution.  Nevertheless, there are many important drug targets that necessitate working in space beyond that which has been defined by the retrospective analyses of marketed drugs and which will require adaptation of some of the guideposts that are useful in directing lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQrUfIwZiIR7Vg90H21EOLACvtfcHk0lggreFHN9eKKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlCitLs%253D&md5=9ddcf6dc81bf8ab0441df5037979ff4e</span></div><a href="/servlet/linkout?suffix=cit52a&amp;dbid=16384&amp;doi=10.1021%2Ftx200211v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200211v%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DImproving%2520drug%2520candidates%2520by%2520design%253A%2520a%2520focus%2520on%2520physicochemical%2520properties%2520as%2520a%2520means%2520of%2520improving%2520compound%2520disposition%2520and%2520safety%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1420%26epage%3D1456%26doi%3D10.1021%2Ftx200211v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit52b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Improving drug design: an update on recent applications of efficiency metrics, strategies for replacing problematic elements and compounds in non-traditional drug space</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">564</span><span class="NLM_x">–</span> <span class="NLM_lpage">616</span><span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00043</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00043" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=564-616&author=N.+A.+Meanwell&title=Improving+drug+design%3A+an+update+on+recent+applications+of+efficiency+metrics%2C+strategies+for+replacing+problematic+elements+and+compounds+in+non-traditional+drug+space&doi=10.1021%2Facs.chemrestox.6b00043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52b&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00043%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DImproving%2520drug%2520design%253A%2520an%2520update%2520on%2520recent%2520applications%2520of%2520efficiency%2520metrics%252C%2520strategies%2520for%2520replacing%2520problematic%2520elements%2520and%2520compounds%2520in%2520non-traditional%2520drug%2520space%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26spage%3D564%26epage%3D616%26doi%3D10.1021%2Facs.chemrestox.6b00043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit52c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Gibson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuire, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span> </span><span class="NLM_article-title">Principal components describing biological activities and molecular diversity of heterocyclic aromatic ring fragments</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">4065</span><span class="NLM_x">–</span> <span class="NLM_lpage">4072</span><span class="refDoi"> DOI: 10.1021/jm960058h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960058h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK28XlsVeqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=4065-4072&author=S.+Gibsonauthor=R.+McGuireauthor=D.+C.+Rees&title=Principal+components+describing+biological+activities+and+molecular+diversity+of+heterocyclic+aromatic+ring+fragments&doi=10.1021%2Fjm960058h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52cR"><div class="casContent"><span class="casTitleNuber">52c</span><div class="casTitle"><span class="NLM_cas:atitle">Principal Components Describing Biological Activities and Molecular Diversity of Heterocyclic Aromatic Ring Fragments</span></div><div class="casAuthors">Gibson, Samuel; McGuire, Ross; Rees, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4065-4072</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ten physicochem. variables have been calcd. for each of 100 different arom. rings.  These variables were selected because of their potential involvement in the mol. recognition of drug-receptor binding interactions, and they include size, lipophilicity, dipole magnitude and orientation, HOMO and LUMO energies, and electronic point charges.  A total of 59 different arom. ring systems were studied including monocyclics and [5.5]-, [6.5]- and [6.6]-fused bicyclics.  A principal components anal. of these results generated four principal components which account for 84% of the total variance in the data.  These principal components provide a quant. measure of mol. diversity, and their relevance for structure-activity relationships is discussed.  The principal components correlate with the in vitro biol. activity of heterocyclic arom. fragments within a series of previously reported HIV-1 reverse transcriptase inhibitors (Saari, W. S.; et al. J. Med. Chem. 1992, 35, 3792-3802).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI1MqV39kUdLVg90H21EOLACvtfcHk0lil1A3_VVUfNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlsVeqtLw%253D&md5=d46c4b9fa14b9cec869e83b7ac2b1980</span></div><a href="/servlet/linkout?suffix=cit52c&amp;dbid=16384&amp;doi=10.1021%2Fjm960058h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960058h%26sid%3Dliteratum%253Aachs%26aulast%3DGibson%26aufirst%3DS.%26aulast%3DMcGuire%26aufirst%3DR.%26aulast%3DRees%26aufirst%3DD.%2BC.%26atitle%3DPrincipal%2520components%2520describing%2520biological%2520activities%2520and%2520molecular%2520diversity%2520of%2520heterocyclic%2520aromatic%2520ring%2520fragments%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D4065%26epage%3D4072%26doi%3D10.1021%2Fjm960058h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span> </span><span class="NLM_article-title">Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">4607</span><span class="NLM_x">–</span> <span class="NLM_lpage">4609</span><span class="refDoi"> DOI: 10.1021/ja711120r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja711120r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtFygur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=4607-4609&author=N.+J.+Livertonauthor=M.+K.+Hollowayauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=J.+W.+Butcherauthor=S.+S.+Carrollauthor=J.+DiMuzioauthor=C.+Fandozziauthor=K.+F.+Gilbertauthor=S.-S.+Maoauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=J.+J.+Romanoauthor=M.+Stahlhutauthor=B.-L.+Wanauthor=D.+B.+Olsenauthor=J.+P.+Vacca&title=Molecular+modeling+based+approach+to+potent+P2-P4+macrocyclic+inhibitors+of+hepatitis+C+NS3%2F4A+protease&doi=10.1021%2Fja711120r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Modeling Based Approach to Potent P2-P4 Macrocyclic Inhibitors of Hepatitis C NS3/4A Protease</span></div><div class="casAuthors">Liverton, Nigel J.; Holloway, M. Katharine; McCauley, John A.; Rudd, Michael T.; Butcher, John W.; Carroll, Steven S.; DiMuzio, Jillian; Fandozzi, Christine; Gilbert, Kevin F.; Mao, Shi-Shan; McIntyre, Charles J.; Nguyen, Kevin T.; Romano, Joseph J.; Stahlhut, Mark; Wan, Bang-Lin; Olsen, David B.; Vacca, Joseph P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4607-4609</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. modeling of inhibitor bound full length HCV NS3/4A protease structures proved to be a valuable tool in the design of a new series of potent NS3 protease inhibitors.  Optimization of initial compds. provided 25a.  The in vitro activity and selectivity as well as the rat pharmacokinetic profile of 25a compare favorably with the data for other NS3/4A protease inhibitors currently in clin. development for the treatment of HCV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppYenMBNqdeLVg90H21EOLACvtfcHk0lggZa2cTwQ1oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtFygur8%253D&md5=5e7bb98bdb19c30bebb30f03a702838d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fja711120r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja711120r%26sid%3Dliteratum%253Aachs%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMao%26aufirst%3DS.-S.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DStahlhut%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DB.-L.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26atitle%3DMolecular%2520modeling%2520based%2520approach%2520to%2520potent%2520P2-P4%2520macrocyclic%2520inhibitors%2520of%2520hepatitis%2520C%2520NS3%252F4A%2520protease%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D4607%26epage%3D4609%26doi%3D10.1021%2Fja711120r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Jenkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcphee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesenberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arora, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilcher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K.</span><span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and <i>in vitro</i> metabolism of BMS-605339: a novel HCV NS3 protease inhibitor</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">1891</span><span class="NLM_x">–</span> <span class="NLM_lpage">1902</span><span class="refDoi"> DOI: 10.1002/jps.23959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fjps.23959" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2014&pages=1891-1902&author=S.+Jenkinsauthor=P.+Scolaauthor=F.+Mcpheeauthor=J.+Knipeauthor=C.+Gesenbergauthor=M.+Sinzauthor=V.+Aroraauthor=G.+Pilcherauthor=K.+Santone&title=Preclinical+pharmacokinetics+and+in+vitro+metabolism+of+BMS-605339%3A+a+novel+HCV+NS3+protease+inhibitor&doi=10.1002%2Fjps.23959"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fjps.23959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23959%26sid%3Dliteratum%253Aachs%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DScola%26aufirst%3DP.%26aulast%3DMcphee%26aufirst%3DF.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DGesenberg%26aufirst%3DC.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DArora%26aufirst%3DV.%26aulast%3DPilcher%26aufirst%3DG.%26aulast%3DSantone%26aufirst%3DK.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520in%2520vitro%2520metabolism%2520of%2520BMS-605339%253A%2520a%2520novel%2520HCV%2520NS3%2520protease%2520inhibitor%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2014%26volume%3D103%26spage%3D1891%26epage%3D1902%26doi%3D10.1002%2Fjps.23959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Scola, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sit, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocuzza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilder, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schartman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donoso, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tredup, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span> </span><span class="NLM_article-title">The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1730</span><span class="NLM_x">–</span> <span class="NLM_lpage">1752</span><span class="refDoi"> DOI: 10.1021/jm500297k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500297k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1730-1752&author=P.+M.+Scolaauthor=L.-Q.+Sunauthor=A.+X.+Wangauthor=J.+Chenauthor=N.+Sinauthor=B.+L.+Venablesauthor=S.-Y.+Sitauthor=Y.+Chenauthor=A.+Cocuzzaauthor=D.+M.+Bilderauthor=S.+V.+D%E2%80%99Andreaauthor=B.+Zhengauthor=P.+Hewawasamauthor=Y.+Tuauthor=J.+Friborgauthor=P.+Falkauthor=D.+Hernandezauthor=S.+Levineauthor=C.+Chenauthor=F.+Yuauthor=A.+K.+Sheafferauthor=G.+Zhaiauthor=D.+Barryauthor=J.+O.+Knipeauthor=Y.-H.+Hanauthor=R.+Schartmanauthor=M.+Donosoauthor=K.+Mosureauthor=M.+W.+Sinzauthor=T.+Zvyagaauthor=A.+C.+Goodauthor=R.+Rajamaniauthor=K.+Kishauthor=J.+Tredupauthor=H.+E.+Kleiauthor=Q.+Gaoauthor=L.+Muellerauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=S.+P.+Adamsauthor=J.+Loyauthor=P.+C.+Levesqueauthor=H.+Sunauthor=H.+Shiauthor=L.+Sunauthor=W.+Warnerauthor=D.+Liauthor=J.+Zhuauthor=N.+A.+Meanwellauthor=F.+McPhee&title=The+discovery+of+asunaprevir+%28BMS-650032%29%2C+an+orally+efficacious+NS3+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Fjm500297k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Scola, Paul M.; Sun, Li-Qiang; Wang, Alan Xiangdong; Chen, Jie; Sin, Ny; Venables, Brian L.; Sit, Sing-Yuen; Chen, Yan; Cocuzza, Anthony; Bilder, Donna M.; D'Andrea, Stanley V.; Zheng, Barbara; Hewawasam, Piyasena; Tu, Yong; Friborg, Jacques; Falk, Paul; Hernandez, Dennis; Levine, Steven; Chen, Chaoqun; Yu, Fei; Sheaffer, Amy K.; Zhai, Guangzhi; Barry, Diana; Knipe, Jay O.; Han, Yong-Hae; Schartman, Richard; Donoso, Maria; Mosure, Kathy; Sinz, Michael W.; Zvyaga, Tatyana; Good, Andrew C.; Rajamani, Ramkumar; Kish, Kevin; Tredup, Jeffrey; Klei, Herbert E.; Gao, Qi; Mueller, Luciano; Colonno, Richard J.; Grasela, Dennis M.; Adams, Stephen P.; Loy, James; Levesque, Paul C.; Sun, Huabin; Shi, Hong; Sun, Lucy; Warner, William; Li, Danshi; Zhu, Jialong; Meanwell, Nicholas A.; McPhee, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1730-1752</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of asunaprevir (BMS-650032) is described.  This tripeptidic acylsulfonamide inhibitor of the NS3/4A enzyme is currently in phase III clin. trials for the treatment of hepatitis C virus infection.  The discovery of Asunaprevir was enabled by employing an isolated rabbit heart model to screen for the cardiovascular (CV) liabilities (changes to HR and SNRT) that were responsible for the discontinuation of an earlier lead from this chem. series, BMS-605339, from clin. trials.  The structure-activity relationships (SARs) developed with respect to CV effects established that small structural changes to the P2* subsite of the mol. had a significant impact on the CV profile of a given compd.  The antiviral activity, preclin. PK profile, and toxicol. studies in rat and dog supported clin. development of BMS-650032.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCzMFiXs8YO7Vg90H21EOLACvtfcHk0lgNRvuO906asQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsLc%253D&md5=e8015d3874b80be645a9b80b5bd05865</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm500297k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500297k%26sid%3Dliteratum%253Aachs%26aulast%3DScola%26aufirst%3DP.%2BM.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DWang%26aufirst%3DA.%2BX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DSit%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCocuzza%26aufirst%3DA.%26aulast%3DBilder%26aufirst%3DD.%2BM.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DS.%2BV.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DFriborg%26aufirst%3DJ.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DLevine%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DHan%26aufirst%3DY.-H.%26aulast%3DSchartman%26aufirst%3DR.%26aulast%3DDonoso%26aufirst%3DM.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DRajamani%26aufirst%3DR.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DMueller%26aufirst%3DL.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DAdams%26aufirst%3DS.%2BP.%26aulast%3DLoy%26aufirst%3DJ.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DWarner%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DMcPhee%26aufirst%3DF.%26atitle%3DThe%2520discovery%2520of%2520asunaprevir%2520%2528BMS-650032%2529%252C%2520an%2520orally%2520efficacious%2520NS3%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1730%26epage%3D1752%26doi%3D10.1021%2Fjm500297k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaniewski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P.</span><span> </span><span class="NLM_article-title">Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5387</span><span class="NLM_x">–</span> <span class="NLM_lpage">5396</span><span class="refDoi"> DOI: 10.1128/AAC.01186-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FAAC.01186-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=22869577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKiu7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=5387-5396&author=F.+McPheeauthor=A.+K.+Sheafferauthor=J.+Friborgauthor=D.+Hernandezauthor=P.+Falkauthor=G.+Zhaiauthor=S.+Levineauthor=S.+Chaniewskiauthor=F.+Yuauthor=D.+Barryauthor=C.+Chenauthor=M.+S.+Leeauthor=K.+Mosureauthor=L.-Q.+Sunauthor=M.+Sinzauthor=N.+A.+Meanwellauthor=R.+J.+Colonnoauthor=J.+Knipeauthor=P.+Scola&title=Preclinical+profile+and+characterization+of+the+hepatitis+C+virus+NS3+protease+inhibitor+asunaprevir+%28BMS-650032%29&doi=10.1128%2FAAC.01186-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)</span></div><div class="casAuthors">McPhee, Fiona; Sheaffer, Amy K.; Friborg, Jacques; Hernandez, Dennis; Falk, Paul; Zhai, Guangzhi; Levine, Steven; Chaniewski, Susan; Yu, Fei; Barry, Diana; Chen, Chaoqun; Lee, Min S.; Mosure, Kathy; Sun, Li-Qiang; Sinz, Michael; Meanwell, Nicholas A.; Colonno, Richard J.; Knipe, Jay; Scola, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5387-5396</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Asunaprevir (ASV; BMS-650032) is a hepatitis C virus (HCV) NS3 protease inhibitor that has demonstrated efficacy in patients chronically infected with HCV genotype 1 when combined with alfa interferon and/or the NS5A replication complex inhibitor daclatasvir.  ASV competitively binds to the NS3/4A protease complex, with Ki values of 0.4 and 0.24 nM against recombinant enzymes representing genotypes 1a (H77) and 1b (J4L6S), resp.  Selectivity was demonstrated by the absence of any significant activity against the closely related GB virus-B NS3 protease and a panel of human serine or cysteine proteases.  In cell culture, ASV inhibited replication of HCV replicons representing genotypes 1 and 4, with 50% effective concns. (EC50s) ranging from 1 to 4 nM, and had weaker activity against genotypes 2 and 3 (EC50, 67 to 1,162 nM).  Selectivity was again demonstrated by the absence of activity (EC50, >12 μM) against a panel of other RNA viruses.  ASV exhibited additive or synergistic activity in combination studies with alfa interferon, ribavirin, and/or inhibitors specifically targeting NS5A or NS5B.  Plasma and tissue exposures in vivo in several animal species indicated that ASV displayed a hepatotropic disposition (liver-to-plasma ratios ranging from 40- to 359-fold across species).  Twenty-four hours postdose, liver exposures across all species tested were ≥110-fold above the inhibitor EC50s obsd. with HCV genotype-1 replicons.  Based on these virol. and exposure properties, ASV holds promise for future utility in a combination with other anti-HCV agents in the treatment of HCV-infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXvSH5FRWqFbVg90H21EOLACvtfcHk0ljxErURDM6h0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKiu7fL&md5=9bbf4ea33b5c4ef48850ade4af9cfd1d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1128%2FAAC.01186-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01186-12%26sid%3Dliteratum%253Aachs%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DFriborg%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DLevine%26aufirst%3DS.%26aulast%3DChaniewski%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DScola%26aufirst%3DP.%26atitle%3DPreclinical%2520profile%2520and%2520characterization%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitor%2520asunaprevir%2520%2528BMS-650032%2529%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D5387%26epage%3D5396%26doi%3D10.1128%2FAAC.01186-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Mosure, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browning, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arora, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, Y.-Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillip, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcphee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balakrishnan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soars, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M.</span><span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and in vitro metabolism of asunaprevir (BMS-650032), a potent hepatitis C virus NS3 protease inhibitor</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">2813</span><span class="NLM_x">–</span> <span class="NLM_lpage">2823</span><span class="refDoi"> DOI: 10.1002/jps.24356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fjps.24356" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2015&pages=2813-2823&author=K.+W.+Mosureauthor=J.+O.+Knipeauthor=M.+Browningauthor=V.+Aroraauthor=Y.-Z.+Shuauthor=T.+Phillipauthor=F.+Mcpheeauthor=P.+Scolaauthor=A.+Balakrishnanauthor=M.+G.+Soarsauthor=K.+Santoneauthor=M.+Sinz&title=Preclinical+pharmacokinetics+and+in+vitro+metabolism+of+asunaprevir+%28BMS-650032%29%2C+a+potent+hepatitis+C+virus+NS3+protease+inhibitor&doi=10.1002%2Fjps.24356"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fjps.24356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.24356%26sid%3Dliteratum%253Aachs%26aulast%3DMosure%26aufirst%3DK.%2BW.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DBrowning%26aufirst%3DM.%26aulast%3DArora%26aufirst%3DV.%26aulast%3DShu%26aufirst%3DY.-Z.%26aulast%3DPhillip%26aufirst%3DT.%26aulast%3DMcphee%26aufirst%3DF.%26aulast%3DScola%26aufirst%3DP.%26aulast%3DBalakrishnan%26aufirst%3DA.%26aulast%3DSoars%26aufirst%3DM.%2BG.%26aulast%3DSantone%26aufirst%3DK.%26aulast%3DSinz%26aufirst%3DM.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520in%2520vitro%2520metabolism%2520of%2520asunaprevir%2520%2528BMS-650032%2529%252C%2520a%2520potent%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitor%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2015%26volume%3D104%26spage%3D2813%26epage%3D2823%26doi%3D10.1002%2Fjps.24356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Pasquinelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villegas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheridan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marbury, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldwater, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demicco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraft, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Talavera, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span> </span><span class="NLM_article-title">Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1838</span><span class="NLM_x">–</span> <span class="NLM_lpage">1844</span><span class="refDoi"> DOI: 10.1128/AAC.05854-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FAAC.05854-11" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=1838-1844&author=C.+Pasquinelliauthor=F.+McPheeauthor=T.+Eleyauthor=C.+Villegasauthor=K.+Sandyauthor=P.+Sheridanauthor=A.+Perssonauthor=S.+P.+Huangauthor=D.+Hernandezauthor=A.+K.+Sheafferauthor=P.+Scolaauthor=T.+Marburyauthor=E.+Lawitzauthor=R.+Goldwaterauthor=M.+Rodriguez-Torresauthor=M.+Demiccoauthor=D.+Wrightauthor=M.+Charltonauthor=W.+K.+Kraftauthor=J.+C.+Lopez-Talaveraauthor=D.+M.+Grasela&title=Single-+and+multiple-ascending-dose+studies+of+the+NS3+protease+inhibitor+asunaprevir+in+subjects+with+or+without+chronic+hepatitis+C&doi=10.1128%2FAAC.05854-11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1128%2FAAC.05854-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.05854-11%26sid%3Dliteratum%253Aachs%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DVillegas%26aufirst%3DC.%26aulast%3DSandy%26aufirst%3DK.%26aulast%3DSheridan%26aufirst%3DP.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DS.%2BP.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DScola%26aufirst%3DP.%26aulast%3DMarbury%26aufirst%3DT.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DGoldwater%26aufirst%3DR.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DDemicco%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DD.%26aulast%3DCharlton%26aufirst%3DM.%26aulast%3DKraft%26aufirst%3DW.%2BK.%26aulast%3DLopez-Talavera%26aufirst%3DJ.%2BC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26atitle%3DSingle-%2520and%2520multiple-ascending-dose%2520studies%2520of%2520the%2520NS3%2520protease%2520inhibitor%2520asunaprevir%2520in%2520subjects%2520with%2520or%2520without%2520chronic%2520hepatitis%2520C%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D1838%26epage%3D1844%26doi%3D10.1128%2FAAC.05854-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Swinney, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, J.</span><span> </span><span class="NLM_article-title">How were new medicines discovered?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span><span class="refDoi"> DOI: 10.1038/nrd3480</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrd3480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=21701501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlCmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=507-519&author=D.+C.+Swinneyauthor=J.+Anthony&title=How+were+new+medicines+discovered%3F&doi=10.1038%2Fnrd3480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59aR"><div class="casContent"><span class="casTitleNuber">59a</span><div class="casTitle"><span class="NLM_cas:atitle">How were new medicines discovered?</span></div><div class="casAuthors">Swinney, David C.; Anthony, Jason</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">507-519</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Preclin. strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biol.-based approaches.  To investigate whether some strategies have been more successful than others in the discovery of new drugs, we analyzed the discovery strategies and the mol. mechanism of action (MMOA) for new mol. entities and new biologics that were approved by the US Food and Drug Administration between 1999 and 2008.  Out of the 259 agents that were approved, 75 were first-in-class drugs with new MMOAs, and out of these, 50 (67%) were small mols. and 25 (33%) were biologics.  The results also show that the contribution of phenotypic screening to the discovery of first-in-class small-mol. drugs exceeded that of target-based approaches - with 28 and 17 of these drugs coming from the two approaches, resp. - in an era in which the major focus was on target-based approaches.  We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE8Ah1iNz76bVg90H21EOLACvtfcHk0ljXmEWjQG5r6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlCmsbs%253D&md5=7503620f8fbadb0a829f6ea2029936a2</span></div><a href="/servlet/linkout?suffix=cit59a&amp;dbid=16384&amp;doi=10.1038%2Fnrd3480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3480%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26aulast%3DAnthony%26aufirst%3DJ.%26atitle%3DHow%2520were%2520new%2520medicines%2520discovered%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D507%26epage%3D519%26doi%3D10.1038%2Fnrd3480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit59b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Macarron, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banks, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bojanic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirovic, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garyantes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D. V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hertzberg, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzen, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paslay, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schopfer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sittampalam, G. S.</span><span> </span><span class="NLM_article-title">Impact of high-throughput screening on biomedical research</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span><span class="refDoi"> DOI: 10.1038/nrd3368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrd3368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=21358738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFensbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=188-195&author=R.+Macarronauthor=M.+N.+Banksauthor=D.+Bojanicauthor=D.+J.+Burnsauthor=D.+A.+Cirovicauthor=T.+Garyantesauthor=D.+V.+S.+Greenauthor=R.+P.+Hertzbergauthor=W.+P.+Janzenauthor=J.+W.+Paslayauthor=U.+Schopferauthor=G.+S.+Sittampalam&title=Impact+of+high-throughput+screening+on+biomedical+research&doi=10.1038%2Fnrd3368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59bR"><div class="casContent"><span class="casTitleNuber">59b</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of high-throughput screening in biomedical research</span></div><div class="casAuthors">Macarron, Ricardo; Banks, Martyn N.; Bojanic, Dejan; Burns, David J.; Cirovic, Dragan A.; Garyantes, Tina; Green, Darren V. S.; Hertzberg, Robert P.; Janzen, William P.; Paslay, Jeff W.; Schopfer, Ulrich; Sittampalam, G. Sitta</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">188-195</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  High-throughput screening (HTS) has been postulated in several quarters to be a contributory factor to the decline in productivity in the pharmaceutical industry.  Moreover, it has been blamed for stifling the creativity that drug discovery demands.  In this article, we aim to dispel these myths and present the case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLnrSVehADbLVg90H21EOLACvtfcHk0ljXmEWjQG5r6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFensbY%253D&md5=cb9853227506f3a3d774791cff9fd79d</span></div><a href="/servlet/linkout?suffix=cit59b&amp;dbid=16384&amp;doi=10.1038%2Fnrd3368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3368%26sid%3Dliteratum%253Aachs%26aulast%3DMacarron%26aufirst%3DR.%26aulast%3DBanks%26aufirst%3DM.%2BN.%26aulast%3DBojanic%26aufirst%3DD.%26aulast%3DBurns%26aufirst%3DD.%2BJ.%26aulast%3DCirovic%26aufirst%3DD.%2BA.%26aulast%3DGaryantes%26aufirst%3DT.%26aulast%3DGreen%26aufirst%3DD.%2BV.%2BS.%26aulast%3DHertzberg%26aufirst%3DR.%2BP.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DPaslay%26aufirst%3DJ.%2BW.%26aulast%3DSchopfer%26aufirst%3DU.%26aulast%3DSittampalam%26aufirst%3DG.%2BS.%26atitle%3DImpact%2520of%2520high-throughput%2520screening%2520on%2520biomedical%2520research%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D188%26epage%3D195%26doi%3D10.1038%2Fnrd3368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit59c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Green, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacs, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span> </span><span class="NLM_article-title">Cell-based assays to identify inhibitors of viral disease</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">676</span><span class="refDoi"> DOI: 10.1517/17460441.3.6.671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1517%2F17460441.3.6.671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=19750206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVyrtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=671-676&author=N.+Greenauthor=R.+D.+Ottauthor=R.+J.+Isaacsauthor=H.+Fang&title=Cell-based+assays+to+identify+inhibitors+of+viral+disease&doi=10.1517%2F17460441.3.6.671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59cR"><div class="casContent"><span class="casTitleNuber">59c</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-based assays to identify inhibitors of viral disease</span></div><div class="casAuthors">Green, Neil; Ott, Robert D.; Isaacs, Richard J.; Fang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">671-676</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Antagonizing the prodn. of infectious viruses inside cells requires drugs that can cross the cell membrane without harming the host cells.  Objective: It is therefore advantageous to establish the intracellular potency of antiviral drug candidates early in the drug discovery pipeline.  Methods: To this end, cell-based assays are being developed and used in high-throughput drug screening, ranging from assays that monitor replication of intact viruses to those that monitor activity of specific viral proteins.  Although numerous cell-based assays have been developed and investigated, rapid counter screens are also needed to define the specific viral targets of identified inhibitors and to eliminate non-specific screening hits.  Results/conclusions: Here, we describe the types of cell-based assays being used in antiviral drug screens and evaluate the equally important counter screens that are being used to reach the full potential of cell-based high-throughput screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBo6AqBISdKLVg90H21EOLACvtfcHk0liDMg_M8R069w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVyrtLw%253D&md5=380dca38ab2261c84ef6993d565b9622</span></div><a href="/servlet/linkout?suffix=cit59c&amp;dbid=16384&amp;doi=10.1517%2F17460441.3.6.671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.3.6.671%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DN.%26aulast%3DOtt%26aufirst%3DR.%2BD.%26aulast%3DIsaacs%26aufirst%3DR.%2BJ.%26aulast%3DFang%26aufirst%3DH.%26atitle%3DCell-based%2520assays%2520to%2520identify%2520inhibitors%2520of%2520viral%2520disease%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D671%26epage%3D676%26doi%3D10.1517%2F17460441.3.6.671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit59d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Keller, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.-Y.</span><span> </span><span class="NLM_article-title">Anti-infectives: can cellular screening deliver?</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span><span class="refDoi"> DOI: 10.1016/j.cbpa.2011.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.cbpa.2011.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=21723774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFClt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=529-533&author=T.+H.+Kellerauthor=P.-Y.+Shiauthor=Q.-Y.+Wang&title=Anti-infectives%3A+can+cellular+screening+deliver%3F&doi=10.1016%2Fj.cbpa.2011.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59dR"><div class="casContent"><span class="casTitleNuber">59d</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-infectives: Can cellular screening deliver?</span></div><div class="casAuthors">Keller, Thomas H.; Shi, Pei-Yong; Wang, Qing-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-533</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In an era of emerging and reemerging infectious diseases, and increasing multidrug resistance, the need to identify novel therapy is imperative.  Unfortunately, the recent shift of the drug discovery paradigm from cellular screening to target-based approaches has not delivered the anticipated benefits.  A recent renaissance of the traditional cell-based approach, on the other hand, has yielded several clin. candidates.  Three successful examples are illustrated in this review, namely spiroindolone, thiazolidinone, and diarylquinoline for the treatment of malaria, hepatitis C virus, and tuberculosis, resp.  We describe in detail their identification, mechanism of action (MoA), and common features in the chem. structures.  The challenges of the cell-based approach for anti-infective drug discovery are also discussed.  We propose a shift from std. libraries to synthetic natural-product-like compd. collections to improve the success of phenotypic lead finding and to facilitate the validation of hits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovjXnq-69ZQLVg90H21EOLACvtfcHk0liDMg_M8R069w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFClt78%253D&md5=0313e255dec7bf47b39b23f6d354987f</span></div><a href="/servlet/linkout?suffix=cit59d&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2011.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2011.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DShi%26aufirst%3DP.-Y.%26aulast%3DWang%26aufirst%3DQ.-Y.%26atitle%3DAnti-infectives%253A%2520can%2520cellular%2520screening%2520deliver%253F%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D15%26spage%3D529%26epage%3D533%26doi%3D10.1016%2Fj.cbpa.2011.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit59e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Prior, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiruta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currais, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dargusch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maher, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, D.</span><span> </span><span class="NLM_article-title">Back to the future with phenotypic screening</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">–</span> <span class="NLM_lpage">513</span><span class="refDoi"> DOI: 10.1021/cn500051h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn500051h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVWjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=503-513&author=M.+Priorauthor=C.+Chirutaauthor=A.+Curraisauthor=J.+Goldbergauthor=J.+Ramseyauthor=R.+Darguschauthor=P.+A.+Maherauthor=D.+Schubert&title=Back+to+the+future+with+phenotypic+screening&doi=10.1021%2Fcn500051h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59eR"><div class="casContent"><span class="casTitleNuber">59e</span><div class="casTitle"><span class="NLM_cas:atitle">Back to the Future with Phenotypic Screening</span></div><div class="casAuthors">Prior, Marguerite; Chiruta, Chandramouli; Currais, Antonio; Goldberg, Josh; Ramsey, Justin; Dargusch, Richard; Maher, Pamela A.; Schubert, David</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">503-513</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  There are no disease-modifying drugs for any old age assocd. neurodegenerative disease or stroke.  This is at least in part due to the failure of drug developers to recognize that the vast majority of neurodegenerative diseases arise from a confluence of multiple toxic insults that accumulate during normal aging and interact with genetic and environmental risk factors.  Thus, it is unlikely that the current single target approach based upon rare dominant mutations or even a few preselected targets is going to yield useful drugs for these conditions.  Therefore, the identification of drug candidates for neurodegeneration should be based upon their efficacy in phenotypic screening assays that reflect the biol. of the aging brain, not a single, preselected target.  It is argued here that this approach to drug discovery is the most likely to produce safe and effective drugs for neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsURT-h5gF77Vg90H21EOLACvtfcHk0ljRrtdXoV8r9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVWjtbY%253D&md5=9d00b537d71aa7bef15fc73d784aba95</span></div><a href="/servlet/linkout?suffix=cit59e&amp;dbid=16384&amp;doi=10.1021%2Fcn500051h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn500051h%26sid%3Dliteratum%253Aachs%26aulast%3DPrior%26aufirst%3DM.%26aulast%3DChiruta%26aufirst%3DC.%26aulast%3DCurrais%26aufirst%3DA.%26aulast%3DGoldberg%26aufirst%3DJ.%26aulast%3DRamsey%26aufirst%3DJ.%26aulast%3DDargusch%26aufirst%3DR.%26aulast%3DMaher%26aufirst%3DP.%2BA.%26aulast%3DSchubert%26aufirst%3DD.%26atitle%3DBack%2520to%2520the%2520future%2520with%2520phenotypic%2520screening%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2014%26volume%3D5%26spage%3D503%26epage%3D513%26doi%3D10.1021%2Fcn500051h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Körner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herian, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theilmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">113</span><span class="refDoi"> DOI: 10.1126/science.285.5424.110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1126%2Fscience.285.5424.110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10390360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK1MXksVCqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1999&pages=110-113&author=V.+Lohmannauthor=F.+K%C3%B6rnerauthor=J.+O.+Kochauthor=U.+Herianauthor=L.+Theilmannauthor=R.+Bartenschlager&title=Replication+of+subgenomic+hepatitis+C+virus+RNAs+in+a+hepatoma+cell+line&doi=10.1126%2Fscience.285.5424.110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line</span></div><div class="casAuthors">Lohmann, V.; Korner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">5424</span>),
    <span class="NLM_cas:pages">110-113</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">An estd. 170 million persons worldwide are infected with hepatitis C virus (HCV), a major cause of chronic liver disease.  Despite increasing knowledge of genome structure and individual viral proteins, studies on virus replication and pathogenesis have been hampered by the lack of reliable and efficient cell culture systems.  A full-length consensus genome was cloned from viral RNA isolated from an infected human liver and used to construct subgenomic selectable replicons.  Upon transfection into a human hepatoma cell line, these RNAs replicated to high levels, permitting metabolic radiolabeling of viral RNA and proteins.  This work defines the structure of HCV replicons functional in cell culture and provides the basis for a long-sought cellular system that should allow detailed mol. studies of HCV and the development of antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7X754RT8y1LVg90H21EOLACvtfcHk0ljRrtdXoV8r9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksVCqurk%253D&md5=b075621b316209ecf4498c9b5b33e4b5</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1126%2Fscience.285.5424.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.285.5424.110%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DK%25C3%25B6rner%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DJ.%2BO.%26aulast%3DHerian%26aufirst%3DU.%26aulast%3DTheilmann%26aufirst%3DL.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DReplication%2520of%2520subgenomic%2520hepatitis%2520C%2520virus%2520RNAs%2520in%2520a%2520hepatoma%2520cell%2520line%26jtitle%3DScience%26date%3D1999%26volume%3D285%26spage%3D110%26epage%3D113%26doi%3D10.1126%2Fscience.285.5424.110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1346</span><span class="NLM_x">–</span> <span class="NLM_lpage">1353</span><span class="refDoi"> DOI: 10.1128/AAC.49.4.1346-1353.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FAAC.49.4.1346-1353.2005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=1346-1353&author=D.+R.+O%E2%80%99Boyleauthor=P.+T.+Nowerauthor=J.+A.+Lemmauthor=L.+Valeraauthor=J.-H.+Sunauthor=K.+Rigatauthor=R.+Colonnoauthor=M.+Gao&title=Development+of+a+cell-based+high-throughput+specificity+screen+using+a+hepatitis+C+virus-bovine+viral+diarrhea+virus+dual+replicon+assay&doi=10.1128%2FAAC.49.4.1346-1353.2005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.4.1346-1353.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.4.1346-1353.2005%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DRigat%26aufirst%3DK.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DDevelopment%2520of%2520a%2520cell-based%2520high-throughput%2520specificity%2520screen%2520using%2520a%2520hepatitis%2520C%2520virus-bovine%2520viral%2520diarrhea%2520virus%2520dual%2520replicon%2520assay%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D1346%26epage%3D1353%26doi%3D10.1128%2FAAC.49.4.1346-1353.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, L. G.</span><span> </span><span class="NLM_article-title">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">465</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span><span class="refDoi"> DOI: 10.1038/nature08960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnature08960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=20410884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=96-100&author=M.+Gaoauthor=R.+E.+Nettlesauthor=M.+Belemaauthor=L.+B.+Snyderauthor=V.+N.+Nguyenauthor=R.+A.+Fridellauthor=M.+H.+Serrano-Wuauthor=D.+R.+Langleyauthor=J.-H.+Sunauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=C.+Wangauthor=J.+O.+Knipeauthor=C.+Chienauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=N.+A.+Meanwellauthor=L.+G.+Hamann&title=Chemical+genetics+strategy+identifies+an+HCV+NS5A+inhibitor+with+a+potent+clinical+effect&doi=10.1038%2Fnature08960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span></div><div class="casAuthors">Gao, Min; Nettles, Richard E.; Belema, Makonen; Snyder, Lawrence B.; Nguyen, Van N.; Fridell, Robert A.; Serrano-Wu, Michael H.; Langley, David R.; Sun, Jin-Hua; O'Boyle, Donald R., II; Lemm, Julie A.; Wang, Chunfu; Knipe, Jay O.; Chien, Caly; Colonno, Richard J.; Grasela, Dennis M.; Meanwell, Nicholas A.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7294</span>),
    <span class="NLM_cas:pages">96-100</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estd. to be approaching 200 million people.  Current therapy relies upon a combination of pegylated interferon-α and ribavirin, a poorly tolerated regimen typically assocd. with less than 50% sustained virol. response rate in those infected with genotype 1 virus.  The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B.  Here we describe the profile of BMS-790052, a small mol. inhibitor of the HCV NS5A protein that exhibits picomolar half-max. effective concns. (EC50) towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture.  In a phase I clin. trial in patients chronically infected with HCV, administration of a single 100-mg dose of BMS-790052 was assocd. with a 3.3 log10 redn. in mean viral load measured 24 h post-dose that was sustained for an addnl. 120 h in two patients infected with genotype 1b virus.  Genotypic anal. of samples taken at baseline, 24 and 144 h post-dose revealed that the major HCV variants obsd. had substitutions at amino-acid positions identified using the in vitro replicon system.  These results provide the first clin. validation of an inhibitor of HCV NS5A, a protein with no known enzymic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations of HCV inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAY7Lig0xT9LVg90H21EOLACvtfcHk0ljYzbDrE-bU6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D&md5=620427e987f2bccd153270cde2ef5027</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnature08960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08960%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DChemical%2520genetics%2520strategy%2520identifies%2520an%2520HCV%2520NS5A%2520inhibitor%2520with%2520a%2520potent%2520clinical%2520effect%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D96%26epage%3D100%26doi%3D10.1038%2Fnature08960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bhatti, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suresh</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandhu, J. S.</span><span> </span><span class="NLM_article-title">Recent pharmacological developments on rhodanines and 2,4-thiazolidinediones</span> <span class="citation_source-journal">Int. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2013</span><span class="NLM_x">, </span> <span class="NLM_fpage">793260</span><span class="refDoi"> DOI: 10.1155/2013/793260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1155%2F2013%2F793260" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=793260&author=R.+S.+Bhattiauthor=S.+Shahauthor=+Sureshauthor=P.+Krishanauthor=J.+S.+Sandhu&title=Recent+pharmacological+developments+on+rhodanines+and+2%2C4-thiazolidinediones&doi=10.1155%2F2013%2F793260"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63a&amp;dbid=16384&amp;doi=10.1155%2F2013%2F793260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F793260%26sid%3Dliteratum%253Aachs%26aulast%3DBhatti%26aufirst%3DR.%2BS.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DSuresh%26aulast%3DKrishan%26aufirst%3DP.%26aulast%3DSandhu%26aufirst%3DJ.%2BS.%26atitle%3DRecent%2520pharmacological%2520developments%2520on%2520rhodanines%2520and%25202%252C4-thiazolidinediones%26jtitle%3DInt.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D2013%26spage%3D793260%26doi%3D10.1155%2F2013%2F793260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit63b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tripathi, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fatima, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonar, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saraf, S. K.</span><span> </span><span class="NLM_article-title">4-Thiazolidinones: the advances continue</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">52</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2013.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.ejmech.2013.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24355348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2014&pages=52-77&author=A.+C.+Tripathiauthor=S.+J.+Guptaauthor=G.+N.+Fatimaauthor=P.+K.+Sonarauthor=A.+Vermaauthor=S.+K.+Saraf&title=4-Thiazolidinones%3A+the+advances+continue&doi=10.1016%2Fj.ejmech.2013.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63bR"><div class="casContent"><span class="casTitleNuber">63b</span><div class="casTitle"><span class="NLM_cas:atitle">4-Thiazolidinones: The advances continue...</span></div><div class="casAuthors">Tripathi, Avinash C.; Gupta, Shiv Ji; Fatima, Gul Naz; Sonar, Pankaj Kumar; Verma, Amit; Saraf, Shailendra K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">52-77</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The diversity in the biol. response of 4-thiazolidinones has attracted the attention of many researchers to explore this framework for its potential.  It is, therefore, of prime importance that the study of this topic and the development of new synthetic strategies should be based on the most recent knowledge, emerging from the latest research.  This review is an endeavor to highlight the progress in the chem. and biol. activity of the 4-thiazolidinones, predominantly after 2006.  The last section of the review encompasses the various patents granted on 4-thiazolidinone analogs/derivs. with World Intellectual Proprietary Organization (WIPO) and United State Patent Trademark Office (USPTO), particularly in the duration of the year 2000 to the year 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIWsGW07DjorVg90H21EOLACvtfcHk0ljDZMlNiHAy9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yktb4%253D&md5=77a5960d66392440998a3c62628cb3ad</span></div><a href="/servlet/linkout?suffix=cit63b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DTripathi%26aufirst%3DA.%2BC.%26aulast%3DGupta%26aufirst%3DS.%2BJ.%26aulast%3DFatima%26aufirst%3DG.%2BN.%26aulast%3DSonar%26aufirst%3DP.%2BK.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DSaraf%26aufirst%3DS.%2BK.%26atitle%3D4-Thiazolidinones%253A%2520the%2520advances%2520continue%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D72%26spage%3D52%26epage%3D77%26doi%3D10.1016%2Fj.ejmech.2013.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit63c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bolli, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abele, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binkert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatfield, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangold, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathys, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menyhart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sippel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strasser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, T.</span><span> </span><span class="NLM_article-title">2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4198</span><span class="NLM_x">–</span> <span class="NLM_lpage">4211</span><span class="refDoi"> DOI: 10.1021/jm100181s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100181s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4198-4211&author=M.+H.+Bolliauthor=S.+Abeleauthor=C.+Binkertauthor=R.+Bravoauthor=S.+Buchmannauthor=D.+Burauthor=J.+Gatfieldauthor=P.+Hessauthor=C.+Kohlauthor=C.+Mangoldauthor=B.+Mathysauthor=K.+Menyhartauthor=C.+M%C3%BCllerauthor=O.+Naylerauthor=M.+Scherzauthor=G.+Schmidtauthor=V.+Sippelauthor=B.+Steinerauthor=D.+Strasserauthor=A.+Treiberauthor=T.+Weller&title=2-Imino-thiazolidin-4-one+derivatives+as+potent%2C+orally+active+S1P1+receptor+agonists&doi=10.1021%2Fjm100181s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63c&amp;dbid=16384&amp;doi=10.1021%2Fjm100181s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100181s%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DAbele%26aufirst%3DS.%26aulast%3DBinkert%26aufirst%3DC.%26aulast%3DBravo%26aufirst%3DR.%26aulast%3DBuchmann%26aufirst%3DS.%26aulast%3DBur%26aufirst%3DD.%26aulast%3DGatfield%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DKohl%26aufirst%3DC.%26aulast%3DMangold%26aufirst%3DC.%26aulast%3DMathys%26aufirst%3DB.%26aulast%3DMenyhart%26aufirst%3DK.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3DScherz%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DG.%26aulast%3DSippel%26aufirst%3DV.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DStrasser%26aufirst%3DD.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DWeller%26aufirst%3DT.%26atitle%3D2-Imino-thiazolidin-4-one%2520derivatives%2520as%2520potent%252C%2520orally%2520active%2520S1P1%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4198%26epage%3D4211%26doi%3D10.1021%2Fjm100181s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshpande, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Identification of hepatitis C virus NS5A inhibitors</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">482</span><span class="NLM_x">–</span> <span class="NLM_lpage">491</span><span class="refDoi"> DOI: 10.1128/JVI.01360-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FJVI.01360-09" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=482-491&author=J.+A.+Lemmauthor=D.+R.+O%E2%80%99Boyleauthor=M.+Liuauthor=P.+T.+Nowerauthor=R.+Colonnoauthor=M.+S.+Deshpandeauthor=L.+B.+Snyderauthor=S.+W.+Martinauthor=D.+R.+St.+Laurentauthor=M.+H.+Serrano-Wuauthor=J.+L.+Romineauthor=N.+A.+Meanwellauthor=M.+Gao&title=Identification+of+hepatitis+C+virus+NS5A+inhibitors&doi=10.1128%2FJVI.01360-09"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1128%2FJVI.01360-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01360-09%26sid%3Dliteratum%253Aachs%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DDeshpande%26aufirst%3DM.%2BS.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitors%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D482%26epage%3D491%26doi%3D10.1128%2FJVI.01360-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pawlotsky, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germanidis, G.</span><span> </span><span class="NLM_article-title">The non-structural 5A protein of hepatitis C virus</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">343</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span><span class="refDoi"> DOI: 10.1046/j.1365-2893.1999.00185.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1046%2Fj.1365-2893.1999.00185.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=343-356&author=J.-M.+Pawlotskyauthor=G.+Germanidis&title=The+non-structural+5A+protein+of+hepatitis+C+virus&doi=10.1046%2Fj.1365-2893.1999.00185.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65a&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2893.1999.00185.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2893.1999.00185.x%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.-M.%26aulast%3DGermanidis%26aufirst%3DG.%26atitle%3DThe%2520non-structural%25205A%2520protein%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D1999%26volume%3D6%26spage%3D343%26epage%3D356%26doi%3D10.1046%2Fj.1365-2893.1999.00185.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit65b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neddermann, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinkühler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallinari, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folgori, A.</span><span> </span><span class="NLM_article-title">Biochemical and immunologic properties of the nonstructural proteins of the hepatitis C virus: implications for development of antiviral agents and vaccines</span> <span class="citation_source-journal">Semin. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1055/s-2000-9504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1055%2Fs-2000-9504" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=69-84&author=R.+De+Francescoauthor=P.+Neddermannauthor=L.+Tomeiauthor=C.+Steink%C3%BChlerauthor=P.+Gallinariauthor=A.+Folgori&title=Biochemical+and+immunologic+properties+of+the+nonstructural+proteins+of+the+hepatitis+C+virus%3A+implications+for+development+of+antiviral+agents+and+vaccines&doi=10.1055%2Fs-2000-9504"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65b&amp;dbid=16384&amp;doi=10.1055%2Fs-2000-9504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2000-9504%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DNeddermann%26aufirst%3DP.%26aulast%3DTomei%26aufirst%3DL.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DGallinari%26aufirst%3DP.%26aulast%3DFolgori%26aufirst%3DA.%26atitle%3DBiochemical%2520and%2520immunologic%2520properties%2520of%2520the%2520nonstructural%2520proteins%2520of%2520the%2520hepatitis%2520C%2520virus%253A%2520implications%2520for%2520development%2520of%2520antiviral%2520agents%2520and%2520vaccines%26jtitle%3DSemin.%2520Liver%2520Dis.%26date%3D2000%26volume%3D20%26spage%3D69%26epage%3D84%26doi%3D10.1055%2Fs-2000-9504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Macdonald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, M.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A: tales of a promiscuous protein</span> <span class="citation_source-journal">J. Gen. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">2485</span><span class="NLM_x">–</span> <span class="NLM_lpage">2502</span><span class="refDoi"> DOI: 10.1099/vir.0.80204-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1099%2Fvir.0.80204-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2004&pages=2485-2502&author=A.+Macdonaldauthor=M.+Harris&title=Hepatitis+C+virus+NS5A%3A+tales+of+a+promiscuous+protein&doi=10.1099%2Fvir.0.80204-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66a&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.80204-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.80204-0%26sid%3Dliteratum%253Aachs%26aulast%3DMacdonald%26aufirst%3DA.%26aulast%3DHarris%26aufirst%3DM.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%253A%2520tales%2520of%2520a%2520promiscuous%2520protein%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2004%26volume%3D85%26spage%3D2485%26epage%3D2502%26doi%3D10.1099%2Fvir.0.80204-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit66b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ross-Thriepland, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, M.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A: enigmatic but still promiscuous 10 years on!</span> <span class="citation_source-journal">J. Gen. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">738</span><span class="refDoi"> DOI: 10.1099/jgv.0.000009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1099%2Fjgv.0.000009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25481754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotVaktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2015&pages=727-738&author=D.+Ross-Thrieplandauthor=M.+Harris&title=Hepatitis+C+virus+NS5A%3A+enigmatic+but+still+promiscuous+10+years+on%21&doi=10.1099%2Fjgv.0.000009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66bR"><div class="casContent"><span class="casTitleNuber">66b</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus NS5A: enigmatic but still promiscuous 10 years on!</span></div><div class="casAuthors">Ross-Thriepland, Douglas; Harris, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">727-738</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">A review.  Since 1 of us co-authored a review on NS5A a decade ago, the hepatitis C virus (HCV) field has changed dramatically, primarily due to the advent of the JFH-1 cell culture infectious clone, which allowed the study of all aspects of the virus life cycle from entry to exit.  We describe advances in our understanding of NS5A biol. over the past decade, highlighting how the JFH-1 system has allowed us to det. that NS5A is essential not only in genome replication but also in the assembly of infectious virions.  We shall review the recent structural insights: NS5A is predicted to comprise 3 domains; X-ray crystallog. has revealed the structure of domain I but there is a lack of detailed structural information about the other 2 domains, which are predicted to be largely unstructured.  Recent insights into the phosphorylation of NS5A will be discussed, and we shall highlight a few pertinent examples from the ever-expanding list of NS5A-binding partners identified over the past decade.  Lastly, we shall review the literature showing that NS5A is a potential target for a new class of highly potent small mols. that function to inhibit virus replication.  These direct-acting antivirals (DAAs) are now either licensed, or in the late stages of approval for clin. use both in the USA and in the UK/Europe.  In combination with other DAAs targeting the viral protease (NS3) and polymerase (NS5B), they are revolutionizing treatment for HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqIagaCVblebVg90H21EOLACvtfcHk0liIkCWY8Mrhiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotVaktL8%253D&md5=a57512232b774a2635cc9b61be9ca982</span></div><a href="/servlet/linkout?suffix=cit66b&amp;dbid=16384&amp;doi=10.1099%2Fjgv.0.000009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fjgv.0.000009%26sid%3Dliteratum%253Aachs%26aulast%3DRoss-Thriepland%26aufirst%3DD.%26aulast%3DHarris%26aufirst%3DM.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%253A%2520enigmatic%2520but%2520still%2520promiscuous%252010%2520years%2520on%2521%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2015%26volume%3D96%26spage%3D727%26epage%3D738%26doi%3D10.1099%2Fjgv.0.000009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Bukh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietschmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieger, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faulk, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engle, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govindarajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Claire, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">14416</span><span class="NLM_x">–</span> <span class="NLM_lpage">14421</span><span class="refDoi"> DOI: 10.1073/pnas.212532699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1073%2Fpnas.212532699" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=14416-14421&author=J.+Bukhauthor=T.+Pietschmannauthor=V.+Lohmannauthor=N.+Kriegerauthor=K.+Faulkauthor=R.+E.+Engleauthor=S.+Govindarajanauthor=M.+Shapiroauthor=M.+St.+Claireauthor=R.+Bartenschlager&title=Mutations+that+permit+efficient+replication+of+hepatitis+C+virus+RNA+in+Huh-7+cells+prevent+productive+replication+in+chimpanzees&doi=10.1073%2Fpnas.212532699"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1073%2Fpnas.212532699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.212532699%26sid%3Dliteratum%253Aachs%26aulast%3DBukh%26aufirst%3DJ.%26aulast%3DPietschmann%26aufirst%3DT.%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DKrieger%26aufirst%3DN.%26aulast%3DFaulk%26aufirst%3DK.%26aulast%3DEngle%26aufirst%3DR.%2BE.%26aulast%3DGovindarajan%26aufirst%3DS.%26aulast%3DShapiro%26aufirst%3DM.%26aulast%3DSt.%2BClaire%26aufirst%3DM.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DMutations%2520that%2520permit%2520efficient%2520replication%2520of%2520hepatitis%2520C%2520virus%2520RNA%2520in%2520Huh-7%2520cells%2520prevent%2520productive%2520replication%2520in%2520chimpanzees%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D14416%26epage%3D14421%26doi%3D10.1073%2Fpnas.212532699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sato, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, N.</span><span> </span><span class="NLM_article-title">Specific hepatitis C virus NS5A sequences determine the outcome of interferon treatment</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">1152</span><span class="NLM_x">–</span> <span class="NLM_lpage">1154</span><span class="refDoi"> DOI: 10.1016/S0016-5085(96)70089-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0016-5085%2896%2970089-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1996&pages=1152-1154&author=C.+Satoauthor=N.+Enomoto&title=Specific+hepatitis+C+virus+NS5A+sequences+determine+the+outcome+of+interferon+treatment&doi=10.1016%2FS0016-5085%2896%2970089-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68a&amp;dbid=16384&amp;doi=10.1016%2FS0016-5085%2896%2970089-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0016-5085%252896%252970089-6%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DC.%26aulast%3DEnomoto%26aufirst%3DN.%26atitle%3DSpecific%2520hepatitis%2520C%2520virus%2520NS5A%2520sequences%2520determine%2520the%2520outcome%2520of%2520interferon%2520treatment%26jtitle%3DGastroenterology%26date%3D1996%26volume%3D111%26spage%3D1152%26epage%3D1154%26doi%3D10.1016%2FS0016-5085%2896%2970089-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit68b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pawlotsky, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germanidis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellerin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frainais, P.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhumeaux, D.</span><span> </span><span class="NLM_article-title">Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">2795</span><span class="NLM_x">–</span> <span class="NLM_lpage">2805</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1998&pages=2795-2805&author=J.-M.+Pawlotskyauthor=G.+Germanidisauthor=A.+U.+Neumannauthor=M.+Pellerinauthor=P.-O.+Frainaisauthor=D.+Dhumeaux&title=Interferon+resistance+of+hepatitis+C+virus+genotype+1b%3A+relationship+to+nonstructural+5A+gene+quasispecies+mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.-M.%26aulast%3DGermanidis%26aufirst%3DG.%26aulast%3DNeumann%26aufirst%3DA.%2BU.%26aulast%3DPellerin%26aufirst%3DM.%26aulast%3DFrainais%26aufirst%3DP.-O.%26aulast%3DDhumeaux%26aufirst%3DD.%26atitle%3DInterferon%2520resistance%2520of%2520hepatitis%2520C%2520virus%2520genotype%25201b%253A%2520relationship%2520to%2520nonstructural%25205A%2520gene%2520quasispecies%2520mutations%26jtitle%3DJ.%2520Virol.%26date%3D1998%26volume%3D72%26spage%3D2795%26epage%3D2805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit68c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Pawlotsky, J. M.</span><span> </span><span class="NLM_article-title">Hepatitis C virus (HCV) NS5A protein: role in HCV replication and resistance to interferon-alpha</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span><span class="refDoi"> DOI: 10.1046/j.1365-2893.1999.00004.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1046%2Fj.1365-2893.1999.00004.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=47-48&issue=Suppl.+1&author=J.+M.+Pawlotsky&title=Hepatitis+C+virus+%28HCV%29+NS5A+protein%3A+role+in+HCV+replication+and+resistance+to+interferon-alpha&doi=10.1046%2Fj.1365-2893.1999.00004.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68c&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2893.1999.00004.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2893.1999.00004.x%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.%2BM.%26atitle%3DHepatitis%2520C%2520virus%2520%2528HCV%2529%2520NS5A%2520protein%253A%2520role%2520in%2520HCV%2520replication%2520and%2520resistance%2520to%2520interferon-alpha%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D1999%26volume%3D6%26issue%3DSuppl.%25201%26spage%3D47%26epage%3D48%26doi%3D10.1046%2Fj.1365-2893.1999.00004.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">The discovery and development of hepatitis C virus NS5A replication complex inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1643</span><span class="NLM_x">–</span> <span class="NLM_lpage">1672</span><span class="refDoi"> DOI: 10.1021/jm401793m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401793m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslygsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1643-1672&author=M.+Belemaauthor=O.+D.+Lopezauthor=J.+A.+Benderauthor=J.+L.+Romineauthor=D.+R.+Laurentauthor=D.+R.+Langleyauthor=J.+A.+Lemmauthor=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=C.+Wangauthor=R.+A.+Fridellauthor=N.+A.+Meanwell&title=The+discovery+and+development+of+hepatitis+C+virus+NS5A+replication+complex+inhibitors&doi=10.1021%2Fjm401793m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors</span></div><div class="casAuthors">Belema, Makonen; Lopez, Omar D.; Bender, John A.; Romine, Jeffrey L.; St. Laurent, Denis R.; Langley, David R.; Lemm, Julie A.; O'Boyle, Donald R., II; Sun, Jin-Hua; Wang, Chunfu; Fridell, Robert A.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1643-1672</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Lead inhibitors that target the function of the hepatitis C virus (HCV) nonstructural 5A (NS5A) protein have been identified by phenotypic screening campaigns using HCV subgenomic replicons.  The demonstration of antiviral activity in HCV-infected subjects by the HCV NS5A replication complex inhibitor (RCI) daclatasvir (1) spawned considerable interest in this mechanistic approach.  In this Perspective, we summarize the medicinal chem. studies that led to the discovery of 1 and other chemotypes for which resistance maps to the NS5A protein and provide synopses of the profiles of many of the compds. currently in clin. trials.  We also summarize what is currently known about the NS5A protein and the studies using NS5A RCIs and labeled analogs that are helping to illuminate aspects of both protein function and inhibitor interaction.  We conclude with a synopsis of the results of notable clin. trials with HCV NS5A RCIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIeKUL517UmLVg90H21EOLACvtfcHk0lhPy3H_0aVatA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslygsbk%253D&md5=cc92046f9edcb633b433a0e6a4ac3fec</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm401793m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401793m%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DLaurent%26aufirst%3DD.%2BR.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DThe%2520discovery%2520and%2520development%2520of%2520hepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1643%26epage%3D1672%26doi%3D10.1021%2Fjm401793m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Romine, J. L.; Martin, S. W.; Snyder, L. B.; Serrano-Wu, M.; Deshpande, M.; Whitehouse, D.; Lemm, J.; O’Boyle, D. R.; Gao, M.; Colonno, R.</span><span> </span><span class="NLM_article-title">Iminothiazolidinones as inhibitors of HCV replication</span>. World Patent Application WO 2004/014852. February 19,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=J.+L.+Romine&author=S.+W.+Martin&author=L.+B.+Snyder&author=M.+Serrano-Wu&author=M.+Deshpande&author=D.+Whitehouse&author=J.+Lemm&author=D.+R.+O%E2%80%99Boyle&author=M.+Gao&author=R.+Colonno&title=Iminothiazolidinones+as+inhibitors+of+HCV+replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26atitle%3DIminothiazolidinones%2520as%2520inhibitors%2520of%2520HCV%2520replication%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit70b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshpande, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">Inhibitors of HCV NS5A: from iminothiazolidinones to symmetrical stilbenes</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">224</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span><span class="refDoi"> DOI: 10.1021/ml1002647</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1002647" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=224-229&author=J.+L.+Romineauthor=D.+R.+St.+Laurentauthor=J.+E.+Leetauthor=S.+W.+Martinauthor=M.+H.+Serrano-Wuauthor=F.+Yangauthor=M.+Gaoauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=J.-H.+Sunauthor=P.+T.+Nowerauthor=X.+Huangauthor=M.+S.+Deshpandeauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=Inhibitors+of+HCV+NS5A%3A+from+iminothiazolidinones+to+symmetrical+stilbenes&doi=10.1021%2Fml1002647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70bR"><div class="casContent"><span class="casTitleNuber">70b</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes</span></div><div class="casAuthors">Romine, Jeffrey L.; St. Laurent, Denis R.; Leet, John E.; Martin, Scott W.; Serrano-Wu, Michael H.; Yang, Fukang; Gao, Min; O'Boyle, Donald R.; Lemm, Julie A.; Sun, Jin-Hua; Nower, Peter T.; Huang, Xiaohua; Deshpande, Milind S.; Meanwell, Nicholas A.; Snyder, Lawrence B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">224-229</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The iminothiazolidinone BMS-858 (2) was identified as a specific inhibitor of HCV replication in a genotype 1b replicon assay via a high-throughput screening campaign.  A more potent analog, BMS-824 (18), was used in resistance mapping studies, which revealed that inhibitory activity was related to disrupting the function of the HCV nonstructural protein 5A.  Despite the development of coherent and interpretable SAR, it was subsequently discovered that in DMSO 18 underwent an oxidn. and structural rearrangement to afford the thiohydantoin 47, a compd. with reduced HCV inhibitory activity.  However, HPLC bioassay fractionation studies performed after incubation of 18 in assay media led to the identification of fractions contg. a dimeric species 48 that exhibited potent antiviral activity.  Excision of the key elements hypothesized to be responsible for antiviral activity based on SAR observations reduced 48 to a simplified, sym., pharmacophore realized most effectively with the stilbene 55, a compd. that demonstrated potent inhibition of HCV in a genotype 1b replicon with an EC50 = 86 pM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj8qij0fE1q7Vg90H21EOLACvtfcHk0lgb1oOvfRuAzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFCmsg%253D%253D&md5=466b1f5dc09b9e2ecc6b581069506169</span></div><a href="/servlet/linkout?suffix=cit70b&amp;dbid=16384&amp;doi=10.1021%2Fml1002647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1002647%26sid%3Dliteratum%253Aachs%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DDeshpande%26aufirst%3DM.%2BS.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DInhibitors%2520of%2520HCV%2520NS5A%253A%2520from%2520iminothiazolidinones%2520to%2520symmetrical%2520stilbenes%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D224%26epage%3D229%26doi%3D10.1021%2Fml1002647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alberts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantone, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3795</span><span class="NLM_x">–</span> <span class="NLM_lpage">3802</span><span class="refDoi"> DOI: 10.1128/AAC.00146-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FAAC.00146-11" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=3795-3802&author=J.+A.+Lemmauthor=J.+E.+Leetauthor=D.+R.+O%E2%80%99Boyleauthor=J.+L.+Romineauthor=X.+S.+Huangauthor=D.+R.+Schroederauthor=J.+Albertsauthor=J.+L.+Cantoneauthor=J.-H.+Sunauthor=P.+T.+Nowerauthor=S.+W.+Martinauthor=M.+H.+Serrano-Wuauthor=N.+A.+Meanwellauthor=L.+B.+Snyderauthor=M.+Gao&title=Discovery+of+potent+hepatitis+C+virus+NS5A+inhibitors+with+dimeric+structures&doi=10.1128%2FAAC.00146-11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1128%2FAAC.00146-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00146-11%26sid%3Dliteratum%253Aachs%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DHuang%26aufirst%3DX.%2BS.%26aulast%3DSchroeder%26aufirst%3DD.%2BR.%26aulast%3DAlberts%26aufirst%3DJ.%26aulast%3DCantone%26aufirst%3DJ.%2BL.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520potent%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitors%2520with%2520dimeric%2520structures%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D3795%26epage%3D3802%26doi%3D10.1128%2FAAC.00146-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Leet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belcastro, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowling, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemeth, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, H. N.</span><span> </span><span class="NLM_article-title">HPLC biogram analysis: a powerful tool used for hit confirmation in early drug discovery</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">681</span><span class="NLM_x">–</span> <span class="NLM_lpage">687</span><span class="refDoi"> DOI: 10.1177/1087057115569160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1177%2F1087057115569160" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=681-687&author=J.+E.+Leetauthor=J.+V.+Belcastroauthor=C.+J.+Dowlingauthor=G.+A.+Nemethauthor=H.+N.+Weller&title=HPLC+biogram+analysis%3A+a+powerful+tool+used+for+hit+confirmation+in+early+drug+discovery&doi=10.1177%2F1087057115569160"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1177%2F1087057115569160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057115569160%26sid%3Dliteratum%253Aachs%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DBelcastro%26aufirst%3DJ.%2BV.%26aulast%3DDowling%26aufirst%3DC.%2BJ.%26aulast%3DNemeth%26aufirst%3DG.%2BA.%26aulast%3DWeller%26aufirst%3DH.%2BN.%26atitle%3DHPLC%2520biogram%2520analysis%253A%2520a%2520powerful%2520tool%2520used%2520for%2520hit%2520confirmation%2520in%2520early%2520drug%2520discovery%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2015%26volume%3D20%26spage%3D681%26epage%3D687%26doi%3D10.1177%2F1087057115569160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Giese, B.</span> <span class="citation_source-book">Radicals in Organic Synthesis: Formation of Carbon-Carbon Bonds</span>; <span class="NLM_publisher-name">Pergamon Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1986</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1986&author=B.+Giese&title=Radicals+in+Organic+Synthesis%3A+Formation+of+Carbon-Carbon+Bonds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGiese%26aufirst%3DB.%26btitle%3DRadicals%2520in%2520Organic%2520Synthesis%253A%2520Formation%2520of%2520Carbon-Carbon%2520Bonds%26pub%3DPergamon%2520Press%26date%3D1986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit73b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Viehe, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janousek, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merenyi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stella, L.</span><span> </span><span class="NLM_article-title">The captodative effect</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">148</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span><span class="refDoi"> DOI: 10.1021/ar00113a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar00113a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaL2MXktlKrs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1985&pages=148-154&author=H.+G.+Vieheauthor=Z.+Janousekauthor=R.+Merenyiauthor=L.+Stella&title=The+captodative+effect&doi=10.1021%2Far00113a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73bR"><div class="casContent"><span class="casTitleNuber">73b</span><div class="casTitle"><span class="NLM_cas:atitle">The captodative effect</span></div><div class="casAuthors">Viehe, Heinz G.; Janousek, Zdenek; Merenyi, Robert; Stella, Lucien</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">148-54</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    </div><div class="casAbstract">The genesis of the captodative effect is reviewed with ∼60 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGont4FOPBPrxLVg90H21EOLACvtfcHk0lgkJY3nWUVLzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXktlKrs7c%253D&md5=58e437aa46c25ef758cb2a2d44ec09cc</span></div><a href="/servlet/linkout?suffix=cit73b&amp;dbid=16384&amp;doi=10.1021%2Far00113a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far00113a004%26sid%3Dliteratum%253Aachs%26aulast%3DViehe%26aufirst%3DH.%2BG.%26aulast%3DJanousek%26aufirst%3DZ.%26aulast%3DMerenyi%26aufirst%3DR.%26aulast%3DStella%26aufirst%3DL.%26atitle%3DThe%2520captodative%2520effect%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1985%26volume%3D18%26spage%3D148%26epage%3D154%26doi%3D10.1021%2Far00113a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Ingold, K. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratt, D. A.</span><span> </span><span class="NLM_article-title">Advances in radical-trapping antioxidant chemistry in the 21st century: a kinetics and mechanisms perspective</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">9022</span><span class="NLM_x">–</span> <span class="NLM_lpage">9046</span><span class="refDoi"> DOI: 10.1021/cr500226n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr500226n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=9022-9046&author=K.+U.+Ingoldauthor=D.+A.+Pratt&title=Advances+in+radical-trapping+antioxidant+chemistry+in+the+21st+century%3A+a+kinetics+and+mechanisms+perspective&doi=10.1021%2Fcr500226n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in Radical-Trapping Antioxidant Chemistry in the 21st Century: A Kinetics and Mechanisms Perspective</span></div><div class="casAuthors">Ingold, Keith U.; Pratt, Derek A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">9022-9046</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozeP_96otNHLVg90H21EOLACvtfcHk0ljNmWxeAIqTUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtLzO&md5=ea5b97ad5071ae648de3e4bea3de7425</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fcr500226n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr500226n%26sid%3Dliteratum%253Aachs%26aulast%3DIngold%26aufirst%3DK.%2BU.%26aulast%3DPratt%26aufirst%3DD.%2BA.%26atitle%3DAdvances%2520in%2520radical-trapping%2520antioxidant%2520chemistry%2520in%2520the%252021st%2520century%253A%2520a%2520kinetics%2520and%2520mechanisms%2520perspective%26jtitle%3DChem.%2520Rev.%26date%3D2014%26volume%3D114%26spage%3D9022%26epage%3D9046%26doi%3D10.1021%2Fcr500226n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75a"><span><span class="NLM_contrib-group">Kates, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombroski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snider, B. B.</span><span> </span><span class="NLM_article-title">Manganese(III)-based oxidative free-radical cyclization of unsaturated β-keto esters, 1,3-diketones, and malonate diesters</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2427</span><span class="NLM_x">–</span> <span class="NLM_lpage">2436</span><span class="refDoi"> DOI: 10.1021/jo00295a035</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00295a035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1990&pages=2427-2436&author=S.+A.+Katesauthor=M.+A.+Dombroskiauthor=B.+B.+Snider&title=Manganese%28III%29-based+oxidative+free-radical+cyclization+of+unsaturated+%CE%B2-keto+esters%2C+1%2C3-diketones%2C+and+malonate+diesters&doi=10.1021%2Fjo00295a035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75a&amp;dbid=16384&amp;doi=10.1021%2Fjo00295a035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00295a035%26sid%3Dliteratum%253Aachs%26aulast%3DKates%26aufirst%3DS.%2BA.%26aulast%3DDombroski%26aufirst%3DM.%2BA.%26aulast%3DSnider%26aufirst%3DB.%2BB.%26atitle%3DManganese%2528III%2529-based%2520oxidative%2520free-radical%2520cyclization%2520of%2520unsaturated%2520%25CE%25B2-keto%2520esters%252C%25201%252C3-diketones%252C%2520and%2520malonate%2520diesters%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1990%26volume%3D55%26spage%3D2427%26epage%3D2436%26doi%3D10.1021%2Fjo00295a035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit75b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Snider, B. B.</span><span> </span><span class="NLM_article-title">Manganese(III)-based oxidative free-radical cyclizations</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">339</span><span class="NLM_x">–</span> <span class="NLM_lpage">363</span><span class="refDoi"> DOI: 10.1021/cr950026m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr950026m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK28XjsVKluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1996&pages=339-363&author=B.+B.+Snider&title=Manganese%28III%29-based+oxidative+free-radical+cyclizations&doi=10.1021%2Fcr950026m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75bR"><div class="casContent"><span class="casTitleNuber">75b</span><div class="casTitle"><span class="NLM_cas:atitle">Manganese(III)-Based Oxidative Free-Radical Cyclizations</span></div><div class="casAuthors">Snider, Barry B.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">339-63</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 171 refs.  Mn(OAc)3 and other oxidants have been used in oxidative cyclizations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZGDd7A7jakLVg90H21EOLACvtfcHk0ljNmWxeAIqTUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjsVKluw%253D%253D&md5=b5e51e70470d149c53a53701c4a7b767</span></div><a href="/servlet/linkout?suffix=cit75b&amp;dbid=16384&amp;doi=10.1021%2Fcr950026m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr950026m%26sid%3Dliteratum%253Aachs%26aulast%3DSnider%26aufirst%3DB.%2BB.%26atitle%3DManganese%2528III%2529-based%2520oxidative%2520free-radical%2520cyclizations%26jtitle%3DChem.%2520Rev.%26date%3D1996%26volume%3D96%26spage%3D339%26epage%3D363%26doi%3D10.1021%2Fcr950026m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Irie, M.</span><span> </span><span class="NLM_article-title">Diarylethenes for memories and switches</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1685</span><span class="NLM_x">–</span> <span class="NLM_lpage">1716</span><span class="refDoi"> DOI: 10.1021/cr980069d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr980069d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFGitLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=1685-1716&author=M.+Irie&title=Diarylethenes+for+memories+and+switches&doi=10.1021%2Fcr980069d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76aR"><div class="casContent"><span class="casTitleNuber">76a</span><div class="casTitle"><span class="NLM_cas:atitle">Diarylethenes for Memories and Switches</span></div><div class="casAuthors">Irie, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1685-1716</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diarylethenes with heterocyclic aryl groups are thermally reversible photochromic compds. with high resistance to fatigue.  These properties are indispensable for applications in optoelectronic devices.  Fundamental properties of these compds. and their applications to optical memory devices and switches are described.  A review with 130 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraGHEiJ_0jY7Vg90H21EOLACvtfcHk0ljj3Qvb1Ssmww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFGitLc%253D&md5=c83c651b39092361b7d52849973cd002</span></div><a href="/servlet/linkout?suffix=cit76a&amp;dbid=16384&amp;doi=10.1021%2Fcr980069d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr980069d%26sid%3Dliteratum%253Aachs%26aulast%3DIrie%26aufirst%3DM.%26atitle%3DDiarylethenes%2520for%2520memories%2520and%2520switches%26jtitle%3DChem.%2520Rev.%26date%3D2000%26volume%3D100%26spage%3D1685%26epage%3D1716%26doi%3D10.1021%2Fcr980069d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit76b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fuss, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trushin, S. A.</span><span> </span><span class="NLM_article-title">The photochemical cis-trans isomerization of free stilbene molecules follows a hula-twist pathway</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">4178</span><span class="NLM_x">–</span> <span class="NLM_lpage">4182</span><span class="refDoi"> DOI: 10.1002/anie.200454221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fanie.200454221" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=4178-4182&author=W.+Fussauthor=C.+Kosmidisauthor=W.+E.+Schmidauthor=S.+A.+Trushin&title=The+photochemical+cis-trans+isomerization+of+free+stilbene+molecules+follows+a+hula-twist+pathway&doi=10.1002%2Fanie.200454221"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76b&amp;dbid=16384&amp;doi=10.1002%2Fanie.200454221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200454221%26sid%3Dliteratum%253Aachs%26aulast%3DFuss%26aufirst%3DW.%26aulast%3DKosmidis%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DW.%2BE.%26aulast%3DTrushin%26aufirst%3DS.%2BA.%26atitle%3DThe%2520photochemical%2520cis-trans%2520isomerization%2520of%2520free%2520stilbene%2520molecules%2520follows%2520a%2520hula-twist%2520pathway%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2004%26volume%3D43%26spage%3D4178%26epage%3D4182%26doi%3D10.1002%2Fanie.200454221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit76c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Takeuchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruhman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuneda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taketsugu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahara, T.</span><span> </span><span class="NLM_article-title">Spectroscopic tracking of structural evolution in ultrafast stilbene photoisomerization</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">322</span><span class="NLM_x">, </span> <span class="NLM_fpage">1073</span><span class="NLM_x">–</span> <span class="NLM_lpage">1077</span><span class="refDoi"> DOI: 10.1126/science.1160902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1126%2Fscience.1160902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=19008439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlGhu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2008&pages=1073-1077&author=S.+Takeuchiauthor=S.+Ruhmanauthor=T.+Tsunedaauthor=M.+Chibaauthor=T.+Taketsuguauthor=T.+Tahara&title=Spectroscopic+tracking+of+structural+evolution+in+ultrafast+stilbene+photoisomerization&doi=10.1126%2Fscience.1160902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76cR"><div class="casContent"><span class="casTitleNuber">76c</span><div class="casTitle"><span class="NLM_cas:atitle">Spectroscopic tracking of structural evolution in ultrafast stilbene photoisomerization</span></div><div class="casAuthors">Takeuchi, Satoshi; Ruhman, Sanford; Tsuneda, Takao; Chiba, Mahito; Taketsugu, Tetsuya; Tahara, Tahei</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">5904</span>),
    <span class="NLM_cas:pages">1073-1077</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Understanding a chem. reaction ultimately requires the knowledge of how each atom in the reactants moves during product formation.  Such knowledge is seldom complete and is often limited to an oversimplified reaction coordinate that neglects global motions across the mol. framework.  To overcome this limit, we recorded transient impulsive Raman spectra during ultrafast photoisomerization of cis-stilbene in soln.  The results demonstrate a gradual frequency shift of a low-frequency spectator vibration, reflecting changes in the restoring force along this coordinate throughout the isomerization.  A high-level quantum-chem. calcn. reproduces this feature and assocs. it with a continuous structural change leading to the twisted configuration.  This combined spectroscopic and computational approach should be amenable to detailed reaction visualization in other photoisomerizing systems as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV4pF4Yg5RXbVg90H21EOLACvtfcHk0ljj3Qvb1Ssmww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlGhu7fP&md5=0defa842e4cfd2e304a051ec55ab12db</span></div><a href="/servlet/linkout?suffix=cit76c&amp;dbid=16384&amp;doi=10.1126%2Fscience.1160902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1160902%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DS.%26aulast%3DRuhman%26aufirst%3DS.%26aulast%3DTsuneda%26aufirst%3DT.%26aulast%3DChiba%26aufirst%3DM.%26aulast%3DTaketsugu%26aufirst%3DT.%26aulast%3DTahara%26aufirst%3DT.%26atitle%3DSpectroscopic%2520tracking%2520of%2520structural%2520evolution%2520in%2520ultrafast%2520stilbene%2520photoisomerization%26jtitle%3DScience%26date%3D2008%26volume%3D322%26spage%3D1073%26epage%3D1077%26doi%3D10.1126%2Fscience.1160902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Benigni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruska, A.</span><span> </span><span class="NLM_article-title">Quantitative structure-activity relationships of mutagenic and carcinogenic aromatic amines</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">3697</span><span class="NLM_x">–</span> <span class="NLM_lpage">3714</span><span class="refDoi"> DOI: 10.1021/cr9901079</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr9901079" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlslSku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=3697-3714&author=R.+Benigniauthor=A.+Giulianiauthor=R.+Frankeauthor=A.+Gruska&title=Quantitative+structure-activity+relationships+of+mutagenic+and+carcinogenic+aromatic+amines&doi=10.1021%2Fcr9901079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77aR"><div class="casContent"><span class="casTitleNuber">77a</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative Structure-Activity Relationships of Mutagenic and Carcinogenic Aromatic Amines</span></div><div class="casAuthors">Benigni, Romualdo; Giuliani, Alessandro; Franke, Rainer; Gruska, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3697-3714</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 76 refs. discusses the value of QSAR models in predicting carcinogenicity of well-defined chem. classes such as the arom. amines detailed in the review. In vivo data were successfully incorporated into a statistically reliable and informative model of arom. amine carcinogenic potential. TD50's as endpoints were used to measure carcinogenic potency and were a reliable basis for modeling even when data came from different labs. It was detd. from the QSAR models reviewed that arom. amines require metabolic activation to yield the ultimate carcinogen or mutagen. The principal pathway(s) of bioactivation involves the formation of a hydroxylamine, which decomps. to a reactive nitrenium ion intermediate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohUfWQFGPvGLVg90H21EOLACvtfcHk0liUK5f0UN_B-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlslSku7g%253D&md5=8e17bc92f38af39517f904dcdcec7bc4</span></div><a href="/servlet/linkout?suffix=cit77a&amp;dbid=16384&amp;doi=10.1021%2Fcr9901079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9901079%26sid%3Dliteratum%253Aachs%26aulast%3DBenigni%26aufirst%3DR.%26aulast%3DGiuliani%26aufirst%3DA.%26aulast%3DFranke%26aufirst%3DR.%26aulast%3DGruska%26aufirst%3DA.%26atitle%3DQuantitative%2520structure-activity%2520relationships%2520of%2520mutagenic%2520and%2520carcinogenic%2520aromatic%2520amines%26jtitle%3DChem.%2520Rev.%26date%3D2000%26volume%3D100%26spage%3D3697%26epage%3D3714%26doi%3D10.1021%2Fcr9901079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit77b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kugler-Steigmeier, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friederich, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graf, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlatter, C.</span><span> </span><span class="NLM_article-title">Genotoxicity of aniline derivatives in various short-term tests</span> <span class="citation_source-journal">Mutat. Res., Fundam. Mol. Mech. Mutagen.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">211</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">289</span><span class="refDoi"> DOI: 10.1016/0027-5107(89)90011-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2F0027-5107%2889%2990011-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=2494442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaL1MXitVOmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=1989&pages=279-289&author=M.+E.+Kugler-Steigmeierauthor=U.+Friederichauthor=U.+Grafauthor=W.+K.+Lutzauthor=P.+Maierauthor=C.+Schlatter&title=Genotoxicity+of+aniline+derivatives+in+various+short-term+tests&doi=10.1016%2F0027-5107%2889%2990011-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77bR"><div class="casContent"><span class="casTitleNuber">77b</span><div class="casTitle"><span class="NLM_cas:atitle">Genotoxicity of aniline derivatives in various short-term tests</span></div><div class="casAuthors">Kugler-Steigmeier, M. E.; Friederich, U.; Graf, U.; Lutz, W. K.; Maier, P.; Schlatter, C.</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, Fundamental and Molecular Mechanisms of Mutagenesis</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-89</span>CODEN:
                <span class="NLM_cas:coden">MUREAV</span>;
        ISSN:<span class="NLM_cas:issn">0027-5107</span>.
    </div><div class="casAbstract">Various substituted aniline derivs. were tested for genotoxicity in several short-term tests to examine the hypothesis that a substitution at both ortho positions (2,6-disubstitution) could prevent genotoxicity due to steric hindrance of an enzymic activation to electrophilic intermediates.  In the Salmonella/microsome assay, 2,6-dialkylsubstituted anilines and 2,4,6-trimethylaniline (2,4,6-TMA) were weakly mutagenic in strain TA100 when 20% S9 mix was used, although effects were small compared to those of 2,4-dimethylaniline and 2,4,5-trimethylaniline (2,4,5-TMA).  In Drosophila melanogaster, however, 2,4,6-TMA and 2,4,6-trichloroaniline were mutagenic in the wing spot test at 2-3 times lower doses than 2,4,5-TMA.  In the 6-thioguanine resistance test in cultured fibroblasts, 2,4,6-TMA was again mutagenic at lower doses than 2,4,5-TMA.  Two methylene-bis-aniline derivs. were also tested with the above methods: 4,4'-methylene-bis-[(2-chloroaniline)] (MOCA) was moderately genotoxic in all 3 tests systems whereas 4,4'-methylene-bis-[(2-ethyl-6-methylaniline)] (MMEA) showed no genotoxicity at all.  DNA binding studies in rats, however, revealed that MOCA and MMEA produced DNA adducts in the liver at levels typically found for moderately strong genotoxic carcinogens.  Thus, the predictive value of the in vitro test systems and particularly the Salmonella/microsome assay is inadequate to detect genotoxicity in arom. amines.  Genotoxicity seems to be a general property of aniline derivs. and does not seem to be greatly influenced by substitution at both ortho positions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7X8K383lt8bVg90H21EOLACvtfcHk0liUK5f0UN_B-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXitVOmtbg%253D&md5=f362df1cf93da42f697b7ca4d19ff59f</span></div><a href="/servlet/linkout?suffix=cit77b&amp;dbid=16384&amp;doi=10.1016%2F0027-5107%2889%2990011-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0027-5107%252889%252990011-0%26sid%3Dliteratum%253Aachs%26aulast%3DKugler-Steigmeier%26aufirst%3DM.%2BE.%26aulast%3DFriederich%26aufirst%3DU.%26aulast%3DGraf%26aufirst%3DU.%26aulast%3DLutz%26aufirst%3DW.%2BK.%26aulast%3DMaier%26aufirst%3DP.%26aulast%3DSchlatter%26aufirst%3DC.%26atitle%3DGenotoxicity%2520of%2520aniline%2520derivatives%2520in%2520various%2520short-term%2520tests%26jtitle%3DMutat.%2520Res.%252C%2520Fundam.%2520Mol.%2520Mech.%2520Mutagen.%26date%3D1989%26volume%3D211%26spage%3D279%26epage%3D289%26doi%3D10.1016%2F0027-5107%2889%2990011-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit77c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Shamovsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Börjesson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordén, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasselgren, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjö, P.</span><span> </span><span class="NLM_article-title">Explanation for main features of structure-genotoxicity relationships of aromatic amines by theoretical studies of their activation pathways in CYP1A2</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">16168</span><span class="NLM_x">–</span> <span class="NLM_lpage">16185</span><span class="refDoi"> DOI: 10.1021/ja206427u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja206427u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=16168-16185&author=I.+Shamovskyauthor=L.+Ripaauthor=L.+B%C3%B6rjessonauthor=C.+Meeauthor=B.+Nord%C3%A9nauthor=P.+Hansenauthor=C.+Hasselgrenauthor=M.+O%E2%80%99Donovanauthor=P.+Sj%C3%B6&title=Explanation+for+main+features+of+structure-genotoxicity+relationships+of+aromatic+amines+by+theoretical+studies+of+their+activation+pathways+in+CYP1A2&doi=10.1021%2Fja206427u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77cR"><div class="casContent"><span class="casTitleNuber">77c</span><div class="casTitle"><span class="NLM_cas:atitle">Explanation for Main Features of Structure-Genotoxicity Relationships of Aromatic Amines by Theoretical Studies of Their Activation Pathways in CYP1A2</span></div><div class="casAuthors">Shamovsky, Igor; Ripa, Lena; Borjesson, Lena; Mee, Christine; Norden, Bo; Hansen, Peter; Hasselgren, Catrin; O'Donovan, Mike; Sjo, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">16168-16185</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Arom. and heteroarom. amines (ArNH2) represent a class of potential mutagens that after being metabolically activated covalently modify DNA.  Activation of ArNH2 in many cases starts with N-hydroxylation by P 450 enzymes, primarily CYP1A2.  Poor understanding of structure-mutagenicity relationships of ArNH2 limits their use in drug discovery programs.  Key factors that facilitate activation of ArNH2 are revealed by exploring their reaction intermediates in CYP1A2 using DFT calcns.  On the basis of these calcns. and extensive anal. of structure-mutagenicity data, we suggest that mutagenic metabolites are generated by ferric peroxo intermediate, (CYP1A2)FeIII-OO-, in a three-step heterolytic mechanism.  First, the distal oxygen of the oxidant abstrs. proton from H-bonded ArNH2.  The subsequent proximal protonation of the resulting (CYP1A2)FeIII-OOH weakens both the O-O and the O-H bonds of the oxidant.  Heterolytic cleavage of the O-O bond leads to N-hydroxylation of ArNH- via SN2 mechanism, whereas cleavage of the O-H bond results in release of hydroperoxy radical.  Thus, our proposed reaction offers a mechanistic explanation for previous observations that metab. of arom. amines could cause oxidative stress.  The primary drivers for mutagenic potency of ArNH2 are (i) binding affinity of ArNH2 in the productive binding mode within the CYP1A2 substrate cavity, (ii) resonance stabilization of the anionic forms of ArNH2, and (iii) exothermicity of proton-assisted heterolytic cleavage of N-O bonds of hydroxylamines and their bioconjugates.  This leads to a strategy for designing mutagenicity free ArNH2: Structural alterations in ArNH2, which disrupt geometric compatibility with CYP1A2, hinder proton abstraction, or strongly destabilize the nitrenium ion, in this order of priority, prevent genotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrctr81IIN2trVg90H21EOLACvtfcHk0lh1MmrINZaVkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvI&md5=9447ee2144a899b65e9350b712ca2a46</span></div><a href="/servlet/linkout?suffix=cit77c&amp;dbid=16384&amp;doi=10.1021%2Fja206427u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja206427u%26sid%3Dliteratum%253Aachs%26aulast%3DShamovsky%26aufirst%3DI.%26aulast%3DRipa%26aufirst%3DL.%26aulast%3DB%25C3%25B6rjesson%26aufirst%3DL.%26aulast%3DMee%26aufirst%3DC.%26aulast%3DNord%25C3%25A9n%26aufirst%3DB.%26aulast%3DHansen%26aufirst%3DP.%26aulast%3DHasselgren%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%26aulast%3DSj%25C3%25B6%26aufirst%3DP.%26atitle%3DExplanation%2520for%2520main%2520features%2520of%2520structure-genotoxicity%2520relationships%2520of%2520aromatic%2520amines%2520by%2520theoretical%2520studies%2520of%2520their%2520activation%2520pathways%2520in%2520CYP1A2%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D16168%26epage%3D16185%26doi%3D10.1021%2Fja206427u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit77d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Sinsheimer, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooberman, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brezzell, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, Z.</span><span> </span><span class="NLM_article-title">The in vivo and in vitro genotoxicity of aromatic amines in relationship to the genotoxicity of benzidine</span> <span class="citation_source-journal">Mutat. Res., Fundam. Mol. Mech. Mutagen.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1016/0027-5107(92)90232-Q</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2F0027-5107%2892%2990232-Q" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1992&pages=255-262&author=J.+E.+Sinsheimerauthor=B.+H.+Hoobermanauthor=S.+K.+Dasauthor=M.+D.+Brezzellauthor=Z.+You&title=The+in+vivo+and+in+vitro+genotoxicity+of+aromatic+amines+in+relationship+to+the+genotoxicity+of+benzidine&doi=10.1016%2F0027-5107%2892%2990232-Q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77d&amp;dbid=16384&amp;doi=10.1016%2F0027-5107%2892%2990232-Q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0027-5107%252892%252990232-Q%26sid%3Dliteratum%253Aachs%26aulast%3DSinsheimer%26aufirst%3DJ.%2BE.%26aulast%3DHooberman%26aufirst%3DB.%2BH.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DBrezzell%26aufirst%3DM.%2BD.%26aulast%3DYou%26aufirst%3DZ.%26atitle%3DThe%2520in%2520vivo%2520and%2520in%2520vitro%2520genotoxicity%2520of%2520aromatic%2520amines%2520in%2520relationship%2520to%2520the%2520genotoxicity%2520of%2520benzidine%26jtitle%3DMutat.%2520Res.%252C%2520Fundam.%2520Mol.%2520Mech.%2520Mutagen.%26date%3D1992%26volume%3D268%26spage%3D255%26epage%3D262%26doi%3D10.1016%2F0027-5107%2892%2990232-Q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit77e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">You, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brezzell, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooberman, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinsheimer, J. E.</span><span> </span><span class="NLM_article-title">Substituent effects on the in vitro and in vivo genotoxicity of 4-aminobiphenyl and 4-aminostilbene derivatives</span> <span class="citation_source-journal">Mutat. Res., Genet. Toxicol. Test.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">320</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span><span class="refDoi"> DOI: 10.1016/0165-1218(94)90058-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2F0165-1218%2894%2990058-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=1994&pages=45-58&author=Z.+Youauthor=M.+D.+Brezzellauthor=S.+K.+Dasauthor=B.+H.+Hoobermanauthor=J.+E.+Sinsheimer&title=Substituent+effects+on+the+in+vitro+and+in+vivo+genotoxicity+of+4-aminobiphenyl+and+4-aminostilbene+derivatives&doi=10.1016%2F0165-1218%2894%2990058-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77e&amp;dbid=16384&amp;doi=10.1016%2F0165-1218%2894%2990058-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-1218%252894%252990058-2%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DZ.%26aulast%3DBrezzell%26aufirst%3DM.%2BD.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DHooberman%26aufirst%3DB.%2BH.%26aulast%3DSinsheimer%26aufirst%3DJ.%2BE.%26atitle%3DSubstituent%2520effects%2520on%2520the%2520in%2520vitro%2520and%2520in%2520vivo%2520genotoxicity%2520of%25204-aminobiphenyl%2520and%25204-aminostilbene%2520derivatives%26jtitle%3DMutat.%2520Res.%252C%2520Genet.%2520Toxicol.%2520Test.%26date%3D1994%26volume%3D320%26spage%3D45%26epage%3D58%26doi%3D10.1016%2F0165-1218%2894%2990058-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit77f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Garcia, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pye, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galbreath, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isovitsch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fradinger, E. A.</span><span> </span><span class="NLM_article-title">The functional group on (<i>E</i>)-4,4′-disubstituted stilbenes influences toxicity and antioxidative activity in differentiated PC-12 cells</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">6355</span><span class="NLM_x">–</span> <span class="NLM_lpage">6359</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.09.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmcl.2013.09.073" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=6355-6359&author=G.+X.+Garciaauthor=S.+W.+Larsenauthor=C.+Pyeauthor=M.+Galbreathauthor=R.+Isovitschauthor=E.+A.+Fradinger&title=The+functional+group+on+%28E%29-4%2C4%E2%80%B2-disubstituted+stilbenes+influences+toxicity+and+antioxidative+activity+in+differentiated+PC-12+cells&doi=10.1016%2Fj.bmcl.2013.09.073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77f&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.09.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.09.073%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DG.%2BX.%26aulast%3DLarsen%26aufirst%3DS.%2BW.%26aulast%3DPye%26aufirst%3DC.%26aulast%3DGalbreath%26aufirst%3DM.%26aulast%3DIsovitsch%26aufirst%3DR.%26aulast%3DFradinger%26aufirst%3DE.%2BA.%26atitle%3DThe%2520functional%2520group%2520on%2520%2528E%2529-4%252C4%25E2%2580%25B2-disubstituted%2520stilbenes%2520influences%2520toxicity%2520and%2520antioxidative%2520activity%2520in%2520differentiated%2520PC-12%2520cells%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D6355%26epage%3D6359%26doi%3D10.1016%2Fj.bmcl.2013.09.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit77g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Cunningham, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, E.</span><span> </span><span class="NLM_article-title">Hydrolysis of oleylanilide in the rat</span> <span class="citation_source-journal">Arch. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span><span class="refDoi"> DOI: 10.1007/BF01261384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1007%2FBF01261384" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1983&pages=157-162&author=V.+J.+Cunninghamauthor=S.+P.+Tuckerauthor=E.+Bailey&title=Hydrolysis+of+oleylanilide+in+the+rat&doi=10.1007%2FBF01261384"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77g&amp;dbid=16384&amp;doi=10.1007%2FBF01261384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01261384%26sid%3Dliteratum%253Aachs%26aulast%3DCunningham%26aufirst%3DV.%2BJ.%26aulast%3DTucker%26aufirst%3DS.%2BP.%26aulast%3DBailey%26aufirst%3DE.%26atitle%3DHydrolysis%2520of%2520oleylanilide%2520in%2520the%2520rat%26jtitle%3DArch.%2520Toxicol.%26date%3D1983%26volume%3D54%26spage%3D157%26epage%3D162%26doi%3D10.1007%2FBF01261384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mondelli, M. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silini, E.</span><span> </span><span class="NLM_article-title">Clinical significance of hepatitis C virus genotypes</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span><span class="refDoi"> DOI: 10.1016/S0168-8278(99)80377-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0168-8278%2899%2980377-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1999&pages=65-70&issue=Suppl.+1&author=M.+U.+Mondelliauthor=E.+Silini&title=Clinical+significance+of+hepatitis+C+virus+genotypes&doi=10.1016%2FS0168-8278%2899%2980377-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78a&amp;dbid=16384&amp;doi=10.1016%2FS0168-8278%2899%2980377-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-8278%252899%252980377-8%26sid%3Dliteratum%253Aachs%26aulast%3DMondelli%26aufirst%3DM.%2BU.%26aulast%3DSilini%26aufirst%3DE.%26atitle%3DClinical%2520significance%2520of%2520hepatitis%2520C%2520virus%2520genotypes%26jtitle%3DJ.%2520Hepatol.%26date%3D1999%26volume%3D31%26issue%3DSuppl.%25201%26spage%3D65%26epage%3D70%26doi%3D10.1016%2FS0168-8278%2899%2980377-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit78b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zein, N. N.</span><span> </span><span class="NLM_article-title">Clinical significance of hepatitis C virus genotypes</span> <span class="citation_source-journal">Clin. Microbiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">235</span><span class="refDoi"> DOI: 10.1128/CMR.13.2.223-235.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FCMR.13.2.223-235.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10755999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtVOqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2000&pages=223-235&author=N.+N.+Zein&title=Clinical+significance+of+hepatitis+C+virus+genotypes&doi=10.1128%2FCMR.13.2.223-235.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78bR"><div class="casContent"><span class="casTitleNuber">78b</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of hepatitis C virus genotypes</span></div><div class="casAuthors">Zein, Nizar N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-235</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">0893-8512</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review with 149 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIyz_GrutS8LVg90H21EOLACvtfcHk0liOLxI8DuGl_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtVOqs7k%253D&md5=c3dbf9e23541db288f77cfabdf5c2e45</span></div><a href="/servlet/linkout?suffix=cit78b&amp;dbid=16384&amp;doi=10.1128%2FCMR.13.2.223-235.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.13.2.223-235.2000%26sid%3Dliteratum%253Aachs%26aulast%3DZein%26aufirst%3DN.%2BN.%26atitle%3DClinical%2520significance%2520of%2520hepatitis%2520C%2520virus%2520genotypes%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2000%26volume%3D13%26spage%3D223%26epage%3D235%26doi%3D10.1128%2FCMR.13.2.223-235.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit78c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Simmonds, P.</span><span> </span><span class="NLM_article-title">Genetic diversity and evolution of hepatitis C virus 15 years on</span> <span class="citation_source-journal">J. Gen. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">3173</span><span class="NLM_x">–</span> <span class="NLM_lpage">3188</span><span class="refDoi"> DOI: 10.1099/vir.0.80401-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1099%2Fvir.0.80401-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2004&pages=3173-3188&author=P.+Simmonds&title=Genetic+diversity+and+evolution+of+hepatitis+C+virus+15+years+on&doi=10.1099%2Fvir.0.80401-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78c&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.80401-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.80401-0%26sid%3Dliteratum%253Aachs%26aulast%3DSimmonds%26aufirst%3DP.%26atitle%3DGenetic%2520diversity%2520and%2520evolution%2520of%2520hepatitis%2520C%2520virus%252015%2520years%2520on%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2004%26volume%3D85%26spage%3D3173%26epage%3D3188%26doi%3D10.1099%2Fvir.0.80401-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit78d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Nainan, O. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alter, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruszon-Moran, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, F.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuillan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolis, H. S.</span><span> </span><span class="NLM_article-title">Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">478</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span><span class="refDoi"> DOI: 10.1053/j.gastro.2006.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1053%2Fj.gastro.2006.06.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2006&pages=478-484&author=O.+V.+Nainanauthor=M.+J.+Alterauthor=D.+Kruszon-Moranauthor=F.-X.+Gaoauthor=G.+Xiaauthor=G.+McQuillanauthor=H.+S.+Margolis&title=Hepatitis+C+virus+genotypes+and+viral+concentrations+in+participants+of+a+general+population+survey+in+the+United+States&doi=10.1053%2Fj.gastro.2006.06.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78d&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2006.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2006.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DNainan%26aufirst%3DO.%2BV.%26aulast%3DAlter%26aufirst%3DM.%2BJ.%26aulast%3DKruszon-Moran%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DF.-X.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DMcQuillan%26aufirst%3DG.%26aulast%3DMargolis%26aufirst%3DH.%2BS.%26atitle%3DHepatitis%2520C%2520virus%2520genotypes%2520and%2520viral%2520concentrations%2520in%2520participants%2520of%2520a%2520general%2520population%2520survey%2520in%2520the%2520United%2520States%26jtitle%3DGastroenterology%26date%3D2006%26volume%3D131%26spage%3D478%26epage%3D484%26doi%3D10.1053%2Fj.gastro.2006.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5057</span><span class="NLM_x">–</span> <span class="NLM_lpage">5071</span><span class="refDoi"> DOI: 10.1021/jm500335h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500335h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsFWgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5057-5071&author=M.+Belemaauthor=N.+A.+Meanwell&title=Discovery+of+daclatasvir%2C+a+pan-genotypic+hepatitis+C+virus+NS5A+replication+complex+inhibitor+with+potent+clinical+effect&doi=10.1021%2Fjm500335h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect</span></div><div class="casAuthors">Belema, Makonen; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5057-5071</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review. The discovery and development of the first-in-class hepatitis C virus (HCV) NS5A replication complex inhibitor daclatasvir provides a compelling example of the power of phenotypic screening to identify leads engaging novel targets in mechanistically unique ways.  HCV NS5A replication complex inhibitors are pan-genotypic in spectrum, and this mechanistic class provides the most potent HCV inhibitors in vitro that have been described to date.  Clin. trials with daclatasvir demonstrated a potent effect on reducing plasma viral load and, in combination with mechanistically orthogonal HCV inhibitors, established the ability to cure even the most difficult infections without the need for immune stimulation.  In this Drug Annotation, the authors describe the discovery of the original high-throughput screening lead BMS-858 and the chem. conundrum and challenges resolved in optimizing to daclatasvir as a clin. candidate and finally the authors summarize the results of select clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiU5qkfNyqXLVg90H21EOLACvtfcHk0lhT3h2NUij5fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsFWgurs%253D&md5=1428746b49ba356ce6993a58b143e5dc</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fjm500335h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500335h%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DDiscovery%2520of%2520daclatasvir%252C%2520a%2520pan-genotypic%2520hepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitor%2520with%2520potent%2520clinical%2520effect%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5057%26epage%3D5071%26doi%3D10.1021%2Fjm500335h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Belema, M.; Schnittman, S. M.; Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Case history: the discovery of the first hepatitis C virus NS5A replication complex inhibitor daclatasvir (Daklinza)</span>. Med. Chem. Rev.<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">, </span>manuscript in press</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+Belema&author=S.+M.+Schnittman&author=N.+A.+Meanwell&title=Case+history%3A+the+discovery+of+the+first+hepatitis+C+virus+NS5A+replication+complex+inhibitor+daclatasvir+%28Daklinza%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26atitle%3DCase%2520history%253A%2520the%2520discovery%2520of%2520the%2520first%2520hepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitor%2520daclatasvir%2520%2528Daklinza%2529%26jtitle%3DMed.%2520Chem.%2520Rev.%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripka, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">779</span><span class="NLM_x">–</span> <span class="NLM_lpage">784</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmcl.2012.11.086" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=779-784&author=O.+D.+Lopezauthor=V.+N.+Nguyenauthor=D.+R.+St.+Laurentauthor=M.+Belemaauthor=M.+H.+Serrano-Wuauthor=J.+T.+Goodrichauthor=F.+Yangauthor=Y.+Qiuauthor=A.+S.+Ripkaauthor=P.+T.+Nowerauthor=L.+Valeraauthor=M.+Liuauthor=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=R.+A.+Fridellauthor=J.+A.+Lemmauthor=M.+Gaoauthor=A.+C.+Goodauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+3%3A+discovery+of+potent+analogs+with+distinct+core+topologies&doi=10.1016%2Fj.bmcl.2012.11.086"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.086%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DGoodrich%26aufirst%3DJ.%2BT.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DRipka%26aufirst%3DA.%2BS.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25203%253A%2520discovery%2520of%2520potent%2520analogs%2520with%2520distinct%2520core%2520topologies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D779%26epage%3D784%26doi%3D10.1016%2Fj.bmcl.2012.11.086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakarla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamides</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6063</span><span class="NLM_x">–</span> <span class="NLM_lpage">6066</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmcl.2012.08.049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6063-6066&author=D.+R.+St.+Laurentauthor=M.+Belemaauthor=M.+Gaoauthor=J.+Goodrichauthor=R.+Kakarlaauthor=J.+O.+Knipeauthor=J.+A.+Lemmauthor=M.+Liuauthor=O.+D.+Lopezauthor=V.+N.+Nguyenauthor=P.+T.+Nowerauthor=D.+O%E2%80%99Boyleauthor=Y.+Qiuauthor=J.+L.+Romineauthor=M.+H.+Serrano-Wuauthor=J.-H.+Sunauthor=L.+Valeraauthor=F.+Yangauthor=X.+Yangauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+2%3A+investigation+of+stilbene+prolinamides&doi=10.1016%2Fj.bmcl.2012.08.049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.049%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGoodrich%26aufirst%3DJ.%26aulast%3DKakarla%26aufirst%3DR.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25202%253A%2520investigation%2520of%2520stilbene%2520prolinamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6063%26epage%3D6066%26doi%3D10.1016%2Fj.bmcl.2012.08.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 4: optimization for genotype 1a replicon inhibitory activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1976</span><span class="NLM_x">–</span> <span class="NLM_lpage">1994</span><span class="refDoi"> DOI: 10.1021/jm301796k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301796k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1976-1994&author=D.+R.+St.+Laurentauthor=M.+H.+Serrano-Wuauthor=M.+Belemaauthor=M.+Dingauthor=H.+Fangauthor=M.+Gaoauthor=J.+T.+Goodrichauthor=R.+G.+Krauseauthor=J.+A.+Lemmauthor=M.+Liuauthor=O.+D.+Lopezauthor=V.+N.+Nguyenauthor=P.+T.+Nowerauthor=D.+R.+O%E2%80%99Boyleauthor=B.+C.+Pearceauthor=J.+L.+Romineauthor=L.+Valeraauthor=J.-H.+Sunauthor=Y.-K.+Wangauthor=F.+Yangauthor=X.+Yangauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+4%3A+optimization+for+genotype+1a+replicon+inhibitory+activity&doi=10.1021%2Fjm301796k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fjm301796k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301796k%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGoodrich%26aufirst%3DJ.%2BT.%26aulast%3DKrause%26aufirst%3DR.%2BG.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DPearce%26aufirst%3DB.%2BC.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25204%253A%2520optimization%2520for%2520genotype%25201a%2520replicon%2520inhibitory%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1976%26epage%3D1994%26doi%3D10.1021%2Fjm301796k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4428</span><span class="NLM_x">–</span> <span class="NLM_lpage">4435</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmcl.2013.05.040" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4428-4435&author=M.+Belemaauthor=V.+N.+Nguyenauthor=D.+R.+St.+Laurentauthor=O.+D.+Lopezauthor=Y.+Qiuauthor=A.+C.+Goodauthor=P.+T.+Nowerauthor=L.+Valeraauthor=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=R.+A.+Fridellauthor=J.+A.+Lemmauthor=M.+Gaoauthor=J.+O.+Knipeauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+5%3A+discovery+of+potent+and+pan-genotypic+glycinamide+cap+derivatives&doi=10.1016%2Fj.bmcl.2013.05.040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.040%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25205%253A%2520discovery%2520of%2520potent%2520and%2520pan-genotypic%2520glycinamide%2520cap%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4428%26epage%3D4435%26doi%3D10.1016%2Fj.bmcl.2013.05.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A replication complex inhibitors. Part 6: the discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotype 1a and 1b replicons</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1995</span><span class="NLM_x">–</span> <span class="NLM_lpage">2012</span><span class="refDoi"> DOI: 10.1021/jm4016203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1995-2012&author=M.+Belemaauthor=V.+N.+Nguyenauthor=J.+L.+Romineauthor=D.+R.+St.+Laurentauthor=O.+D.+Lopezauthor=J.+Goodrichauthor=P.+T.+Nowerauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=R.+A.+Fridellauthor=M.+Gaoauthor=H.+Fangauthor=R.+G.+Krauseauthor=Y.-K.+Wangauthor=A.+J.+Oliverauthor=A.+C.+Goodauthor=J.+O.+Knipeauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=Hepatitis+C+virus+NS5A+replication+complex+inhibitors.+Part+6%3A+the+discovery+of+a+novel+and+highly+potent+biarylimidazole+chemotype+with+inhibitory+activity+toward+genotype+1a+and+1b+replicons&doi=10.1021%2Fjm4016203"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fjm4016203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016203%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DGoodrich%26aufirst%3DJ.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DKrause%26aufirst%3DR.%2BG.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DOliver%26aufirst%3DA.%2BJ.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25206%253A%2520the%2520discovery%2520of%2520a%2520novel%2520and%2520highly%2520potent%2520biarylimidazole%2520chemotype%2520with%2520inhibitory%2520activity%2520toward%2520genotype%25201a%2520and%25201b%2520replicons%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1995%26epage%3D2012%26doi%3D10.1021%2Fjm4016203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachand, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deon, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavoie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruediger, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chimalakonda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, L. G.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2013</span><span class="NLM_x">–</span> <span class="NLM_lpage">2032</span><span class="refDoi"> DOI: 10.1021/jm401836p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401836p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVWhsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2013-2032&author=M.+Belemaauthor=V.+N.+Nguyenauthor=C.+Bachandauthor=D.+H.+Deonauthor=J.+T.+Goodrichauthor=R.+Lavoieauthor=C.+A.+Jamesauthor=O.+D.+Lopezauthor=A.+Martelauthor=J.+L.+Romineauthor=E.+H.+Ruedigerauthor=L.+B.+Snyderauthor=D.+R.+St.+Laurentauthor=A.+C.+Goodauthor=D.+R.+Langleyauthor=A.+Chimalakondaauthor=A.+Furaauthor=J.+O.+Knipeauthor=P.+T.+Nowerauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=R.+A.+Fridellauthor=M.+Gaoauthor=N.+A.+Meanwellauthor=L.+G.+Hamann&title=Hepatitis+C+virus+NS5A+replication+complex+inhibitors%3A+the+discovery+of+daclatasvir&doi=10.1021%2Fjm401836p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir</span></div><div class="casAuthors">Belema, Makonen; Nguyen, Van N.; Bachand, Carol; Deon, Dan H.; Goodrich, Jason T.; James, Clint A.; Lavoie, Rico; Lopez, Omar D.; Martel, Alain; Romine, Jeffrey L.; Ruediger, Edward H.; Snyder, Lawrence B.; St. Laurent, Denis R.; Yang, Fukang; Zhu, Juliang; Wong, Henry S.; Langley, David R.; Adams, Stephen P.; Cantor, Glenn H.; Chimalakonda, Anjaneya; Fura, Aberra; Johnson, Benjamin M.; Knipe, Jay O.; Parker, Dawn D.; Santone, Kenneth S.; Fridell, Robert A.; Lemm, Julie A.; O'Boyle, Donald R., II; Colonno, Richard J.; Gao, Min; Meanwell, Nicholas A.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2013-2032</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The biphenyl derivs. I (R = NHCO2Me, NMe2) are prototypes of a novel class of NS5A replication complex inhibitors that demonstrate high inhibitory potency toward a panel of clin. relevant HCV strains encompassing genotypes 1-6.  However, these compds. exhibit poor systemic exposure in rat pharmacokinetic studies after oral dosing.  The structure-activity relationship investigations that improved the exposure properties of the parent bis-phenylimidazole chemotype, culminating in the identification of the highly potent NS5A replication complex inhibitor daclatasvir (II, X = 4,4'-biphenylene) are described.  An element crit. to success was the realization that the arylglycine cap of I (R = NHCO2Me) could be replaced with an alkylglycine deriv. and still maintain the high inhibitory potency of the series if accompanied with a stereoinversion, a finding that enabled a rapid optimization of exposure properties.  Compd. II had EC50 values of 50 and 9 pM toward genotype-1a and -1b replicons, resp., and oral bioavailabilities of 38-108% in preclin. species.  Compd. II provided clin. proof-of-concept for the NS5A replication complex inhibitor class, and regulatory approval to market it with the NS3/4A protease inhibitor asunaprevir for the treatment of HCV genotype-1b infection has recently been sought in Japan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYnJILm4L3mbVg90H21EOLACvtfcHk0lgTM25FLmsbSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVWhsr8%253D&md5=ca5c44e9b15fda7cb4632066ef2a673a</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fjm401836p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401836p%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DBachand%26aufirst%3DC.%26aulast%3DDeon%26aufirst%3DD.%2BH.%26aulast%3DGoodrich%26aufirst%3DJ.%2BT.%26aulast%3DLavoie%26aufirst%3DR.%26aulast%3DJames%26aufirst%3DC.%2BA.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DMartel%26aufirst%3DA.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DRuediger%26aufirst%3DE.%2BH.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitors%253A%2520the%2520discovery%2520of%2520daclatasvir%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2013%26epage%3D2032%26doi%3D10.1021%2Fjm401836p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Wakita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietschmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Date, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murthy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habermann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraeusslich, H.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizokami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, T. J.</span><span> </span><span class="NLM_article-title">Production of infectious hepatitis C virus in tissue culture from a cloned viral genome</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">791</span><span class="NLM_x">–</span> <span class="NLM_lpage">796</span><span class="refDoi"> DOI: 10.1038/nm1268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnm1268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=15951748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1aju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=791-796&author=T.+Wakitaauthor=T.+Pietschmannauthor=T.+Katoauthor=T.+Dateauthor=M.+Miyamotoauthor=Z.+Zhaoauthor=K.+Murthyauthor=A.+Habermannauthor=H.-G.+Kraeusslichauthor=M.+Mizokamiauthor=R.+Bartenschlagerauthor=T.+J.+Liang&title=Production+of+infectious+hepatitis+C+virus+in+tissue+culture+from+a+cloned+viral+genome&doi=10.1038%2Fnm1268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Production of infectious hepatitis C virus in tissue culture from a cloned viral genome</span></div><div class="casAuthors">Wakita, Takaji; Pietschmann, Thomas; Kato, Takanobu; Date, Tomoko; Miyamoto, Michiko; Zhao, Zijiang; Murthy, Krishna; Habermann, Anja; Kraeusslich, Hans-Georg; Mizokami, Masashi; Bartenschlager, Ralf; Liang, T. Jake</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">791-796</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection causes chronic liver diseases and is a global public health problem.  Detailed analyses of HCV have been hampered by the lack of viral culture systems.  Subgenomic replicons of the JFH1 genotype 2a strain cloned from an individual with fulminant hepatitis replicate efficiently in cell culture.  Here we show that the JFH1 genome replicates efficiently and supports secretion of viral particles after transfection into a human hepatoma cell line (Huh7).  Particles have a d. of about 1.15-1.17 g/mL and a spherical morphol. with an av. diam. of about 55 nm.  Secreted virus is infectious for Huh7 cells and infectivity can be neutralized by CD81-specific antibodies and by Igs from chronically infected individuals.  The cell culture-generated HCV is infectious for chimpanzee.  This system provides a powerful tool for studying the viral life cycle and developing antiviral strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqra8QhVAEyJ7Vg90H21EOLACvtfcHk0lgTM25FLmsbSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1aju7c%253D&md5=91235eedec98d1b3d6a4bc4bc68f6d11</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fnm1268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1268%26sid%3Dliteratum%253Aachs%26aulast%3DWakita%26aufirst%3DT.%26aulast%3DPietschmann%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DT.%26aulast%3DDate%26aufirst%3DT.%26aulast%3DMiyamoto%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DMurthy%26aufirst%3DK.%26aulast%3DHabermann%26aufirst%3DA.%26aulast%3DKraeusslich%26aufirst%3DH.-G.%26aulast%3DMizokami%26aufirst%3DM.%26aulast%3DBartenschlager%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DT.%2BJ.%26atitle%3DProduction%2520of%2520infectious%2520hepatitis%2520C%2520virus%2520in%2520tissue%2520culture%2520from%2520a%2520cloned%2520viral%2520genome%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D791%26epage%3D796%26doi%3D10.1038%2Fnm1268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ascher, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wielens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nero, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doughty, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M. W.</span><span> </span><span class="NLM_article-title">Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_elocation-id">4765</span><span class="refDoi"> DOI: 10.1038/srep04765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fsrep04765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24755925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC2cnlvFOktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&author=D.+B.+Ascherauthor=J.+Wielensauthor=T.+L.+Neroauthor=L.+Doughtyauthor=C.+J.+Mortonauthor=M.+W.+Parker&title=Potent+hepatitis+C+inhibitors+bind+directly+to+NS5A+and+reduce+its+affinity+for+RNA&doi=10.1038%2Fsrep04765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88aR"><div class="casContent"><span class="casTitleNuber">88a</span><div class="casTitle"><span class="NLM_cas:atitle">Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA</span></div><div class="casAuthors">Ascher David B; Nero Tracy L; Doughty Larissa; Morton Craig J; Wielens Jerome; Parker Michael W</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4765</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hepatitis C virus (HCV) infection affects more than 170 million people.  The high genetic variability of HCV and the rapid development of drug-resistant strains are driving the urgent search for new direct-acting antiviral agents.  A new class of agents has recently been developed that are believed to target the HCV protein NS5A although precisely where they interact and how they affect function is unknown.  Here we describe an in vitro assay based on microscale thermophoresis and demonstrate that two clinically relevant inhibitors bind tightly to NS5A domain 1 and inhibit RNA binding.  Conversely, RNA binding inhibits compound binding.  The compounds bind more weakly to known resistance mutants L31V and Y93H.  The compounds do not affect NS5A dimerisation.  We propose that current NS5A inhibitors act by favouring a dimeric structure of NS5A that does not bind RNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxEeB9BnDI1kloaUqgkFHkfW6udTcc2ebb4N3WhyaZgbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnlvFOktw%253D%253D&md5=2496f9f19e614aa099e18509e86c9e02</span></div><a href="/servlet/linkout?suffix=cit88a&amp;dbid=16384&amp;doi=10.1038%2Fsrep04765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep04765%26sid%3Dliteratum%253Aachs%26aulast%3DAscher%26aufirst%3DD.%2BB.%26aulast%3DWielens%26aufirst%3DJ.%26aulast%3DNero%26aufirst%3DT.%2BL.%26aulast%3DDoughty%26aufirst%3DL.%26aulast%3DMorton%26aufirst%3DC.%2BJ.%26aulast%3DParker%26aufirst%3DM.%2BW.%26atitle%3DPotent%2520hepatitis%2520C%2520inhibitors%2520bind%2520directly%2520to%2520NS5A%2520and%2520reduce%2520its%2520affinity%2520for%2520RNA%26jtitle%3DSci.%2520Rep.%26date%3D2014%26volume%3D4%26doi%3D10.1038%2Fsrep04765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit88b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kwon, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niedziela-Majka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brendza, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Link, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakowicz, R.</span><span> </span><span class="NLM_article-title">Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">e0122844</span><span class="refDoi"> DOI: 10.1371/journal.pone.0122844</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1371%2Fjournal.pone.0122844" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0122844&issue=4&author=H.+J.+Kwonauthor=W.+Xingauthor=K.+Chanauthor=A.+Niedziela-Majkaauthor=K.+M.+Brendzaauthor=T.+Kirschbergauthor=D.+Katoauthor=J.+O.+Linkauthor=G.+Chengauthor=X.+Liuauthor=R.+Sakowicz&title=Direct+binding+of+ledipasvir+to+HCV+NS5A%3A+mechanism+of+resistance+to+an+HCV+antiviral+agent&doi=10.1371%2Fjournal.pone.0122844"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0122844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0122844%26sid%3Dliteratum%253Aachs%26aulast%3DKwon%26aufirst%3DH.%2BJ.%26aulast%3DXing%26aufirst%3DW.%26aulast%3DChan%26aufirst%3DK.%26aulast%3DNiedziela-Majka%26aufirst%3DA.%26aulast%3DBrendza%26aufirst%3DK.%2BM.%26aulast%3DKirschberg%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DD.%26aulast%3DLink%26aufirst%3DJ.%2BO.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSakowicz%26aufirst%3DR.%26atitle%3DDirect%2520binding%2520of%2520ledipasvir%2520to%2520HCV%2520NS5A%253A%2520mechanism%2520of%2520resistance%2520to%2520an%2520HCV%2520antiviral%2520agent%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D4%26spage%3De0122844%26doi%3D10.1371%2Fjournal.pone.0122844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Tellinghuisen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotrigiano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">435</span><span class="NLM_x">, </span> <span class="NLM_fpage">374</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span><span class="refDoi"> DOI: 10.1038/nature03580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnature03580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=15902263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkt1Wkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=435&publication_year=2005&pages=374-379&author=T.+L.+Tellinghuisenauthor=J.+Marcotrigianoauthor=C.+M.+Rice&title=Structure+of+the+zinc-binding+domain+of+an+essential+component+of+the+hepatitis+C+virus+replicase&doi=10.1038%2Fnature03580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase</span></div><div class="casAuthors">Tellinghuisen, Timothy L.; Marcotrigiano, Joseph; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">435</span>
        (<span class="NLM_cas:issue">7040</span>),
    <span class="NLM_cas:pages">374-379</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a human pathogen affecting nearly 3% of the world's population.  Chronic infections can lead to cirrhosis and liver cancer.  The RNA replication machine of HCV is a multi-subunit membrane-assocd. complex.  The non-structural protein NS5A is an active component of HCV replicase, as well as a pivotal regulator of replication and a modulator of cellular processes ranging from innate immunity to dysregulated cell growth.  NS5A is a large phosphoprotein (56-58 kDa) with an amphipathic α-helix at its amino terminus that promotes membrane assocn.  After this helix region, NS5A is organized into three domains.  The N-terminal domain (domain I) coordinates a single zinc atom per protein mol.  Mutations disrupting either the membrane anchor or zinc binding of NS5A are lethal for RNA replication.  However, probing the role of NS5A in replication has been hampered by a lack of structural information about this multifunctional protein.  Here we report the structure of NS5A domain I at 2.5-Å resoln., which contains a novel fold, a new zinc-coordination motif and a disulfide bond.  We use mol. surface anal. to suggest the location of protein-, RNA- and membrane-interaction sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe6tBo4Nrq7rVg90H21EOLACvtfcHk0lhN02bicEcfCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkt1Wkt7Y%253D&md5=0f74b457e5921d4aa1993df8e9a08d46</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fnature03580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03580%26sid%3Dliteratum%253Aachs%26aulast%3DTellinghuisen%26aufirst%3DT.%2BL.%26aulast%3DMarcotrigiano%26aufirst%3DJ.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DStructure%2520of%2520the%2520zinc-binding%2520domain%2520of%2520an%2520essential%2520component%2520of%2520the%2520hepatitis%2520C%2520virus%2520replicase%26jtitle%3DNature%26date%3D2005%26volume%3D435%26spage%3D374%26epage%3D379%26doi%3D10.1038%2Fnature03580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Love, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodsky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, C. N.</span><span> </span><span class="NLM_article-title">Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">4395</span><span class="NLM_x">–</span> <span class="NLM_lpage">4403</span><span class="refDoi"> DOI: 10.1128/JVI.02352-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FJVI.02352-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=19244328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlt1Kqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2009&pages=4395-4403&author=R.+A.+Loveauthor=O.+Brodskyauthor=M.+J.+Hickeyauthor=P.+A.+Wellsauthor=C.+N.+Cronin&title=Crystal+structure+of+a+novel+dimeric+form+of+NS5A+domain+I+protein+from+hepatitis+C+virus&doi=10.1128%2FJVI.02352-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90aR"><div class="casContent"><span class="casTitleNuber">90a</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus</span></div><div class="casAuthors">Love, Robert A.; Brodsky, Oleg; Hickey, Michael J.; Wells, Peter A.; Cronin, Ciaran N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4395-4403</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A new protein expression vector design utilizing an N-terminal six-histidine tag and tobacco etch virus protease cleavage site upstream of the hepatitis C virus NS5A sequence has resulted in a more straightforward purifn. method and improved yields of purified NS5A domain I protein.  High-resoln. diffracting crystals of NS5A domain I (amino acids 33 to 202) [NS5A(33-202)] were obtained by using detergent additive crystn. screens, leading to the structure of a homodimer which is organized differently from that published previously, yet is consistent with a membrane assocn. model for NS5A.  The monomer-monomer interface of NS5A(33-202) features an extensive buried surface area involving the most-highly conserved face of each monomer.  The two alternate structural forms of domain I now available may be indicative of the multiple roles emerging for NS5A in viral RNA replication and viral particle assembly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNYc2eJlR_hLVg90H21EOLACvtfcHk0lhN02bicEcfCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlt1Kqu7s%253D&md5=70ea61461a99afb962e76a4c3f5495db</span></div><a href="/servlet/linkout?suffix=cit90a&amp;dbid=16384&amp;doi=10.1128%2FJVI.02352-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02352-08%26sid%3Dliteratum%253Aachs%26aulast%3DLove%26aufirst%3DR.%2BA.%26aulast%3DBrodsky%26aufirst%3DO.%26aulast%3DHickey%26aufirst%3DM.%2BJ.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DCronin%26aufirst%3DC.%2BN.%26atitle%3DCrystal%2520structure%2520of%2520a%2520novel%2520dimeric%2520form%2520of%2520NS5A%2520domain%2520I%2520protein%2520from%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Virol.%26date%3D2009%26volume%3D83%26spage%3D4395%26epage%3D4403%26doi%3D10.1128%2FJVI.02352-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit90b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lambert, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedgethorne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, S. J.</span><span> </span><span class="NLM_article-title">The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">723</span><span class="NLM_x">–</span> <span class="NLM_lpage">734</span><span class="refDoi"> DOI: 10.1002/pro.2456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fpro.2456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24639329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXot1ynsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=723-734&author=S.+M.+Lambertauthor=D.+R.+Langleyauthor=J.+A.+Garnettauthor=K.+Hedgethorneauthor=N.+A.+Meanwellauthor=S.+J.+Matthews&title=The+crystal+structure+of+NS5A+domain+1+from+genotype+1a+reveals+new+clues+to+the+mechanism+of+action+for+dimeric+HCV+inhibitors&doi=10.1002%2Fpro.2456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90bR"><div class="casContent"><span class="casTitleNuber">90b</span><div class="casTitle"><span class="NLM_cas:atitle">The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors</span></div><div class="casAuthors">Lambert, Sebastian M.; Langley, David R.; Garnett, James A.; Angell, Richard; Hedgethorne, Katy; Meanwell, Nicholas A.; Matthews, Steve J.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">723-734</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">New direct acting antivirals (DAAs) such as daclatasvir (DCV; BMS-790052), which target NS5A function with picomolar potency, are showing promise in clin. trials.  The exact nature of how these compds. have an inhibitory effect on HCV is unknown; however, major resistance mutations appear in the N-terminal region of NS5A that include the amphipathic helix and domain 1.  The dimeric symmetry of these compds. suggests that they act on a dimer of NS5A, which is also consistent with the presence of dimers in crystals of NS5A domain 1 from genotype 1b.  Genotype 1a HCV is less potently affected by these compds. and resistance mutations have a greater effect than in the 1b genotypes.  We have obtained crystals of domain 1 of the important 1a NS5A homolog and intriguingly, our X-ray crystal structure reveals two new dimeric forms of this domain.  Furthermore, the high solvent content (75%) makes it ideal for ligand-soaking.  Daclatasvir (DCV) shows twofold symmetry suggesting NS5A dimers may be of physiol. importance and serve as potential binding sites for DCV.  These dimers also allow for new conformations of a NS5A expansive network which could explain its operation on the membranous web.  Addnl., sulfates bound in the crystal structure may provide evidence for the previously proposed RNA binding groove, or explain regulation of NS5A domain 2 and 3 function and phosphorylation, by domain 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxWMcrYirNTLVg90H21EOLACvtfcHk0ljmpmvhmp407w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXot1ynsLo%253D&md5=726ec7c39e3be54c1924dacd16f20263</span></div><a href="/servlet/linkout?suffix=cit90b&amp;dbid=16384&amp;doi=10.1002%2Fpro.2456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.2456%26sid%3Dliteratum%253Aachs%26aulast%3DLambert%26aufirst%3DS.%2BM.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DGarnett%26aufirst%3DJ.%2BA.%26aulast%3DHedgethorne%26aufirst%3DK.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DMatthews%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520crystal%2520structure%2520of%2520NS5A%2520domain%25201%2520from%2520genotype%25201a%2520reveals%2520new%2520clues%2520to%2520the%2520mechanism%2520of%2520action%2520for%2520dimeric%2520HCV%2520inhibitors%26jtitle%3DProtein%2520Sci.%26date%3D2014%26volume%3D23%26spage%3D723%26epage%3D734%26doi%3D10.1002%2Fpro.2456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Appel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">From structure to function: new insights into hepatitis C virus RNA replication</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">9833</span><span class="NLM_x">–</span> <span class="NLM_lpage">9836</span><span class="refDoi"> DOI: 10.1074/jbc.R500026200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1074%2Fjbc.R500026200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=9833-9836&author=N.+Appelauthor=T.+Schallerauthor=F.+Peninauthor=R.+Bartenschlager&title=From+structure+to+function%3A+new+insights+into+hepatitis+C+virus+RNA+replication&doi=10.1074%2Fjbc.R500026200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R500026200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R500026200%26sid%3Dliteratum%253Aachs%26aulast%3DAppel%26aufirst%3DN.%26aulast%3DSchaller%26aufirst%3DT.%26aulast%3DPenin%26aufirst%3DF.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DFrom%2520structure%2520to%2520function%253A%2520new%2520insights%2520into%2520hepatitis%2520C%2520virus%2520RNA%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D9833%26epage%3D9836%26doi%3D10.1074%2Fjbc.R500026200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moulin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nophsker, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">527</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">258</span><span class="refDoi"> DOI: 10.1038/nature15711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnature15711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26536115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOrtLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=527&publication_year=2015&pages=245-258&author=J.-H.+Sunauthor=D.+R.+O%E2%80%99Boyleauthor=R.+A.+Fridellauthor=D.+R.+Langleyauthor=C.+Wangauthor=S.+B.+Robertsauthor=P.+Nowerauthor=B.+M.+Johnsonauthor=F.+Moulinauthor=M.+J.+Nophskerauthor=Y.-K.+Wangauthor=M.+Liuauthor=K.+Rigatauthor=Y.+Tuauthor=P.+Hewawasamauthor=J.+Kadowauthor=N.+A.+Meanwellauthor=M.+Cockettauthor=J.+A.+Lemmauthor=M.+Kramerauthor=M.+Belemaauthor=M.+Gao&title=Resensitizing+daclatasvir-resistant+hepatitis+C+variants+by+allosteric+modulation+of+NS5A&doi=10.1038%2Fnature15711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A</span></div><div class="casAuthors">Sun, Jin-Hua; O'Boyle, Donald R., II; Fridell, Robert A.; Langley, David R.; Wang, Chunfu; Roberts, Susan B.; Nower, Peter; Johnson, Benjamin M.; Moulin, Frederic; Nophsker, Michelle J.; Wang, Ying-Kai; Liu, Mengping; Rigat, Karen; Tu, Yong; Hewawasam, Piyasena; Kadow, John; Meanwell, Nicholas A.; Cockett, Mark; Lemm, Julie A.; Kramer, Melissa; Belema, Makonen; Gao, Min</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">527</span>
        (<span class="NLM_cas:issue">7577</span>),
    <span class="NLM_cas:pages">245-248</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">It is estd. that more than 170 million people are infected with hepatitis C virus (HCV) worldwide.  Clin. trials have demonstrated that, for the first time in human history, the potential exists to eradicate a chronic viral disease using combination therapies that contain only direct-acting antiviral agents.  HCV non-structural protein 5A (NS5A) is a multifunctional protein required for several stages of the virus replication cycle.  NS5A replication complex inhibitors, exemplified by daclatasvir (DCV; also known as BMS-790052 and Daklinza), belong to the most potent class of direct-acting anti-HCV agents described so far, with in vitro activity in the picomolar (pM) to low nanomolar (nM) range.  The potency obsd. in vitro has translated into clin. efficacy, with HCV RNA declining by ∼3-4 log10 in infected patients after administration of single oral doses of DCV.  Understanding the exceptional potency of DCV was a key objective of this study.  Although DCV and an NS5A inhibitor analog (Syn-395) are inactive against certain NS5A resistance variants, combinations of the pair enhance DCV potency by >1000-fold, restoring activity to the pM range.  This synergistic effect was validated in vivo using an HCV-infected chimeric mouse model.  The cooperative interaction of a pair of compds. suggests that NS5A protein mols. communicate with each other: one inhibitor binds to resistant NS5A, causing a conformational change that is transmitted to adjacent NS5As, resensitizing resistant NS5A so that the second inhibitor can act to restore inhibition.  This unprecedented synergistic anti-HCV activity also enhances the resistance barrier of DCV, providing addnl. options for HCV combination therapy and new insight into the role of NS5A in the HCV replication cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz6u8iN4_EYbVg90H21EOLACvtfcHk0ljmpmvhmp407w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOrtLbN&md5=b5eb912480b1c321b17701cc5ef30204</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fnature15711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature15711%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DNower%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DB.%2BM.%26aulast%3DMoulin%26aufirst%3DF.%26aulast%3DNophsker%26aufirst%3DM.%2BJ.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DRigat%26aufirst%3DK.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DKadow%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DCockett%26aufirst%3DM.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DKramer%26aufirst%3DM.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DResensitizing%2520daclatasvir-resistant%2520hepatitis%2520C%2520variants%2520by%2520allosteric%2520modulation%2520of%2520NS5A%26jtitle%3DNature%26date%3D2015%26volume%3D527%26spage%3D245%26epage%3D258%26doi%3D10.1038%2Fnature15711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargittai, M. R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raney, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span> </span><span class="NLM_article-title">Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">36417</span><span class="NLM_x">–</span> <span class="NLM_lpage">36428</span><span class="refDoi"> DOI: 10.1074/jbc.M508175200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1074%2Fjbc.M508175200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=36417-36428&author=L.+Huangauthor=J.+Hwangauthor=S.+D.+Sharmaauthor=M.+R.+S.+Hargittaiauthor=Y.+Chenauthor=J.+J.+Arnoldauthor=K.+D.+Raneyauthor=C.+E.+Cameron&title=Hepatitis+C+virus+nonstructural+protein+5A+%28NS5A%29+is+an+RNA-binding+protein&doi=10.1074%2Fjbc.M508175200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93a&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M508175200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M508175200%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DHwang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BD.%26aulast%3DHargittai%26aufirst%3DM.%2BR.%2BS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DArnold%26aufirst%3DJ.%2BJ.%26aulast%3DRaney%26aufirst%3DK.%2BD.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26atitle%3DHepatitis%2520C%2520virus%2520nonstructural%2520protein%25205A%2520%2528NS5A%2529%2520is%2520an%2520RNA-binding%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D36417%26epage%3D36428%26doi%3D10.1074%2Fjbc.M508175200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit93b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hwang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordek, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kihara, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raney, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span> </span><span class="NLM_article-title">Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">12480</span><span class="NLM_x">–</span> <span class="NLM_lpage">12491</span><span class="refDoi"> DOI: 10.1128/JVI.01319-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FJVI.01319-10" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=12480-12491&author=J.+Hwangauthor=L.+Huangauthor=D.+G.+Cordekauthor=R.+Vaughanauthor=S.+L.+Reynoldsauthor=G.+Kiharaauthor=K.+D.+Raneyauthor=C.+C.+Kaoauthor=C.+E.+Cameron&title=Hepatitis+C+virus+nonstructural+protein+5A%3A+biochemical+characterization+of+a+novel+structural+class+of+RNA-binding+proteins&doi=10.1128%2FJVI.01319-10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93b&amp;dbid=16384&amp;doi=10.1128%2FJVI.01319-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01319-10%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DCordek%26aufirst%3DD.%2BG.%26aulast%3DVaughan%26aufirst%3DR.%26aulast%3DReynolds%26aufirst%3DS.%2BL.%26aulast%3DKihara%26aufirst%3DG.%26aulast%3DRaney%26aufirst%3DK.%2BD.%26aulast%3DKao%26aufirst%3DC.%2BC.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26atitle%3DHepatitis%2520C%2520virus%2520nonstructural%2520protein%25205A%253A%2520biochemical%2520characterization%2520of%2520a%2520novel%2520structural%2520class%2520of%2520RNA-binding%2520proteins%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D12480%26epage%3D12491%26doi%3D10.1128%2FJVI.01319-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Lim, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterju, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordek, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Rivera, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Targett-Adams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallay, P. A.</span><span> </span><span class="NLM_article-title">Correlation between NS5A dimerization and HCV replication</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">30861</span><span class="NLM_x">–</span> <span class="NLM_lpage">30873</span><span class="refDoi"> DOI: 10.1074/jbc.M112.376822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1074%2Fjbc.M112.376822" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=30861-30873&author=P.+J.+Limauthor=U.+Chatterjuauthor=D.+Cordekauthor=S.+D.+Sharmaauthor=J.+A.+Garcia-Riveraauthor=C.+E.+Cameronauthor=K.+Linauthor=P.+Targett-Adamsauthor=P.+A.+Gallay&title=Correlation+between+NS5A+dimerization+and+HCV+replication&doi=10.1074%2Fjbc.M112.376822"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.376822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.376822%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DP.%2BJ.%26aulast%3DChatterju%26aufirst%3DU.%26aulast%3DCordek%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DS.%2BD.%26aulast%3DGarcia-Rivera%26aufirst%3DJ.%2BA.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DTargett-Adams%26aufirst%3DP.%26aulast%3DGallay%26aufirst%3DP.%2BA.%26atitle%3DCorrelation%2520between%2520NS5A%2520dimerization%2520and%2520HCV%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D30861%26epage%3D30873%26doi%3D10.1074%2Fjbc.M112.376822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Guedj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansone, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotler, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Layden, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uprichard, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">3991</span><span class="NLM_x">–</span> <span class="NLM_lpage">3996</span><span class="refDoi"> DOI: 10.1073/pnas.1203110110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1073%2Fpnas.1203110110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=23431163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVWms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=3991-3996&author=J.+Guedjauthor=H.+Dahariauthor=L.+Rongauthor=N.+D.+Sansoneauthor=R.+E.+Nettlesauthor=S.+J.+Cotlerauthor=T.+J.+Laydenauthor=S.+L.+Uprichardauthor=A.+S.+Perelson&title=Modeling+shows+that+the+NS5A+inhibitor+daclatasvir+has+two+modes+of+action+and+yields+a+shorter+estimate+of+the+hepatitis+C+virus+half-life&doi=10.1073%2Fpnas.1203110110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life</span></div><div class="casAuthors">Guedj, Jeremie; Dahari, Harel; Rong, Libin; Sansone, Natasha D.; Nettles, Richard E.; Cotler, Scott J.; Layden, Thomas J.; Uprichard, Susan L.; Perelson, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3991-3996, S3991/1-S3991/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The nonstructural 5A (NS5A) protein is a target for drug development against hepatitis C virus (HCV).  Interestingly, the NS5A inhibitor daclatasvir (BMS-790052) caused a decrease in serum HCV RNA levels by about two orders of magnitude within 6 h of administration.  However, NS5A has no known enzymic functions, making it difficult to understand daclatasvir's mode of action (MOA) and to est. its antiviral effectiveness.  Modeling viral kinetics during therapy has provided important insights into the MOA and effectiveness of a variety of anti-HCV agents.  Here, we show that understanding the effects of daclatasvir in vivo requires a multiscale model that incorporates drug effects on the HCV intracellular lifecycle, and we validated this approach with in vitro HCV infection expts.  The model predicts that daclatasvir efficiently blocks two distinct stages of the viral lifecycle, namely viral RNA synthesis and virion assembly/secretion with mean effectiveness of 99% and 99.8%, resp., and yields a more precise est. of the serum HCV half-life, 45 min, i.e., around four times shorter than previous ests.  Intracellular HCV RNA in HCV-infected cells treated with daclatasvir and the HCV polymerase inhibitor NM107 showed a similar pattern of decline.  However, daclatasvir treatment led to an immediate and rapid decline of extracellular HCV titers compared to a delayed (6-9 h) and slower decline with NM107, confirming an effect of daclatasvir on both viral replication and assembly/secretion.  The multiscale modeling approach, validated with in vitro kinetic expts., brings a unique conceptual framework for understanding the mechanism of action of a variety of agents in development for the treatment of HCV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSYdT4WQUN7LVg90H21EOLACvtfcHk0liCEKffdrn-rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVWms7g%253D&md5=81f3b8c49b97120f70b440211b4bf979</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1203110110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1203110110%26sid%3Dliteratum%253Aachs%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DRong%26aufirst%3DL.%26aulast%3DSansone%26aufirst%3DN.%2BD.%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DCotler%26aufirst%3DS.%2BJ.%26aulast%3DLayden%26aufirst%3DT.%2BJ.%26aulast%3DUprichard%26aufirst%3DS.%2BL.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DModeling%2520shows%2520that%2520the%2520NS5A%2520inhibitor%2520daclatasvir%2520has%2520two%2520modes%2520of%2520action%2520and%2520yields%2520a%2520shorter%2520estimate%2520of%2520the%2520hepatitis%2520C%2520virus%2520half-life%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D3991%26epage%3D3996%26doi%3D10.1073%2Fpnas.1203110110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Appel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zayas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krijnse-Locker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friebe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1000035</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1000035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1371%2Fjournal.ppat.1000035" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=e1000035&author=N.+Appelauthor=M.+Zayasauthor=S.+Millerauthor=J.+Krijnse-Lockerauthor=T.+Schallerauthor=P.+Friebeauthor=S.+Kallisauthor=U.+Engelauthor=R.+Bartenschlager&title=Essential+role+of+domain+III+of+nonstructural+protein+5A+for+hepatitis+C+virus+infectious+particle+assembly&doi=10.1371%2Fjournal.ppat.1000035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96a&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1000035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1000035%26sid%3Dliteratum%253Aachs%26aulast%3DAppel%26aufirst%3DN.%26aulast%3DZayas%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DS.%26aulast%3DKrijnse-Locker%26aufirst%3DJ.%26aulast%3DSchaller%26aufirst%3DT.%26aulast%3DFriebe%26aufirst%3DP.%26aulast%3DKallis%26aufirst%3DS.%26aulast%3DEngel%26aufirst%3DU.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DEssential%2520role%2520of%2520domain%2520III%2520of%2520nonstructural%2520protein%25205A%2520for%2520hepatitis%2520C%2520virus%2520infectious%2520particle%2520assembly%26jtitle%3DPLoS%2520Pathog.%26date%3D2008%26volume%3D4%26spage%3De1000035%26doi%3D10.1371%2Fjournal.ppat.1000035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit96b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tellinghuisen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foss, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treadaway, J.</span><span> </span><span class="NLM_article-title">Regulation of hepatitis C virion production via phosphorylation of the NS5A protein</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1000032</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1000032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1371%2Fjournal.ppat.1000032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=e1000032&author=T.+L.+Tellinghuisenauthor=K.+L.+Fossauthor=J.+Treadaway&title=Regulation+of+hepatitis+C+virion+production+via+phosphorylation+of+the+NS5A+protein&doi=10.1371%2Fjournal.ppat.1000032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1000032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1000032%26sid%3Dliteratum%253Aachs%26aulast%3DTellinghuisen%26aufirst%3DT.%2BL.%26aulast%3DFoss%26aufirst%3DK.%2BL.%26aulast%3DTreadaway%26aufirst%3DJ.%26atitle%3DRegulation%2520of%2520hepatitis%2520C%2520virion%2520production%2520via%2520phosphorylation%2520of%2520the%2520NS5A%2520protein%26jtitle%3DPLoS%2520Pathog.%26date%3D2008%26volume%3D4%26spage%3De1000032%26doi%3D10.1371%2Fjournal.ppat.1000032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit96c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hughes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, M.</span><span> </span><span class="NLM_article-title">Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles</span> <span class="citation_source-journal">J. Gen. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">1329</span><span class="NLM_x">–</span> <span class="NLM_lpage">1334</span><span class="refDoi"> DOI: 10.1099/vir.0.009332-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1099%2Fvir.0.009332-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=19264615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmvFCls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2009&pages=1329-1334&author=M.+Hughesauthor=S.+Griffinauthor=M.+Harris&title=Domain+III+of+NS5A+contributes+to+both+RNA+replication+and+assembly+of+hepatitis+C+virus+particles&doi=10.1099%2Fvir.0.009332-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96cR"><div class="casContent"><span class="casTitleNuber">96c</span><div class="casTitle"><span class="NLM_cas:atitle">Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles</span></div><div class="casAuthors">Hughes, Mair; Griffin, Stephen; Harris, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1329-1334</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) NS5A protein plays a crit. role in viral RNA replication and has recently been shown to play a role in particle prodn. in the infectious genotype 2a HCV clone (JFH-1).  Here, we show that alanine substitutions of serines 2428/2430 within the C-terminal domain III of NS5A do not affect subgenomic replicon RNA replication but do reduce particle prodn.  In contrast, substitution of serines 2390/2391 had no effect on either RNA replication or particle prodn.  Relative to genotype 1, all genotype 2 HCV isolates contain a 19 residue insertion near the C terminus of domain III which, when deleted (Δ2408-2426), resulted in a delay to both RNA replication and particle prodn.  None of these mutations affected the ratio of basal to hyperphosphorylated NS5A, suggesting that serines between residues 2390 and 2430 are not phosphorylated.  We propose that although domain III is dispensable for RNA replication, it nevertheless influences this process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJlH2lNItkx7Vg90H21EOLACvtfcHk0liO88-YuNOmFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmvFCls7s%253D&md5=efda79b2a76a7c4b1a76980d22b91904</span></div><a href="/servlet/linkout?suffix=cit96c&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.009332-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.009332-0%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DM.%26atitle%3DDomain%2520III%2520of%2520NS5A%2520contributes%2520to%2520both%2520RNA%2520replication%2520and%2520assembly%2520of%2520hepatitis%2520C%2520virus%2520particles%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2009%26volume%3D90%26spage%3D1329%26epage%3D1334%26doi%3D10.1099%2Fvir.0.009332-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit96d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Lindenbach, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">The ins and outs of hepatitis C virus entry and assembly</span> <span class="citation_source-journal">Nat. Rev. Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">688</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span><span class="refDoi"> DOI: 10.1038/nrmicro3098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrmicro3098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24018384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSku7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=688-700&author=B.+D.+Lindenbachauthor=C.+M.+Rice&title=The+ins+and+outs+of+hepatitis+C+virus+entry+and+assembly&doi=10.1038%2Fnrmicro3098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96dR"><div class="casContent"><span class="casTitleNuber">96d</span><div class="casTitle"><span class="NLM_cas:atitle">The ins and outs of Hepatitis C virus entry and assembly</span></div><div class="casAuthors">Lindenbach, Brett D.; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">688-700</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus, a major human pathogen, produces infectious virus particles with several unique features, such as an ability to interact with serum lipoproteins, a dizzyingly complicated process of virus entry, and a pathway of virus assembly and release that is closely linked to lipoprotein secretion.  Here, we review these unique features, with an emphasis on recent discoveries concerning virus particle structure, virus entry and virus particle assembly and release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ9p4sl_7FALVg90H21EOLACvtfcHk0lgBX0cZC4LOXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSku7rE&md5=1153290b9a49d66f837935f0de45be7f</span></div><a href="/servlet/linkout?suffix=cit96d&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro3098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro3098%26sid%3Dliteratum%253Aachs%26aulast%3DLindenbach%26aufirst%3DB.%2BD.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DThe%2520ins%2520and%2520outs%2520of%2520hepatitis%2520C%2520virus%2520entry%2520and%2520assembly%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2013%26volume%3D11%26spage%3D688%26epage%3D700%26doi%3D10.1038%2Fnrmicro3098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hashimoto, H.; Mizutani, K.; Yoshida, A.</span><span> </span><span class="NLM_article-title">Preparation of heterocyclic compounds as remedies for hepatitis C</span>. World Patent Application WO 2001/047883, May 7,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=H.+Hashimoto&author=K.+Mizutani&author=A.+Yoshida&title=Preparation+of+heterocyclic+compounds+as+remedies+for+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DH.%26atitle%3DPreparation%2520of%2520heterocyclic%2520compounds%2520as%2520remedies%2520for%2520hepatitis%2520C%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit97b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avolio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Filippo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliaccio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, F.</span><span> </span><span class="NLM_article-title">Development and preliminary optimization of indole-<i>N</i>-acetamide inhibitors of hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1314</span><span class="NLM_x">–</span> <span class="NLM_lpage">1317</span><span class="refDoi"> DOI: 10.1021/jm049122i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049122i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1314-1317&author=S.+Harperauthor=B.+Paciniauthor=S.+Avolioauthor=M.+Di+Filippoauthor=G.+Migliaccioauthor=R.+Lauferauthor=R.+De+Francescoauthor=M.+Rowleyauthor=F.+Narjes&title=Development+and+preliminary+optimization+of+indole-N-acetamide+inhibitors+of+hepatitis+C+virus+NS5B+polymerase&doi=10.1021%2Fjm049122i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97b&amp;dbid=16384&amp;doi=10.1021%2Fjm049122i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049122i%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DPacini%26aufirst%3DB.%26aulast%3DAvolio%26aufirst%3DS.%26aulast%3DDi%2BFilippo%26aufirst%3DM.%26aulast%3DMigliaccio%26aufirst%3DG.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DNarjes%26aufirst%3DF.%26atitle%3DDevelopment%2520and%2520preliminary%2520optimization%2520of%2520indole-N-acetamide%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1314%26epage%3D1317%26doi%3D10.1021%2Fjm049122i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit97c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bykowski, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansereau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duceppe, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haché, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakalian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagacé, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKercher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreault, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thauvette, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span> </span><span class="NLM_article-title">Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4987</span><span class="NLM_x">–</span> <span class="NLM_lpage">4993</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2006.07.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmcl.2006.07.074" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4987-4993&author=P.+L.+Beaulieuauthor=J.+Gillardauthor=D.+Bykowskiauthor=C.+Brochuauthor=N.+Dansereauauthor=J.+S.+Duceppeauthor=B.+Hach%C3%A9author=A.+Jakalianauthor=L.+Lagac%C3%A9author=S.+LaPlanteauthor=G.+McKercherauthor=E.+Moreauauthor=S.+Perreaultauthor=T.+Stammersauthor=L.+Thauvetteauthor=J.+Warringtonauthor=G.+Kukolj&title=Improved+replicon+cellular+activity+of+non-nucleoside+allosteric+inhibitors+of+HCV+NS5B+polymerase%3A+from+benzimidazole+to+indole+scaffolds&doi=10.1016%2Fj.bmcl.2006.07.074"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.07.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.07.074%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DGillard%26aufirst%3DJ.%26aulast%3DBykowski%26aufirst%3DD.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DDansereau%26aufirst%3DN.%26aulast%3DDuceppe%26aufirst%3DJ.%2BS.%26aulast%3DHach%25C3%25A9%26aufirst%3DB.%26aulast%3DJakalian%26aufirst%3DA.%26aulast%3DLagac%25C3%25A9%26aufirst%3DL.%26aulast%3DLaPlante%26aufirst%3DS.%26aulast%3DMcKercher%26aufirst%3DG.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DStammers%26aufirst%3DT.%26aulast%3DThauvette%26aufirst%3DL.%26aulast%3DWarrington%26aufirst%3DJ.%26aulast%3DKukolj%26aufirst%3DG.%26atitle%3DImproved%2520replicon%2520cellular%2520activity%2520of%2520non-nucleoside%2520allosteric%2520inhibitors%2520of%2520HCV%2520NS5B%2520polymerase%253A%2520from%2520benzimidazole%2520to%2520indole%2520scaffolds%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4987%26epage%3D4993%26doi%3D10.1016%2Fj.bmcl.2006.07.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit97d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolicoeur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M. A.</span><span> </span><span class="NLM_article-title">From benzimidazole to indole-5-carboxamide thumb pocket I inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">3658</span><span class="NLM_x">–</span> <span class="NLM_lpage">3663</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.04.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmcl.2011.04.059" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=3658-3663&author=P.+L.+Beaulieuauthor=J.+Gillardauthor=E.+Jolicoeurauthor=J.+Duanauthor=M.+Garneauauthor=G.+Kukoljauthor=M.+A.+Poupart&title=From+benzimidazole+to+indole-5-carboxamide+thumb+pocket+I+inhibitors+of+HCV+NS5B+polymerase.+Part+1%3A+indole+C-2+SAR+and+discovery+of+diamide+derivatives+with+nanomolar+potency+in+cell-based+subgenomic+replicons&doi=10.1016%2Fj.bmcl.2011.04.059"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.059%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DGillard%26aufirst%3DJ.%26aulast%3DJolicoeur%26aufirst%3DE.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DPoupart%26aufirst%3DM.%2BA.%26atitle%3DFrom%2520benzimidazole%2520to%2520indole-5-carboxamide%2520thumb%2520pocket%2520I%2520inhibitors%2520of%2520HCV%2520NS5B%2520polymerase.%2520Part%25201%253A%2520indole%2520C-2%2520SAR%2520and%2520discovery%2520of%2520diamide%2520derivatives%2520with%2520nanomolar%2520potency%2520in%2520cell-based%2520subgenomic%2520replicons%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D3658%26epage%3D3663%26doi%3D10.1016%2Fj.bmcl.2011.04.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudyma, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witmer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camac, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheriff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beno, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelosi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentles, R. G.</span><span> </span><span class="NLM_article-title">Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2925</span><span class="NLM_x">–</span> <span class="NLM_lpage">2929</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.03.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmcl.2011.03.067" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2925-2929&author=X.+Zhengauthor=T.+W.+Hudymaauthor=S.+W.+Martinauthor=C.+Bergstromauthor=M.+Dingauthor=F.+Heauthor=J.+Romineauthor=M.+A.+Possauthor=J.+F.+Kadowauthor=C.+H.+Changauthor=J.+Wanauthor=M.+R.+Witmerauthor=P.+Morinauthor=D.+M.+Camacauthor=S.+Sheriffauthor=B.+R.+Benoauthor=K.+L.+Rigatauthor=Y.+K.+Wangauthor=R.+Fridellauthor=J.+Lemmauthor=D.+Qiuauthor=M.+Liuauthor=S.+Vossauthor=L.+Pelosiauthor=S.+B.+Robertsauthor=M.+Gaoauthor=J.+Knipeauthor=R.+G.+Gentles&title=Syntheses+and+initial+evaluation+of+a+series+of+indolo-fused+heterocyclic+inhibitors+of+the+polymerase+enzyme+%28NS5B%29+of+the+hepatitis+C+virus&doi=10.1016%2Fj.bmcl.2011.03.067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.03.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.03.067%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DHudyma%26aufirst%3DT.%2BW.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DBergstrom%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DRomine%26aufirst%3DJ.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DChang%26aufirst%3DC.%2BH.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DMorin%26aufirst%3DP.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DRigat%26aufirst%3DK.%2BL.%26aulast%3DWang%26aufirst%3DY.%2BK.%26aulast%3DFridell%26aufirst%3DR.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DPelosi%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26atitle%3DSyntheses%2520and%2520initial%2520evaluation%2520of%2520a%2520series%2520of%2520indolo-fused%2520heterocyclic%2520inhibitors%2520of%2520the%2520polymerase%2520enzyme%2520%2528NS5B%2529%2520of%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2925%26epage%3D2929%26doi%3D10.1016%2Fj.bmcl.2011.03.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">te Velthuis, A. J. W.</span><span> </span><span class="NLM_article-title">Common and unique features of viral RNA-dependent polymerase</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">4403</span><span class="NLM_x">–</span> <span class="NLM_lpage">442</span><span class="refDoi"> DOI: 10.1007/s00018-014-1695-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1007%2Fs00018-014-1695-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2014&pages=4403-442&author=A.+J.+W.+te+Velthuis&title=Common+and+unique+features+of+viral+RNA-dependent+polymerase&doi=10.1007%2Fs00018-014-1695-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99a&amp;dbid=16384&amp;doi=10.1007%2Fs00018-014-1695-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-014-1695-z%26sid%3Dliteratum%253Aachs%26aulast%3Dte%2BVelthuis%26aufirst%3DA.%2BJ.%2BW.%26atitle%3DCommon%2520and%2520unique%2520features%2520of%2520viral%2520RNA-dependent%2520polymerase%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2014%26volume%3D71%26spage%3D4403%26epage%3D442%26doi%3D10.1007%2Fs00018-014-1695-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit99b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Choi, K. H.</span><span> </span><span class="NLM_article-title">Viral polymerases</span> <span class="citation_source-journal">Adv. Exp. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">726</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">304</span><span class="refDoi"> DOI: 10.1007/978-1-4614-0980-9_12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1007%2F978-1-4614-0980-9_12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=726&publication_year=2012&pages=267-304&author=K.+H.+Choi&title=Viral+polymerases&doi=10.1007%2F978-1-4614-0980-9_12"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99b&amp;dbid=16384&amp;doi=10.1007%2F978-1-4614-0980-9_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4614-0980-9_12%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DK.%2BH.%26atitle%3DViral%2520polymerases%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2012%26volume%3D726%26spage%3D267%26epage%3D304%26doi%3D10.1007%2F978-1-4614-0980-9_12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentles, R. G.</span><span> </span><span class="NLM_article-title">The synthesis of novel heteroaryl-fused 7,8,9,10-tetrahydro-6<i>H</i>-azepino[1,2-<i>a</i>]indoles, 4-oxo-2,3-dihydro-1<i>H</i>-[1,4]diazepino[1,7-<i>a</i>]indoles and 1,2,4,5-tetrahydro-[1,4]oxazepino[4,5-<i>a</i>]indoles. Effective inhibitors of HCV NS5B polymerase</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">6654</span><span class="NLM_x">–</span> <span class="NLM_lpage">6662</span><span class="refDoi"> DOI: 10.1039/c1ob05525a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1039%2Fc1ob05525a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=21800000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCrtL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=6654-6662&author=M.+Dingauthor=F.+Heauthor=M.+A.+Possauthor=K.+L.+Rigatauthor=Y.-K.+Wangauthor=S.+B.+Robertsauthor=D.+Qiuauthor=R.+A.+Fridellauthor=M.+Gaoauthor=R.+G.+Gentles&title=The+synthesis+of+novel+heteroaryl-fused+7%2C8%2C9%2C10-tetrahydro-6H-azepino%5B1%2C2-a%5Dindoles%2C+4-oxo-2%2C3-dihydro-1H-%5B1%2C4%5Ddiazepino%5B1%2C7-a%5Dindoles+and+1%2C2%2C4%2C5-tetrahydro-%5B1%2C4%5Doxazepino%5B4%2C5-a%5Dindoles.+Effective+inhibitors+of+HCV+NS5B+polymerase&doi=10.1039%2Fc1ob05525a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100aR"><div class="casContent"><span class="casTitleNuber">100a</span><div class="casTitle"><span class="NLM_cas:atitle">The synthesis of novel heteroaryl-fused 7,8,9,10-tetrahydro-6H-azepino[1,2-a]indoles, 4-oxo-2,3-dihydro-1H-[1,4]diazepino[1,7-a]indoles and 1,2,4,5-tetrahydro-[1,4]oxazepino[4,5-a]indoles. Effective inhibitors of HCV NS5B polymerase</span></div><div class="casAuthors">Ding, Min; He, Feng; Poss, Michael A.; Rigat, Karen L.; Wang, Ying-Kai; Roberts, Susan B.; Qiu, Dike; Fridell, Robert A.; Gao, Min; Gentles, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6654-6662</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Three synthetic approaches have been developed that allow efficient access to novel heteroaryl fused indole ring systems, including: 7,8,9,10-tetrahydro-6H-azepino[1,2-a]indoles, 4-oxo-2,3-dihydro-1H-[1,4]diazepino[1,7-a]indoles, and 1,2,4,5-tetrahydro[1,4]oxazepino[4,5-a]indoles.  Each strategy is fully exemplified and the relative merits and limitations of the approaches are discussed.  The hepatitis C virus (HCV) non-structural 5B (NS5B) polymerase inhibitory activities of select examples from each mol. class are briefly presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJOYGwyYtw97Vg90H21EOLACvtfcHk0ljMfPVSZ0WSBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCrtL7L&md5=32a10811ab2d90f8672ff47937f7d9b6</span></div><a href="/servlet/linkout?suffix=cit100a&amp;dbid=16384&amp;doi=10.1039%2Fc1ob05525a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1ob05525a%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DRigat%26aufirst%3DK.%2BL.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DQiu%26aufirst%3DD.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26atitle%3DThe%2520synthesis%2520of%2520novel%2520heteroaryl-fused%25207%252C8%252C9%252C10-tetrahydro-6H-azepino%255B1%252C2-a%255Dindoles%252C%25204-oxo-2%252C3-dihydro-1H-%255B1%252C4%255Ddiazepino%255B1%252C7-a%255Dindoles%2520and%25201%252C2%252C4%252C5-tetrahydro-%255B1%252C4%255Doxazepino%255B4%252C5-a%255Dindoles.%2520Effective%2520inhibitors%2520of%2520HCV%2520NS5B%2520polymerase%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2011%26volume%3D9%26spage%3D6654%26epage%3D6662%26doi%3D10.1039%2Fc1ob05525a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit100b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudyma, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beno, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelosi, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentles, R. G.</span><span> </span><span class="NLM_article-title">Synthesis and SAR studies of novel heteroaryl fused tetracyclic indole-diamide compounds: potent allosteric inhibitors of the hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2866</span><span class="NLM_x">–</span> <span class="NLM_lpage">2871</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.02.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmcl.2012.02.063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2866-2871&author=M.+Dingauthor=F.+Heauthor=T.+W.+Hudymaauthor=X.+Zhengauthor=M.+A.+Possauthor=J.+F.+Kadowauthor=B.+R.+Benoauthor=K.+L.+Rigatauthor=Y.+K.+Wangauthor=R.+A.+Fridellauthor=J.+A.+Lemmauthor=D.+Qiuauthor=M.+Liuauthor=S.+Vossauthor=L.+A.+Pelosiauthor=S.+B.+Robertsauthor=M.+Gaoauthor=J.+Knipeauthor=R.+G.+Gentles&title=Synthesis+and+SAR+studies+of+novel+heteroaryl+fused+tetracyclic+indole-diamide+compounds%3A+potent+allosteric+inhibitors+of+the+hepatitis+C+virus+NS5B+polymerase&doi=10.1016%2Fj.bmcl.2012.02.063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.02.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.02.063%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DHudyma%26aufirst%3DT.%2BW.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DRigat%26aufirst%3DK.%2BL.%26aulast%3DWang%26aufirst%3DY.%2BK.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DQiu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DPelosi%26aufirst%3DL.%2BA.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26atitle%3DSynthesis%2520and%2520SAR%2520studies%2520of%2520novel%2520heteroaryl%2520fused%2520tetracyclic%2520indole-diamide%2520compounds%253A%2520potent%2520allosteric%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2866%26epage%3D2871%26doi%3D10.1016%2Fj.bmcl.2012.02.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Gentles, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant-Young, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudyma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regueiro-Ren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, K.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beno, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camac, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheriff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tredup, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witmer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanumegowda, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelosi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span> </span><span class="NLM_article-title">Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1855</span><span class="NLM_x">–</span> <span class="NLM_lpage">1879</span><span class="refDoi"> DOI: 10.1021/jm4016894</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016894" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1855-1879&author=R.+G.+Gentlesauthor=M.+Dingauthor=J.+A.+Benderauthor=C.+P.+Bergstromauthor=K.+Grant-Youngauthor=P.+Hewawasamauthor=T.+Hudymaauthor=S.+Martinauthor=A.+Nickelauthor=A.+Regueiro-Renauthor=Y.+Tuauthor=Z.+Yangauthor=K.-S.+Yeungauthor=X.+Zhengauthor=S.+Chaoauthor=J.-H.+Sunauthor=B.+R.+Benoauthor=D.+M.+Camacauthor=C.-H.+Changauthor=M.+Gaoauthor=P.+E.+Morinauthor=S.+Sheriffauthor=J.+Tredupauthor=J.+Wanauthor=M.+R.+Witmerauthor=D.+Xieauthor=U.+Hanumegowdaauthor=J.+Knipeauthor=K.+Mosureauthor=K.+S.+Santoneauthor=D.+D.+Parkerauthor=X.+Zhuoauthor=J.+Lemmauthor=M.+Liuauthor=L.+Pelosiauthor=K.+Rigatauthor=S.+Vossauthor=Y.+Wangauthor=Y.-K.+Wangauthor=R.+J.+Colonnoauthor=M.+Gaoauthor=S.+B.+Robertsauthor=Q.+Gaoauthor=A.+Ngauthor=N.+A.+Meanwellauthor=J.+F.+Kadow&title=Discovery+and+preclinical+characterization+of+the+cyclopropylindolobenzazepine+BMS-791325%2C+a+potent+allosteric+inhibitor+of+the+hepatitis+C+virus+NS5B+polymerase&doi=10.1021%2Fjm4016894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase</span></div><div class="casAuthors">Gentles, Robert G.; Ding, Min; Bender, John A.; Bergstrom, Carl P.; Grant-Young, Katharine; Hewawasam, Piyasena; Hudyma, Thomas; Martin, Scott; Nickel, Andrew; Regueiro-Ren, Alicia; Tu, Yong; Yang, Zhong; Yeung, Kap-Sun; Zheng, Xiaofan; Beno, Brett R.; Camac, Daniel M.; Chang, Chong-Hwan; Gao, Mian; Morin, Paul E.; Sheriff, Steven; Tredup, Jeff; Wan, John; Witmer, Mark R.; Xie, Dianlin; Hanumegowda, Umesh; Knipe, Jay; Mosure, Kathy; Santone, Kenneth S.; Parker, Dawn D.; Zhuo, Xiaoliang; Lemm, Julie; Liu, Mengping; Pelosi, Lenore; Rigat, Karen; Voss, Stacey; Wang, Yi; Wang, Ying-Kai; Colonno, Richard C.; Gao, Min; Roberts, Susan B.; Gao, Qi; Ng, Alicia; Meanwell, Nicholas A.; Kadow, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1855-1879</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Described herein are structure-activity relationship studies that resulted in the optimization of the activity of members of a class of cyclopropyl-fused indolobenzazepine HCV NS5B polymerase inhibitors.  Subsequent iterations of analog design and syntheses successfully addressed off-target activities, most notably human pregnane X receptor (hPXR) transactivation, and led to significant improvements in the physicochem. properties of lead compds.  Those analogs exhibiting improved soly. and membrane permeability were shown to have notably enhanced pharmacokinetic profiles.  Addnl., a series of alkyl bridged piperazine carboxamides was identified as being of particular interest, and from which the compd. BMS-791325 (I) was found to have distinguishing antiviral, safety, and pharmacokinetic properties that resulted in its selection for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn4YKQoSYkS7Vg90H21EOLACvtfcHk0liNhWZ5dbZByA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKkuw%253D%253D&md5=f13f5d86a1c17737784e905c7843ff72</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjm4016894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016894%26sid%3Dliteratum%253Aachs%26aulast%3DGentles%26aufirst%3DR.%2BG.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DBergstrom%26aufirst%3DC.%2BP.%26aulast%3DGrant-Young%26aufirst%3DK.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DHudyma%26aufirst%3DT.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DNickel%26aufirst%3DA.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYeung%26aufirst%3DK.-S.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DChao%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DChang%26aufirst%3DC.-H.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DMorin%26aufirst%3DP.%2BE.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DHanumegowda%26aufirst%3DU.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DPelosi%26aufirst%3DL.%26aulast%3DRigat%26aufirst%3DK.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DNg%26aufirst%3DA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26atitle%3DDiscovery%2520and%2520preclinical%2520characterization%2520of%2520the%2520cyclopropylindolobenzazepine%2520BMS-791325%252C%2520a%2520potent%2520allosteric%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1855%26epage%3D1879%26doi%3D10.1021%2Fjm4016894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudyma, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentles, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">A practical and efficient synthesis of 6-carboalkoxy-13-cycloalkyl-5<i>H</i>-indolo[2,1-<i>a</i>][2] benzazepine-10-carboxylic acid derivatives</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1148</span><span class="NLM_x">–</span> <span class="NLM_lpage">1153</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2013.12.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.tetlet.2013.12.085" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1148-1153&author=P.+Hewawasamauthor=Y.+Tuauthor=T.+W.+Hudymaauthor=X.+Zhangauthor=R.+G.+Gentlesauthor=J.+F.+Kadowauthor=N.+A.+Meanwell&title=A+practical+and+efficient+synthesis+of+6-carboalkoxy-13-cycloalkyl-5H-indolo%5B2%2C1-a%5D%5B2%5D+benzazepine-10-carboxylic+acid+derivatives&doi=10.1016%2Fj.tetlet.2013.12.085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2013.12.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2013.12.085%26sid%3Dliteratum%253Aachs%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DHudyma%26aufirst%3DT.%2BW.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DA%2520practical%2520and%2520efficient%2520synthesis%2520of%25206-carboalkoxy-13-cycloalkyl-5H-indolo%255B2%252C1-a%255D%255B2%255D%2520benzazepine-10-carboxylic%2520acid%2520derivatives%26jtitle%3DTetrahedron%2520Lett.%26date%3D2014%26volume%3D55%26spage%3D1148%26epage%3D1153%26doi%3D10.1016%2Fj.tetlet.2013.12.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Sinz, M. W.</span><span> </span><span class="NLM_article-title">Pregnane X receptor: prediction and attenuation of human CYP3A4 enzyme induction and drug-drug interactions</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">418</span><span class="refDoi"> DOI: 10.1016/S0065-7743(08)00023-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0065-7743%2808%2900023-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2008&pages=405-418&author=M.+W.+Sinz&title=Pregnane+X+receptor%3A+prediction+and+attenuation+of+human+CYP3A4+enzyme+induction+and+drug-drug+interactions&doi=10.1016%2FS0065-7743%2808%2900023-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2808%2900023-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252808%252900023-7%26sid%3Dliteratum%253Aachs%26aulast%3DSinz%26aufirst%3DM.%2BW.%26atitle%3DPregnane%2520X%2520receptor%253A%2520prediction%2520and%2520attenuation%2520of%2520human%2520CYP3A4%2520enzyme%2520induction%2520and%2520drug-drug%2520interactions%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2008%26volume%3D43%26spage%3D405%26epage%3D418%26doi%3D10.1016%2FS0065-7743%2808%2900023-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentles, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelosi, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3485</span><span class="NLM_x">–</span> <span class="NLM_lpage">3495</span><span class="refDoi"> DOI: 10.1128/AAC.02495-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FAAC.02495-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24733465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCntLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=3485-3495&author=J.+A.+Lemmauthor=M.+Liuauthor=R.+G.+Gentlesauthor=M.+Dingauthor=S.+Vossauthor=L.+A.+Pelosiauthor=Y.+K.+Wangauthor=K.+L.+Rigatauthor=K.+W.+Mosureauthor=J.+A.+Benderauthor=J.+O.+Knipeauthor=R.+Colonnoauthor=N.+A.+Meanwellauthor=J.+F.+Kadowauthor=K.+S.+Santoneauthor=S.+B.+Robertsauthor=M.+Gao&title=Preclinical+characterization+of+BMS-791325%2C+an+allosteric+inhibitor+of+hepatitis+C+Virus+NS5B+polymerase&doi=10.1128%2FAAC.02495-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C virus NS5B polymerase</span></div><div class="casAuthors">Lemm, Julie A.; Liu, Mengping; Gentles, Robert G.; Ding, Min; Voss, Stacey; Pelosi, Lenore A.; Wang, Ying-Kai; Rigat, Karen L.; Mosure, Kathleen W.; Bender, John A.; Knipe, Jay O.; Colonno, Richard; Meanwell, Nicholas A.; Kadow, John F.; Santone, Kenneth S.; Roberts, Susan B.; Gao, Min</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3485-3495, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">BMS-791325 is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase.  BMS-791325 inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4 and 5 at 50 % inhibitory concns. (IC50) below 28 nM.  In cell culture, BMS-791325 inhibited replication of HCV subgenomic replicons representing genotypes 1a and 1b at 50% effective concns. (EC50s) of 3 nM and 6 nM, resp., with similar (3 to 18 nM) values for genotypes 3a, 4a and 5a.  Potency against genotype 6a showed more variability (9 to 125 nM) and activity was weaker against genotype 2 (EC50, 87 to 925 nM).  Specificity was demonstrated by the absence of activity (EC50s of >4 μM) against a panel of mammalian viruses and cytotoxic concns. (50%) were >3,000-fold above the HCV EC50.  Resistance substitutions selected by BMS-791325 in genotype 1 replicons mostly mapped to a single site, NS5B amino acid 495 (P495A/S/L/T).  Additive or synergistic activity was obsd. in combination studies using BMS-791325 with alfa interferon plus ribavirin, inhibitors of NS3 protease or NS5A and other classes of NS5B inhibitor (palm site 2-binding or nucleoside analogs).  Plasma and liver exposuresin vivo in several animal species indicated that BMS-791325 has a hepatotropic disposition (liver-to-plasma ratios ranging from 1.6- to 60-fold across species).  Twenty-four hours postdose, liver exposures across all species tested were ≥10-fold above the inhibitor EC50s obsd. with HCV genotype 1 replicons.  These findings support the evaluation of BMS-791325 in combination regimens for the treatment of HCV.  Phase 3 studies are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEqRFEKxGsgbVg90H21EOLACvtfcHk0liEzOc6V78CBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCntLjF&md5=d3f934398d420d4ef91f9eb7b71b5059</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1128%2FAAC.02495-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02495-13%26sid%3Dliteratum%253Aachs%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DPelosi%26aufirst%3DL.%2BA.%26aulast%3DWang%26aufirst%3DY.%2BK.%26aulast%3DRigat%26aufirst%3DK.%2BL.%26aulast%3DMosure%26aufirst%3DK.%2BW.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DPreclinical%2520characterization%2520of%2520BMS-791325%252C%2520an%2520allosteric%2520inhibitor%2520of%2520hepatitis%2520C%2520Virus%2520NS5B%2520polymerase%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D3485%26epage%3D3495%26doi%3D10.1128%2FAAC.02495-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Gentile, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zappulo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonomo, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maraolo, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, G.</span><span> </span><span class="NLM_article-title">Beclabuvir for the treatment of hepatitis C</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1111</span><span class="NLM_x">–</span> <span class="NLM_lpage">1121</span><span class="refDoi"> DOI: 10.1517/13543784.2015.1059820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1517%2F13543784.2015.1059820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26156630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCksb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1111-1121&author=I.+Gentileauthor=E.+Zappuloauthor=A.+R.+Buonomoauthor=A.+E.+Maraoloauthor=G.+Borgia&title=Beclabuvir+for+the+treatment+of+hepatitis+C&doi=10.1517%2F13543784.2015.1059820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Beclabuvir for the treatment of hepatitis C</span></div><div class="casAuthors">Gentile, Ivan; Zappulo, Emanuela; Buonomo, Antonio Riccardo; Maraolo, Alberto Enrico; Borgia, Guglielmo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1111-1121</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: About 185,000,000 people worldwide are chronically infected with hepatitis C virus (HCV).  Currently, the most successful HCV infection antiviral therapies reduce the chance of progression towards the advanced phases of the hepatopathy (liver cirrhosis, hepatocellular carcinoma and death).  Recently, however, several new direct-acting antivirals against HCV are available or are in an advanced phase of clin. development.  Areas covered: This review focuses on beclabuvir, an allosteric non-nucleotide inhibitor of HCV polymerase.  The article covers its pharmacokinetics, mechanism of action, in addn. to its tolerability and safety profile as well as its resistance pattern.  Expert opinion: The pharmacokinetic, efficacy and tolerability profile of beclabuvir, as well as its barrier to resistance, are very favorable.  In particular, the combination of beclabuvir with asunaprevir and daclatasvir achieves very high rates of viral eradication (about 90%) in patients infected with HCV genotype 1, which is the most common genotype worldwide.  Therefore, beclabuvir represents a powerful weapon against HCV infection and has to be considered an optimal option in tailored IFN-free combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomjiRJtkTLmrVg90H21EOLACvtfcHk0ljWdyBLE4WfEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCksb3N&md5=c0781930e17ca4764d7da0e80ac2dc7a</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1059820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1059820%26sid%3Dliteratum%253Aachs%26aulast%3DGentile%26aufirst%3DI.%26aulast%3DZappulo%26aufirst%3DE.%26aulast%3DBuonomo%26aufirst%3DA.%2BR.%26aulast%3DMaraolo%26aufirst%3DA.%2BE.%26aulast%3DBorgia%26aufirst%3DG.%26atitle%3DBeclabuvir%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1111%26epage%3D1121%26doi%3D10.1517%2F13543784.2015.1059820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuttle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span> </span><span class="NLM_article-title">Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">7416</span><span class="NLM_x">–</span> <span class="NLM_lpage">7423</span><span class="refDoi"> DOI: 10.1128/AAC.03851-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FAAC.03851-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25267677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVymsLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=7416-7423&author=M.+Liuauthor=M.+Tuttleauthor=M.+Gaoauthor=J.+A.+Lemm&title=Potency+and+resistance+analysis+of+hepatitis+C+virus+NS5B+polymerase+inhibitor+BMS-791325+on+all+major+genotypes&doi=10.1128%2FAAC.03851-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes</span></div><div class="casAuthors">Liu, Mengping; Tuttle, Maria; Gao, Min; Lemm, Julie A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">7416-7423, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">BMS-791325 is a hepatitis C virus (HCV) inhibitor binding to the thumb domain of the NS5B RNA-dependent RNA polymerase.  BMS-791325 is well characterized in genotype 1 (GT1) and exhibits good inhibitory activity (50% effective concn. [EC50], <10 nM) against hybrid replicons contg. patient NS5B sequences from GT3a, -4a, and -5a while potency against GT2 is significantly reduced.  BMS-791325 potency against GT6a hybrid replicons is more variable, with two of three hybrid clones having EC50s similar to that for GT1 while a third patient clone was ∼10 times less susceptible to BMS-791325.  To characterize the resistance profile of BMS-791325 beyond GT1, curing studies were performed across GT1a and -3a to -6a and demonstrated that GT1a has the highest resistance barrier vs. BMS-791325 while GT6a has the lowest.  Selection of GT3 to -6 NS5B chimeric replicon cells at different concns. of BMS-791325 revealed substitutions in the thumb domain of NS5B at residues 494 and 495 that conferred different levels of resistance to BMS-791325 but remained susceptible to NS5A or NS3 protease inhibitors.  In addn., we demonstrate that the reduced potency of BMS-791325 against one GT6a patient is due to an A494 polymorphism present in ∼21% of sequences in the European HCV database.  The results from this report suggest that BMS-791325 is a candidate for combination treatment of HCV GT3 to -6 chronic infections, and the resistance profiles identified will provide useful information for future clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5_mdXydNNWLVg90H21EOLACvtfcHk0ljWdyBLE4WfEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVymsLzL&md5=8c28943f5323ac850671503c57974cb0</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1128%2FAAC.03851-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03851-14%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DTuttle%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26atitle%3DPotency%2520and%2520resistance%2520analysis%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%2520inhibitor%2520BMS-791325%2520on%2520all%2520major%2520genotypes%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D7416%26epage%3D7423%26doi%3D10.1128%2FAAC.03851-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Rigat, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Argyrou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanslau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcinkeviciene, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentles, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abell, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span> </span><span class="NLM_article-title">Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">33456</span><span class="NLM_x">–</span> <span class="NLM_lpage">33468</span><span class="refDoi"> DOI: 10.1074/jbc.M114.613653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1074%2Fjbc.M114.613653" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=33456-33468&author=K.+L.+Rigatauthor=H.+Luauthor=Y.+K.+Wangauthor=A.+Argyrouauthor=C.+Fanslauauthor=B.+Benoauthor=Y.+Wangauthor=J.+Marcinkevicieneauthor=M.+Dingauthor=R.+G.+Gentlesauthor=M.+Gaoauthor=L.+M.+Abellauthor=S.+B.+Roberts&title=Mechanism+of+inhibition+for+BMS-791325%2C+a+novel+non-nucleoside+inhibitor+of+hepatitis+C+virus+NS5B+polymerase&doi=10.1074%2Fjbc.M114.613653"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.613653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.613653%26sid%3Dliteratum%253Aachs%26aulast%3DRigat%26aufirst%3DK.%2BL.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%2BK.%26aulast%3DArgyrou%26aufirst%3DA.%26aulast%3DFanslau%26aufirst%3DC.%26aulast%3DBeno%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMarcinkeviciene%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DAbell%26aufirst%3DL.%2BM.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26atitle%3DMechanism%2520of%2520inhibition%2520for%2520BMS-791325%252C%2520a%2520novel%2520non-nucleoside%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D33456%26epage%3D33468%26doi%3D10.1074%2Fjbc.M114.613653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yuan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouyang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinsanya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moehlenkamp, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubry, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, M. E.</span><span> </span><span class="NLM_article-title">A validated LC-MS/MS method for the simultaneous determination of BMS-791325, a hepatitis C virus NS5B RNA polymerase inhibitor, and its metabolite in plasma</span> <span class="citation_source-journal">J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">973</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.1016/j.jchromb.2014.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jchromb.2014.10.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=973&publication_year=2014&pages=1-8&author=L.+Yuanauthor=H.+Jiangauthor=N.+Zhengauthor=Y.+Q.+Xiaauthor=Z.+Ouyangauthor=J.+Zengauthor=B.+Akinsanyaauthor=J.+L.+Valentineauthor=J.+D.+Moehlenkampauthor=Y.+Dengauthor=A.+F.+Aubryauthor=M.+E.+Arnold&title=A+validated+LC-MS%2FMS+method+for+the+simultaneous+determination+of+BMS-791325%2C+a+hepatitis+C+virus+NS5B+RNA+polymerase+inhibitor%2C+and+its+metabolite+in+plasma&doi=10.1016%2Fj.jchromb.2014.10.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108a&amp;dbid=16384&amp;doi=10.1016%2Fj.jchromb.2014.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jchromb.2014.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DXia%26aufirst%3DY.%2BQ.%26aulast%3DOuyang%26aufirst%3DZ.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DAkinsanya%26aufirst%3DB.%26aulast%3DValentine%26aufirst%3DJ.%2BL.%26aulast%3DMoehlenkamp%26aufirst%3DJ.%2BD.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DAubry%26aufirst%3DA.%2BF.%26aulast%3DArnold%26aufirst%3DM.%2BE.%26atitle%3DA%2520validated%2520LC-MS%252FMS%2520method%2520for%2520the%2520simultaneous%2520determination%2520of%2520BMS-791325%252C%2520a%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA%2520polymerase%2520inhibitor%252C%2520and%2520its%2520metabolite%2520in%2520plasma%26jtitle%3DJ.%2520Chromatogr.%2520B%253A%2520Anal.%2520Technol.%2520Biomed.%2520Life%2520Sci.%26date%3D2014%26volume%3D973%26spage%3D1%26epage%3D8%26doi%3D10.1016%2Fj.jchromb.2014.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit108b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kandoussi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadiyala, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cojocaru, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubry, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, J.</span><span> </span><span class="NLM_article-title">Sensitive and accurate liquid chromatography-tandem mass spectrometry methods for quantitative determination of a novel hepatitis C NS5B inhibitor BMS-791325 and its active metabolite in human plasma and urine</span> <span class="citation_source-journal">J. Pharm. Biomed. Anal.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1016/j.jpba.2014.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jpba.2014.12.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2015&pages=17-23&author=H.+Jiangauthor=R.+Demersauthor=H.+Kandoussiauthor=R.+Burrellauthor=T.+Eleyauthor=P.+Kadiyalaauthor=L.+Cojocaruauthor=C.+Bakerauthor=J.+Ryanauthor=A.+F.+Aubryauthor=M.+E.+Arnoldauthor=J.+Zeng&title=Sensitive+and+accurate+liquid+chromatography-tandem+mass+spectrometry+methods+for+quantitative+determination+of+a+novel+hepatitis+C+NS5B+inhibitor+BMS-791325+and+its+active+metabolite+in+human+plasma+and+urine&doi=10.1016%2Fj.jpba.2014.12.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108b&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2014.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2014.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DDemers%26aufirst%3DR.%26aulast%3DKandoussi%26aufirst%3DH.%26aulast%3DBurrell%26aufirst%3DR.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DKadiyala%26aufirst%3DP.%26aulast%3DCojocaru%26aufirst%3DL.%26aulast%3DBaker%26aufirst%3DC.%26aulast%3DRyan%26aufirst%3DJ.%26aulast%3DAubry%26aufirst%3DA.%2BF.%26aulast%3DArnold%26aufirst%3DM.%2BE.%26aulast%3DZeng%26aufirst%3DJ.%26atitle%3DSensitive%2520and%2520accurate%2520liquid%2520chromatography-tandem%2520mass%2520spectrometry%2520methods%2520for%2520quantitative%2520determination%2520of%2520a%2520novel%2520hepatitis%2520C%2520NS5B%2520inhibitor%2520BMS-791325%2520and%2520its%2520active%2520metabolite%2520in%2520human%2520plasma%2520and%2520urine%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2015%26volume%3D107%26spage%3D17%26epage%3D23%26doi%3D10.1016%2Fj.jpba.2014.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Sims, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berglind, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vutikullird, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span> </span><span class="NLM_article-title">Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3496</span><span class="NLM_x">–</span> <span class="NLM_lpage">3503</span><span class="refDoi"> DOI: 10.1128/AAC.02579-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FAAC.02579-13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=3496-3503&author=K.+D.+Simsauthor=J.+Lemmauthor=T.+Eleyauthor=M.+Liuauthor=A.+Berglindauthor=D.+Shermanauthor=E.+Lawitzauthor=A.+B.+Vutikullirdauthor=P.+Tebasauthor=M.+Gaoauthor=C.+Pasquinelliauthor=D.+M.+Grasela&title=Randomized%2C+placebo-controlled%2C+single-ascending-dose+study+of+BMS-791325%2C+a+hepatitis+C+virus+%28HCV%29+NS5B+polymerase+inhibitor%2C+in+HCV+genotype+1+infection&doi=10.1128%2FAAC.02579-13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1128%2FAAC.02579-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02579-13%26sid%3Dliteratum%253Aachs%26aulast%3DSims%26aufirst%3DK.%2BD.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DBerglind%26aufirst%3DA.%26aulast%3DSherman%26aufirst%3DD.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DVutikullird%26aufirst%3DA.%2BB.%26aulast%3DTebas%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26atitle%3DRandomized%252C%2520placebo-controlled%252C%2520single-ascending-dose%2520study%2520of%2520BMS-791325%252C%2520a%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%2520NS5B%2520polymerase%2520inhibitor%252C%2520in%2520HCV%2520genotype%25201%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D3496%26epage%3D3503%26doi%3D10.1128%2FAAC.02579-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Nettles, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marbury, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldwater, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMicco, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vutikullird, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Talavera, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span> </span><span class="NLM_article-title">Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1956</span><span class="NLM_x">–</span> <span class="NLM_lpage">1965</span><span class="refDoi"> DOI: 10.1002/hep.24609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.24609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=21837752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1956-1965&author=R.+E.+Nettlesauthor=M.+Gaoauthor=M.+Bifanoauthor=E.+Chungauthor=A.+Perssonauthor=T.+C.+Marburyauthor=R.+Goldwaterauthor=M.+P.+DeMiccoauthor=M.+Rodriguez-Torresauthor=A.+Vutikullirdauthor=E.+Fuentesauthor=E.+Lawitzauthor=J.+C.+Lopez-Talaveraauthor=D.+M.+Grasela&title=Multiple+ascending+dose+study+of+BMS-790052%2C+a+nonstructural+protein+5A+replication+complex+inhibitor%2C+in+patients+infected+with+hepatitis+C+virus+genotype+1&doi=10.1002%2Fhep.24609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1</span></div><div class="casAuthors">Nettles, Richard E.; Gao, Min; Bifano, Marc; Chung, Ellen; Persson, Anna; Marbury, Thomas C.; Goldwater, Ronald; DeMicco, Michael P.; Rodriguez-Torres, Maribel; Vutikullird, Apinya; Fuentes, Ernesto; Lawitz, Eric; Lopez-Talavera, Juan Carlos; Grasela, Dennis M.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1956-1965</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The antiviral activity, resistance profile, pharmacokinetics (PK), safety, and tolerability of BMS-790052, a nonstructural protein 5A (NS5A) replication complex inhibitor, were evaluated in a double-blind, placebo-controlled, sequential panel, multiple ascending dose study.  Thirty patients with chronic hepatitis C virus (HCV) genotype 1 infection were randomized to receive a 14-day course of BMS-790052 (1, 10, 30, 60, or 100 mg once daily or 30 mg twice daily) or placebo in a ratio of 4:1.  The mean max. decline from baseline in HCV RNA ranged from 2.8 to 4.1 log10 IU/mL; the placebo group showed no evidence of antiviral activity.  Most patients experienced viral rebound on or before day 7 of treatment with BMS-790052 monotherapy; viral rebound was assocd. with viral variants that had been previously implicated in resistance development in the in vitro replicon system.  The PK profile was supportive of once-daily dosing with median peak plasma concns. at 1-2 h postdose and mean terminal half-life of 12-15 h.  Steady state was achieved following 3-4 days of daily dosing.  BMS-790052 was well tolerated in all dose groups, with adverse events occurring with a similar frequency in BMS-790052- and placebo-treated groups.  There were no clin. relevant changes in vital signs, lab., or ECG parameters.  Conclusion: BMS-7590052 is the first NS5A replication complex inhibitor with multiple dose proof-of-concept in clinic.  At doses of 1-100 mg daily, BMS-790052 was well tolerated, had a PK profile supportive of once-daily dosing, and produced a rapid and substantial decrease in HCV-RNA levels in patients chronically infected with HCV genotype 1. (HEPATOl.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjY1mjsJbg-LVg90H21EOLACvtfcHk0ljuOxVMfwmDcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsLrJ&md5=080f30aec3629e68b832fe6491c54d16</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1002%2Fhep.24609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24609%26sid%3Dliteratum%253Aachs%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DBifano%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DMarbury%26aufirst%3DT.%2BC.%26aulast%3DGoldwater%26aufirst%3DR.%26aulast%3DDeMicco%26aufirst%3DM.%2BP.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DVutikullird%26aufirst%3DA.%26aulast%3DFuentes%26aufirst%3DE.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DLopez-Talavera%26aufirst%3DJ.%2BC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26atitle%3DMultiple%2520ascending%2520dose%2520study%2520of%2520BMS-790052%252C%2520a%2520nonstructural%2520protein%25205A%2520replication%2520complex%2520inhibitor%252C%2520in%2520patients%2520infected%2520with%2520hepatitis%2520C%2520virus%2520genotype%25201%26jtitle%3DHepatology%26date%3D2011%26volume%3D54%26spage%3D1956%26epage%3D1965%26doi%3D10.1002%2Fhep.24609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Liu-Young, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozal, M. J.</span><span> </span><span class="NLM_article-title">Hepatitis C protease and polymerase inhibitors in development</span> <span class="citation_source-journal">AIDS Patient Care STDS</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">457</span><span class="refDoi"> DOI: 10.1089/apc.2007.0199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1089%2Fapc.2007.0199" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=449-457&author=G.+Liu-Youngauthor=M.+J.+Kozal&title=Hepatitis+C+protease+and+polymerase+inhibitors+in+development&doi=10.1089%2Fapc.2007.0199"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1089%2Fapc.2007.0199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fapc.2007.0199%26sid%3Dliteratum%253Aachs%26aulast%3DLiu-Young%26aufirst%3DG.%26aulast%3DKozal%26aufirst%3DM.%2BJ.%26atitle%3DHepatitis%2520C%2520protease%2520and%2520polymerase%2520inhibitors%2520in%2520development%26jtitle%3DAIDS%2520Patient%2520Care%2520STDS%26date%3D2008%26volume%3D22%26spage%3D449%26epage%3D457%26doi%3D10.1089%2Fapc.2007.0199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Marks, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span> </span><span class="NLM_article-title">The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">–</span> <span class="NLM_lpage">1121</span><span class="refDoi"> DOI: 10.3851/IMP2424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.3851%2FIMP2424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=23188750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVCks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1119-1121&author=K.+M.+Marksauthor=I.+M.+Jacobson&title=The+first+wave%3A+HCV+NS3+protease+inhibitors+telaprevir+and+boceprevir&doi=10.3851%2FIMP2424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir</span></div><div class="casAuthors">Marks, Kristen M.; Jacobson, Ira M.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Therapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6, Pt. B</span>),
    <span class="NLM_cas:pages">1119-1131</span>CODEN:
                <span class="NLM_cas:coden">ANTHFA</span>;
        ISSN:<span class="NLM_cas:issn">1359-6535</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press</span>)
        </div><div class="casAbstract">A review.  Boceprevir and telaprevir are peptidomimetic serine protease inhibitors that have been recently approved for the treatment of HCV chronic infection.  The addn. of these drugs to the prior std. of care, pegylated interferon and ribavirin, improves sustained virol. response rates for treatment-naive and treatment-experienced patients and shortens the duration of treatment for over half of treatment-naive patients.  This review describes the clin. data supporting the approval and use of telaprevir and boceprevir, the algorithm for the use of these drugs, their adverse effects, as well as their important drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZHoeJhY2iNbVg90H21EOLACvtfcHk0lhBRrWNwf0tXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVCks7Y%253D&md5=6e1aaf842302212cb85b4eb68d7355d5</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.3851%2FIMP2424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2424%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DK.%2BM.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26atitle%3DThe%2520first%2520wave%253A%2520HCV%2520NS3%2520protease%2520inhibitors%2520telaprevir%2520and%2520boceprevir%26jtitle%3DAntiviral%2520Ther.%26date%3D2012%26volume%3D17%26spage%3D1119%26epage%3D1121%26doi%3D10.3851%2FIMP2424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113a"><span><span class="NLM_contrib-group">Butt, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanwal, F.</span><span> </span><span class="NLM_article-title">Boceprevir and telaprevir in the management of hepatitis c virus-infected patients</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span><span class="refDoi"> DOI: 10.1093/cid/cir774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1093%2Fcid%2Fcir774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=22156853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs12gsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2012&pages=96-104&author=A.+A.+Buttauthor=F.+Kanwal&title=Boceprevir+and+telaprevir+in+the+management+of+hepatitis+c+virus-infected+patients&doi=10.1093%2Fcid%2Fcir774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113aR"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Boceprevir and Telaprevir in the Management of Hepatitis C Virus-Infected Patients</span></div><div class="casAuthors">Saravolatz, Louis D.; Butt, Adeel A.; Kanwal, Fasiha</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-104</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Recent approval of direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) offers a major advance in the management of HCV infection.  These DAAs, boceprevir and telaprevir, when given with pegylated interferon alpha (Peg-IFN) and ribavirin (RBV), result in a much higher sustained virol. response rate compared with Peg-IFN and RBV.  The DAA-contg. regimens are approved for HCV genotype 1 infection in HCV treatment-naive and HCV treatment-experienced patients.  In this review, we present an overview of pharmacol., efficacy, adverse events, and emergence of resistance-assocd. variants with the use of these agents.  As with all drugs, esp. newly approved drugs, clinicians must consult the package insert for detailed prescribing information, list of all reported adverse events, contraindications, and drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojATMQ3wLXdrVg90H21EOLACvtfcHk0lhBRrWNwf0tXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs12gsr7F&md5=d650f9930f42fa11521a8682df53ae80</span></div><a href="/servlet/linkout?suffix=cit113a&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcir774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcir774%26sid%3Dliteratum%253Aachs%26aulast%3DButt%26aufirst%3DA.%2BA.%26aulast%3DKanwal%26aufirst%3DF.%26atitle%3DBoceprevir%2520and%2520telaprevir%2520in%2520the%2520management%2520of%2520hepatitis%2520c%2520virus-infected%2520patients%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2012%26volume%3D54%26spage%3D96%26epage%3D104%26doi%3D10.1093%2Fcid%2Fcir774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit113b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Park, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawson, K. A.</span><span> </span><span class="NLM_article-title">Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis</span> <span class="citation_source-journal">J. Clin. Pharm. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span><span class="refDoi"> DOI: 10.1111/jcpt.12106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fjcpt.12106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=14-24&author=C.+Parkauthor=S.+Jiangauthor=K.+A.+Lawson&title=Efficacy+and+safety+of+telaprevir+and+boceprevir+in+patients+with+hepatitis+C+genotype+1%3A+a+meta-analysis&doi=10.1111%2Fjcpt.12106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113b&amp;dbid=16384&amp;doi=10.1111%2Fjcpt.12106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcpt.12106%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DLawson%26aufirst%3DK.%2BA.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520telaprevir%2520and%2520boceprevir%2520in%2520patients%2520with%2520hepatitis%2520C%2520genotype%25201%253A%2520a%2520meta-analysis%26jtitle%3DJ.%2520Clin.%2520Pharm.%2520Ther.%26date%3D2014%26volume%3D39%26spage%3D14%26epage%3D24%26doi%3D10.1111%2Fjcpt.12106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Keating, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, M. P.</span><span> </span><span class="NLM_article-title">Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">701</span><span class="NLM_x">–</span> <span class="NLM_lpage">730</span><span class="refDoi"> DOI: 10.2165/00003495-200363070-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.2165%2F00003495-200363070-00008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=701-730&author=G.+M.+Keatingauthor=M.+P.+Curran&title=Peginterferon-alpha-2a+%2840kD%29+plus+ribavirin%3A+a+review+of+its+use+in+the+management+of+chronic+hepatitis+C&doi=10.2165%2F00003495-200363070-00008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114a&amp;dbid=16384&amp;doi=10.2165%2F00003495-200363070-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200363070-00008%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26aulast%3DCurran%26aufirst%3DM.%2BP.%26atitle%3DPeginterferon-alpha-2a%2520%252840kD%2529%2520plus%2520ribavirin%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520management%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DDrugs%26date%3D2003%26volume%3D63%26spage%3D701%26epage%3D730%26doi%3D10.2165%2F00003495-200363070-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit114b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Keam, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cvetković, R. S.</span><span> </span><span class="NLM_article-title">Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">1273</span><span class="NLM_x">–</span> <span class="NLM_lpage">1317</span><span class="refDoi"> DOI: 10.2165/00003495-200868090-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.2165%2F00003495-200868090-00006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=1273-1317&author=S.+J.+Keamauthor=R.+S.+Cvetkovi%C4%87&title=Peginterferon-alpha-2a+%2840+kD%29+plus+ribavirin%3A+a+review+of+its+use+in+the+management+of+chronic+hepatitis+C+mono-infection&doi=10.2165%2F00003495-200868090-00006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114b&amp;dbid=16384&amp;doi=10.2165%2F00003495-200868090-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200868090-00006%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26aulast%3DCvetkovi%25C4%2587%26aufirst%3DR.%2BS.%26atitle%3DPeginterferon-alpha-2a%2520%252840%2520kD%2529%2520plus%2520ribavirin%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520management%2520of%2520chronic%2520hepatitis%2520C%2520mono-infection%26jtitle%3DDrugs%26date%3D2008%26volume%3D68%26spage%3D1273%26epage%3D1317%26doi%3D10.2165%2F00003495-200868090-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit114c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Aghemo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grazia Rumi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, M.</span><span> </span><span class="NLM_article-title">Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">494</span><span class="refDoi"> DOI: 10.1038/nrgastro.2010.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrgastro.2010.101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=485-494&author=A.+Aghemoauthor=M.+Grazia+Rumiauthor=M.+Colombo&title=Pegylated+interferons+%CE%B12a+and+%CE%B12b+in+the+treatment+of+chronic+hepatitis+C&doi=10.1038%2Fnrgastro.2010.101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114c&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2010.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2010.101%26sid%3Dliteratum%253Aachs%26aulast%3DAghemo%26aufirst%3DA.%26aulast%3DGrazia%2BRumi%26aufirst%3DM.%26aulast%3DColombo%26aufirst%3DM.%26atitle%3DPegylated%2520interferons%2520%25CE%25B12a%2520and%2520%25CE%25B12b%2520in%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2010%26volume%3D7%26spage%3D485%26epage%3D494%26doi%3D10.1038%2Fnrgastro.2010.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Gish, R. G.</span><span> </span><span class="NLM_article-title">Treating HCV with ribavirin analogues and ribavirin-like molecules</span> <span class="citation_source-journal">J. Antimicrob. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span><span class="refDoi"> DOI: 10.1093/jac/dki405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1093%2Fjac%2Fdki405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=16293677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFyruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2006&pages=8-13&author=R.+G.+Gish&title=Treating+HCV+with+ribavirin+analogues+and+ribavirin-like+molecules&doi=10.1093%2Fjac%2Fdki405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Treating HCV with ribavirin analogues and ribavirin-like molecules</span></div><div class="casAuthors">Gish, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-13</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Nucleos(t)ide analogs have proven useful in the treatment of viral infections.  Ribavirin is a nucleoside, guanosine analog, whose mechanisms of action include inhibition of inosine monophosphate dehydrogenase (IMPDH), which is the key step in de novo guanine synthesis, a requirement for viral replication.  In combination with pegylated interferon alfa, ribavirin is the std. of care for the treatment of chronic hepatitis C today.  However, the medication is assocd. with significant hemolytic anemia, which may require dose redn., discontinuation or treatment with recombinant human erythropoietin.  Dose redn. also appears to decrease sustained viral clearance rates.  Newer IMPDH inhibitors are in various stages of development.  Viramidine, a liver-targeting prodrug of ribavirin, has demonstrated significant antiviral activity and erythrocyte-sparing properties.  It is currently in Phase 3 trials.  Clin. trials of merimepodib, another investigational IMPDH inhibitor, have completed enrollment for a Phase 2b study as a third medication for administration with pegylated interferon plus ribavirin.  Although other IMDPH inhibitors also have antiviral activity, these medications appear best suited as immunosuppressive medications at this time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrduaZ9nO9-ULVg90H21EOLACvtfcHk0li9nwZpI4_SfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFyruw%253D%253D&md5=f8793466b8e56e5ed2fc7428f544d7b6</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdki405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdki405%26sid%3Dliteratum%253Aachs%26aulast%3DGish%26aufirst%3DR.%2BG.%26atitle%3DTreating%2520HCV%2520with%2520ribavirin%2520analogues%2520and%2520ribavirin-like%2520molecules%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2006%26volume%3D57%26spage%3D8%26epage%3D13%26doi%3D10.1093%2Fjac%2Fdki405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ara, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span> </span><span class="NLM_article-title">New direct-acting antiviral therapies for treatment of chronic hepatitis C virus infection</span> <span class="citation_source-journal">Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">458</span><span class="NLM_x">–</span> <span class="NLM_lpage">466</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=458-466&author=A.+K.+Araauthor=P.+J.+Pockros&title=New+direct-acting+antiviral+therapies+for+treatment+of+chronic+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAra%26aufirst%3DA.%2BK.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26atitle%3DNew%2520direct-acting%2520antiviral%2520therapies%2520for%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DGastroenterol.%2520Hepatol.%26date%3D2015%26volume%3D11%26spage%3D458%26epage%3D466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit116b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Price, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shvachko, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauly, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manos, M. M.</span><span> </span><span class="NLM_article-title">Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting</span> <span class="citation_source-journal">Dig. Dis. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3043</span><span class="NLM_x">–</span> <span class="NLM_lpage">3052</span><span class="refDoi"> DOI: 10.1007/s10620-014-3294-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1007%2Fs10620-014-3294-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=3043-3052&author=J.+C.+Priceauthor=R.+C.+Murphyauthor=V.+A.+Shvachkoauthor=M.+P.+Paulyauthor=M.+M.+Manos&title=Effectiveness+of+telaprevir+and+boceprevir+triple+therapy+for+patients+with+hepatitis+C+virus+infection+in+a+large+integrated+care+setting&doi=10.1007%2Fs10620-014-3294-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116b&amp;dbid=16384&amp;doi=10.1007%2Fs10620-014-3294-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10620-014-3294-0%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DJ.%2BC.%26aulast%3DMurphy%26aufirst%3DR.%2BC.%26aulast%3DShvachko%26aufirst%3DV.%2BA.%26aulast%3DPauly%26aufirst%3DM.%2BP.%26aulast%3DManos%26aufirst%3DM.%2BM.%26atitle%3DEffectiveness%2520of%2520telaprevir%2520and%2520boceprevir%2520triple%2520therapy%2520for%2520patients%2520with%2520hepatitis%2520C%2520virus%2520infection%2520in%2520a%2520large%2520integrated%2520care%2520setting%26jtitle%3DDig.%2520Dis.%2520Sci.%26date%3D2014%26volume%3D59%26spage%3D3043%26epage%3D3052%26doi%3D10.1007%2Fs10620-014-3294-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit116c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Backus, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belperio, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahoumian, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mole, L. A.</span><span> </span><span class="NLM_article-title">Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort</span> <span class="citation_source-journal">Aliment. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">93</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span><span class="refDoi"> DOI: 10.1111/apt.12546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fapt.12546" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=93-103&author=L.+I.+Backusauthor=P.+S.+Belperioauthor=T.+A.+Shahoumianauthor=R.+Cheungauthor=L.+A.+Mole&title=Comparative+effectiveness+of+the+hepatitis+C+virus+protease+inhibitors+boceprevir+and+telaprevir+in+a+large+U.S.+cohort&doi=10.1111%2Fapt.12546"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116c&amp;dbid=16384&amp;doi=10.1111%2Fapt.12546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fapt.12546%26sid%3Dliteratum%253Aachs%26aulast%3DBackus%26aufirst%3DL.%2BI.%26aulast%3DBelperio%26aufirst%3DP.%2BS.%26aulast%3DShahoumian%26aufirst%3DT.%2BA.%26aulast%3DCheung%26aufirst%3DR.%26aulast%3DMole%26aufirst%3DL.%2BA.%26atitle%3DComparative%2520effectiveness%2520of%2520the%2520hepatitis%2520C%2520virus%2520protease%2520inhibitors%2520boceprevir%2520and%2520telaprevir%2520in%2520a%2520large%2520U.S.%2520cohort%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D39%26spage%3D93%26epage%3D103%26doi%3D10.1111%2Fapt.12546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit116d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearlman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Argo, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maliakkal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alam, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vainorius, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">HCV-TARGET Study Group.</span><span> </span><span class="NLM_article-title">Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">286</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span><span class="refDoi"> DOI: 10.1016/j.jhep.2014.08.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2014.08.052" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=286-293&author=S.+C.+Gordonauthor=A.+J.+Muirauthor=J.+K.+Limauthor=B.+Pearlmanauthor=C.+K.+Argoauthor=A.+Ramaniauthor=B.+Maliakkalauthor=I.+Alamauthor=T.+G.+Stewartauthor=M.+Vainoriusauthor=J.+Peterauthor=D.+R.+Nelsonauthor=M.+W.+Friedauthor=K.+R.+Reddyauthor=HCV-TARGET+Study+Group.&title=Safety+profile+of+boceprevir+and+telaprevir+in+chronic+hepatitis+C%3A+real+world+experience+from+HCV-TARGET&doi=10.1016%2Fj.jhep.2014.08.052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116d&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.08.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.08.052%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DPearlman%26aufirst%3DB.%26aulast%3DArgo%26aufirst%3DC.%2BK.%26aulast%3DRamani%26aufirst%3DA.%26aulast%3DMaliakkal%26aufirst%3DB.%26aulast%3DAlam%26aufirst%3DI.%26aulast%3DStewart%26aufirst%3DT.%2BG.%26aulast%3DVainorius%26aufirst%3DM.%26aulast%3DPeter%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DFried%26aufirst%3DM.%2BW.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3D%26atitle%3DSafety%2520profile%2520of%2520boceprevir%2520and%2520telaprevir%2520in%2520chronic%2520hepatitis%2520C%253A%2520real%2520world%2520experience%2520from%2520HCV-TARGET%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26spage%3D286%26epage%3D293%26doi%3D10.1016%2Fj.jhep.2014.08.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit116e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Smith, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Love, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammad, R. A.</span><span> </span><span class="NLM_article-title">The changing landscape of adverse drug events associated with chronic hepatitis C virus therapy</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1649</span><span class="NLM_x">–</span> <span class="NLM_lpage">1652</span><span class="refDoi"> DOI: 10.1517/14740338.2015.1088002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1517%2F14740338.2015.1088002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26365685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWhsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1649-1652&author=M.+A.+Smithauthor=B.+L.+Loveauthor=R.+A.+Mohammad&title=The+changing+landscape+of+adverse+drug+events+associated+with+chronic+hepatitis+C+virus+therapy&doi=10.1517%2F14740338.2015.1088002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116eR"><div class="casContent"><span class="casTitleNuber">116e</span><div class="casTitle"><span class="NLM_cas:atitle">The changing landscape of adverse drug events associated with chronic hepatitis C virus therapy</span></div><div class="casAuthors">Smith, Michael A.; Love, Bryan L.; Mohammad, Rima A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1649-1652</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Treatment of chronic hepatitis C virus (HCV) therapy has rapidly changed since the approval of IFN in the 1990s.  Early treatment brought about significant and therapy limiting adverse drug events (ADEs) such as anemia.  Since the direct-acting antivirals were first approved in 2011 and then advanced in 2013, treatment-related ADEs and therapy discontinuations have rapidly decreased, while sustained virol. response rates have significantly increased.  As the market for treating chronic HCV therapy has changed, so too has the ADE profile clinicians may need to manage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpunv_cYC0DILVg90H21EOLACvtfcHk0lgdMoQGHmMkoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWhsbzP&md5=7ffa79c393a587077c724434c6152b48</span></div><a href="/servlet/linkout?suffix=cit116e&amp;dbid=16384&amp;doi=10.1517%2F14740338.2015.1088002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2015.1088002%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DM.%2BA.%26aulast%3DLove%26aufirst%3DB.%2BL.%26aulast%3DMohammad%26aufirst%3DR.%2BA.%26atitle%3DThe%2520changing%2520landscape%2520of%2520adverse%2520drug%2520events%2520associated%2520with%2520chronic%2520hepatitis%2520C%2520virus%2520therapy%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2015%26volume%3D14%26spage%3D1649%26epage%3D1652%26doi%3D10.1517%2F14740338.2015.1088002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit116f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">De Clercq, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span> </span><span class="NLM_article-title">Approved antiviral drugs over the past 50 years</span> <span class="citation_source-journal">Clin. Microbiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span><span class="refDoi"> DOI: 10.1128/CMR.00102-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FCMR.00102-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=27281742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252Fos12htA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=695-747&author=E.+De+Clercqauthor=G.+Li&title=Approved+antiviral+drugs+over+the+past+50+years&doi=10.1128%2FCMR.00102-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116fR"><div class="casContent"><span class="casTitleNuber">116f</span><div class="casTitle"><span class="NLM_cas:atitle">Approved Antiviral Drugs over the Past 50 Years</span></div><div class="casAuthors">De Clercq Erik; Li Guangdi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical microbiology reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">695-747</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs categorized into 13 functional groups have been formally approved for the treatment of the following 9 human infectious diseases: (i) HIV infections (protease inhibitors, integrase inhibitors, entry inhibitors, nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and acyclic nucleoside phosphonate analogues), (ii) hepatitis B virus (HBV) infections (lamivudine, interferons, nucleoside analogues, and acyclic nucleoside phosphonate analogues), (iii) hepatitis C virus (HCV) infections (ribavirin, interferons, NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors), (iv) herpesvirus infections (5-substituted 2'-deoxyuridine analogues, entry inhibitors, nucleoside analogues, pyrophosphate analogues, and acyclic guanosine analogues), (v) influenza virus infections (ribavirin, matrix 2 protein inhibitors, RNA polymerase inhibitors, and neuraminidase inhibitors), (vi) human cytomegalovirus infections (acyclic guanosine analogues, acyclic nucleoside phosphonate analogues, pyrophosphate analogues, and oligonucleotides), (vii) varicella-zoster virus infections (acyclic guanosine analogues, nucleoside analogues, 5-substituted 2'-deoxyuridine analogues, and antibodies), (viii) respiratory syncytial virus infections (ribavirin and antibodies), and (ix) external anogenital warts caused by human papillomavirus infections (imiquimod, sinecatechins, and podofilox).  Here, we present for the first time a comprehensive overview of antiviral drugs approved over the past 50 years, shedding light on the development of effective antiviral treatments against current and emerging infectious diseases worldwide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbPpNpCY_qYTEC-75aqa5AfW6udTcc2eZz0Pedd0dtzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252Fos12htA%253D%253D&md5=1d25d961c1c6a72d6bc4634041bbb6fe</span></div><a href="/servlet/linkout?suffix=cit116f&amp;dbid=16384&amp;doi=10.1128%2FCMR.00102-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00102-15%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DG.%26atitle%3DApproved%2520antiviral%2520drugs%2520over%2520the%2520past%252050%2520years%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2016%26volume%3D29%26spage%3D695%26epage%3D747%26doi%3D10.1128%2FCMR.00102-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Melnikova, I.</span><span> </span><span class="NLM_article-title">Hepatitis C therapies</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">799</span><span class="NLM_x">–</span> <span class="NLM_lpage">800</span><span class="refDoi"> DOI: 10.1038/nrd2661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrd2661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFOlu7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=799-800&author=I.+Melnikova&title=Hepatitis+C+therapies&doi=10.1038%2Fnrd2661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C therapies</span></div><div class="casAuthors">Melnikova, Irena</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">799-800</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwmcuz35JAU7Vg90H21EOLACvtfcHk0lh07zaL4wYoAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFOlu7vI&md5=13eaab781a0fdbc9eb174db07603bf8a</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fnrd2661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2661%26sid%3Dliteratum%253Aachs%26aulast%3DMelnikova%26aufirst%3DI.%26atitle%3DHepatitis%2520C%2520therapies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D799%26epage%3D800%26doi%3D10.1038%2Fnrd2661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sarrazin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartels, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanzelka, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müh, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wincheringer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weegink, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reesink, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, A. D.</span><span> </span><span class="NLM_article-title">Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">1767</span><span class="NLM_x">–</span> <span class="NLM_lpage">1777</span><span class="refDoi"> DOI: 10.1053/j.gastro.2007.02.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1053%2Fj.gastro.2007.02.037" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2007&pages=1767-1777&author=C.+Sarrazinauthor=T.+L.+Kiefferauthor=D.+Bartelsauthor=B.+Hanzelkaauthor=U.+M%C3%BChauthor=M.+Welkerauthor=D.+Wincheringerauthor=Y.+Zhouauthor=H.+M.+Chuauthor=C.+Linauthor=C.+Weeginkauthor=H.+Reesinkauthor=S.+Zeuzemauthor=A.+D.+Kwong&title=Dynamic+hepatitis+C+virus+genotypic+and+phenotypic+changes+in+patients+treated+with+the+protease+inhibitor+telaprevir&doi=10.1053%2Fj.gastro.2007.02.037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118a&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2007.02.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2007.02.037%26sid%3Dliteratum%253Aachs%26aulast%3DSarrazin%26aufirst%3DC.%26aulast%3DKieffer%26aufirst%3DT.%2BL.%26aulast%3DBartels%26aufirst%3DD.%26aulast%3DHanzelka%26aufirst%3DB.%26aulast%3DM%25C3%25BCh%26aufirst%3DU.%26aulast%3DWelker%26aufirst%3DM.%26aulast%3DWincheringer%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DChu%26aufirst%3DH.%2BM.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DWeegink%26aufirst%3DC.%26aulast%3DReesink%26aufirst%3DH.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DKwong%26aufirst%3DA.%2BD.%26atitle%3DDynamic%2520hepatitis%2520C%2520virus%2520genotypic%2520and%2520phenotypic%2520changes%2520in%2520patients%2520treated%2520with%2520the%2520protease%2520inhibitor%2520telaprevir%26jtitle%3DGastroenterology%26date%3D2007%26volume%3D132%26spage%3D1767%26epage%3D1777%26doi%3D10.1053%2Fj.gastro.2007.02.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit118b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Susser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermehren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forestier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welker, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grigorian, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Füller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarrazin, C.</span><span> </span><span class="NLM_article-title">Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir</span> <span class="citation_source-journal">J. Clin. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span><span class="refDoi"> DOI: 10.1016/j.jcv.2011.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jcv.2011.08.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=321-327&author=S.+Susserauthor=J.+Vermehrenauthor=N.+Forestierauthor=M.+W.+Welkerauthor=N.+Grigorianauthor=C.+F%C3%BCllerauthor=D.+Pernerauthor=S.+Zeuzemauthor=C.+Sarrazin&title=Analysis+of+long-term+persistence+of+resistance+mutations+within+the+hepatitis+C+virus+NS3+protease+after+treatment+with+telaprevir+or+boceprevir&doi=10.1016%2Fj.jcv.2011.08.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118b&amp;dbid=16384&amp;doi=10.1016%2Fj.jcv.2011.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcv.2011.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DSusser%26aufirst%3DS.%26aulast%3DVermehren%26aufirst%3DJ.%26aulast%3DForestier%26aufirst%3DN.%26aulast%3DWelker%26aufirst%3DM.%2BW.%26aulast%3DGrigorian%26aufirst%3DN.%26aulast%3DF%25C3%25BCller%26aufirst%3DC.%26aulast%3DPerner%26aufirst%3DD.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DSarrazin%26aufirst%3DC.%26atitle%3DAnalysis%2520of%2520long-term%2520persistence%2520of%2520resistance%2520mutations%2520within%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520after%2520treatment%2520with%2520telaprevir%2520or%2520boceprevir%26jtitle%3DJ.%2520Clin.%2520Virol.%26date%3D2011%26volume%3D52%26spage%3D321%26epage%3D327%26doi%3D10.1016%2Fj.jcv.2011.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit118c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bartels, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, E. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcial, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrn, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeiffer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tigges, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adiwijaya, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, T. L.</span><span> </span><span class="NLM_article-title">Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects</span> <span class="citation_source-journal">J. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">198</span><span class="NLM_x">, </span> <span class="NLM_fpage">800</span><span class="NLM_x">–</span> <span class="NLM_lpage">807</span><span class="refDoi"> DOI: 10.1086/591141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1086%2F591141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2008&pages=800-807&author=D.+J.+Bartelsauthor=Y.+Zhouauthor=E.+Z.+Zhangauthor=M.+Marcialauthor=R.+A.+Byrnauthor=T.+Pfeifferauthor=A.+M.+Tiggesauthor=B.+S.+Adiwijayaauthor=C.+Linauthor=A.+D.+Kwongauthor=T.+L.+Kieffer&title=Natural+prevalence+of+hepatitis+C+virus+variants+with+decreased+sensitivity+to+NS3.4A+protease+inhibitors+in+treatment-naive+subjects&doi=10.1086%2F591141"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118c&amp;dbid=16384&amp;doi=10.1086%2F591141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F591141%26sid%3Dliteratum%253Aachs%26aulast%3DBartels%26aufirst%3DD.%2BJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DE.%2BZ.%26aulast%3DMarcial%26aufirst%3DM.%26aulast%3DByrn%26aufirst%3DR.%2BA.%26aulast%3DPfeiffer%26aufirst%3DT.%26aulast%3DTigges%26aufirst%3DA.%2BM.%26aulast%3DAdiwijaya%26aufirst%3DB.%2BS.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DKwong%26aufirst%3DA.%2BD.%26aulast%3DKieffer%26aufirst%3DT.%2BL.%26atitle%3DNatural%2520prevalence%2520of%2520hepatitis%2520C%2520virus%2520variants%2520with%2520decreased%2520sensitivity%2520to%2520NS3.4A%2520protease%2520inhibitors%2520in%2520treatment-naive%2520subjects%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2008%26volume%3D198%26spage%3D800%26epage%3D807%26doi%3D10.1086%2F591141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Boyle, D. R.,  2nd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kienzle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1924</span><span class="NLM_x">–</span> <span class="NLM_lpage">1935</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1924-1935&author=R.+A.+Fridellauthor=C.+Wangauthor=J.-H.+Sunauthor=D.+R.+O%27Boyleauthor=P.+Nowerauthor=L.+Valeraauthor=D.+Qiuauthor=S.+Robertsauthor=X.+Huangauthor=B.+Kienzleauthor=M.+Bifanoauthor=R.+E.+Nettlesauthor=M.+Gao&title=Genotypic+and+phenotypic+analysis+of+variants+resistant+to+hepatitis+C+virus+nonstructural+protein+5A+replication+complex+inhibitor+BMS-790052+in+humans%3A+in+vitro+and+in+vivo+correlations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DO%2527Boyle%26aufirst%3DD.%2BR.%26aulast%3DNower%26aufirst%3DP.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DQiu%26aufirst%3DD.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DKienzle%26aufirst%3DB.%26aulast%3DBifano%26aufirst%3DM.%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DGenotypic%2520and%2520phenotypic%2520analysis%2520of%2520variants%2520resistant%2520to%2520hepatitis%2520C%2520virus%2520nonstructural%2520protein%25205A%2520replication%2520complex%2520inhibitor%2520BMS-790052%2520in%2520humans%253A%2520in%2520vitro%2520and%2520in%2520vivo%2520correlations%26jtitle%3DHepatology%26date%3D2011%26volume%3D54%26spage%3D1924%26epage%3D1935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit119b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Boyle, D. R.,  2nd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2054</span><span class="NLM_x">–</span> <span class="NLM_lpage">2065</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=2054-2065&author=C.+Wangauthor=J.-H.+Sunauthor=D.+R.+O%27Boyleauthor=P.+Nowerauthor=L.+Valeraauthor=S.+Robertsauthor=R.+A.+Fridellauthor=M.+Gao&title=Persistence+of+resistant+variants+in+hepatitis+C+virus-infected+patients+treated+with+the+NS5A+replication+complex+inhibitor+daclatasvir"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DO%2527Boyle%26aufirst%3DD.%2BR.%26aulast%3DNower%26aufirst%3DP.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DPersistence%2520of%2520resistant%2520variants%2520in%2520hepatitis%2520C%2520virus-infected%2520patients%2520treated%2520with%2520the%2520NS5A%2520replication%2520complex%2520inhibitor%2520daclatasvir%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D2054%26epage%3D2065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Powdrill, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchesnokov, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozak, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svarovskaia, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouyos, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Götte, M.</span><span> </span><span class="NLM_article-title">Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">20509</span><span class="NLM_x">–</span> <span class="NLM_lpage">20513</span><span class="refDoi"> DOI: 10.1073/pnas.1105797108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1073%2Fpnas.1105797108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=20509-20513&author=M.+H.+Powdrillauthor=E.+P.+Tchesnokovauthor=R.+A.+Kozakauthor=R.+S.+Russellauthor=R.+Martinauthor=E.+S.+Svarovskaiaauthor=H.+Moauthor=R.+D.+Kouyosauthor=M.+G%C3%B6tte&title=Contribution+of+a+mutational+bias+in+hepatitis+C+virus+replication+to+the+genetic+barrier+in+the+development+of+drug+resistance&doi=10.1073%2Fpnas.1105797108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1105797108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1105797108%26sid%3Dliteratum%253Aachs%26aulast%3DPowdrill%26aufirst%3DM.%2BH.%26aulast%3DTchesnokov%26aufirst%3DE.%2BP.%26aulast%3DKozak%26aufirst%3DR.%2BA.%26aulast%3DRussell%26aufirst%3DR.%2BS.%26aulast%3DMartin%26aufirst%3DR.%26aulast%3DSvarovskaia%26aufirst%3DE.%2BS.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DKouyos%26aufirst%3DR.%2BD.%26aulast%3DG%25C3%25B6tte%26aufirst%3DM.%26atitle%3DContribution%2520of%2520a%2520mutational%2520bias%2520in%2520hepatitis%2520C%2520virus%2520replication%2520to%2520the%2520genetic%2520barrier%2520in%2520the%2520development%2520of%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D20509%26epage%3D20513%26doi%3D10.1073%2Fpnas.1105797108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit120b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wyles, D. L.</span><span> </span><span class="NLM_article-title">Antiviral resistance and the future landscape of hepatitis C virus infection therapy</span> <span class="citation_source-journal">J. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">207</span><span class="NLM_x"> (</span><span class="NLM_issue">S1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S33</span><span class="NLM_x">–</span> <span class="NLM_lpage">S39</span><span class="refDoi"> DOI: 10.1093/infdis/jis761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1093%2Finfdis%2Fjis761" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=2013&pages=S33-S39&issue=S1&author=D.+L.+Wyles&title=Antiviral+resistance+and+the+future+landscape+of+hepatitis+C+virus+infection+therapy&doi=10.1093%2Finfdis%2Fjis761"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120b&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjis761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjis761%26sid%3Dliteratum%253Aachs%26aulast%3DWyles%26aufirst%3DD.%2BL.%26atitle%3DAntiviral%2520resistance%2520and%2520the%2520future%2520landscape%2520of%2520hepatitis%2520C%2520virus%2520infection%2520therapy%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2013%26volume%3D207%26issue%3DS1%26spage%3DS33%26epage%3DS39%26doi%3D10.1093%2Finfdis%2Fjis761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit120c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wyles, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, J. A.</span><span> </span><span class="NLM_article-title">Importance of HCV genotype 1 subtypes for drug resistance and response to therapy</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">240</span><span class="refDoi"> DOI: 10.1111/jvh.12230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fjvh.12230" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=229-240&author=D.+L.+Wylesauthor=J.+A.+Gutierrez&title=Importance+of+HCV+genotype+1+subtypes+for+drug+resistance+and+response+to+therapy&doi=10.1111%2Fjvh.12230"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120c&amp;dbid=16384&amp;doi=10.1111%2Fjvh.12230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.12230%26sid%3Dliteratum%253Aachs%26aulast%3DWyles%26aufirst%3DD.%2BL.%26aulast%3DGutierrez%26aufirst%3DJ.%2BA.%26atitle%3DImportance%2520of%2520HCV%2520genotype%25201%2520subtypes%2520for%2520drug%2520resistance%2520and%2520response%2520to%2520therapy%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2014%26volume%3D21%26spage%3D229%26epage%3D240%26doi%3D10.1111%2Fjvh.12230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirschfield, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghesquiere, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sievert, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafran, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatum, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waked, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esmat, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serfaty, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vierling, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiland, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunetto, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwo, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bräu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noviello, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnittman, S.</span><span> </span><span class="NLM_article-title">Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">948</span><span class="NLM_x">–</span> <span class="NLM_lpage">956</span><span class="refDoi"> DOI: 10.1136/gutjnl-2014-307498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1136%2Fgutjnl-2014-307498" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=948-956&author=C.+H%C3%A9zodeauthor=G.+M.+Hirschfieldauthor=W.+Ghesquiereauthor=W.+Sievertauthor=M.+Rodriguez-Torresauthor=S.+D.+Shafranauthor=P.+J.+Thuluvathauthor=H.+A.+Tatumauthor=I.+Wakedauthor=G.+E.+Esmatauthor=E.+J.+Lawitzauthor=V.+K.+Rustgiauthor=S.+Polauthor=N.+Weisauthor=P.+J.+Pockrosauthor=M.+Bourli%C3%A8reauthor=L.+Serfatyauthor=J.+M.+Vierlingauthor=M.+W.+Friedauthor=O.+Weilandauthor=M.+R.+Brunettoauthor=G.+T.+Eversonauthor=S.+Zeuzemauthor=P.+Y.+Kwoauthor=M.+Sulkowskiauthor=N.+Br%C3%A4uauthor=D.+Hernandezauthor=F.+McPheeauthor=M.+Wind-Rotoloauthor=Z.+Liuauthor=S.+Novielloauthor=E.+A.+Hughesauthor=P.+D.+Yinauthor=S.+Schnittman&title=Daclatasvir+plus+peginterferon+alfa+and+ribavirin+for+treatment-naive+chronic+hepatitis+C+genotype+1+or+4+infection%3A+a+randomised+study&doi=10.1136%2Fgutjnl-2014-307498"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121a&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2014-307498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2014-307498%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DHirschfield%26aufirst%3DG.%2BM.%26aulast%3DGhesquiere%26aufirst%3DW.%26aulast%3DSievert%26aufirst%3DW.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DShafran%26aufirst%3DS.%2BD.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DTatum%26aufirst%3DH.%2BA.%26aulast%3DWaked%26aufirst%3DI.%26aulast%3DEsmat%26aufirst%3DG.%2BE.%26aulast%3DLawitz%26aufirst%3DE.%2BJ.%26aulast%3DRustgi%26aufirst%3DV.%2BK.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DWeis%26aufirst%3DN.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DSerfaty%26aufirst%3DL.%26aulast%3DVierling%26aufirst%3DJ.%2BM.%26aulast%3DFried%26aufirst%3DM.%2BW.%26aulast%3DWeiland%26aufirst%3DO.%26aulast%3DBrunetto%26aufirst%3DM.%2BR.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DKwo%26aufirst%3DP.%2BY.%26aulast%3DSulkowski%26aufirst%3DM.%26aulast%3DBr%25C3%25A4u%26aufirst%3DN.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DNoviello%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DYin%26aufirst%3DP.%2BD.%26aulast%3DSchnittman%26aufirst%3DS.%26atitle%3DDaclatasvir%2520plus%2520peginterferon%2520alfa%2520and%2520ribavirin%2520for%2520treatment-naive%2520chronic%2520hepatitis%2520C%2520genotype%25201%2520or%25204%2520infection%253A%2520a%2520randomised%2520study%26jtitle%3DGut%26date%3D2015%26volume%3D64%26spage%3D948%26epage%3D956%26doi%3D10.1136%2Fgutjnl-2014-307498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit121b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dore, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafran, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramji, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatum, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taliani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunetto, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaltron, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strasser, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghesquiere, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harley, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Lédinghen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooney, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noviello, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span> </span><span class="NLM_article-title">Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">148</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">366</span><span class="refDoi"> DOI: 10.1053/j.gastro.2014.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1053%2Fj.gastro.2014.10.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2015&pages=355-366&author=G.+J.+Doreauthor=E.+Lawitzauthor=C.+H%C3%A9zodeauthor=S.+D.+Shafranauthor=A.+Ramjiauthor=H.+A.+Tatumauthor=G.+Talianiauthor=A.+Tranauthor=M.+R.+Brunettoauthor=S.+Zaltronauthor=S.+I.+Strasserauthor=N.+Weisauthor=W.+Ghesquiereauthor=S.+S.+Leeauthor=D.+Larreyauthor=S.+Polauthor=H.+Harleyauthor=J.+Georgeauthor=S.+K.+Fungauthor=V.+de+L%C3%A9dinghenauthor=P.+Hagensauthor=F.+McPheeauthor=D.+Hernandezauthor=D.+Cohenauthor=E.+Cooneyauthor=S.+Novielloauthor=E.+Hughes&title=Daclatasvir+plus+peginterferon+and+ribavirin+is+noninferior+to+peginterferon+and+ribavirin+alone%2C+and+reduces+the+duration+of+treatment+for+HCV+genotype+2+or+3+infection&doi=10.1053%2Fj.gastro.2014.10.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121b&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2014.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2014.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DDore%26aufirst%3DG.%2BJ.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DShafran%26aufirst%3DS.%2BD.%26aulast%3DRamji%26aufirst%3DA.%26aulast%3DTatum%26aufirst%3DH.%2BA.%26aulast%3DTaliani%26aufirst%3DG.%26aulast%3DTran%26aufirst%3DA.%26aulast%3DBrunetto%26aufirst%3DM.%2BR.%26aulast%3DZaltron%26aufirst%3DS.%26aulast%3DStrasser%26aufirst%3DS.%2BI.%26aulast%3DWeis%26aufirst%3DN.%26aulast%3DGhesquiere%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DS.%2BS.%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DHarley%26aufirst%3DH.%26aulast%3DGeorge%26aufirst%3DJ.%26aulast%3DFung%26aufirst%3DS.%2BK.%26aulast%3Dde%2BL%25C3%25A9dinghen%26aufirst%3DV.%26aulast%3DHagens%26aufirst%3DP.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DCohen%26aufirst%3DD.%26aulast%3DCooney%26aufirst%3DE.%26aulast%3DNoviello%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DE.%26atitle%3DDaclatasvir%2520plus%2520peginterferon%2520and%2520ribavirin%2520is%2520noninferior%2520to%2520peginterferon%2520and%2520ribavirin%2520alone%252C%2520and%2520reduces%2520the%2520duration%2520of%2520treatment%2520for%2520HCV%2520genotype%25202%2520or%25203%2520infection%26jtitle%3DGastroenterology%26date%3D2015%26volume%3D148%26spage%3D355%26epage%3D366%26doi%3D10.1053%2Fj.gastro.2014.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Bronowicki, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratziu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bessone, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martorell, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span> </span><span class="NLM_article-title">Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1220</span><span class="NLM_x">–</span> <span class="NLM_lpage">1227</span><span class="refDoi"> DOI: 10.1016/j.jhep.2014.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2014.07.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=1220-1227&author=J.+P.+Bronowickiauthor=V.+Ratziuauthor=A.+Gadanoauthor=P.+J.+Thuluvathauthor=F.+Bessoneauthor=C.+T.+Martorellauthor=S.+Polauthor=R.+Tergauthor=Z.+Younesauthor=B.+Heauthor=T.+Eleyauthor=D.+Cohenauthor=F.+Yuauthor=D.+Hernandezauthor=F.+McPheeauthor=P.+Mendezauthor=E.+Hughes&title=Randomized+trial+of+asunaprevir+plus+peginterferon+alfa+and+ribavirin+for+previously+untreated+genotype+1+or+4+chronic+hepatitis+C&doi=10.1016%2Fj.jhep.2014.07.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DBronowicki%26aufirst%3DJ.%2BP.%26aulast%3DRatziu%26aufirst%3DV.%26aulast%3DGadano%26aufirst%3DA.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DBessone%26aufirst%3DF.%26aulast%3DMartorell%26aufirst%3DC.%2BT.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DTerg%26aufirst%3DR.%26aulast%3DYounes%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DCohen%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DMendez%26aufirst%3DP.%26aulast%3DHughes%26aufirst%3DE.%26atitle%3DRandomized%2520trial%2520of%2520asunaprevir%2520plus%2520peginterferon%2520alfa%2520and%2520ribavirin%2520for%2520previously%2520untreated%2520genotype%25201%2520or%25204%2520chronic%2520hepatitis%2520C%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D61%26spage%3D1220%26epage%3D1227%26doi%3D10.1016%2Fj.jhep.2014.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lok, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martorell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reindollar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrova, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span> </span><span class="NLM_article-title">Preliminary study of two antiviral agents for hepatitis C genotype 1</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">216</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span><span class="refDoi"> DOI: 10.1056/NEJMoa1104430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1104430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=22256805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=216-224&author=A.+S.+Lokauthor=D.+F.+Gardinerauthor=E.+Lawitzauthor=C.+Martorellauthor=G.+T.+Eversonauthor=R.+Ghalibauthor=R.+Reindollarauthor=V.+Rustgiauthor=F.+McPheeauthor=M.+Wind-Rotoloauthor=A.+Perssonauthor=K.+Zhuauthor=D.+I.+Dimitrovaauthor=T.+Eleyauthor=T.+Guoauthor=D.+M.+Graselaauthor=C.+Pasquinelli&title=Preliminary+study+of+two+antiviral+agents+for+hepatitis+C+genotype+1&doi=10.1056%2FNEJMoa1104430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123aR"><div class="casContent"><span class="casTitleNuber">123a</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary study of two antiviral agents for hepatitis C genotype 1</span></div><div class="casAuthors">Lok, Anna S.; Gardiner, David F.; Lawitz, Eric; Martorell, Claudia; Everson, Gregory T.; Ghalib, Reem; Reindollar, Robert; Rustgi, Vinod; McPhee, Fiona; Wind-Rotolo, Megan; Persson, Anna; Zhu, Kurt; Dimitrova, Dessislava I.; Eley, Timothy; Guo, Tong; Grasela, Dennis M.; Pasquinelli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">216-224</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addn. of multiple direct-acting antiviral agents to their treatment regimen.  METHODS: This open-label, phase 2a study included an exploratory cohort of 21 patients with chronic HCV genotype 1 infection who had not had a response to previous therapy (i.e., had not had ≥2 log10 decline in HCV RNA after ≥12 wk of treatment with peginterferon and ribavirin).  We randomly assigned patients to receive the NS5A replication complex inhibitor daclatasvir (60 mg once daily) and the NS3 protease inhibitor asunaprevir (600 mg twice daily) alone (group A, 11 patients) or in combination with peginterferon alfa-2a and ribavirin (group B, 10 patients) for 24 wk.  The primary end point was the percentage of patients with a sustained virol. response 12 wk after the end of the treatment period.  RESULTS: A total of 4 patients in group A (36%; 2 of 9 with HCV genotype la and 2 of 2 with genotype lb) had a sustained virol. response at 12 wk after treatment and also at 24 wk after treatment.  Six patients (all with HCV genotype la) had viral breakthrough while receiving therapy, and resistance mutations to both antiviral agents were found in all cases; 1 patient had a viral response at the end of treatment but had a relapse after the treatment period.  All 10 patients in group B had a sustained virol. response at 12 wk after treatment, and 9 had a sustained virol. response at 24 wk after treatment Diarrhea was the most common adverse event in both groups.  Six patients had transient elevations of alanine aminotransferase levels to more than 3 times the upper limit of the normal range.  CONCLUSIONS: This preliminary study involving patients with HCV genotype 1 infection who had not had a response to prior therapy showed that a sustained virol. response can be achieved with two direct-acting antiviral agents only.  In addn., a high rate of sustained virol. response was achieved when the two direct-acting antiviral agents were combined with peginterferon alfa-2a and ribavirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiY7QiDziiRbVg90H21EOLACvtfcHk0ljYlk4eWjexiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yltrw%253D&md5=5b986bac6ea53144898c91e8e2eaf5bc</span></div><a href="/servlet/linkout?suffix=cit123a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1104430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1104430%26sid%3Dliteratum%253Aachs%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DMartorell%26aufirst%3DC.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DReindollar%26aufirst%3DR.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DDimitrova%26aufirst%3DD.%2BI.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DPasquinelli%26aufirst%3DC.%26atitle%3DPreliminary%2520study%2520of%2520two%2520antiviral%2520agents%2520for%2520hepatitis%2520C%2520genotype%25201%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D216%26epage%3D224%26doi%3D10.1056%2FNEJMoa1104430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit123b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lok, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serfaty, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span> </span><span class="NLM_article-title">Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">490</span><span class="NLM_x">–</span> <span class="NLM_lpage">499</span><span class="refDoi"> DOI: 10.1016/j.jhep.2013.10.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2013.10.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24444658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=490-499&author=A.+S.+Lokauthor=D.+F.+Gardinerauthor=C.+H%C3%A9zodeauthor=E.+J.+Lawitzauthor=M.+Bourli%C3%A8reauthor=G.+T.+Eversonauthor=P.+Marcellinauthor=M.+Rodriguez-Torresauthor=S.+Polauthor=L.+Serfatyauthor=T.+Eleyauthor=S.-P.+Huangauthor=J.+Liauthor=M.+Wind-Rotoloauthor=F.+Yuauthor=F.+McPheeauthor=D.+M.+Graselaauthor=C.+Pasquinelli&title=Randomized+trial+of+daclatasvir+and+asunaprevir+with+or+without+PegIFN%2FRBV+for+hepatitis+C+virus+genotype+1+null+responders&doi=10.1016%2Fj.jhep.2013.10.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123bR"><div class="casContent"><span class="casTitleNuber">123b</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders</span></div><div class="casAuthors">Lok, Anna S.; Gardiner, David F.; Hezode, Christophe; Lawitz, Eric J.; Bourliere, Marc; Everson, Gregory T.; Marcellin, Patrick; Rodriguez-Torres, Maribel; Pol, Stanislas; Serfaty, Lawrence; Eley, Timothy; Huang, Shu-Pang; Li, Jianling; Wind-Rotolo, Megan; Yu, Fei; McPhee, Fiona; Grasela, Dennis M.; Pasquinelli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">490-499</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Patients with chronic hepatitis C virus (HCV) infection and prior null response (<2 log HCV RNA decline after ≥12 wk of PegIFN/RBV) have limited options.  We evaluated daclatasvir plus once- or twice-daily asunaprevir in non-cirrhotic genotype 1 null responders.  In this randomized, phase 2a, open-label, 24-wk treatment study, 101 patients received daclatasvir (60 mg) once-daily.  In addn., 38 genotype 1b patients received asunaprevir (200 mg) twice- (DUAL A1) or once-daily (DUAL A2); 36 genotype 1a and 5 genotype 1b patients received asunaprevir twice- (QUAD B1) or once-daily (QUAD B2) plus PegIFN/RBV; and 18 genotype 1a and 4 genotype 1b patients received asunaprevir twice-daily plus ribavirin (TRIPLE B3).  The primary endpoint was undetectable HCV RNA 12 wk post-treatment (sustained virol. response, SVR12).  Across all groups, mean HCV RNA was ≥6 log IU/mL, and 99% of patients had a non-CC IL28B genotype.  SVR12 rates were 78% (A1), 65% (A2), 95% (B1), and 95% (B2).  In B3, most genotype 1a patients experienced virol. breakthrough.  The most common adverse events were headache, diarrhea, and asthenia.  Grade 3-4 aminotransferase elevations were infrequent and not treatment-limiting.  In genotype 1 null responders, daclatasvir plus twice-daily asunaprevir DUAL therapy is effective for most genotype 1b patients, and daclatasvir, asunaprevir, and PegIFN/RBV QUAD therapy is effective for nearly all genotype 1a and 1b patients; but neither DUAL nor TRIPLE therapy is effective for genotype 1a patients.  Interferon-free regimens including daclatasvir and twice-daily asunaprevir for genotype 1 null responders should be tailored to subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmaQLpKkbNoLVg90H21EOLACvtfcHk0liUkkj06qpRVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlartw%253D%253D&md5=d216b31a62adc838c4f2215fcfff4838</span></div><a href="/servlet/linkout?suffix=cit123b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2013.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2013.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DLawitz%26aufirst%3DE.%2BJ.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DSerfaty%26aufirst%3DL.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DPasquinelli%26aufirst%3DC.%26atitle%3DRandomized%2520trial%2520of%2520daclatasvir%2520and%2520asunaprevir%2520with%2520or%2520without%2520PegIFN%252FRBV%2520for%2520hepatitis%2520C%2520virus%2520genotype%25201%2520null%2520responders%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D60%26spage%3D490%26epage%3D499%26doi%3D10.1016%2Fj.jhep.2013.10.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Gane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stedman, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angus, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritchie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ipe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcos, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Najera, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopatin, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berrey, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laughlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shulman, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. F.</span><span> </span><span class="NLM_article-title">Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">376</span><span class="NLM_x">, </span> <span class="NLM_fpage">1467</span><span class="NLM_x">–</span> <span class="NLM_lpage">1475</span><span class="refDoi"> DOI: 10.1016/S0140-6736(10)61384-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0140-6736%2810%2961384-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=1467-1475&author=E.+J.+Ganeauthor=S.+K.+Robertsauthor=C.+A.+Stedmanauthor=P.+W.+Angusauthor=B.+Ritchieauthor=R.+Elstonauthor=D.+Ipeauthor=P.+N.+Morcosauthor=L.+Baherauthor=I.+Najeraauthor=T.+Chuauthor=U.+Lopatinauthor=M.+M.+Berreyauthor=W.+Bradfordauthor=M.+Laughlinauthor=N.+S.+Shulmanauthor=P.+F.+Smith&title=Oral+combination+therapy+with+a+nucleoside+polymerase+inhibitor+%28RG7128%29+and+danoprevir+for+chronic+hepatitis+C+genotype+1+infection+%28INFORM-1%29%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+dose-escalation+trial&doi=10.1016%2FS0140-6736%2810%2961384-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2961384-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252961384-0%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DRoberts%26aufirst%3DS.%2BK.%26aulast%3DStedman%26aufirst%3DC.%2BA.%26aulast%3DAngus%26aufirst%3DP.%2BW.%26aulast%3DRitchie%26aufirst%3DB.%26aulast%3DElston%26aufirst%3DR.%26aulast%3DIpe%26aufirst%3DD.%26aulast%3DMorcos%26aufirst%3DP.%2BN.%26aulast%3DBaher%26aufirst%3DL.%26aulast%3DNajera%26aufirst%3DI.%26aulast%3DChu%26aufirst%3DT.%26aulast%3DLopatin%26aufirst%3DU.%26aulast%3DBerrey%26aufirst%3DM.%2BM.%26aulast%3DBradford%26aufirst%3DW.%26aulast%3DLaughlin%26aufirst%3DM.%26aulast%3DShulman%26aufirst%3DN.%2BS.%26aulast%3DSmith%26aufirst%3DP.%2BF.%26atitle%3DOral%2520combination%2520therapy%2520with%2520a%2520nucleoside%2520polymerase%2520inhibitor%2520%2528RG7128%2529%2520and%2520danoprevir%2520for%2520chronic%2520hepatitis%2520C%2520genotype%25201%2520infection%2520%2528INFORM-1%2529%253A%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%252C%2520dose-escalation%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26spage%3D1467%26epage%3D1475%26doi%3D10.1016%2FS0140-6736%2810%2961384-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lange, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span> </span><span class="NLM_article-title">IL28B single nucleotide polymorphisms in the treatment of hepatitis C</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">692</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span><span class="refDoi"> DOI: 10.1016/j.jhep.2011.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2011.03.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=692-701&author=C.+M.+Langeauthor=S.+Zeuzem&title=IL28B+single+nucleotide+polymorphisms+in+the+treatment+of+hepatitis+C&doi=10.1016%2Fj.jhep.2011.03.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125a&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2011.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2011.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DC.%2BM.%26aulast%3DZeuzem%26aufirst%3DS.%26atitle%3DIL28B%2520single%2520nucleotide%2520polymorphisms%2520in%2520the%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DJ.%2520Hepatol.%26date%3D2011%26volume%3D55%26spage%3D692%26epage%3D701%26doi%3D10.1016%2Fj.jhep.2011.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit125b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hayes, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aikata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span> </span><span class="NLM_article-title">Genetics of IL28B and HCV - response to infection and treatment</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">406</span><span class="NLM_x">–</span> <span class="NLM_lpage">417</span><span class="refDoi"> DOI: 10.1038/nrgastro.2012.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrgastro.2012.101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=406-417&author=C.+N.+Hayesauthor=M.+Imamuraauthor=H.+Aikataauthor=K.+Chayama&title=Genetics+of+IL28B+and+HCV+-+response+to+infection+and+treatment&doi=10.1038%2Fnrgastro.2012.101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125b&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2012.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2012.101%26sid%3Dliteratum%253Aachs%26aulast%3DHayes%26aufirst%3DC.%2BN.%26aulast%3DImamura%26aufirst%3DM.%26aulast%3DAikata%26aufirst%3DH.%26aulast%3DChayama%26aufirst%3DK.%26atitle%3DGenetics%2520of%2520IL28B%2520and%2520HCV%2520-%2520response%2520to%2520infection%2520and%2520treatment%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2012%26volume%3D9%26spage%3D406%26epage%3D417%26doi%3D10.1038%2Fnrgastro.2012.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit125c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cariani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Missale, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trenti, T.</span><span> </span><span class="NLM_article-title">Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis</span> <span class="citation_source-journal">Pharmacogenomics J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span><span class="refDoi"> DOI: 10.1038/tpj.2015.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Ftpj.2015.28" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=18-29&author=E.+Carianiauthor=L.+Roliauthor=G.+Missaleauthor=E.+Villaauthor=C.+Ferrariauthor=T.+Trenti&title=Interleukin+28B+polymorphisms+as+predictors+of+sustained+virological+response+in+chronic+hepatitis+C%3A+systematic+review+and+meta-analysis&doi=10.1038%2Ftpj.2015.28"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125c&amp;dbid=16384&amp;doi=10.1038%2Ftpj.2015.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ftpj.2015.28%26sid%3Dliteratum%253Aachs%26aulast%3DCariani%26aufirst%3DE.%26aulast%3DRoli%26aufirst%3DL.%26aulast%3DMissale%26aufirst%3DG.%26aulast%3DVilla%26aufirst%3DE.%26aulast%3DFerrari%26aufirst%3DC.%26aulast%3DTrenti%26aufirst%3DT.%26atitle%3DInterleukin%252028B%2520polymorphisms%2520as%2520predictors%2520of%2520sustained%2520virological%2520response%2520in%2520chronic%2520hepatitis%2520C%253A%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DPharmacogenomics%2520J.%26date%3D2016%26volume%3D16%26spage%3D18%26epage%3D29%26doi%3D10.1038%2Ftpj.2015.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Neumann, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gretch, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiley, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Layden, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1126/science.282.5386.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1126%2Fscience.282.5386.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=9756471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK1cXmsFOjsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=1998&pages=103-107&author=A.+U.+Neumannauthor=N.+P.+Lamauthor=H.+Dahariauthor=D.+R.+Gretchauthor=T.+E.+Wileyauthor=T.+J.+Laydenauthor=A.+S.+Perelson&title=Hepatitis+C+viral+dynamics+in+vivo+and+the+antiviral+efficacy+of+interferon-%CE%B1+therapy&doi=10.1126%2Fscience.282.5386.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126aR"><div class="casContent"><span class="casTitleNuber">126a</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy</span></div><div class="casAuthors">Neumann, Avidan U.; Lam, Nancy P.; Dahari, Harel; Gretch, David R.; Wiley, Thelma E.; Layden, Thomas J.; Perelson, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">5386</span>),
    <span class="NLM_cas:pages">103-107</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">To better understand the dynamics of hepatitis C virus and the antiviral effect of interferon-α-2b (IFN), viral decline in 23 patients during therapy was analyzed with a math. model.  The anal. indicates that the major initial effect of IFN is to block virion prodn. or release, with blocking efficacies of 81, 95, and 96% for daily doses of 5, 10, and 15 million IU, resp.  The estd. virion half-life (t1/2) was, on av., 2.7 h, with pretreatment prodn. and clearance of 1012 virions per day.  The estd. infected cell death rate exhibited large inter-patient variation (corresponding t1/2=1.7 to 70 days), was inversely correlated with baseline viral load, and was pos. correlated with alanine aminotransferase levels.  Fast death rates were predictive of virus being undetectable by polymerase chain reaction at 3 mo.  These findings show that infection with hepatitis C virus is highly dynamic and that early monitoring of viral load can help guide therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQOathmcXps7Vg90H21EOLACvtfcHk0ljBapegWc6wTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsFOjsLc%253D&md5=d349eda98ccf4883a81211b02ed553e8</span></div><a href="/servlet/linkout?suffix=cit126a&amp;dbid=16384&amp;doi=10.1126%2Fscience.282.5386.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.282.5386.103%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DA.%2BU.%26aulast%3DLam%26aufirst%3DN.%2BP.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DGretch%26aufirst%3DD.%2BR.%26aulast%3DWiley%26aufirst%3DT.%2BE.%26aulast%3DLayden%26aufirst%3DT.%2BJ.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DHepatitis%2520C%2520viral%2520dynamics%2520in%2520vivo%2520and%2520the%2520antiviral%2520efficacy%2520of%2520interferon-%25CE%25B1%2520therapy%26jtitle%3DScience%26date%3D1998%26volume%3D282%26spage%3D103%26epage%3D107%26doi%3D10.1126%2Fscience.282.5386.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit126b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Perelson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micol, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span> </span><span class="NLM_article-title">New kinetic models for the hepatitis C virus</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">749</span><span class="NLM_x">–</span> <span class="NLM_lpage">754</span><span class="refDoi"> DOI: 10.1002/hep.20882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.20882" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2005&pages=749-754&author=A.+S.+Perelsonauthor=E.+Herrmannauthor=F.+Micolauthor=S.+Zeuzem&title=New+kinetic+models+for+the+hepatitis+C+virus&doi=10.1002%2Fhep.20882"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126b&amp;dbid=16384&amp;doi=10.1002%2Fhep.20882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.20882%26sid%3Dliteratum%253Aachs%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26aulast%3DHerrmann%26aufirst%3DE.%26aulast%3DMicol%26aufirst%3DF.%26aulast%3DZeuzem%26aufirst%3DS.%26atitle%3DNew%2520kinetic%2520models%2520for%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DHepatology%26date%3D2005%26volume%3D42%26spage%3D749%26epage%3D754%26doi%3D10.1002%2Fhep.20882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit126c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Rapid emergence of protease inhibitor resistance in hepatitis C virus</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">30ra32</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3000544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1126%2Fscitranslmed.3000544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=20445200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC3czhsVCksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=30ra32&author=L.+Rongauthor=H.+Dahariauthor=R.+M.+Ribeiroauthor=A.+S.+Perelson&title=Rapid+emergence+of+protease+inhibitor+resistance+in+hepatitis+C+virus&doi=10.1126%2Fscitranslmed.3000544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126cR"><div class="casContent"><span class="casTitleNuber">126c</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid emergence of protease inhibitor resistance in hepatitis C virus</span></div><div class="casAuthors">Rong Libin; Dahari Harel; Ribeiro Ruy M; Perelson Alan S</div><div class="citationInfo"><span class="NLM_cas:title">Science translational medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">30ra32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">About 170 million people worldwide are infected with hepatitis C virus (HCV).  The current standard therapy leads to sustained viral elimination in only approximately 50% of the treated patients.  Telaprevir, an HCV protease inhibitor, has substantial antiviral activity in patients with chronic HCV infection.  However, in clinical trials, drug-resistant variants emerge at frequencies of 5 to 20% of the total virus population as early as the second day after the beginning of treatment.  Here, using probabilistic and viral dynamic models, we show that such rapid emergence of drug resistance is expected.  We calculate that all possible single- and double-mutant viruses preexist before treatment and that one additional mutation is expected to arise during therapy.  Examining data from a clinical trial of telaprevir therapy for HCV infection in detail, we show that our model fits the observed dynamics of both drug-sensitive and drug-resistant viruses and argue that therapy with only direct antivirals will require drug combinations that have a genetic barrier of four or more mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSA6aX3zCRlexsqfvU0ziafW6udTcc2eZ1LdsvPCbHQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czhsVCksw%253D%253D&md5=6ca2fe0702a2cc59599e7658c278895f</span></div><a href="/servlet/linkout?suffix=cit126c&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000544%26sid%3Dliteratum%253Aachs%26aulast%3DRong%26aufirst%3DL.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DRibeiro%26aufirst%3DR.%2BM.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DRapid%2520emergence%2520of%2520protease%2520inhibitor%2520resistance%2520in%2520hepatitis%2520C%2520virus%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D30ra32%26doi%3D10.1126%2Fscitranslmed.3000544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit126d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Guedj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1030</span><span class="NLM_x">–</span> <span class="NLM_lpage">1037</span><span class="refDoi"> DOI: 10.1002/hep.24788</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.24788" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1030-1037&author=J.+Guedjauthor=H.+Dahariauthor=E.+Shudoauthor=P.+Smithauthor=A.+S.+Perelson&title=Hepatitis+C+viral+kinetics+with+the+nucleoside+polymerase+inhibitor+mericitabine+%28RG7128%29&doi=10.1002%2Fhep.24788"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126d&amp;dbid=16384&amp;doi=10.1002%2Fhep.24788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24788%26sid%3Dliteratum%253Aachs%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DShudo%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DHepatitis%2520C%2520viral%2520kinetics%2520with%2520the%2520nucleoside%2520polymerase%2520inhibitor%2520mericitabine%2520%2528RG7128%2529%26jtitle%3DHepatology%26date%3D2012%26volume%3D55%26spage%3D1030%26epage%3D1037%26doi%3D10.1002%2Fhep.24788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit126e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Rong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffield, D. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model</span> <span class="citation_source-journal">PLoS Comput. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">e1002959</span><span class="refDoi"> DOI: 10.1371/journal.pcbi.1002959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1371%2Fjournal.pcbi.1002959" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=e1002959&issue=3&author=L.+Rongauthor=J.+Guedjauthor=H.+Dahariauthor=D.+J.+Coffieldauthor=M.+Leviauthor=P.+Smithauthor=A.+S.+Perelson&title=Analysis+of+hepatitis+C+virus+decline+during+treatment+with+the+protease+inhibitor+danoprevir+using+a+multiscale+model&doi=10.1371%2Fjournal.pcbi.1002959"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126e&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1002959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1002959%26sid%3Dliteratum%253Aachs%26aulast%3DRong%26aufirst%3DL.%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DCoffield%26aufirst%3DD.%2BJ.%26aulast%3DLevi%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DAnalysis%2520of%2520hepatitis%2520C%2520virus%2520decline%2520during%2520treatment%2520with%2520the%2520protease%2520inhibitor%2520danoprevir%2520using%2520a%2520multiscale%2520model%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2013%26volume%3D9%26issue%3D3%26spage%3De1002959%26doi%3D10.1371%2Fjournal.pcbi.1002959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit126f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Shudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Modeling HCV kinetics under therapy using PK and PD information</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">332</span><span class="refDoi"> DOI: 10.1517/17425250902787616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1517%2F17425250902787616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=19331594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkt1SmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=321-332&author=E.+Shudoauthor=R.+M.+Ribeiroauthor=A.+S.+Perelson&title=Modeling+HCV+kinetics+under+therapy+using+PK+and+PD+information&doi=10.1517%2F17425250902787616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126fR"><div class="casContent"><span class="casTitleNuber">126f</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling HCV kinetics under therapy using PK and PD information</span></div><div class="casAuthors">Shudo, Emi; Ribeiro, Ruy M.; Perelson, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">321-332</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Math. models have proven helpful in analyzing the virol. response to antiviral therapy in hepatitis C virus (HCV) infected subjects.  Objective: To summarize the uses and limitations of different models for analyzing HCV kinetic data under pegylated IFN therapy.  Methods: We formulate math. models and fit them by nonlinear least square regression to patient data to est. model parameters.  We compare the goodness of fit and parameter values estd. by different models statistically.  Results/conclusion: The best model for parameter estn. depends on the availability and the quality of data as well as the therapy used.  We also discuss the math. models that will be needed to analyze HCV kinetic data from clin. trials with new antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7kS3YsFzpdrVg90H21EOLACvtfcHk0liLvfMRzSCg7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkt1SmtL8%253D&md5=eb7d5f818c186ce3e2f80bf6e29a5b4a</span></div><a href="/servlet/linkout?suffix=cit126f&amp;dbid=16384&amp;doi=10.1517%2F17425250902787616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250902787616%26sid%3Dliteratum%253Aachs%26aulast%3DShudo%26aufirst%3DE.%26aulast%3DRibeiro%26aufirst%3DR.%2BM.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DModeling%2520HCV%2520kinetics%2520under%2520therapy%2520using%2520PK%2520and%2520PD%2520information%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26spage%3D321%26epage%3D332%26doi%3D10.1517%2F17425250902787616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit126g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Rong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling</span> <span class="citation_source-journal">Crit. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1615/CritRevImmunol.v30.i2.30</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1615%2FCritRevImmunol.v30.i2.30" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=20370626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntValsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=131-148&author=L.+Rongauthor=A.+S.+Perelson&title=Treatment+of+hepatitis+C+virus+infection+with+interferon+and+small+molecule+direct+antivirals%3A+viral+kinetics+and+modeling&doi=10.1615%2FCritRevImmunol.v30.i2.30"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126gR"><div class="casContent"><span class="casTitleNuber">126g</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling</span></div><div class="casAuthors">Rong, Libin; Perelson, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-148</span>CODEN:
                <span class="NLM_cas:coden">CCRIDE</span>;
        ISSN:<span class="NLM_cas:issn">1040-8401</span>.
    
            (<span class="NLM_cas:orgname">Begell House, Inc.</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) infection remains a threat to global public health.  Treatment with pegylated interferon (IFN) plus ribavirin leads to a sustained virol. response in about 50% of patients.  New therapies using direct antiviral agents have the potential to cure patients unresponsive to IFN-based therapies.  Math. modeling has played an important role in studying HCV kinetics.  Using models, one can evaluate the effectiveness of new treatment agents, est. important parameters that govern virus-host interactions, explore possible mechanisms of drug action against HCV, investigate the development of drug resistance, and study quasispecies dynamics during therapy.  Here we review our current knowledge of HCV kinetics under IFN-based therapy and newly developed antiviral agents specifically targeted to attack HCV, and show how math. models have helped to improve our understanding of HCV infection and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRdLbw3w12frVg90H21EOLACvtfcHk0lgIp-0SRbYuzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntValsr4%253D&md5=ee1f9e95d0f1670f51739b4fa377e840</span></div><a href="/servlet/linkout?suffix=cit126g&amp;dbid=16384&amp;doi=10.1615%2FCritRevImmunol.v30.i2.30&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1615%252FCritRevImmunol.v30.i2.30%26sid%3Dliteratum%253Aachs%26aulast%3DRong%26aufirst%3DL.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DTreatment%2520of%2520hepatitis%2520C%2520virus%2520infection%2520with%2520interferon%2520and%2520small%2520molecule%2520direct%2520antivirals%253A%2520viral%2520kinetics%2520and%2520modeling%26jtitle%3DCrit.%2520Rev.%2520Immunol.%26date%3D2010%26volume%3D30%26spage%3D131%26epage%3D148%26doi%3D10.1615%2FCritRevImmunol.v30.i2.30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit126h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Ribeiro, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoddard, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Learn, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korber, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrish, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">e1002881</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1002881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1371%2Fjournal.ppat.1002881" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=e1002881&issue=8&author=R.+M.+Ribeiroauthor=H.+Liauthor=S.+Wangauthor=M.+B.+Stoddardauthor=G.+H.+Learnauthor=B.+T.+Korberauthor=T.+Bhattacharyaauthor=J.+Guedjauthor=E.+H.+Parrishauthor=B.+H.+Hahnauthor=G.+M.+Shawauthor=A.+S.+Perelson&title=Quantifying+the+diversification+of+hepatitis+C+virus+%28HCV%29+during+primary+infection%3A+estimates+of+the+in+vivo+mutation+rate&doi=10.1371%2Fjournal.ppat.1002881"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126h&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1002881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1002881%26sid%3Dliteratum%253Aachs%26aulast%3DRibeiro%26aufirst%3DR.%2BM.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DStoddard%26aufirst%3DM.%2BB.%26aulast%3DLearn%26aufirst%3DG.%2BH.%26aulast%3DKorber%26aufirst%3DB.%2BT.%26aulast%3DBhattacharya%26aufirst%3DT.%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DParrish%26aufirst%3DE.%2BH.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DShaw%26aufirst%3DG.%2BM.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DQuantifying%2520the%2520diversification%2520of%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%2520during%2520primary%2520infection%253A%2520estimates%2520of%2520the%2520in%2520vivo%2520mutation%2520rate%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26issue%3D8%26spage%3De1002881%26doi%3D10.1371%2Fjournal.ppat.1002881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit126i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Chatterjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Mathematical modeling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1171</span><span class="NLM_x">–</span> <span class="NLM_lpage">1182</span><span class="refDoi"> DOI: 10.3851/IMP2428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.3851%2FIMP2428" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1171-1182&author=A.+Chatterjeeauthor=J.+Guedjauthor=A.+S.+Perelson&title=Mathematical+modeling+of+HCV+infection%3A+what+can+it+teach+us+in+the+era+of+direct-acting+antiviral+agents%3F&doi=10.3851%2FIMP2428"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126i&amp;dbid=16384&amp;doi=10.3851%2FIMP2428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2428%26sid%3Dliteratum%253Aachs%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DMathematical%2520modeling%2520of%2520HCV%2520infection%253A%2520what%2520can%2520it%2520teach%2520us%2520in%2520the%2520era%2520of%2520direct-acting%2520antiviral%2520agents%253F%26jtitle%3DAntiviral%2520Ther.%26date%3D2012%26volume%3D17%26spage%3D1171%26epage%3D1182%26doi%3D10.3851%2FIMP2428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit126j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Perelson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedj, J.</span><span> </span><span class="NLM_article-title">Modelling hepatitis C therapy--predicting effects of treatment</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">445</span><span class="refDoi"> DOI: 10.1038/nrgastro.2015.97</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrgastro.2015.97" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=437-445&author=A.+S.+Perelsonauthor=J.+Guedj&title=Modelling+hepatitis+C+therapy%2D%2Dpredicting+effects+of+treatment&doi=10.1038%2Fnrgastro.2015.97"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126j&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2015.97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2015.97%26sid%3Dliteratum%253Aachs%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26aulast%3DGuedj%26aufirst%3DJ.%26atitle%3DModelling%2520hepatitis%2520C%2520therapy--predicting%2520effects%2520of%2520treatment%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2015%26volume%3D12%26spage%3D437%26epage%3D445%26doi%3D10.1038%2Fnrgastro.2015.97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Chung, R. T.</span><span> </span><span class="NLM_article-title">A watershed moment in the treatment of hepatitis C</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span><span class="refDoi"> DOI: 10.1056/NEJMe1113272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMe1113272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=22256811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Gns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=273-275&author=R.+T.+Chung&title=A+watershed+moment+in+the+treatment+of+hepatitis+C&doi=10.1056%2FNEJMe1113272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">A watershed moment in the treatment of hepatitis C</span></div><div class="casAuthors">Chung, Raymond T.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-275</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv3ffT6ZbaILVg90H21EOLACvtfcHk0lgA0kDCX9T6bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Gns7s%253D&md5=a0a82b76f878d91ed04bb09ed6a6339e</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1056%2FNEJMe1113272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe1113272%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DR.%2BT.%26atitle%3DA%2520watershed%2520moment%2520in%2520the%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D273%26epage%3D275%26doi%3D10.1056%2FNEJMe1113272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lee, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, M.</span><span> </span><span class="NLM_article-title">New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials</span> <span class="citation_source-journal">Int. J. Clin. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">355</span><span class="refDoi"> DOI: 10.1111/j.1742-1241.2012.02895.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fj.1742-1241.2012.02895.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=22420497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKhsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2012&pages=342-355&author=L.+Y.+Leeauthor=C.+Y.+Tongauthor=T.+Wongauthor=M.+Wilkinson&title=New+therapies+for+chronic+hepatitis+C+infection%3A+a+systematic+review+of+evidence+from+clinical+trials&doi=10.1111%2Fj.1742-1241.2012.02895.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128aR"><div class="casContent"><span class="casTitleNuber">128a</span><div class="casTitle"><span class="NLM_cas:atitle">New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials</span></div><div class="casAuthors">Lee, L. Y.; Tong, C. Y. W.; Wong, T.; Wilkinson, M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Practice</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">342-355</span>CODEN:
                <span class="NLM_cas:coden">IJCPF9</span>;
        ISSN:<span class="NLM_cas:issn">1742-1241</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Introduction: Hepatitis C virus (HCV) affects approx. 3% of the world population.  The current std. of care for treatment of HCV is a combination of pegylated interferon and ribavirin.  Approx. 10% of patients will stop treatment and 30% of patients require dose redn. because of side effects.  For genotype 1 HCV-infected patients, only 40% of patients will achieve undetectable viral load 26 wk posttreatment.  Aims: The objectives of this review were to identify new treatments that are in clin. trials.  These include boceprevir and telaprevir which are in routine clin. use and form part of the American Assocn. for the Study of Liver Diseases (AASLD) 2011 guidelines as well as drugs based on observational studies, improving/modifying ribavirin or interferon-based therapies, modifying the host response and finally the use of direct-acting antiviral agents (DAA).  Materials and methods: MEDLINE and EMBASE databases were searched from 2008 to 2011 for treatments for hepatitis C.  Furthermore, abstrs. and poster presentations for the annual European Assocn. Study of the Liver, AASLD, Digestive Disease Week and Asian Pacific Assocn. for the study of the Liver were searched for relevant material.  Results: All four classes of DAA; NS3/NS4a serine protease inhibitors, cyclophilin inhibitors, NS5b polymerase inhibitors and NS5a inhibitors, show good success rates.  Trials have been performed without ribavirin or interferon and demonstrate good antiviral activity with a decreased side effect profile.  Combinations of DAA are a promising area of research with a high success rate.  Conclusions: Clin. trials show that future HCV therapy could be personalised, achieve higher success rates with decreased adverse incidents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcnWdjumn__7Vg90H21EOLACvtfcHk0lgA0kDCX9T6bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKhsr8%253D&md5=9620ce54c3ed4bb62e1bdc134725facd</span></div><a href="/servlet/linkout?suffix=cit128a&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-1241.2012.02895.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-1241.2012.02895.x%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DL.%2BY.%26aulast%3DTong%26aufirst%3DC.%2BY.%26aulast%3DWong%26aufirst%3DT.%26aulast%3DWilkinson%26aufirst%3DM.%26atitle%3DNew%2520therapies%2520for%2520chronic%2520hepatitis%2520C%2520infection%253A%2520a%2520systematic%2520review%2520of%2520evidence%2520from%2520clinical%2520trials%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2012%26volume%3D66%26spage%3D342%26epage%3D355%26doi%3D10.1111%2Fj.1742-1241.2012.02895.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit128b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Liang, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghany, M. G.</span><span> </span><span class="NLM_article-title">Current and future therapies for hepatitis C virus infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">1907</span><span class="NLM_x">–</span> <span class="NLM_lpage">1917</span><span class="refDoi"> DOI: 10.1056/NEJMra1213651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMra1213651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=23675659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsl2gs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=1907-1917&author=T.+J.+Liangauthor=M.+G.+Ghany&title=Current+and+future+therapies+for+hepatitis+C+virus+infection&doi=10.1056%2FNEJMra1213651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128bR"><div class="casContent"><span class="casTitleNuber">128b</span><div class="casTitle"><span class="NLM_cas:atitle">Current and future therapies for hepatitis C virus infection</span></div><div class="casAuthors">Liang, T. Jake; Ghany, Marc G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1907-1917</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The recent approval of two direct-acting antiviral agents for hepatitis C viral (HCV) infection that specifically inhibit viral replication has dramatically increased the viral clearance rate.  It is anticipated that in the course of such a screening process, a large no. of persons will be found to be infected with HCV; this article reviews the current therapy for HCV infection and the landscape of drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4zjjmKeKrZrVg90H21EOLACvtfcHk0lilV9iIkeCtfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsl2gs78%253D&md5=6be058d0298a4441a180ac076d7293aa</span></div><a href="/servlet/linkout?suffix=cit128b&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1213651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1213651%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DT.%2BJ.%26aulast%3DGhany%26aufirst%3DM.%2BG.%26atitle%3DCurrent%2520and%2520future%2520therapies%2520for%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D1907%26epage%3D1917%26doi%3D10.1056%2FNEJMra1213651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit128c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kohli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottilil, S.</span><span> </span><span class="NLM_article-title">Treatment of hepatitis C: a systematic review. <i>JAMA</i></span> <span class="citation_source-journal">J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">631</span><span class="NLM_x">–</span> <span class="NLM_lpage">640</span><span class="refDoi"> DOI: 10.1001/jama.2014.7085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1001%2Fjama.2014.7085" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2014&pages=631-640&author=A.+Kohliauthor=A.+Shafferauthor=A.+Shermanauthor=S.+Kottilil&title=Treatment+of+hepatitis+C%3A+a+systematic+review.+JAMA&doi=10.1001%2Fjama.2014.7085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128c&amp;dbid=16384&amp;doi=10.1001%2Fjama.2014.7085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2014.7085%26sid%3Dliteratum%253Aachs%26aulast%3DKohli%26aufirst%3DA.%26aulast%3DShaffer%26aufirst%3DA.%26aulast%3DSherman%26aufirst%3DA.%26aulast%3DKottilil%26aufirst%3DS.%26atitle%3DTreatment%2520of%2520hepatitis%2520C%253A%2520a%2520systematic%2520review.%2520JAMA%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2014%26volume%3D312%26spage%3D631%26epage%3D640%26doi%3D10.1001%2Fjama.2014.7085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Toyoda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, J.</span><span> </span><span class="NLM_article-title">Changes in hepatitis C virus genotype distribution in Japan</span> <span class="citation_source-journal">Epidemiol. Infect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">142</span><span class="NLM_x">, </span> <span class="NLM_fpage">2624</span><span class="NLM_x">–</span> <span class="NLM_lpage">2628</span><span class="refDoi"> DOI: 10.1017/S0950268814000478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1017%2FS0950268814000478" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2014&pages=2624-2628&author=H.+Toyodaauthor=T.+Kumadaauthor=K.+Takaguchiauthor=N.+Shimadaauthor=J.+Tanaka&title=Changes+in+hepatitis+C+virus+genotype+distribution+in+Japan&doi=10.1017%2FS0950268814000478"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1017%2FS0950268814000478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0950268814000478%26sid%3Dliteratum%253Aachs%26aulast%3DToyoda%26aufirst%3DH.%26aulast%3DKumada%26aufirst%3DT.%26aulast%3DTakaguchi%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DJ.%26atitle%3DChanges%2520in%2520hepatitis%2520C%2520virus%2520genotype%2520distribution%2520in%2520Japan%26jtitle%3DEpidemiol.%2520Infect.%26date%3D2014%26volume%3D142%26spage%3D2624%26epage%3D2628%26doi%3D10.1017%2FS0950268814000478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span><span class="refDoi"> DOI: 10.1002/hep.24724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.24724" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=742-748&author=K.+Chayamaauthor=S.+Takahashiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Ikedaauthor=H.+Ishikawaauthor=H.+Watanabeauthor=F.+McPheeauthor=E.+Hughesauthor=H.+Kumada&title=Dual+therapy+with+the+nonstructural+protein+5A+inhibitor%2C+daclatasvir%2C+and+the+nonstructural+protein+3+protease+inhibitor%2C+asunaprevir%2C+in+hepatitis+C+virus+genotype+1b-infected+null+responders&doi=10.1002%2Fhep.24724"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130a&amp;dbid=16384&amp;doi=10.1002%2Fhep.24724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24724%26sid%3Dliteratum%253Aachs%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DDual%2520therapy%2520with%2520the%2520nonstructural%2520protein%25205A%2520inhibitor%252C%2520daclatasvir%252C%2520and%2520the%2520nonstructural%2520protein%25203%2520protease%2520inhibitor%252C%2520asunaprevir%252C%2520in%2520hepatitis%2520C%2520virus%2520genotype%25201b-infected%2520null%2520responders%26jtitle%3DHepatology%26date%3D2012%26volume%3D55%26spage%3D742%26epage%3D748%26doi%3D10.1002%2Fhep.24724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit130b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">646</span><span class="NLM_x">–</span> <span class="NLM_lpage">654</span><span class="refDoi"> DOI: 10.1016/j.jhep.2012.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2012.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=23178977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvFeksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=646-654&author=Y.+Karinoauthor=J.+Toyotaauthor=K.+Ikedaauthor=F.+Suzukiauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=H.+Ishikawaauthor=H.+Watanabeauthor=D.+Hernandezauthor=F.+Yuauthor=F.+McPheeauthor=H.+Kumada&title=Characterization+of+virologic+escape+in+hepatitis+C+virus+genotype+1b+patients+treated+with+the+direct-acting+antivirals+daclatasvir+and+asunaprevir&doi=10.1016%2Fj.jhep.2012.11.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130bR"><div class="casContent"><span class="casTitleNuber">130b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir</span></div><div class="casAuthors">Karino, Yoshiyasu; Toyota, Joji; Ikeda, Kenji; Suzuki, Fumitaka; Chayama, Kazuaki; Kawakami, Yoshiiku; Ishikawa, Hiroki; Watanabe, Hideaki; Hernandez, Dennis; Yu, Fei; McPhee, Fiona; Kumada, Hiromitsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">646-654</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Daclatasvir and asunaprevir are NS5A and NS3 protease-targeted antivirals currently under development for treatment of chronic hepatitis C virus infection.  Clin. data on baseline and on-treatment correlates of drug resistance and response to these agents are currently limited.Hepatitis C virus genotype 1b Japanese patients (prior null responders to PegIFN-α/RBV [n = 21] or PegIFN-α/RBV ineligible or intolerant [n = 22]) were administered daclatasvir/asunaprevir for 24 wk during a phase 2a open-label study.  Genotypic and phenotypic analyses of NS3 and NS5A substitutions were performed at baseline, after virol. failure, and post-treatment through follow-up week 36.There were three viral breakthroughs and four relapsers.  Baseline NS3 polymorphisms (T54S, Q80L, V170M) at amino acid positions previously assocd. with low-level resistance (<9-fold) to select NS3 protease inhibitors were detected in four null responders and three ineligibles, but were not assocd. with virol. failure.  Baseline NS5A polymorphisms (L28M, L31M, Y93H) assocd. with daclatasvir resistance (<25-fold) were detected in five null responders and six ineligibles.  All three viral breakthroughs and 2/4 relapsers carried a baseline NS5A-Y93H polymorphism.  NS3 and NS5A resistance-assocd. variants were detected together (NS3-D168A/V, NS5A-L31M/V-Y93H) after virol. failure.  Generally, daclatasvir-resistant substitutions persisted through 48 wk post-treatment, whereas asunaprevir-resistant substitutions were no longer detectable.  Overall, 5/10 patients with baseline NS5A-Y93H experienced virol. failure, while 5/10 achieved a sustained virol. response.The potential assocn. of a pre-existing NS5A-Y93H polymorphism with virol. failure on daclatasvir/asunaprevir combination treatment will be examd. in larger studies.  The persistence of treatment-emergent daclatasvir- and asunaprevir-resistant substitutions will require assessment in longer-term follow-up studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6FdD0algZ2rVg90H21EOLACvtfcHk0lgW0ne0hJd_Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvFeksQ%253D%253D&md5=be5c769092743c85ce74039cb262b6ac</span></div><a href="/servlet/linkout?suffix=cit130b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DF.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DCharacterization%2520of%2520virologic%2520escape%2520in%2520hepatitis%2520C%2520virus%2520genotype%25201b%2520patients%2520treated%2520with%2520the%2520direct-acting%2520antivirals%2520daclatasvir%2520and%2520asunaprevir%26jtitle%3DJ.%2520Hepatol.%26date%3D2013%26volume%3D58%26spage%3D646%26epage%3D654%26doi%3D10.1016%2Fj.jhep.2012.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit130c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span><span class="refDoi"> DOI: 10.1016/j.jhep.2012.09.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2012.09.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=23183526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2jtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=655-662&author=Y.+Suzukiauthor=K.+Ikedaauthor=F.+Suzukiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=H.+Ishikawaauthor=J.+Watanabeauthor=W.+Huauthor=T.+Eleyauthor=F.+McPheeauthor=E.+Hughesauthor=H.+Kumada&title=Dual+oral+therapy+with+daclatasvir+and+asunaprevir+for+patients+with+HCV+genotype+1b+infection+and+limited+treatment+options&doi=10.1016%2Fj.jhep.2012.09.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130cR"><div class="casContent"><span class="casTitleNuber">130c</span><div class="casTitle"><span class="NLM_cas:atitle">Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options</span></div><div class="casAuthors">Suzuki, Yoshiyuki; Ikeda, Kenji; Suzuki, Fumitaka; Toyota, Joji; Karino, Yoshiyasu; Chayama, Kazuaki; Kawakami, Yoshiiku; Ishikawa, Hiroki; Watanabe, Hideaki; Hu, Wenhua; Eley, Timothy; McPhee, Fiona; Hughes, Eric; Kumada, Hiromitsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">655-662</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Improved therapeutic options for chronic hepatitis C virus (HCV) infection are needed for patients who are poor candidates for treatment with current regimens due to anticipated intolerability or low likelihood of response.  In this open-label, phase 2a study of Japanese patients with chronic HCV genotype 1b infection, 21 null responders (<2 log10 HCV RNA redn. after 12 wk of peginterferon/ribavirin) and 22 patients intolerant to or medically ineligible for peginterferon/ribavirin therapy received dual oral treatment for 24 wk with the NS5A replication complex inhibitor daclatasvir (DCV) and the NS3 protease inhibitor asunaprevir (ASV).  The primary efficacy end point was sustained virol. response at 12 wk post-treatment (SVR12).  Thirty-six of 43 enrolled patients completed 24 wk of therapy.  Serum HCV RNA levels declined rapidly, becoming undetectable in all patients on therapy by week 8.  Overall, 76.7% of patients achieved SVR12 and SVR24, including 90.5% of null responders and 63.6% of ineligible/intolerant patients.  There were no virol. failures among null responders.  Three ineligible/intolerant patients experienced viral breakthrough and four relapsed post-treatment.  Diarrhea, nasopharyngitis, headache, and ALT/AST increases, generally mild, were the most common adverse events; three discontinuations before week 24 were due to adverse events that included hyperbilirubinemia and transaminase elevations (two patients).  Dual therapy with daclatasvir and asunaprevir, without peginterferon/ribavirin, was well tolerated and achieved high SVR rates in two groups of difficult-to-treat patients with hepatitis C virus genotype 1b infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq1ZlrHtPRHLVg90H21EOLACvtfcHk0lg0-2ftuOQiQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2jtbw%253D&md5=48caec88fbfc444ea629aac577c2ed95</span></div><a href="/servlet/linkout?suffix=cit130c&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.09.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.09.037%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DF.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DDual%2520oral%2520therapy%2520with%2520daclatasvir%2520and%2520asunaprevir%2520for%2520patients%2520with%2520HCV%2520genotype%25201b%2520infection%2520and%2520limited%2520treatment%2520options%26jtitle%3DJ.%2520Hepatol.%26date%3D2013%26volume%3D58%26spage%3D655%26epage%3D662%26doi%3D10.1016%2Fj.jhep.2012.09.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit130c1"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Kumada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ido, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izumi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koike, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takehara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagoshi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damokosh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span> </span><span class="NLM_article-title">Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">2083</span><span class="NLM_x">–</span> <span class="NLM_lpage">2091</span><span class="refDoi"> DOI: 10.1002/hep.27113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130c1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.27113" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=2083-2091&author=H.+Kumadaauthor=Y.+Suzukiauthor=K.+Ikedaauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=A.+Idoauthor=K.+Yamamotoauthor=K.+Takaguchiauthor=N.+Izumiauthor=K.+Koikeauthor=T.+Takeharaauthor=N.+Kawadaauthor=M.+Sataauthor=H.+Miyagoshiauthor=T.+Eleyauthor=F.+McPheeauthor=A.+Damokoshauthor=H.+Ishikawaauthor=E.+Hughes&title=Daclatasvir+plus+asunaprevir+for+chronic+HCV+genotype+1b+infection&doi=10.1002%2Fhep.27113"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130c1&amp;dbid=16384&amp;doi=10.1002%2Fhep.27113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27113%26sid%3Dliteratum%253Aachs%26aulast%3DKumada%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIdo%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DTakaguchi%26aufirst%3DK.%26aulast%3DIzumi%26aufirst%3DN.%26aulast%3DKoike%26aufirst%3DK.%26aulast%3DTakehara%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DN.%26aulast%3DSata%26aufirst%3DM.%26aulast%3DMiyagoshi%26aufirst%3DH.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DDamokosh%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DHughes%26aufirst%3DE.%26atitle%3DDaclatasvir%2520plus%2520asunaprevir%2520for%2520chronic%2520HCV%2520genotype%25201b%2520infection%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26spage%3D2083%26epage%3D2091%26doi%3D10.1002%2Fhep.27113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit130d"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhore, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms</span> <span class="citation_source-journal">Adv. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">637</span><span class="NLM_x">–</span> <span class="NLM_lpage">649</span><span class="refDoi"> DOI: 10.1007/s12325-015-0221-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1007%2Fs12325-015-0221-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=637-649&author=F.+McPheeauthor=Y.+Suzukiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=M.+L.+Yuauthor=S.+H.+Ahnauthor=H.+Ishikawaauthor=R.+Bhoreauthor=N.+Zhouauthor=D.+Hernandezauthor=P.+Mendezauthor=H.+Kumada&title=High+sustained+virologic+response+to+daclatasvir+plus+asunaprevir+in+elderly+and+cirrhotic+patients+with+hepatitis+C+virus+genotype+1b+without+baseline+NS5A+polymorphisms&doi=10.1007%2Fs12325-015-0221-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130d&amp;dbid=16384&amp;doi=10.1007%2Fs12325-015-0221-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-015-0221-5%26sid%3Dliteratum%253Aachs%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DM.%2BL.%26aulast%3DAhn%26aufirst%3DS.%2BH.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DBhore%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DMendez%26aufirst%3DP.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DHigh%2520sustained%2520virologic%2520response%2520to%2520daclatasvir%2520plus%2520asunaprevir%2520in%2520elderly%2520and%2520cirrhotic%2520patients%2520with%2520hepatitis%2520C%2520virus%2520genotype%25201b%2520without%2520baseline%2520NS5A%2520polymorphisms%26jtitle%3DAdv.%2520Ther.%26date%3D2015%26volume%3D32%26spage%3D637%26epage%3D649%26doi%3D10.1007%2Fs12325-015-0221-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit130e"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Kanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasui, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haga, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imazeki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokosuka, O.</span><span> </span><span class="NLM_article-title">Daclatasvir plus asunaprevir treatment for real-world HCV genotype 1-infected patients in Japan</span> <span class="citation_source-journal">Int. J. Med. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">418</span><span class="NLM_x">–</span> <span class="NLM_lpage">423</span><span class="refDoi"> DOI: 10.7150/ijms.15519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.7150%2Fijms.15519" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=418-423&author=T.+Kandaauthor=S.+Yasuiauthor=M.+Nakamuraauthor=E.+Suzukiauthor=M.+Araiauthor=Y.+Hagaauthor=R.+Sasakiauthor=S.+Wuauthor=S.+Nakamotoauthor=F.+Imazekiauthor=O.+Yokosuka&title=Daclatasvir+plus+asunaprevir+treatment+for+real-world+HCV+genotype+1-infected+patients+in+Japan&doi=10.7150%2Fijms.15519"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130e&amp;dbid=16384&amp;doi=10.7150%2Fijms.15519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fijms.15519%26sid%3Dliteratum%253Aachs%26aulast%3DKanda%26aufirst%3DT.%26aulast%3DYasui%26aufirst%3DS.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DE.%26aulast%3DArai%26aufirst%3DM.%26aulast%3DHaga%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DNakamoto%26aufirst%3DS.%26aulast%3DImazeki%26aufirst%3DF.%26aulast%3DYokosuka%26aufirst%3DO.%26atitle%3DDaclatasvir%2520plus%2520asunaprevir%2520treatment%2520for%2520real-world%2520HCV%2520genotype%25201-infected%2520patients%2520in%2520Japan%26jtitle%3DInt.%2520J.%2520Med.%2520Sci.%26date%3D2016%26volume%3D13%26spage%3D418%26epage%3D423%26doi%3D10.7150%2Fijms.15519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Poole, R. M.</span><span> </span><span class="NLM_article-title">Daclatasvir + asunaprevir: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1559</span><span class="NLM_x">–</span> <span class="NLM_lpage">1571</span><span class="refDoi"> DOI: 10.1007/s40265-014-0279-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1007%2Fs40265-014-0279-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25117197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtl2gu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1559-1571&author=R.+M.+Poole&title=Daclatasvir+%2B+asunaprevir%3A+first+global+approval&doi=10.1007%2Fs40265-014-0279-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir + Asunaprevir: First Global Approval</span></div><div class="casAuthors">Poole, Raewyn M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1559-1571</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  The combination of daclatasvir + asunaprevir [Daklinza + Sunvepra (Japan)], two direct-acting antiviral agents, has been developed by Bristol-Myers Squibb for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infections, including those with compensated cirrhosis.  Daclatasvir + asunaprevir has received its first global approval in this indication in Japan.  Daclatasvir + asunaprevir is the first all-oral, interferon- and ribavirin-free regimen for this indication.  This article summarizes the milestones in the development of daclatasvir + asunaprevir leading to this first approval for the treatment of chronic HCV genotype 1 infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF9-lXzdKBdbVg90H21EOLACvtfcHk0lh4teuhHyaSDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtl2gu77M&md5=efde97ee214598388e1db80bb303d1c6</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0279-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0279-4%26sid%3Dliteratum%253Aachs%26aulast%3DPoole%26aufirst%3DR.%2BM.%26atitle%3DDaclatasvir%2520%252B%2520asunaprevir%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D1559%26epage%3D1571%26doi%3D10.1007%2Fs40265-014-0279-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sievert, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mollison, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angus, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronowicki, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz-Lasanta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Ledinghen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boparai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">UNITY-1 Study Group.</span><span> </span><span class="NLM_article-title">Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">1728</span><span class="NLM_x">–</span> <span class="NLM_lpage">1735</span><span class="refDoi"> DOI: 10.1001/jama.2015.3860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1001%2Fjama.2015.3860" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2015&pages=1728-1735&author=F.+Poordadauthor=W.+Sievertauthor=L.+Mollisonauthor=M.+Bennettauthor=E.+Tseauthor=N.+Brauauthor=J.+Levinauthor=T.+Sepeauthor=S.+S.+Leeauthor=P.+Angusauthor=B.+Conwayauthor=S.+Polauthor=N.+Boyerauthor=J.-P.+Bronowickiauthor=I.+Jacobsonauthor=A.+J.+Muirauthor=K.+R.+Reddyauthor=E.+Tamauthor=G.+Ortiz-Lasantaauthor=V.+de+Ledinghenauthor=M.+Sulkowskiauthor=N.+Boparaiauthor=F.+McPheeauthor=E.+Hughesauthor=E.+S.+Swensonauthor=P.+D.+Yinauthor=UNITY-1+Study+Group.&title=Fixed-dose+combination+therapy+with+daclatasvir%2C+asunaprevir%2C+and+beclabuvir+for+noncirrhotic+patients+with+HCV+genotype+1+infection&doi=10.1001%2Fjama.2015.3860"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132a&amp;dbid=16384&amp;doi=10.1001%2Fjama.2015.3860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2015.3860%26sid%3Dliteratum%253Aachs%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DSievert%26aufirst%3DW.%26aulast%3DMollison%26aufirst%3DL.%26aulast%3DBennett%26aufirst%3DM.%26aulast%3DTse%26aufirst%3DE.%26aulast%3DBrau%26aufirst%3DN.%26aulast%3DLevin%26aufirst%3DJ.%26aulast%3DSepe%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DS.%2BS.%26aulast%3DAngus%26aufirst%3DP.%26aulast%3DConway%26aufirst%3DB.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DBoyer%26aufirst%3DN.%26aulast%3DBronowicki%26aufirst%3DJ.-P.%26aulast%3DJacobson%26aufirst%3DI.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DTam%26aufirst%3DE.%26aulast%3DOrtiz-Lasanta%26aufirst%3DG.%26aulast%3Dde%2BLedinghen%26aufirst%3DV.%26aulast%3DSulkowski%26aufirst%3DM.%26aulast%3DBoparai%26aufirst%3DN.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DSwenson%26aufirst%3DE.%2BS.%26aulast%3DYin%26aufirst%3DP.%2BD.%26aulast%3D%26atitle%3DFixed-dose%2520combination%2520therapy%2520with%2520daclatasvir%252C%2520asunaprevir%252C%2520and%2520beclabuvir%2520for%2520noncirrhotic%2520patients%2520with%2520HCV%2520genotype%25201%2520infection%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2015%26volume%3D313%26spage%3D1728%26epage%3D1735%26doi%3D10.1001%2Fjama.2015.3860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit132b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herring, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheikh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yozviak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramji, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vierling, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghesquiere, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, P. D.</span><span> </span><span class="NLM_article-title">Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">1736</span><span class="NLM_x">–</span> <span class="NLM_lpage">1744</span><span class="refDoi"> DOI: 10.1001/jama.2015.3868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1001%2Fjama.2015.3868" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2015&pages=1736-1744&author=A.+J.+Muirauthor=F.+Poordadauthor=J.+Lalezariauthor=G.+Eversonauthor=G.+J.+Doreauthor=R.+Herringauthor=A.+Sheikhauthor=P.+Kwoauthor=C.+H%C3%A9zodeauthor=P.+J.+Pockrosauthor=A.+Tranauthor=J.+Yozviakauthor=N.+Reauauthor=A.+Ramjiauthor=K.+Stuartauthor=A.+J.+Thompsonauthor=J.+Vierlingauthor=B.+Freilichauthor=J.+Cooperauthor=W.+Ghesquiereauthor=R.+Yangauthor=F.+McPheeauthor=E.+A.+Hughesauthor=E.+S.+Swensonauthor=P.+D.+Yin&title=Daclatasvir+in+combination+with+asunaprevir+and+beclabuvir+for+hepatitis+C+virus+genotype+1+infection+with+compensated+cirrhosis&doi=10.1001%2Fjama.2015.3868"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132b&amp;dbid=16384&amp;doi=10.1001%2Fjama.2015.3868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2015.3868%26sid%3Dliteratum%253Aachs%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DEverson%26aufirst%3DG.%26aulast%3DDore%26aufirst%3DG.%2BJ.%26aulast%3DHerring%26aufirst%3DR.%26aulast%3DSheikh%26aufirst%3DA.%26aulast%3DKwo%26aufirst%3DP.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DTran%26aufirst%3DA.%26aulast%3DYozviak%26aufirst%3DJ.%26aulast%3DReau%26aufirst%3DN.%26aulast%3DRamji%26aufirst%3DA.%26aulast%3DStuart%26aufirst%3DK.%26aulast%3DThompson%26aufirst%3DA.%2BJ.%26aulast%3DVierling%26aufirst%3DJ.%26aulast%3DFreilich%26aufirst%3DB.%26aulast%3DCooper%26aufirst%3DJ.%26aulast%3DGhesquiere%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DSwenson%26aufirst%3DE.%2BS.%26aulast%3DYin%26aufirst%3DP.%2BD.%26atitle%3DDaclatasvir%2520in%2520combination%2520with%2520asunaprevir%2520and%2520beclabuvir%2520for%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%2520with%2520compensated%2520cirrhosis%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2015%26volume%3D313%26spage%3D1736%26epage%3D1744%26doi%3D10.1001%2Fjama.2015.3868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Conjeevaram, H.</span><span> </span><span class="NLM_article-title">Continued progress against hepatitis C infection</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">1716</span><span class="NLM_x">–</span> <span class="NLM_lpage">1717</span><span class="refDoi"> DOI: 10.1001/jama.2015.4368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1001%2Fjama.2015.4368" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2015&pages=1716-1717&author=H.+Conjeevaram&title=Continued+progress+against+hepatitis+C+infection&doi=10.1001%2Fjama.2015.4368"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1001%2Fjama.2015.4368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2015.4368%26sid%3Dliteratum%253Aachs%26aulast%3DConjeevaram%26aufirst%3DH.%26atitle%3DContinued%2520progress%2520against%2520hepatitis%2520C%2520infection%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2015%26volume%3D313%26spage%3D1716%26epage%3D1717%26doi%3D10.1001%2Fjama.2015.4368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fontana, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appelman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hindes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifano, M.</span><span> </span><span class="NLM_article-title">Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation</span> <span class="citation_source-journal">Liver Transpl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1053</span><span class="NLM_x">–</span> <span class="NLM_lpage">1059</span><span class="refDoi"> DOI: 10.1002/lt.23482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Flt.23482" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1053-1059&author=R.+J.+Fontanaauthor=E.+A.+Hughesauthor=H.+Appelmanauthor=R.+Hindesauthor=D.+Dimitrovaauthor=M.+Bifano&title=Case+report+of+successful+peginterferon%2C+ribavirin%2C+and+daclatasvir+therapy+for+recurrent+cholestatic+hepatitis+C+after+liver+retransplantation&doi=10.1002%2Flt.23482"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134a&amp;dbid=16384&amp;doi=10.1002%2Flt.23482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Flt.23482%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DAppelman%26aufirst%3DH.%26aulast%3DHindes%26aufirst%3DR.%26aulast%3DDimitrova%26aufirst%3DD.%26aulast%3DBifano%26aufirst%3DM.%26atitle%3DCase%2520report%2520of%2520successful%2520peginterferon%252C%2520ribavirin%252C%2520and%2520daclatasvir%2520therapy%2520for%2520recurrent%2520cholestatic%2520hepatitis%2520C%2520after%2520liver%2520retransplantation%26jtitle%3DLiver%2520Transpl.%26date%3D2012%26volume%3D18%26spage%3D1053%26epage%3D1059%26doi%3D10.1002%2Flt.23482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit134b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fontana, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appelman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hindes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span> </span><span class="NLM_article-title">Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C</span> <span class="citation_source-journal">Am. J. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1601</span><span class="NLM_x">–</span> <span class="NLM_lpage">1605</span><span class="refDoi"> DOI: 10.1111/ajt.12209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fajt.12209" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1601-1605&author=R.+J.+Fontanaauthor=E.+A.+Hughesauthor=M.+Bifanoauthor=H.+Appelmanauthor=D.+Dimitrovaauthor=R.+Hindesauthor=W.+T.+Symonds&title=Sofosbuvir+and+daclatasvir+combination+therapy+in+a+liver+transplant+recipient+with+severe+recurrent+cholestatic+hepatitis+C&doi=10.1111%2Fajt.12209"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134b&amp;dbid=16384&amp;doi=10.1111%2Fajt.12209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fajt.12209%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DBifano%26aufirst%3DM.%26aulast%3DAppelman%26aufirst%3DH.%26aulast%3DDimitrova%26aufirst%3DD.%26aulast%3DHindes%26aufirst%3DR.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26atitle%3DSofosbuvir%2520and%2520daclatasvir%2520combination%2520therapy%2520in%2520a%2520liver%2520transplant%2520recipient%2520with%2520severe%2520recurrent%2520cholestatic%2520hepatitis%2520C%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2013%26volume%3D13%26spage%3D1601%26epage%3D1605%26doi%3D10.1111%2Fajt.12209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit134c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Leroy, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumortier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coilly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebagh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fougerou-Leurent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radenne, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durand, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvain, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebray, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houssel-Debry, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">d’Alteroche, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov-Sanchez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diallo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pageaux, G.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duclos-Vallee, J.-C.</span><span> </span><span class="NLM_article-title">Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation</span> <span class="citation_source-journal">Clin. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1993</span><span class="NLM_x">–</span> <span class="NLM_lpage">2001</span><span class="refDoi"> DOI: 10.1016/j.cgh.2015.05.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.cgh.2015.05.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=1993-2001&author=V.+Leroyauthor=J.+Dumortierauthor=A.+Coillyauthor=M.+Sebaghauthor=C.+Fougerou-Leurentauthor=S.+Radenneauthor=D.+Bottaauthor=F.+Durandauthor=C.+Silvainauthor=P.+Lebrayauthor=P.+Houssel-Debryauthor=N.+Kamarauthor=L.+d%E2%80%99Alterocheauthor=V.+Petrov-Sanchezauthor=A.+Dialloauthor=G.-P.+Pageauxauthor=J.-C.+Duclos-Vallee&title=Efficacy+of+sofosbuvir+and+daclatasvir+in+patients+with+fibrosing+cholestatic+hepatitis+C+after+liver+transplantation&doi=10.1016%2Fj.cgh.2015.05.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134c&amp;dbid=16384&amp;doi=10.1016%2Fj.cgh.2015.05.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cgh.2015.05.030%26sid%3Dliteratum%253Aachs%26aulast%3DLeroy%26aufirst%3DV.%26aulast%3DDumortier%26aufirst%3DJ.%26aulast%3DCoilly%26aufirst%3DA.%26aulast%3DSebagh%26aufirst%3DM.%26aulast%3DFougerou-Leurent%26aufirst%3DC.%26aulast%3DRadenne%26aufirst%3DS.%26aulast%3DBotta%26aufirst%3DD.%26aulast%3DDurand%26aufirst%3DF.%26aulast%3DSilvain%26aufirst%3DC.%26aulast%3DLebray%26aufirst%3DP.%26aulast%3DHoussel-Debry%26aufirst%3DP.%26aulast%3DKamar%26aufirst%3DN.%26aulast%3Dd%25E2%2580%2599Alteroche%26aufirst%3DL.%26aulast%3DPetrov-Sanchez%26aufirst%3DV.%26aulast%3DDiallo%26aufirst%3DA.%26aulast%3DPageaux%26aufirst%3DG.-P.%26aulast%3DDuclos-Vallee%26aufirst%3DJ.-C.%26atitle%3DEfficacy%2520of%2520sofosbuvir%2520and%2520daclatasvir%2520in%2520patients%2520with%2520fibrosing%2520cholestatic%2520hepatitis%2520C%2520after%2520liver%2520transplantation%26jtitle%3DClin.%2520Gastroenterol.%2520Hepatol.%26date%3D2015%26volume%3D13%26spage%3D1993%26epage%3D2001%26doi%3D10.1016%2Fj.cgh.2015.05.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit134d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akamatsu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasegawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kokudo, N.</span><span> </span><span class="NLM_article-title">Daclatasvir and asunaprevir for recurrent hepatitis C following living-donor liver transplantation with human immunodeficiency virus coinfection</span> <span class="citation_source-journal">Hepatol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">829</span><span class="NLM_x">–</span> <span class="NLM_lpage">832</span><span class="refDoi"> DOI: 10.1111/hepr.12614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fhepr.12614" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2016&pages=829-832&author=T.+Tanakaauthor=N.+Akamatsuauthor=J.+Kanekoauthor=J.+Aritaauthor=S.+Tamuraauthor=K.+Hasegawaauthor=Y.+Sakamotoauthor=N.+Kokudo&title=Daclatasvir+and+asunaprevir+for+recurrent+hepatitis+C+following+living-donor+liver+transplantation+with+human+immunodeficiency+virus+coinfection&doi=10.1111%2Fhepr.12614"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134d&amp;dbid=16384&amp;doi=10.1111%2Fhepr.12614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fhepr.12614%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DAkamatsu%26aufirst%3DN.%26aulast%3DKaneko%26aufirst%3DJ.%26aulast%3DArita%26aufirst%3DJ.%26aulast%3DTamura%26aufirst%3DS.%26aulast%3DHasegawa%26aufirst%3DK.%26aulast%3DSakamoto%26aufirst%3DY.%26aulast%3DKokudo%26aufirst%3DN.%26atitle%3DDaclatasvir%2520and%2520asunaprevir%2520for%2520recurrent%2520hepatitis%2520C%2520following%2520living-donor%2520liver%2520transplantation%2520with%2520human%2520immunodeficiency%2520virus%2520coinfection%26jtitle%3DHepatol.%2520Res.%26date%3D2016%26volume%3D46%26spage%3D829%26epage%3D832%26doi%3D10.1111%2Fhepr.12614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit134e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Herzer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos-Köhn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Achterfeld, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canbay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerken, G.</span><span> </span><span class="NLM_article-title">Daclatasvir, simeprevir and ribavirin as a promising interferon-free triple regimen for HCV recurrence after liver transplant</span> <span class="citation_source-journal">Digestion</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">326</span><span class="NLM_x">–</span> <span class="NLM_lpage">333</span><span class="refDoi"> DOI: 10.1159/000382075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1159%2F000382075" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2015&pages=326-333&author=K.+Herzerauthor=A.+Papadopoulos-K%C3%B6hnauthor=A.+Walkerauthor=A.+Achterfeldauthor=A.+Paulauthor=A.+Canbayauthor=J.+Timmauthor=G.+Gerken&title=Daclatasvir%2C+simeprevir+and+ribavirin+as+a+promising+interferon-free+triple+regimen+for+HCV+recurrence+after+liver+transplant&doi=10.1159%2F000382075"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134e&amp;dbid=16384&amp;doi=10.1159%2F000382075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000382075%26sid%3Dliteratum%253Aachs%26aulast%3DHerzer%26aufirst%3DK.%26aulast%3DPapadopoulos-K%25C3%25B6hn%26aufirst%3DA.%26aulast%3DWalker%26aufirst%3DA.%26aulast%3DAchterfeld%26aufirst%3DA.%26aulast%3DPaul%26aufirst%3DA.%26aulast%3DCanbay%26aufirst%3DA.%26aulast%3DTimm%26aufirst%3DJ.%26aulast%3DGerken%26aufirst%3DG.%26atitle%3DDaclatasvir%252C%2520simeprevir%2520and%2520ribavirin%2520as%2520a%2520promising%2520interferon-free%2520triple%2520regimen%2520for%2520HCV%2520recurrence%2520after%2520liver%2520transplant%26jtitle%3DDigestion%26date%3D2015%26volume%3D91%26spage%3D326%26epage%3D333%26doi%3D10.1159%2F000382075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit134f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Coilly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duclos-Vallée, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuel, D.</span><span> </span><span class="NLM_article-title">Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">44</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span><span class="refDoi"> DOI: 10.1111/liv.12728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fliv.12728" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=44-50&issue=Suppl.+1&author=A.+Coillyauthor=B.+Rocheauthor=J.+C.+Duclos-Vall%C3%A9eauthor=D.+Samuel&title=Optimal+therapy+in+hepatitis+C+virus+liver+transplant+patients+with+direct+acting+antivirals&doi=10.1111%2Fliv.12728"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134f&amp;dbid=16384&amp;doi=10.1111%2Fliv.12728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fliv.12728%26sid%3Dliteratum%253Aachs%26aulast%3DCoilly%26aufirst%3DA.%26aulast%3DRoche%26aufirst%3DB.%26aulast%3DDuclos-Vall%25C3%25A9e%26aufirst%3DJ.%2BC.%26aulast%3DSamuel%26aufirst%3DD.%26atitle%3DOptimal%2520therapy%2520in%2520hepatitis%2520C%2520virus%2520liver%2520transplant%2520patients%2520with%2520direct%2520acting%2520antivirals%26jtitle%3DLiver%2520Int.%26date%3D2015%26volume%3D35%26issue%3DSuppl.%25201%26spage%3D44%26epage%3D50%26doi%3D10.1111%2Fliv.12728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit134g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Righi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Londero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnelutti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassetti, M.</span><span> </span><span class="NLM_article-title">Impact of new treatment options for hepatitis C virus infection in liver transplantation</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">10760</span><span class="NLM_x">–</span> <span class="NLM_lpage">10775</span><span class="refDoi"> DOI: 10.3748/wjg.v21.i38.10760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.3748%2Fwjg.v21.i38.10760" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=10760-10775&author=E.+Righiauthor=A.+Londeroauthor=A.+Carneluttiauthor=U.+Baccaraniauthor=M.+Bassetti&title=Impact+of+new+treatment+options+for+hepatitis+C+virus+infection+in+liver+transplantation&doi=10.3748%2Fwjg.v21.i38.10760"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134g&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v21.i38.10760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v21.i38.10760%26sid%3Dliteratum%253Aachs%26aulast%3DRighi%26aufirst%3DE.%26aulast%3DLondero%26aufirst%3DA.%26aulast%3DCarnelutti%26aufirst%3DA.%26aulast%3DBaccarani%26aufirst%3DU.%26aulast%3DBassetti%26aufirst%3DM.%26atitle%3DImpact%2520of%2520new%2520treatment%2520options%2520for%2520hepatitis%2520C%2520virus%2520infection%2520in%2520liver%2520transplantation%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2015%26volume%3D21%26spage%3D10760%26epage%3D10775%26doi%3D10.3748%2Fwjg.v21.i38.10760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassanein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lok, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinestrosa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P.J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hindes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span> </span><span class="NLM_article-title">for the AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span><span class="refDoi"> DOI: 10.1056/NEJMoa1306218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1306218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24428467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFymtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=211-221&author=M.+S.+Sulkowskiauthor=D.+F.+Gardinerauthor=M.+Rodriguez-Torresauthor=K.+R.+Reddyauthor=T.+Hassaneinauthor=I.+Jacobsonauthor=E.+Lawitzauthor=A.+S.+Lokauthor=F.+Hinestrosaauthor=P.J.+Thuluvathauthor=H.+Schwartzauthor=D.+R.+Nelsonauthor=G.+T.+Eversonauthor=T.+Eleyauthor=M.+Wind-Rotoloauthor=S.-P.+Huangauthor=M.+Gaoauthor=D.+Hernandezauthor=F.+McPheeauthor=D.+Shermanauthor=R.+Hindesauthor=W.+Symondsauthor=C.+Pasquinelliauthor=D.+M.+Grasela&title=for+the+AI444040+Study+Group.+Daclatasvir+plus+sofosbuvir+for+previously+treated+or+untreated+chronic+HCV+infection&doi=10.1056%2FNEJMoa1306218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135aR"><div class="casContent"><span class="casTitleNuber">135a</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection</span></div><div class="casAuthors">Sulkowski, Mark S.; Gardiner, David F.; Rodriguez-Torres, Maribel; Reddy, K. Rajender; Hassanein, Tarek; Jacobson, Ira; Lawitz, Eric; Lok, Anna S.; Hinestrosa, Federico; Thuluvath, Paul J.; Schwartz, Howard; Nelson, David R.; Everson, Gregory T.; Eley, Timothy; Wind-Rotolo, Megan; Huang, Shu-Pang; Gao, Min; Hernandez, Dennis; McPhee, Fiona; Sherman, Diane; Hindes, Robert; Symonds, William; Pasquinelli, Claudio; Grasela, Dennis M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211-221</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection.  We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analog HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3.  METHODS In this open-label study, we initially randomly assigned 44 previously untreated patients with HCV genotype 1 infection and 44 patients infected with HCV genotype 2 or 3 to daclatasvir at a dose of 60 mg orally once daily plus sofosbuvir at a dose of 400 mg orally once daily, with or without ribavirin, for 24 wk.  The study was expanded to include 123 addnl. patients with genotype 1 infection who were randomly assigned to daclatasvir plus sofosbuvir, with or without ribavirin, for 12 wk (82 previously untreated patients) or 24 wk (41 patients who had previous virol. failure with telaprevir or boceprevir plus peginterferon alfa ribavirin).  The primary end point was a sustained virol. response (an HCV RNA level of <25 IU per mL) at week 12 after the end of therapy.  RESULTS Overall, 211 patients received treatment.  Among patients with genotype 1 infection, 98% of 126 previously untreated patients and 98% of 41 patients who did not have a sustained virol. response with HCV protease inhibitors had a sustained virol. response at week 12 after the end of therapy.  A total of 92% of 26 patients with genotype 2 infection and 89% of 18 patients with genotype 3 infection had a sustained virol. response at week 12.  High rates of sustained virol. response at week 12 were obsd. among patients with HCV subtypes 1a and 1b (98% and 100%, resp.) and those with CC and non-CC IL28B genotypes (93% and 98%, resp.), as well as among patients who received ribavirin and those who did not (94% and 98%, resp.).  The most common adverse events were fatigue, headache, and nausea.  CONCLUSIONS Once-daily oral daclatasvir plus sofosbuvir was assocd. with high rates of sustained virol. response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMiCkoKS-KUrVg90H21EOLACvtfcHk0lhQEL_Ysf-B7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFymtb0%253D&md5=bc9eff52401d2f1e00505d30fcffd2c5</span></div><a href="/servlet/linkout?suffix=cit135a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306218%26sid%3Dliteratum%253Aachs%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DI.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DHinestrosa%26aufirst%3DF.%26aulast%3DThuluvath%26aufirst%3DP.J.%26aulast%3DSchwartz%26aufirst%3DH.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DSherman%26aufirst%3DD.%26aulast%3DHindes%26aufirst%3DR.%26aulast%3DSymonds%26aufirst%3DW.%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26atitle%3Dfor%2520the%2520AI444040%2520Study%2520Group.%2520Daclatasvir%2520plus%2520sofosbuvir%2520for%2520previously%2520treated%2520or%2520untreated%2520chronic%2520HCV%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D211%26epage%3D221%26doi%3D10.1056%2FNEJMoa1306218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit135b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wyles, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruane, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dieterich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luetkemeyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dretler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fishbein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gathe, J. C.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinestrosa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huynh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overton, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramgopal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rashbaum, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarsella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yozviak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noviello, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ackerman, P.</span><span> </span><span class="NLM_article-title">for the ALLY-2 Investigators. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">714</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span><span class="refDoi"> DOI: 10.1056/NEJMoa1503153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1503153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26196502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC28XpslOltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=714-725&author=D.+L.+Wylesauthor=P.+J.+Ruaneauthor=M.+S.+Sulkowskiauthor=D.+Dieterichauthor=A.+Luetkemeyerauthor=T.+R.+Morganauthor=K.+E.+Shermanauthor=R.+Dretlerauthor=D.+Fishbeinauthor=J.+C.+Gatheauthor=S.+Hennauthor=F.+Hinestrosaauthor=C.+Huynhauthor=C.+McDonaldauthor=A.+Millsauthor=E.+T.+Overtonauthor=M.+Ramgopalauthor=B.+Rashbaumauthor=G.+Rayauthor=A.+Scarsellaauthor=J.+Yozviakauthor=F.+McPheeauthor=Z.+Liuauthor=E.+Hughesauthor=P.+D.+Yinauthor=S.+Novielloauthor=P.+Ackerman&title=for+the+ALLY-2+Investigators.+Daclatasvir+plus+sofosbuvir+for+HCV+in+patients+coinfected+with+HIV-1&doi=10.1056%2FNEJMoa1503153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135bR"><div class="casContent"><span class="casTitleNuber">135b</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1</span></div><div class="casAuthors">Wyles, D. L.; Ruane, P. J.; Sulkowski, M. S.; Dieterich, D.; Luetkemeyer, A.; Morgan, T. R.; Sherman, K. E.; Dretler, R.; Fishbein, D.; Gathe, J. C., Jr.; Henn, S.; Hinestrosa, F.; Huynh, C.; McDonald, C.; Mills, A.; Overton, E. T.; Ramgopal, M.; Rashbaum, B.; Ray, G.; Scarsella, A.; Yozviak, J.; McPhee, F.; Liu, Z.; Hughes, E.; Yin, P. D.; Noviello, S.; Ackerman, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">714-725</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The combination of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor sofosbuvir has shown efficacy in patients with HCV monoinfection.  Data are lacking on the efficacy and safety of this combination in patients coinfected with human immunodeficiency virus type 1 (HIV-1).  Methods: This was an open-label study involving 151 patients who had not received HCV treatment and 52 previously treated patients, all of whom were coinfected with HIV-1.  Previously untreated patients were randomly assigned in a 2:1 ratio to receive either 12 wk or 8 wk of daclatasvir at a std. dose of 60 mg daily (with dose adjustment for concomitant antiretroviral medications) plus 400 mg of sofosbuvir daily.  Previously treated patients were assigned to undergo 12 wk of therapy at the same doses.  The primary end point was a sustained virol. response at week 12 after the end of therapy among previously untreated patients with HCV genotype 1 who were treated for 12 wk.  Results: Patients had HCV genotypes 1 through 4 (83% with genotype 1), and 14% had compensated cirrhosis; 98% were receiving antiretroviral therapy.  Among patients with genotype 1, a sustained virol. response was reported in 96.4% (95% confidence interval [CI], 89.8 to 99.2) who were treated for 12 wk and in 75.6% (95% CI, 59.7 to 87.6) who were treated for 8 wk among previously untreated patients and in 97.7% (95% CI, 88.0 to 99.9) who were treated for 12 wk among previously treated patients.  Rates of sustained virol. response across all genotypes were 97.0% (95% CI, 91.6 to 99.4), 76.0% (95% CI, 61.8 to 86.9), and 98.1% (95% CI, 89.7 to 100), resp.  The most common adverse events were fatigue, nausea, and headache.  There were no study-drug discontinuations because of adverse events.  HIV-1 suppression was not compromised.  Conclusions: Among previously untreated HIV-HCV coinfected patients receiving daclatasvir plus sofosbuvir for HCV infection, the rate of sustained virol. response across all genotypes was 97.0% after 12 wk of treatment and 76.0% after 8 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1QHYpFV8ML7Vg90H21EOLACvtfcHk0lhQEL_Ysf-B7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpslOltA%253D%253D&md5=f514ea5a2ce454efd22e2d4ed172aaa5</span></div><a href="/servlet/linkout?suffix=cit135b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1503153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1503153%26sid%3Dliteratum%253Aachs%26aulast%3DWyles%26aufirst%3DD.%2BL.%26aulast%3DRuane%26aufirst%3DP.%2BJ.%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DDieterich%26aufirst%3DD.%26aulast%3DLuetkemeyer%26aufirst%3DA.%26aulast%3DMorgan%26aufirst%3DT.%2BR.%26aulast%3DSherman%26aufirst%3DK.%2BE.%26aulast%3DDretler%26aufirst%3DR.%26aulast%3DFishbein%26aufirst%3DD.%26aulast%3DGathe%26aufirst%3DJ.%2BC.%26aulast%3DHenn%26aufirst%3DS.%26aulast%3DHinestrosa%26aufirst%3DF.%26aulast%3DHuynh%26aufirst%3DC.%26aulast%3DMcDonald%26aufirst%3DC.%26aulast%3DMills%26aufirst%3DA.%26aulast%3DOverton%26aufirst%3DE.%2BT.%26aulast%3DRamgopal%26aufirst%3DM.%26aulast%3DRashbaum%26aufirst%3DB.%26aulast%3DRay%26aufirst%3DG.%26aulast%3DScarsella%26aufirst%3DA.%26aulast%3DYozviak%26aufirst%3DJ.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DYin%26aufirst%3DP.%2BD.%26aulast%3DNoviello%26aufirst%3DS.%26aulast%3DAckerman%26aufirst%3DP.%26atitle%3Dfor%2520the%2520ALLY-2%2520Investigators.%2520Daclatasvir%2520plus%2520sofosbuvir%2520for%2520HCV%2520in%2520patients%2520coinfected%2520with%2520HIV-1%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D714%26epage%3D725%26doi%3D10.1056%2FNEJMoa1503153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit135c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nelson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harlan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oguchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz-Lasanta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinovitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravendhran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheikh, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varunok, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennicken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rana, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span> </span><span class="NLM_article-title">ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1127</span><span class="NLM_x">–</span> <span class="NLM_lpage">1135</span><span class="refDoi"> DOI: 10.1002/hep.27726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.27726" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25614962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlt1WktLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=1127-1135&author=D.+R.+Nelsonauthor=J.+N.+Cooperauthor=J.+P.+Lalezariauthor=E.+Lawitzauthor=P.+J.+Pockrosauthor=N.+Gitlinauthor=B.+F.+Freilichauthor=Z.+H.+Younesauthor=W.+Harlanauthor=R.+Ghalibauthor=G.+Oguchiauthor=P.+J.+Thuluvathauthor=G.+Ortiz-Lasantaauthor=M.+Rabinovitzauthor=D.+Bernsteinauthor=M.+Bennettauthor=T.+Hawkinsauthor=N.+Ravendhranauthor=A.+M.+Sheikhauthor=P.+Varunokauthor=K.+V.+Kowdleyauthor=D.+Hennickenauthor=F.+McPheeauthor=K.+Ranaauthor=E.+A.+Hughes&title=ALLY-3+Study+Team.+All-oral+12-week+treatment+with+daclatasvir+plus+sofosbuvir+in+patients+with+hepatitis+C+virus+genotype+3+infection%3A+ALLY-3+phase+III+study&doi=10.1002%2Fhep.27726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135cR"><div class="casContent"><span class="casTitleNuber">135c</span><div class="casTitle"><span class="NLM_cas:atitle">All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study</span></div><div class="casAuthors">Nelson, David R.; Cooper, James N.; Lalezari, Jacob P.; Lawitz, Eric; Pockros, Paul J.; Gitlin, Norman; Freilich, Bradley F.; Younes, Ziad H.; Harlan, William; Ghalib, Reem; Oguchi, Godson; Thuluvath, Paul J.; Ortiz-Lasanta, Grisell; Rabinovitz, Mordechai; Bernstein, David; Bennett, Michael; Hawkins, Trevor; Ravendhran, Natarajan; Sheikh, Aasim M.; Varunok, Peter; Kowdley, Kris V.; Hennicken, Delphine; McPhee, Fiona; Rana, Khurram; Hughes, Eric A.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1127-1135</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are limited, with the currently approved all-oral regimens requiring 24-wk treatment and the addn. of ribavirin (RBV).  This phase III study (ALLY-3; : NCT02032901) evaluated the 12-wk regimen of daclatasvir (DCV; pangenotypic nonstructural protein [NS]5A inhibitor) plus sofosbuvir (SOF; pangenotypic NS5B inhibitor) in patients infected with genotype 3.  Patients were either treatment naive (n = 101) or treatment experienced (n = 51) and received DCV 60 mg plus SOF 400 mg once-daily for 12 wk.  Coprimary endpoints were the proportions of treatment-naive and treatment-experienced patients achieving a sustained virol. response (SVR) at post-treatment week 12 (SVR12).  SVR12 rates were 90% (91 of 101) and 86% (44 of 51) in treatment-naive and treatment-experienced patients, resp.; no virol. breakthrough was obsd., and ≥99% of patients had a virol. response (VR) at the end of treatment.  SVR12 rates were higher in patients without cirrhosis (96%; 105 of 109) than in those with cirrhosis (63%; 20 of 32).  Five of seven patients who previously failed treatment with an SOF-contg. regimen and 2 of 2 who previously failed treatment with an alisporivir-contg. regimen achieved SVR12.  Baseline characteristics, including gender, age, HCV-RNA levels, and interleukin-28B genotype, did not impact virol. outcome.  DCV plus SOF was well tolerated; there were no adverse events (AEs) leading to discontinuation and only 1 serious AE on-treatment, which was unrelated to study medications.  The few treatment-emergent grade 3/4 lab. abnormalities that were obsd. were transient.  Conclusion: A 12-wk regimen of DCV plus SOF achieved SVR12 in 96% of patients with genotype 3 infection without cirrhosis and was well tolerated.  Addnl. evaluation to optimize efficacy in genotype 3-infected patients with cirrhosis is underway. (Hepatol. 2015;61:1127-1135).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqACqGC7OGEIrVg90H21EOLACvtfcHk0ljVoAB7PhLlFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlt1WktLw%253D&md5=477b15de820348180ad3bcd6694e2170</span></div><a href="/servlet/linkout?suffix=cit135c&amp;dbid=16384&amp;doi=10.1002%2Fhep.27726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27726%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DCooper%26aufirst%3DJ.%2BN.%26aulast%3DLalezari%26aufirst%3DJ.%2BP.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DGitlin%26aufirst%3DN.%26aulast%3DFreilich%26aufirst%3DB.%2BF.%26aulast%3DYounes%26aufirst%3DZ.%2BH.%26aulast%3DHarlan%26aufirst%3DW.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DOguchi%26aufirst%3DG.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DOrtiz-Lasanta%26aufirst%3DG.%26aulast%3DRabinovitz%26aufirst%3DM.%26aulast%3DBernstein%26aufirst%3DD.%26aulast%3DBennett%26aufirst%3DM.%26aulast%3DHawkins%26aufirst%3DT.%26aulast%3DRavendhran%26aufirst%3DN.%26aulast%3DSheikh%26aufirst%3DA.%2BM.%26aulast%3DVarunok%26aufirst%3DP.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DHennicken%26aufirst%3DD.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DRana%26aufirst%3DK.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26atitle%3DALLY-3%2520Study%2520Team.%2520All-oral%252012-week%2520treatment%2520with%2520daclatasvir%2520plus%2520sofosbuvir%2520in%2520patients%2520with%2520hepatitis%2520C%2520virus%2520genotype%25203%2520infection%253A%2520ALLY-3%2520phase%2520III%2520study%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D1127%26epage%3D1135%26doi%3D10.1002%2Fhep.27726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vierling, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noviello, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, E. S.</span><span> </span><span class="NLM_article-title">Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1493</span><span class="NLM_x">–</span> <span class="NLM_lpage">1505</span><span class="refDoi"> DOI: 10.1002/hep.28446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.28446" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2016&pages=1493-1505&author=F.+Poordadauthor=E.+R.+Schiffauthor=J.+M.+Vierlingauthor=C.+Landisauthor=R.+J.+Fontanaauthor=R.+Yangauthor=F.+McPheeauthor=E.+A.+Hughesauthor=S.+Novielloauthor=E.+S.+Swenson&title=Daclatasvir+with+sofosbuvir+and+ribavirin+for+hepatitis+C+virus+infection+with+advanced+cirrhosis+or+post-liver+transplantation+recurrence&doi=10.1002%2Fhep.28446"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2Fhep.28446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.28446%26sid%3Dliteratum%253Aachs%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DSchiff%26aufirst%3DE.%2BR.%26aulast%3DVierling%26aufirst%3DJ.%2BM.%26aulast%3DLandis%26aufirst%3DC.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DNoviello%26aufirst%3DS.%26aulast%3DSwenson%26aufirst%3DE.%2BS.%26atitle%3DDaclatasvir%2520with%2520sofosbuvir%2520and%2520ribavirin%2520for%2520hepatitis%2520C%2520virus%2520infection%2520with%2520advanced%2520cirrhosis%2520or%2520post-liver%2520transplantation%2520recurrence%26jtitle%3DHepatology%26date%3D2016%26volume%3D63%26spage%3D1493%26epage%3D1505%26doi%3D10.1002%2Fhep.28446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronowicki, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loustaud-Ratti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gea, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olveira, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banyai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Assi, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thabut, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pruitt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beumont-Mauviel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouwerkerk-Mahadevan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picchio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boparai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noviello, S.</span><span> </span><span class="NLM_article-title">LEAGUE-1 Study Team. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span><span class="refDoi"> DOI: 10.1016/j.jhep.2015.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2015.09.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=292-300&author=S.+Zeuzemauthor=C.+H%C3%A9zodeauthor=J.+P.+Bronowickiauthor=V.+Loustaud-Rattiauthor=F.+Geaauthor=M.+Butiauthor=A.+Olveiraauthor=T.+Banyaiauthor=M.+T.+Al-Assiauthor=J.+Petersenauthor=D.+Thabutauthor=A.+Gadanoauthor=R.+Pruittauthor=M.+Makaraauthor=M.+Bourli%C3%A8reauthor=S.+Polauthor=M.+Beumont-Mauvielauthor=S.+Ouwerkerk-Mahadevanauthor=G.+Picchioauthor=M.+Bifanoauthor=F.+McPheeauthor=N.+Boparaiauthor=K.+Cheungauthor=E.+A.+Hughesauthor=S.+Noviello&title=LEAGUE-1+Study+Team.+Daclatasvir+plus+simeprevir+with+or+without+ribavirin+for+the+treatment+of+chronic+hepatitis+C+virus+genotype+1+infection&doi=10.1016%2Fj.jhep.2015.09.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2015.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2015.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DBronowicki%26aufirst%3DJ.%2BP.%26aulast%3DLoustaud-Ratti%26aufirst%3DV.%26aulast%3DGea%26aufirst%3DF.%26aulast%3DButi%26aufirst%3DM.%26aulast%3DOlveira%26aufirst%3DA.%26aulast%3DBanyai%26aufirst%3DT.%26aulast%3DAl-Assi%26aufirst%3DM.%2BT.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DThabut%26aufirst%3DD.%26aulast%3DGadano%26aufirst%3DA.%26aulast%3DPruitt%26aufirst%3DR.%26aulast%3DMakara%26aufirst%3DM.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DBeumont-Mauviel%26aufirst%3DM.%26aulast%3DOuwerkerk-Mahadevan%26aufirst%3DS.%26aulast%3DPicchio%26aufirst%3DG.%26aulast%3DBifano%26aufirst%3DM.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DBoparai%26aufirst%3DN.%26aulast%3DCheung%26aufirst%3DK.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DNoviello%26aufirst%3DS.%26atitle%3DLEAGUE-1%2520Study%2520Team.%2520Daclatasvir%2520plus%2520simeprevir%2520with%2520or%2520without%2520ribavirin%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D64%26spage%3D292%26epage%3D300%26doi%3D10.1016%2Fj.jhep.2015.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Afdhal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chojkier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puoti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero-Gomez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarski, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggisch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bräu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span> </span><span class="NLM_article-title">for the ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1889</span><span class="NLM_x">–</span> <span class="NLM_lpage">1898</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1402454" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1889-1898&author=N.+Afdhalauthor=S.+Zeuzemauthor=P.+Kwoauthor=M.+Chojkierauthor=N.+Gitlinauthor=M.+Puotiauthor=M.+Romero-Gomezauthor=J.-P.+Zarskiauthor=K.+Agarwalauthor=P.+Buggischauthor=G.+R.+Fosterauthor=N.+Br%C3%A4uauthor=M.+Butiauthor=I.+M.+Jacobsonauthor=G.+M.+Subramanianauthor=X.+Dingauthor=H.+Moauthor=J.+C.+Yangauthor=P.+S.+Pangauthor=W.+T.+Symondsauthor=J.+G.+McHutchisonauthor=A.+J.+Muirauthor=A.+Mangiaauthor=P.+Marcellin&title=for+the+ION-1+Investigators.+Ledipasvir+and+sofosbuvir+for+untreated+HCV+genotype+1+infection&doi=10.1056%2FNEJMoa1402454"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402454%26sid%3Dliteratum%253Aachs%26aulast%3DAfdhal%26aufirst%3DN.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DKwo%26aufirst%3DP.%26aulast%3DChojkier%26aufirst%3DM.%26aulast%3DGitlin%26aufirst%3DN.%26aulast%3DPuoti%26aufirst%3DM.%26aulast%3DRomero-Gomez%26aufirst%3DM.%26aulast%3DZarski%26aufirst%3DJ.-P.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DBuggisch%26aufirst%3DP.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DBr%25C3%25A4u%26aufirst%3DN.%26aulast%3DButi%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DMarcellin%26aufirst%3DP.%26atitle%3Dfor%2520the%2520ION-1%2520Investigators.%2520Ledipasvir%2520and%2520sofosbuvir%2520for%2520untreated%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1889%26epage%3D1898%26doi%3D10.1056%2FNEJMoa1402454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit138b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Afdhal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahass, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herring, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bisceglie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arora, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvory-Sobol, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwo, P.</span><span> </span><span class="NLM_article-title">for the ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1483</span><span class="NLM_x">–</span> <span class="NLM_lpage">1493</span><span class="refDoi"> DOI: 10.1056/NEJMoa1316366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1316366" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1483-1493&author=N.+Afdhalauthor=K.+R.+Reddyauthor=D.+R.+Nelsonauthor=E.+Lawitzauthor=S.+C.+Gordonauthor=E.+Schiffauthor=R.+Nahassauthor=R.+Ghalibauthor=N.+Gitlinauthor=R.+Herringauthor=J.+Lalezariauthor=Z.+H.+Younesauthor=P.+J.+Pockrosauthor=A.+M.+Di+Bisceglieauthor=S.+Aroraauthor=G.+M.+Subramanianauthor=Y.+Zhuauthor=H.+Dvory-Sobolauthor=J.+C.+Yangauthor=P.+S.+Pangauthor=W.+T.+Symondsauthor=J.+G.+McHutchisonauthor=A.+J.+Muirauthor=M.+Sulkowskiauthor=P.+Kwo&title=for+the+ION-2+Investigators.+Ledipasvir+and+sofosbuvir+for+previously+treated+HCV+genotype+1+infection&doi=10.1056%2FNEJMoa1316366"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1316366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1316366%26sid%3Dliteratum%253Aachs%26aulast%3DAfdhal%26aufirst%3DN.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DSchiff%26aufirst%3DE.%26aulast%3DNahass%26aufirst%3DR.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DGitlin%26aufirst%3DN.%26aulast%3DHerring%26aufirst%3DR.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DYounes%26aufirst%3DZ.%2BH.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DDi%2BBisceglie%26aufirst%3DA.%2BM.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DDvory-Sobol%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DSulkowski%26aufirst%3DM.%26aulast%3DKwo%26aufirst%3DP.%26atitle%3Dfor%2520the%2520ION-2%2520Investigators.%2520Ledipasvir%2520and%2520sofosbuvir%2520for%2520previously%2520treated%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1483%26epage%3D1493%26doi%3D10.1056%2FNEJMoa1316366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit138c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossaro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiffman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chojkier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herring, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bisceglie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svarovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pound, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ION-3 Investigators.</span><span> </span><span class="NLM_article-title">Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1879</span><span class="NLM_x">–</span> <span class="NLM_lpage">1888</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1402355" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1879-1888&author=K.+V.+Kowdleyauthor=S.+C.+Gordonauthor=K.+R.+Reddyauthor=L.+Rossaroauthor=D.+E.+Bernsteinauthor=E.+Lawitzauthor=M.+L.+Shiffmanauthor=E.+Schiffauthor=R.+Ghalibauthor=M.+Ryanauthor=V.+Rustgiauthor=M.+Chojkierauthor=R.+Herringauthor=A.+M.+Di+Bisceglieauthor=P.+J.+Pockrosauthor=G.+M.+Subramanianauthor=D.+Anauthor=E.+Svarovskaiaauthor=R.+H.+Hylandauthor=P.+S.+Pangauthor=W.+T.+Symondsauthor=J.+G.+McHutchisonauthor=A.+J.+Muirauthor=D.+Poundauthor=M.+W.+Friedauthor=ION-3+Investigators.&title=Ledipasvir+and+sofosbuvir+for+8+or+12+weeks+for+chronic+HCV+without+cirrhosis&doi=10.1056%2FNEJMoa1402355"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402355%26sid%3Dliteratum%253Aachs%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DRossaro%26aufirst%3DL.%26aulast%3DBernstein%26aufirst%3DD.%2BE.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DShiffman%26aufirst%3DM.%2BL.%26aulast%3DSchiff%26aufirst%3DE.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DRyan%26aufirst%3DM.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DChojkier%26aufirst%3DM.%26aulast%3DHerring%26aufirst%3DR.%26aulast%3DDi%2BBisceglie%26aufirst%3DA.%2BM.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DAn%26aufirst%3DD.%26aulast%3DSvarovskaia%26aufirst%3DE.%26aulast%3DHyland%26aufirst%3DR.%2BH.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DPound%26aufirst%3DD.%26aulast%3DFried%26aufirst%3DM.%2BW.%26aulast%3D%26atitle%3DLedipasvir%2520and%2520sofosbuvir%2520for%25208%2520or%252012%2520weeks%2520for%2520chronic%2520HCV%2520without%2520cirrhosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1879%26epage%3D1888%26doi%3D10.1056%2FNEJMoa1402355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit138d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Alqahtani, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afdhal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pound, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M.</span><span> </span><span class="NLM_article-title">Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.1002/hep.27890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.27890" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=25-30&author=S.+A.+Alqahtaniauthor=N.+Afdhalauthor=S.+Zeuzemauthor=S.+C.+Gordonauthor=A.+Mangiaauthor=P.+Kwoauthor=M.+Friedauthor=J.+C.+Yangauthor=X.+Dingauthor=P.+S.+Pangauthor=J.+G.+McHutchisonauthor=D.+Poundauthor=K.+R.+Reddyauthor=P.+Marcellinauthor=K.+V.+Kowdleyauthor=M.+Sulkowski&title=Safety+and+tolerability+of+ledipasvir%2Fsofosbuvir+with+and+without+ribavirin+in+patients+with+chronic+hepatitis+C+virus+genotype+1+infection%3A+analysis+of+phase+III+ION+trials&doi=10.1002%2Fhep.27890"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138d&amp;dbid=16384&amp;doi=10.1002%2Fhep.27890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27890%26sid%3Dliteratum%253Aachs%26aulast%3DAlqahtani%26aufirst%3DS.%2BA.%26aulast%3DAfdhal%26aufirst%3DN.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DKwo%26aufirst%3DP.%26aulast%3DFried%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DPound%26aufirst%3DD.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DSulkowski%26aufirst%3DM.%26atitle%3DSafety%2520and%2520tolerability%2520of%2520ledipasvir%252Fsofosbuvir%2520with%2520and%2520without%2520ribavirin%2520in%2520patients%2520with%2520chronic%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%253A%2520analysis%2520of%2520phase%2520III%2520ION%2520trials%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D25%26epage%3D30%26doi%3D10.1002%2Fhep.27890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit138e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Naggie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saag, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workowski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruane, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towner, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luetkemeyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baden, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sax, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santana-Bagur, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">German, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvory-Sobol, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J.G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stedman, C. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales-Ramirez, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bräu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaweera, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colson, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dieterich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M.</span><span> </span><span class="NLM_article-title">for the ION-4 Investigators. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">705</span><span class="NLM_x">–</span> <span class="NLM_lpage">713</span><span class="refDoi"> DOI: 10.1056/NEJMoa1501315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1501315" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=705-713&author=S.+Naggieauthor=C.+Cooperauthor=M.+Saagauthor=K.+Workowskiauthor=P.+Ruaneauthor=W.+J.+Townerauthor=K.+Marksauthor=A.+Luetkemeyerauthor=R.+P.+Badenauthor=P.+E.+Saxauthor=E.+Ganeauthor=J.+Santana-Bagurauthor=L.+M.+Stammauthor=J.+C.+Yangauthor=P.+Germanauthor=M.+Dvory-Sobolauthor=L.+Niauthor=P.+S.+Pangauthor=J.G.+McHutchisonauthor=C.+A.+M.+Stedmanauthor=J.+O.+Morales-Ramirezauthor=N.+Br%C3%A4uauthor=D.+Jayaweeraauthor=A.+E.+Colsonauthor=P.+Tebasauthor=D.+K.+Wongauthor=D.+Dieterichauthor=M.+Sulkowski&title=for+the+ION-4+Investigators.+Ledipasvir+and+sofosbuvir+for+HCV+in+patients+coinfected+with+HIV-1&doi=10.1056%2FNEJMoa1501315"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138e&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1501315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1501315%26sid%3Dliteratum%253Aachs%26aulast%3DNaggie%26aufirst%3DS.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DSaag%26aufirst%3DM.%26aulast%3DWorkowski%26aufirst%3DK.%26aulast%3DRuane%26aufirst%3DP.%26aulast%3DTowner%26aufirst%3DW.%2BJ.%26aulast%3DMarks%26aufirst%3DK.%26aulast%3DLuetkemeyer%26aufirst%3DA.%26aulast%3DBaden%26aufirst%3DR.%2BP.%26aulast%3DSax%26aufirst%3DP.%2BE.%26aulast%3DGane%26aufirst%3DE.%26aulast%3DSantana-Bagur%26aufirst%3DJ.%26aulast%3DStamm%26aufirst%3DL.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DGerman%26aufirst%3DP.%26aulast%3DDvory-Sobol%26aufirst%3DM.%26aulast%3DNi%26aufirst%3DL.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DMcHutchison%26aufirst%3DJ.G.%26aulast%3DStedman%26aufirst%3DC.%2BA.%2BM.%26aulast%3DMorales-Ramirez%26aufirst%3DJ.%2BO.%26aulast%3DBr%25C3%25A4u%26aufirst%3DN.%26aulast%3DJayaweera%26aufirst%3DD.%26aulast%3DColson%26aufirst%3DA.%2BE.%26aulast%3DTebas%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DD.%2BK.%26aulast%3DDieterich%26aufirst%3DD.%26aulast%3DSulkowski%26aufirst%3DM.%26atitle%3Dfor%2520the%2520ION-4%2520Investigators.%2520Ledipasvir%2520and%2520sofosbuvir%2520for%2520HCV%2520in%2520patients%2520coinfected%2520with%2520HIV-1%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D705%26epage%3D713%26doi%3D10.1056%2FNEJMoa1501315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit138f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Kohli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osinusi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meissner, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marti, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotb, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolley, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidharthan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Townsend, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egerson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapoor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spurlin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sneller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proschan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teferi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talwani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleiner, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbott, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polis, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fauci, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masur, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottilil, S.</span><span> </span><span class="NLM_article-title">Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2a cohort study</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">385</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1113</span><span class="refDoi"> DOI: 10.1016/S0140-6736(14)61228-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0140-6736%2814%2961228-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=1107-1113&author=A.+Kohliauthor=A.+Osinusiauthor=Z.+Simsauthor=A.+Nelsonauthor=E.+G.+Meissnerauthor=L.+L.+Barrettauthor=D.+Bonauthor=M.+M.+Martiauthor=R.+Silkauthor=C.+Kotbauthor=C.+Grossauthor=T.+A.+Jolleyauthor=S.+Sidharthanauthor=T.+Petersenauthor=K.+Townsendauthor=D.+Egersonauthor=R.+Kapoorauthor=E.+Spurlinauthor=M.+Snellerauthor=M.+Proschanauthor=E.+Herrmannauthor=R.+Kwanauthor=G.+Teferiauthor=R.+Talwaniauthor=G.+Diazauthor=D.+E.+Kleinerauthor=B.+J.+Woodauthor=J.+Chavezauthor=S.+Abbottauthor=W.+T.+Symondsauthor=G.+M.+Subramanianauthor=P.+S.+Pangauthor=J.+McHutchisonauthor=M.+A.+Polisauthor=A.+S.+Fauciauthor=H.+Masurauthor=S.+Kottilil&title=Virological+response+after+6+week+triple-drug+regimens+for+hepatitis+C%3A+a+proof-of-concept+phase+2a+cohort+study&doi=10.1016%2FS0140-6736%2814%2961228-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138f&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2961228-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252961228-9%26sid%3Dliteratum%253Aachs%26aulast%3DKohli%26aufirst%3DA.%26aulast%3DOsinusi%26aufirst%3DA.%26aulast%3DSims%26aufirst%3DZ.%26aulast%3DNelson%26aufirst%3DA.%26aulast%3DMeissner%26aufirst%3DE.%2BG.%26aulast%3DBarrett%26aufirst%3DL.%2BL.%26aulast%3DBon%26aufirst%3DD.%26aulast%3DMarti%26aufirst%3DM.%2BM.%26aulast%3DSilk%26aufirst%3DR.%26aulast%3DKotb%26aufirst%3DC.%26aulast%3DGross%26aufirst%3DC.%26aulast%3DJolley%26aufirst%3DT.%2BA.%26aulast%3DSidharthan%26aufirst%3DS.%26aulast%3DPetersen%26aufirst%3DT.%26aulast%3DTownsend%26aufirst%3DK.%26aulast%3DEgerson%26aufirst%3DD.%26aulast%3DKapoor%26aufirst%3DR.%26aulast%3DSpurlin%26aufirst%3DE.%26aulast%3DSneller%26aufirst%3DM.%26aulast%3DProschan%26aufirst%3DM.%26aulast%3DHerrmann%26aufirst%3DE.%26aulast%3DKwan%26aufirst%3DR.%26aulast%3DTeferi%26aufirst%3DG.%26aulast%3DTalwani%26aufirst%3DR.%26aulast%3DDiaz%26aufirst%3DG.%26aulast%3DKleiner%26aufirst%3DD.%2BE.%26aulast%3DWood%26aufirst%3DB.%2BJ.%26aulast%3DChavez%26aufirst%3DJ.%26aulast%3DAbbott%26aufirst%3DS.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DMcHutchison%26aufirst%3DJ.%26aulast%3DPolis%26aufirst%3DM.%2BA.%26aulast%3DFauci%26aufirst%3DA.%2BS.%26aulast%3DMasur%26aufirst%3DH.%26aulast%3DKottilil%26aufirst%3DS.%26atitle%3DVirological%2520response%2520after%25206%2520week%2520triple-drug%2520regimens%2520for%2520hepatitis%2520C%253A%2520a%2520proof-of-concept%2520phase%25202a%2520cohort%2520study%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D1107%26epage%3D1113%26doi%3D10.1016%2FS0140-6736%2814%2961228-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit138g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Kohli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapoor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidharthan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotb, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teferi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osinusi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polis, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masur, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottilil, S.</span><span> </span><span class="NLM_article-title">Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study</span> <span class="citation_source-journal">Lancet Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1049</span><span class="NLM_x">–</span> <span class="NLM_lpage">1054</span><span class="refDoi"> DOI: 10.1016/S1473-3099(15)00157-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS1473-3099%2815%2900157-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=1049-1054&author=A.+Kohliauthor=R.+Kapoorauthor=Z.+Simsauthor=A.+Nelsonauthor=S.+Sidharthanauthor=B.+Lamauthor=R.+Silkauthor=C.+Kotbauthor=C.+Grossauthor=G.+Teferiauthor=K.+Sugarmanauthor=P.+S.+Pangauthor=A.+Osinusiauthor=M.+A.+Polisauthor=V.+Rustgiauthor=H.+Masurauthor=S.+Kottilil&title=Ledipasvir+and+sofosbuvir+for+hepatitis+C+genotype+4%3A+a+proof-of-concept%2C+single-centre%2C+open-label+phase+2a+cohort+study&doi=10.1016%2FS1473-3099%2815%2900157-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138g&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2815%2900157-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252815%252900157-7%26sid%3Dliteratum%253Aachs%26aulast%3DKohli%26aufirst%3DA.%26aulast%3DKapoor%26aufirst%3DR.%26aulast%3DSims%26aufirst%3DZ.%26aulast%3DNelson%26aufirst%3DA.%26aulast%3DSidharthan%26aufirst%3DS.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DSilk%26aufirst%3DR.%26aulast%3DKotb%26aufirst%3DC.%26aulast%3DGross%26aufirst%3DC.%26aulast%3DTeferi%26aufirst%3DG.%26aulast%3DSugarman%26aufirst%3DK.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DOsinusi%26aufirst%3DA.%26aulast%3DPolis%26aufirst%3DM.%2BA.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DMasur%26aufirst%3DH.%26aulast%3DKottilil%26aufirst%3DS.%26atitle%3DLedipasvir%2520and%2520sofosbuvir%2520for%2520hepatitis%2520C%2520genotype%25204%253A%2520a%2520proof-of-concept%252C%2520single-centre%252C%2520open-label%2520phase%25202a%2520cohort%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2015%26volume%3D15%26spage%3D1049%26epage%3D1054%26doi%3D10.1016%2FS1473-3099%2815%2900157-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Kumari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, M. H.</span><span> </span><span class="NLM_article-title">Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span><span class="refDoi"> DOI: 10.1517/14656566.2015.1013938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1517%2F14656566.2015.1013938" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=739-748&author=R.+Kumariauthor=M.+H.+Nguyen&title=Fixed-dose+combination+of+sofosbuvir+and+ledipasvir+for+the+treatment+of+chronic+hepatitis+C+genotype+1&doi=10.1517%2F14656566.2015.1013938"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1517%2F14656566.2015.1013938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2015.1013938%26sid%3Dliteratum%253Aachs%26aulast%3DKumari%26aufirst%3DR.%26aulast%3DNguyen%26aufirst%3DM.%2BH.%26atitle%3DFixed-dose%2520combination%2520of%2520sofosbuvir%2520and%2520ledipasvir%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520genotype%25201%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26volume%3D16%26spage%3D739%26epage%3D748%26doi%3D10.1517%2F14656566.2015.1013938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Deeks, E. D.</span><span> </span><span class="NLM_article-title">Ombitasvir/paritaprevir/ritonavir plus dasabuvir: a review in chronic HCV genotype 1 infection</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1027</span><span class="NLM_x">–</span> <span class="NLM_lpage">1038</span><span class="refDoi"> DOI: 10.1007/s40265-015-0412-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1007%2Fs40265-015-0412-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26059288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKlsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1027-1038&author=E.+D.+Deeks&title=Ombitasvir%2Fparitaprevir%2Fritonavir+plus+dasabuvir%3A+a+review+in+chronic+HCV+genotype+1+infection&doi=10.1007%2Fs40265-015-0412-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1027-1038</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A fixed-dose tablet comprising ombitasvir (an NS5A replication complex inhibitor), paritaprevir (an NS3/4A protease inhibitor) and ritonavir (a cytochrome P 450 inhibitor) taken in combination with dasabuvir (an NS5B polymerase inhibitor) is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in several countries, including the USA (copackaged as Viekira Pak) and those of the EU (Viekirax and Exviera).  In phase II and III trials, this interferon-free regimen, taken ± ribavirin, provided high rates of sustained virol. response 12 wk post-treatment in adults with chronic HCV genotype 1a or 1b infection, including those with compensated cirrhosis, liver transplants or HIV-1 co-infection.  The regimen was generally well tolerated, with nausea, insomnia, asthenia, pruritus, other skin reactions and fatigue being among the most common tolerability issues.  Thus, ombitasvir/paritaprevir/ritonavir plus dasabuvir is an effective interferon-free, direct-acting antiviral regimen for use ± ribavirin in a broad range of adults chronically infected with HCV genotype 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW5HI8UPXjAbVg90H21EOLACvtfcHk0ljaJGFPxyxeeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKlsr3K&md5=d15144247ccea647d11855b4b087c3fa</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0412-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0412-z%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DOmbitasvir%252Fparitaprevir%252Fritonavir%2520plus%2520dasabuvir%253A%2520a%2520review%2520in%2520chronic%2520HCV%2520genotype%25201%2520infection%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1027%26epage%3D1038%26doi%3D10.1007%2Fs40265-015-0412-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ferenci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marinho, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enayati, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baruch, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhandari, B.R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexandru Caruntu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chulanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janczewska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzardini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gervain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassanein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podsadecki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span> </span><span class="NLM_article-title">ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1983</span><span class="NLM_x">–</span> <span class="NLM_lpage">1992</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1402338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24795200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1983-1992&author=P.+Ferenciauthor=D.+Bernsteinauthor=J.+Lalezariauthor=D.+Cohenauthor=Y.+Luoauthor=C.+Cooperauthor=E.+Tamauthor=R.+T.+Marinhoauthor=N.+Tsaiauthor=A.+Nybergauthor=T.+D.+Boxauthor=Z.+Younesauthor=P.+Enayatiauthor=S.+Greenauthor=Y.+Baruchauthor=B.R.+Bhandariauthor=F.+Alexandru+Caruntuauthor=T.+Sepeauthor=V.+Chulanovauthor=E.+Janczewskaauthor=G.+Rizzardiniauthor=J.+Gervainauthor=R.+Planasauthor=C.+Morenoauthor=T.+Hassaneinauthor=W.+Xieauthor=M.+Kingauthor=T.+Podsadeckiauthor=K.+R.+Reddy&title=ABT-450%2Fr-ombitasvir+and+dasabuvir+with+or+without+ribavirin+for+HCV&doi=10.1056%2FNEJMoa1402338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141aR"><div class="casContent"><span class="casTitleNuber">141a</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-450/r-mbitasvir and dasabuvir with or without ribavirin for HCV</span></div><div class="casAuthors">Ferenci, Peter; Bernstein, David; Lalezari, Jacob; Cohen, Daniel; Luo, Yan; Cooper, Curtis; Tam, Edward; Marinho, Rui T.; Tsai, Naoky; Nyberg, Anders; Box, Terry D.; Younes, Ziad; Enayati, Pedram; Green, Sinikka; Baruch, Yaacov; Bhandari, Bal Raj; Caruntu, Florin Alexandru; Sepe, Thomas; Chulanov, Vladimir; Janczewska, Ewa; Rizzardini, Giuliano; Gervain, Judit; Planas, Ramon; Moreno, Christophe; Hassanein, Tarek; Xie, Wangang; King, Martin; Podsadecki, Thomas; Reddy, K. Rajender</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1983-1992, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir, and dasabuvir with or without ribavirin has shown efficacy in inducing a sustained virol. response in a phase 2 study involving patients with hepatitis C virus (HCV) genotype 1 infection.  We conducted two phase 3 trials to examine the efficacy and safety of this regimen in previously untreated patients with HCV genotype 1 infection and no cirrhosis.  Methods: We randomly assigned 419 patients with HCV genotype 1b infection (PEARL-III study) and 305 patients with genotype 1a infection (PEARL-IV study) to 12 wk of ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir), dasabuvir (250 mg twice daily), and ribavirin administered according to body wt. or to matching placebo for ribavirin.  The primary efficacy end point was a sustained virol. response (an HCV RNA level of <25 IU per mL) 12 wk after the end of treatment.  Results: The study regimen resulted in high rates of sustained virol. response among patients with HCV genotype 1b infection (99.5% with ribavirin and 99.0% without ribavirin) and among those with genotype 1a infection (97.0% and 90.2%, resp.).  Of patients with genotype 1b infection, 1 had virol. failure, and 2 did not have data available at post-treatment week 12.  Among patients with genotype 1a infection, the rate of virol. failure was higher in the ribavirin-free group than in the ribavirin group (7.8% vs. 2.0%).  In both studies, decreases in the Hb level were significantly more common in patients receiving ribavirin.  Two patients (0.3%) discontinued the study drugs owing to adverse events.  The most common adverse events were fatigue, headache, and nausea.  Conclusions: Twelve weeks of treatment with ABT-450/r-ombitasvir and dasabuvir without ribavirin was assocd. with high rates of sustained virol. response among previously untreated patients with HCV genotype 1 infection.  Rates of virol. failure were higher without ribavirin than with ribavirin among patients with genotype 1a infection but not among those with genotype 1b infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru0b7jyqCe37Vg90H21EOLACvtfcHk0ljRB3VA5T68Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnN&md5=b08a13aba3156a82bdcdd71203269b28</span></div><a href="/servlet/linkout?suffix=cit141a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402338%26sid%3Dliteratum%253Aachs%26aulast%3DFerenci%26aufirst%3DP.%26aulast%3DBernstein%26aufirst%3DD.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DE.%26aulast%3DMarinho%26aufirst%3DR.%2BT.%26aulast%3DTsai%26aufirst%3DN.%26aulast%3DNyberg%26aufirst%3DA.%26aulast%3DBox%26aufirst%3DT.%2BD.%26aulast%3DYounes%26aufirst%3DZ.%26aulast%3DEnayati%26aufirst%3DP.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DBaruch%26aufirst%3DY.%26aulast%3DBhandari%26aufirst%3DB.R.%26aulast%3DAlexandru%2BCaruntu%26aufirst%3DF.%26aulast%3DSepe%26aufirst%3DT.%26aulast%3DChulanov%26aufirst%3DV.%26aulast%3DJanczewska%26aufirst%3DE.%26aulast%3DRizzardini%26aufirst%3DG.%26aulast%3DGervain%26aufirst%3DJ.%26aulast%3DPlanas%26aufirst%3DR.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DKing%26aufirst%3DM.%26aulast%3DPodsadecki%26aufirst%3DT.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26atitle%3DABT-450%252Fr-ombitasvir%2520and%2520dasabuvir%2520with%2520or%2520without%2520ribavirin%2520for%2520HCV%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1983%26epage%3D1992%26doi%3D10.1056%2FNEJMoa1402338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit141b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hezode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trinh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiffman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedemeyer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forns, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Silva-Tillmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podsadecki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, B.</span><span> </span><span class="NLM_article-title">ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1973</span><span class="NLM_x">–</span> <span class="NLM_lpage">1982</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402869</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1402869" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1973-1982&author=F.+Poordadauthor=C.+Hezodeauthor=R.+Trinhauthor=K.+V.+Kowdleyauthor=S.+Zeuzemauthor=K.+Agarwalauthor=M.+L.+Shiffmanauthor=H.+Wedemeyerauthor=T.+Bergauthor=E.+M.+Yoshidaauthor=X.+Fornsauthor=S.+S.+Lovellauthor=B.+Da+Silva-Tillmannauthor=C.+A.+Collinsauthor=A.+L.+Campbellauthor=T.+Podsadeckiauthor=B.+Bernstein&title=ABT-450%2Fr-ombitasvir+and+dasabuvir+with+ribavirin+for+hepatitis+C+with+cirrhosis&doi=10.1056%2FNEJMoa1402869"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402869%26sid%3Dliteratum%253Aachs%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DHezode%26aufirst%3DC.%26aulast%3DTrinh%26aufirst%3DR.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DShiffman%26aufirst%3DM.%2BL.%26aulast%3DWedemeyer%26aufirst%3DH.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DE.%2BM.%26aulast%3DForns%26aufirst%3DX.%26aulast%3DLovell%26aufirst%3DS.%2BS.%26aulast%3DDa%2BSilva-Tillmann%26aufirst%3DB.%26aulast%3DCollins%26aufirst%3DC.%2BA.%26aulast%3DCampbell%26aufirst%3DA.%2BL.%26aulast%3DPodsadecki%26aufirst%3DT.%26aulast%3DBernstein%26aufirst%3DB.%26atitle%3DABT-450%252Fr-ombitasvir%2520and%2520dasabuvir%2520with%2520ribavirin%2520for%2520hepatitis%2520C%2520with%2520cirrhosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1973%26epage%3D1982%26doi%3D10.1056%2FNEJMoa1402869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit141c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baykal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marinho, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedemeyer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desmond, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bisceglie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varunok, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassanein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilot-Matias, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DaSilva-Tillmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podsadecki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, B.</span><span> </span><span class="NLM_article-title">Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1604</span><span class="NLM_x">–</span> <span class="NLM_lpage">1614</span><span class="refDoi"> DOI: 10.1056/NEJMoa1401561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1401561" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1604-1614&author=S.+Zeuzemauthor=I.+M.+Jacobsonauthor=T.+Baykalauthor=R.+T.+Marinhoauthor=F.+Poordadauthor=M.+Bourli%C3%A8reauthor=M.+S.+Sulkowskiauthor=H.+Wedemeyerauthor=E.+Tamauthor=P.+Desmondauthor=D.+M.+Jensenauthor=A.+M.+Di+Bisceglieauthor=P.+Varunokauthor=T.+Hassaneinauthor=J.+Xiongauthor=T.+Pilot-Matiasauthor=B.+DaSilva-Tillmannauthor=L.+Larsenauthor=T.+Podsadeckiauthor=B.+Bernstein&title=Retreatment+of+HCV+with+ABT-450%2Fr-ombitasvir+and+dasabuvir+with+ribavirin&doi=10.1056%2FNEJMoa1401561"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1401561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1401561%26sid%3Dliteratum%253Aachs%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DBaykal%26aufirst%3DT.%26aulast%3DMarinho%26aufirst%3DR.%2BT.%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DWedemeyer%26aufirst%3DH.%26aulast%3DTam%26aufirst%3DE.%26aulast%3DDesmond%26aufirst%3DP.%26aulast%3DJensen%26aufirst%3DD.%2BM.%26aulast%3DDi%2BBisceglie%26aufirst%3DA.%2BM.%26aulast%3DVarunok%26aufirst%3DP.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DXiong%26aufirst%3DJ.%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DDaSilva-Tillmann%26aufirst%3DB.%26aulast%3DLarsen%26aufirst%3DL.%26aulast%3DPodsadecki%26aufirst%3DT.%26aulast%3DBernstein%26aufirst%3DB.%26atitle%3DRetreatment%2520of%2520HCV%2520with%2520ABT-450%252Fr-ombitasvir%2520and%2520dasabuvir%2520with%2520ribavirin%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1604%26epage%3D1614%26doi%3D10.1056%2FNEJMoa1401561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit141d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eron, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trinh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gathe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruane, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elion, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bredeek, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blick, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khatri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredrick, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilot-Matias, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Silva-Tillmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGovern, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podsadecki, T.</span><span> </span><span class="NLM_article-title">Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1. A Randomized Trial</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">1223</span><span class="NLM_x">–</span> <span class="NLM_lpage">1231</span><span class="refDoi"> DOI: 10.1001/jama.2015.1328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1001%2Fjama.2015.1328" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2015&pages=1223-1231&author=M.+S.+Sulkowskiauthor=J.+J.+Eronauthor=D.+Wylesauthor=R.+Trinhauthor=J.+Lalezariauthor=C.+Wangauthor=J.+Slimauthor=L.+Bhattiauthor=J.+Gatheauthor=P.+J.+Ruaneauthor=R.+Elionauthor=F.+Bredeekauthor=R.+Brennanauthor=G.+Blickauthor=A.+Khatriauthor=K.+Gibbonsauthor=Y.+B.+Huauthor=L.+Fredrickauthor=G.+Schnellauthor=T.+Pilot-Matiasauthor=R.+Tripathiauthor=B.+Da+Silva-Tillmannauthor=B.+McGovernauthor=A.+L.+Campbellauthor=T.+Podsadecki&title=Ombitasvir%2C+paritaprevir+co-dosed+with+ritonavir%2C+dasabuvir%2C+and+ribavirin+for+hepatitis+C+in+patients+co-infected+with+HIV-1.+A+Randomized+Trial&doi=10.1001%2Fjama.2015.1328"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141d&amp;dbid=16384&amp;doi=10.1001%2Fjama.2015.1328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2015.1328%26sid%3Dliteratum%253Aachs%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DEron%26aufirst%3DJ.%2BJ.%26aulast%3DWyles%26aufirst%3DD.%26aulast%3DTrinh%26aufirst%3DR.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSlim%26aufirst%3DJ.%26aulast%3DBhatti%26aufirst%3DL.%26aulast%3DGathe%26aufirst%3DJ.%26aulast%3DRuane%26aufirst%3DP.%2BJ.%26aulast%3DElion%26aufirst%3DR.%26aulast%3DBredeek%26aufirst%3DF.%26aulast%3DBrennan%26aufirst%3DR.%26aulast%3DBlick%26aufirst%3DG.%26aulast%3DKhatri%26aufirst%3DA.%26aulast%3DGibbons%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DY.%2BB.%26aulast%3DFredrick%26aufirst%3DL.%26aulast%3DSchnell%26aufirst%3DG.%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DTripathi%26aufirst%3DR.%26aulast%3DDa%2BSilva-Tillmann%26aufirst%3DB.%26aulast%3DMcGovern%26aufirst%3DB.%26aulast%3DCampbell%26aufirst%3DA.%2BL.%26aulast%3DPodsadecki%26aufirst%3DT.%26atitle%3DOmbitasvir%252C%2520paritaprevir%2520co-dosed%2520with%2520ritonavir%252C%2520dasabuvir%252C%2520and%2520ribavirin%2520for%2520hepatitis%2520C%2520in%2520patients%2520co-infected%2520with%2520HIV-1.%2520A%2520Randomized%2520Trial%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2015%26volume%3D313%26spage%3D1223%26epage%3D1231%26doi%3D10.1001%2Fjama.2015.1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit141e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asselah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassanein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berenguer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleischer-Stepniewska, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilot-Matias, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mobashery, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilchez, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span> </span><span class="NLM_article-title">Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">385</span><span class="NLM_x">, </span> <span class="NLM_fpage">2502</span><span class="NLM_x">–</span> <span class="NLM_lpage">2509</span><span class="refDoi"> DOI: 10.1016/S0140-6736(15)60159-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0140-6736%2815%2960159-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=2502-2509&author=C.+H%C3%A9zodeauthor=T.+Asselahauthor=K.+R.+Reddyauthor=T.+Hassaneinauthor=M.+Berenguerauthor=K.+Fleischer-Stepniewskaauthor=P.+Marcellinauthor=C.+Hallauthor=G.+Schnellauthor=T.+Pilot-Matiasauthor=N.+Mobasheryauthor=R.+Redmanauthor=R.+A.+Vilchezauthor=S.+Pol&title=Ombitasvir+plus+paritaprevir+plus+ritonavir+with+or+without+ribavirin+in+treatment-naive+and+treatment-experienced+patients+with+genotype+4+chronic+hepatitis+C+virus+infection+%28PEARL-I%29%3A+a+randomised%2C+open-label+trial&doi=10.1016%2FS0140-6736%2815%2960159-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141e&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2960159-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252960159-3%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DBerenguer%26aufirst%3DM.%26aulast%3DFleischer-Stepniewska%26aufirst%3DK.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DHall%26aufirst%3DC.%26aulast%3DSchnell%26aufirst%3DG.%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DMobashery%26aufirst%3DN.%26aulast%3DRedman%26aufirst%3DR.%26aulast%3DVilchez%26aufirst%3DR.%2BA.%26aulast%3DPol%26aufirst%3DS.%26atitle%3DOmbitasvir%2520plus%2520paritaprevir%2520plus%2520ritonavir%2520with%2520or%2520without%2520ribavirin%2520in%2520treatment-naive%2520and%2520treatment-experienced%2520patients%2520with%2520genotype%25204%2520chronic%2520hepatitis%2520C%2520virus%2520infection%2520%2528PEARL-I%2529%253A%2520a%2520randomised%252C%2520open-label%2520trial%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D2502%26epage%3D2509%26doi%3D10.1016%2FS0140-6736%2815%2960159-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Kwo, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantry, P.S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coakley, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Te, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitsky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terrault, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, J. R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setze, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilot-Matias, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilchez, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forns, X.</span><span> </span><span class="NLM_article-title">An interferon-free antiviral regimen for HCV after liver transplantation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">2375</span><span class="NLM_x">–</span> <span class="NLM_lpage">2382</span><span class="refDoi"> DOI: 10.1056/NEJMoa1408921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1408921" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=2375-2382&author=P.+Y.+Kwoauthor=P.S.+Mantryauthor=E.+Coakleyauthor=H.+S.+Teauthor=H.+E.+Vargasauthor=R.+Brownauthor=F.+Gordonauthor=J.+Levitskyauthor=N.+A.+Terraultauthor=J.+R.+Burtonauthor=W.+Xieauthor=C.+Setzeauthor=P.+Badriauthor=T.+Pilot-Matiasauthor=R.+A.+Vilchezauthor=X.+Forns&title=An+interferon-free+antiviral+regimen+for+HCV+after+liver+transplantation&doi=10.1056%2FNEJMoa1408921"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1408921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1408921%26sid%3Dliteratum%253Aachs%26aulast%3DKwo%26aufirst%3DP.%2BY.%26aulast%3DMantry%26aufirst%3DP.S.%26aulast%3DCoakley%26aufirst%3DE.%26aulast%3DTe%26aufirst%3DH.%2BS.%26aulast%3DVargas%26aufirst%3DH.%2BE.%26aulast%3DBrown%26aufirst%3DR.%26aulast%3DGordon%26aufirst%3DF.%26aulast%3DLevitsky%26aufirst%3DJ.%26aulast%3DTerrault%26aufirst%3DN.%2BA.%26aulast%3DBurton%26aufirst%3DJ.%2BR.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DSetze%26aufirst%3DC.%26aulast%3DBadri%26aufirst%3DP.%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DVilchez%26aufirst%3DR.%2BA.%26aulast%3DForns%26aufirst%3DX.%26atitle%3DAn%2520interferon-free%2520antiviral%2520regimen%2520for%2520HCV%2520after%2520liver%2520transplantation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D2375%26epage%3D2382%26doi%3D10.1056%2FNEJMoa1408921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Keating, G. M.</span><span> </span><span class="NLM_article-title">Elbasvir/grazoprevir: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span><span class="refDoi"> DOI: 10.1007/s40265-016-0558-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1007%2Fs40265-016-0558-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=617-624&author=G.+M.+Keating&title=Elbasvir%2Fgrazoprevir%3A+first+global+approval&doi=10.1007%2Fs40265-016-0558-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0558-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0558-3%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DElbasvir%252Fgrazoprevir%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D617%26epage%3D624%26doi%3D10.1007%2Fs40265-016-0558-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Carrion, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, P.</span><span> </span><span class="NLM_article-title">Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">883</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span><span class="refDoi"> DOI: 10.1080/14740338.2016.1179278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1080%2F14740338.2016.1179278" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=883-890&author=A.+F.+Carrionauthor=P.+Martin&title=Safety+and+efficacy+of+elbasvir+and+grazoprevir+for+treatment+of+hepatitis+C&doi=10.1080%2F14740338.2016.1179278"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144a&amp;dbid=16384&amp;doi=10.1080%2F14740338.2016.1179278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14740338.2016.1179278%26sid%3Dliteratum%253Aachs%26aulast%3DCarrion%26aufirst%3DA.%2BF.%26aulast%3DMartin%26aufirst%3DP.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520elbasvir%2520and%2520grazoprevir%2520for%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2016%26volume%3D15%26spage%3D883%26epage%3D890%26doi%3D10.1080%2F14740338.2016.1179278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit144b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Alric, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnet, D.</span><span> </span><span class="NLM_article-title">Grazoprevir + elbasvir for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">735</span><span class="NLM_x">–</span> <span class="NLM_lpage">742</span><span class="refDoi"> DOI: 10.1517/14656566.2016.1161028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1517%2F14656566.2016.1161028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=735-742&author=L.+Alricauthor=D.+Bonnet&title=Grazoprevir+%2B+elbasvir+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1517%2F14656566.2016.1161028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144b&amp;dbid=16384&amp;doi=10.1517%2F14656566.2016.1161028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2016.1161028%26sid%3Dliteratum%253Aachs%26aulast%3DAlric%26aufirst%3DL.%26aulast%3DBonnet%26aufirst%3DD.%26atitle%3DGrazoprevir%2520%252B%2520elbasvir%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2016%26volume%3D17%26spage%3D735%26epage%3D742%26doi%3D10.1517%2F14656566.2016.1161028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit144c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Landaverde, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, J. L.</span><span> </span><span class="NLM_article-title">Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection</span> <span class="citation_source-journal">Expert Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">419</span><span class="NLM_x">–</span> <span class="NLM_lpage">429</span><span class="refDoi"> DOI: 10.1586/17474124.2016.1147346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1586%2F17474124.2016.1147346" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=419-429&author=C.+Landaverdeauthor=J.+Wellsauthor=R.+Hamnerauthor=J.+L.+Goldstein&title=Dual+therapy+of+grazoprevir+and+elbasvir+for+the+treatment+of+hepatitis+C+infection&doi=10.1586%2F17474124.2016.1147346"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144c&amp;dbid=16384&amp;doi=10.1586%2F17474124.2016.1147346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F17474124.2016.1147346%26sid%3Dliteratum%253Aachs%26aulast%3DLandaverde%26aufirst%3DC.%26aulast%3DWells%26aufirst%3DJ.%26aulast%3DHamner%26aufirst%3DR.%26aulast%3DGoldstein%26aufirst%3DJ.%2BL.%26atitle%3DDual%2520therapy%2520of%2520grazoprevir%2520and%2520elbasvir%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520infection%26jtitle%3DExpert%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2016%26volume%3D10%26spage%3D419%26epage%3D429%26doi%3D10.1586%2F17474124.2016.1147346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit144d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Roensholt, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerstoft, J.</span><span> </span><span class="NLM_article-title">Grazoprevir and elbasvir: a second-generation protease inhibitor and a second-generation NS5A inhibitor in a combination regimen for treatment of chronic hepatitis C</span> <span class="citation_source-journal">Future Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">698</span><span class="refDoi"> DOI: 10.2217/fvl.15.40</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.2217%2Ffvl.15.40" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=691-698&author=F.+F.+Roensholtauthor=J.+Gerstoft&title=Grazoprevir+and+elbasvir%3A+a+second-generation+protease+inhibitor+and+a+second-generation+NS5A+inhibitor+in+a+combination+regimen+for+treatment+of+chronic+hepatitis+C&doi=10.2217%2Ffvl.15.40"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144d&amp;dbid=16384&amp;doi=10.2217%2Ffvl.15.40&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffvl.15.40%26sid%3Dliteratum%253Aachs%26aulast%3DRoensholt%26aufirst%3DF.%2BF.%26aulast%3DGerstoft%26aufirst%3DJ.%26atitle%3DGrazoprevir%2520and%2520elbasvir%253A%2520a%2520second-generation%2520protease%2520inhibitor%2520and%2520a%2520second-generation%2520NS5A%2520inhibitor%2520in%2520a%2520combination%2520regimen%2520for%2520treatment%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DFuture%2520Virol.%26date%3D2015%26volume%3D10%26spage%3D691%26epage%3D698%26doi%3D10.2217%2Ffvl.15.40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ari, Z. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNubile, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterton, J. R.</span><span> </span><span class="NLM_article-title">Grazoprevir-elbasvir combination therapy for treatment-naïve cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span><span class="refDoi"> DOI: 10.7326/M15-0785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.7326%2FM15-0785" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2015&pages=1-13&author=S.+Zeuzemauthor=R.+Ghalibauthor=K.+R.+Reddyauthor=P.+J.+Pockrosauthor=Z.+B.+Ariauthor=Y.+Zhaoauthor=D.+D.+Brownauthor=S.+Wanauthor=M.+J.+DiNubileauthor=B.-Y.+Nguyenauthor=M.+N.+Robertsonauthor=J.+Wahlauthor=E.+Barrauthor=J.+R.+Butterton&title=Grazoprevir-elbasvir+combination+therapy+for+treatment-na%C3%AFve+cirrhotic+and+noncirrhotic+patients+with+chronic+HCV+genotype+1%2C+4%2C+or+6+infection%3A+a+randomized+trial&doi=10.7326%2FM15-0785"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.7326%2FM15-0785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252FM15-0785%26sid%3Dliteratum%253Aachs%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DAri%26aufirst%3DZ.%2BB.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DD.%2BD.%26aulast%3DWan%26aufirst%3DS.%26aulast%3DDiNubile%26aufirst%3DM.%2BJ.%26aulast%3DNguyen%26aufirst%3DB.-Y.%26aulast%3DRobertson%26aufirst%3DM.%2BN.%26aulast%3DWahl%26aufirst%3DJ.%26aulast%3DBarr%26aufirst%3DE.%26aulast%3DButterton%26aufirst%3DJ.%2BR.%26atitle%3DGrazoprevir-elbasvir%2520combination%2520therapy%2520for%2520treatment-na%25C3%25AFve%2520cirrhotic%2520and%2520noncirrhotic%2520patients%2520with%2520chronic%2520HCV%2520genotype%25201%252C%25204%252C%2520or%25206%2520infection%253A%2520a%2520randomized%2520trial%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2015%26volume%3D163%26spage%3D1%26epage%3D13%26doi%3D10.7326%2FM15-0785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Feld, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asselah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruane, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruener, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abergel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzotta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafran, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towner, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNally, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osinusi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svarovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span> </span><span class="NLM_article-title">for the ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">2599</span><span class="NLM_x">–</span> <span class="NLM_lpage">2607</span><span class="refDoi"> DOI: 10.1056/NEJMoa1512610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1512610" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2599-2607&author=J.+J.+Feldauthor=I.+M.+Jacobsonauthor=C.+H%C3%A9zodeauthor=T.+Asselahauthor=P.+J.+Ruaneauthor=N.+Gruenerauthor=A.+Abergelauthor=A.+Mangiaauthor=C.+L.+Laiauthor=H.+L.+Chanauthor=F.+Mazzottaauthor=C.+Morenoauthor=E.+Yoshidaauthor=S.+D.+Shafranauthor=W.+J.+Townerauthor=T.+T.+Tranauthor=J.+McNallyauthor=A.+Osinusiauthor=E.+Svarovskaiaauthor=Y.+Zhuauthor=D.+M.+Brainardauthor=J.+G.+McHutchisonauthor=K.+Agarwalauthor=S.+Zeuzem&title=for+the+ASTRAL-1+Investigators.+Sofosbuvir+and+velpatasvir+for+HCV+genotype+1%2C+2%2C+4%2C+5%2C+and+6+infection&doi=10.1056%2FNEJMoa1512610"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1512610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1512610%26sid%3Dliteratum%253Aachs%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DRuane%26aufirst%3DP.%2BJ.%26aulast%3DGruener%26aufirst%3DN.%26aulast%3DAbergel%26aufirst%3DA.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DC.%2BL.%26aulast%3DChan%26aufirst%3DH.%2BL.%26aulast%3DMazzotta%26aufirst%3DF.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DYoshida%26aufirst%3DE.%26aulast%3DShafran%26aufirst%3DS.%2BD.%26aulast%3DTowner%26aufirst%3DW.%2BJ.%26aulast%3DTran%26aufirst%3DT.%2BT.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DOsinusi%26aufirst%3DA.%26aulast%3DSvarovskaia%26aufirst%3DE.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DZeuzem%26aufirst%3DS.%26atitle%3Dfor%2520the%2520ASTRAL-1%2520Investigators.%2520Sofosbuvir%2520and%2520velpatasvir%2520for%2520HCV%2520genotype%25201%252C%25202%252C%25204%252C%25205%252C%2520and%25206%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2599%26epage%3D2607%26doi%3D10.1056%2FNEJMoa1512610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit146b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Foster, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afdhal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bräu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pianko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiffman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towner, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruane, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asselah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stedman, C. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvory-Sobol, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNally, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osinusi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzotta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M.</span><span> </span><span class="NLM_article-title">for the ASTRAL-2 and ASTRAL-3 Investigators. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">2608</span><span class="NLM_x">–</span> <span class="NLM_lpage">2617</span><span class="refDoi"> DOI: 10.1056/NEJMoa1512612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1512612" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2608-2617&author=G.+R.+Fosterauthor=N.+Afdhalauthor=S.+K.+Robertsauthor=N.+Br%C3%A4uauthor=E.+J.+Ganeauthor=S.+Piankoauthor=E.+Lawitzauthor=A.+Thompsonauthor=M.+L.+Shiffmanauthor=C.+Cooperauthor=W.+J.+Townerauthor=B.+Conwayauthor=P.+Ruaneauthor=M.+Bourli%C3%A8reauthor=T.+Asselahauthor=T.+Bergauthor=S.+Zeuzemauthor=W.+Rosenbergauthor=K.+Agarwalauthor=C.+A.+M.+Stedmanauthor=H.+Moauthor=H.+Dvory-Sobolauthor=L.+Hanauthor=J.+Wangauthor=J.+McNallyauthor=A.+Osinusiauthor=D.+M.+Brainardauthor=J.+G.+McHutchisonauthor=F.+Mazzottaauthor=T.+T.+Tranauthor=S.+C.+Gordonauthor=K.+Patelauthor=N.+Reauauthor=A.+Mangiaauthor=M.+Sulkowski&title=for+the+ASTRAL-2+and+ASTRAL-3+Investigators.+Sofosbuvir+and+velpatasvir+for+HCV+genotype+2+and+3+infection&doi=10.1056%2FNEJMoa1512612"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1512612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1512612%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DAfdhal%26aufirst%3DN.%26aulast%3DRoberts%26aufirst%3DS.%2BK.%26aulast%3DBr%25C3%25A4u%26aufirst%3DN.%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DPianko%26aufirst%3DS.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DShiffman%26aufirst%3DM.%2BL.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DTowner%26aufirst%3DW.%2BJ.%26aulast%3DConway%26aufirst%3DB.%26aulast%3DRuane%26aufirst%3DP.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DRosenberg%26aufirst%3DW.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DStedman%26aufirst%3DC.%2BA.%2BM.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DDvory-Sobol%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DOsinusi%26aufirst%3DA.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMazzotta%26aufirst%3DF.%26aulast%3DTran%26aufirst%3DT.%2BT.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DReau%26aufirst%3DN.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DSulkowski%26aufirst%3DM.%26atitle%3Dfor%2520the%2520ASTRAL-2%2520and%2520ASTRAL-3%2520Investigators.%2520Sofosbuvir%2520and%2520velpatasvir%2520for%2520HCV%2520genotype%25202%2520and%25203%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2608%26epage%3D2617%26doi%3D10.1056%2FNEJMoa1512612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit146c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Curry, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Leary, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bzowej, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korenblat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenkel, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flamm, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiano, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teperman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doehle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNally, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osinusi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R. S.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, M.</span><span> </span><span class="NLM_article-title">for the ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">2618</span><span class="NLM_x">–</span> <span class="NLM_lpage">2628</span><span class="refDoi"> DOI: 10.1056/NEJMoa1512614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1512614" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2618-2628&author=M.+P.+Curryauthor=J.+G.+O%E2%80%99Learyauthor=N.+Bzowejauthor=A.+J.+Muirauthor=K.+M.+Korenblatauthor=J.+M.+Fenkelauthor=K.+R.+Reddyauthor=E.+Lawitzauthor=S.+L.+Flammauthor=T.+Schianoauthor=L.+Tepermanauthor=R.+Fontanaauthor=E.+Schiffauthor=M.+Friedauthor=B.+Doehleauthor=D.+Anauthor=J.+McNallyauthor=A.+Osinusiauthor=D.+M.+Brainardauthor=J.+G.+McHutchisonauthor=R.+S.+Brownauthor=M.+Charlton&title=for+the+ASTRAL-4+Investigators.+Sofosbuvir+and+velpatasvir+for+HCV+in+patients+with+decompensated+cirrhosis&doi=10.1056%2FNEJMoa1512614"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1512614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1512614%26sid%3Dliteratum%253Aachs%26aulast%3DCurry%26aufirst%3DM.%2BP.%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DJ.%2BG.%26aulast%3DBzowej%26aufirst%3DN.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DKorenblat%26aufirst%3DK.%2BM.%26aulast%3DFenkel%26aufirst%3DJ.%2BM.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DFlamm%26aufirst%3DS.%2BL.%26aulast%3DSchiano%26aufirst%3DT.%26aulast%3DTeperman%26aufirst%3DL.%26aulast%3DFontana%26aufirst%3DR.%26aulast%3DSchiff%26aufirst%3DE.%26aulast%3DFried%26aufirst%3DM.%26aulast%3DDoehle%26aufirst%3DB.%26aulast%3DAn%26aufirst%3DD.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DOsinusi%26aufirst%3DA.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DBrown%26aufirst%3DR.%2BS.%26aulast%3DCharlton%26aufirst%3DM.%26atitle%3Dfor%2520the%2520ASTRAL-4%2520Investigators.%2520Sofosbuvir%2520and%2520velpatasvir%2520for%2520HCV%2520in%2520patients%2520with%2520decompensated%2520cirrhosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2618%26epage%3D2628%26doi%3D10.1056%2FNEJMoa1512614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit146d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towner, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyles, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahass, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etzkorn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinestrosa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinovitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNally, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doehle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. T.</span><span> </span><span class="NLM_article-title">Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">818</span><span class="NLM_x">–</span> <span class="NLM_lpage">826</span><span class="refDoi"> DOI: 10.7326/M15-1000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.7326%2FM15-1000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26551051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC28vgt1agtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2015&pages=818-826&author=G.+T.+Eversonauthor=W.+J.+Townerauthor=M.+N.+Davisauthor=D.+L.+Wylesauthor=R.+G.+Nahassauthor=P.+J.+Thuluvathauthor=K.+Etzkornauthor=F.+Hinestrosaauthor=M.+Tongauthor=M.+Rabinovitzauthor=J.+McNallyauthor=D.+M.+Brainardauthor=L.+Hanauthor=B.+Doehleauthor=J.+G.+McHutchisonauthor=T.+Morganauthor=R.+T.+Chungauthor=T.+T.+Tran&title=Sofosbuvir+with+velpatasvir+in+treatment-naive+noncirrhotic+patients+with+genotype+1+to+6+hepatitis+C+virus+infection%3A+a+randomized+trial&doi=10.7326%2FM15-1000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146dR"><div class="casContent"><span class="casTitleNuber">146d</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial</span></div><div class="casAuthors">Everson Gregory T; Towner William J; Davis Mitchell N; Wyles David L; Nahass Ronald G; Thuluvath Paul J; Etzkorn Kyle; Hinestrosa Federico; Tong Myron; Rabinovitz Mordechai; McNally John; Brainard Diana M; Han Lingling; Doehle Brian; McHutchison John G; Morgan Timothy; Chung Raymond T; Tran Tram T</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">818-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Effective, pangenotypic treatments for hepatitis C virus (HCV) infection are needed.  OBJECTIVE:  To assess the safety and efficacy of sofosbuvir with velpatasvir in patients infected with HCV genotypes 1 to 6.  DESIGN:  Randomized, phase 2, open-label study. (ClinicalTrials.gov: NCT01858766).  SETTING:  48 U.S. sites.  PATIENTS:  377 treatment-naive noncirrhotic patients.  In part A, patients infected with HCV genotypes 1 to 6 were randomly assigned to sofosbuvir, 400 mg, with velpatasvir, 25 or 100 mg, for 12 weeks.  In part B, patients with genotype 1 or 2 HCV infection were randomly assigned to sofosbuvir, 400 mg, and velpatasvir, 25 or 100 mg, with or without ribavirin for 8 weeks.  MEASUREMENTS:  Sustained virologic response at 12 weeks (SVR12).  RESULTS:  In part A, SVR12 rates were 96% (26 of 27) with velpatasvir, 25 mg, and 100% (28 of 28) with velpatasvir, 100 mg, for genotype 1; 93% (25 of 27) in both groups for genotype 3; and 96% (22 of 23) with velpatasvir, 25 mg, and 95% (21 of 22) with velpatasvir, 100 mg, for genotypes 2, 4, 5, and 6.  In part B, for genotype 1, SVR12 rates were 87% (26 of 30) with velpatasvir, 25 mg; 83% (25 of 30) with velpatasvir, 25 mg, plus ribavirin; 90% (26 of 29) with velpatasvir, 100 mg; and 81% (25 of 31) with velpatasvir, 100 mg, plus ribavirin.  For genotype 2, SVR12 rates were 77% (20 of 26) with velpatasvir, 25 mg; 88% (22 of 25) with velpatasvir, 25 mg, plus ribavirin; 88% (23 of 26) with velpatasvir, 100 mg; and 88% (23 of 26) with velpatasvir, 100 mg, plus ribavirin.  Adverse events included fatigue (21%), headache (20%), and nausea (12%).  One patient committed suicide.  LIMITATION:  The study was open-label, no inferential statistics were planned, and sample sizes were small.  CONCLUSION:  Twelve weeks of sofosbuvir, 400 mg, and velpatasvir, 100 mg, was well-tolerated and resulted in high SVR in patients infected with HCV genotypes 1 to 6.  PRIMARY FUNDING SOURCE:  Gilead Sciences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSe_4IC_iyrYa2q3xNe7a7QfW6udTcc2eZfR0LkI7zAArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vgt1agtg%253D%253D&md5=d849efe4192fca8ae7921dd1e2bebfcb</span></div><a href="/servlet/linkout?suffix=cit146d&amp;dbid=16384&amp;doi=10.7326%2FM15-1000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252FM15-1000%26sid%3Dliteratum%253Aachs%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DTowner%26aufirst%3DW.%2BJ.%26aulast%3DDavis%26aufirst%3DM.%2BN.%26aulast%3DWyles%26aufirst%3DD.%2BL.%26aulast%3DNahass%26aufirst%3DR.%2BG.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DEtzkorn%26aufirst%3DK.%26aulast%3DHinestrosa%26aufirst%3DF.%26aulast%3DTong%26aufirst%3DM.%26aulast%3DRabinovitz%26aufirst%3DM.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DDoehle%26aufirst%3DB.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMorgan%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DR.%2BT.%26aulast%3DTran%26aufirst%3DT.%2BT.%26atitle%3DSofosbuvir%2520with%2520velpatasvir%2520in%2520treatment-naive%2520noncirrhotic%2520patients%2520with%2520genotype%25201%2520to%25206%2520hepatitis%2520C%2520virus%2520infection%253A%2520a%2520randomized%2520trial%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2015%26volume%3D163%26spage%3D818%26epage%3D826%26doi%3D10.7326%2FM15-1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Lawitz, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Riordan, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asatryan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overcash, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kort, J.</span><span> </span><span class="NLM_article-title">Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1546</span><span class="NLM_x">–</span> <span class="NLM_lpage">1555</span><span class="refDoi"> DOI: 10.1128/AAC.02264-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FAAC.02264-15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=1546-1555&author=E.+J.+Lawitzauthor=W.+D.+O%E2%80%99Riordanauthor=A.+Asatryanauthor=B.+L.+Freilichauthor=T.+D.+Boxauthor=J.+S.+Overcashauthor=S.+Lovellauthor=T.+I.+Ngauthor=W.+Liuauthor=A.+Campbellauthor=C.+W.+Linauthor=B.+Yaoauthor=J.+Kort&title=Potent+antiviral+activities+of+the+direct-acting+antivirals+ABT-493+and+ABT-530+with+three-day+monotherapy+for+hepatitis+C+virus+genotype+1+infection&doi=10.1128%2FAAC.02264-15"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1128%2FAAC.02264-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02264-15%26sid%3Dliteratum%253Aachs%26aulast%3DLawitz%26aufirst%3DE.%2BJ.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DW.%2BD.%26aulast%3DAsatryan%26aufirst%3DA.%26aulast%3DFreilich%26aufirst%3DB.%2BL.%26aulast%3DBox%26aufirst%3DT.%2BD.%26aulast%3DOvercash%26aufirst%3DJ.%2BS.%26aulast%3DLovell%26aufirst%3DS.%26aulast%3DNg%26aufirst%3DT.%2BI.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DC.%2BW.%26aulast%3DYao%26aufirst%3DB.%26aulast%3DKort%26aufirst%3DJ.%26atitle%3DPotent%2520antiviral%2520activities%2520of%2520the%2520direct-acting%2520antivirals%2520ABT-493%2520and%2520ABT-530%2520with%2520three-day%2520monotherapy%2520for%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D1546%26epage%3D1555%26doi%3D10.1128%2FAAC.02264-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bisceglie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvory-Sobol, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krefetz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marbury, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span> </span><span class="NLM_article-title">GS-9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double-blind, dose-ranging phase 1 study</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">614</span><span class="refDoi"> DOI: 10.1111/jvh.12527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fjvh.12527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26957110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOkurbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=614&author=M.+Rodriguez-Torresauthor=S.+Glassauthor=J.+Hillauthor=B.+Freilichauthor=D.+Hassmanauthor=A.+M.+Di+Bisceglieauthor=J.+G.+Taylorauthor=B.+J.+Kirbyauthor=H.+Dvory-Sobolauthor=J.+C.+Yangauthor=D.+Anauthor=L.+M.+Stammauthor=D.+M.+Brainardauthor=S.+Kimauthor=D.+Krefetzauthor=W.+Smithauthor=T.+Marburyauthor=E.+Lawitz&title=GS-9857+in+patients+with+chronic+hepatitis+C+virus+genotype+1%E2%80%934+infection%3A+a+randomized%2C+double-blind%2C+dose-ranging+phase+1+study&doi=10.1111%2Fjvh.12527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study</span></div><div class="casAuthors">Rodriguez-Torres, M.; Glass, S.; Hill, J.; Freilich, B.; Hassman, D.; Di Bisceglie, A. M.; Taylor, J. G.; Kirby, B. J.; Dvory-Sobol, H.; Yang, J. C.; An, D.; Stamm, L. M.; Brainard, D. M.; Kim, S.; Krefetz, D.; Smith, W.; Marbury, T.; Lawitz, E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Viral Hepatitis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">614-622</span>CODEN:
                <span class="NLM_cas:coden">JVHEER</span>;
        ISSN:<span class="NLM_cas:issn">1365-2893</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Summary : GS-9857, an inhibitor of the hepatitis C virus (HCV) nonstructural protein (NS) 3/4A, demonstrates potent activity against HCV genotypes 1-6 and improved coverage against commonly encountered NS3 resistance-assocd. variants (RAVs).  In this study, the safety, tolerability, antiviral activity and pharmacokinetics (PK) of GS-9857 were evaluated in patients with chronic HCV genotype 1-4 infection.  Patients with genotype 1-4 infection received placebo or once-daily GS-9857 at doses ranging from 50 to 300 mg for 3 days under fasting conditions.  GS-9857 was well tolerated; all reported adverse events (AEs) were mild or moderate in severity.  Diarrhoea and headache were the most commonly reported AEs.  Grade 3 or 4 lab. abnormalities were obsd. in 17% of patients receiving GS-9857; there were no Grade 3 or 4 abnormalities in alanine aminotransferase, aspartate aminotransferase or alk. phosphatase levels.  GS-9857 demonstrated potent antiviral activity in patients with chronic HCV infection, achieving mean and median max. redns. in HCV RNA of ≥3 log10 IU/mL following administration of a 100-mg dose in patients with HCV genotype 1a, 1b, 2, 3 or 4 infection.  The antiviral activity of GS-9857 was unaffected by the presence of pretreatment NS3 RAVs.  In patients with genotype 1-4 infection, GS-9857 exhibited linear PK and was assocd. with a median half-life of 29-42 h, supporting once-daily dosing.  Thus, the tolerability, efficacy and pharmacokinetic profile of GS-9857 support its further evaluation for treatment of patients with chronic HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8oJDwl-bOdbVg90H21EOLACvtfcHk0lgZhNGWNX-TmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOkurbK&md5=257769b545cb4289b8f9fc5298454f91</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1111%2Fjvh.12527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.12527%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DGlass%26aufirst%3DS.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DFreilich%26aufirst%3DB.%26aulast%3DHassman%26aufirst%3DD.%26aulast%3DDi%2BBisceglie%26aufirst%3DA.%2BM.%26aulast%3DTaylor%26aufirst%3DJ.%2BG.%26aulast%3DKirby%26aufirst%3DB.%2BJ.%26aulast%3DDvory-Sobol%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DAn%26aufirst%3DD.%26aulast%3DStamm%26aufirst%3DL.%2BM.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DKrefetz%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DW.%26aulast%3DMarbury%26aufirst%3DT.%26aulast%3DLawitz%26aufirst%3DE.%26atitle%3DGS-9857%2520in%2520patients%2520with%2520chronic%2520hepatitis%2520C%2520virus%2520genotype%25201%25E2%2580%25934%2520infection%253A%2520a%2520randomized%252C%2520double-blind%252C%2520dose-ranging%2520phase%25201%2520study%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2016%26volume%3D23%26spage%3D614%26doi%3D10.1111%2Fjvh.12527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Gane, E.J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwabe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svarovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stedman, C. A.</span><span> </span><span class="NLM_article-title">Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naïve or previously treated patients with HCV genotype 1 or 3 infections</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1053/j.gastro.2016.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1053%2Fj.gastro.2016.05.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=E.J.+Ganeauthor=C.+Schwabeauthor=R.+H.+Hylandauthor=Y.+Yangauthor=E.+Svarovskaiaauthor=L.+M.+Stammauthor=D.+M.+Brainardauthor=J.+G.+McHutchisonauthor=C.+A.+Stedman&title=Efficacy+of+the+combination+of+sofosbuvir%2C+velpatasvir%2C+and+the+NS3%2F4A+protease+inhibitor+GS-9857+in+treatment-na%C3%AFve+or+previously+treated+patients+with+HCV+genotype+1+or+3+infections&doi=10.1053%2Fj.gastro.2016.05.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2016.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2016.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.J.%26aulast%3DSchwabe%26aufirst%3DC.%26aulast%3DHyland%26aufirst%3DR.%2BH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DSvarovskaia%26aufirst%3DE.%26aulast%3DStamm%26aufirst%3DL.%2BM.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DStedman%26aufirst%3DC.%2BA.%26atitle%3DEfficacy%2520of%2520the%2520combination%2520of%2520sofosbuvir%252C%2520velpatasvir%252C%2520and%2520the%2520NS3%252F4A%2520protease%2520inhibitor%2520GS-9857%2520in%2520treatment-na%25C3%25AFve%2520or%2520previously%2520treated%2520patients%2520with%2520HCV%2520genotype%25201%2520or%25203%2520infections%26jtitle%3DGastroenterology%26date%3D2016%26doi%3D10.1053%2Fj.gastro.2016.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Kwong, A. D.</span><span> </span><span class="NLM_article-title">The HCV revolution did not happen overnight</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span><span class="refDoi"> DOI: 10.1021/ml500070q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500070q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1yltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=214-220&author=A.+D.+Kwong&title=The+HCV+revolution+did+not+happen+overnight&doi=10.1021%2Fml500070q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">The HCV Revolution Did Not Happen Overnight</span></div><div class="casAuthors">Kwong, Ann D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">214-220</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The progress in HCV therapy in the last three years is similar to the progress that took HIV therapy ∼14 years.  We are at the brink of approval for an all-oral drug combination that is dosed once daily as a single pill, has >95% efficacy, and is well tolerated.  This article summarizes the path to this success and the challenges still ahead.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg5BynQvE32rVg90H21EOLACvtfcHk0ljTMZnaVESSxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1yltr0%253D&md5=719af45391278d0c65f0e35f579a0c83</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Fml500070q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500070q%26sid%3Dliteratum%253Aachs%26aulast%3DKwong%26aufirst%3DA.%2BD.%26atitle%3DThe%2520HCV%2520revolution%2520did%2520not%2520happen%2520overnight%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D214%26epage%3D220%26doi%3D10.1021%2Fml500070q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koszalka, G. W.</span><span> </span><span class="NLM_article-title">2007: a difficult year for HCV drug development</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">128</span><span class="NLM_x">–</span> <span class="NLM_lpage">131</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=18246515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FovVahuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=128-131&author=N.+A.+Meanwellauthor=G.+W.+Koszalka&title=2007%3A+a+difficult+year+for+HCV+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">2007: a difficult year for HCV drug development</span></div><div class="casAuthors">Meanwell Nicholas A; Koszalka George W</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in investigational drugs (London, England : 2000)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">128-31</span>
        ISSN:<span class="NLM_cas:issn">1472-4472</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbNRSEMlKlqjC850By6mxpfW6udTcc2eacycOezl-ilbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FovVahuw%253D%253D&md5=40fbf1852de9cb2914e88c69d55d8d8b</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKoszalka%26aufirst%3DG.%2BW.%26atitle%3D2007%253A%2520a%2520difficult%2520year%2520for%2520HCV%2520drug%2520development%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D9%26spage%3D128%26epage%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Williams, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pico, A. R.</span><span> </span><span class="NLM_article-title">From scientific discovery to cures: bright stars within a galaxy</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1016/j.cell.2015.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.cell.2015.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26406364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKqtrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2015&pages=21-23&author=R.+S.+Williamsauthor=S.+Lotiaauthor=A.+K.+Hollowayauthor=A.+R.+Pico&title=From+scientific+discovery+to+cures%3A+bright+stars+within+a+galaxy&doi=10.1016%2Fj.cell.2015.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">From Scientific Discovery to Cures: Bright Stars within a Galaxy</span></div><div class="casAuthors">Williams, R. Sanders; Lotia, Samad; Holloway, Alisha K.; Pico, Alexander R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-23</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We propose that data mining and network anal. utilizing public databases can identify and quantify relationships between scientific discoveries and major advances in medicine (cures).  Further development of such approaches could help to increase public understanding and governmental support for life science research and could enhance decision making in the quest for cures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptIzvc7ZBDRLVg90H21EOLACvtfcHk0lih5KDZ5gZu3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKqtrvN&md5=17df22c69780c25df589f4ff8227c337</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DR.%2BS.%26aulast%3DLotia%26aufirst%3DS.%26aulast%3DHolloway%26aufirst%3DA.%2BK.%26aulast%3DPico%26aufirst%3DA.%2BR.%26atitle%3DFrom%2520scientific%2520discovery%2520to%2520cures%253A%2520bright%2520stars%2520within%2520a%2520galaxy%26jtitle%3DCell%26date%3D2015%26volume%3D163%26spage%3D21%26epage%3D23%26doi%3D10.1016%2Fj.cell.2015.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Calcoen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elias, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span> </span><span class="NLM_article-title">What does it take to produce a breakthrough drug?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span><span class="refDoi"> DOI: 10.1038/nrd4570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrd4570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25722234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC2Mrpt1yquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=161-162&author=D.+Calcoenauthor=L.+Eliasauthor=X.+Yu&title=What+does+it+take+to+produce+a+breakthrough+drug%3F&doi=10.1038%2Fnrd4570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">What does it take to produce a breakthrough drug?</span></div><div class="casAuthors">Calcoen Dirk; Elias Laura; Yu Xiaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQynMISMHL85z69zv1FsJFMfW6udTcc2ebNpxC4mvj2Tbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mrpt1yquw%253D%253D&md5=aa00201a6a9fe7a72032eb4bf3bd1e74</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1038%2Fnrd4570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4570%26sid%3Dliteratum%253Aachs%26aulast%3DCalcoen%26aufirst%3DD.%26aulast%3DElias%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DX.%26atitle%3DWhat%2520does%2520it%2520take%2520to%2520produce%2520a%2520breakthrough%2520drug%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D161%26epage%3D162%26doi%3D10.1038%2Fnrd4570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kola, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, J.</span><span> </span><span class="NLM_article-title">Can the pharmaceutical industry reduce attrition rates?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">711</span><span class="NLM_x">–</span> <span class="NLM_lpage">715</span><span class="refDoi"> DOI: 10.1038/nrd1470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrd1470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=15286737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=711-715&author=I.+Kolaauthor=J.+Landis&title=Can+the+pharmaceutical+industry+reduce+attrition+rates%3F&doi=10.1038%2Fnrd1470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154aR"><div class="casContent"><span class="casTitleNuber">154a</span><div class="casTitle"><span class="NLM_cas:atitle">Opinion: Can the pharmaceutical industry reduce attrition rates?</span></div><div class="casAuthors">Kola, Ismail; Landis, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-716</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry faces considerable challenges, both politically and fiscally.  Politically, governments around the world are trying to contain costs and, as health care budgets constitute a very significant part of governmental spending, these costs are the subject of intense scrutiny.  In the United States, drug costs are also the subject of intense political discourse.  This article deals with the fiscal pressures that face the industry from the perspective of R&D.  What impinges on productivity How can we improve current reduced R&D productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruAlrpFPFmiLVg90H21EOLACvtfcHk0lhqXi6sOPhd3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtLs%253D&md5=f9025c13a1506f607aaf68415570ed01</span></div><a href="/servlet/linkout?suffix=cit154a&amp;dbid=16384&amp;doi=10.1038%2Fnrd1470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1470%26sid%3Dliteratum%253Aachs%26aulast%3DKola%26aufirst%3DI.%26aulast%3DLandis%26aufirst%3DJ.%26atitle%3DCan%2520the%2520pharmaceutical%2520industry%2520reduce%2520attrition%2520rates%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D711%26epage%3D715%26doi%3D10.1038%2Fnrd1470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit154b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Waring, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrowsmith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandrell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennie, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, A.</span><span> </span><span class="NLM_article-title">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">–</span> <span class="NLM_lpage">486</span><span class="refDoi"> DOI: 10.1038/nrd4609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrd4609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26091267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=475-486&author=M.+J.+Waringauthor=J.+Arrowsmithauthor=A.+R.+Leachauthor=P.+D.+Leesonauthor=S.+Mandrellauthor=R.+M.+Owenauthor=G.+Pairaudeauauthor=W.+D.+Pennieauthor=S.+D.+Pickettauthor=J.+Wangauthor=O.+Wallaceauthor=A.+Weir&title=An+analysis+of+the+attrition+of+drug+candidates+from+four+major+pharmaceutical+companies&doi=10.1038%2Fnrd4609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154bR"><div class="casContent"><span class="casTitleNuber">154b</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span></div><div class="casAuthors">Waring, Michael J.; Arrowsmith, John; Leach, Andrew R.; Leeson, Paul D.; Mandrell, Sam; Owen, Robert M.; Pairaudeau, Garry; Pennie, William D.; Pickett, Stephen D.; Wang, Jibo; Wallace, Owen; Weir, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-486</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development.  Attempts to reduce the no. of efficacy- and safety-related failures by analyzing possible links to the physicochem. properties of small-mol. drug candidates have been inconclusive because of the limited size of data sets from individual companies.  Here, we describe the compilation and anal. of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer.  The anal. reaffirms that control of physicochem. properties during compd. optimization is beneficial in identifying compds. of candidate drug quality and indicates for the first time a link between the physicochem. properties of compds. and clin. failure due to safety issues.  The results also suggest that further control of physicochem. properties is unlikely to have a significant effect on attrition rates and that addnl. work is required to address safety-related failures.  Further cross-company collaborations will be crucial to future progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLfBWrLC3ZLVg90H21EOLACvtfcHk0liD--j-4_BSKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM&md5=1fdc374d32816b1e91438152299dd1b1</span></div><a href="/servlet/linkout?suffix=cit154b&amp;dbid=16384&amp;doi=10.1038%2Fnrd4609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4609%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DMandrell%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPennie%26aufirst%3DW.%2BD.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DWeir%26aufirst%3DA.%26atitle%3DAn%2520analysis%2520of%2520the%2520attrition%2520of%2520drug%2520candidates%2520from%2520four%2520major%2520pharmaceutical%2520companies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D475%26epage%3D486%26doi%3D10.1038%2Fnrd4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit154c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craighead, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Economides, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenthal, J.</span><span> </span><span class="NLM_article-title">Clinical development success rates for investigational drugs</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">40</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1038/nbt.2786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnbt.2786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24406927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFyjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=40-51&author=M.+Hayauthor=D.+W.+Thomasauthor=J.+L.+Craigheadauthor=C.+Economidesauthor=J.+Rosenthal&title=Clinical+development+success+rates+for+investigational+drugs&doi=10.1038%2Fnbt.2786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154cR"><div class="casContent"><span class="casTitleNuber">154c</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development success rates for investigational drugs</span></div><div class="casAuthors">Hay, Michael; Thomas, David W.; Craighead, John L.; Economides, Celia; Rosenthal, Jesse</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-51</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The most comprehensive survey of clin. success rates across the drug industry to date shows productivity may be even lower than previous ests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdqyRgsoFYDbVg90H21EOLACvtfcHk0lhBwHXvXT5pmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFyjsA%253D%253D&md5=87a63ec8d8bb213b3d42519395725038</span></div><a href="/servlet/linkout?suffix=cit154c&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2786%26sid%3Dliteratum%253Aachs%26aulast%3DHay%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DD.%2BW.%26aulast%3DCraighead%26aufirst%3DJ.%2BL.%26aulast%3DEconomides%26aufirst%3DC.%26aulast%3DRosenthal%26aufirst%3DJ.%26atitle%3DClinical%2520development%2520success%2520rates%2520for%2520investigational%2520drugs%26jtitle%3DNat.%2520Biotechnol.%26date%3D2014%26volume%3D32%26spage%3D40%26epage%3D51%26doi%3D10.1038%2Fnbt.2786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit154d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Arrowsmith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, P.</span><span> </span><span class="NLM_article-title">Phase II and Phase III attrition rates 2011–2012</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">569</span><span class="refDoi"> DOI: 10.1038/nrd4090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrd4090" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=569&author=J.+Arrowsmithauthor=P.+Miller&title=Phase+II+and+Phase+III+attrition+rates+2011%E2%80%932012&doi=10.1038%2Fnrd4090"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154d&amp;dbid=16384&amp;doi=10.1038%2Fnrd4090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4090%26sid%3Dliteratum%253Aachs%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DP.%26atitle%3DPhase%2520II%2520and%2520Phase%2520III%2520attrition%2520rates%25202011%25E2%2580%25932012%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D569%26doi%3D10.1038%2Fnrd4090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Lam, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younoszai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazel, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younossi, Z. M.</span><span> </span><span class="NLM_article-title">The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment</span> <span class="citation_source-journal">Ther. Adv. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">312</span><span class="refDoi"> DOI: 10.1177/1756283X15587481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1177%2F1756283X15587481" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=298-312&author=B.+P.+Lamauthor=T.+Jeffersauthor=Z.+Younoszaiauthor=Y.+Fazelauthor=Z.+M.+Younossi&title=The+changing+landscape+of+hepatitis+C+virus+therapy%3A+focus+on+interferon-free+treatment&doi=10.1177%2F1756283X15587481"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1177%2F1756283X15587481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1756283X15587481%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DB.%2BP.%26aulast%3DJeffers%26aufirst%3DT.%26aulast%3DYounoszai%26aufirst%3DZ.%26aulast%3DFazel%26aufirst%3DY.%26aulast%3DYounossi%26aufirst%3DZ.%2BM.%26atitle%3DThe%2520changing%2520landscape%2520of%2520hepatitis%2520C%2520virus%2520therapy%253A%2520focus%2520on%2520interferon-free%2520treatment%26jtitle%3DTher.%2520Adv.%2520Gastroenterol.%26date%3D2015%26volume%3D8%26spage%3D298%26epage%3D312%26doi%3D10.1177%2F1756283X15587481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Azvolinsky, A.</span><span> </span><span class="NLM_article-title">Industry chases pan-genotypic and shorter HCV treatments</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">576</span><span class="refDoi"> DOI: 10.1038/nbt0615-575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnbt0615-575" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=575-576&author=A.+Azvolinsky&title=Industry+chases+pan-genotypic+and+shorter+HCV+treatments&doi=10.1038%2Fnbt0615-575"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1038%2Fnbt0615-575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt0615-575%26sid%3Dliteratum%253Aachs%26aulast%3DAzvolinsky%26aufirst%3DA.%26atitle%3DIndustry%2520chases%2520pan-genotypic%2520and%2520shorter%2520HCV%2520treatments%26jtitle%3DNat.%2520Biotechnol.%26date%3D2015%26volume%3D33%26spage%3D575%26epage%3D576%26doi%3D10.1038%2Fnbt0615-575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Horner, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naggie, S.</span><span> </span><span class="NLM_article-title">Successes and challenges on the road to cure hepatitis C</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">e1004854</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1004854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1371%2Fjournal.ppat.1004854" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=e1004854&issue=6&author=S.+M.+Hornerauthor=S.+Naggie&title=Successes+and+challenges+on+the+road+to+cure+hepatitis+C&doi=10.1371%2Fjournal.ppat.1004854"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1004854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1004854%26sid%3Dliteratum%253Aachs%26aulast%3DHorner%26aufirst%3DS.%2BM.%26aulast%3DNaggie%26aufirst%3DS.%26atitle%3DSuccesses%2520and%2520challenges%2520on%2520the%2520road%2520to%2520cure%2520hepatitis%2520C%26jtitle%3DPLoS%2520Pathog.%26date%3D2015%26volume%3D11%26issue%3D6%26spage%3De1004854%26doi%3D10.1371%2Fjournal.ppat.1004854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dore, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feld, J. J.</span><span> </span><span class="NLM_article-title">Hepatitis C virus therapeutic development: in pursuit of "perfectovir"</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1829</span><span class="NLM_x">–</span> <span class="NLM_lpage">1836</span><span class="refDoi"> DOI: 10.1093/cid/civ197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1093%2Fcid%2Fciv197" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2015&pages=1829-1836&author=G.+J.+Doreauthor=J.+J.+Feld&title=Hepatitis+C+virus+therapeutic+development%3A+in+pursuit+of+%22perfectovir%22&doi=10.1093%2Fcid%2Fciv197"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158a&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciv197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciv197%26sid%3Dliteratum%253Aachs%26aulast%3DDore%26aufirst%3DG.%2BJ.%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26atitle%3DHepatitis%2520C%2520virus%2520therapeutic%2520development%253A%2520in%2520pursuit%2520of%2520%2522perfectovir%2522%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2015%26volume%3D60%26spage%3D1829%26epage%3D1836%26doi%3D10.1093%2Fcid%2Fciv197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit158b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">De Clercq, E.</span><span> </span><span class="NLM_article-title">Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace</span> <span class="citation_source-journal">Rev. Med. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">254</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span><span class="refDoi"> DOI: 10.1002/rmv.1842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Frmv.1842" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=254-267&author=E.+De+Clercq&title=Development+of+antiviral+drugs+for+the+treatment+of+hepatitis+C+at+an+accelerating+pace&doi=10.1002%2Frmv.1842"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158b&amp;dbid=16384&amp;doi=10.1002%2Frmv.1842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frmv.1842%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DDevelopment%2520of%2520antiviral%2520drugs%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520at%2520an%2520accelerating%2520pace%26jtitle%3DRev.%2520Med.%2520Virol.%26date%3D2015%26volume%3D25%26spage%3D254%26epage%3D267%26doi%3D10.1002%2Frmv.1842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit158c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nyalakonda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utay, N. S.</span><span> </span><span class="NLM_article-title">A new era of therapy for hepatitis C virus infection</span> <span class="citation_source-journal">Curr. Opin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">478</span><span class="refDoi"> DOI: 10.1097/QCO.0000000000000190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1097%2FQCO.0000000000000190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26203851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVeqtrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=471-478&author=H.+Nyalakondaauthor=N.+S.+Utay&title=A+new+era+of+therapy+for+hepatitis+C+virus+infection&doi=10.1097%2FQCO.0000000000000190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158cR"><div class="casContent"><span class="casTitleNuber">158c</span><div class="casTitle"><span class="NLM_cas:atitle">A new era of therapy for hepatitis C virus infection</span></div><div class="casAuthors">Nyalakonda, Harita; Utay, Netanya S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Infectious Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">471-478</span>CODEN:
                <span class="NLM_cas:coden">COIDE5</span>;
        ISSN:<span class="NLM_cas:issn">0951-7375</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Previous treatments with pegylated interferon (PEG-IFN) and ribavirin for hepatitis C virus (HCV) infection resulted in significant adverse events and low cure rates, even with the addn. of first-generation protease inhibitors.  The std. of care for chronic HCV infection changed dramatically in 2013 with the approval of second-generation direct-acting antivirals, which led the way for IFN-free combination regimens.  Recent findings: All-oral combinations of direct-acting antivirals, with or without ribavirin, have shown high efficacy and are well tolerated in patients with the predominant genotypes, advanced fibrosis stages, and HIV co-infection.  New fixed-dose co-formulations of direct-acting antivirals have allowed simpler regimens with shorter treatment durations and low rates of discontinuation, but are assocd. with substantial costs.  Summary: Since 2013, all-oral, IFN-free regimens with direct-acting antivirals have quickly become the mainstay of treatment for HCV infection as they provide high rates of sustained virol. response with a relatively short duration of treatment and low side-effect profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocUgZvQ9EvB7Vg90H21EOLACvtfcHk0li4RGm_qL7teA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVeqtrvJ&md5=7fc449f6c3bd851ac1f0e057cc868cbd</span></div><a href="/servlet/linkout?suffix=cit158c&amp;dbid=16384&amp;doi=10.1097%2FQCO.0000000000000190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQCO.0000000000000190%26sid%3Dliteratum%253Aachs%26aulast%3DNyalakonda%26aufirst%3DH.%26aulast%3DUtay%26aufirst%3DN.%2BS.%26atitle%3DA%2520new%2520era%2520of%2520therapy%2520for%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DCurr.%2520Opin.%2520Infect.%2520Dis.%26date%3D2015%26volume%3D28%26spage%3D471%26epage%3D478%26doi%3D10.1097%2FQCO.0000000000000190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit158d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">McConachie, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kale-Pradhan, P. B.</span><span> </span><span class="NLM_article-title">New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir</span> <span class="citation_source-journal">Expert Rev. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span><span class="refDoi"> DOI: 10.1586/17512433.2016.1129272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1586%2F17512433.2016.1129272" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=287-302&author=S.+M.+McConachieauthor=S.+M.+Wilhelmauthor=P.+B.+Kale-Pradhan&title=New+direct-acting+antivirals+in+hepatitis+C+therapy%3A+a+review+of+sofosbuvir%2C+ledipasvir%2C+daclatasvir%2C+simeprevir%2C+paritaprevir%2C+ombitasvir+and+dasabuvir&doi=10.1586%2F17512433.2016.1129272"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158d&amp;dbid=16384&amp;doi=10.1586%2F17512433.2016.1129272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F17512433.2016.1129272%26sid%3Dliteratum%253Aachs%26aulast%3DMcConachie%26aufirst%3DS.%2BM.%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DKale-Pradhan%26aufirst%3DP.%2BB.%26atitle%3DNew%2520direct-acting%2520antivirals%2520in%2520hepatitis%2520C%2520therapy%253A%2520a%2520review%2520of%2520sofosbuvir%252C%2520ledipasvir%252C%2520daclatasvir%252C%2520simeprevir%252C%2520paritaprevir%252C%2520ombitasvir%2520and%2520dasabuvir%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2016%26volume%3D9%26spage%3D287%26epage%3D302%26doi%3D10.1586%2F17512433.2016.1129272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizokami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, A. E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, J. W.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gojobori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alter, H. J.</span><span> </span><span class="NLM_article-title">A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">15584</span><span class="NLM_x">–</span> <span class="NLM_lpage">15589</span><span class="refDoi"> DOI: 10.1073/pnas.242608099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1073%2Fpnas.242608099" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=15584-15589&author=Y.+Tanakaauthor=K.+Hanadaauthor=M.+Mizokamiauthor=A.+E.+T.+Yeoauthor=J.+W.-K.+Shihauthor=T.+Gojoboriauthor=H.+J.+Alter&title=A+comparison+of+the+molecular+clock+of+hepatitis+C+virus+in+the+United+States+and+Japan+predicts+that+hepatocellular+carcinoma+incidence+in+the+United+States+will+increase+over+the+next+two+decades&doi=10.1073%2Fpnas.242608099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1073%2Fpnas.242608099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.242608099%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DHanada%26aufirst%3DK.%26aulast%3DMizokami%26aufirst%3DM.%26aulast%3DYeo%26aufirst%3DA.%2BE.%2BT.%26aulast%3DShih%26aufirst%3DJ.%2BW.-K.%26aulast%3DGojobori%26aufirst%3DT.%26aulast%3DAlter%26aufirst%3DH.%2BJ.%26atitle%3DA%2520comparison%2520of%2520the%2520molecular%2520clock%2520of%2520hepatitis%2520C%2520virus%2520in%2520the%2520United%2520States%2520and%2520Japan%2520predicts%2520that%2520hepatocellular%2520carcinoma%2520incidence%2520in%2520the%2520United%2520States%2520will%2520increase%2520over%2520the%2520next%2520two%2520decades%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D15584%26epage%3D15589%26doi%3D10.1073%2Fpnas.242608099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wong, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuillan, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poynard, T.</span><span> </span><span class="NLM_article-title">Estimating future hepatitis C morbidity, mortality, and costs in the United States</span> <span class="citation_source-journal">Am. J. Public Health</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">1562</span><span class="NLM_x">–</span> <span class="NLM_lpage">1569</span><span class="refDoi"> DOI: 10.2105/AJPH.90.10.1562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.2105%2FAJPH.90.10.1562" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2000&pages=1562-1569&author=J.+B.+Wongauthor=G.+M.+McQuillanauthor=J.+G.+McHutchisonauthor=T.+Poynard&title=Estimating+future+hepatitis+C+morbidity%2C+mortality%2C+and+costs+in+the+United+States&doi=10.2105%2FAJPH.90.10.1562"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160a&amp;dbid=16384&amp;doi=10.2105%2FAJPH.90.10.1562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2105%252FAJPH.90.10.1562%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DJ.%2BB.%26aulast%3DMcQuillan%26aufirst%3DG.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DPoynard%26aufirst%3DT.%26atitle%3DEstimating%2520future%2520hepatitis%2520C%2520morbidity%252C%2520mortality%252C%2520and%2520costs%2520in%2520the%2520United%2520States%26jtitle%3DAm.%2520J.%2520Public%2520Health%26date%3D2000%26volume%3D90%26spage%3D1562%26epage%3D1569%26doi%3D10.2105%2FAJPH.90.10.1562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit160b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Volk, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tocco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lok, A. S.</span><span> </span><span class="NLM_article-title">Public health impact of antiviral therapy for hepatitis C in the United States</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1750</span><span class="NLM_x">–</span> <span class="NLM_lpage">1755</span><span class="refDoi"> DOI: 10.1002/hep.23220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.23220" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=1750-1755&author=M.+L.+Volkauthor=R.+Toccoauthor=S.+Sainiauthor=A.+S.+Lok&title=Public+health+impact+of+antiviral+therapy+for+hepatitis+C+in+the+United+States&doi=10.1002%2Fhep.23220"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160b&amp;dbid=16384&amp;doi=10.1002%2Fhep.23220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.23220%26sid%3Dliteratum%253Aachs%26aulast%3DVolk%26aufirst%3DM.%2BL.%26aulast%3DTocco%26aufirst%3DR.%26aulast%3DSaini%26aufirst%3DS.%26aulast%3DLok%26aufirst%3DA.%2BS.%26atitle%3DPublic%2520health%2520impact%2520of%2520antiviral%2520therapy%2520for%2520hepatitis%2520C%2520in%2520the%2520United%2520States%26jtitle%3DHepatology%26date%3D2009%26volume%3D50%26spage%3D1750%26epage%3D1755%26doi%3D10.1002%2Fhep.23220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit160c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rein, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittenborn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinbaum, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesesne, S. B.</span><span> </span><span class="NLM_article-title">Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States</span> <span class="citation_source-journal">Dig. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">66</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.1016/j.dld.2010.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.dld.2010.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=20739252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FivFantA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2011&pages=66-72&author=D.+B.+Reinauthor=J.+S.+Wittenbornauthor=C.+M.+Weinbaumauthor=M.+Sabinauthor=B.+D.+Smithauthor=S.+B.+Lesesne&title=Forecasting+the+morbidity+and+mortality+associated+with+prevalent+cases+of+pre-cirrhotic+chronic+hepatitis+C+in+the+United+States&doi=10.1016%2Fj.dld.2010.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160cR"><div class="casContent"><span class="casTitleNuber">160c</span><div class="casTitle"><span class="NLM_cas:atitle">Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States</span></div><div class="casAuthors">Rein David B; Wittenborn John S; Weinbaum Cindy M; Sabin Miriam; Smith Bryce D; Lesesne Sarah B</div><div class="citationInfo"><span class="NLM_cas:title">Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66-72</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Without diagnosis and antiviral therapy, many patients with chronic hepatitis C infections will develop end-stage liver disease and die from complications.  AIMS:  To evaluate the future impacts of preventive interventions and treatment advances, this paper forecasts a baseline estimate of the future morbidity and mortality of prevalent hepatitis C when left untreated.  METHODS:  We simulated the future disease progression and death for all Americans with prevalent hepatitis C in 2005.  To validate the model, we used past seroprevalence to forecast contemporary outcomes.  We used the validated model to forecast future cases of end-stage liver disease, transplants, and deaths from 2010 to 2060, and we estimated credible intervals using Monte Carlo simulation.  RESULTS:  When programmed with past data, our model predicted current levels of hepatitis C outcomes with accuracy between ±1% and 13%.  Morbidity and mortality from hepatitis C will rise from 2010 to a peak between the years 2030 and 2035.  We forecasted a peak of 38,600 incident cases of end-stage liver disease; 3200 referrals for transplant; and 36,100 deaths.  CONCLUSIONS:  Because current rates of screening and treatment are low, future morbidity and mortality from hepatitis C are likely to increase substantially without public health interventions to increase treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_cA6-nOPYw__I8Jvzw4xCfW6udTcc2eZDaVHx3HFRqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FivFantA%253D%253D&md5=f7eeeddbc5d78e9182d8c1da09d34fe2</span></div><a href="/servlet/linkout?suffix=cit160c&amp;dbid=16384&amp;doi=10.1016%2Fj.dld.2010.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dld.2010.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DRein%26aufirst%3DD.%2BB.%26aulast%3DWittenborn%26aufirst%3DJ.%2BS.%26aulast%3DWeinbaum%26aufirst%3DC.%2BM.%26aulast%3DSabin%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DLesesne%26aufirst%3DS.%2BB.%26atitle%3DForecasting%2520the%2520morbidity%2520and%2520mortality%2520associated%2520with%2520prevalent%2520cases%2520of%2520pre-cirrhotic%2520chronic%2520hepatitis%2520C%2520in%2520the%2520United%2520States%26jtitle%3DDig.%2520Liver%2520Dis.%26date%3D2011%26volume%3D43%26spage%3D66%26epage%3D72%26doi%3D10.1016%2Fj.dld.2010.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit160d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ly, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klevens, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiles, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmberg, S. D.</span><span> </span><span class="NLM_article-title">The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">278</span><span class="refDoi"> DOI: 10.7326/0003-4819-156-4-201202210-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.7326%2F0003-4819-156-4-201202210-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=22351712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC383kvFCkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2012&pages=271-278&author=K.+N.+Lyauthor=J.+Xingauthor=R.+M.+Klevensauthor=R.+B.+Jilesauthor=J.+W.+Wardauthor=S.+D.+Holmberg&title=The+increasing+burden+of+mortality+from+viral+hepatitis+in+the+United+States+between+1999+and+2007&doi=10.7326%2F0003-4819-156-4-201202210-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160dR"><div class="casContent"><span class="casTitleNuber">160d</span><div class="casTitle"><span class="NLM_cas:atitle">The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007</span></div><div class="casAuthors">Ly Kathleen N; Xing Jian; Klevens R Monina; Jiles Ruth B; Ward John W; Holmberg Scott D</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">271-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The increasing health burden and mortality from hepatitis B virus (HBV) and hepatitis C virus (HCV) in the United States are underappreciated.  OBJECTIVE:  To examine mortality from HBV; HCV; and, for comparison, HIV.  DESIGN:  Analysis of U.S. multiple-cause mortality data from 1999 to 2007 from the National Center for Health Statistics.  SETTING:  All U.S. states and the District of Columbia.  PARTICIPANTS:  Approximately 22 million decedents.  MEASUREMENTS:  Age-adjusted mortality rates from HBV, HCV, and HIV.  Logistic regression analyses of 2007 data generated 4 independent models per outcome (HCV- or HBV-related deaths) that each included 1 of 4 comorbid conditions and all sociodemographic characteristics.  RESULTS:  Between 1999 and 2007, recorded deaths from HCV [corrected] increased significantly to 15,106, whereas deaths from HIV declined to 12,734 by 2007.  Factors associated with HCV-related deaths included chronic liver disease, HBV co-infection, alcohol-related conditions, minority status, and HIV co-infection.  Factors that increased odds of HBV-related death included chronic liver disease, HCV co-infection, Asian or Pacific Islander descent, HIV co-infection, and alcohol-related conditions.  Most deaths from HBV and HCV occurred in middle-aged persons.  LIMITATION:  A person other than the primary physician of the decedent frequently completed the death certificate, and HCV and HBV often were not detected and thus not reported as causes of death.  CONCLUSION:  By 2007, HCV had superseded HIV as a cause of death in the United States, and deaths from HCV and HBV disproportionately occurred in middle-aged persons.  To achieve decreases in mortality similar to those seen with HIV requires new policy initiatives to detect patients with chronic hepatitis and link them to care and treatment.  PRIMARY FUNDING SOURCE:  Centers for Disease Control and Prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4NjyWh_C-GsrRqEXsZufAfW6udTcc2eai6ZdNN-_eZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383kvFCkuw%253D%253D&md5=365f7666e37e4aefd608b4e3cd2a8d8c</span></div><a href="/servlet/linkout?suffix=cit160d&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-156-4-201202210-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-156-4-201202210-00004%26sid%3Dliteratum%253Aachs%26aulast%3DLy%26aufirst%3DK.%2BN.%26aulast%3DXing%26aufirst%3DJ.%26aulast%3DKlevens%26aufirst%3DR.%2BM.%26aulast%3DJiles%26aufirst%3DR.%2BB.%26aulast%3DWard%26aufirst%3DJ.%2BW.%26aulast%3DHolmberg%26aufirst%3DS.%2BD.%26atitle%3DThe%2520increasing%2520burden%2520of%2520mortality%2520from%2520viral%2520hepatitis%2520in%2520the%2520United%2520States%2520between%25201999%2520and%25202007%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2012%26volume%3D156%26spage%3D271%26epage%3D278%26doi%3D10.7326%2F0003-4819-156-4-201202210-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit160e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Klevens, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiles, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmberg, S. D.</span><span> </span><span class="NLM_article-title">Evolving epidemiology of hepatitis C virus in the United States</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">S3</span><span class="NLM_x">–</span> <span class="NLM_lpage">S9</span><span class="refDoi"> DOI: 10.1093/cid/cis393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1093%2Fcid%2Fcis393" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=S3-S9&author=R.+M.+Klevensauthor=D.+J.+Huauthor=R.+Jilesauthor=S.+D.+Holmberg&title=Evolving+epidemiology+of+hepatitis+C+virus+in+the+United+States&doi=10.1093%2Fcid%2Fcis393"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160e&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcis393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcis393%26sid%3Dliteratum%253Aachs%26aulast%3DKlevens%26aufirst%3DR.%2BM.%26aulast%3DHu%26aufirst%3DD.%2BJ.%26aulast%3DJiles%26aufirst%3DR.%26aulast%3DHolmberg%26aufirst%3DS.%2BD.%26atitle%3DEvolving%2520epidemiology%2520of%2520hepatitis%2520C%2520virus%2520in%2520the%2520United%2520States%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2012%26volume%3D55%26spage%3DS3%26epage%3DS9%26doi%3D10.1093%2Fcid%2Fcis393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit160f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Razavi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkhoury, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elbasha, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasini, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poynard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span> </span><span class="NLM_article-title">Chronic hepatitis C virus (HCV) disease burden and cost in the United States</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2164</span><span class="NLM_x">–</span> <span class="NLM_lpage">2170</span><span class="refDoi"> DOI: 10.1002/hep.26218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.26218" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=2164-2170&author=H.+Razaviauthor=A.+C.+Elkhouryauthor=E.+Elbashaauthor=C.+Estesauthor=K.+Pasiniauthor=T.+Poynardauthor=R.+Kumar&title=Chronic+hepatitis+C+virus+%28HCV%29+disease+burden+and+cost+in+the+United+States&doi=10.1002%2Fhep.26218"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160f&amp;dbid=16384&amp;doi=10.1002%2Fhep.26218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26218%26sid%3Dliteratum%253Aachs%26aulast%3DRazavi%26aufirst%3DH.%26aulast%3DElkhoury%26aufirst%3DA.%2BC.%26aulast%3DElbasha%26aufirst%3DE.%26aulast%3DEstes%26aufirst%3DC.%26aulast%3DPasini%26aufirst%3DK.%26aulast%3DPoynard%26aufirst%3DT.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DChronic%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%2520disease%2520burden%2520and%2520cost%2520in%2520the%2520United%2520States%26jtitle%3DHepatology%26date%3D2013%26volume%3D57%26spage%3D2164%26epage%3D2170%26doi%3D10.1002%2Fhep.26218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit160g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Razavi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waked, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarrazin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Idilman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calinas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendes Correa, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lázaro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akarca, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aleman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balık, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bihl, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilodeau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blasco, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandão Mello, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggmann, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calleja, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheinquer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coelho, H. S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramp, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doss, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duberg, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Sayed, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ergör, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esmat, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falconer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Félix, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferraz, M. L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Samaniego, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerstoft, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giria, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonçales, F. L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gower, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gschwantler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guimarães Pessôa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hindman, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kåberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaita, K. D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kautz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaymakoglu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krajden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krarup, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laleman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavanchy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marinho, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marotta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negro, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemecek, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Örmeci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Øvrehus, A. L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasini, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltekian, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramji, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roudot-Thoraval, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarmento-Castro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semela, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiha, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sievert, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stärkel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauber, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbanek, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Damme, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Thiel, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Vlierberghe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandijck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedemeyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiegand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yosry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zekry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müllhaupt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estes, C.</span><span> </span><span class="NLM_article-title">The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl.. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span><span class="refDoi"> DOI: 10.1111/jvh.12248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fjvh.12248" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=34-59&issue=Suppl..+1&author=H.+Razaviauthor=I.+Wakedauthor=C.+Sarrazinauthor=R.+P.+Myersauthor=R.+Idilmanauthor=F.+Calinasauthor=W.+Vogelauthor=M.+C.+Mendes+Correaauthor=C.+H%C3%A9zodeauthor=P.+L%C3%A1zaroauthor=U.+Akarcaauthor=S.+Alemanauthor=I.+Bal%C4%B1kauthor=T.+Bergauthor=F.+Bihlauthor=M.+Bilodeauauthor=A.+J.+Blascoauthor=C.+E.+Brand%C3%A3o+Melloauthor=P.+Bruggmannauthor=M.+Butiauthor=J.+L.+Callejaauthor=H.+Cheinquerauthor=P.+B.+Christensenauthor=M.+Clausenauthor=H.+S.+M.+Coelhoauthor=M.+E.+Crampauthor=G.+J.+Doreauthor=W.+Dossauthor=A.+S.+Dubergauthor=M.+H.+El-Sayedauthor=G.+Erg%C3%B6rauthor=G.+Esmatauthor=K.+Falconerauthor=J.+F%C3%A9lixauthor=M.+L.+G.+Ferrazauthor=P.+R.+Ferreiraauthor=S.+Frankovaauthor=J.+Garc%C3%ADa-Samaniegoauthor=J.+Gerstoftauthor=J.+A.+Giriaauthor=F.+L.+Gon%C3%A7alesauthor=E.+Gowerauthor=M.+Gschwantlerauthor=M.+Guimar%C3%A3es+Pess%C3%B4aauthor=S.+J.+Hindmanauthor=H.+Hoferauthor=P.+Husaauthor=M.+K%C3%A5bergauthor=K.+D.+E.+Kaitaauthor=A.+Kautzauthor=S.+Kaymakogluauthor=M.+Krajdenauthor=H.+Krarupauthor=W.+Lalemanauthor=D.+Lavanchyauthor=R.+T.+Marinhoauthor=P.+Marottaauthor=S.+Maussauthor=C.+Morenoauthor=K.+Murphyauthor=F.+Negroauthor=V.+Nemecekauthor=V.+%C3%96rmeciauthor=A.+L.+H.+%C3%98vrehusauthor=J.+Parkesauthor=K.+Pasiniauthor=K.+M.+Peltekianauthor=A.+Ramjiauthor=N.+Reisauthor=S.+K.+Robertsauthor=W.+M.+Rosenbergauthor=F.+Roudot-Thoravalauthor=S.+D.+Ryderauthor=R.+Sarmento-Castroauthor=D.+Semelaauthor=M.+Shermanauthor=G.+E.+Shihaauthor=W.+Sievertauthor=J.+Sperlauthor=P.+St%C3%A4rkelauthor=R.+E.+Stauberauthor=A.+J.+Thompsonauthor=P.+Urbanekauthor=P.+Van+Dammeauthor=I.+van+Thielauthor=H.+Van+Vlierbergheauthor=D.+Vandijckauthor=D.+Wedemeyerauthor=N.+Weisauthor=J.+Wiegandauthor=A.+Yosryauthor=A.+Zekryauthor=M.+Cornbergauthor=B.+M%C3%BCllhauptauthor=C.+Estes&title=The+present+and+future+disease+burden+of+hepatitis+C+virus+%28HCV%29+infection+with+today%E2%80%99s+treatment+paradigm&doi=10.1111%2Fjvh.12248"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160g&amp;dbid=16384&amp;doi=10.1111%2Fjvh.12248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.12248%26sid%3Dliteratum%253Aachs%26aulast%3DRazavi%26aufirst%3DH.%26aulast%3DWaked%26aufirst%3DI.%26aulast%3DSarrazin%26aufirst%3DC.%26aulast%3DMyers%26aufirst%3DR.%2BP.%26aulast%3DIdilman%26aufirst%3DR.%26aulast%3DCalinas%26aufirst%3DF.%26aulast%3DVogel%26aufirst%3DW.%26aulast%3DMendes%2BCorrea%26aufirst%3DM.%2BC.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DL%25C3%25A1zaro%26aufirst%3DP.%26aulast%3DAkarca%26aufirst%3DU.%26aulast%3DAleman%26aufirst%3DS.%26aulast%3DBal%25C4%25B1k%26aufirst%3DI.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DBihl%26aufirst%3DF.%26aulast%3DBilodeau%26aufirst%3DM.%26aulast%3DBlasco%26aufirst%3DA.%2BJ.%26aulast%3DBrand%25C3%25A3o%2BMello%26aufirst%3DC.%2BE.%26aulast%3DBruggmann%26aufirst%3DP.%26aulast%3DButi%26aufirst%3DM.%26aulast%3DCalleja%26aufirst%3DJ.%2BL.%26aulast%3DCheinquer%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DP.%2BB.%26aulast%3DClausen%26aufirst%3DM.%26aulast%3DCoelho%26aufirst%3DH.%2BS.%2BM.%26aulast%3DCramp%26aufirst%3DM.%2BE.%26aulast%3DDore%26aufirst%3DG.%2BJ.%26aulast%3DDoss%26aufirst%3DW.%26aulast%3DDuberg%26aufirst%3DA.%2BS.%26aulast%3DEl-Sayed%26aufirst%3DM.%2BH.%26aulast%3DErg%25C3%25B6r%26aufirst%3DG.%26aulast%3DEsmat%26aufirst%3DG.%26aulast%3DFalconer%26aufirst%3DK.%26aulast%3DF%25C3%25A9lix%26aufirst%3DJ.%26aulast%3DFerraz%26aufirst%3DM.%2BL.%2BG.%26aulast%3DFerreira%26aufirst%3DP.%2BR.%26aulast%3DFrankova%26aufirst%3DS.%26aulast%3DGarc%25C3%25ADa-Samaniego%26aufirst%3DJ.%26aulast%3DGerstoft%26aufirst%3DJ.%26aulast%3DGiria%26aufirst%3DJ.%2BA.%26aulast%3DGon%25C3%25A7ales%26aufirst%3DF.%2BL.%26aulast%3DGower%26aufirst%3DE.%26aulast%3DGschwantler%26aufirst%3DM.%26aulast%3DGuimar%25C3%25A3es%2BPess%25C3%25B4a%26aufirst%3DM.%26aulast%3DHindman%26aufirst%3DS.%2BJ.%26aulast%3DHofer%26aufirst%3DH.%26aulast%3DHusa%26aufirst%3DP.%26aulast%3DK%25C3%25A5berg%26aufirst%3DM.%26aulast%3DKaita%26aufirst%3DK.%2BD.%2BE.%26aulast%3DKautz%26aufirst%3DA.%26aulast%3DKaymakoglu%26aufirst%3DS.%26aulast%3DKrajden%26aufirst%3DM.%26aulast%3DKrarup%26aufirst%3DH.%26aulast%3DLaleman%26aufirst%3DW.%26aulast%3DLavanchy%26aufirst%3DD.%26aulast%3DMarinho%26aufirst%3DR.%2BT.%26aulast%3DMarotta%26aufirst%3DP.%26aulast%3DMauss%26aufirst%3DS.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DMurphy%26aufirst%3DK.%26aulast%3DNegro%26aufirst%3DF.%26aulast%3DNemecek%26aufirst%3DV.%26aulast%3D%25C3%2596rmeci%26aufirst%3DV.%26aulast%3D%25C3%2598vrehus%26aufirst%3DA.%2BL.%2BH.%26aulast%3DParkes%26aufirst%3DJ.%26aulast%3DPasini%26aufirst%3DK.%26aulast%3DPeltekian%26aufirst%3DK.%2BM.%26aulast%3DRamji%26aufirst%3DA.%26aulast%3DReis%26aufirst%3DN.%26aulast%3DRoberts%26aufirst%3DS.%2BK.%26aulast%3DRosenberg%26aufirst%3DW.%2BM.%26aulast%3DRoudot-Thoraval%26aufirst%3DF.%26aulast%3DRyder%26aufirst%3DS.%2BD.%26aulast%3DSarmento-Castro%26aufirst%3DR.%26aulast%3DSemela%26aufirst%3DD.%26aulast%3DSherman%26aufirst%3DM.%26aulast%3DShiha%26aufirst%3DG.%2BE.%26aulast%3DSievert%26aufirst%3DW.%26aulast%3DSperl%26aufirst%3DJ.%26aulast%3DSt%25C3%25A4rkel%26aufirst%3DP.%26aulast%3DStauber%26aufirst%3DR.%2BE.%26aulast%3DThompson%26aufirst%3DA.%2BJ.%26aulast%3DUrbanek%26aufirst%3DP.%26aulast%3DVan%2BDamme%26aufirst%3DP.%26aulast%3Dvan%2BThiel%26aufirst%3DI.%26aulast%3DVan%2BVlierberghe%26aufirst%3DH.%26aulast%3DVandijck%26aufirst%3DD.%26aulast%3DWedemeyer%26aufirst%3DD.%26aulast%3DWeis%26aufirst%3DN.%26aulast%3DWiegand%26aufirst%3DJ.%26aulast%3DYosry%26aufirst%3DA.%26aulast%3DZekry%26aufirst%3DA.%26aulast%3DCornberg%26aufirst%3DM.%26aulast%3DM%25C3%25BCllhaupt%26aufirst%3DB.%26aulast%3DEstes%26aufirst%3DC.%26atitle%3DThe%2520present%2520and%2520future%2520disease%2520burden%2520of%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%2520infection%2520with%2520today%25E2%2580%2599s%2520treatment%2520paradigm%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2014%26volume%3D21%26issue%3DSuppl..%25201%26spage%3D34%26epage%3D59%26doi%3D10.1111%2Fjvh.12248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Basnayake, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Easterbrook, P. J.</span><span> </span><span class="NLM_article-title">Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">549</span><span class="refDoi"> DOI: 10.1111/jvh.12519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fjvh.12519" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=545-549&author=S.+K.+Basnayakeauthor=P.+J.+Easterbrook&title=Wide+variation+in+estimates+of+global+prevalence+and+burden+of+chronic+hepatitis+B+and+C+infection+cited+in+published+literature&doi=10.1111%2Fjvh.12519"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161a&amp;dbid=16384&amp;doi=10.1111%2Fjvh.12519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.12519%26sid%3Dliteratum%253Aachs%26aulast%3DBasnayake%26aufirst%3DS.%2BK.%26aulast%3DEasterbrook%26aufirst%3DP.%2BJ.%26atitle%3DWide%2520variation%2520in%2520estimates%2520of%2520global%2520prevalence%2520and%2520burden%2520of%2520chronic%2520hepatitis%2520B%2520and%2520C%2520infection%2520cited%2520in%2520published%2520literature%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2016%26volume%3D23%26spage%3D545%26epage%3D549%26doi%3D10.1111%2Fjvh.12519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit161b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chhatwal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabiri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donohue, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanwal, F.</span><span> </span><span class="NLM_article-title">Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1002/hep.28571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.28571" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+Chhatwalauthor=X.+Wangauthor=T.+Ayerauthor=M.+Kabiriauthor=R.+T.+Chungauthor=C.+Hurauthor=J.+M.+Donohueauthor=M.+S.+Robertsauthor=F.+Kanwal&title=Hepatitis+C+disease+burden+in+the+United+States+in+the+era+of+oral+direct-acting+antivirals&doi=10.1002%2Fhep.28571"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161b&amp;dbid=16384&amp;doi=10.1002%2Fhep.28571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.28571%26sid%3Dliteratum%253Aachs%26aulast%3DChhatwal%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DAyer%26aufirst%3DT.%26aulast%3DKabiri%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DR.%2BT.%26aulast%3DHur%26aufirst%3DC.%26aulast%3DDonohue%26aufirst%3DJ.%2BM.%26aulast%3DRoberts%26aufirst%3DM.%2BS.%26aulast%3DKanwal%26aufirst%3DF.%26atitle%3DHepatitis%2520C%2520disease%2520burden%2520in%2520the%2520United%2520States%2520in%2520the%2520era%2520of%2520oral%2520direct-acting%2520antivirals%26jtitle%3DHepatology%26date%3D2016%26doi%3D10.1002%2Fhep.28571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit161c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ward, J. W.</span><span> </span><span class="NLM_article-title">The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease</span> <span class="citation_source-journal">Top. Antiviral Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=15-19&author=J.+W.+Ward&title=The+hidden+epidemic+of+hepatitis+C+virus+infection+in+the+United+States%3A+occult+transmission+and+burden+of+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DJ.%2BW.%26atitle%3DThe%2520hidden%2520epidemic%2520of%2520hepatitis%2520C%2520virus%2520infection%2520in%2520the%2520United%2520States%253A%2520occult%2520transmission%2520and%2520burden%2520of%2520disease%26jtitle%3DTop.%2520Antiviral%2520Med.%26date%3D2013%26volume%3D21%26spage%3D15%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit161d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Edlin, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckhardt, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmberg, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swan, T.</span><span> </span><span class="NLM_article-title">Toward a more accurate estimate of the prevalence of hepatitis C in the United States</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1353</span><span class="NLM_x">–</span> <span class="NLM_lpage">1363</span><span class="refDoi"> DOI: 10.1002/hep.27978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.27978" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=1353-1363&author=B.+R.+Edlinauthor=B.+J.+Eckhardtauthor=M.+A.+Shuauthor=S.+D.+Holmbergauthor=T.+Swan&title=Toward+a+more+accurate+estimate+of+the+prevalence+of+hepatitis+C+in+the+United+States&doi=10.1002%2Fhep.27978"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161d&amp;dbid=16384&amp;doi=10.1002%2Fhep.27978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27978%26sid%3Dliteratum%253Aachs%26aulast%3DEdlin%26aufirst%3DB.%2BR.%26aulast%3DEckhardt%26aufirst%3DB.%2BJ.%26aulast%3DShu%26aufirst%3DM.%2BA.%26aulast%3DHolmberg%26aufirst%3DS.%2BD.%26aulast%3DSwan%26aufirst%3DT.%26atitle%3DToward%2520a%2520more%2520accurate%2520estimate%2520of%2520the%2520prevalence%2520of%2520hepatitis%2520C%2520in%2520the%2520United%2520States%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D1353%26epage%3D1363%26doi%3D10.1002%2Fhep.27978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mühlberger, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lettmeier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sroczynski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siebert, U.</span><span> </span><span class="NLM_article-title">HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality</span> <span class="citation_source-journal">BMC Public Health</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="refDoi"> DOI: 10.1186/1471-2458-9-34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1186%2F1471-2458-9-34" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=34&author=N.+M%C3%BChlbergerauthor=R.+Schwarzerauthor=B.+Lettmeierauthor=G.+Sroczynskiauthor=S.+Zeuzemauthor=U.+Siebert&title=HCV-related+burden+of+disease+in+Europe%3A+a+systematic+assessment+of+incidence%2C+prevalence%2C+morbidity%2C+and+mortality&doi=10.1186%2F1471-2458-9-34"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162a&amp;dbid=16384&amp;doi=10.1186%2F1471-2458-9-34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2458-9-34%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BChlberger%26aufirst%3DN.%26aulast%3DSchwarzer%26aufirst%3DR.%26aulast%3DLettmeier%26aufirst%3DB.%26aulast%3DSroczynski%26aufirst%3DG.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DSiebert%26aufirst%3DU.%26atitle%3DHCV-related%2520burden%2520of%2520disease%2520in%2520Europe%253A%2520a%2520systematic%2520assessment%2520of%2520incidence%252C%2520prevalence%252C%2520morbidity%252C%2520and%2520mortality%26jtitle%3DBMC%2520Public%2520Health%26date%3D2009%26volume%3D9%26spage%3D34%26doi%3D10.1186%2F1471-2458-9-34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit162b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Harris, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Angelis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, H. E.</span><span> </span><span class="NLM_article-title">Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">530</span><span class="NLM_x">–</span> <span class="NLM_lpage">537</span><span class="refDoi"> DOI: 10.1016/j.jhep.2014.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2014.05.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=530-537&author=R.+J.+Harrisauthor=B.+Thomasauthor=J.+Griffithsauthor=A.+Costellaauthor=R.+Chapmanauthor=M.+Ramsayauthor=D.+De+Angelisauthor=H.+E.+Harris&title=Increased+uptake+and+new+therapies+are+needed+to+avert+rising+hepatitis+C-related+end+stage+liver+disease+in+England%3A+modelling+the+predicted+impact+of+treatment+under+different+scenarios&doi=10.1016%2Fj.jhep.2014.05.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DR.%2BJ.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DGriffiths%26aufirst%3DJ.%26aulast%3DCostella%26aufirst%3DA.%26aulast%3DChapman%26aufirst%3DR.%26aulast%3DRamsay%26aufirst%3DM.%26aulast%3DDe%2BAngelis%26aufirst%3DD.%26aulast%3DHarris%26aufirst%3DH.%2BE.%26atitle%3DIncreased%2520uptake%2520and%2520new%2520therapies%2520are%2520needed%2520to%2520avert%2520rising%2520hepatitis%2520C-related%2520end%2520stage%2520liver%2520disease%2520in%2520England%253A%2520modelling%2520the%2520predicted%2520impact%2520of%2520treatment%2520under%2520different%2520scenarios%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D61%26spage%3D530%26epage%3D537%26doi%3D10.1016%2Fj.jhep.2014.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Edlin, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkelstein, E. R.</span><span> </span><span class="NLM_article-title">Can hepatitis C be eradicated in the United States?</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">79</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2014.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.antiviral.2014.07.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2014&pages=79-93&author=B.+R.+Edlinauthor=E.+R.+Winkelstein&title=Can+hepatitis+C+be+eradicated+in+the+United+States%3F&doi=10.1016%2Fj.antiviral.2014.07.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163a&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DEdlin%26aufirst%3DB.%2BR.%26aulast%3DWinkelstein%26aufirst%3DE.%2BR.%26atitle%3DCan%2520hepatitis%2520C%2520be%2520eradicated%2520in%2520the%2520United%2520States%253F%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D110%26spage%3D79%26epage%3D93%26doi%3D10.1016%2Fj.antiviral.2014.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit163b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ippolito, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capobianchi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonelli, G.</span><span> </span><span class="NLM_article-title">Is hepatitis C virus eradication around the corner only 25 years after its discovery?</span> <span class="citation_source-journal">Int. J. Antimicrob. Agents</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1016/j.ijantimicag.2014.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.ijantimicag.2014.09.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=111-112&author=G.+Ippolitoauthor=M.+R.+Capobianchiauthor=S.+Laniniauthor=G.+Antonelli&title=Is+hepatitis+C+virus+eradication+around+the+corner+only+25+years+after+its+discovery%3F&doi=10.1016%2Fj.ijantimicag.2014.09.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163b&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2014.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2014.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DIppolito%26aufirst%3DG.%26aulast%3DCapobianchi%26aufirst%3DM.%2BR.%26aulast%3DLanini%26aufirst%3DS.%26aulast%3DAntonelli%26aufirst%3DG.%26atitle%3DIs%2520hepatitis%2520C%2520virus%2520eradication%2520around%2520the%2520corner%2520only%252025%2520years%2520after%2520its%2520discovery%253F%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2015%26volume%3D45%26spage%3D111%26epage%3D112%26doi%3D10.1016%2Fj.ijantimicag.2014.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit163c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Pawlotsky, J.-M.</span><span> </span><span class="NLM_article-title">Hepatitis C virus: from discovery to eradication in 40 years?</span> <span class="citation_source-journal">Clin. Microbiol. Infect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span><span class="refDoi"> DOI: 10.1111/j.1469-0691.2010.03435.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fj.1469-0691.2010.03435.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=105-106&author=J.-M.+Pawlotsky&title=Hepatitis+C+virus%3A+from+discovery+to+eradication+in+40+years%3F&doi=10.1111%2Fj.1469-0691.2010.03435.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163c&amp;dbid=16384&amp;doi=10.1111%2Fj.1469-0691.2010.03435.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1469-0691.2010.03435.x%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.-M.%26atitle%3DHepatitis%2520C%2520virus%253A%2520from%2520discovery%2520to%2520eradication%2520in%252040%2520years%253F%26jtitle%3DClin.%2520Microbiol.%2520Infect.%26date%3D2011%26volume%3D17%26spage%3D105%26epage%3D106%26doi%3D10.1111%2Fj.1469-0691.2010.03435.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit163d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Gane, E.</span><span> </span><span class="NLM_article-title">Hepatitis C beware - the end is nigh</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">384</span><span class="NLM_x">, </span> <span class="NLM_fpage">1557</span><span class="NLM_x">–</span> <span class="NLM_lpage">1560</span><span class="refDoi"> DOI: 10.1016/S0140-6736(14)61225-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0140-6736%2814%2961225-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2014&pages=1557-1560&author=E.+Gane&title=Hepatitis+C+beware+-+the+end+is+nigh&doi=10.1016%2FS0140-6736%2814%2961225-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163d&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2961225-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252961225-3%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%26atitle%3DHepatitis%2520C%2520beware%2520-%2520the%2520end%2520is%2520nigh%26jtitle%3DLancet%26date%3D2014%26volume%3D384%26spage%3D1557%26epage%3D1560%26doi%3D10.1016%2FS0140-6736%2814%2961225-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Linthicum, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez Gonzalez, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulligan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreyfus, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juday, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marx, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakdawalla, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlin, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brookmeyer, R.</span><span> </span><span class="NLM_article-title">Value of expanding HCV screening and treatment policies in the United States</span> <span class="citation_source-journal">Am. J. Manag. Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">Spec. Issue No. 6</span><span class="NLM_x">) </span> <span class="NLM_fpage">SP227</span><span class="NLM_x">–</span> <span class="NLM_lpage">SP235</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=SP227-SP235&issue=Spec.+Issue+No.+6&author=M.+T.+Linthicumauthor=Y.+Sanchez+Gonzalezauthor=K.+Mulliganauthor=G.+A.+Morenoauthor=D.+Dreyfusauthor=T.+Judayauthor=S.+E.+Marxauthor=D.+N.+Lakdawallaauthor=B.+R.+Edlinauthor=R.+Brookmeyer&title=Value+of+expanding+HCV+screening+and+treatment+policies+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLinthicum%26aufirst%3DM.%2BT.%26aulast%3DSanchez%2BGonzalez%26aufirst%3DY.%26aulast%3DMulligan%26aufirst%3DK.%26aulast%3DMoreno%26aufirst%3DG.%2BA.%26aulast%3DDreyfus%26aufirst%3DD.%26aulast%3DJuday%26aufirst%3DT.%26aulast%3DMarx%26aufirst%3DS.%2BE.%26aulast%3DLakdawalla%26aufirst%3DD.%2BN.%26aulast%3DEdlin%26aufirst%3DB.%2BR.%26aulast%3DBrookmeyer%26aufirst%3DR.%26atitle%3DValue%2520of%2520expanding%2520HCV%2520screening%2520and%2520treatment%2520policies%2520in%2520the%2520United%2520States%26jtitle%3DAm.%2520J.%2520Manag.%2520Care%26date%3D2016%26volume%3D22%26issue%3DSpec.%2520Issue%2520No.%25206%26spage%3DSP227%26epage%3DSP235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit164b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chahal, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marseille, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tice, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ollendorf, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, J. G.</span><span> </span><span class="NLM_article-title">Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population</span> <span class="citation_source-journal">JAMA Int. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">176</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span><span class="refDoi"> DOI: 10.1001/jamainternmed.2015.6011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1001%2Fjamainternmed.2015.6011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2016&pages=65-73&author=H.+S.+Chahalauthor=E.+A.+Marseilleauthor=J.+A.+Ticeauthor=S.+D.+Pearsonauthor=D.+A.+Ollendorfauthor=R.+K.+Foxauthor=J.+G.+Kahn&title=Cost-effectiveness+of+early+treatment+of+hepatitis+C+virus+genotype+1+by+stage+of+liver+fibrosis+in+a+US+treatment-naive+population&doi=10.1001%2Fjamainternmed.2015.6011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164b&amp;dbid=16384&amp;doi=10.1001%2Fjamainternmed.2015.6011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamainternmed.2015.6011%26sid%3Dliteratum%253Aachs%26aulast%3DChahal%26aufirst%3DH.%2BS.%26aulast%3DMarseille%26aufirst%3DE.%2BA.%26aulast%3DTice%26aufirst%3DJ.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BD.%26aulast%3DOllendorf%26aufirst%3DD.%2BA.%26aulast%3DFox%26aufirst%3DR.%2BK.%26aulast%3DKahn%26aufirst%3DJ.%2BG.%26atitle%3DCost-effectiveness%2520of%2520early%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520genotype%25201%2520by%2520stage%2520of%2520liver%2520fibrosis%2520in%2520a%2520US%2520treatment-naive%2520population%26jtitle%3DJAMA%2520Int.%2520Med.%26date%3D2016%26volume%3D176%26spage%3D65%26epage%3D73%26doi%3D10.1001%2Fjamainternmed.2015.6011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Heim, M. H.</span><span> </span><span class="NLM_article-title">25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">535</span><span class="NLM_x">–</span> <span class="NLM_lpage">542</span><span class="refDoi"> DOI: 10.1038/nri3463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnri3463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=23743475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovFamurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=535-542&author=M.+H.+Heim&title=25+years+of+interferon-based+treatment+of+chronic+hepatitis+C%3A+an+epoch+coming+to+an+end&doi=10.1038%2Fnri3463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165aR"><div class="casContent"><span class="casTitleNuber">165a</span><div class="casTitle"><span class="NLM_cas:atitle">25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end</span></div><div class="casAuthors">Heim, Markus H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">535-542</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chronic hepatitis caused by infection with hepatitis C virus C (HCV) (therefore known as chronic hepatitis C (CHC)) is a leading cause of liver disease worldwide.  For the past 25 years, recombinant interferon-α (IFNα) has been the main component of treatments for HCV infection.  Treatment efficacy has shown a stepwise improvement following the pegylation of IFNα and its use in combination with other antiviral drugs.  However, viral escape mechanisms, refractory IFNα signalling in the liver and substantial drug toxicity still limit the efficacy of this treatment.  A new generation of HCV-specific antiviral drugs will probably improve response rates and might replace IFNs in CHC treatment in the next few years.  This Timeline article summarizes the history of CHC treatment using recombinant IFNα with an emphasis on the mechanisms of action and the causes of non-response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKQQMKuR1xXLVg90H21EOLACvtfcHk0lhbDIBDVqeIMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovFamurc%253D&md5=29af7191c765714e2020f354979e0e50</span></div><a href="/servlet/linkout?suffix=cit165a&amp;dbid=16384&amp;doi=10.1038%2Fnri3463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3463%26sid%3Dliteratum%253Aachs%26aulast%3DHeim%26aufirst%3DM.%2BH.%26atitle%3D25%2520years%2520of%2520interferon-based%2520treatment%2520of%2520chronic%2520hepatitis%2520C%253A%2520an%2520epoch%2520coming%2520to%2520an%2520end%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D13%26spage%3D535%26epage%3D542%26doi%3D10.1038%2Fnri3463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit165b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sheridan, C.</span><span> </span><span class="NLM_article-title">FDA approvals usher in the post-interferon era in HCV</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span><span class="refDoi"> DOI: 10.1038/nbt0114-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnbt0114-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24406908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltVOjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=3-5&author=C.+Sheridan&title=FDA+approvals+usher+in+the+post-interferon+era+in+HCV&doi=10.1038%2Fnbt0114-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165bR"><div class="casContent"><span class="casTitleNuber">165b</span><div class="casTitle"><span class="NLM_cas:atitle">FDA approvals usher in the post-interferon era in HCV</span></div><div class="casAuthors">Sheridan, Cormac</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-5</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPpDya1nSFUbVg90H21EOLACvtfcHk0lhbDIBDVqeIMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltVOjsw%253D%253D&md5=4c9a6b443360f6dc44fd62fb78e92d04</span></div><a href="/servlet/linkout?suffix=cit165b&amp;dbid=16384&amp;doi=10.1038%2Fnbt0114-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt0114-3%26sid%3Dliteratum%253Aachs%26aulast%3DSheridan%26aufirst%3DC.%26atitle%3DFDA%2520approvals%2520usher%2520in%2520the%2520post-interferon%2520era%2520in%2520HCV%26jtitle%3DNat.%2520Biotechnol.%26date%3D2014%26volume%3D32%26spage%3D3%26epage%3D5%26doi%3D10.1038%2Fnbt0114-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Thomas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghany, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, T. J.</span><span> </span><span class="NLM_article-title">The application and mechanism of action of ribavirin in therapy of hepatitis C</span> <span class="citation_source-journal">Antiviral Chem. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.3851/IMP2125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.3851%2FIMP2125" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=1-12&author=E.+Thomasauthor=M.+G.+Ghanyauthor=T.+J.+Liang&title=The+application+and+mechanism+of+action+of+ribavirin+in+therapy+of+hepatitis+C&doi=10.3851%2FIMP2125"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166a&amp;dbid=16384&amp;doi=10.3851%2FIMP2125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2125%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DE.%26aulast%3DGhany%26aufirst%3DM.%2BG.%26aulast%3DLiang%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520application%2520and%2520mechanism%2520of%2520action%2520of%2520ribavirin%2520in%2520therapy%2520of%2520hepatitis%2520C%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D2012%26volume%3D23%26spage%3D1%26epage%3D12%26doi%3D10.3851%2FIMP2125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit166b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Clark, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. R.</span><span> </span><span class="NLM_article-title">The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1111/j.1478-3231.2011.02711.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fj.1478-3231.2011.02711.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=103-107&author=V.+Clarkauthor=D.+R.+Nelson&title=The+role+of+ribavirin+in+direct+acting+antiviral+drug+regimens+for+chronic+hepatitis+C&doi=10.1111%2Fj.1478-3231.2011.02711.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166b&amp;dbid=16384&amp;doi=10.1111%2Fj.1478-3231.2011.02711.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1478-3231.2011.02711.x%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DV.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26atitle%3DThe%2520role%2520of%2520ribavirin%2520in%2520direct%2520acting%2520antiviral%2520drug%2520regimens%2520for%2520chronic%2520hepatitis%2520C%26jtitle%3DLiver%2520Int.%26date%3D2012%26volume%3D32%26spage%3D103%26epage%3D107%26doi%3D10.1111%2Fj.1478-3231.2011.02711.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit166c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Brillanti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roda, E.</span><span> </span><span class="NLM_article-title">Ribavirin for chronic hepatitis C: and the mystery goes on</span> <span class="citation_source-journal">Dig. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span><span class="refDoi"> DOI: 10.1016/j.dld.2010.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.dld.2010.10.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2011&pages=425-430&author=S.+Brillantiauthor=G.+Mazzellaauthor=E.+Roda&title=Ribavirin+for+chronic+hepatitis+C%3A+and+the+mystery+goes+on&doi=10.1016%2Fj.dld.2010.10.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166c&amp;dbid=16384&amp;doi=10.1016%2Fj.dld.2010.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dld.2010.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DBrillanti%26aufirst%3DS.%26aulast%3DMazzella%26aufirst%3DG.%26aulast%3DRoda%26aufirst%3DE.%26atitle%3DRibavirin%2520for%2520chronic%2520hepatitis%2520C%253A%2520and%2520the%2520mystery%2520goes%2520on%26jtitle%3DDig.%2520Liver%2520Dis.%26date%3D2011%26volume%3D43%26spage%3D425%26epage%3D430%26doi%3D10.1016%2Fj.dld.2010.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit166d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Jain, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoellner, C.</span><span> </span><span class="NLM_article-title">Role of ribavirin in HCV treatment response: now and in the future</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">673</span><span class="NLM_x">–</span> <span class="NLM_lpage">683</span><span class="refDoi"> DOI: 10.1517/14656560903580001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1517%2F14656560903580001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=673-683&author=M.+K.+Jainauthor=C.+Zoellner&title=Role+of+ribavirin+in+HCV+treatment+response%3A+now+and+in+the+future&doi=10.1517%2F14656560903580001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166d&amp;dbid=16384&amp;doi=10.1517%2F14656560903580001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656560903580001%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DM.%2BK.%26aulast%3DZoellner%26aufirst%3DC.%26atitle%3DRole%2520of%2520ribavirin%2520in%2520HCV%2520treatment%2520response%253A%2520now%2520and%2520in%2520the%2520future%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2010%26volume%3D11%26spage%3D673%26epage%3D683%26doi%3D10.1517%2F14656560903580001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit166e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronowicki, J. P.</span><span> </span><span class="NLM_article-title">Ideal oral combinations to eradicate HCV: the role of ribavirin</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span><span class="refDoi"> DOI: 10.1016/j.jhep.2015.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2015.09.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=215-225&author=C.+H%C3%A9zodeauthor=J.+P.+Bronowicki&title=Ideal+oral+combinations+to+eradicate+HCV%3A+the+role+of+ribavirin&doi=10.1016%2Fj.jhep.2015.09.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166e&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2015.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2015.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DBronowicki%26aufirst%3DJ.%2BP.%26atitle%3DIdeal%2520oral%2520combinations%2520to%2520eradicate%2520HCV%253A%2520the%2520role%2520of%2520ribavirin%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D64%26spage%3D215%26epage%3D225%26doi%3D10.1016%2Fj.jhep.2015.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit166f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Shiffman, M. L.</span><span> </span><span class="NLM_article-title">What future for ribavirin?</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">68</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span><span class="refDoi"> DOI: 10.1111/j.1478-3231.2008.01936.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fj.1478-3231.2008.01936.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=68-73&issue=Suppl.+1&author=M.+L.+Shiffman&title=What+future+for+ribavirin%3F&doi=10.1111%2Fj.1478-3231.2008.01936.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166f&amp;dbid=16384&amp;doi=10.1111%2Fj.1478-3231.2008.01936.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1478-3231.2008.01936.x%26sid%3Dliteratum%253Aachs%26aulast%3DShiffman%26aufirst%3DM.%2BL.%26atitle%3DWhat%2520future%2520for%2520ribavirin%253F%26jtitle%3DLiver%2520Int.%26date%3D2009%26volume%3D29%26issue%3DSuppl.%25201%26spage%3D68%26epage%3D73%26doi%3D10.1111%2Fj.1478-3231.2008.01936.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">Alonso-Zaldivar, R.</span> $1,000 per pill drug overtaken by pricier successor. <a href="https://www.yahoo.com/news/1-000-per-pill-drug-overtaken-pricier-successor-121337557--finance.html" class="extLink">https://www.yahoo.com/news/1-000-per-pill-drug-overtaken-pricier-successor-121337557--finance.html</a> (accessed on June 4,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Alonso-Zaldivar%2C+R.+%241%2C000+per+pill+drug+overtaken+by+pricier+successor.+https%3A%2F%2Fwww.yahoo.com%2Fnews%2F1-000-per-pill-drug-overtaken-pricier-successor-121337557%2D%2Dfinance.html+%28accessed+on+June+4%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso-Zaldivar%26aufirst%3DR.%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pawlotsky, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feld, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoofnagle, J. H.</span><span> </span><span class="NLM_article-title">From non-A, non-B hepatitis to hepatitis C virus cure</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">S87</span><span class="NLM_x">–</span> <span class="NLM_lpage">S89</span><span class="refDoi"> DOI: 10.1016/j.jhep.2015.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2015.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25920094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFChur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=S87-S89&author=J.-M.+Pawlotskyauthor=J.+J.+Feldauthor=S.+Zeuzemauthor=J.+H.+Hoofnagle&title=From+non-A%2C+non-B+hepatitis+to+hepatitis+C+virus+cure&doi=10.1016%2Fj.jhep.2015.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168aR"><div class="casContent"><span class="casTitleNuber">168a</span><div class="casTitle"><span class="NLM_cas:atitle">From non-A, non-B hepatitis to hepatitis C virus cure</span></div><div class="casAuthors">Pawlotsky, Jean-Michel; Feld, Jordan J.; Zeuzem, Stefan; Hoofnagle, Jay H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1_Suppl.</span>),
    <span class="NLM_cas:pages">S87-S99</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) was discovered in the late 1980s.  Interferon (IFN)-α was proposed as an antiviral treatment for chronic hepatitis C at about the same time.  Successive improvements in IFN-α-based therapy (dose finding, pegylation, addn. of ribavirin) increased the rates of sustained virol. response, i.e. the rates of curing HCV infection.  These rates were further improved by adding the first available direct-acting antiviral (DAA) drugs to the combination of pegylated IFN-α and ribavirin.  An IFN-free era finally started in 2014, yielding rates of sustained virol. response over 90% in patients treated for 8 to 24 wk with all-oral regimens.  Major challenges however remain in implementation of these new treatment strategies, not only in low- to middle-income countries, but also in high-income countries where the price of these therapies is still prohibitive.  Elimination of HCV infection through treatment in certain areas is possible but raises major public health issues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6T_7lvdy2bbVg90H21EOLACvtfcHk0lhW7AI40-4-Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFChur4%253D&md5=da525df1d2b9303f5afea1c8f0538952</span></div><a href="/servlet/linkout?suffix=cit168a&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2015.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2015.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.-M.%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DHoofnagle%26aufirst%3DJ.%2BH.%26atitle%3DFrom%2520non-A%252C%2520non-B%2520hepatitis%2520to%2520hepatitis%2520C%2520virus%2520cure%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26spage%3DS87%26epage%3DS89%26doi%3D10.1016%2Fj.jhep.2015.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit168b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ward, J. W.</span><span> </span><span class="NLM_article-title">Hepatitis C virus: the 25-year journey from discovery to cure</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1479</span><span class="NLM_x">–</span> <span class="NLM_lpage">1482</span><span class="refDoi"> DOI: 10.1002/hep.27377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.27377" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=1479-1482&author=J.+W.+Ward&title=Hepatitis+C+virus%3A+the+25-year+journey+from+discovery+to+cure&doi=10.1002%2Fhep.27377"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168b&amp;dbid=16384&amp;doi=10.1002%2Fhep.27377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27377%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DJ.%2BW.%26atitle%3DHepatitis%2520C%2520virus%253A%2520the%252025-year%2520journey%2520from%2520discovery%2520to%2520cure%26jtitle%3DHepatology%26date%3D2014%26volume%3D60%26spage%3D1479%26epage%3D1482%26doi%3D10.1002%2Fhep.27377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group">Chung, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumert, T. F.</span><span> </span><span class="NLM_article-title">Curing chronic hepatitis C - the arc of a medical triumph</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1576</span><span class="NLM_x">–</span> <span class="NLM_lpage">1578</span><span class="refDoi"> DOI: 10.1056/NEJMp1400986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMp1400986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24720678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnt1Grsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1576-1578&author=R.+T.+Chungauthor=T.+F.+Baumert&title=Curing+chronic+hepatitis+C+-+the+arc+of+a+medical+triumph&doi=10.1056%2FNEJMp1400986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: curing chronic hepatitis C - the arc of a medical triumph</span></div><div class="casAuthors">Chung, Raymond T.; Baumert, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1576-1578</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgQ-Eau5Mvq7Vg90H21EOLACvtfcHk0lhW7AI40-4-Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnt1Grsrw%253D&md5=7690e941509eac54c37f1339df6c555e</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1056%2FNEJMp1400986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp1400986%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DR.%2BT.%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26atitle%3DCuring%2520chronic%2520hepatitis%2520C%2520-%2520the%2520arc%2520of%2520a%2520medical%2520triumph%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1576%26epage%3D1578%26doi%3D10.1056%2FNEJMp1400986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4a','cit4b','cit4c'],'ref5':['cit5a','cit5b'],'ref6':['cit6a','cit6b','cit6c','cit6d'],'ref7':['cit7a','cit7b','cit7c','cit7d'],'ref8':['cit8a','cit8b','cit8c'],'ref9':['cit9a','cit9b','cit9c','cit9d','cit9e','cit9f'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12a','cit12b'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15a','cit15b','cit15c'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18a','cit18b'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21a','cit21b','cit21c'],'ref22':['cit22a','cit22b'],'ref23':['cit23a','cit23b','cit23c'],'ref24':['cit24a','cit24b','cit24c','cit24d','cit24e','cit24f'],'ref25':['cit25a','cit25b','cit25c'],'ref26':['cit26a','cit26b','cit26c','cit26d'],'ref27':['cit27'],'ref28':['cit28a','cit28b','cit28c','cit28d'],'ref29':['cit29a','cit29b','cit29c'],'ref30':['cit30a','cit30b','cit30c'],'ref31':['cit31a','cit31b'],'ref32':['cit32a','cit32b','cit32c'],'ref33':['cit33a','cit33b'],'ref34':['cit34a','cit34b','cit34c'],'ref35':['cit35a','cit35b'],'ref36':['cit36'],'ref37':['cit37a','cit37b'],'ref38':['cit38a','cit38b'],'ref39':['cit39a','cit39b','cit39c'],'ref40':['cit40a','cit40b','cit40c','cit40d','cit40e'],'ref41':['cit41'],'ref42':['cit42a','cit42b','cit42c'],'ref43':['cit43a','cit43b'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47a','cit47b','cit47c','cit47d'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51a','cit51b','cit51c','cit51d'],'ref52':['cit52a','cit52b','cit52c'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59a','cit59b','cit59c','cit59d','cit59e'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63a','cit63b','cit63c'],'ref64':['cit64'],'ref65':['cit65a','cit65b'],'ref66':['cit66a','cit66b'],'ref67':['cit67'],'ref68':['cit68a','cit68b','cit68c'],'ref69':['cit69'],'ref70':['cit70a','cit70b'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73a','cit73b'],'ref74':['cit74'],'ref75':['cit75a','cit75b'],'ref76':['cit76a','cit76b','cit76c'],'ref77':['cit77a','cit77b','cit77c','cit77d','cit77e','cit77f','cit77g'],'ref78':['cit78a','cit78b','cit78c','cit78d'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88a','cit88b'],'ref89':['cit89'],'ref90':['cit90a','cit90b'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93a','cit93b'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96a','cit96b','cit96c','cit96d'],'ref97':['cit97a','cit97b','cit97c','cit97d'],'ref98':['cit98'],'ref99':['cit99a','cit99b'],'ref100':['cit100a','cit100b'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108a','cit108b'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113a','cit113b'],'ref114':['cit114a','cit114b','cit114c'],'ref115':['cit115'],'ref116':['cit116a','cit116b','cit116c','cit116d','cit116e','cit116f'],'ref117':['cit117'],'ref118':['cit118a','cit118b','cit118c'],'ref119':['cit119a','cit119b'],'ref120':['cit120a','cit120b','cit120c'],'ref121':['cit121a','cit121b'],'ref122':['cit122'],'ref123':['cit123a','cit123b'],'ref124':['cit124'],'ref125':['cit125a','cit125b','cit125c'],'ref126':['cit126a','cit126b','cit126c','cit126d','cit126e','cit126f','cit126g','cit126h','cit126i','cit126j'],'ref127':['cit127'],'ref128':['cit128a','cit128b','cit128c'],'ref129':['cit129'],'ref130':['cit130a','cit130b','cit130c','cit130c1','cit130d','cit130e'],'ref131':['cit131'],'ref132':['cit132a','cit132b'],'ref133':['cit133'],'ref134':['cit134a','cit134b','cit134c','cit134d','cit134e','cit134f','cit134g'],'ref135':['cit135a','cit135b','cit135c'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138a','cit138b','cit138c','cit138d','cit138e','cit138f','cit138g'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141a','cit141b','cit141c','cit141d','cit141e'],'ref142':['cit142'],'ref143':['cit143a'],'ref144':['cit144a','cit144b','cit144c','cit144d'],'ref145':['cit145'],'ref146':['cit146a','cit146b','cit146c','cit146d'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154a','cit154b','cit154c','cit154d'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158a','cit158b','cit158c','cit158d'],'ref159':['cit159'],'ref160':['cit160a','cit160b','cit160c','cit160d','cit160e','cit160f','cit160g'],'ref161':['cit161a','cit161b','cit161c','cit161d'],'ref162':['cit162a','cit162b'],'ref163':['cit163a','cit163b','cit163c','cit163d'],'ref164':['cit164a','cit164b'],'ref165':['cit165a','cit165b'],'ref166':['cit166a','cit166b','cit166c','cit166d','cit166e','cit166f'],'ref167':['cit167'],'ref168':['cit168a','cit168b'],'ref169':['cit169']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 27 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Chao Hang, Antonio Ramirez, Collin Chan, Yi Hsiao, Albert J. DelMonte, <span class="NLM_string-name hlFld-ContribAuthor">Eric M. Simmons</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanistic Studies of a Pd-Catalyzed Direct Arylation En Route to Beclabuvir: Dual Role of a Tetramethylammonium Cation and an Unusual Turnover-Limiting Step. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2021,</strong> <em>11 </em>
                                    (5)
                                     , 2460-2472. <a href="https://doi.org/10.1021/acscatal.0c05533" title="DOI URL">https://doi.org/10.1021/acscatal.0c05533</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.0c05533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.0c05533%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DMechanistic%252BStudies%252Bof%252Ba%252BPd-Catalyzed%252BDirect%252BArylation%252BEn%252BRoute%252Bto%252BBeclabuvir%25253A%252BDual%252BRole%252Bof%252Ba%252BTetramethylammonium%252BCation%252Band%252Ban%252BUnusual%252BTurnover-Limiting%252BStep%26aulast%3DHang%26aufirst%3DChao%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D2021%26date%3D17122020%26date%3D25012021%26date%3D10022021%26volume%3D11%26issue%3D5%26spage%3D2460%26epage%3D2472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nicholas A. Meanwell, Gunda I. Georg, <span class="NLM_string-name hlFld-ContribAuthor">Shaomeng Wang</span>. </span><span class="cited-content_cbyCitation_article-title">The 2020 Nobel Prize in Physiology or Medicine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13197-13204. <a href="https://doi.org/10.1021/acs.jmedchem.0c01877" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01877</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01877%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252B2020%252BNobel%252BPrize%252Bin%252BPhysiology%252Bor%252BMedicine%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2020%26date%3D2020%26date%3D05112020%26volume%3D63%26issue%3D22%26spage%3D13197%26epage%3D13204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kap-Sun Yeung, Brett R. Beno, Kathy Mosure, Juliang Zhu, Katherine A. Grant-Young, Kyle Parcella, Prakash Anjanappa, Rajesh Onkardas Bora, Kumaravel Selvakumar, Ying-Kai Wang, Hua Fang, Rudolph Krause, Karen Rigat, Mengping Liu, Julie Lemm, Steven Sheriff, Mark Witmer, Jeffrey Tredup, Adam Jardel, Kevin Kish, Dawn Parker, Roy Haskell, Kenneth Santone, Nicholas A. Meanwell, Matthew G. Soars, Susan B. Roberts, <span class="NLM_string-name hlFld-ContribAuthor">John F. Kadow</span>. </span><span class="cited-content_cbyCitation_article-title">Structure–Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (12)
                                     , 1217-1222. <a href="https://doi.org/10.1021/acsmedchemlett.8b00379" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00379</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00379%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure%2525E2%252580%252593Property%252BBasis%252Bfor%252BSolving%252BTransporter-Mediated%252BEfflux%252Band%252BPan-Genotypic%252BInhibition%252Bin%252BHCV%252BNS5B%252BInhibitors%26aulast%3DYeung%26aufirst%3DKap-Sun%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D16082018%26date%3D05112018%26date%3D08112018%26date%3D05112018%26volume%3D9%26issue%3D12%26spage%3D1217%26epage%3D1222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robert J. Young, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Leeson</span>. </span><span class="cited-content_cbyCitation_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6421-6467. <a href="https://doi.org/10.1021/acs.jmedchem.8b00180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMapping%252Bthe%252BEfficiency%252Band%252BPhysicochemical%252BTrajectories%252Bof%252BSuccessful%252BOptimizations%26aulast%3DYoung%26aufirst%3DRobert%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03022018%26date%3D25042018%26date%3D05042018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bao-Qu  Wang</span>, <span class="hlFld-ContribAuthor ">Cong-Hai  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao-Xue  Tian</span>, <span class="hlFld-ContribAuthor ">Jun  Lin</span>, and <span class="hlFld-ContribAuthor ">Sheng-Jiao  Yan</span>  . </span><span class="cited-content_cbyCitation_article-title">Cascade Reaction of Isatins with 1,1-Enediamines: Synthesis of Multisubstituted Quinoline-4-carboxamides. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (3)
                                     , 660-663. <a href="https://doi.org/10.1021/acs.orglett.7b03803" title="DOI URL">https://doi.org/10.1021/acs.orglett.7b03803</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.7b03803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.7b03803%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCascade%252BReaction%252Bof%252BIsatins%252Bwith%252B1%25252C1-Enediamines%25253A%252BSynthesis%252Bof%252BMultisubstituted%252BQuinoline-4-carboxamides%26aulast%3DWang%26aufirst%3DBao-Qu%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D06122017%26date%3D11012018%26date%3D02022018%26volume%3D20%26issue%3D3%26spage%3D660%26epage%3D663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liang  Chen</span>, <span class="hlFld-ContribAuthor ">Rong  Huang</span>, <span class="hlFld-ContribAuthor ">Ling-Bin  Kong</span>, <span class="hlFld-ContribAuthor ">Jun  Lin</span>, and <span class="hlFld-ContribAuthor ">Sheng-Jiao  Yan</span>  . </span><span class="cited-content_cbyCitation_article-title">Facile Route to the Synthesis of 1,3-Diazahetero-Cycle-Fused [1,2-a]Quinoline Derivatives via Cascade Reactions. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (1)
                                     , 1126-1136. <a href="https://doi.org/10.1021/acsomega.7b01856" title="DOI URL">https://doi.org/10.1021/acsomega.7b01856</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.7b01856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.7b01856%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DFacile%252BRoute%252Bto%252Bthe%252BSynthesis%252Bof%252B1%25252C3-Diazahetero-Cycle-Fused%252B%25255B1%25252C2-a%25255DQuinoline%252BDerivatives%252Bvia%252BCascade%252BReactions%26aulast%3DChen%26aufirst%3DLiang%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D27112017%26date%3D12012018%26date%3D31012018%26volume%3D3%26issue%3D1%26spage%3D1126%26epage%3D1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashley N.  Matthew</span>, <span class="hlFld-ContribAuthor ">Jacqueto  Zephyr</span>, <span class="hlFld-ContribAuthor ">Caitlin. J.  Hill</span>, <span class="hlFld-ContribAuthor ">Muhammad  Jahangir</span>, <span class="hlFld-ContribAuthor ">Alicia  Newton</span>, <span class="hlFld-ContribAuthor ">Christos J.  Petropoulos</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Nese  Kurt-Yilmaz</span>, <span class="hlFld-ContribAuthor ">Celia A.  Schiffer</span>, and <span class="hlFld-ContribAuthor ">Akbar  Ali</span>  . </span><span class="cited-content_cbyCitation_article-title">Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (13)
                                     , 5699-5716. <a href="https://doi.org/10.1021/acs.jmedchem.7b00426" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00426</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00426%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHepatitis%252BC%252BVirus%252BNS3%25252F4A%252BProtease%252BInhibitors%252BIncorporating%252BFlexible%252BP2%252BQuinoxalines%252BTarget%252BDrug%252BResistant%252BViral%252BVariants%26aulast%3DMatthew%26aufirst%3DAshley%2BN.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D16032017%26date%3D19062017%26date%3D13072017%26date%3D08062017%26volume%3D60%26issue%3D13%26spage%3D5699%26epage%3D5716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kap-Sun  Yeung</span>, <span class="hlFld-ContribAuthor ">Brett R.  Beno</span>, <span class="hlFld-ContribAuthor ">Kyle  Parcella</span>, <span class="hlFld-ContribAuthor ">John A.  Bender</span>, <span class="hlFld-ContribAuthor ">Katherine A.  Grant-Young</span>, <span class="hlFld-ContribAuthor ">Andrew  Nickel</span>, <span class="hlFld-ContribAuthor ">Prashantha  Gunaga</span>, <span class="hlFld-ContribAuthor ">Prakash  Anjanappa</span>, <span class="hlFld-ContribAuthor ">Rajesh Onkardas  Bora</span>, <span class="hlFld-ContribAuthor ">Kumaravel  Selvakumar</span>, <span class="hlFld-ContribAuthor ">Karen  Rigat</span>, <span class="hlFld-ContribAuthor ">Ying-Kai  Wang</span>, <span class="hlFld-ContribAuthor ">Mengping  Liu</span>, <span class="hlFld-ContribAuthor ">Julie  Lemm</span>, <span class="hlFld-ContribAuthor ">Kathy  Mosure</span>, <span class="hlFld-ContribAuthor ">Steven  Sheriff</span>, <span class="hlFld-ContribAuthor ">Changhong  Wan</span>, <span class="hlFld-ContribAuthor ">Mark  Witmer</span>, <span class="hlFld-ContribAuthor ">Kevin  Kish</span>, <span class="hlFld-ContribAuthor ">Umesh  Hanumegowda</span>, <span class="hlFld-ContribAuthor ">Xiaoliang  Zhuo</span>, <span class="hlFld-ContribAuthor ">Yue-Zhong  Shu</span>, <span class="hlFld-ContribAuthor ">Dawn  Parker</span>, <span class="hlFld-ContribAuthor ">Roy  Haskell</span>, <span class="hlFld-ContribAuthor ">Alicia  Ng</span>, <span class="hlFld-ContribAuthor ">Qi  Gao</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Colston</span>, <span class="hlFld-ContribAuthor ">Joseph  Raybon</span>, <span class="hlFld-ContribAuthor ">Dennis M.  Grasela</span>, <span class="hlFld-ContribAuthor ">Kenneth  Santone</span>, <span class="hlFld-ContribAuthor ">Min  Gao</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Michael  Sinz</span>, <span class="hlFld-ContribAuthor ">Matthew G.  Soars</span>, <span class="hlFld-ContribAuthor ">Jay O.  Knipe</span>, <span class="hlFld-ContribAuthor ">Susan B.  Roberts</span>, and <span class="hlFld-ContribAuthor ">John F.  Kadow</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (10)
                                     , 4369-4385. <a href="https://doi.org/10.1021/acs.jmedchem.7b00328" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00328</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00328%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BHepatitis%252BC%252BVirus%252BNS5B%252BReplicase%252BPalm%252BSite%252BAllosteric%252BInhibitor%252B%252528BMS-929075%252529%252BAdvanced%252Bto%252BPhase%252B1%252BClinical%252BStudies%26aulast%3DYeung%26aufirst%3DKap-Sun%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D03032017%26date%3D04052017%26date%3D25052017%26date%3D21042017%26volume%3D60%26issue%3D10%26spage%3D4369%26epage%3D4385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">The Design and Application of Bioisosteres in Drug Design. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-81. <a href="https://doi.org/10.1002/0471266949.bmc259" title="DOI URL">https://doi.org/10.1002/0471266949.bmc259</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc259%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BDesign%252Band%252BApplication%252Bof%252BBioisosteres%252Bin%252BDrug%252BDesign%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D81%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryoya  Iioka</span>, <span class="hlFld-ContribAuthor ">Kohei  Yorozu</span>, <span class="hlFld-ContribAuthor ">Yoko  Sakai</span>, <span class="hlFld-ContribAuthor ">Rika  Kawai</span>, <span class="hlFld-ContribAuthor ">Noriyuki  Hatae</span>, <span class="hlFld-ContribAuthor ">Katsuki  Takashima</span>, <span class="hlFld-ContribAuthor ">Genzoh  Tanabe</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Wasada</span>, <span class="hlFld-ContribAuthor ">Mitsuhiro  Yoshimatsu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Azepino[1,2‐
              a
              ]indole‐10‐amines via [6+1] Annulation of Ynenitriles with Reformatsky Reagent. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>2021 </em>
                                    (10)
                                     , 1553-1558. <a href="https://doi.org/10.1002/ejoc.202100021" title="DOI URL">https://doi.org/10.1002/ejoc.202100021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202100021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202100021%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BAzepino%25255B1%25252C2%2525E2%252580%252590%252Ba%252B%25255Dindole%2525E2%252580%25259010%2525E2%252580%252590amines%252Bvia%252B%25255B6%25252B1%25255D%252BAnnulation%252Bof%252BYnenitriles%252Bwith%252BReformatsky%252BReagent%26aulast%3DIioka%26aufirst%3DRyoya%26date%3D2021%26date%3D2021%26volume%3D2021%26issue%3D10%26spage%3D1553%26epage%3D1558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Byeong Wook  Kim</span>, <span class="hlFld-ContribAuthor ">Hwa  Lee</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>, <span class="hlFld-ContribAuthor ">B. Moon  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-activity relationship (SAR) studies on the mutagenic properties of 2,7-diaminofluorene and 2,7-diaminocarbazole derivatives. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>31 </em>, 127662. <a href="https://doi.org/10.1016/j.bmcl.2020.127662" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127662</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127662%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure-activity%252Brelationship%252B%252528SAR%252529%252Bstudies%252Bon%252Bthe%252Bmutagenic%252Bproperties%252Bof%252B2%25252C7-diaminofluorene%252Band%252B2%25252C7-diaminocarbazole%252Bderivatives%26aulast%3DKim%26aufirst%3DByeong%2BWook%26date%3D2021%26volume%3D31%26spage%3D127662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rachel M.  Wypych</span>, <span class="hlFld-ContribAuthor ">Steven R.  LaPlante</span>, <span class="hlFld-ContribAuthor ">Peter W.  White</span>, <span class="hlFld-ContribAuthor ">Stephen F.  Martin</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-thermodynamics-relationships of hepatitis C viral NS3 protease inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112195. <a href="https://doi.org/10.1016/j.ejmech.2020.112195" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112195</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112195%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-thermodynamics-relationships%252Bof%252Bhepatitis%252BC%252Bviral%252BNS3%252Bprotease%252Binhibitors%26aulast%3DWypych%26aufirst%3DRachel%2BM.%26date%3D2020%26volume%3D192%26spage%3D112195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Collin  Chan</span>, <span class="hlFld-ContribAuthor ">Albert J.  DelMonte</span>, <span class="hlFld-ContribAuthor ">Chao  Hang</span>, <span class="hlFld-ContribAuthor ">Yi  Hsiao</span>, <span class="hlFld-ContribAuthor ">Eric M.  Simmons</span>. </span><span class="cited-content_cbyCitation_article-title">Development and Scale‐Up of a Palladium‐Catalyzed Intramolecular Direct Arylation in the Commercial Synthesis of Beclabuvir. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 137-170. <a href="https://doi.org/10.1002/9783527819201.ch6" title="DOI URL">https://doi.org/10.1002/9783527819201.ch6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527819201.ch6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527819201.ch6%26sid%3Dliteratum%253Aachs%26atitle%3DDevelopment%252Band%252BScale%2525E2%252580%252590Up%252Bof%252Ba%252BPalladium%2525E2%252580%252590Catalyzed%252BIntramolecular%252BDirect%252BArylation%252Bin%252Bthe%252BCommercial%252BSynthesis%252Bof%252BBeclabuvir%26aulast%3DChan%26aufirst%3DCollin%26date%3D2020%26date%3D2020%26spage%3D137%26epage%3D170%26pub%3DWiley%26atitle%3DOrganometallic%252BChemistry%252Bin%252BIndustry%26aulast%3DColacot%26aufirst%3DThomas%2BJ.%26date%3D2020%26date%3D2020%26volume%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun  Li</span>, <span class="hlFld-ContribAuthor ">Martin D.  Eastgate</span>. </span><span class="cited-content_cbyCitation_article-title">Making better decisions during synthetic route design: leveraging prediction to achieve greenness-by-design. </span><span class="cited-content_cbyCitation_journal-name">Reaction Chemistry & Engineering</span><span> <strong>2019,</strong> <em>4 </em>
                                    (9)
                                     , 1595-1607. <a href="https://doi.org/10.1039/C9RE00019D" title="DOI URL">https://doi.org/10.1039/C9RE00019D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9RE00019D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9RE00019D%26sid%3Dliteratum%253Aachs%26jtitle%3DReaction%2520Chemistry%2520%2526%2520Engineering%26atitle%3DMaking%252Bbetter%252Bdecisions%252Bduring%252Bsynthetic%252Broute%252Bdesign%25253A%252Bleveraging%252Bprediction%252Bto%252Bachieve%252Bgreenness-by-design%26aulast%3DLi%26aufirst%3DJun%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D9%26spage%3D1595%26epage%3D1607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdolali  Alizadeh</span>, <span class="hlFld-ContribAuthor ">Atefeh  Roosta</span>, <span class="hlFld-ContribAuthor ">Mohammadreza  Halvagar</span>. </span><span class="cited-content_cbyCitation_article-title">Four-Component Regio- and Diastereoselective Synthesis of Pyrrolizidines Incorporating Spiro-Oxindole/Indanedione via 1,3-Dipolar Cycloaddition Reaction of Azomethine Ylides. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2019,</strong> <em>4 </em>
                                    (1)
                                     , 71-74. <a href="https://doi.org/10.1002/slct.201803418" title="DOI URL">https://doi.org/10.1002/slct.201803418</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201803418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201803418%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DFour-Component%252BRegio-%252Band%252BDiastereoselective%252BSynthesis%252Bof%252BPyrrolizidines%252BIncorporating%252BSpiro-Oxindole%25252FIndanedione%252Bvia%252B1%25252C3-Dipolar%252BCycloaddition%252BReaction%252Bof%252BAzomethine%252BYlides%26aulast%3DAlizadeh%26aufirst%3DAbdolali%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D1%26spage%3D71%26epage%3D74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert G.  Gentles</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Beclabuvir: A Potent Allosteric Inhibitor of the Hepatitis C Virus Polymerase. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 193-228. <a href="https://doi.org/10.1007/7355_2018_38" title="DOI URL">https://doi.org/10.1007/7355_2018_38</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2018_38&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2018_38%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Bof%252BBeclabuvir%25253A%252BA%252BPotent%252BAllosteric%252BInhibitor%252Bof%252Bthe%252BHepatitis%252BC%252BVirus%252BPolymerase%26aulast%3DGentles%26aufirst%3DRobert%2BG.%26date%3D2019%26date%3D2019%26spage%3D193%26epage%3D228%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DHCV%25253A%252BThe%252BJourney%252Bfrom%252BDiscovery%252Bto%252Ba%252BCure%26aulast%3DSofia%26aufirst%3DMichael%2BJ.%26date%3D2019%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Ramkumar  Rajamani</span>, <span class="hlFld-ContribAuthor ">Paul M.  Scola</span>, <span class="hlFld-ContribAuthor ">Li-Qiang  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 317-354. <a href="https://doi.org/10.1007/7355_2018_58" title="DOI URL">https://doi.org/10.1007/7355_2018_58</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2018_58&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2018_58%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BDiscovery%252Band%252BEarly%252BClinical%252BEvaluation%252Bof%252Bthe%252BHCV%252BNS3%25252F4A%252BProtease%252BInhibitor%252BAsunaprevir%252B%252528BMS-650032%252529%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2019%26date%3D2019%26spage%3D317%26epage%3D354%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DHCV%25253A%252BThe%252BJourney%252Bfrom%252BDiscovery%252Bto%252Ba%252BCure%26aulast%3DSofia%26aufirst%3DMichael%2BJ.%26date%3D2019%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N. V.  Yashin</span>. </span><span class="cited-content_cbyCitation_article-title">Methods for the preparation of 1-Aminocyclopropanecarboxylic Acids. </span><span class="cited-content_cbyCitation_journal-name">Review Journal of Chemistry</span><span> <strong>2018,</strong> <em>8 </em>
                                    (4)
                                     , 373-401. <a href="https://doi.org/10.1134/S2079978018040040" title="DOI URL">https://doi.org/10.1134/S2079978018040040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S2079978018040040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS2079978018040040%26sid%3Dliteratum%253Aachs%26jtitle%3DReview%2520Journal%2520of%2520Chemistry%26atitle%3DMethods%252Bfor%252Bthe%252Bpreparation%252Bof%252B1-Aminocyclopropanecarboxylic%252BAcids%26aulast%3DYashin%26aufirst%3DN.%2BV.%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D4%26spage%3D373%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manu  De Rycker</span>, <span class="hlFld-ContribAuthor ">Beatriz  Baragaña</span>, <span class="hlFld-ContribAuthor ">Suzanne L.  Duce</span>, <span class="hlFld-ContribAuthor ">Ian H.  Gilbert</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges and recent progress in drug discovery for tropical diseases. </span><span class="cited-content_cbyCitation_journal-name">Nature</span><span> <strong>2018,</strong> <em>559 </em>
                                    (7715)
                                     , 498-506. <a href="https://doi.org/10.1038/s41586-018-0327-4" title="DOI URL">https://doi.org/10.1038/s41586-018-0327-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41586-018-0327-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41586-018-0327-4%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%26atitle%3DChallenges%252Band%252Brecent%252Bprogress%252Bin%252Bdrug%252Bdiscovery%252Bfor%252Btropical%252Bdiseases%26aulast%3DDe%2BRycker%26aufirst%3DManu%26date%3D2018%26date%3D2018%26volume%3D559%26issue%3D7715%26spage%3D498%26epage%3D506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andhavaram  Ramaraju</span>, <span class="hlFld-ContribAuthor ">Neeraj Kumar  Chouhan</span>, <span class="hlFld-ContribAuthor ">Owk  Ravi</span>, <span class="hlFld-ContribAuthor ">Balasubramanian  Sridhar</span>, <span class="hlFld-ContribAuthor ">Surendar Reddy  Bathula</span>. </span><span class="cited-content_cbyCitation_article-title">Cu-Catalyzed Coupling of
              O
              -Acyl Oximes with Isatins: Domino Rearrangement Strategy for Direct Access to Quinoline-4-Carboxamides by C-N Bond Cleavage. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>2018 </em>
                                    (23)
                                     , 2963-2971. <a href="https://doi.org/10.1002/ejoc.201800501" title="DOI URL">https://doi.org/10.1002/ejoc.201800501</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201800501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201800501%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DCu-Catalyzed%252BCoupling%252Bof%252BO%252B-Acyl%252BOximes%252Bwith%252BIsatins%25253A%252BDomino%252BRearrangement%252BStrategy%252Bfor%252BDirect%252BAccess%252Bto%252BQuinoline-4-Carboxamides%252Bby%252BC-N%252BBond%252BCleavage%26aulast%3DRamaraju%26aufirst%3DAndhavaram%26date%3D2018%26date%3D2018%26volume%3D2018%26issue%3D23%26spage%3D2963%26epage%3D2971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonid I.  Belen’kii</span>, <span class="hlFld-ContribAuthor ">Yulia B.  Evdokimenkova</span>. </span><span class="cited-content_cbyCitation_article-title">The Literature of Heterocyclic Chemistry, Part XVI, 2016. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 173-254. <a href="https://doi.org/10.1016/bs.aihch.2018.02.003" title="DOI URL">https://doi.org/10.1016/bs.aihch.2018.02.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2018.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2018.02.003%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BLiterature%252Bof%252BHeterocyclic%252BChemistry%25252C%252BPart%252BXVI%25252C%252B2016%26aulast%3DBelen%25E2%2580%2599kii%26aufirst%3DLeonid%2BI.%26date%3D2018%26spage%3D173%26epage%3D254%26pub%3DElsevier%26date%3D2018%26volume%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Calcaterra</span>, <span class="hlFld-ContribAuthor ">Ilaria  D’Acquarica</span>. </span><span class="cited-content_cbyCitation_article-title">The market of chiral drugs: Chiral switches versus de novo enantiomerically pure compounds. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical and Biomedical Analysis</span><span> <strong>2018,</strong> <em>147 </em>, 323-340. <a href="https://doi.org/10.1016/j.jpba.2017.07.008" title="DOI URL">https://doi.org/10.1016/j.jpba.2017.07.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpba.2017.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpba.2017.07.008%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520and%2520Biomedical%2520Analysis%26atitle%3DThe%252Bmarket%252Bof%252Bchiral%252Bdrugs%25253A%252BChiral%252Bswitches%252Bversus%252Bde%252Bnovo%252Benantiomerically%252Bpure%252Bcompounds%26aulast%3DCalcaterra%26aufirst%3DAndrea%26date%3D2018%26volume%3D147%26spage%3D323%26epage%3D340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Youngsu  You</span>, <span class="hlFld-ContribAuthor ">Hee Sun  Kim</span>, <span class="hlFld-ContribAuthor ">Jung Woo  Park</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>, <span class="hlFld-ContribAuthor ">Sung Key  Jang</span>, <span class="hlFld-ContribAuthor ">B. Moon  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Sulfur(
              vi
              ) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure–activity relationship studies. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2018,</strong> <em>8 </em>
                                    (55)
                                     , 31803-31821. <a href="https://doi.org/10.1039/C8RA05471A" title="DOI URL">https://doi.org/10.1039/C8RA05471A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8RA05471A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8RA05471A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DSulfur%252528%252Bvi%252B%252529%252Bfluoride%252Bexchange%252Bas%252Ba%252Bkey%252Breaction%252Bfor%252Bsynthesizing%252Bbiaryl%252Bsulfate%252Bcore%252Bderivatives%252Bas%252Bpotent%252Bhepatitis%252BC%252Bvirus%252BNS5A%252Binhibitors%252Band%252Btheir%252Bstructure%2525E2%252580%252593activity%252Brelationship%252Bstudies%26aulast%3DYou%26aufirst%3DYoungsu%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D55%26spage%3D31803%26epage%3D31821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanling  Wu</span>, <span class="hlFld-ContribAuthor ">Shibo  Jiang</span>, <span class="hlFld-ContribAuthor ">Tianlei  Ying</span>. </span><span class="cited-content_cbyCitation_article-title">Single-Domain Antibodies As Therapeutics against Human Viral Diseases. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Immunology</span><span> <strong>2017,</strong> <em>8 </em><a href="https://doi.org/10.3389/fimmu.2017.01802" title="DOI URL">https://doi.org/10.3389/fimmu.2017.01802</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fimmu.2017.01802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffimmu.2017.01802%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Immunology%26atitle%3DSingle-Domain%252BAntibodies%252BAs%252BTherapeutics%252Bagainst%252BHuman%252BViral%252BDiseases%26aulast%3DWu%26aufirst%3DYanling%26date%3D2017%26date%3D2017%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephen J.  Chawner</span>, <span class="hlFld-ContribAuthor ">Manuel J.  Cases-Thomas</span>, <span class="hlFld-ContribAuthor ">James A.  Bull</span>. </span><span class="cited-content_cbyCitation_article-title">Divergent Synthesis of Cyclopropane-Containing Lead-Like Compounds, Fragments and Building Blocks through a Cobalt Catalyzed Cyclopropanation of Phenyl Vinyl Sulfide. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>2017 </em>
                                    (34)
                                     , 5015-5024. <a href="https://doi.org/10.1002/ejoc.201701030" title="DOI URL">https://doi.org/10.1002/ejoc.201701030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201701030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201701030%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDivergent%252BSynthesis%252Bof%252BCyclopropane-Containing%252BLead-Like%252BCompounds%25252C%252BFragments%252Band%252BBuilding%252BBlocks%252Bthrough%252Ba%252BCobalt%252BCatalyzed%252BCyclopropanation%252Bof%252BPhenyl%252BVinyl%252BSulfide%26aulast%3DChawner%26aufirst%3DStephen%2BJ.%26date%3D2017%26date%3D2017%26volume%3D2017%26issue%3D34%26spage%3D5015%26epage%3D5024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingkuan  Meng</span>, <span class="hlFld-ContribAuthor ">Qi  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Tang</span>, <span class="hlFld-ContribAuthor ">Sulong  Xiao</span>, <span class="hlFld-ContribAuthor ">Lihe  Zhang</span>, <span class="hlFld-ContribAuthor ">Demin  Zhou</span>, <span class="hlFld-ContribAuthor ">Fei  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of Pentacyclic Triterpene Dimers as HCV Entry Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chinese Journal of Chemistry</span><span> <strong>2017,</strong> <em>35 </em>
                                    (8)
                                     , 1322-1328. <a href="https://doi.org/10.1002/cjoc.201700272" title="DOI URL">https://doi.org/10.1002/cjoc.201700272</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cjoc.201700272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcjoc.201700272%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Journal%2520of%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BPentacyclic%252BTriterpene%252BDimers%252Bas%252BHCV%252BEntry%252BInhibitors%26aulast%3DMeng%26aufirst%3DLingkuan%26date%3D2017%26date%3D2017%26volume%3D35%26issue%3D8%26spage%3D1322%26epage%3D1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Veaceslav  Boldescu</span>, <span class="hlFld-ContribAuthor ">Mira A. M.  Behnam</span>, <span class="hlFld-ContribAuthor ">Nikos  Vasilakis</span>, <span class="hlFld-ContribAuthor ">Christian D.  Klein</span>. </span><span class="cited-content_cbyCitation_article-title">Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2017,</strong> <em>16 </em>
                                    (8)
                                     , 565-586. <a href="https://doi.org/10.1038/nrd.2017.33" title="DOI URL">https://doi.org/10.1038/nrd.2017.33</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrd.2017.33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrd.2017.33%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DBroad-spectrum%252Bagents%252Bfor%252Bflaviviral%252Binfections%25253A%252Bdengue%25252C%252BZika%252Band%252Bbeyond%26aulast%3DBoldescu%26aufirst%3DVeaceslav%26date%3D2017%26date%3D2017%26volume%3D16%26issue%3D8%26spage%3D565%26epage%3D586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0059.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Genetic organization of HCV that comprises 5′- and 3′-untranslated regions and encodes for structural and nonstructural proteins with the sites of cleavage of the polypeptide depicted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Key drug–target interactions between the acylsulfonamide moiety of <b>21</b> and the NS3 protease protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0015.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparative Procedure for Cyclopropanesulfonamide (<b>32</b>) and 1-Subsituted Cyclopropanesulfonamide Derivatives <b>33</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Mean reduction in plasma viral RNA following the administration of single oral doses of <b>36</b> to HCV-infected subjects. Figure reproduced with permission from  <cite>Journal of Medicinal Chemistry</cite> (<span class="NLM_year">2014</span>, <em>57</em>, 1708–1729).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Copyright 2014 American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effects of <b>36</b> on heart rate and sinoatrial node recovery time in a rabbit Langendorff heart preparation. Reproduced with permission from  <cite>Journal of Medicinal Chemistry</cite> (<span class="NLM_year">2014</span>, <em>57</em>, 1730–1752).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Copyright 2014 American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Overlay of the cardiac effects of <b>36</b> and <b>64</b> perfused at a concentration of 10 μM for 60 min. Reproduced with permission from  <cite>Journal of Medicinal Chemistry</cite> (<span class="NLM_year">2014</span>, <em>57</em>, 1730–1752).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Copyright 2014 American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Mean maximum change in viremia associated with escalating doses of <b>64</b> administered to HCV-infected subjects in a SAD clinical study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structure and replicon EC<sub>50</sub> values for <b>65</b> and a select set of analogues that define fundamental aspects of the SARs of the screening lead.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0016.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Chemical Degradation Pathways Associated with the Thiazolidinone Derivative <b>77</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Antiviral activity of the series of stilbene-based proline amide HCV NS5A RCIs <b>97</b>–<b>101</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0009.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structural evolution of the 1,2-diphenyl alkyne core of NS5A inhibitors to that of an imidazole–4,4′-biphenyl–imidazole motif.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0010.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Mean maximal reductions in viral load following oral administration of <b>117</b> to HCV-infected subjects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0017.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Approach Developed To Access 6-Carboalkoxy-13-cycloalkyl-5<i>H</i>-indolo[2,1-<i>a</i>][2]benzazepine-10-carboxylic Acid Derivatives</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0011.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Mean maximal reductions in viral load following oral administration of <b>142</b> to HCV-infected subjects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0012.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Historical timelines for key events in the development of HCV DAAs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0013.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. SVR<sub>12</sub> and SVR<sub>24</sub> rates following 24 weeks of therapy with drug regimens containing <b>64</b> and <b>117</b>. (a) Percentage of patients achieving undetectable HCV RNA in response to the combination of <b>64</b>, <b>117</b>, PEG IFN-α, and <b>12</b> administered to GT-1-infected subjects for 24 weeks. (b) Percentage of patients achieving undetectable HCV RNA in response to the dual combination of the HCV DAAs <b>64</b> and <b>117</b> administered to GT-1-infected subjects for 24 weeks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/medium/jm-2016-00915a_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0014.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Evolution of HCV therapy and associated cure rates for GT-1 infection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00915/20160819/images/large/jm-2016-00915a_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00915&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i33">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04370" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04370" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 169 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Lichtenberg, F. R.</span><span> </span><span class="NLM_article-title">Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000–2009</span> <span class="citation_source-journal">Health Policy Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span><span class="refDoi"> DOI: 10.1016/j.hlpt.2013.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.hlpt.2013.09.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=36-58&author=F.+R.+Lichtenberg&title=Pharmaceutical+innovation+and+longevity+growth+in+30+developing+and+high-income+countries%2C+2000%E2%80%932009&doi=10.1016%2Fj.hlpt.2013.09.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.hlpt.2013.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hlpt.2013.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DLichtenberg%26aufirst%3DF.%2BR.%26atitle%3DPharmaceutical%2520innovation%2520and%2520longevity%2520growth%2520in%252030%2520developing%2520and%2520high-income%2520countries%252C%25202000%25E2%2580%25932009%26jtitle%3DHealth%2520Policy%2520Technol.%26date%3D2014%26volume%3D3%26spage%3D36%26epage%3D58%26doi%3D10.1016%2Fj.hlpt.2013.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Meanwell, N. A.; Olson, R. E.; Cheng, P. T.</span><span> </span><span class="NLM_article-title">The practice of medicinal chemistry and its contributions to therapy</span>. In  <span class="citation_source-book">2015 Medicinal Chemistry Reviews</span>; <span class="NLM_publisher-name">Medicinal Chemistry Division of the ACS</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">50</span>, pp  <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=359-393&author=N.+A.+Meanwell&author=R.+E.+Olson&author=P.+T.+Cheng&title=2015+Medicinal+Chemistry+Reviews"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DThe%2520practice%2520of%2520medicinal%2520chemistry%2520and%2520its%2520contributions%2520to%2520therapy%26btitle%3D2015%2520Medicinal%2520Chemistry%2520Reviews%26pub%3DMedicinal%2520Chemistry%2520Division%2520of%2520the%2520ACS%26date%3D2015%26volume%3D50%26spage%3D359%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Lichtenberg, F. R.</span><span> </span><span class="NLM_article-title">The effect of new drug approvals on HIV mortality in the US, 1987–1998</span> <span class="citation_source-journal">Economics Human Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span><span class="refDoi"> DOI: 10.1016/S1570-677X(02)00031-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS1570-677X%2802%2900031-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=15463977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BD2cvpsF2nsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2003&pages=259-266&author=F.+R.+Lichtenberg&title=The+effect+of+new+drug+approvals+on+HIV+mortality+in+the+US%2C+1987%E2%80%931998&doi=10.1016%2FS1570-677X%2802%2900031-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of new drug approvals on HIV mortality in the US, 1987-1998</span></div><div class="casAuthors">Lichtenberg Frank R</div><div class="citationInfo"><span class="NLM_cas:title">Economics and human biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">259-66</span>
        ISSN:<span class="NLM_cas:issn">1570-677X</span>.
    </div><div class="casAbstract">After increasing steadily from 1987 to 1995, the number of US deaths caused by human immunodeficiency virus (HIV) declined sharply from 1995 to 1998.  We analyse aggregate data to consider the hypothesis that this decline was due to a rapid increase in the number of drugs available to treat HIV.  The evidence suggests that new drugs played a key role in the post-1995 decline in HIV mortality.  The annual number of HIV deaths is estimated to have been reduced by over 6000, on average, by an additional HIV drug approval.  The social return to HIV drug innovation appears to be extremely large.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUogft9D3NgO2mnZh2OgS0fW6udTcc2ebM0HR_EWe1kLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cvpsF2nsA%253D%253D&md5=413dd70908820061629010d9b69415db</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1570-677X%2802%2900031-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1570-677X%252802%252900031-X%26sid%3Dliteratum%253Aachs%26aulast%3DLichtenberg%26aufirst%3DF.%2BR.%26atitle%3DThe%2520effect%2520of%2520new%2520drug%2520approvals%2520on%2520HIV%2520mortality%2520in%2520the%2520US%252C%25201987%25E2%2580%25931998%26jtitle%3DEconomics%2520Human%2520Biol.%26date%3D2003%26volume%3D1%26spage%3D259%26epage%3D266%26doi%3D10.1016%2FS1570-677X%2802%2900031-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Maartens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celum, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewin, S. R.</span><span> </span><span class="NLM_article-title">HIV infection: epidemiology, pathogenesis, treatment, and prevention</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">384</span><span class="NLM_x">, </span> <span class="NLM_fpage">258</span><span class="NLM_x">–</span> <span class="NLM_lpage">271</span><span class="refDoi"> DOI: 10.1016/S0140-6736(14)60164-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0140-6736%2814%2960164-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24907868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC2cfgt1amuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2014&pages=258-271&author=G.+Maartensauthor=C.+Celumauthor=S.+R.+Lewin&title=HIV+infection%3A+epidemiology%2C+pathogenesis%2C+treatment%2C+and+prevention&doi=10.1016%2FS0140-6736%2814%2960164-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">HIV infection: epidemiology, pathogenesis, treatment, and prevention</span></div><div class="casAuthors">Maartens Gary; Celum Connie; Lewin Sharon R</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">384</span>
        (<span class="NLM_cas:issue">9939</span>),
    <span class="NLM_cas:pages">258-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">HIV prevalence is increasing worldwide because people on antiretroviral therapy are living longer, although new infections decreased from 3.3 million in 2002, to 2.3 million in 2012.  Global AIDS-related deaths peaked at 2.3 million in 2005, and decreased to 1.6 million by 2012.  An estimated 9.7 million people in low-income and middle-income countries had started antiretroviral therapy by 2012.  New insights into the mechanisms of latent infection and the importance of reservoirs of infection might eventually lead to a cure.  The role of immune activation in the pathogenesis of non-AIDS clinical events (major causes of morbidity and mortality in people on antiretroviral therapy) is receiving increased recognition.  Breakthroughs in the prevention of HIV important to public health include male medical circumcision, antiretrovirals to prevent mother-to-child transmission, antiretroviral therapy in people with HIV to prevent transmission, and antiretrovirals for pre-exposure prophylaxis.  Research into other prevention interventions, notably vaccines and vaginal microbicides, is in progress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQfcH_dOE8ahDDnmmyUf5qOfW6udTcc2eZpXCnLVy7rarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfgt1amuw%253D%253D&md5=1ef5b9d6369e3a5865a8d0eaa4757345</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2960164-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252960164-1%26sid%3Dliteratum%253Aachs%26aulast%3DMaartens%26aufirst%3DG.%26aulast%3DCelum%26aufirst%3DC.%26aulast%3DLewin%26aufirst%3DS.%2BR.%26atitle%3DHIV%2520infection%253A%2520epidemiology%252C%2520pathogenesis%252C%2520treatment%252C%2520and%2520prevention%26jtitle%3DLancet%26date%3D2014%26volume%3D384%26spage%3D258%26epage%3D271%26doi%3D10.1016%2FS0140-6736%2814%2960164-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Deeks, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewin, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havlir, D. V.</span><span> </span><span class="NLM_article-title">The end of AIDS: HIV infection as a chronic disease</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">382</span><span class="NLM_x">, </span> <span class="NLM_fpage">1525</span><span class="NLM_x">–</span> <span class="NLM_lpage">1533</span><span class="refDoi"> DOI: 10.1016/S0140-6736(13)61809-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0140-6736%2813%2961809-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2013&pages=1525-1533&author=S.+G.+Deeksauthor=S.+R.+Lewinauthor=D.+V.+Havlir&title=The+end+of+AIDS%3A+HIV+infection+as+a+chronic+disease&doi=10.1016%2FS0140-6736%2813%2961809-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2813%2961809-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252813%252961809-7%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DS.%2BG.%26aulast%3DLewin%26aufirst%3DS.%2BR.%26aulast%3DHavlir%26aufirst%3DD.%2BV.%26atitle%3DThe%2520end%2520of%2520AIDS%253A%2520HIV%2520infection%2520as%2520a%2520chronic%2520disease%26jtitle%3DLancet%26date%3D2013%26volume%3D382%26spage%3D1525%26epage%3D1533%26doi%3D10.1016%2FS0140-6736%2813%2961809-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Günthard, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aberg, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eron, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoy, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Telenti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glesby, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saag, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volberding, P. A.</span><span> </span><span class="NLM_article-title">International Antiviral Society-USA Panel. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">410</span><span class="NLM_x">–</span> <span class="NLM_lpage">425</span><span class="refDoi"> DOI: 10.1001/jama.2014.8722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1001%2Fjama.2014.8722" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2014&pages=410-425&author=H.+F.+G%C3%BCnthardauthor=J.+A.+Abergauthor=J.+J.+Eronauthor=J.+F.+Hoyauthor=A.+Telentiauthor=C.+A.+Bensonauthor=D.+M.+Burgerauthor=P.+Cahnauthor=J.+E.+Gallantauthor=M.+J.+Glesbyauthor=P.+Reissauthor=M.+S.+Saagauthor=D.+L.+Thomasauthor=D.+M.+Jacobsenauthor=P.+A.+Volberding&title=International+Antiviral+Society-USA+Panel.+Antiretroviral+treatment+of+adult+HIV+infection%3A+2014+recommendations+of+the+International+Antiviral+Society-USA+Panel&doi=10.1001%2Fjama.2014.8722"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1001%2Fjama.2014.8722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2014.8722%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnthard%26aufirst%3DH.%2BF.%26aulast%3DAberg%26aufirst%3DJ.%2BA.%26aulast%3DEron%26aufirst%3DJ.%2BJ.%26aulast%3DHoy%26aufirst%3DJ.%2BF.%26aulast%3DTelenti%26aufirst%3DA.%26aulast%3DBenson%26aufirst%3DC.%2BA.%26aulast%3DBurger%26aufirst%3DD.%2BM.%26aulast%3DCahn%26aufirst%3DP.%26aulast%3DGallant%26aufirst%3DJ.%2BE.%26aulast%3DGlesby%26aufirst%3DM.%2BJ.%26aulast%3DReiss%26aufirst%3DP.%26aulast%3DSaag%26aufirst%3DM.%2BS.%26aulast%3DThomas%26aufirst%3DD.%2BL.%26aulast%3DJacobsen%26aufirst%3DD.%2BM.%26aulast%3DVolberding%26aufirst%3DP.%2BA.%26atitle%3DInternational%2520Antiviral%2520Society-USA%2520Panel.%2520Antiretroviral%2520treatment%2520of%2520adult%2520HIV%2520infection%253A%25202014%2520recommendations%2520of%2520the%2520International%2520Antiviral%2520Society-USA%2520Panel%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2014%26volume%3D312%26spage%3D410%26epage%3D425%26doi%3D10.1001%2Fjama.2014.8722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dienstag, J. L.</span><span> </span><span class="NLM_article-title">Hepatitis B virus infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">359</span><span class="NLM_x">, </span> <span class="NLM_fpage">1486</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span><span class="refDoi"> DOI: 10.1056/NEJMra0801644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMra0801644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=18832247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFOru7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2008&pages=1486-1500&author=J.+L.+Dienstag&title=Hepatitis+B+virus+infection&doi=10.1056%2FNEJMra0801644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B virus infection</span></div><div class="casAuthors">Dienstag, Jules L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1486-1500</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review with refs. on drug therapy of chronic hepatitis B, its co-infection with HIV viral infection, mono- and combination therapy and overcoming antiviral resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5ybm-V9V7urVg90H21EOLACvtfcHk0ljHJ5MybS_2Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFOru7bL&md5=e4ca2dbdb0fa268fa483eb7b77cf4643</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0801644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0801644%26sid%3Dliteratum%253Aachs%26aulast%3DDienstag%26aufirst%3DJ.%2BL.%26atitle%3DHepatitis%2520B%2520virus%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D359%26spage%3D1486%26epage%3D1500%26doi%3D10.1056%2FNEJMra0801644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tang, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yau, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span> </span><span class="NLM_article-title">Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">6262</span><span class="NLM_x">–</span> <span class="NLM_lpage">6278</span><span class="refDoi"> DOI: 10.3748/wjg.v20.i20.6262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.3748%2Fwjg.v20.i20.6262" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=6262-6278&author=C.-M.+Tangauthor=T.+O.+Yauauthor=J.+Yu&title=Management+of+chronic+hepatitis+B+infection%3A+current+treatment+guidelines%2C+challenges%2C+and+new+developments&doi=10.3748%2Fwjg.v20.i20.6262"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v20.i20.6262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v20.i20.6262%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DC.-M.%26aulast%3DYau%26aufirst%3DT.%2BO.%26aulast%3DYu%26aufirst%3DJ.%26atitle%3DManagement%2520of%2520chronic%2520hepatitis%2520B%2520infection%253A%2520current%2520treatment%2520guidelines%252C%2520challenges%252C%2520and%2520new%2520developments%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2014%26volume%3D20%26spage%3D6262%26epage%3D6278%26doi%3D10.3748%2Fwjg.v20.i20.6262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selwyn, P. A.</span><span> </span><span class="NLM_article-title">Complications of HIV infection: a systems-based approach</span> <span class="citation_source-journal">Am. Fam. Physician</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">406</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2011&pages=395-406&author=C.+Chuauthor=P.+A.+Selwyn&title=Complications+of+HIV+infection%3A+a+systems-based+approach"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DC.%26aulast%3DSelwyn%26aufirst%3DP.%2BA.%26atitle%3DComplications%2520of%2520HIV%2520infection%253A%2520a%2520systems-based%2520approach%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2011%26volume%3D83%26spage%3D395%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rockstroh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guaraldi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deray, G.</span><span> </span><span class="NLM_article-title">HIV and the body: a review of multidisciplinary management</span> <span class="citation_source-journal">HIV Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.1111/j.1468-1293.2010.00859.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fj.1468-1293.2010.00859.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1-8&issue=Suppl.+2&author=J.+Rockstrohauthor=G.+Guaraldiauthor=G.+Deray&title=HIV+and+the+body%3A+a+review+of+multidisciplinary+management&doi=10.1111%2Fj.1468-1293.2010.00859.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1111%2Fj.1468-1293.2010.00859.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1468-1293.2010.00859.x%26sid%3Dliteratum%253Aachs%26aulast%3DRockstroh%26aufirst%3DJ.%26aulast%3DGuaraldi%26aufirst%3DG.%26aulast%3DDeray%26aufirst%3DG.%26atitle%3DHIV%2520and%2520the%2520body%253A%2520a%2520review%2520of%2520multidisciplinary%2520management%26jtitle%3DHIV%2520Med.%26date%3D2010%26volume%3D11%26issue%3DSuppl.%25202%26spage%3D1%26epage%3D8%26doi%3D10.1111%2Fj.1468-1293.2010.00859.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Brown, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glesby, M. J.</span><span> </span><span class="NLM_article-title">Management of the metabolic effects of HIV and HIV drugs</span> <span class="citation_source-journal">Nat. Rev. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1038/nrendo.2011.151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrendo.2011.151" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=11-21&author=T.+T.+Brownauthor=M.+J.+Glesby&title=Management+of+the+metabolic+effects+of+HIV+and+HIV+drugs&doi=10.1038%2Fnrendo.2011.151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2011.151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2011.151%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DT.%2BT.%26aulast%3DGlesby%26aufirst%3DM.%2BJ.%26atitle%3DManagement%2520of%2520the%2520metabolic%2520effects%2520of%2520HIV%2520and%2520HIV%2520drugs%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2011%26volume%3D8%26spage%3D11%26epage%3D21%26doi%3D10.1038%2Fnrendo.2011.151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Kitahata, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gange, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merriman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saag, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justice, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deeks, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eron, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rourke, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosch, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sterling, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Napravnik, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rachlis, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calzavara, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horberg, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverberg, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebo, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goedert, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Rompaey, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crane, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKaig, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, R. D.</span><span> </span><span class="NLM_article-title">NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">360</span><span class="NLM_x">, </span> <span class="NLM_fpage">1815</span><span class="NLM_x">–</span> <span class="NLM_lpage">1826</span><span class="refDoi"> DOI: 10.1056/NEJMoa0807252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa0807252" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=1815-1826&author=M.+M.+Kitahataauthor=S.+J.+Gangeauthor=A.+G.+Abrahamauthor=B.+Merrimanauthor=M.+S.+Saagauthor=A.+C.+Justiceauthor=R.+S.+Hoggauthor=S.+G.+Deeksauthor=J.+J.+Eronauthor=J.+T.+Brooksauthor=S.+B.+Rourkeauthor=M.+J.+Gillauthor=R.+J.+Boschauthor=J.+N.+Martinauthor=M.+B.+Kleinauthor=L.+P.+Jacobsonauthor=B.+Rodriguezauthor=T.+R.+Sterlingauthor=G.+D.+Kirkauthor=S.+Napravnikauthor=A.+R.+Rachlisauthor=L.+M.+Calzavaraauthor=M.+A.+Horbergauthor=M.+J.+Silverbergauthor=K.+A.+Geboauthor=J.+J.+Goedertauthor=C.+A.+Bensonauthor=A.+C.+Collierauthor=S.+E.+Van+Rompaeyauthor=H.+M.+Craneauthor=R.+G.+McKaigauthor=B.+Lauauthor=A.+M.+Freemanauthor=R.+D.+Moore&title=NA-ACCORD+Investigators.+Effect+of+early+versus+deferred+antiretroviral+therapy+for+HIV+on+survival&doi=10.1056%2FNEJMoa0807252"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0807252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0807252%26sid%3Dliteratum%253Aachs%26aulast%3DKitahata%26aufirst%3DM.%2BM.%26aulast%3DGange%26aufirst%3DS.%2BJ.%26aulast%3DAbraham%26aufirst%3DA.%2BG.%26aulast%3DMerriman%26aufirst%3DB.%26aulast%3DSaag%26aufirst%3DM.%2BS.%26aulast%3DJustice%26aufirst%3DA.%2BC.%26aulast%3DHogg%26aufirst%3DR.%2BS.%26aulast%3DDeeks%26aufirst%3DS.%2BG.%26aulast%3DEron%26aufirst%3DJ.%2BJ.%26aulast%3DBrooks%26aufirst%3DJ.%2BT.%26aulast%3DRourke%26aufirst%3DS.%2BB.%26aulast%3DGill%26aufirst%3DM.%2BJ.%26aulast%3DBosch%26aufirst%3DR.%2BJ.%26aulast%3DMartin%26aufirst%3DJ.%2BN.%26aulast%3DKlein%26aufirst%3DM.%2BB.%26aulast%3DJacobson%26aufirst%3DL.%2BP.%26aulast%3DRodriguez%26aufirst%3DB.%26aulast%3DSterling%26aufirst%3DT.%2BR.%26aulast%3DKirk%26aufirst%3DG.%2BD.%26aulast%3DNapravnik%26aufirst%3DS.%26aulast%3DRachlis%26aufirst%3DA.%2BR.%26aulast%3DCalzavara%26aufirst%3DL.%2BM.%26aulast%3DHorberg%26aufirst%3DM.%2BA.%26aulast%3DSilverberg%26aufirst%3DM.%2BJ.%26aulast%3DGebo%26aufirst%3DK.%2BA.%26aulast%3DGoedert%26aufirst%3DJ.%2BJ.%26aulast%3DBenson%26aufirst%3DC.%2BA.%26aulast%3DCollier%26aufirst%3DA.%2BC.%26aulast%3DVan%2BRompaey%26aufirst%3DS.%2BE.%26aulast%3DCrane%26aufirst%3DH.%2BM.%26aulast%3DMcKaig%26aufirst%3DR.%2BG.%26aulast%3DLau%26aufirst%3DB.%26aulast%3DFreeman%26aufirst%3DA.%2BM.%26aulast%3DMoore%26aufirst%3DR.%2BD.%26atitle%3DNA-ACCORD%2520Investigators.%2520Effect%2520of%2520early%2520versus%2520deferred%2520antiretroviral%2520therapy%2520for%2520HIV%2520on%2520survival%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D1815%26epage%3D1826%26doi%3D10.1056%2FNEJMoa0807252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ahmed, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eltayebi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyrrell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barakat, K.</span><span> </span><span class="NLM_article-title">Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">548</span><span class="NLM_x">–</span> <span class="NLM_lpage">561</span><span class="refDoi"> DOI: 10.1016/j.drudis.2015.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.drudis.2015.01.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=548-561&author=M.+Ahmedauthor=F.+Wangauthor=A.+Levinauthor=C.+Leauthor=Y.+Eltayebiauthor=M.+Houghtonauthor=L.+Tyrrellauthor=K.+Barakat&title=Targeting+the+Achilles+heel+of+the+hepatitis+B+virus%3A+a+review+of+current+treatments+against+covalently+closed+circular+DNA&doi=10.1016%2Fj.drudis.2015.01.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DAhmed%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLevin%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DC.%26aulast%3DEltayebi%26aufirst%3DY.%26aulast%3DHoughton%26aufirst%3DM.%26aulast%3DTyrrell%26aufirst%3DL.%26aulast%3DBarakat%26aufirst%3DK.%26atitle%3DTargeting%2520the%2520Achilles%2520heel%2520of%2520the%2520hepatitis%2520B%2520virus%253A%2520a%2520review%2520of%2520current%2520treatments%2520against%2520covalently%2520closed%2520circular%2520DNA%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D548%26epage%3D561%26doi%3D10.1016%2Fj.drudis.2015.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lucifora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protzer, U.</span><span> </span><span class="NLM_article-title">Attacking hepatitis B virus cccDNA-the holy grail to hepatitis B cure</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x"> (</span><span class="NLM_issue">1 Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">S41</span><span class="NLM_x">–</span> <span class="NLM_lpage">S48</span><span class="refDoi"> DOI: 10.1016/j.jhep.2016.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2016.02.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=S41-S48&issue=1+Suppl.&author=J.+Luciforaauthor=U.+Protzer&title=Attacking+hepatitis+B+virus+cccDNA-the+holy+grail+to+hepatitis+B+cure&doi=10.1016%2Fj.jhep.2016.02.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2016.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2016.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DProtzer%26aufirst%3DU.%26atitle%3DAttacking%2520hepatitis%2520B%2520virus%2520cccDNA-the%2520holy%2520grail%2520to%2520hepatitis%2520B%2520cure%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D64%26issue%3D1%2520Suppl%26spage%3DS41%26epage%3DS48%26doi%3D10.1016%2Fj.jhep.2016.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Levrero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollicino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belloni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raimondo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandri, M.</span><span> </span><span class="NLM_article-title">Control of cccDNA function in hepatitis B virus infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">592</span><span class="refDoi"> DOI: 10.1016/j.jhep.2009.05.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2009.05.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=19616338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFyhs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2009&pages=581-592&author=M.+Levreroauthor=T.+Pollicinoauthor=J.+Petersenauthor=L.+Belloniauthor=G.+Raimondoauthor=M.+Dandri&title=Control+of+cccDNA+function+in+hepatitis+B+virus+infection&doi=10.1016%2Fj.jhep.2009.05.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Control of cccDNA function in hepatitis B virus infection</span></div><div class="casAuthors">Levrero, Massimo; Pollicino, Teresa; Petersen, Jorg; Belloni, Laura; Raimondo, Giovanni; Dandri, Maura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">581-592</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The template of hepatitis B virus (HBV) transcription, the covalently closed circular DNA (cccDNA), plays a key role in the life cycle of the virus and permits the persistence of infection.  Novel mol. techniques have opened new possibilities to investigate the organization and the activity of the cccDNA minichromosome in vivo, and recent advances have started to shed light on the complexity of the mechanisms controlling cccDNA function.  Nuclear cccDNA accumulates in hepatocyte nuclei as a stable minichromosome organized by histone and non-histone viral and cellular proteins.  Identification of the mol. mechanisms regulating cccDNA stability and its transcriptional activity at the RNA, DNA and epigenetic levels in the course of chronic hepatitis B (CH-B) infection may reveal new potential therapeutic targets for anti-HBV drugs and hence assist in the design of strategies aimed at silencing and eventually depleting the cccDNA reservoir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo04ONkDq_te7Vg90H21EOLACvtfcHk0ljifSsrnddaAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFyhs7k%253D&md5=365616a92ba84ddc3cf7835162d3d900</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2009.05.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2009.05.022%26sid%3Dliteratum%253Aachs%26aulast%3DLevrero%26aufirst%3DM.%26aulast%3DPollicino%26aufirst%3DT.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DBelloni%26aufirst%3DL.%26aulast%3DRaimondo%26aufirst%3DG.%26aulast%3DDandri%26aufirst%3DM.%26atitle%3DControl%2520of%2520cccDNA%2520function%2520in%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2009%26volume%3D51%26spage%3D581%26epage%3D592%26doi%3D10.1016%2Fj.jhep.2009.05.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Rehermann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nascimbeni, M.</span><span> </span><span class="NLM_article-title">Immunology of hepatitis B virus and hepatitis C virus infection</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span><span class="refDoi"> DOI: 10.1038/nri1573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnri1573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=15738952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslSju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=215-229&author=B.+Rehermannauthor=M.+Nascimbeni&title=Immunology+of+hepatitis+B+virus+and+hepatitis+C+virus+infection&doi=10.1038%2Fnri1573"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7dR"><div class="casContent"><span class="casTitleNuber">7d</span><div class="casTitle"><span class="NLM_cas:atitle">Immunology of hepatitis B virus and hepatitis C virus infection</span></div><div class="casAuthors">Rehermann, Barbara; Nascimbeni, Michelina</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-229</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  More than 500 million people worldwide are persistently infected with the hepatitis B virus (HBV) and/or hepatitis C virus (HCV) and are at risk of developing chronic liver disease, cirrhosis and hepatocellular carcinoma.  Despite many common features in the pathogenesis of HBV- and HCV-related liver disease, these viruses markedly differ in their virol. properties and in their immune escape and survival strategies.  This review assesses recent advances in our understanding of viral hepatitis, contrasts mechanisms of virus-host interaction in acute hepatitis B and hepatitis C, and outlines areas for future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK_aXbF6__BLVg90H21EOLACvtfcHk0liuGm_fWDWxUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslSju7k%253D&md5=d9ceed9473106d0f31fade725d16c1a6</span></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=10.1038%2Fnri1573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1573%26sid%3Dliteratum%253Aachs%26aulast%3DRehermann%26aufirst%3DB.%26aulast%3DNascimbeni%26aufirst%3DM.%26atitle%3DImmunology%2520of%2520hepatitis%2520B%2520virus%2520and%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2005%26volume%3D5%26spage%3D215%26epage%3D229%26doi%3D10.1038%2Fnri1573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dahabieh, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battivelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdin, E.</span><span> </span><span class="NLM_article-title">Understanding HIV latency: the road to an HIV cure</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span><span class="refDoi"> DOI: 10.1146/annurev-med-092112-152941</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1146%2Fannurev-med-092112-152941" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2015&pages=407-421&author=M.+S.+Dahabiehauthor=E.+Battivelliauthor=E.+Verdin&title=Understanding+HIV+latency%3A+the+road+to+an+HIV+cure&doi=10.1146%2Fannurev-med-092112-152941"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-092112-152941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-092112-152941%26sid%3Dliteratum%253Aachs%26aulast%3DDahabieh%26aufirst%3DM.%2BS.%26aulast%3DBattivelli%26aufirst%3DE.%26aulast%3DVerdin%26aufirst%3DE.%26atitle%3DUnderstanding%2520HIV%2520latency%253A%2520the%2520road%2520to%2520an%2520HIV%2520cure%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2015%26volume%3D66%26spage%3D407%26epage%3D421%26doi%3D10.1146%2Fannurev-med-092112-152941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Passaes, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sáez-Cirión, A.</span><span> </span><span class="NLM_article-title">HIV cure research: advances and prospects</span> <span class="citation_source-journal">Virology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">454–455</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span><span class="refDoi"> DOI: 10.1016/j.virol.2014.02.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.virol.2014.02.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=454%E2%80%93455&publication_year=2014&pages=340-352&author=C.+P.+Passaesauthor=A.+S%C3%A1ez-Ciri%C3%B3n&title=HIV+cure+research%3A+advances+and+prospects&doi=10.1016%2Fj.virol.2014.02.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2014.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2014.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DPassaes%26aufirst%3DC.%2BP.%26aulast%3DS%25C3%25A1ez-Ciri%25C3%25B3n%26aufirst%3DA.%26atitle%3DHIV%2520cure%2520research%253A%2520advances%2520and%2520prospects%26jtitle%3DVirology%26date%3D2014%26volume%3D454%25E2%2580%2593455%26spage%3D340%26epage%3D352%26doi%3D10.1016%2Fj.virol.2014.02.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Spivak, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planelles, V.</span><span> </span><span class="NLM_article-title">HIV-1 eradication: early trials (and tribulations)</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">10</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1016/j.molmed.2015.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.molmed.2015.11.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=10-27&author=A.+M.+Spivakauthor=V.+Planelles&title=HIV-1+eradication%3A+early+trials+%28and+tribulations%29&doi=10.1016%2Fj.molmed.2015.11.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2015.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2015.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DSpivak%26aufirst%3DA.%2BM.%26aulast%3DPlanelles%26aufirst%3DV.%26atitle%3DHIV-1%2520eradication%253A%2520early%2520trials%2520%2528and%2520tribulations%2529%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2016%26volume%3D22%26spage%3D10%26epage%3D27%26doi%3D10.1016%2Fj.molmed.2015.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lucifora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepo, C.</span><span> </span><span class="NLM_article-title">Hepatitis: after HCV cure, HBV cure?</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">376</span><span class="NLM_x">–</span> <span class="NLM_lpage">378</span><span class="refDoi"> DOI: 10.1038/nrgastro.2015.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrgastro.2015.103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=376-378&author=J.+Luciforaauthor=C.+Trepo&title=Hepatitis%3A+after+HCV+cure%2C+HBV+cure%3F&doi=10.1038%2Fnrgastro.2015.103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2015.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2015.103%26sid%3Dliteratum%253Aachs%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DTrepo%26aufirst%3DC.%26atitle%3DHepatitis%253A%2520after%2520HCV%2520cure%252C%2520HBV%2520cure%253F%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2015%26volume%3D12%26spage%3D376%26epage%3D378%26doi%3D10.1038%2Fnrgastro.2015.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Revill, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testoni, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locarnini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoulim, F.</span><span> </span><span class="NLM_article-title">Global strategies are required to cure and eliminate HBV infection</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">239</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span><span class="refDoi"> DOI: 10.1038/nrgastro.2016.7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrgastro.2016.7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=239-248&author=P.+Revillauthor=B.+Testoniauthor=S.+Locarniniauthor=F.+Zoulim&title=Global+strategies+are+required+to+cure+and+eliminate+HBV+infection&doi=10.1038%2Fnrgastro.2016.7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2016.7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2016.7%26sid%3Dliteratum%253Aachs%26aulast%3DRevill%26aufirst%3DP.%26aulast%3DTestoni%26aufirst%3DB.%26aulast%3DLocarnini%26aufirst%3DS.%26aulast%3DZoulim%26aufirst%3DF.%26atitle%3DGlobal%2520strategies%2520are%2520required%2520to%2520cure%2520and%2520eliminate%2520HBV%2520infection%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2016%26volume%3D13%26spage%3D239%26epage%3D248%26doi%3D10.1038%2Fnrgastro.2016.7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Zeisel, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucifora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sureau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beck, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levrero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knolle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benkirane, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durantel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Autran, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosset, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strick-Marchand, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trépo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrat, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacombe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schinazi, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barré-Sinoussi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delfraissy, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoulim, F.</span><span> </span><span class="NLM_article-title">Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">1314</span><span class="NLM_x">–</span> <span class="NLM_lpage">1326</span><span class="refDoi"> DOI: 10.1136/gutjnl-2014-308943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1136%2Fgutjnl-2014-308943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25670809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVCrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=1314-1326&author=M.+B.+Zeiselauthor=J.+Luciforaauthor=W.+S.+Masonauthor=C.+Sureauauthor=J.+Beckauthor=M.+Levreroauthor=M.+Kannauthor=P.+A.+Knolleauthor=M.+Benkiraneauthor=D.+Durantelauthor=M.+L.+Michelauthor=B.+Autranauthor=F.+L.+Cossetauthor=H.+Strick-Marchandauthor=C.+Tr%C3%A9poauthor=J.+H.+Kaoauthor=F.+Carratauthor=K.+Lacombeauthor=R.+F.+Schinaziauthor=F.+Barr%C3%A9-Sinoussiauthor=J.+F.+Delfraissyauthor=F.+Zoulim&title=Towards+an+HBV+cure%3A+state-of-the-art+and+unresolved+questions%2D%2Dreport+of+the+ANRS+workshop+on+HBV+cure&doi=10.1136%2Fgutjnl-2014-308943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9cR"><div class="casContent"><span class="casTitleNuber">9c</span><div class="casTitle"><span class="NLM_cas:atitle">Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure</span></div><div class="casAuthors">Zeisel, Mirjam B.; Lucifora, Julie; Mason, William S.; Sureau, Camille; Beck, Jurgen; Levrero, Massimo; Kann, Michael; Knolle, Percy A.; Benkirane, Monsef; Durantel, David; Michel, Marie-Louise; Autran, Brigitte; Cosset, Francois-Loic; Strick-Marchand, Helene; Trepo, Christian; Kao, Jia-Horng; Carrat, Fabrice; Lacombe, Karine; Schinazi, Raymond F.; Barre-Sinoussi, Francoise; Delfraissy, Jean-Francois; Zoulim, Fabien</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1314-1326</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma.  Although HBV infection can be efficiently prevented by vaccination, and treatments are available, to date there is no reliable cure for the >240 million individuals that are chronically infected worldwide.  Current treatments can only achieve viral suppression, and lifelong therapy is needed in the majority of infected persons.  In the framework of the French National Agency for Research on AIDS and Viral Hepatitis 'HBV Cure' program, a scientific workshop was held in Paris in June 2014 to define the state-ofthe- art and unanswered questions regarding HBV pathobiol., and to develop a concerted strategy towards an HBV cure.  This review summarizes our current understanding of HBV host-interactions leading to viral persistence, as well as the roadblocks to be overcome to ultimately address unmet medical needs in the treatment of chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq3d3BmB6kC7Vg90H21EOLACvtfcHk0liVs0Cx2vYu7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVCrt7g%253D&md5=3fb4876ea829381ac9fbf8f9f3deeda7</span></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2014-308943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2014-308943%26sid%3Dliteratum%253Aachs%26aulast%3DZeisel%26aufirst%3DM.%2BB.%26aulast%3DLucifora%26aufirst%3DJ.%26aulast%3DMason%26aufirst%3DW.%2BS.%26aulast%3DSureau%26aufirst%3DC.%26aulast%3DBeck%26aufirst%3DJ.%26aulast%3DLevrero%26aufirst%3DM.%26aulast%3DKann%26aufirst%3DM.%26aulast%3DKnolle%26aufirst%3DP.%2BA.%26aulast%3DBenkirane%26aufirst%3DM.%26aulast%3DDurantel%26aufirst%3DD.%26aulast%3DMichel%26aufirst%3DM.%2BL.%26aulast%3DAutran%26aufirst%3DB.%26aulast%3DCosset%26aufirst%3DF.%2BL.%26aulast%3DStrick-Marchand%26aufirst%3DH.%26aulast%3DTr%25C3%25A9po%26aufirst%3DC.%26aulast%3DKao%26aufirst%3DJ.%2BH.%26aulast%3DCarrat%26aufirst%3DF.%26aulast%3DLacombe%26aufirst%3DK.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DBarr%25C3%25A9-Sinoussi%26aufirst%3DF.%26aulast%3DDelfraissy%26aufirst%3DJ.%2BF.%26aulast%3DZoulim%26aufirst%3DF.%26atitle%3DTowards%2520an%2520HBV%2520cure%253A%2520state-of-the-art%2520and%2520unresolved%2520questions--report%2520of%2520the%2520ANRS%2520workshop%2520on%2520HBV%2520cure%26jtitle%3DGut%26date%3D2015%26volume%3D64%26spage%3D1314%26epage%3D1326%26doi%3D10.1136%2Fgutjnl-2014-308943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Nassal, M.</span><span> </span><span class="NLM_article-title">HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">1972</span><span class="NLM_x">–</span> <span class="NLM_lpage">1984</span><span class="refDoi"> DOI: 10.1136/gutjnl-2015-309809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1136%2Fgutjnl-2015-309809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26048673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvVSrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=1972-1984&author=M.+Nassal&title=HBV+cccDNA%3A+viral+persistence+reservoir+and+key+obstacle+for+a+cure+of+chronic+hepatitis+B&doi=10.1136%2Fgutjnl-2015-309809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9dR"><div class="casContent"><span class="casTitleNuber">9d</span><div class="casTitle"><span class="NLM_cas:atitle">HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B</span></div><div class="casAuthors">Nassal, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1972-1984</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">At least 250 million people worldwide are chronically infected with HBV, a small hepatotropic DNA virus that replicates through reverse transcription.  Chronic infection greatly increases the risk for terminal liver disease.  Current therapies rarely achieve a cure due to the refractory nature of an intracellular viral replication intermediate termed covalently closed circular (ccc) DNA.  Upon infection, cccDNA is generated as a plasmid-like episome in the host cell nucleus from the protein-linked relaxed circular (RC) DNA genome in incoming virions.  Its fundamental role is that as template for all viral RNAs, and in consequence new virions.  Biosynthesis of RC-DNA by reverse transcription of the viral pregenomic RNA is now understood in considerable detail, yet conversion of RC-DNA to cccDNA is still obscure, foremostly due to the lack of feasible, cccDNA-dependent assay systems.  Conceptual and recent exptl. data link cccDNA formation to cellular DNA repair, which is increasingly appreciated as a crit. interface between cells and viruses.  Together with new in vitro HBV infection systems, based on the identification of the bile acid transporter sodium taurocholate cotransporting polypeptide as an HBV entry receptor, this offers novel opportunities to decipher, and eventually interfere with, formation of the HBV persistence reservoir.  After a brief overview of the role of cccDNA in the HBV infectious cycle, this review aims to summarize current knowledge on cccDNA mol. biol., to highlight the exptl. restrictions that have hitherto hampered faster progress and to discuss cccDNA as target for new, potentially curative therapies of chronic hepatitis B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQaHzOzO1JXLVg90H21EOLACvtfcHk0liOQJ866kciuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvVSrsbg%253D&md5=7cbbbccef38636fd9bbcae0a9b869bc9</span></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2015-309809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2015-309809%26sid%3Dliteratum%253Aachs%26aulast%3DNassal%26aufirst%3DM.%26atitle%3DHBV%2520cccDNA%253A%2520viral%2520persistence%2520reservoir%2520and%2520key%2520obstacle%2520for%2520a%2520cure%2520of%2520chronic%2520hepatitis%2520B%26jtitle%3DGut%26date%3D2015%26volume%3D64%26spage%3D1972%26epage%3D1984%26doi%3D10.1136%2Fgutjnl-2015-309809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Dusheiko, G.</span><span> </span><span class="NLM_article-title">Towards the elimination and eradication of hepatitis B</span> <span class="citation_source-journal">J. Virus Eradication</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=4-12&author=G.+Dusheiko&title=Towards+the+elimination+and+eradication+of+hepatitis+B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDusheiko%26aufirst%3DG.%26atitle%3DTowards%2520the%2520elimination%2520and%2520eradication%2520of%2520hepatitis%2520B%26jtitle%3DJ.%2520Virus%2520Eradication%26date%3D2015%26volume%3D1%26spage%3D4%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Zoulim, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durantel, D.</span><span> </span><span class="NLM_article-title">Antiviral therapies and prospects for a cure of chronic hepatitis B</span> <span class="citation_source-journal">Cold Spring Harbor Perspect. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">a021501</span><span class="refDoi"> DOI: 10.1101/cshperspect.a021501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1101%2Fcshperspect.a021501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25833942" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=a021501&author=F.+Zoulimauthor=D.+Durantel&title=Antiviral+therapies+and+prospects+for+a+cure+of+chronic+hepatitis+B&doi=10.1101%2Fcshperspect.a021501"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9f&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a021501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a021501%26sid%3Dliteratum%253Aachs%26aulast%3DZoulim%26aufirst%3DF.%26aulast%3DDurantel%26aufirst%3DD.%26atitle%3DAntiviral%2520therapies%2520and%2520prospects%2520for%2520a%2520cure%2520of%2520chronic%2520hepatitis%2520B%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2015%26volume%3D5%26spage%3Da021501%26doi%3D10.1101%2Fcshperspect.a021501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Choo, Q. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overby, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, M.</span><span> </span><span class="NLM_article-title">Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">244</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span><span class="refDoi"> DOI: 10.1126/science.2523562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1126%2Fscience.2523562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=2523562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaL1MXit1Khtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=1989&pages=359-362&author=Q.+L.+Chooauthor=G.+Kuoauthor=A.+J.+Weinerauthor=L.+R.+Overbyauthor=D.+W.+Bradleyauthor=M.+Houghton&title=Isolation+of+a+cDNA+clone+derived+from+a+blood-borne+non-A%2C+non-B+viral+hepatitis+genome&doi=10.1126%2Fscience.2523562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome</span></div><div class="casAuthors">Choo, Qui Lim; Kuo, George; Weiner, Amy J.; Overby, Lacy R.; Bradley, Daniel W.; Houghton, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">4902</span>),
    <span class="NLM_cas:pages">359-62</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A random-primed cDNA library was constructed from plasma contg. the uncharacterized non-A, non-B hepatitis (NANBH) agent and screened with serum from a patient diagnosed with NANBH.  A cDNA clone was isolated that was shown to encode an antigen assocd. specifically with NANBH infections.  This clone is not derived from host DNA but from an RNA mol. present in NANBH infections that consists of ≥10,000 nucleotides, and that is pos.-stranded with respect to the encoded NANBH antigen.  These data indicate that this clone is derived from the genome of the NANBH agent and are consistent with the agent being similar to the togaviridae or flaviviridae.  This mol. approach should be of great value in the isolation and characterization of other unidentified infectious agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqorpVFx7nEkrVg90H21EOLACvtfcHk0lhvuCrwvVLirA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXit1Khtrk%253D&md5=25161cf212790856dd29d3aaf78f20b8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscience.2523562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.2523562%26sid%3Dliteratum%253Aachs%26aulast%3DChoo%26aufirst%3DQ.%2BL.%26aulast%3DKuo%26aufirst%3DG.%26aulast%3DWeiner%26aufirst%3DA.%2BJ.%26aulast%3DOverby%26aufirst%3DL.%2BR.%26aulast%3DBradley%26aufirst%3DD.%2BW.%26aulast%3DHoughton%26aufirst%3DM.%26atitle%3DIsolation%2520of%2520a%2520cDNA%2520clone%2520derived%2520from%2520a%2520blood-borne%2520non-A%252C%2520non-B%2520viral%2520hepatitis%2520genome%26jtitle%3DScience%26date%3D1989%26volume%3D244%26spage%3D359%26epage%3D362%26doi%3D10.1126%2Fscience.2523562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Trepo, C.</span><span> </span><span class="NLM_article-title">A brief history of hepatitis milestones</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">29</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span><span class="refDoi"> DOI: 10.1111/liv.12409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fliv.12409" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=29-37&issue=Suppl.+1&author=C.+Trepo&title=A+brief+history+of+hepatitis+milestones&doi=10.1111%2Fliv.12409"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fliv.12409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fliv.12409%26sid%3Dliteratum%253Aachs%26aulast%3DTrepo%26aufirst%3DC.%26atitle%3DA%2520brief%2520history%2520of%2520hepatitis%2520milestones%26jtitle%3DLiver%2520Int.%26date%3D2014%26volume%3D34%26issue%3DSuppl.%25201%26spage%3D29%26epage%3D37%26doi%3D10.1111%2Fliv.12409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Houghton, M.</span><span> </span><span class="NLM_article-title">Discovery of the hepatitis C virus</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">82</span><span class="NLM_x">–</span> <span class="NLM_lpage">88</span><span class="refDoi"> DOI: 10.1111/j.1478-3231.2008.01925.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fj.1478-3231.2008.01925.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=82-88&author=M.+Houghton&title=Discovery+of+the+hepatitis+C+virus&doi=10.1111%2Fj.1478-3231.2008.01925.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1111%2Fj.1478-3231.2008.01925.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1478-3231.2008.01925.x%26sid%3Dliteratum%253Aachs%26aulast%3DHoughton%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DLiver%2520Int.%26date%3D2009%26volume%3D29%26spage%3D82%26epage%3D88%26doi%3D10.1111%2Fj.1478-3231.2008.01925.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Houghton, M.</span><span> </span><span class="NLM_article-title">The long and winding road leading to the identification of the hepatitis C virus</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">939</span><span class="NLM_x">–</span> <span class="NLM_lpage">948</span><span class="refDoi"> DOI: 10.1016/j.jhep.2009.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2009.08.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2009&pages=939-948&author=M.+Houghton&title=The+long+and+winding+road+leading+to+the+identification+of+the+hepatitis+C+virus&doi=10.1016%2Fj.jhep.2009.08.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2009.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2009.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DHoughton%26aufirst%3DM.%26atitle%3DThe%2520long%2520and%2520winding%2520road%2520leading%2520to%2520the%2520identification%2520of%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Hepatol.%26date%3D2009%26volume%3D51%26spage%3D939%26epage%3D948%26doi%3D10.1016%2Fj.jhep.2009.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Choo, Q. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallegos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coit, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina-Selby, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, M.</span><span> </span><span class="NLM_article-title">Genetic organization and diversity of the hepatitis C virus</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">2451</span><span class="NLM_x">–</span> <span class="NLM_lpage">2455</span><span class="refDoi"> DOI: 10.1073/pnas.88.6.2451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1073%2Fpnas.88.6.2451" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=2451-2455&author=Q.+L.+Chooauthor=K.+H.+Richmanauthor=J.+H.+Hanauthor=K.+Bergerauthor=C.+Leeauthor=C.+Dongauthor=C.+Gallegosauthor=D.+Coitauthor=R.+Medina-Selbyauthor=P.+J.+Barrauthor=A.+J.+Weinerauthor=D.+W.+Bradleyauthor=G.+Kuoauthor=M.+Houghton&title=Genetic+organization+and+diversity+of+the+hepatitis+C+virus&doi=10.1073%2Fpnas.88.6.2451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.88.6.2451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.88.6.2451%26sid%3Dliteratum%253Aachs%26aulast%3DChoo%26aufirst%3DQ.%2BL.%26aulast%3DRichman%26aufirst%3DK.%2BH.%26aulast%3DHan%26aufirst%3DJ.%2BH.%26aulast%3DBerger%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DGallegos%26aufirst%3DC.%26aulast%3DCoit%26aufirst%3DD.%26aulast%3DMedina-Selby%26aufirst%3DR.%26aulast%3DBarr%26aufirst%3DP.%2BJ.%26aulast%3DWeiner%26aufirst%3DA.%2BJ.%26aulast%3DBradley%26aufirst%3DD.%2BW.%26aulast%3DKuo%26aufirst%3DG.%26aulast%3DHoughton%26aufirst%3DM.%26atitle%3DGenetic%2520organization%2520and%2520diversity%2520of%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1991%26volume%3D88%26spage%3D2451%26epage%3D2455%26doi%3D10.1073%2Fpnas.88.6.2451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Kato, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hijikata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ootsuyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkoshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugimura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimotohno, K.</span><span> </span><span class="NLM_article-title">Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">9524</span><span class="NLM_x">–</span> <span class="NLM_lpage">9528</span><span class="refDoi"> DOI: 10.1073/pnas.87.24.9524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1073%2Fpnas.87.24.9524" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1990&pages=9524-9528&author=N.+Katoauthor=M.+Hijikataauthor=Y.+Ootsuyamaauthor=M.+Nakagawaauthor=S.+Ohkoshiauthor=T.+Sugimuraauthor=K.+Shimotohno&title=Molecular+cloning+of+the+human+hepatitis+C+virus+genome+from+Japanese+patients+with+non-A%2C+non-B+hepatitis&doi=10.1073%2Fpnas.87.24.9524"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.87.24.9524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.87.24.9524%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DN.%26aulast%3DHijikata%26aufirst%3DM.%26aulast%3DOotsuyama%26aufirst%3DY.%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DOhkoshi%26aufirst%3DS.%26aulast%3DSugimura%26aufirst%3DT.%26aulast%3DShimotohno%26aufirst%3DK.%26atitle%3DMolecular%2520cloning%2520of%2520the%2520human%2520hepatitis%2520C%2520virus%2520genome%2520from%2520Japanese%2520patients%2520with%2520non-A%252C%2520non-B%2520hepatitis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1990%26volume%3D87%26spage%3D9524%26epage%3D9528%26doi%3D10.1073%2Fpnas.87.24.9524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Grakoui, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCourt, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wychowski, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinstone, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">2832</span><span class="NLM_x">–</span> <span class="NLM_lpage">2843</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FJVI.67.5.2832-2843.1993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=8386278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK3sXktVClsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1993&pages=2832-2843&author=A.+Grakouiauthor=D.+W.+McCourtauthor=C.+Wychowskiauthor=S.+M.+Feinstoneauthor=C.+M.+Rice&title=Characterization+of+the+hepatitis+C+virus-encoded+serine+proteinase%3A+determination+of+proteinase-dependent+polyprotein+cleavage+sites"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the hepatitis C virus-encoded serine proteinase: Determination of proteinase-dependent polyprotein cleavage sites</span></div><div class="casAuthors">Grakoui, Arash; McCourt, David W.; Wychowski, Czeslaw; Feinstone, Stephen M.; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2832-43</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">Processing of the hepatitis C virus (HCV) H strain polyprotein yields at least nine distinct cleavage products: NH2-C-E1-E2- NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH.  Site-directed mutagenesis and transient expression analyses were used to study the role of a putative serine proteinase domain, located in the N-terminal one-third of the NS3 protein, in proteolytic processing of HCV polyproteins.  All four cleavages which occur C terminal to the proteinase domain (3/4A, 4A/4B, 4B/5A, and 5A/5B) were abolished by substitution of alanine for either of two predicted residues (His-1083 and Ser-1165) in the proteinase catalytic triad.  However, such substitutions have no observable effect on cleavages in the structural region or at the 2/3 site.  Deletion analyses suggest that the structural and NS2 regions of the polyprotein are not required for the HCV NS3 proteinase activity.  NS3 proteinase-dependent cleavage sites were localized by N-terminal sequence anal. of NS4a, NS4B, NS5A, and NS5B.  Sequence comparison of the residues flanking these cleavage sites for all sequenced HCV strains reveals conserved residues which may play a role in detg. HCV NS3 proteinase substrate specificity.  These features include an acidic residue (Asp or Glu) at the P6 position, a Cys or Thr residue at the P1 position, and a Ser or Ala residue at the P1' position.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoXwT-StOiG7Vg90H21EOLACvtfcHk0lhGrtbxwcLqgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktVClsrY%253D&md5=c80cee9b19dfba43766fb0026d566d1d</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1128%2FJVI.67.5.2832-2843.1993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.67.5.2832-2843.1993%26sid%3Dliteratum%253Aachs%26aulast%3DGrakoui%26aufirst%3DA.%26aulast%3DMcCourt%26aufirst%3DD.%2BW.%26aulast%3DWychowski%26aufirst%3DC.%26aulast%3DFeinstone%26aufirst%3DS.%2BM.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DCharacterization%2520of%2520the%2520hepatitis%2520C%2520virus-encoded%2520serine%2520proteinase%253A%2520determination%2520of%2520proteinase-dependent%2520polyprotein%2520cleavage%2520sites%26jtitle%3DJ.%2520Virol.%26date%3D1993%26volume%3D67%26spage%3D2832%26epage%3D2843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahlborn-Laake, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mous, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, H.</span><span> </span><span class="NLM_article-title">Nonstructural protein 3 of the hepatitis C virus encodes a serine type proteinase required for cleavage at the NS3/4 and NS4/5 junctions</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">3835</span><span class="NLM_x">–</span> <span class="NLM_lpage">3844</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1993&pages=3835-3844&author=R.+Bartenschlagerauthor=R.+Ahlborn-Laakeauthor=J.+Mousauthor=H.+Jacobsen&title=Nonstructural+protein+3+of+the+hepatitis+C+virus+encodes+a+serine+type+proteinase+required+for+cleavage+at+the+NS3%2F4+and+NS4%2F5+junctions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBartenschlager%26aufirst%3DR.%26aulast%3DAhlborn-Laake%26aufirst%3DR.%26aulast%3DMous%26aufirst%3DJ.%26aulast%3DJacobsen%26aufirst%3DH.%26atitle%3DNonstructural%2520protein%25203%2520of%2520the%2520hepatitis%2520C%2520virus%2520encodes%2520a%2520serine%2520type%2520proteinase%2520required%2520for%2520cleavage%2520at%2520the%2520NS3%252F4%2520and%2520NS4%252F5%2520junctions%26jtitle%3DJ.%2520Virol.%26date%3D1993%26volume%3D67%26spage%3D3835%26epage%3D3844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Eckart, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selby, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masiarz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, Q. L.</span><span> </span><span class="NLM_article-title">The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">192</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">406</span><span class="refDoi"> DOI: 10.1006/bbrc.1993.1429</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1006%2Fbbrc.1993.1429" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=1993&pages=399-406&author=M.+R.+Eckartauthor=M.+Selbyauthor=F.+Masiarzauthor=C.+Leeauthor=K.+Bergerauthor=K.+Crawfordauthor=C.+Kuoauthor=G.+Kuoauthor=M.+Houghtonauthor=Q.+L.+Choo&title=The+hepatitis+C+virus+encodes+a+serine+protease+involved+in+processing+of+the+putative+nonstructural+proteins+from+the+viral+polyprotein+precursor&doi=10.1006%2Fbbrc.1993.1429"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1993.1429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1993.1429%26sid%3Dliteratum%253Aachs%26aulast%3DEckart%26aufirst%3DM.%2BR.%26aulast%3DSelby%26aufirst%3DM.%26aulast%3DMasiarz%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DBerger%26aufirst%3DK.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DKuo%26aufirst%3DC.%26aulast%3DKuo%26aufirst%3DG.%26aulast%3DHoughton%26aufirst%3DM.%26aulast%3DChoo%26aufirst%3DQ.%2BL.%26atitle%3DThe%2520hepatitis%2520C%2520virus%2520encodes%2520a%2520serine%2520protease%2520involved%2520in%2520processing%2520of%2520the%2520putative%2520nonstructural%2520proteins%2520from%2520the%2520viral%2520polyprotein%2520precursor%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1993%26volume%3D192%26spage%3D399%26epage%3D406%26doi%3D10.1006%2Fbbrc.1993.1429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Hijikata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizushima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakiuchi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimotohno, K.</span><span> </span><span class="NLM_article-title">Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4665</span><span class="NLM_x">–</span> <span class="NLM_lpage">4675</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=8392606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK3sXlsFChsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1993&pages=4665-4675&author=M.+Hijikataauthor=H.+Mizushimaauthor=T.+Akagiauthor=S.+Moriauthor=N.+Kakiuchiauthor=N.+Katoauthor=T.+Tanakaauthor=K.+Kimuraauthor=K.+Shimotohno&title=Two+distinct+proteinase+activities+required+for+the+processing+of+a+putative+nonstructural+precursor+protein+of+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus</span></div><div class="casAuthors">Hijikata, Makoto; Mizushima, Hiroto; Akagi, Tsuyoshi; Mori, Shigehisa; Kakiuchi, Nobuko; Kato, Nobuyuki; Tanaka, Torahiko; Kimura, Koichi; Shimotohno, Kunitada</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4665-75</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">Gene products of hepatitis C virus (HCV), a possible major causative agent of posttransfusion non-A, non-B hepatitis, are considered to be produced from a precursor polyprotein via proteolytic processing mediated by either host cell or viral proteinases.  The presence of HCV serine proteinase has been proposed from analyses of amino acid sequence homol.  To examine the processing mechanism of the HCV precursor polyprotein, the amino-terminal region of the putative nonstructural protein region of the HCV genome, contg. the serine proteinase motif, was expressed and analyzed by using an in vitro transcription/translation system and a transient expression system in cultured cells.  Two distinct proteinase activities which function in the prodn. of a 70-kDa protein (p70) from the precursor polyprotein were detected.  One of these proteinase activities, which cleaved the C-terminal side of p70, required the presence of the serine proteinase motif, which is located in the N-terminal region of p70.  This suggested that the predicted HCV serine proteinase was functional.  The other activity, which was responsible for the cleavage of the N-terminal side of p70, required the expression of the region upstream and downstream of that cleavage site, including the p70 serine proteinase domain.  From the results of pulse-chase anal., using proteinase inhibitors coupled with a point mutation anal., the latter activity was proposed to be a novel zinc-dependent metalloproteinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZzbnHoEE0Q7Vg90H21EOLACvtfcHk0lgXK9Hra-jvxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsFChsLk%253D&md5=aef2e23cfd63d9841d5161b53ef4af34</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHijikata%26aufirst%3DM.%26aulast%3DMizushima%26aufirst%3DH.%26aulast%3DAkagi%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DS.%26aulast%3DKakiuchi%26aufirst%3DN.%26aulast%3DKato%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKimura%26aufirst%3DK.%26aulast%3DShimotohno%26aufirst%3DK.%26atitle%3DTwo%2520distinct%2520proteinase%2520activities%2520required%2520for%2520the%2520processing%2520of%2520a%2520putative%2520nonstructural%2520precursor%2520protein%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Virol.%26date%3D1993%26volume%3D67%26spage%3D4665%26epage%3D4675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Körner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herian, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">8416</span><span class="NLM_x">–</span> <span class="NLM_lpage">8428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=9343198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK2sXmvV2hs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1997&pages=8416-8428&author=V.+Lohmannauthor=F.+K%C3%B6rnerauthor=U.+Herianauthor=R.+Bartenschlager&title=Biochemical+properties+of+hepatitis+C+virus+NS5B+RNA-dependent+RNA+polymerase+and+identification+of+amino+acid+sequence+motifs+essential+for+enzymatic+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymic activity</span></div><div class="casAuthors">Lohmann, Volker; Korner, Frank; Herian, Ulrike; Bartenschlager, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">8416-8428</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The NS5B protein of the hepatitis C virus (HCV) is an RNA-dependent RNA polymerase (RdRp) (S.-E. Behrens, L. Tomei, and R. De Francesco, EMBO J. 15:12-22, 1996) that is assumed to be required for replication of the viral genome.  To further study the biochem. and structural properties of this enzyme, an NS5B-hexahistidine fusion protein was expressed with recombinant baculoviruses in insect cells and purified to near homogeneity.  The enzyme was found to have a primer-dependent RdRp activity that was able to copy a complete in vitro-transcribed HCV genome in the absence of addnl. viral or cellular factors.  Filter binding assays and competition expts. showed that the purified enzyme binds RNA with no clear preference for HCV 3'-end sequences.  Binding to homopolymeric RNAs was also examd., and the following order of specificity was obsd.: poly(U) > poly(G) > poly(A) > poly(C).  An inverse order was found for the RdRp activity, which used poly(C) most efficiently as a template but was inactive on poly(U) and poly(G), suggesting that a high binding affinity between polymerase and template interferes with processivity.  By using a mutational anal., four amino acid sequence motifs crucial for RdRp activity were identified.  While most substitutions of conserved residues within these motifs severely reduced the enzymic activities, a single substitution in motif D which enhanced the RdRp activity by about 50% was found.  Deletion studies indicate that amino acid residues at the very termini, in particular the amino terminus, are important for RdRp activity but not for RNA binding.  Finally, we found a terminal transferase activity assocd. with the purified enzyme.  However, this activity was also detected with NS5B proteins with an inactive RdRp, with an NS4B protein purified in the same way, and with wild-type baculovirus, suggesting that it is not an inherent activity of NS5B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdCeTDzvlRArVg90H21EOLACvtfcHk0lgXK9Hra-jvxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvV2hs7s%253D&md5=98640d185270f0b331db0fa0624865cd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DK%25C3%25B6rner%26aufirst%3DF.%26aulast%3DHerian%26aufirst%3DU.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DBiochemical%2520properties%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA-dependent%2520RNA%2520polymerase%2520and%2520identification%2520of%2520amino%2520acid%2520sequence%2520motifs%2520essential%2520for%2520enzymatic%2520activity%26jtitle%3DJ.%2520Virol.%26date%3D1997%26volume%3D71%26spage%3D8416%26epage%3D8428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">4373</span><span class="NLM_x">–</span> <span class="NLM_lpage">4380</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=7769699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK2MXmt1agsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1995&pages=4373-4380&author=C.+Linauthor=J.+A.+Thomsonauthor=C.+M.+Rice&title=A+central+region+in+the+hepatitis+C+virus+NS4A+protein+allows+formation+of+an+active+NS3-NS4A+serine+proteinase+complex+in+vivo+and+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro</span></div><div class="casAuthors">Lin, Chao; Thomson, John A.; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4373-80</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A virus-encoded serine proteinase mediates four site-specific cleavages in the hepatitis C virus polyprotein.  In addn. to the catalytic domain, which is located in the N-terminal one-third of nonstructural protein NS3, the 54-residue NS4A protein is required for cleavage at some but not all sites.  Here, the authors provide evidence for a non-ionic detergent-stable interaction between NS4A and the NS3 serine proteinase domain and demonstrate that the central region of NS4A plays a key role in NS4A-dependent processing.  Hydrophobic residues, in particular Ile-29, were shown to be important for NS4A activity, and a synthetic peptide, spanning NS4A residues 22 to 34, could substitute for intact NS4A in a cell-free trans cleavage assay.  Furthermore, NS4A mutations, which abolished or inhibited processing, correlated with destabilization of the NS3-NS4A complex.  These results suggest that a stable interaction exists between the central region of NS4A and the NS3 catalytic domain which is required for NS4A-dependent processing.  Since NS4A is required for processing at certain serine proteinase-dependent cleavage sites, this interaction may represent a new target for development of antiviral compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMCmcNIeRxo7Vg90H21EOLACvtfcHk0lgjfvH79PP_iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmt1agsrg%253D&md5=2b8f528b4ac4bcee3033adf6b100243d</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.%26aulast%3DThomson%26aufirst%3DJ.%2BA.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DA%2520central%2520region%2520in%2520the%2520hepatitis%2520C%2520virus%2520NS4A%2520protein%2520allows%2520formation%2520of%2520an%2520active%2520NS3-NS4A%2520serine%2520proteinase%2520complex%2520in%2520vivo%2520and%2520in%2520vitro%26jtitle%3DJ.%2520Virol.%26date%3D1995%26volume%3D69%26spage%3D4373%26epage%3D4380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Landro, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raybuck, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luong, Y. P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Malley, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harebeson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgenstern, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livingston, D. J.</span><span> </span><span class="NLM_article-title">Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect <i>via</i> kinetic analysis and inhibitor mapping</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">9340</span><span class="NLM_x">–</span> <span class="NLM_lpage">9348</span><span class="refDoi"> DOI: 10.1021/bi963054n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi963054n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=9340-9348&author=J.+A.+Landroauthor=S.+A.+Raybuckauthor=Y.+P.+C.+Luongauthor=E.+T.+O%E2%80%99Malleyauthor=S.+L.+Harebesonauthor=K.+A.+Morgensternauthor=G.+Raoauthor=D.+J.+Livingston&title=Mechanistic+role+of+an+NS4A+peptide+cofactor+with+the+truncated+NS3+protease+of+hepatitis+C+virus%3A+elucidation+of+the+NS4A+stimulatory+effect+via+kinetic+analysis+and+inhibitor+mapping&doi=10.1021%2Fbi963054n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1021%2Fbi963054n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi963054n%26sid%3Dliteratum%253Aachs%26aulast%3DLandro%26aufirst%3DJ.%2BA.%26aulast%3DRaybuck%26aufirst%3DS.%2BA.%26aulast%3DLuong%26aufirst%3DY.%2BP.%2BC.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DE.%2BT.%26aulast%3DHarebeson%26aufirst%3DS.%2BL.%26aulast%3DMorgenstern%26aufirst%3DK.%2BA.%26aulast%3DRao%26aufirst%3DG.%26aulast%3DLivingston%26aufirst%3DD.%2BJ.%26atitle%3DMechanistic%2520role%2520of%2520an%2520NS4A%2520peptide%2520cofactor%2520with%2520the%2520truncated%2520NS3%2520protease%2520of%2520hepatitis%2520C%2520virus%253A%2520elucidation%2520of%2520the%2520NS4A%2520stimulatory%2520effect%2520via%2520kinetic%2520analysis%2520and%2520inhibitor%2520mapping%26jtitle%3DBiochemistry%26date%3D1997%26volume%3D36%26spage%3D9340%26epage%3D9348%26doi%3D10.1021%2Fbi963054n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Suzich, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer-Hill, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrener, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grakoui, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinstone, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collett, M. S.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS3 protein polynucleotide stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">6152</span><span class="NLM_x">–</span> <span class="NLM_lpage">6158</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1993&pages=6152-6158&author=J.+A.+Suzichauthor=J.+K.+Tamuraauthor=F.+Palmer-Hillauthor=P.+Warrenerauthor=A.+Grakouiauthor=C.+M.+Riceauthor=S.+M.+Feinstoneauthor=M.+S.+Collett&title=Hepatitis+C+virus+NS3+protein+polynucleotide+stimulated+nucleoside+triphosphatase+and+comparison+with+the+related+pestivirus+and+flavivirus+enzymes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSuzich%26aufirst%3DJ.%2BA.%26aulast%3DTamura%26aufirst%3DJ.%2BK.%26aulast%3DPalmer-Hill%26aufirst%3DF.%26aulast%3DWarrener%26aufirst%3DP.%26aulast%3DGrakoui%26aufirst%3DA.%26aulast%3DRice%26aufirst%3DC.%2BM.%26aulast%3DFeinstone%26aufirst%3DS.%2BM.%26aulast%3DCollett%26aufirst%3DM.%2BS.%26atitle%3DHepatitis%2520C%2520virus%2520NS3%2520protein%2520polynucleotide%2520stimulated%2520nucleoside%2520triphosphatase%2520and%2520comparison%2520with%2520the%2520related%2520pestivirus%2520and%2520flavivirus%2520enzymes%26jtitle%3DJ.%2520Virol.%26date%3D1993%26volume%3D67%26spage%3D6152%26epage%3D6158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Kolykhalov, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihalik, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinstone, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′-nontranslated region are essential for virus replication <i>in vivo</i></span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">2046</span><span class="NLM_x">–</span> <span class="NLM_lpage">2051</span><span class="refDoi"> DOI: 10.1128/JVI.74.4.2046-2051.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FJVI.74.4.2046-2051.2000" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2000&pages=2046-2051&author=A.+A.+Kolykhalovauthor=K.+Mihalikauthor=S.+M.+Feinstoneauthor=C.+M.+Rice&title=Hepatitis+C+virus-encoded+enzymatic+activities+and+conserved+RNA+elements+in+the+3%E2%80%B2-nontranslated+region+are+essential+for+virus+replication+in+vivo&doi=10.1128%2FJVI.74.4.2046-2051.2000"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1128%2FJVI.74.4.2046-2051.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.74.4.2046-2051.2000%26sid%3Dliteratum%253Aachs%26aulast%3DKolykhalov%26aufirst%3DA.%2BA.%26aulast%3DMihalik%26aufirst%3DK.%26aulast%3DFeinstone%26aufirst%3DS.%2BM.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DHepatitis%2520C%2520virus-encoded%2520enzymatic%2520activities%2520and%2520conserved%2520RNA%2520elements%2520in%2520the%25203%25E2%2580%25B2-nontranslated%2520region%2520are%2520essential%2520for%2520virus%2520replication%2520in%2520vivo%26jtitle%3DJ.%2520Virol.%26date%3D2000%26volume%3D74%26spage%3D2046%26epage%3D2051%26doi%3D10.1128%2FJVI.74.4.2046-2051.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Hepatitis C virus replicons: potential role for drug development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">911</span><span class="NLM_x">–</span> <span class="NLM_lpage">916</span><span class="refDoi"> DOI: 10.1038/nrd942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrd942" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=911-916&author=R.+Bartenschlager&title=Hepatitis+C+virus+replicons%3A+potential+role+for+drug+development&doi=10.1038%2Fnrd942"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1038%2Fnrd942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd942%26sid%3Dliteratum%253Aachs%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DHepatitis%2520C%2520virus%2520replicons%253A%2520potential%2520role%2520for%2520drug%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D911%26epage%3D916%26doi%3D10.1038%2Fnrd942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">The hepatitis C virus replicon system: from basic research to clinical application</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">216</span><span class="refDoi"> DOI: 10.1016/j.jhep.2005.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2005.05.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2005&pages=210-216&author=R.+Bartenschlager&title=The+hepatitis+C+virus+replicon+system%3A+from+basic+research+to+clinical+application&doi=10.1016%2Fj.jhep.2005.05.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2005.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2005.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DThe%2520hepatitis%2520C%2520virus%2520replicon%2520system%253A%2520from%2520basic%2520research%2520to%2520clinical%2520application%26jtitle%3DJ.%2520Hepatol.%26date%3D2005%26volume%3D43%26spage%3D210%26epage%3D216%26doi%3D10.1016%2Fj.jhep.2005.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">On the history of hepatitis C virus cell culture systems</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1627</span><span class="NLM_x">–</span> <span class="NLM_lpage">1642</span><span class="refDoi"> DOI: 10.1021/jm401401n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401401n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ylsrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1627-1642&author=V.+Lohmannauthor=R.+Bartenschlager&title=On+the+history+of+hepatitis+C+virus+cell+culture+systems&doi=10.1021%2Fjm401401n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21cR"><div class="casContent"><span class="casTitleNuber">21c</span><div class="casTitle"><span class="NLM_cas:atitle">On the History of Hepatitis C Virus Cell Culture Systems</span></div><div class="casAuthors">Lohmann, Volker; Bartenschlager, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1627-1642</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  HCV infections are a major global health burden.  After the identification of the virus in 1989, insights into viral replication and drug development have long been hampered by the lack of efficient cell culture models.  Their establishment was an important prerequisite for the development of selective antivirals.  This review describes the initial difficulties to achieve HCV replication in cell culture, finally leading to the establishment of subgenomic replicons and the infectious virus model (HCVcc).  The review further summarizes the current state of HCV cell culture systems with respect to available virus isolates, engineered genomes, and cell types allowing efficient HCV propagation.  Finally, we comment on how these cell culture models contributed to the development of directly acting antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYlObUbN-_cLVg90H21EOLACvtfcHk0lifo2uXIKCY9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ylsrnP&md5=09643efac2375d3c08c5d40e515a697f</span></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=10.1021%2Fjm401401n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401401n%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DOn%2520the%2520history%2520of%2520hepatitis%2520C%2520virus%2520cell%2520culture%2520systems%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1627%26epage%3D1642%26doi%3D10.1021%2Fjm401401n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Morikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lange, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gouttenoire, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meylan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brass, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moradpour, D.</span><span> </span><span class="NLM_article-title">Nonstructural protein 3–4A: the Swiss army knife of hepatitis C virus</span> <span class="citation_source-journal">J. Viral. Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span><span class="refDoi"> DOI: 10.1111/j.1365-2893.2011.01451.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fj.1365-2893.2011.01451.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=305-315&author=K.+Morikawaauthor=C.+M.+Langeauthor=J.+Gouttenoireauthor=E.+Meylanauthor=V.+Brassauthor=F.+Peninauthor=D.+Moradpour&title=Nonstructural+protein+3%E2%80%934A%3A+the+Swiss+army+knife+of+hepatitis+C+virus&doi=10.1111%2Fj.1365-2893.2011.01451.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2893.2011.01451.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2893.2011.01451.x%26sid%3Dliteratum%253Aachs%26aulast%3DMorikawa%26aufirst%3DK.%26aulast%3DLange%26aufirst%3DC.%2BM.%26aulast%3DGouttenoire%26aufirst%3DJ.%26aulast%3DMeylan%26aufirst%3DE.%26aulast%3DBrass%26aufirst%3DV.%26aulast%3DPenin%26aufirst%3DF.%26aulast%3DMoradpour%26aufirst%3DD.%26atitle%3DNonstructural%2520protein%25203%25E2%2580%25934A%253A%2520the%2520Swiss%2520army%2520knife%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Viral.%2520Hepatitis%26date%3D2011%26volume%3D18%26spage%3D305%26epage%3D315%26doi%3D10.1111%2Fj.1365-2893.2011.01451.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Raney, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moustafa, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span> </span><span class="NLM_article-title">Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">22725</span><span class="NLM_x">–</span> <span class="NLM_lpage">22731</span><span class="refDoi"> DOI: 10.1074/jbc.R110.125294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1074%2Fjbc.R110.125294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=20457607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFenu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=22725-22731&author=K.+D.+Raneyauthor=S.+D.+Sharmaauthor=I.+M.+Moustafaauthor=C.+E.+Cameron&title=Hepatitis+C+virus+non-structural+protein+3+%28HCV+NS3%29%3A+a+multifunctional+antiviral+target&doi=10.1074%2Fjbc.R110.125294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C Virus Non-structural Protein 3 (HCV NS3): A Multifunctional Antiviral Target</span></div><div class="casAuthors">Raney, Kevin D.; Sharma, Suresh D.; Moustafa, Ibrahim M.; Cameron, Craig E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">22725-22731</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus non-structural protein 3 contains a serine protease and an RNA helicase.  Protease cleaves the genome-encoded polyprotein and inactivates cellular proteins required for innate immunity.  Protease has emerged as an important target for the development of antiviral therapeutics, but drug resistance has turned out to be an obstacle in the clinic.  Helicase is required for both genome replication and virus assembly.  Mechanistic and structural studies of helicase have hurled this enzyme into a prominent position in the field of helicase enzymol.  Nevertheless, studies of helicase as an antiviral target remain in their infancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI9DvVa0U07rVg90H21EOLACvtfcHk0lhe_0ADuBVaXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFenu70%253D&md5=0e7a635cf9517099ca66d4d1aaa4bfe0</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R110.125294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R110.125294%26sid%3Dliteratum%253Aachs%26aulast%3DRaney%26aufirst%3DK.%2BD.%26aulast%3DSharma%26aufirst%3DS.%2BD.%26aulast%3DMoustafa%26aufirst%3DI.%2BM.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26atitle%3DHepatitis%2520C%2520virus%2520non-structural%2520protein%25203%2520%2528HCV%2520NS3%2529%253A%2520a%2520multifunctional%2520antiviral%2520target%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D22725%26epage%3D22731%26doi%3D10.1074%2Fjbc.R110.125294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Behrens, S.-E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span> </span><span class="NLM_article-title">Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1996&pages=12-22&author=S.-E.+Behrensauthor=L.+Tomeiauthor=R.+De+Francesco&title=Identification+and+properties+of+the+RNA-dependent+RNA+polymerase+of+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBehrens%26aufirst%3DS.-E.%26aulast%3DTomei%26aufirst%3DL.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26atitle%3DIdentification%2520and%2520properties%2520of%2520the%2520RNA-dependent%2520RNA%2520polymerase%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DEMBO%2520J.%26date%3D1996%26volume%3D15%26spage%3D12%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Körner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus</span> <span class="citation_source-journal">Virology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">249</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.1006/viro.1998.9311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1006%2Fviro.1998.9311" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=249&publication_year=1998&pages=108-118&author=V.+Lohmannauthor=A.+Roosauthor=F.+K%C3%B6rnerauthor=J.+O.+Kochauthor=R.+Bartenschlager&title=Biochemical+and+kinetic+analyses+of+NS5B+RNA-dependent+RNA+polymerase+of+the+hepatitis+C+virus&doi=10.1006%2Fviro.1998.9311"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1006%2Fviro.1998.9311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fviro.1998.9311%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DRoos%26aufirst%3DA.%26aulast%3DK%25C3%25B6rner%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DJ.%2BO.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DBiochemical%2520and%2520kinetic%2520analyses%2520of%2520NS5B%2520RNA-dependent%2520RNA%2520polymerase%2520of%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DVirology%26date%3D1998%26volume%3D249%26spage%3D108%26epage%3D118%26doi%3D10.1006%2Fviro.1998.9311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sofia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosley, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, B. S.</span><span> </span><span class="NLM_article-title">Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2481</span><span class="NLM_x">–</span> <span class="NLM_lpage">2531</span><span class="refDoi"> DOI: 10.1021/jm201384j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201384j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1aqu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2481-2531&author=M.+J.+Sofiaauthor=W.+Changauthor=P.+A.+Furmanauthor=R.+T.+Mosleyauthor=B.+S.+Ross&title=Nucleoside%2C+nucleotide%2C+and+non-nucleoside+inhibitors+of+hepatitis+C+virus+NS5B+RNA-dependent+RNA-polymerase&doi=10.1021%2Fjm201384j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23cR"><div class="casContent"><span class="casTitleNuber">23c</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase</span></div><div class="casAuthors">Sofia, Michael J.; Chang, Wonsuk; Furman, Phillip A.; Mosley, Ralph T.; Ross, Bruce S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2481-2531</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This is a Perspectives review and does not require an abstr.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWh0maPUC6grVg90H21EOLACvtfcHk0lgkKQMecIvocw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1aqu7rF&md5=3236ff10d16104b1a39d77f04774ac77</span></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=10.1021%2Fjm201384j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201384j%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26atitle%3DNucleoside%252C%2520nucleotide%252C%2520and%2520non-nucleoside%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA-dependent%2520RNA-polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2481%26epage%3D2531%26doi%3D10.1021%2Fjm201384j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wieland, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chisari, F. V.</span><span> </span><span class="NLM_article-title">Stealth and cunning: hepatitis B and hepatitis C viruses</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">9369</span><span class="NLM_x">–</span> <span class="NLM_lpage">9380</span><span class="refDoi"> DOI: 10.1128/JVI.79.15.9369-9380.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FJVI.79.15.9369-9380.2005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=9369-9380&author=S.+F.+Wielandauthor=F.+V.+Chisari&title=Stealth+and+cunning%3A+hepatitis+B+and+hepatitis+C+viruses&doi=10.1128%2FJVI.79.15.9369-9380.2005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.15.9369-9380.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.15.9369-9380.2005%26sid%3Dliteratum%253Aachs%26aulast%3DWieland%26aufirst%3DS.%2BF.%26aulast%3DChisari%26aufirst%3DF.%2BV.%26atitle%3DStealth%2520and%2520cunning%253A%2520hepatitis%2520B%2520and%2520hepatitis%2520C%2520viruses%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D9369%26epage%3D9380%26doi%3D10.1128%2FJVI.79.15.9369-9380.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Guidotti, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chisari, F. V.</span><span> </span><span class="NLM_article-title">Immunobiology and pathogenesis of viral hepatitis</span> <span class="citation_source-journal">Annu. Rev. Pathol.: Mech. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1146/annurev.pathol.1.110304.100230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1146%2Fannurev.pathol.1.110304.100230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=18039107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD28XktVOitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=23-61&author=L.+G.+Guidottiauthor=F.+V.+Chisari&title=Immunobiology+and+pathogenesis+of+viral+hepatitis&doi=10.1146%2Fannurev.pathol.1.110304.100230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Immunobiology and pathogenesis of viral hepatitis</span></div><div class="casAuthors">Guidotti, Luca G.; Chisari, Francis V.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pathology: Mechanisms of Disease</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23-61</span>CODEN:
                <span class="NLM_cas:coden">ARPMCU</span>;
        ISSN:<span class="NLM_cas:issn">1553-4006</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Among the many viruses that are known to infect the human liver, hepatitis B virus (HBV) and hepatitis C virus (HCV) are unique because of their prodigious capacity to cause persistent infection, cirrhosis, and liver cancer.  HBV and HCV are noncytopathic viruses and, thus, immunol. mediated events play an important role in the pathogenesis and outcome of these infections.  The adaptive immune response mediates virtually all of the liver disease assocd. with viral hepatitis.  However, it is becoming increasingly clear that antigen-nonspecific inflammatory cells exacerbate cytotoxic T lymphocyte (CTL)-induced immunopathol. and that platelets enhance the accumulation of CTLs in the liver.  Chronic hepatitis is characterized by an inefficient T cell response unable to completely clear HBV or HCV from the liver, which consequently sustains continuous cycles of low-level cell destruction.  Over long periods of time, recurrent immune-mediated liver damage contributes to the development of cirrhosis and hepatocellular carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eRjyvjhbi7Vg90H21EOLACvtfcHk0ljysnQ495EAdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktVOitb4%253D&md5=c740de97e8b1d52a3e3f9e3e7be3bd89</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pathol.1.110304.100230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pathol.1.110304.100230%26sid%3Dliteratum%253Aachs%26aulast%3DGuidotti%26aufirst%3DL.%2BG.%26aulast%3DChisari%26aufirst%3DF.%2BV.%26atitle%3DImmunobiology%2520and%2520pathogenesis%2520of%2520viral%2520hepatitis%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2006%26volume%3D1%26spage%3D23%26epage%3D61%26doi%3D10.1146%2Fannurev.pathol.1.110304.100230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rehermann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nascimbeni, M.</span><span> </span><span class="NLM_article-title">Immunology of hepatitis B virus and hepatitis C virus infection</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span><span class="refDoi"> DOI: 10.1038/nri1573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnri1573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=15738952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslSju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=215-229&author=B.+Rehermannauthor=M.+Nascimbeni&title=Immunology+of+hepatitis+B+virus+and+hepatitis+C+virus+infection&doi=10.1038%2Fnri1573"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24cR"><div class="casContent"><span class="casTitleNuber">24c</span><div class="casTitle"><span class="NLM_cas:atitle">Immunology of hepatitis B virus and hepatitis C virus infection</span></div><div class="casAuthors">Rehermann, Barbara; Nascimbeni, Michelina</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-229</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  More than 500 million people worldwide are persistently infected with the hepatitis B virus (HBV) and/or hepatitis C virus (HCV) and are at risk of developing chronic liver disease, cirrhosis and hepatocellular carcinoma.  Despite many common features in the pathogenesis of HBV- and HCV-related liver disease, these viruses markedly differ in their virol. properties and in their immune escape and survival strategies.  This review assesses recent advances in our understanding of viral hepatitis, contrasts mechanisms of virus-host interaction in acute hepatitis B and hepatitis C, and outlines areas for future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK_aXbF6__BLVg90H21EOLACvtfcHk0ljysnQ495EAdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslSju7k%253D&md5=d9ceed9473106d0f31fade725d16c1a6</span></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=10.1038%2Fnri1573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1573%26sid%3Dliteratum%253Aachs%26aulast%3DRehermann%26aufirst%3DB.%26aulast%3DNascimbeni%26aufirst%3DM.%26atitle%3DImmunology%2520of%2520hepatitis%2520B%2520virus%2520and%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2005%26volume%3D5%26spage%3D215%26epage%3D229%26doi%3D10.1038%2Fnri1573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Sklan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charuworn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glenn, J. S.</span><span> </span><span class="NLM_article-title">Mechanisms of HCV survival in the host</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1038/nrgastro.2009.32</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrgastro.2009.32" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=217-227&author=E.+H.+Sklanauthor=P.+Charuwornauthor=P.+S.+Pangauthor=J.+S.+Glenn&title=Mechanisms+of+HCV+survival+in+the+host&doi=10.1038%2Fnrgastro.2009.32"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24d&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2009.32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2009.32%26sid%3Dliteratum%253Aachs%26aulast%3DSklan%26aufirst%3DE.%2BH.%26aulast%3DCharuworn%26aufirst%3DP.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DGlenn%26aufirst%3DJ.%2BS.%26atitle%3DMechanisms%2520of%2520HCV%2520survival%2520in%2520the%2520host%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2009%26volume%3D6%26spage%3D217%26epage%3D227%26doi%3D10.1038%2Fnrgastro.2009.32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Horner, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, M.,  Jr.</span><span> </span><span class="NLM_article-title">Regulation of hepatic innate immunity by hepatitis C virus</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">888</span><span class="refDoi"> DOI: 10.1038/nm.3253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnm.3253" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=879-888&author=S.+M.+Hornerauthor=M.+Gale&title=Regulation+of+hepatic+innate+immunity+by+hepatitis+C+virus&doi=10.1038%2Fnm.3253"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24e&amp;dbid=16384&amp;doi=10.1038%2Fnm.3253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3253%26sid%3Dliteratum%253Aachs%26aulast%3DHorner%26aufirst%3DS.%2BM.%26aulast%3DGale%26aufirst%3DM.%26atitle%3DRegulation%2520of%2520hepatic%2520innate%2520immunity%2520by%2520hepatitis%2520C%2520virus%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D879%26epage%3D888%26doi%3D10.1038%2Fnm.3253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Horner, S. M.</span><span> </span><span class="NLM_article-title">Activation and evasion of antiviral innate immunity by hepatitis C virus</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">426</span><span class="NLM_x">, </span> <span class="NLM_fpage">1198</span><span class="NLM_x">–</span> <span class="NLM_lpage">1209</span><span class="refDoi"> DOI: 10.1016/j.jmb.2013.10.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jmb.2013.10.032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2014&pages=1198-1209&author=S.+M.+Horner&title=Activation+and+evasion+of+antiviral+innate+immunity+by+hepatitis+C+virus&doi=10.1016%2Fj.jmb.2013.10.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24f&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2013.10.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2013.10.032%26sid%3Dliteratum%253Aachs%26aulast%3DHorner%26aufirst%3DS.%2BM.%26atitle%3DActivation%2520and%2520evasion%2520of%2520antiviral%2520innate%2520immunity%2520by%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D426%26spage%3D1198%26epage%3D1209%26doi%3D10.1016%2Fj.jmb.2013.10.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Smith, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuiken, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muerhoff, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stapleton, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmonds, P.</span><span> </span><span class="NLM_article-title">Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">318</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span><span class="refDoi"> DOI: 10.1002/hep.26744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.26744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24115039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FktFWnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=318-327&author=D.+B.+Smithauthor=J.+Bukhauthor=C.+Kuikenauthor=A.+S.+Muerhoffauthor=C.+M.+Riceauthor=J.+T.+Stapletonauthor=P.+Simmonds&title=Expanded+classification+of+hepatitis+C+virus+into+7+genotypes+and+67+subtypes%3A+updated+criteria+and+genotype+assignment+web+resource&doi=10.1002%2Fhep.26744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource</span></div><div class="casAuthors">Smith Donald B; Bukh Jens; Kuiken Carla; Muerhoff A Scott; Rice Charles M; Stapleton Jack T; Simmonds Peter</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Baltimore, Md.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">318-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  The 2005 consensus proposal for the classification of hepatitis C virus (HCV) presented an agreed and uniform nomenclature for HCV variants and the criteria for their assignment into genotypes and subtypes.  Since its publication, the available dataset of HCV sequences has vastly expanded through advancement in nucleotide sequencing technologies and an increasing focus on the role of HCV genetic variation in disease and treatment outcomes.  The current study represents a major update to the previous consensus HCV classification, incorporating additional sequence information derived from over 1,300 (near-)complete genome sequences of HCV available on public databases in May 2013.  Analysis resolved several nomenclature conflicts between genotype designations and using consensus criteria created a classification of HCV into seven confirmed genotypes and 67 subtypes.  There are 21 additional complete coding region sequences of unassigned subtype.  The study additionally describes the development of a Web resource hosted by the International Committee for Taxonomy of Viruses (ICTV) that maintains and regularly updates tables of reference isolates, accession numbers, and annotated alignments (http://talk.ictvonline.org/links/hcv/hcv-classification.htm).  The Flaviviridae Study Group urges those who need to check or propose new genotypes or subtypes of HCV to contact the Study Group in advance of publication to avoid nomenclature conflicts appearing in the literature.  While the criteria for assigning genotypes and subtypes remain unchanged from previous consensus proposals, changes are proposed in the assignment of provisional subtypes, subtype numbering beyond "w," and the nomenclature of intergenotypic recombinant.  CONCLUSION:  This study represents an important reference point for the consensus classification of HCV variants that will be of value to researchers working in clinical and basic science fields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgofAQo7eS9BWfpMXQLRstfW6udTcc2eYp2icCBphoSLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FktFWnsg%253D%253D&md5=b0bfea063822f132a1204a8973081876</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1002%2Fhep.26744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26744%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BB.%26aulast%3DBukh%26aufirst%3DJ.%26aulast%3DKuiken%26aufirst%3DC.%26aulast%3DMuerhoff%26aufirst%3DA.%2BS.%26aulast%3DRice%26aufirst%3DC.%2BM.%26aulast%3DStapleton%26aufirst%3DJ.%2BT.%26aulast%3DSimmonds%26aufirst%3DP.%26atitle%3DExpanded%2520classification%2520of%2520hepatitis%2520C%2520virus%2520into%25207%2520genotypes%2520and%252067%2520subtypes%253A%2520updated%2520criteria%2520and%2520genotype%2520assignment%2520web%2520resource%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26spage%3D318%26epage%3D327%26doi%3D10.1002%2Fhep.26744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Messina, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaxman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pybus, O. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, E.</span><span> </span><span class="NLM_article-title">Global distribution and prevalence of hepatitis C virus genotypes</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span><span class="refDoi"> DOI: 10.1002/hep.27259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.27259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25069599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC2cbms1CgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=77-87&author=J.+P.+Messinaauthor=I.+Humphreysauthor=A.+Flaxmanauthor=A.+Brownauthor=G.+S.+Cookeauthor=O.+G.+Pybusauthor=E.+Barnes&title=Global+distribution+and+prevalence+of+hepatitis+C+virus+genotypes&doi=10.1002%2Fhep.27259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Global distribution and prevalence of hepatitis C virus genotypes</span></div><div class="casAuthors">Messina Jane P; Humphreys Isla; Flaxman Abraham; Brown Anthony; Cooke Graham S; Pybus Oliver G; Barnes Eleanor</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Baltimore, Md.)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-87</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Hepatitis C virus (HCV) exhibits high genetic diversity, characterized by regional variations in genotype prevalence.  This poses a challenge to the improved development of vaccines and pan-genotypic treatments, which require the consideration of global trends in HCV genotype prevalence.  Here we provide the first comprehensive survey of these trends.  To approximate national HCV genotype prevalence, studies published between 1989 and 2013 reporting HCV genotypes are reviewed and combined with overall HCV prevalence estimates from the Global Burden of Disease (GBD) project.  We also generate regional and global genotype prevalence estimates, inferring data for countries lacking genotype information.  We include 1,217 studies in our analysis, representing 117 countries and 90% of the global population.  We calculate that HCV genotype 1 is the most prevalent worldwide, comprising 83.4 million cases (46.2% of all HCV cases), approximately one-third of which are in East Asia.  Genotype 3 is the next most prevalent globally (54.3 million, 30.1%); genotypes 2, 4, and 6 are responsible for a total 22.8% of all cases; genotype 5 comprises the remaining <1%.  While genotypes 1 and 3 dominate in most countries irrespective of economic status, the largest proportions of genotypes 4 and 5 are in lower-income countries.  CONCLUSION:  Although genotype 1 is most common worldwide, nongenotype 1 HCV cases--which are less well served by advances in vaccine and drug development--still comprise over half of all HCV cases.  Relative genotype proportions are needed to inform healthcare models, which must be geographically tailored to specific countries or regions in order to improve access to new treatments.  Genotype surveillance data are needed from many countries to improve estimates of unmet need.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2Xg9XEOxbiuQ4Pl9hzjQhfW6udTcc2eZ2DK0hrWZHG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbms1CgtA%253D%253D&md5=4ad9cc1d6592acffdc485d0baccfe939</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1002%2Fhep.27259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27259%26sid%3Dliteratum%253Aachs%26aulast%3DMessina%26aufirst%3DJ.%2BP.%26aulast%3DHumphreys%26aufirst%3DI.%26aulast%3DFlaxman%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DCooke%26aufirst%3DG.%2BS.%26aulast%3DPybus%26aufirst%3DO.%2BG.%26aulast%3DBarnes%26aufirst%3DE.%26atitle%3DGlobal%2520distribution%2520and%2520prevalence%2520of%2520hepatitis%2520C%2520virus%2520genotypes%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D77%26epage%3D87%26doi%3D10.1002%2Fhep.27259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Alberti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacoin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morais, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefevre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abogunrin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iheanacho, I.</span><span> </span><span class="NLM_article-title">A literature review of the distribution of hepatitis C virus genotypes across Europe</span> <span class="citation_source-journal">J. Med. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1002/jmv.24573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fjmv.24573" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=A.+Albertiauthor=L.+Lacoinauthor=E.+Moraisauthor=C.+Lefevreauthor=S.+Abogunrinauthor=I.+Iheanacho&title=A+literature+review+of+the+distribution+of+hepatitis+C+virus+genotypes+across+Europe&doi=10.1002%2Fjmv.24573"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=10.1002%2Fjmv.24573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjmv.24573%26sid%3Dliteratum%253Aachs%26aulast%3DAlberti%26aufirst%3DA.%26aulast%3DLacoin%26aufirst%3DL.%26aulast%3DMorais%26aufirst%3DE.%26aulast%3DLefevre%26aufirst%3DC.%26aulast%3DAbogunrin%26aufirst%3DS.%26aulast%3DIheanacho%26aufirst%3DI.%26atitle%3DA%2520literature%2520review%2520of%2520the%2520distribution%2520of%2520hepatitis%2520C%2520virus%2520genotypes%2520across%2520Europe%26jtitle%3DJ.%2520Med.%2520Virol.%26date%3D2016%26doi%3D10.1002%2Fjmv.24573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pawlotsky, J. M.</span><span> </span><span class="NLM_article-title">Pathophysiology of hepatitis C virus infection and related liver disease</span> <span class="citation_source-journal">Trends Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span><span class="refDoi"> DOI: 10.1016/j.tim.2003.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.tim.2003.12.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=96-102&author=J.+M.+Pawlotsky&title=Pathophysiology+of+hepatitis+C+virus+infection+and+related+liver+disease&doi=10.1016%2Fj.tim.2003.12.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2003.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2003.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.%2BM.%26atitle%3DPathophysiology%2520of%2520hepatitis%2520C%2520virus%2520infection%2520and%2520related%2520liver%2520disease%26jtitle%3DTrends%2520Microbiol.%26date%3D2004%26volume%3D12%26spage%3D96%26epage%3D102%26doi%3D10.1016%2Fj.tim.2003.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">McCombs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonnu-Mihara, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saab, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">L’italien, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juday, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Y.</span><span> </span><span class="NLM_article-title">The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry</span> <span class="citation_source-journal">JAMA Int. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">174</span><span class="NLM_x">, </span> <span class="NLM_fpage">204</span><span class="NLM_x">–</span> <span class="NLM_lpage">212</span><span class="refDoi"> DOI: 10.1001/jamainternmed.2013.12505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1001%2Fjamainternmed.2013.12505" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2014&pages=204-212&author=J.+McCombsauthor=T.+Matsudaauthor=I.+Tonnu-Miharaauthor=S.+Saabauthor=P.+Hinesauthor=G.+L%E2%80%99italienauthor=T.+Judayauthor=Y.+Yuan&title=The+risk+of+long-term+morbidity+and+mortality+in+patients+with+chronic+hepatitis+C%3A+results+from+an+analysis+of+data+from+a+Department+of+Veterans+Affairs+Clinical+Registry&doi=10.1001%2Fjamainternmed.2013.12505"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1001%2Fjamainternmed.2013.12505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamainternmed.2013.12505%26sid%3Dliteratum%253Aachs%26aulast%3DMcCombs%26aufirst%3DJ.%26aulast%3DMatsuda%26aufirst%3DT.%26aulast%3DTonnu-Mihara%26aufirst%3DI.%26aulast%3DSaab%26aufirst%3DS.%26aulast%3DHines%26aufirst%3DP.%26aulast%3DL%25E2%2580%2599italien%26aufirst%3DG.%26aulast%3DJuday%26aufirst%3DT.%26aulast%3DYuan%26aufirst%3DY.%26atitle%3DThe%2520risk%2520of%2520long-term%2520morbidity%2520and%2520mortality%2520in%2520patients%2520with%2520chronic%2520hepatitis%2520C%253A%2520results%2520from%2520an%2520analysis%2520of%2520data%2520from%2520a%2520Department%2520of%2520Veterans%2520Affairs%2520Clinical%2520Registry%26jtitle%3DJAMA%2520Int.%2520Med.%26date%3D2014%26volume%3D174%26spage%3D204%26epage%3D212%26doi%3D10.1001%2Fjamainternmed.2013.12505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Alter, H. J.</span><span> </span><span class="NLM_article-title">HCV natural history: the retrospective and prospective in perspective</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">550</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span><span class="refDoi"> DOI: 10.1016/j.jhep.2005.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2005.07.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2005&pages=550-552&author=H.+J.+Alter&title=HCV+natural+history%3A+the+retrospective+and+prospective+in+perspective&doi=10.1016%2Fj.jhep.2005.07.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26c&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2005.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2005.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DAlter%26aufirst%3DH.%2BJ.%26atitle%3DHCV%2520natural%2520history%253A%2520the%2520retrospective%2520and%2520prospective%2520in%2520perspective%26jtitle%3DJ.%2520Hepatol.%26date%3D2005%26volume%3D43%26spage%3D550%26epage%3D552%26doi%3D10.1016%2Fj.jhep.2005.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Thursz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontanet, A.</span><span> </span><span class="NLM_article-title">HCV transmission in industrialized countries and resource-constrained areas</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1038/nrgastro.2013.179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrgastro.2013.179" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=28-35&author=M.+Thurszauthor=A.+Fontanet&title=HCV+transmission+in+industrialized+countries+and+resource-constrained+areas&doi=10.1038%2Fnrgastro.2013.179"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26d&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2013.179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2013.179%26sid%3Dliteratum%253Aachs%26aulast%3DThursz%26aufirst%3DM.%26aulast%3DFontanet%26aufirst%3DA.%26atitle%3DHCV%2520transmission%2520in%2520industrialized%2520countries%2520and%2520resource-constrained%2520areas%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2014%26volume%3D11%26spage%3D28%26epage%3D35%26doi%3D10.1038%2Fnrgastro.2013.179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Racela, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Specific inhibition of bovine viral diarrhea virus replicase</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">6753</span><span class="NLM_x">–</span> <span class="NLM_lpage">6760</span><span class="refDoi"> DOI: 10.1128/JVI.77.12.6753-6760.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FJVI.77.12.6753-6760.2003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2003&pages=6753-6760&author=J.-H.+Sunauthor=J.+A.+Lemmauthor=D.+R.+O%E2%80%99Boyleauthor=J.+Racelaauthor=R.+Colonnoauthor=M.+Gao&title=Specific+inhibition+of+bovine+viral+diarrhea+virus+replicase&doi=10.1128%2FJVI.77.12.6753-6760.2003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1128%2FJVI.77.12.6753-6760.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.77.12.6753-6760.2003%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DRacela%26aufirst%3DJ.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DSpecific%2520inhibition%2520of%2520bovine%2520viral%2520diarrhea%2520virus%2520replicase%26jtitle%3DJ.%2520Virol.%26date%3D2003%26volume%3D77%26spage%3D6753%26epage%3D6760%26doi%3D10.1128%2FJVI.77.12.6753-6760.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Groutas, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brubaker, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkataraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epp, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houser-Archield, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClenahan, J. J.</span><span> </span><span class="NLM_article-title">Potential mechanism-based inhibitors of proteolytic enzymes</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)80445-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0960-894X%2801%2980445-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1992&pages=175-180&author=W.+C.+Groutasauthor=M.+J.+Brubakerauthor=R.+Venkataramanauthor=J.+B.+Eppauthor=N.+Houser-Archieldauthor=L.+S.+Chongauthor=J.+J.+McClenahan&title=Potential+mechanism-based+inhibitors+of+proteolytic+enzymes&doi=10.1016%2FS0960-894X%2801%2980445-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2980445-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252980445-5%26sid%3Dliteratum%253Aachs%26aulast%3DGroutas%26aufirst%3DW.%2BC.%26aulast%3DBrubaker%26aufirst%3DM.%2BJ.%26aulast%3DVenkataraman%26aufirst%3DR.%26aulast%3DEpp%26aufirst%3DJ.%2BB.%26aulast%3DHouser-Archield%26aufirst%3DN.%26aulast%3DChong%26aufirst%3DL.%2BS.%26aulast%3DMcClenahan%26aufirst%3DJ.%2BJ.%26atitle%3DPotential%2520mechanism-based%2520inhibitors%2520of%2520proteolytic%2520enzymes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1992%26volume%3D2%26spage%3D175%26epage%3D180%26doi%3D10.1016%2FS0960-894X%2801%2980445-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hlasta, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boaz, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Court, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franke, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mura, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunlap, R. A.</span><span> </span><span class="NLM_article-title">Benzisothiazolone class of potent, selective mechanism-based inhibitors of human leukocyte elastase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1801</span><span class="NLM_x">–</span> <span class="NLM_lpage">1806</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)80374-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0960-894X%2801%2980374-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1994&pages=1801-1806&author=D.+J.+Hlastaauthor=M.+R.+Bellauthor=N.+W.+Boazauthor=J.+J.+Courtauthor=R.+C.+Desaiauthor=C.+A.+Frankeauthor=A.+J.+Muraauthor=C.+Subramanyamauthor=R.+A.+Dunlap&title=Benzisothiazolone+class+of+potent%2C+selective+mechanism-based+inhibitors+of+human+leukocyte+elastase&doi=10.1016%2FS0960-894X%2801%2980374-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2980374-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252980374-7%26sid%3Dliteratum%253Aachs%26aulast%3DHlasta%26aufirst%3DD.%2BJ.%26aulast%3DBell%26aufirst%3DM.%2BR.%26aulast%3DBoaz%26aufirst%3DN.%2BW.%26aulast%3DCourt%26aufirst%3DJ.%2BJ.%26aulast%3DDesai%26aufirst%3DR.%2BC.%26aulast%3DFranke%26aufirst%3DC.%2BA.%26aulast%3DMura%26aufirst%3DA.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DDunlap%26aufirst%3DR.%2BA.%26atitle%3DBenzisothiazolone%2520class%2520of%2520potent%252C%2520selective%2520mechanism-based%2520inhibitors%2520of%2520human%2520leukocyte%2520elastase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1994%26volume%3D4%26spage%3D1801%26epage%3D1806%26doi%3D10.1016%2FS0960-894X%2801%2980374-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hlasta, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Court, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cundy, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maycock, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span> </span><span class="NLM_article-title">The design of potent and stable benzisothiazolone inhibitors of human leukocyte elastase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1016/0960-894X(95)00030-W</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2F0960-894X%2895%2900030-W" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1995&pages=331-336&author=D.+J.+Hlastaauthor=M.+R.+Bellauthor=J.+J.+Courtauthor=K.+C.+Cundyauthor=R.+C.+Desaiauthor=E.+W.+Fergusonauthor=R.+J.+Gordonauthor=V.+Kumarauthor=A.+L.+Maycockauthor=C.+Subramanyam&title=The+design+of+potent+and+stable+benzisothiazolone+inhibitors+of+human+leukocyte+elastase&doi=10.1016%2F0960-894X%2895%2900030-W"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28c&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2895%2900030-W&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252895%252900030-W%26sid%3Dliteratum%253Aachs%26aulast%3DHlasta%26aufirst%3DD.%2BJ.%26aulast%3DBell%26aufirst%3DM.%2BR.%26aulast%3DCourt%26aufirst%3DJ.%2BJ.%26aulast%3DCundy%26aufirst%3DK.%2BC.%26aulast%3DDesai%26aufirst%3DR.%2BC.%26aulast%3DFerguson%26aufirst%3DE.%2BW.%26aulast%3DGordon%26aufirst%3DR.%2BJ.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DMaycock%26aufirst%3DA.%2BL.%26aulast%3DSubramanyam%26aufirst%3DC.%26atitle%3DThe%2520design%2520of%2520potent%2520and%2520stable%2520benzisothiazolone%2520inhibitors%2520of%2520human%2520leukocyte%2520elastase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1995%26volume%3D5%26spage%3D331%26epage%3D336%26doi%3D10.1016%2F0960-894X%2895%2900030-W" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Groutas, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkataraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epp, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houser-Archield, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoidal, J. R.</span><span> </span><span class="NLM_article-title">Amino acid-derived phthalimide and saccharin derivatives as inhibitors of human leukocyte elastase, cathepsin G and proteinase 3</span> <span class="citation_source-journal">Arch. Biochem. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1006/abbi.1996.0350</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1006%2Fabbi.1996.0350" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=1996&pages=335-340&author=W.+C.+Groutasauthor=L.+S.+Chongauthor=R.+Venkataramanauthor=R.+Kuangauthor=J.+B.+Eppauthor=N.+Houser-Archieldauthor=H.+Huangauthor=J.+R.+Hoidal&title=Amino+acid-derived+phthalimide+and+saccharin+derivatives+as+inhibitors+of+human+leukocyte+elastase%2C+cathepsin+G+and+proteinase+3&doi=10.1006%2Fabbi.1996.0350"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28d&amp;dbid=16384&amp;doi=10.1006%2Fabbi.1996.0350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabbi.1996.0350%26sid%3Dliteratum%253Aachs%26aulast%3DGroutas%26aufirst%3DW.%2BC.%26aulast%3DChong%26aufirst%3DL.%2BS.%26aulast%3DVenkataraman%26aufirst%3DR.%26aulast%3DKuang%26aufirst%3DR.%26aulast%3DEpp%26aufirst%3DJ.%2BB.%26aulast%3DHouser-Archield%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHoidal%26aufirst%3DJ.%2BR.%26atitle%3DAmino%2520acid-derived%2520phthalimide%2520and%2520saccharin%2520derivatives%2520as%2520inhibitors%2520of%2520human%2520leukocyte%2520elastase%252C%2520cathepsin%2520G%2520and%2520proteinase%25203%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D1996%26volume%3D332%26spage%3D335%26epage%3D340%26doi%3D10.1006%2Fabbi.1996.0350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yeung, K.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span> </span><span class="NLM_article-title">A facile construction of 4-hydroxymethylbenzisothiazolone-1,1-dioxide</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1483</span><span class="NLM_x">–</span> <span class="NLM_lpage">1486</span><span class="refDoi"> DOI: 10.1016/S0040-4039(98)00011-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0040-4039%2898%2900011-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=1483-1486&author=K.-S.+Yeungauthor=N.+A.+Meanwellauthor=Y.+Liauthor=Q.+Gao&title=A+facile+construction+of+4-hydroxymethylbenzisothiazolone-1%2C1-dioxide&doi=10.1016%2FS0040-4039%2898%2900011-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2898%2900011-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252898%252900011-2%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DK.-S.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DQ.%26atitle%3DA%2520facile%2520construction%2520of%25204-hydroxymethylbenzisothiazolone-1%252C1-dioxide%26jtitle%3DTetrahedron%2520Lett.%26date%3D1998%26volume%3D39%26spage%3D1483%26epage%3D1486%26doi%3D10.1016%2FS0040-4039%2898%2900011-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit29b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Yeung, K.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">A synthesis of 4-thiomethylbenzisothiazolone-1,1-dioxide using HDPT</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">5309</span><span class="NLM_x">–</span> <span class="NLM_lpage">5312</span><span class="refDoi"> DOI: 10.1016/S0040-4039(98)01074-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0040-4039%2898%2901074-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=5309-5312&author=K.-S.+Yeungauthor=N.+A.+Meanwell&title=A+synthesis+of+4-thiomethylbenzisothiazolone-1%2C1-dioxide+using+HDPT&doi=10.1016%2FS0040-4039%2898%2901074-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2898%2901074-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252898%252901074-0%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DK.-S.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DA%2520synthesis%2520of%25204-thiomethylbenzisothiazolone-1%252C1-dioxide%2520using%2520HDPT%26jtitle%3DTetrahedron%2520Lett.%26date%3D1998%26volume%3D39%26spage%3D5309%26epage%3D5312%26doi%3D10.1016%2FS0040-4039%2898%2901074-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit29c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulgeze, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zulan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisacchi, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, D. G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiler, S. M.</span><span> </span><span class="NLM_article-title">1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">4854</span><span class="NLM_x">–</span> <span class="NLM_lpage">4860</span><span class="refDoi"> DOI: 10.1021/jm9804580</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9804580" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=4854-4860&author=K.+D.+Combrinkauthor=H.+B.+Gulgezeauthor=N.+A.+Meanwellauthor=B.+C.+Pearceauthor=P.+Zulanauthor=G.+S.+Bisacchiauthor=D.+G.+M.+Robertsauthor=P.+Stanleyauthor=S.+M.+Seiler&title=1%2C2-Benzisothiazol-3-one+1%2C1-dioxide+inhibitors+of+human+mast+cell+tryptase&doi=10.1021%2Fjm9804580"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29c&amp;dbid=16384&amp;doi=10.1021%2Fjm9804580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9804580%26sid%3Dliteratum%253Aachs%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DGulgeze%26aufirst%3DH.%2BB.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DPearce%26aufirst%3DB.%2BC.%26aulast%3DZulan%26aufirst%3DP.%26aulast%3DBisacchi%26aufirst%3DG.%2BS.%26aulast%3DRoberts%26aufirst%3DD.%2BG.%2BM.%26aulast%3DStanley%26aufirst%3DP.%26aulast%3DSeiler%26aufirst%3DS.%2BM.%26atitle%3D1%252C2-Benzisothiazol-3-one%25201%252C1-dioxide%2520inhibitors%2520of%2520human%2520mast%2520cell%2520tryptase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D4854%26epage%3D4860%26doi%3D10.1021%2Fjm9804580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Katz, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finer-Moore, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroud, R. M.</span><span> </span><span class="NLM_article-title">Design of potent selective zinc-mediated serine protease inhibitors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">391</span><span class="NLM_x">, </span> <span class="NLM_fpage">608</span><span class="NLM_x">–</span> <span class="NLM_lpage">612</span><span class="refDoi"> DOI: 10.1038/35422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2F35422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=9468142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK1cXhtVSrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=1998&pages=608-612&author=B.+A.+Katzauthor=J.+M.+Clarkauthor=J.+S.+Finer-Mooreauthor=T.+E.+Jenkinsauthor=C.+R.+Johnsonauthor=M.+J.+Rossauthor=C.+Luongauthor=W.+R.+Mooreauthor=R.+M.+Stroud&title=Design+of+potent+selective+zinc-mediated+serine+protease+inhibitors&doi=10.1038%2F35422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30aR"><div class="casContent"><span class="casTitleNuber">30a</span><div class="casTitle"><span class="NLM_cas:atitle">Design of potent selective zinc-mediated serine protease inhibitors</span></div><div class="casAuthors">Katz, Bradley A.; Clark, James M.; Finer-Moore, Janet S.; Jenkins, Thomas E.; Johnson, Charles R.; Ross, Michael J.; Luong, Christine; Moore, William R.; Stroud, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">6667</span>),
    <span class="NLM_cas:pages">608-612</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Many serine proteases are targets for therapeutic intervention because they often play key roles in disease.  Small mol. inhibitors of serine proteases with high affinity are esp. interesting as they could be used as scaffolds from which to develop drugs selective for protease targets.  One such inhibitor is bis(5-amidino-2-benzimidazolyl)methane (BABIM), standing out as the best inhibitor of trypsin (by a factor of over 100) in over 60 relatively closely related analogs.  By probing the structural basis of inhibition, the authors discovered, using crystallog. methods, a new mode of high-affinity binding in which a Zn2+ ion is tetrahedrally coordinated between two chelating nitrogens of BABIM and two active site residues, His 57 and Ser 195, Zn2+, at sub-physiol. levels, enhances inhibition by over 103-fold.  The distinct Zn2+ coordination geometry implies a strong dependence of affinity on substituents.  This unique structural paradigm has enabled development of potent, highly selective, Zn2+-dependent inhibitors of several therapeutically important serine proteases, using a physiol. ubiquitous metal ion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8qw3xlj3NJ7Vg90H21EOLACvtfcHk0licP7tRvAOcuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtVSrtrY%253D&md5=091ffd477397892356b7a5384f3cc5fa</span></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=10.1038%2F35422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35422%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DB.%2BA.%26aulast%3DClark%26aufirst%3DJ.%2BM.%26aulast%3DFiner-Moore%26aufirst%3DJ.%2BS.%26aulast%3DJenkins%26aufirst%3DT.%2BE.%26aulast%3DJohnson%26aufirst%3DC.%2BR.%26aulast%3DRoss%26aufirst%3DM.%2BJ.%26aulast%3DLuong%26aufirst%3DC.%26aulast%3DMoore%26aufirst%3DW.%2BR.%26aulast%3DStroud%26aufirst%3DR.%2BM.%26atitle%3DDesign%2520of%2520potent%2520selective%2520zinc-mediated%2520serine%2520protease%2520inhibitors%26jtitle%3DNature%26date%3D1998%26volume%3D391%26spage%3D608%26epage%3D612%26doi%3D10.1038%2F35422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit30b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Katz, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luong, C.</span><span> </span><span class="NLM_article-title">Recruiting Zn<sup>2+</sup> to mediate potent, specific inhibition of serine proteases</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">292</span><span class="NLM_x">, </span> <span class="NLM_fpage">669</span><span class="NLM_x">–</span> <span class="NLM_lpage">684</span><span class="refDoi"> DOI: 10.1006/jmbi.1999.3071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1006%2Fjmbi.1999.3071" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=1999&pages=669-684&author=B.+A.+Katzauthor=C.+Luong&title=Recruiting+Zn2%2B+to+mediate+potent%2C+specific+inhibition+of+serine+proteases&doi=10.1006%2Fjmbi.1999.3071"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1999.3071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1999.3071%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DB.%2BA.%26aulast%3DLuong%26aufirst%3DC.%26atitle%3DRecruiting%2520Zn2%252B%2520to%2520mediate%2520potent%252C%2520specific%2520inhibition%2520of%2520serine%2520proteases%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1999%26volume%3D292%26spage%3D669%26epage%3D684%26doi%3D10.1006%2Fjmbi.1999.3071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit30c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Janc, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warne, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elrod, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, W. R.</span><span> </span><span class="NLM_article-title">A novel approach to serine protease inhibition: kinetic characterization of inhibitors whose potencies and selectivities are dramatically enhanced by zinc(II)</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">4792</span><span class="NLM_x">–</span> <span class="NLM_lpage">4800</span><span class="refDoi"> DOI: 10.1021/bi992182j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi992182j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=4792-4800&author=J.+W.+Jancauthor=J.+M.+Clarkauthor=R.+L.+Warneauthor=K.+C.+Elrodauthor=B.+A.+Katzauthor=W.+R.+Moore&title=A+novel+approach+to+serine+protease+inhibition%3A+kinetic+characterization+of+inhibitors+whose+potencies+and+selectivities+are+dramatically+enhanced+by+zinc%28II%29&doi=10.1021%2Fbi992182j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30c&amp;dbid=16384&amp;doi=10.1021%2Fbi992182j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi992182j%26sid%3Dliteratum%253Aachs%26aulast%3DJanc%26aufirst%3DJ.%2BW.%26aulast%3DClark%26aufirst%3DJ.%2BM.%26aulast%3DWarne%26aufirst%3DR.%2BL.%26aulast%3DElrod%26aufirst%3DK.%2BC.%26aulast%3DKatz%26aufirst%3DB.%2BA.%26aulast%3DMoore%26aufirst%3DW.%2BR.%26atitle%3DA%2520novel%2520approach%2520to%2520serine%2520protease%2520inhibition%253A%2520kinetic%2520characterization%2520of%2520inhibitors%2520whose%2520potencies%2520and%2520selectivities%2520are%2520dramatically%2520enhanced%2520by%2520zinc%2528II%2529%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D4792%26epage%3D4800%26doi%3D10.1021%2Fbi992182j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yeung, K.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janc, J. W.</span><span> </span><span class="NLM_article-title">Structure-activity relationship studies of a bisbenzimidazole-based, Zn<sup>2+</sup>-dependent inhibitor of HCV NS3 serine protease</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2355</span><span class="NLM_x">–</span> <span class="NLM_lpage">2359</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00457-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0960-894X%2801%2900457-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=2355-2359&author=K.-S.+Yeungauthor=N.+A.+Meanwellauthor=Z.+Qiuauthor=D.+Hernandezauthor=S.+Zhangauthor=F.+McPheeauthor=S.+Weinheimerauthor=J.+M.+Clarkauthor=J.+W.+Janc&title=Structure-activity+relationship+studies+of+a+bisbenzimidazole-based%2C+Zn2%2B-dependent+inhibitor+of+HCV+NS3+serine+protease&doi=10.1016%2FS0960-894X%2801%2900457-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900457-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900457-7%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DK.-S.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DWeinheimer%26aufirst%3DS.%26aulast%3DClark%26aufirst%3DJ.%2BM.%26aulast%3DJanc%26aufirst%3DJ.%2BW.%26atitle%3DStructure-activity%2520relationship%2520studies%2520of%2520a%2520bisbenzimidazole-based%252C%2520Zn2%252B-dependent%2520inhibitor%2520of%2520HCV%2520NS3%2520serine%2520protease%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D2355%26epage%3D2359%26doi%3D10.1016%2FS0960-894X%2801%2900457-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sperandio, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangloff, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litvak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hataye, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elrod, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janc, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, K.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staab, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, J. R.</span><span> </span><span class="NLM_article-title">Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">3129</span><span class="NLM_x">–</span> <span class="NLM_lpage">3133</span><span class="refDoi"> DOI: 10.1016/S0960-894X(02)00680-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0960-894X%2802%2900680-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=3129-3133&author=D.+Sperandioauthor=A.+R.+Gangloffauthor=J.+Litvakauthor=R.+Goldsmithauthor=J.+M.+Hatayeauthor=V.+R.+Wangauthor=E.+J.+Sheltonauthor=K.+Elrodauthor=J.+W.+Jancauthor=J.+M.+Clarkauthor=K.+Riceauthor=S.+Weinheimerauthor=K.-S.+Yeungauthor=N.+A.+Meanwellauthor=D.+Hernandezauthor=A.+J.+Staabauthor=B.+L.+Venablesauthor=J.+R.+Spencer&title=Highly+potent+non-peptidic+inhibitors+of+the+HCV+NS3%2FNS4A+serine+protease&doi=10.1016%2FS0960-894X%2802%2900680-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900680-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900680-7%26sid%3Dliteratum%253Aachs%26aulast%3DSperandio%26aufirst%3DD.%26aulast%3DGangloff%26aufirst%3DA.%2BR.%26aulast%3DLitvak%26aufirst%3DJ.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DHataye%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DV.%2BR.%26aulast%3DShelton%26aufirst%3DE.%2BJ.%26aulast%3DElrod%26aufirst%3DK.%26aulast%3DJanc%26aufirst%3DJ.%2BW.%26aulast%3DClark%26aufirst%3DJ.%2BM.%26aulast%3DRice%26aufirst%3DK.%26aulast%3DWeinheimer%26aufirst%3DS.%26aulast%3DYeung%26aufirst%3DK.-S.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DStaab%26aufirst%3DA.%2BJ.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DSpencer%26aufirst%3DJ.%2BR.%26atitle%3DHighly%2520potent%2520non-peptidic%2520inhibitors%2520of%2520the%2520HCV%2520NS3%252FNS4A%2520serine%2520protease%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D3129%26epage%3D3133%26doi%3D10.1016%2FS0960-894X%2802%2900680-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Steinkühler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span> </span><span class="NLM_article-title"><i>In vitro</i> activity of hepatitis C virus protease NS3 purified from recombinant baculovirus-infected Sf9 cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">271</span><span class="NLM_x">, </span> <span class="NLM_fpage">6367</span><span class="NLM_x">–</span> <span class="NLM_lpage">6373</span><span class="refDoi"> DOI: 10.1074/jbc.271.11.6367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1074%2Fjbc.271.11.6367" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1996&pages=6367-6373&author=C.+Steink%C3%BChlerauthor=L.+Tomeiauthor=R.+De+Francesco&title=In+vitro+activity+of+hepatitis+C+virus+protease+NS3+purified+from+recombinant+baculovirus-infected+Sf9+cells&doi=10.1074%2Fjbc.271.11.6367"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1074%2Fjbc.271.11.6367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.271.11.6367%26sid%3Dliteratum%253Aachs%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DTomei%26aufirst%3DL.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26atitle%3DIn%2520vitro%2520activity%2520of%2520hepatitis%2520C%2520virus%2520protease%2520NS3%2520purified%2520from%2520recombinant%2520baculovirus-infected%2520Sf9%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1996%26volume%3D271%26spage%3D6367%26epage%3D6373%26doi%3D10.1074%2Fjbc.271.11.6367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windsor, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNemar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, H. V.</span><span> </span><span class="NLM_article-title">Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">6208</span><span class="NLM_x">–</span> <span class="NLM_lpage">6213</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1997&pages=6208-6213&author=R.+Zhangauthor=J.+Durkinauthor=W.+T.+Windsorauthor=C.+McNemarauthor=L.+Ramanathanauthor=H.+V.+Le&title=Probing+the+substrate+specificity+of+hepatitis+C+virus+NS3+serine+protease+by+using+synthetic+peptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DDurkin%26aufirst%3DJ.%26aulast%3DWindsor%26aufirst%3DW.%2BT.%26aulast%3DMcNemar%26aufirst%3DC.%26aulast%3DRamanathan%26aufirst%3DL.%26aulast%3DLe%26aufirst%3DH.%2BV.%26atitle%3DProbing%2520the%2520substrate%2520specificity%2520of%2520hepatitis%2520C%2520virus%2520NS3%2520serine%2520protease%2520by%2520using%2520synthetic%2520peptides%26jtitle%3DJ.%2520Virol.%26date%3D1997%26volume%3D71%26spage%3D6208%26epage%3D6213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Urbani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tramontano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinkühler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessi, A.</span><span> </span><span class="NLM_article-title">Substrate specificity of the hepatitis C virus serine protease NS3</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">9204</span><span class="NLM_x">–</span> <span class="NLM_lpage">9209</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=9204-9209&author=A.+Urbaniauthor=E.+Bianchiauthor=F.+Narjesauthor=A.+Tramontanoauthor=R.+De+Francescoauthor=C.+Steink%C3%BChlerauthor=A.+Pessi&title=Substrate+specificity+of+the+hepatitis+C+virus+serine+protease+NS3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUrbani%26aufirst%3DA.%26aulast%3DBianchi%26aufirst%3DE.%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DTramontano%26aufirst%3DA.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DPessi%26aufirst%3DA.%26atitle%3DSubstrate%2520specificity%2520of%2520the%2520hepatitis%2520C%2520virus%2520serine%2520protease%2520NS3%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D9204%26epage%3D9209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Love, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parge, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickersham, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habuka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moomaw, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomska, Z.</span><span> </span><span class="NLM_article-title">The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)81350-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0092-8674%2800%2981350-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=8861916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK28XmsVGhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1996&pages=331-342&author=R.+A.+Loveauthor=H.+E.+Pargeauthor=J.+A.+Wickershamauthor=Z.+Hostomskyauthor=N.+Habukaauthor=E.+W.+Moomawauthor=T.+Adachiauthor=Z.+Hostomska&title=The+crystal+structure+of+hepatitis+C+virus+NS3+proteinase+reveals+a+trypsin-like+fold+and+a+structural+zinc+binding+site&doi=10.1016%2FS0092-8674%2800%2981350-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site</span></div><div class="casAuthors">Love, Robert A.; parge, Hans E.; Wickersham, John A.; Hostomsky, Zdenek; Habuka, Noriyuki; Moomaw, Ellen W.; Adachi, Tsuyoshi; Hostomska, Zuzana</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">331-342</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">During replication of hepatitis C virus (HCV), the final steps of polyprotein processing are performed by a viral proteinase located in the N-terminal 1/3 of nonstructural protein 3 (NS3).  Here, the structure of NS3 proteinase (I) from HCV BK strain was detd. by x-ray crystallog. at 2.4 Å resoln.  I folded as a trypsin-like proteinase with 2 β-barrels and a catalytic triad of His-57, Asp-81, Ser-139.  The I structure had a substrate-binding site consistent with the cleavage specificity of the enzyme.  Novel features included a structural Zn-binding site and a long N-terminus that interacted with neighboring mols. by binding to a hydrophobic surface patch.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokLfJmy4sb-7Vg90H21EOLACvtfcHk0lhBOMntH5t0Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVGhsb0%253D&md5=1dbf21ea1276378b47b809971969d895</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981350-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981350-1%26sid%3Dliteratum%253Aachs%26aulast%3DLove%26aufirst%3DR.%2BA.%26aulast%3DParge%26aufirst%3DH.%2BE.%26aulast%3DWickersham%26aufirst%3DJ.%2BA.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DMoomaw%26aufirst%3DE.%2BW.%26aulast%3DAdachi%26aufirst%3DT.%26aulast%3DHostomska%26aufirst%3DZ.%26atitle%3DThe%2520crystal%2520structure%2520of%2520hepatitis%2520C%2520virus%2520NS3%2520proteinase%2520reveals%2520a%2520trypsin-like%2520fold%2520and%2520a%2520structural%2520zinc%2520binding%2520site%26jtitle%3DCell%26date%3D1996%26volume%3D87%26spage%3D331%26epage%3D342%26doi%3D10.1016%2FS0092-8674%2800%2981350-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgenstern, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landro, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markland, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepre, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Malley, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harbeson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murcko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, J. A.</span><span> </span><span class="NLM_article-title">Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">343</span><span class="NLM_x">–</span> <span class="NLM_lpage">355</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)81351-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0092-8674%2800%2981351-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=8861917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK28XmsVGhsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1996&pages=343-355&author=J.+L.+Kimauthor=K.+A.+Morgensternauthor=C.+Linauthor=T.+Foxauthor=M.+D.+Dwyerauthor=J.+A.+Landroauthor=S.+P.+Chambersauthor=W.+Marklandauthor=C.+A.+Lepreauthor=E.+T.+O%E2%80%99Malleyauthor=S.+L.+Harbesonauthor=C.+M.+Riceauthor=M.+A.+Murckoauthor=P.+R.+Caronauthor=J.+A.+Thomson&title=Crystal+structure+of+the+hepatitis+C+virus+NS3+protease+domain+complexed+with+a+synthetic+NS4A+cofactor+peptide&doi=10.1016%2FS0092-8674%2800%2981351-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide</span></div><div class="casAuthors">Kim, J. L.; Morgenstern, K. A.; Lin, C.; Fox, T.; Dwyer, M. D.; Landro, J. A.; Chambers, S. P.; Markland, W.; Lepre, C. A.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">343-355</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">An estd. 1% of the global human population is infected by hepatitis C viruses (HCVs), and there are no broadly effective treatments for the debilitating progression of chronic hepatitis C.  A serine protease located within the HCV NS3 protein processes the viral polyprotein at four specific sites and is considered essential for replication.  Thus, it emerges as an attractive target for drug design.  We report here the 2.5 Å resoln. X-ray crystal structure of the NS3 protease domain complexed with a synthetic NS4A activator peptide.  The protease has a chymotrypsin-like fold and features a tetrahedrally coordinated metal ion distal to the active site.  The NS4A peptide intercalates within a β sheet of the enzyme core.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX5CClA0eyj7Vg90H21EOLACvtfcHk0lgC4tq6Uh9TRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsVGhsbo%253D&md5=c6bdc0d069608e019fee3960c76df429</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981351-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981351-3%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DMorgenstern%26aufirst%3DK.%2BA.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DFox%26aufirst%3DT.%26aulast%3DDwyer%26aufirst%3DM.%2BD.%26aulast%3DLandro%26aufirst%3DJ.%2BA.%26aulast%3DChambers%26aufirst%3DS.%2BP.%26aulast%3DMarkland%26aufirst%3DW.%26aulast%3DLepre%26aufirst%3DC.%2BA.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DE.%2BT.%26aulast%3DHarbeson%26aufirst%3DS.%2BL.%26aulast%3DRice%26aufirst%3DC.%2BM.%26aulast%3DMurcko%26aufirst%3DM.%2BA.%26aulast%3DCaron%26aufirst%3DP.%2BR.%26aulast%3DThomson%26aufirst%3DJ.%2BA.%26atitle%3DCrystal%2520structure%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520domain%2520complexed%2520with%2520a%2520synthetic%2520NS4A%2520cofactor%2520peptide%26jtitle%3DCell%26date%3D1996%26volume%3D87%26spage%3D343%26epage%3D355%26doi%3D10.1016%2FS0092-8674%2800%2981351-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laplante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurice, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibeault, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span> </span><span class="NLM_article-title">Peptide-based inhibitors of the hepatitis C virus serine protease</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1713</span><span class="NLM_x">–</span> <span class="NLM_lpage">1718</span><span class="refDoi"> DOI: 10.1016/S0960-894X(98)00299-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0960-894X%2898%2900299-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=1713-1718&author=M.+Llin%C3%A0s-Brunetauthor=M.+Baileyauthor=G.+Fazalauthor=S.+Gouletauthor=T.+Halmosauthor=S.+Laplanteauthor=R.+Mauriceauthor=M.+Poirierauthor=M.-A.+Poupartauthor=D.+Thibeaultauthor=D.+Wernicauthor=D.+Lamarre&title=Peptide-based+inhibitors+of+the+hepatitis+C+virus+serine+protease&doi=10.1016%2FS0960-894X%2898%2900299-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900299-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900299-6%26sid%3Dliteratum%253Aachs%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DFazal%26aufirst%3DG.%26aulast%3DGoulet%26aufirst%3DS.%26aulast%3DHalmos%26aufirst%3DT.%26aulast%3DLaplante%26aufirst%3DS.%26aulast%3DMaurice%26aufirst%3DR.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DPoupart%26aufirst%3DM.-A.%26aulast%3DThibeault%26aufirst%3DD.%26aulast%3DWernic%26aufirst%3DD.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DPeptide-based%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520serine%2520protease%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D1713%26epage%3D1718%26doi%3D10.1016%2FS0960-894X%2898%2900299-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit34b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Steinkühler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biasiol, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortese, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span> </span><span class="NLM_article-title">Product inhibition of the hepatitis C virus NS3 protease</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">8899</span><span class="NLM_x">–</span> <span class="NLM_lpage">8905</span><span class="refDoi"> DOI: 10.1021/bi980313v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi980313v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=8899-8905&author=C.+Steink%C3%BChlerauthor=G.+Biasiolauthor=M.+Brunettiauthor=A.+Urbaniauthor=U.+Kochauthor=R.+Corteseauthor=A.+Pessiauthor=R.+De+Francesco&title=Product+inhibition+of+the+hepatitis+C+virus+NS3+protease&doi=10.1021%2Fbi980313v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.1021%2Fbi980313v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi980313v%26sid%3Dliteratum%253Aachs%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DBiasiol%26aufirst%3DG.%26aulast%3DBrunetti%26aufirst%3DM.%26aulast%3DUrbani%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DCortese%26aufirst%3DR.%26aulast%3DPessi%26aufirst%3DA.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26atitle%3DProduct%2520inhibition%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D8899%26epage%3D8905%26doi%3D10.1021%2Fbi980313v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit34c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ingallinella, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taliani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingenito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortese, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinkühler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pessi, A.</span><span> </span><span class="NLM_article-title">Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">8906</span><span class="NLM_x">–</span> <span class="NLM_lpage">8914</span><span class="refDoi"> DOI: 10.1021/bi980314n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi980314n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK1cXjsFeiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=8906-8914&author=P.+Ingallinellaauthor=S.+Altamuraauthor=E.+Bianchiauthor=M.+Talianiauthor=R.+Ingenitoauthor=R.+Corteseauthor=R.+De+Francescoauthor=C.+Steink%C3%BChlerauthor=A.+Pessi&title=Potent+peptide+inhibitors+of+human+hepatitis+C+virus+NS3+protease+are+obtained+by+optimizing+the+cleavage+products&doi=10.1021%2Fbi980314n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34cR"><div class="casContent"><span class="casTitleNuber">34c</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage Products</span></div><div class="casAuthors">Ingallinella, Paolo; Altamura, Sergio; Bianchi, Elisabetta; Taliani, Marina; Ingenito, Raffaele; Cortese, Riccardo; De Francesco, Raffaele; Steinkuehler, Christian; Pessi, Antonello</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">8906-8914</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the absence of a broadly effective cure for hepatitis caused by hepatitis C virus (HCV), much effort is currently devoted to the search for inhibitors of the virally encoded protease NS3.  This chymotrypsin-like serine protease is required for the maturation of the viral polyprotein, cleaving it at the NS3-NS4A, NS4A-NS4B, NS4B-NS5A, and NS5A-NS5B sites.  In the course of our studies on the substrate specificity of NS3, the authors found that the products of cleavage corresponding to the P6-P1 region of the substrates act as competitive inhibitors of the enzyme, with IC50s ranging from 360 to 1 μM.  A detailed study of product inhibition by the natural NS3 substrates is described in the preceding paper [Steinkuhler, C., et al. (1997) Biochem. 37].  Here the authors report the results of a study of the structure-activity relationship of the NS3 product inhibitors, which suggest that the mode of binding of the P region-derived products is similar to the ground-state binding of the corresponding substrates, with addnl. binding energy provided by the C-terminal carboxylate.  Optimal binding requires a dual anchor: an "acid anchor" at the N terminus and a "P1 anchor" at the C-terminal part of the mol.  The authors have then optimized the sequence of the product inhibitors by using single mutations and combinatorial peptide libraries based on the most potent natural product, Ac-Asp-Glu-Met-Glu-Glu-Cys-OH (Ki = 0.6 μM), derived from cleavage at the NS4A-NS4B junction.  By sequentially optimizing positions P2, P4, P3, and P5, the authors obtained several nanomolar inhibitors of the enzyme.  These compds. are useful both as a starting point for the development of peptidomimetic drugs and as structural probes for investigating the substrate binding site of NS3 by modeling, NMR, and crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4KmZ8PDEEKrVg90H21EOLACvtfcHk0lhMWdmIwoVEJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjsFeiu70%253D&md5=d6ad2b6766249fc695c3e91167bbdc1b</span></div><a href="/servlet/linkout?suffix=cit34c&amp;dbid=16384&amp;doi=10.1021%2Fbi980314n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi980314n%26sid%3Dliteratum%253Aachs%26aulast%3DIngallinella%26aufirst%3DP.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DBianchi%26aufirst%3DE.%26aulast%3DTaliani%26aufirst%3DM.%26aulast%3DIngenito%26aufirst%3DR.%26aulast%3DCortese%26aufirst%3DR.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DPessi%26aufirst%3DA.%26atitle%3DPotent%2520peptide%2520inhibitors%2520of%2520human%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520are%2520obtained%2520by%2520optimizing%2520the%2520cleavage%2520products%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D8906%26epage%3D8914%26doi%3D10.1021%2Fbi980314n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Narjes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colarusso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinkühler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matassa, V. G.</span><span> </span><span class="NLM_article-title">A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">701</span><span class="NLM_x">–</span> <span class="NLM_lpage">704</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00842-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0960-894X%2801%2900842-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=11844705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtFKqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=701-704&author=F.+Narjesauthor=K.+F.+Koehlerauthor=U.+Kochauthor=B.+Gerlachauthor=S.+Colarussoauthor=C.+Steink%C3%BChlerauthor=M.+Brunettiauthor=S.+Altamuraauthor=R.+De+Francescoauthor=V.+G.+Matassa&title=A+designed+P1+cysteine+mimetic+for+covalent+and+non-covalent+inhibitors+of+HCV+NS3+protease&doi=10.1016%2FS0960-894X%2801%2900842-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35aR"><div class="casContent"><span class="casTitleNuber">35a</span><div class="casTitle"><span class="NLM_cas:atitle">A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease</span></div><div class="casAuthors">Narjes, Frank; Koehler, Konrad F.; Koch, Uwe; Gerlach, Benjamin; Colarusso, Stefania; Steinkuhler, Christian; Brunetti, Mirko; Altamura, Sergio; De Francesco, Raffaele; Matassa, Victor G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">701-704</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The difluoromethyl group was designed by computational chem. methods as a mimetic of the canonical P1 cysteine thiol for inhibitors of the hepatitis C virus NS3 protease.  This modification led to the development of competitive, non-covalent inhibitor AcAspGlu-NHCH(CHPH2)CO-Glu-NHCH(CH2C6H11)CONHCH(CH2CHF2)R (I, R = CHO) Ki 30 nM and reversible covalent inhibitors (I, R = CO2H) Ki 0.5 nM; and (I, R = COCO2H) Ki* 10 pM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVoMg5xhUdXbVg90H21EOLACvtfcHk0lgB43kt_mNBzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtFKqur8%253D&md5=3797b78c5827e4db42a7170844d0c0cb</span></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900842-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900842-3%26sid%3Dliteratum%253Aachs%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DKoehler%26aufirst%3DK.%2BF.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DGerlach%26aufirst%3DB.%26aulast%3DColarusso%26aufirst%3DS.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DBrunetti%26aufirst%3DM.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DMatassa%26aufirst%3DV.%2BG.%26atitle%3DA%2520designed%2520P1%2520cysteine%2520mimetic%2520for%2520covalent%2520and%2520non-covalent%2520inhibitors%2520of%2520HCV%2520NS3%2520protease%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D701%26epage%3D704%26doi%3D10.1016%2FS0960-894X%2801%2900842-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Erickson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLoughlin, J. I.</span><span> </span><span class="NLM_article-title">Hydrogen bond donor properties of the difluoromethyl group</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1626</span><span class="NLM_x">–</span> <span class="NLM_lpage">1631</span><span class="refDoi"> DOI: 10.1021/jo00111a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00111a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK2MXktleksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1995&pages=1626-1631&author=J.+A.+Ericksonauthor=J.+I.+McLoughlin&title=Hydrogen+bond+donor+properties+of+the+difluoromethyl+group&doi=10.1021%2Fjo00111a021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35bR"><div class="casContent"><span class="casTitleNuber">35b</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrogen Bond Donor Properties of the Difluoromethyl Group</span></div><div class="casAuthors">Erickson, Jon A.; McLoughlin, Jim I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1626-31</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A theor. and exptl. study of the existence and the properties of the difluoromethyl group acting as a hydrogen bond donor has been carried out.  An intramol. CF2H...O:C interaction was examd. using semiempirical MO calcns. of both a non-hydrogen-bonded and hydrogen-bonded conformation of a CF2H-substituted pyrazolecarboxamide fungicide.  Results revealed a short H...O contact, a significant energy stabilization, and a lowering in the IR spectrum of 22 cm-1.  The exptl. IR spectrum of this mol. gave two carbonyl stretching frequencies, one lower by 18 cm-1, very similar to the calcd. no.  Low-temp. NMR results are also consistent with a geometry having the possibility of an intramol. CF2H...O:C hydrogen bond.  The hydrogen bond in this system may be related to the enhanced biol. activity of the CF2H compd. over its CF3 counterpart.  In addn., ab initio MO methods were employed to examine inter- and intramol. hydrogen-bonding models of the difluoromethyl group.  The results showed that the CF2H...O:C interaction has a binding energy of ∼1.0 kcal mol-1 and a H...O distance of ∼2.4 Å.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV4ifnttVlabVg90H21EOLACvtfcHk0lgB43kt_mNBzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXktleksrY%253D&md5=efa305f99bfa66ac92aa3b72942289b4</span></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=10.1021%2Fjo00111a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00111a021%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DJ.%2BA.%26aulast%3DMcLoughlin%26aufirst%3DJ.%2BI.%26atitle%3DHydrogen%2520bond%2520donor%2520properties%2520of%2520the%2520difluoromethyl%2520group%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1995%26volume%3D60%26spage%3D1626%26epage%3D1631%26doi%3D10.1021%2Fjo00111a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Synopsis of some recent tactical application of bioisosteres in drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2529</span><span class="NLM_x">–</span> <span class="NLM_lpage">2591</span><span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+some+recent+tactical+application+of+bioisosteres+in+drug+design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0lhXRMu27xQ9qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520some%2520recent%2520tactical%2520application%2520of%2520bioisosteres%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Narjes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colarusso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biasiol, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fattori, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francesco, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matassa, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinkühler, C.</span><span> </span><span class="NLM_article-title">α-Ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1849</span><span class="NLM_x">–</span> <span class="NLM_lpage">1861</span><span class="refDoi"> DOI: 10.1021/bi9924260</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi9924260" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2000&pages=1849-1861&author=F.+Narjesauthor=M.+Brunettiauthor=S.+Colarussoauthor=B.+Gerlachauthor=U.+Kochauthor=G.+Biasiolauthor=D.+Fattoriauthor=R.+D.+Francescoauthor=V.+G.+Matassaauthor=C.+Steink%C3%BChler&title=%CE%B1-Ketoacids+are+potent+slow+binding+inhibitors+of+the+hepatitis+C+virus+NS3+protease&doi=10.1021%2Fbi9924260"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=10.1021%2Fbi9924260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi9924260%26sid%3Dliteratum%253Aachs%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DBrunetti%26aufirst%3DM.%26aulast%3DColarusso%26aufirst%3DS.%26aulast%3DGerlach%26aufirst%3DB.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DBiasiol%26aufirst%3DG.%26aulast%3DFattori%26aufirst%3DD.%26aulast%3DFrancesco%26aufirst%3DR.%2BD.%26aulast%3DMatassa%26aufirst%3DV.%2BG.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26atitle%3D%25CE%25B1-Ketoacids%2520are%2520potent%2520slow%2520binding%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%26jtitle%3DBiochemistry%26date%3D2000%26volume%3D39%26spage%3D1849%26epage%3D1861%26doi%3D10.1021%2Fbi9924260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Di Marco, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colarusso, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matassa, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sollazzo, M.</span><span> </span><span class="NLM_article-title">Inhibition of the hepatitis C virus NS3/4A protease: the crystal structures of two protease-inhibitor complexes</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">275</span><span class="NLM_x">, </span> <span class="NLM_fpage">7152</span><span class="NLM_x">–</span> <span class="NLM_lpage">7157</span><span class="refDoi"> DOI: 10.1074/jbc.275.10.7152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1074%2Fjbc.275.10.7152" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=7152-7157&author=S.+Di+Marcoauthor=M.+Rizziauthor=C.+Volpariauthor=M.+A.+Walshauthor=F.+Narjesauthor=S.+Colarussoauthor=R.+De+Francescoauthor=V.+G.+Matassaauthor=M.+Sollazzo&title=Inhibition+of+the+hepatitis+C+virus+NS3%2F4A+protease%3A+the+crystal+structures+of+two+protease-inhibitor+complexes&doi=10.1074%2Fjbc.275.10.7152"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.275.10.7152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.275.10.7152%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMarco%26aufirst%3DS.%26aulast%3DRizzi%26aufirst%3DM.%26aulast%3DVolpari%26aufirst%3DC.%26aulast%3DWalsh%26aufirst%3DM.%2BA.%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DColarusso%26aufirst%3DS.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DMatassa%26aufirst%3DV.%2BG.%26aulast%3DSollazzo%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%252F4A%2520protease%253A%2520the%2520crystal%2520structures%2520of%2520two%2520protease-inhibitor%2520complexes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D7152%26epage%3D7157%26doi%3D10.1074%2Fjbc.275.10.7152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perni, R. B.</span><span> </span><span class="NLM_article-title">Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3–4A serine protease</span> <span class="citation_source-journal">Infect. Disord.: Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span><span class="refDoi"> DOI: 10.2174/187152606776056706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.2174%2F187152606776056706" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=3-16&author=C.+Linauthor=A.+D.+Kwongauthor=R.+B.+Perni&title=Discovery+and+development+of+VX-950%2C+a+novel%2C+covalent%2C+and+reversible+inhibitor+of+hepatitis+C+virus+NS3%E2%80%934A+serine+protease&doi=10.2174%2F187152606776056706"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=10.2174%2F187152606776056706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152606776056706%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.%26aulast%3DKwong%26aufirst%3DA.%2BD.%26aulast%3DPerni%26aufirst%3DR.%2BB.%26atitle%3DDiscovery%2520and%2520development%2520of%2520VX-950%252C%2520a%2520novel%252C%2520covalent%252C%2520and%2520reversible%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520NS3%25E2%2580%25934A%2520serine%2520protease%26jtitle%3DInfect.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2006%26volume%3D6%26spage%3D3%26epage%3D16%26doi%3D10.2174%2F187152606776056706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit38b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kwong, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauffman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, P.</span><span> </span><span class="NLM_article-title">Discovery and development of telaprevir: an NS3–4A protease inhibitor for treating genotype 1 chronic hepatitis C virus</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">993</span><span class="NLM_x">–</span> <span class="NLM_lpage">1003</span><span class="refDoi"> DOI: 10.1038/nbt.2020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnbt.2020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=22068541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVCntLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=993-1003&author=A.+D.+Kwongauthor=R.+S.+Kauffmanauthor=P.+Hurterauthor=P.+Mueller&title=Discovery+and+development+of+telaprevir%3A+an+NS3%E2%80%934A+protease+inhibitor+for+treating+genotype+1+chronic+hepatitis+C+virus&doi=10.1038%2Fnbt.2020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38bR"><div class="casContent"><span class="casTitleNuber">38b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus</span></div><div class="casAuthors">Kwong, Ann D.; Kauffman, Robert S.; Hurter, Patricia; Mueller, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">993-1003</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Infection with hepatitis C virus (HCV) is a major medical problem with over 170 million people infected worldwide.  Substantial morbidity and mortality are assocd. with hepatic manifestations (cirrhosis and hepatocellular carcinoma), which develop with increasing frequency in people infected with HCV for more than 20 years.  Less well known is the burden of HCV disease assocd. with extrahepatic manifestations (diabetes, B-cell proliferative disorders, depression, cognitive disorders, arthritis and Sjoegren's syndrome).  For patients infected with genotype 1 HCV, treatment with polyethylene glycol decorated interferon (peginterferon) α and ribavirin (PR) is assocd. with a low (40-50%) success rate, substantial treatment-limiting side effects and a long (48-wk) duration of treatment.  In the past 15 years, major scientific advances have enabled the development of new classes of HCV therapy, the direct-acting antiviral agents, also known as specifically targeted antiviral therapy for hepatitis C (STAT-C).  In combination with PR, the HCV NS3-4A protease inhibitor telaprevir has recently been approved for treatment of genotype 1 chronic HCV in the United States, Canada, European Union and Japan.  Compared with PR, telaprevir combination therapy offers significantly improved viral cure rates and the possibility of shortened treatment duration for diverse patient populations.  Developers of innovative drugs have to blaze a new path with few validated sign posts to guide the way.  Indeed, telaprevir's development was once put on hold because of its performance in a std. IC50 assay.  Data from new hypotheses and novel expts. were required to justify further investment and reduce risk that the drug might fail in the clinic.  In addn., the poor drug-like properties of telaprevir were a formidable hurdle, which the manufg. and formulation teams had to overcome to make the drug.  Finally, novel clin. trial designs were developed to improve efficacy and shorten treatment in parallel instead of sequentially.  Lessons learned from the development of telaprevir suggest that makers of innovative medicines cannot rely solely on traditional drug discovery metrics, but must develop innovative, scientifically guided pathways for success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodUEHshXTAvbVg90H21EOLACvtfcHk0lhc9LAVtO1izA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVCntLvJ&md5=952966419a2e72107550d0a63c337ae4</span></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2020%26sid%3Dliteratum%253Aachs%26aulast%3DKwong%26aufirst%3DA.%2BD.%26aulast%3DKauffman%26aufirst%3DR.%2BS.%26aulast%3DHurter%26aufirst%3DP.%26aulast%3DMueller%26aufirst%3DP.%26atitle%3DDiscovery%2520and%2520development%2520of%2520telaprevir%253A%2520an%2520NS3%25E2%2580%25934A%2520protease%2520inhibitor%2520for%2520treating%2520genotype%25201%2520chronic%2520hepatitis%2520C%2520virus%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D993%26epage%3D1003%26doi%3D10.1038%2Fnbt.2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, N.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piwinski, J. J.</span><span> </span><span class="NLM_article-title">Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">50</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span><span class="refDoi"> DOI: 10.1021/ar700109k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar700109k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlCgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=50-59&author=F.+G.+Njorogeauthor=K.+X.+Chenauthor=N.-Y.+Shihauthor=J.+J.+Piwinski&title=Challenges+in+modern+drug+discovery%3A+a+case+study+of+boceprevir%2C+an+HCV+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Far700109k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges in Modern Drug Discovery: A Case Study of Boceprevir, an HCV Protease Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Njoroge, F. George; Chen, Kevin X.; Shih, Neng-Yang; Piwinski, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-59</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  More than 170 million people worldwide are affected by the hepatitis C virus (HCV).  The disease has been described as a "silent epidemic" and "a serious global health crisis".  HCV infection is a leading cause of chronic liver disease such as cirrhosis, carcinoma, or liver failure.  The current pegylated interferon and ribavirin combination therapy is effective in only 50% of patients.  Its moderate efficacy and apparent side effects underscore the need for safer and more effective treatments.  The nonstructural NS3 protease of the virus plays a vital role in the replication of the HCV virus.  The development of small mol. inhibitors of NS3 protease as antiviral agents has been intensively pursued as a viable strategy to eradicate HCV infection.  However, it is a daunting task.  The protease has a shallow and solvent-exposed substrate binding region, and the inhibitor binding energy is mainly derived from weak lipophilic and electrostatic interactions.  Moreover, lack of a robust in vitro cell culture system and the absence of a convenient small animal model have hampered the assessment of both in vitro and in vivo efficacy of any antiviral compds.  Despite the tremendous challenges, with access to a recently developed cell-based replicon system, major progress has been made toward a more effective small mol. HCV drug.  In our HCV program, facing no leads from our screening effort, a structure-based drug design approach was carried out.  An α-ketoamide-type electrofile was designed to trap the serine hydroxyl of the protease.  Early ketoamide inhibitors mimicked the structures of the peptide substrates.  With the aid of X-ray structures, we successfully truncated the undecapeptide lead that had a mol. wt. of 1265 Da stepwise to a tripeptide with a mol. wt. of 500 Da.  In an attempt to depeptidize the inhibitors, various strategies such as hydrazine urea replacement of amide bonds and P2 to P4 and P1 to P3 macrocyclizations were examd.  Further optimization of the tripeptide inhibitors led to the identification of the best moieties for each site: primary ketoamide at P', cyclobutylalanine at P1, gem-dimethylcyclopropylproline at P2, tert-leucine at P3, and tert-Bu urea as capping agent.  The combination of these led to the discovery of compd. 8 (SCH 503034, boceprevir), our clin. candidate.  It is a potent inhibitor in both enzyme assay (Ki* = 14 nM) and cell-based replicon assay (EC90 = 0.35 μM).  It is highly selective (2200×) against human neutrophil elastase (HNE).  Boceprevir is well tolerated in humans and demonstrated antiviral activity in phase I clin. trials.  It is currently in phase II trials.  This Account details the complexity and challenges encountered in the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouDZPm8xBmjrVg90H21EOLACvtfcHk0ljyfNvmHrF6Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlCgsw%253D%253D&md5=98c07ae0d013b72c6f06a06655ba8d82</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1021%2Far700109k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far700109k%26sid%3Dliteratum%253Aachs%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26aulast%3DChen%26aufirst%3DK.%2BX.%26aulast%3DShih%26aufirst%3DN.-Y.%26aulast%3DPiwinski%26aufirst%3DJ.%2BJ.%26atitle%3DChallenges%2520in%2520modern%2520drug%2520discovery%253A%2520a%2520case%2520study%2520of%2520boceprevir%252C%2520an%2520HCV%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D50%26epage%3D59%26doi%3D10.1021%2Far700109k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit39b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Venkatraman, S.</span><span> </span><span class="NLM_article-title">Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">289</span><span class="refDoi"> DOI: 10.1016/j.tips.2012.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.tips.2012.03.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=289-289&author=S.+Venkatraman&title=Discovery+of+boceprevir%2C+a+direct-acting+NS3%2F4A+protease+inhibitor+for+treatment+of+chronic+hepatitis+C+infections&doi=10.1016%2Fj.tips.2012.03.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2012.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2012.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatraman%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520boceprevir%252C%2520a%2520direct-acting%2520NS3%252F4A%2520protease%2520inhibitor%2520for%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520infections%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2012%26volume%3D33%26spage%3D289%26epage%3D289%26doi%3D10.1016%2Fj.tips.2012.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit39c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Venkatraman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogen, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arasappan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jao, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parekh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santhanam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vibulbhan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butkiewicz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingravallo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pichardo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baroudy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malcolm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prongay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madison, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broske, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brisson, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prelusky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korfmacher, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogdanowich-Knipp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlovsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saksena, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganguly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piwinski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girijavallabhan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njoroge, F. G.</span><span> </span><span class="NLM_article-title">Discovery of (1<i>R</i>,5<i>S</i>)-<i>N</i>-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(<i>S</i>)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(<i>S</i>)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6074</span><span class="NLM_x">–</span> <span class="NLM_lpage">6086</span><span class="refDoi"> DOI: 10.1021/jm060325b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060325b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlOlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6074-6086&author=S.+Venkatramanauthor=S.+L.+Bogenauthor=A.+Arasappanauthor=F.+Bennettauthor=K.+Chenauthor=E.+Jaoauthor=Y.-T.+Liuauthor=R.+Loveyauthor=S.+Hendrataauthor=Y.+Huangauthor=W.+Panauthor=T.+Parekhauthor=P.+Pintoauthor=V.+Popovauthor=R.+Pikeauthor=S.+Ruanauthor=B.+Santhanamauthor=B.+Vibulbhanauthor=W.+Wuauthor=W.+Yangauthor=J.+Kongauthor=X.+Liangauthor=J.+Wongauthor=R.+Liuauthor=N.+Butkiewiczauthor=R.+Chaseauthor=A.+Hartauthor=S.+Agrawalauthor=P.+Ingravalloauthor=J.+Pichardoauthor=R.+Kongauthor=B.+Baroudyauthor=B.+Malcolmauthor=Z.+Guoauthor=A.+Prongayauthor=V.+Madisonauthor=L.+Broskeauthor=X.+Cuiauthor=K.-C.+Chengauthor=Y.+Hsiehauthor=J.-M.+Brissonauthor=D.+Preluskyauthor=W.+Korfmacherauthor=R.+Whiteauthor=S.+Bogdanowich-Knippauthor=A.+Pavlovskyauthor=P.+Bradleyauthor=A.+K.+Saksenaauthor=A.+Gangulyauthor=J.+Piwinskiauthor=V.+Girijavallabhanauthor=F.+G.+Njoroge&title=Discovery+of+%281R%2C5S%29-N-%5B3-amino-1-%28cyclobutylmethyl%29-2%2C3-dioxopropyl%5D-3-%5B2%28S%29-%5B%5B%5B%281%2C1-dimethylethyl%29amino%5Dcarbonyl%5Damino%5D-3%2C3-dimethyl-1-oxobutyl%5D-6%2C6-dimethyl-3-azabicyclo%5B3.1.0%5Dhexan-2%28S%29-carboxamide+%28SCH+503034%29%2C+a+selective%2C+potent%2C+orally+bioavailable+hepatitis+C+virus+NS3+protease+inhibitor%3A+a+potential+therapeutic+agent+for+the+treatment+of+hepatitis+C+infection&doi=10.1021%2Fjm060325b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39cR"><div class="casContent"><span class="casTitleNuber">39c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection</span></div><div class="casAuthors">Venkatraman, Srikanth; Bogen, Stephane L.; Arasappan, Ashok; Bennett, Frank; Chen, Kevin; Jao, Edwin; Liu, Yi-Tsung; Lovey, Raymond; Hendrata, Siska; Huang, Yuhua; Pan, Weidong; Parekh, Tejal; Pinto, Patrick; Popov, Veljko; Pike, Russel; Ruan, Sumei; Santhanam, Bama; Vibulbhan, Bancha; Wu, Wanli; Yang, Weiying; Kong, Jianshe; Liang, Xiang; Wong, Jesse; Liu, Rong; Butkiewicz, Nancy; Chase, Robert; Hart, Andrea; Agrawal, Sony; Ingravallo, Paul; Pichardo, John; Kong, Rong; Baroudy, Bahige; Malcolm, Bruce; Guo, Zhuyan; Prongay, Andrew; Madison, Vincent; Broske, Lisa; Cui, Xiaoming; Cheng, Kuo-Chi; Hsieh, Tony Y.; Brisson, Jean-Marc; Prelusky, Danial; Korfmacher, Walter; White, Ronald; Bogdanowich-Knipp, Susan; Pavlovsky, Anastasia; Bradley, Prudence; Saksena, Anil K.; Ganguly, Ashit; Piwinski, John; Girijavallabhan, Viyyoor; Njoroge, F. George</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6074-6086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide.  Currently the only therapeutic regimens are s.c. interferon-α or polyethylene glycol (PEG)-interferon-α alone or in combination with oral ribavirin.  Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virol. response.  Herein, the SAR leading to the discovery of SCH 503034 (I), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clin. trials in human beings for the treatment of hepatitis C viral infections is described.  X-ray structure of I complexed with the NS3 protease and biol. data are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjAR2KjtnJV7Vg90H21EOLACvtfcHk0ljgHTrTVsQigg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlOlsLg%253D&md5=e48b2e2d3eb19f7f28aaa76f96d03414</span></div><a href="/servlet/linkout?suffix=cit39c&amp;dbid=16384&amp;doi=10.1021%2Fjm060325b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060325b%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DBogen%26aufirst%3DS.%2BL.%26aulast%3DArasappan%26aufirst%3DA.%26aulast%3DBennett%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DJao%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DY.-T.%26aulast%3DLovey%26aufirst%3DR.%26aulast%3DHendrata%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DParekh%26aufirst%3DT.%26aulast%3DPinto%26aufirst%3DP.%26aulast%3DPopov%26aufirst%3DV.%26aulast%3DPike%26aufirst%3DR.%26aulast%3DRuan%26aufirst%3DS.%26aulast%3DSanthanam%26aufirst%3DB.%26aulast%3DVibulbhan%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DButkiewicz%26aufirst%3DN.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DHart%26aufirst%3DA.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DPichardo%26aufirst%3DJ.%26aulast%3DKong%26aufirst%3DR.%26aulast%3DBaroudy%26aufirst%3DB.%26aulast%3DMalcolm%26aufirst%3DB.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DProngay%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DBroske%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DK.-C.%26aulast%3DHsieh%26aufirst%3DY.%26aulast%3DBrisson%26aufirst%3DJ.-M.%26aulast%3DPrelusky%26aufirst%3DD.%26aulast%3DKorfmacher%26aufirst%3DW.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DBogdanowich-Knipp%26aufirst%3DS.%26aulast%3DPavlovsky%26aufirst%3DA.%26aulast%3DBradley%26aufirst%3DP.%26aulast%3DSaksena%26aufirst%3DA.%2BK.%26aulast%3DGanguly%26aufirst%3DA.%26aulast%3DPiwinski%26aufirst%3DJ.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DDiscovery%2520of%2520%25281R%252C5S%2529-N-%255B3-amino-1-%2528cyclobutylmethyl%2529-2%252C3-dioxopropyl%255D-3-%255B2%2528S%2529-%255B%255B%255B%25281%252C1-dimethylethyl%2529amino%255Dcarbonyl%255Damino%255D-3%252C3-dimethyl-1-oxobutyl%255D-6%252C6-dimethyl-3-azabicyclo%255B3.1.0%255Dhexan-2%2528S%2529-carboxamide%2520%2528SCH%2520503034%2529%252C%2520a%2520selective%252C%2520potent%252C%2520orally%2520bioavailable%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitor%253A%2520a%2520potential%2520therapeutic%2520agent%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6074%26epage%3D6086%26doi%3D10.1021%2Fjm060325b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lamarre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bös, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordingley, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faucher, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagace, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rancourt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sentjens, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St George, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simoneau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibeault, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weldon, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span> </span><span class="NLM_article-title">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">426</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span><span class="refDoi"> DOI: 10.1038/nature02099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnature02099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=14578911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2003&pages=186-189&author=D.+Lamarreauthor=P.+C.+Andersonauthor=M.+Baileyauthor=P.+Beaulieuauthor=G.+Bolgerauthor=P.+Bonneauauthor=M.+B%C3%B6sauthor=D.+R.+Cameronauthor=M.+Cartierauthor=M.+G.+Cordingleyauthor=A.+M.+Faucherauthor=N.+Goudreauauthor=S.+H.+Kawaiauthor=G.+Kukoljauthor=L.+Lagaceauthor=S.+R.+LaPlanteauthor=H.+Narjesauthor=M.+A.+Poupartauthor=J.+Rancourtauthor=R.+E.+Sentjensauthor=R.+St+Georgeauthor=B.+Simoneauauthor=G.+Steinmannauthor=D.+Thibeaultauthor=Y.+S.+Tsantrizosauthor=S.+M.+Weldonauthor=C.+L.+Yongauthor=M.+Llin%C3%A0s-Brunet&title=An+NS3+protease+inhibitor+with+antiviral+effects+in+humans+infected+with+hepatitis+C+virus&doi=10.1038%2Fnature02099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40aR"><div class="casContent"><span class="casTitleNuber">40a</span><div class="casTitle"><span class="NLM_cas:atitle">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span></div><div class="casAuthors">Lamarre, Daniel; Anderson, Paul C.; Bailey, Murray; Beaulieu, Pierre; Bolger, Gordon; Bonneau, Pierre; Boes, Michael; Cameron, Dale R.; Cartier, Mireille; Cordingley, Michael G.; Faucher, Anne-Marie; Goudreau, Nathalie; Kawai, Stephen H.; Kukolj, George; Lagace, Lisette; LaPlante, Steven R.; Narjes, Hans; Poupart, Marc-Andre; Rancourt, Jean; Sentjens, Roel E.; St. George, Roger; Simoneau, Bruno; Steinmann, Gerhard; Thibeault, Diane; Tsantrizos, Youla S.; Weldon, Steven M.; Yong, Chan-Loi; Llinas-Brunet, Montse</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">6963</span>),
    <span class="NLM_cas:pages">186-189</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide with more than 170 million infected individuals at risk of developing significant morbidity and mortality.  Current interferon-based therapies are suboptimal esp. in patients infected with HCV genotype 1, and they are poorly tolerated, highlighting the unmet medical need for new therapeutics.  The HCV-encoded NS3 protease is essential for viral replication and has long been considered an attractive target for therapeutic intervention in HCV-infected patients.  Here we identify a class of specific and potent NS3 protease inhibitors and report the evaluation of BILN 2061, a small mol. inhibitor biol. available through oral ingestion and the first of its class in human trials.  Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive redn. of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor.  Our results further illustrate the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPnVapDO21RLVg90H21EOLACvtfcHk0ljwL30vqj18hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D&md5=36db818d5af257d3ebeef1a061ca68cb</span></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=10.1038%2Fnature02099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02099%26sid%3Dliteratum%253Aachs%26aulast%3DLamarre%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DP.%2BC.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DBeaulieu%26aufirst%3DP.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DB%25C3%25B6s%26aufirst%3DM.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DCartier%26aufirst%3DM.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26aulast%3DFaucher%26aufirst%3DA.%2BM.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DKawai%26aufirst%3DS.%2BH.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLagace%26aufirst%3DL.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DNarjes%26aufirst%3DH.%26aulast%3DPoupart%26aufirst%3DM.%2BA.%26aulast%3DRancourt%26aufirst%3DJ.%26aulast%3DSentjens%26aufirst%3DR.%2BE.%26aulast%3DSt%2BGeorge%26aufirst%3DR.%26aulast%3DSimoneau%26aufirst%3DB.%26aulast%3DSteinmann%26aufirst%3DG.%26aulast%3DThibeault%26aufirst%3DD.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DWeldon%26aufirst%3DS.%2BM.%26aulast%3DYong%26aufirst%3DC.%2BL.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26atitle%3DAn%2520NS3%2520protease%2520inhibitor%2520with%2520antiviral%2520effects%2520in%2520humans%2520infected%2520with%2520hepatitis%2520C%2520virus%26jtitle%3DNature%26date%3D2003%26volume%3D426%26spage%3D186%26epage%3D189%26doi%3D10.1038%2Fnature02099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit40b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faucher, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorys, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grand-Maître, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapeyre-Paquette, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liard, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhéaume, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span> </span><span class="NLM_article-title">Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1605</span><span class="NLM_x">–</span> <span class="NLM_lpage">1608</span><span class="refDoi"> DOI: 10.1021/jm0342414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0342414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1ylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1605-1608&author=M.+Llin%C3%A0s-Brunetauthor=M.+D.+Baileyauthor=G.+Bolgerauthor=C.+Brochuauthor=A.-M.+Faucherauthor=J.+M.+Ferlandauthor=M.+Garneauauthor=E.+Ghiroauthor=V.+Gorysauthor=C.+Grand-Ma%C3%AEtreauthor=T.+Halmosauthor=N.+Lapeyre-Paquetteauthor=F.+Liardauthor=M.+Poirierauthor=M.+Rh%C3%A9aumeauthor=Y.+S.+Tsantrizosauthor=D.+Lamarre&title=Structure-activity+study+on+a+novel+series+of+macrocyclic+inhibitors+of+the+hepatitis+C+virus+NS3+protease+leading+to+the+discovery+of+BILN+2061&doi=10.1021%2Fjm0342414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40bR"><div class="casContent"><span class="casTitleNuber">40b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061</span></div><div class="casAuthors">Llinas-Brunet, Montse; Bailey, Murray D.; Bolger, Gordon; Brochu, Christian; Faucher, Anne-Marie; Ferland, Jean Marie; Garneau, Michel; Ghiro, Elise; Gorys, Vida; Grand-Maitre, Chantal; Halmos, Ted; Lapeyre-Paquette, Nicole; Liard, Francine; Poirier, Martin; Rheaume, Manon; Tsantrizos, Youla S.; Lamarre, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1605-1608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">From the discovery of competitive hexapeptide inhibitors, potent and selective HCV NS3 protease macrocyclic inhibitors have been identified.  Structure-activity relationship studies were performed focusing on optimizing the N-terminal carbamate and the arom. substituent on the (4R)-hydroxyproline moiety.  Inhibitors meeting the potency criteria in the cell-based assay and with improved oral bioavailability in rats were identified.  BILN 2061 was selected as the best compd., the first NS3 protease inhibitor reported with antiviral activity in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_KmuWcS2jSrVg90H21EOLACvtfcHk0ljwL30vqj18hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1ylsLo%253D&md5=d4d8116d2a688e4088e94be617fc396b</span></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=10.1021%2Fjm0342414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0342414%26sid%3Dliteratum%253Aachs%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DM.%2BD.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DFaucher%26aufirst%3DA.-M.%26aulast%3DFerland%26aufirst%3DJ.%2BM.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DGhiro%26aufirst%3DE.%26aulast%3DGorys%26aufirst%3DV.%26aulast%3DGrand-Ma%25C3%25AEtre%26aufirst%3DC.%26aulast%3DHalmos%26aufirst%3DT.%26aulast%3DLapeyre-Paquette%26aufirst%3DN.%26aulast%3DLiard%26aufirst%3DF.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DRh%25C3%25A9aume%26aufirst%3DM.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DStructure-activity%2520study%2520on%2520a%2520novel%2520series%2520of%2520macrocyclic%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520leading%2520to%2520the%2520discovery%2520of%2520BILN%25202061%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1605%26epage%3D1608%26doi%3D10.1021%2Fjm0342414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit40c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span> </span><span class="NLM_article-title">The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061 - from the NMR tube to the clinic</span> <span class="citation_source-journal">Biopolymers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">323</span><span class="refDoi"> DOI: 10.1002/bip.20127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fbip.20127" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=309-323&author=Y.+S.+Tsantrizos&title=The+design+of+a+potent+inhibitor+of+the+hepatitis+C+virus+NS3+protease%3A+BILN+2061+-+from+the+NMR+tube+to+the+clinic&doi=10.1002%2Fbip.20127"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40c&amp;dbid=16384&amp;doi=10.1002%2Fbip.20127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.20127%26sid%3Dliteratum%253Aachs%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26atitle%3DThe%2520design%2520of%2520a%2520potent%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%253A%2520BILN%25202061%2520-%2520from%2520the%2520NMR%2520tube%2520to%2520the%2520clinic%26jtitle%3DBiopolymers%26date%3D2004%26volume%3D76%26spage%3D309%26epage%3D323%26doi%3D10.1002%2Fbip.20127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit40d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Tsantrizos, Y.</span><span> </span><span class="NLM_article-title">Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1252</span><span class="NLM_x">–</span> <span class="NLM_lpage">1263</span><span class="refDoi"> DOI: 10.1021/ar8000519</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar8000519" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=1252-1263&author=Y.+Tsantrizos&title=Peptidomimetic+therapeutic+agents+targeting+the+protease+enzyme+of+the+human+immunodeficiency+virus+and+hepatitis+C+virus&doi=10.1021%2Far8000519"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40d&amp;dbid=16384&amp;doi=10.1021%2Far8000519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far8000519%26sid%3Dliteratum%253Aachs%26aulast%3DTsantrizos%26aufirst%3DY.%26atitle%3DPeptidomimetic%2520therapeutic%2520agents%2520targeting%2520the%2520protease%2520enzyme%2520of%2520the%2520human%2520immunodeficiency%2520virus%2520and%2520hepatitis%2520C%2520virus%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D1252%26epage%3D1263%26doi%3D10.1021%2Far8000519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit40e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span> </span><span class="NLM_article-title">Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1356</span><span class="NLM_x">–</span> <span class="NLM_lpage">1360</span><span class="refDoi"> DOI: 10.1002/anie.200390347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fanie.200390347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlygsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=1356-1360&author=Y.+S.+Tsantrizosauthor=G.+Bolgerauthor=P.+Bonneauauthor=D.+R.+Cameronauthor=N.+Goudreauauthor=G.+Kukoljauthor=S.+R.+LaPlanteauthor=M.+Llin%C3%A0s-Brunetauthor=H.+Narauthor=D.+Lamarre&title=Macrocyclic+inhibitors+of+the+NS3+protease+as+potential+therapeutic+agents+of+hepatitis+C+virus+infection&doi=10.1002%2Fanie.200390347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40eR"><div class="casContent"><span class="casTitleNuber">40e</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection</span></div><div class="casAuthors">Tsantrizos, Youla S.; Bolger, Gordon; Bonneau, Pierre; Cameron, Dale R.; Goudreau, Nathalie; Kukolj, George; LaPlante, Steven R.; Llinas-Brunet, Montse; Nar, Herbert; Lamarre, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1356-1360</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A novel class of selective inhibitors of the hepatitis C virus NS3 protease, an enzyme which is essential for viral replication in vivo, was developed.  The inhibitors are based on the structure-activity relationship between a substrate-based peptidomimetic ligand and the HCV NS3 serine protease.  The designed HCV inhibitor and its satd. analogs are the first inhibitors of the NS3 protease which inhibit HCV RNA replication in the cell-based replicon assay.  In addn., they are orally absorbed and stable to metabolic breakdown.  Thus, these compds. show many of the desirable properties of a druglike archetype and could lead t a clin. useful antiviral agent for the treatment of hepatitis C viral infections in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCij3shP5tmLVg90H21EOLACvtfcHk0li_9DCvj-K63Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlygsrc%253D&md5=e0a3c98ee0096bfc3d058bf0b92b81c3</span></div><a href="/servlet/linkout?suffix=cit40e&amp;dbid=16384&amp;doi=10.1002%2Fanie.200390347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200390347%26sid%3Dliteratum%253Aachs%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DMacrocyclic%2520inhibitors%2520of%2520the%2520NS3%2520protease%2520as%2520potential%2520therapeutic%2520agents%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D1356%26epage%3D1360%26doi%3D10.1002%2Fanie.200390347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorys, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurice, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rancourt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibeault, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span> </span><span class="NLM_article-title">Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2267</span><span class="NLM_x">–</span> <span class="NLM_lpage">2270</span><span class="refDoi"> DOI: 10.1016/S0960-894X(00)00465-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0960-894X%2800%2900465-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=11055335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntF2lu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=2267-2270&author=M.+Llin%C3%A0s-Brunetauthor=M.+Baileyauthor=G.+Fazalauthor=E.+Ghiroauthor=V.+Gorysauthor=S.+Gouletauthor=T.+Halmosauthor=R.+Mauriceauthor=M.+Poirierauthor=M.+A.+Poupartauthor=J.+Rancourtauthor=D.+Thibeaultauthor=D.+Wernicauthor=D.+Lamarre&title=Highly+potent+and+selective+peptide-based+inhibitors+of+the+hepatitis+C+virus+serine+protease%3A+towards+smaller+inhibitors&doi=10.1016%2FS0960-894X%2800%2900465-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors</span></div><div class="casAuthors">Llinas-Brunet, M.; Bailey, M.; Fazal, G.; Ghiro, E.; Gorys, V.; Goulet, S.; Halmos, T.; Maurice, R.; Poirier, M.; Poupart, M.-A.; Rancourt, J.; Thibeault, D.; Wernic, D.; Lamarre, D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2267-2270</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Structure-activity studies on a hexapeptide N-terminal cleavage product of a dodecamer substrate led to the identification of very potent and highly specific inhibitors of the HCV NS3 protease/NS4A cofactor peptide complex.  The largest increase in potency was accomplished by the introduction of a (4R)-naphthalen-1-yl-4-methoxy substituent to the P2 proline.  N-Terminal truncation resulted in tetrapeptides contg. a C-terminal carboxylic acid, which exhibited low micromolar activity against the HCV serine protease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJanVq8aCK0LVg90H21EOLACvtfcHk0li_9DCvj-K63Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntF2lu70%253D&md5=e5c3a87c7242007d27e161c5472dc245</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900465-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900465-0%26sid%3Dliteratum%253Aachs%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DFazal%26aufirst%3DG.%26aulast%3DGhiro%26aufirst%3DE.%26aulast%3DGorys%26aufirst%3DV.%26aulast%3DGoulet%26aufirst%3DS.%26aulast%3DHalmos%26aufirst%3DT.%26aulast%3DMaurice%26aufirst%3DR.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DPoupart%26aufirst%3DM.%2BA.%26aulast%3DRancourt%26aufirst%3DJ.%26aulast%3DThibeault%26aufirst%3DD.%26aulast%3DWernic%26aufirst%3DD.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DHighly%2520potent%2520and%2520selective%2520peptide-based%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520serine%2520protease%253A%2520towards%2520smaller%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D2267%26epage%3D2270%26doi%3D10.1016%2FS0960-894X%2800%2900465-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubry, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurice, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibeault, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span> </span><span class="NLM_article-title">Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">18618</span><span class="NLM_x">–</span> <span class="NLM_lpage">18624</span><span class="refDoi"> DOI: 10.1074/jbc.274.26.18618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1074%2Fjbc.274.26.18618" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=18618-18624&author=S.+R.+LaPlanteauthor=D.+R.+Cameronauthor=N.+Aubryauthor=S.+Lefebvreauthor=G.+Kukoljauthor=R.+Mauriceauthor=D.+Thibeaultauthor=D.+Lamarreauthor=M.+Llin%C3%A0s-Brunet&title=Solution+structure+of+substrate-based+ligands+when+bound+to+hepatitis+C+virus+NS3+protease+domain&doi=10.1074%2Fjbc.274.26.18618"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42a&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.26.18618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.26.18618%26sid%3Dliteratum%253Aachs%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DAubry%26aufirst%3DN.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DMaurice%26aufirst%3DR.%26aulast%3DThibeault%26aufirst%3DD.%26aulast%3DLamarre%26aufirst%3DD.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26atitle%3DSolution%2520structure%2520of%2520substrate-based%2520ligands%2520when%2520bound%2520to%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D18618%26epage%3D18624%26doi%3D10.1074%2Fjbc.274.26.18618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit42b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubry, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Déziel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, P.</span><span> </span><span class="NLM_article-title">Transferred <sup>13</sup>C <i>T</i><sub>1</sub> relaxation at natural isotopic abundance: a practical method for determining site-specific changes in ligand flexibility upon binding to a macromolecule</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">12530</span><span class="NLM_x">–</span> <span class="NLM_lpage">12535</span><span class="refDoi"> DOI: 10.1021/ja0017817</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0017817" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2000&pages=12530-12535&author=S.+R.+LaPlanteauthor=N.+Aubryauthor=R.+D%C3%A9zielauthor=F.+Niauthor=P.+Xu&title=Transferred+13C+T1+relaxation+at+natural+isotopic+abundance%3A+a+practical+method+for+determining+site-specific+changes+in+ligand+flexibility+upon+binding+to+a+macromolecule&doi=10.1021%2Fja0017817"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42b&amp;dbid=16384&amp;doi=10.1021%2Fja0017817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0017817%26sid%3Dliteratum%253Aachs%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DAubry%26aufirst%3DN.%26aulast%3DD%25C3%25A9ziel%26aufirst%3DR.%26aulast%3DNi%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DP.%26atitle%3DTransferred%252013C%2520T1%2520relaxation%2520at%2520natural%2520isotopic%2520abundance%253A%2520a%2520practical%2520method%2520for%2520determining%2520site-specific%2520changes%2520in%2520ligand%2520flexibility%2520upon%2520binding%2520to%2520a%2520macromolecule%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2000%26volume%3D122%26spage%3D12530%26epage%3D12535%26doi%3D10.1021%2Fja0017817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit42c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakalian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubry, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, S. H.</span><span> </span><span class="NLM_article-title">Ligand bioactive conformation plays a critical role in the design of drugs that target the hepatitis C Virus NS3 protease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1777</span><span class="NLM_x">–</span> <span class="NLM_lpage">1789</span><span class="refDoi"> DOI: 10.1021/jm401338c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401338c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Cktb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1777-1789&author=S.+R.+LaPlanteauthor=H.+Narauthor=C.+T.+Lemkeauthor=A.+Jakalianauthor=N.+Aubryauthor=S.+H.+Kawai&title=Ligand+bioactive+conformation+plays+a+critical+role+in+the+design+of+drugs+that+target+the+hepatitis+C+Virus+NS3+protease&doi=10.1021%2Fjm401338c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42cR"><div class="casContent"><span class="casTitleNuber">42c</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand Bioactive Conformation Plays a Critical Role in the Design of Drugs That Target the Hepatitis C Virus NS3 Protease</span></div><div class="casAuthors">LaPlante, Steven R.; Nar, Herbert; Lemke, Christopher T.; Jakalian, Araz; Aubry, Norman; Kawai, Stephen H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1777-1789</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A ligand-focused strategy employed NMR, X-ray, modeling, and medicinal chem. to expose the crit. role that bioactive conformation played in the design of a variety of drugs that target the HCV protease.  The bioactive conformation (bound states) were detd. for key inhibitors identified along our drug discovery pathway from the hit to clin. compds.  All adopt similar bioactive conformations for the common core derived from the hit peptide DDIVPC.  A carefully designed SAR anal., based on the advanced inhibitor 1 in which the P1 to P3 side chains and the N-terminal Boc were sequentially truncated, revealed a correlation between affinity and the relative predominance of the bioactive conformation in the free state.  Interestingly, synergistic conformation effects on potency were also noted.  Comparisons with clin. and recently marketed drugs from the pharmaceutical industry showed that all have the same core and similar bioactive conformations.  This suggested that the variety of appendages discovered for these compds. also properly satisfy the bioactive conformation requirements and allowed for a large variety of HCV protease drug candidates to be designed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFi-4R4F9wwbVg90H21EOLACvtfcHk0lhm0ZfvQzkw4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Cktb7P&md5=2ccb36504903255ba012223529318a69</span></div><a href="/servlet/linkout?suffix=cit42c&amp;dbid=16384&amp;doi=10.1021%2Fjm401338c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401338c%26sid%3Dliteratum%253Aachs%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DLemke%26aufirst%3DC.%2BT.%26aulast%3DJakalian%26aufirst%3DA.%26aulast%3DAubry%26aufirst%3DN.%26aulast%3DKawai%26aufirst%3DS.%2BH.%26atitle%3DLigand%2520bioactive%2520conformation%2520plays%2520a%2520critical%2520role%2520in%2520the%2520design%2520of%2520drugs%2520that%2520target%2520the%2520hepatitis%2520C%2520Virus%2520NS3%2520protease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1777%26epage%3D1789%26doi%3D10.1021%2Fjm401338c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Llinas-Brunet, M.; Bailey, M. D.; Cameron, D.; Faucher, A.-M; Ghiro, E.; Goudreau, N.; Halmos, T.; Poupart, M.-A.; Rancourt, J.; Tsantrizos, Y. S.; Wernic, D. M.; Simoneau, B.</span><span> </span><span class="NLM_article-title">Preparation of hepatitis C inhibitory tripeptides</span>. World Patent Application WO 2000/0009543, February 24,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=M.+Llinas-Brunet&author=M.+D.+Bailey&author=D.+Cameron&author=A.-M+Faucher&author=E.+Ghiro&author=N.+Goudreau&author=T.+Halmos&author=M.-A.+Poupart&author=J.+Rancourt&author=Y.+S.+Tsantrizos&author=D.+M.+Wernic&author=B.+Simoneau&title=Preparation+of+hepatitis+C+inhibitory+tripeptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLlinas-Brunet%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520hepatitis%2520C%2520inhibitory%2520tripeptides%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit43b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Llinas-Brunet, M.; Bailey, M.; Cameron, D.; Ghiro, E.; Goudreau, N.; Poupart, M.-A.; Rancourt, J.; Tsantrizos, Y. S.</span><span> </span><span class="NLM_article-title">Hepatitis C inhibitor peptides</span>. World Patent Application WO 2000/0009558, February 24,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=M.+Llinas-Brunet&author=M.+Bailey&author=D.+Cameron&author=E.+Ghiro&author=N.+Goudreau&author=M.-A.+Poupart&author=J.+Rancourt&author=Y.+S.+Tsantrizos&title=Hepatitis+C+inhibitor+peptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLlinas-Brunet%26aufirst%3DM.%26atitle%3DHepatitis%2520C%2520inhibitor%2520peptides%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Campbell, J. A.; Good, A.</span><span> </span><span class="NLM_article-title">Hepatitis C tripeptide inhibitors</span>. World Patent Application WO 2002/060926, August 8,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=J.+A.+Campbell&author=A.+Good&title=Hepatitis+C+tripeptide+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DJ.%2BA.%26atitle%3DHepatitis%2520C%2520tripeptide%2520inhibitors%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Scola, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combrink, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sit, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocuzza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilder, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuring, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesenberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span> </span><span class="NLM_article-title">Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1708</span><span class="NLM_x">–</span> <span class="NLM_lpage">1729</span><span class="refDoi"> DOI: 10.1021/jm401840s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401840s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVaqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1708-1729&author=P.+M.+Scolaauthor=A.+X.+Wangauthor=A.+C.+Goodauthor=L.-Q.+Sunauthor=K.+D.+Combrinkauthor=J.+A.+Campbellauthor=J.+Chenauthor=Y.+Tuauthor=N.+Sinauthor=B.+L.+Venablesauthor=S.-Y.+Sitauthor=Y.+Chenauthor=A.+Cocuzzaauthor=D.+M.+Bilderauthor=S.+D%E2%80%99Andreaauthor=B.+Zhengauthor=P.+Hewawasamauthor=M.+Dingauthor=J.+Thuringauthor=J.+Liauthor=D.+Hernandezauthor=F.+Yuauthor=P.+Falkauthor=G.+Zhaiauthor=A.+K.+Sheafferauthor=C.+Chenauthor=M.+S.+Leeauthor=D.+Barryauthor=J.+O.+Knipeauthor=W.+Liauthor=Y.-H.+Hanauthor=S.+Jenkinsauthor=C.+Gesenbergauthor=Q.+Gaoauthor=M.+W.+Sinzauthor=K.+S.+Santoneauthor=T.+Zvyagaauthor=R.+Rajamaniauthor=H.+E.+Kleiauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=E.+Hughesauthor=C.+Chienauthor=S.+Adamsauthor=P.+C.+Levesqueauthor=D.+Liauthor=J.+Zhuauthor=N.+A.+Meanwellauthor=F.+McPhee&title=Discovery+and+early+clinical+evaluation+of+BMS-605339%2C+a+potent+and+orally+efficacious+tripeptidic+acylsulfonamide+NS3+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Fjm401840s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Scola, Paul M.; Wang, Alan Xiangdong; Good, Andrew C.; Sun, Li-Qiang; Combrink, Keith D.; Campbell, Jeffrey A.; Chen, Jie; Tu, Yong; Sin, Ny; Venables, Brian L.; Sit, Sing-Yuen; Chen, Yan; Cocuzza, Anthony; Bilder, Donna M.; D'Andrea, Stanley; Zheng, Barbara; Hewawasam, Piyasena; Ding, Min; Thuring, Jan; Li, Jianqing; Hernandez, Dennis; Yu, Fei; Falk, Paul; Zhai, Guangzhi; Sheaffer, Amy K.; Chen, Chaoqun; Lee, Min S.; Barry, Diana; Knipe, Jay O.; Li, Wenying; Han, Yong-Hae; Jenkins, Susan; Gesenberg, Christoph; Gao, Qi; Sinz, Michael W.; Santone, Kenneth S.; Zvyaga, Tatyana; Rajamani, Ramkumar; Klei, Herbert E.; Colonno, Richard J.; Grasela, Dennis M.; Hughes, Eric; Chien, Caly; Adams, Stephen; Levesque, Paul C.; Li, Danshi; Zhu, Jialong; Meanwell, Nicholas A.; McPhee, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1708-1729</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of BMS-605339 (35), a tripeptidic inhibitor of the NS3/4A enzyme, is described.  This compd. incorporates a cyclopropylacylsulfonamide moiety that was designed to improve the potency of carboxylic acid prototypes through the introduction of favorable nonbonding interactions within the S1' site of the protease.  The identification of 35 was enabled through the optimization and balance of crit. properties including potency and pharmacokinetics (PK).  This was achieved through modulation of the P2* subsite of the inhibitor which identified the isoquinoline ring system as a key template for improving PK properties with further optimization achieved through functionalization.  A methoxy moiety at the C6 position of this isoquinoline ring system proved to be optimal with respect to potency and PK, thus providing the clin. compd. 35 which demonstrated antiviral activity in HCV-infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJmlq7vS_NcLVg90H21EOLACvtfcHk0lhFkLjYp3jqLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVaqsL4%253D&md5=cac18d2020ecf9d3ac1a8e1237e0ea7c</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm401840s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401840s%26sid%3Dliteratum%253Aachs%26aulast%3DScola%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DA.%2BX.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DCombrink%26aufirst%3DK.%2BD.%26aulast%3DCampbell%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DSit%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCocuzza%26aufirst%3DA.%26aulast%3DBilder%26aufirst%3DD.%2BM.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DThuring%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DY.-H.%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DGesenberg%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DRajamani%26aufirst%3DR.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DMcPhee%26aufirst%3DF.%26atitle%3DDiscovery%2520and%2520early%2520clinical%2520evaluation%2520of%2520BMS-605339%252C%2520a%2520potent%2520and%2520orally%2520efficacious%2520tripeptidic%2520acylsulfonamide%2520NS3%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1708%26epage%3D1729%26doi%3D10.1021%2Fjm401840s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Imperiali, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abeles, R. H.</span><span> </span><span class="NLM_article-title">Extended binding inhibitors of chymotrypsin that interact with leaving group subsites S1′–S3′</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">4474</span><span class="NLM_x">–</span> <span class="NLM_lpage">4477</span><span class="refDoi"> DOI: 10.1021/bi00388a044</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00388a044" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1987&pages=4474-4477&author=B.+Imperialiauthor=R.+H.+Abeles&title=Extended+binding+inhibitors+of+chymotrypsin+that+interact+with+leaving+group+subsites+S1%E2%80%B2%E2%80%93S3%E2%80%B2&doi=10.1021%2Fbi00388a044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fbi00388a044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00388a044%26sid%3Dliteratum%253Aachs%26aulast%3DImperiali%26aufirst%3DB.%26aulast%3DAbeles%26aufirst%3DR.%2BH.%26atitle%3DExtended%2520binding%2520inhibitors%2520of%2520chymotrypsin%2520that%2520interact%2520with%2520leaving%2520group%2520subsites%2520S1%25E2%2580%25B2%25E2%2580%2593S3%25E2%2580%25B2%26jtitle%3DBiochemistry%26date%3D1987%26volume%3D26%26spage%3D4474%26epage%3D4477%26doi%3D10.1021%2Fbi00388a044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Johansson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poliakov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Åkerblom, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiklund, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeberg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winiwarter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danielson, U. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuelsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallberg, A.</span><span> </span><span class="NLM_article-title">Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-length NS3 (protease-helicase/NTPase) - a comparative study of different C-terminals</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2551</span><span class="NLM_x">–</span> <span class="NLM_lpage">2568</span><span class="refDoi"> DOI: 10.1016/S0968-0896(03)00179-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0968-0896%2803%2900179-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=2551-2568&author=A.+Johanssonauthor=A.+Poliakovauthor=E.+%C3%85kerblomauthor=K.+Wiklundauthor=G.+Lindebergauthor=S.+Winiwarterauthor=U.+H.+Danielsonauthor=B.+Samuelssonauthor=A.+Hallberg&title=Acyl+sulfonamides+as+potent+protease+inhibitors+of+the+hepatitis+C+virus+full-length+NS3+%28protease-helicase%2FNTPase%29+-+a+comparative+study+of+different+C-terminals&doi=10.1016%2FS0968-0896%2803%2900179-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2803%2900179-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252803%252900179-2%26sid%3Dliteratum%253Aachs%26aulast%3DJohansson%26aufirst%3DA.%26aulast%3DPoliakov%26aufirst%3DA.%26aulast%3D%25C3%2585kerblom%26aufirst%3DE.%26aulast%3DWiklund%26aufirst%3DK.%26aulast%3DLindeberg%26aufirst%3DG.%26aulast%3DWiniwarter%26aufirst%3DS.%26aulast%3DDanielson%26aufirst%3DU.%2BH.%26aulast%3DSamuelsson%26aufirst%3DB.%26aulast%3DHallberg%26aufirst%3DA.%26atitle%3DAcyl%2520sulfonamides%2520as%2520potent%2520protease%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520full-length%2520NS3%2520%2528protease-helicase%252FNTPase%2529%2520-%2520a%2520comparative%2520study%2520of%2520different%2520C-terminals%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D2551%26epage%3D2568%26doi%3D10.1016%2FS0968-0896%2803%2900179-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit47b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Oertqvist, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aakerblom, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gossas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabnis, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeberg, G.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1448</span><span class="NLM_x">–</span> <span class="NLM_lpage">1474</span><span class="refDoi"> DOI: 10.1016/j.bmc.2006.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmc.2006.11.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=1448-1474&author=P.+Oertqvistauthor=S.+D.+Petersonauthor=E.+Aakerblomauthor=T.+Gossasauthor=Y.+A.+Sabnisauthor=R.+Franssonauthor=G.+Lindeberg&title=Phenylglycine+as+a+novel+P2+scaffold+in+hepatitis+C+virus+NS3+protease+inhibitors&doi=10.1016%2Fj.bmc.2006.11.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DOertqvist%26aufirst%3DP.%26aulast%3DPeterson%26aufirst%3DS.%2BD.%26aulast%3DAakerblom%26aufirst%3DE.%26aulast%3DGossas%26aufirst%3DT.%26aulast%3DSabnis%26aufirst%3DY.%2BA.%26aulast%3DFransson%26aufirst%3DR.%26aulast%3DLindeberg%26aufirst%3DG.%26atitle%3DPhenylglycine%2520as%2520a%2520novel%2520P2%2520scaffold%2520in%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D1448%26epage%3D1474%26doi%3D10.1016%2Fj.bmc.2006.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit47c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lampa, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafsson, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alogheli, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akerblom, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeberg, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artursson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danielson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandstrom, A.</span><span> </span><span class="NLM_article-title">Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2–P1′ Region</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">254</span><span class="refDoi"> DOI: 10.1021/ml400217r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400217r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=249-254&author=A.+K.+Lampaauthor=S.+M.+Bergmanauthor=S.+S.+Gustafssonauthor=H.+Alogheliauthor=E.+B.+Akerblomauthor=G.+G.+Lindebergauthor=R.+M.+Svenssonauthor=P.+Arturssonauthor=H.+Danielsonauthor=A.+Karlenauthor=A.+Sandstrom&title=Novel+Peptidomimetic+Hepatitis+C+Virus+NS3%2F4A+Protease+Inhibitors+Spanning+the+P2%E2%80%93P1%E2%80%B2+Region&doi=10.1021%2Fml400217r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47c&amp;dbid=16384&amp;doi=10.1021%2Fml400217r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400217r%26sid%3Dliteratum%253Aachs%26aulast%3DLampa%26aufirst%3DA.%2BK.%26aulast%3DBergman%26aufirst%3DS.%2BM.%26aulast%3DGustafsson%26aufirst%3DS.%2BS.%26aulast%3DAlogheli%26aufirst%3DH.%26aulast%3DAkerblom%26aufirst%3DE.%2BB.%26aulast%3DLindeberg%26aufirst%3DG.%2BG.%26aulast%3DSvensson%26aufirst%3DR.%2BM.%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DDanielson%26aufirst%3DH.%26aulast%3DKarlen%26aufirst%3DA.%26aulast%3DSandstrom%26aufirst%3DA.%26atitle%3DNovel%2520Peptidomimetic%2520Hepatitis%2520C%2520Virus%2520NS3%252F4A%2520Protease%2520Inhibitors%2520Spanning%2520the%2520P2%25E2%2580%2593P1%25E2%2580%25B2%2520Region%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D249%26epage%3D254%26doi%3D10.1021%2Fml400217r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit47d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Roenn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gossas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabnis, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daoud, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aakerblom, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danielson, U. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandstroem, A.</span><span> </span><span class="NLM_article-title">Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">4057</span><span class="NLM_x">–</span> <span class="NLM_lpage">4068</span><span class="refDoi"> DOI: 10.1016/j.bmc.2007.03.089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmc.2007.03.089" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=4057-4068&author=R.+Roennauthor=T.+Gossasauthor=Y.+A.+Sabnisauthor=H.+Daoudauthor=E.+Aakerblomauthor=U.+H.+Danielsonauthor=A.+Sandstroem&title=Evaluation+of+a+diverse+set+of+potential+P1+carboxylic+acid+bioisosteres+in+hepatitis+C+virus+NS3+protease+inhibitors&doi=10.1016%2Fj.bmc.2007.03.089"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.03.089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.03.089%26sid%3Dliteratum%253Aachs%26aulast%3DRoenn%26aufirst%3DR.%26aulast%3DGossas%26aufirst%3DT.%26aulast%3DSabnis%26aufirst%3DY.%2BA.%26aulast%3DDaoud%26aufirst%3DH.%26aulast%3DAakerblom%26aufirst%3DE.%26aulast%3DDanielson%26aufirst%3DU.%2BH.%26aulast%3DSandstroem%26aufirst%3DA.%26atitle%3DEvaluation%2520of%2520a%2520diverse%2520set%2520of%2520potential%2520P1%2520carboxylic%2520acid%2520bioisosteres%2520in%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D4057%26epage%3D4068%26doi%3D10.1016%2Fj.bmc.2007.03.089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Gunaydin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartberger, M. B.</span><span> </span><span class="NLM_article-title">Stacking with no planarity?</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">344</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00099</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00099" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=341-344&author=H.+Gunaydinauthor=M.+B.+Bartberger&title=Stacking+with+no+planarity%3F&doi=10.1021%2Facsmedchemlett.6b00099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00099%26sid%3Dliteratum%253Aachs%26aulast%3DGunaydin%26aufirst%3DH.%26aulast%3DBartberger%26aufirst%3DM.%2BB.%26atitle%3DStacking%2520with%2520no%2520planarity%253F%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D341%26epage%3D344%26doi%3D10.1021%2Facsmedchemlett.6b00099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">De Clercq, E.</span><span> </span><span class="NLM_article-title">Current race in the development of DAAs (direct-acting antivirals) against HCV</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">452</span><span class="refDoi"> DOI: 10.1016/j.bcp.2014.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bcp.2014.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24735613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslGmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2014&pages=441-452&author=E.+De+Clercq&title=Current+race+in+the+development+of+DAAs+%28direct-acting+antivirals%29+against+HCV&doi=10.1016%2Fj.bcp.2014.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Current race in the development of DAAs (direct-acting antivirals) against HCV</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, narlaprevir and simeprevir, in addn. to those that are already developed [telaprevir (Incivek) and boceprevir (Victrelis)], (ii) NS5A protein inhibitors: ABT-267, daclatasvir, ledipasvir, ACH-2928, ACH-3102, PPI-668, AZD-7295, MK-8742, and GSK 2336805; (iii) NS5B (nucleoside-type) polymerase inhibitors: sofosbuvir (now approved by the FDA since 6 Dec. 2013), GS-0938, mericitabine, VX-135, ALS 2158 and TMC 649128; (iv) NS5B (non-nucleoside-type) polymerase inhibitors: VX-222, ABT-072, ABT-333, deleobuvir, tegobuvir, setrobuvir, VCH-916, VCH-759, BMS-791325 and TMC-647055.  Future drug combinations will likely exist of two or more DAAs belonging to any of the 4 categories, with the aim to achieve (i) pan-genotypic hepatitis C virus (HCV) activity, (ii) little or no risk for resistance; (iii) short duration (i.e. 12 wk) of treatment, and (iv) a sustained viral response (SVR) and definite cure of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpohrsiqE5QLVg90H21EOLACvtfcHk0ljNeTwDQjXRIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslGmsrY%253D&md5=9259fadafae600a93b2703bbe95a47ec</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2014.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2014.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DCurrent%2520race%2520in%2520the%2520development%2520of%2520DAAs%2520%2528direct-acting%2520antivirals%2529%2520against%2520HCV%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2014%26volume%3D89%26spage%3D441%26epage%3D452%26doi%3D10.1016%2Fj.bcp.2014.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P. M.</span><span> </span><span class="NLM_article-title">A facile synthesis of 1-substituted cyclopropylsulfonamides</span> <span class="citation_source-journal">Synlett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_fpage">725</span><span class="NLM_x">–</span> <span class="NLM_lpage">728</span><span class="refDoi"> DOI: 10.1055/s-2006-933130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1055%2Fs-2006-933130" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=725-728&author=J.+Liauthor=D.+Smithauthor=H.+S.+Wongauthor=J.+A.+Campbellauthor=N.+A.+Meanwellauthor=P.+M.+Scola&title=A+facile+synthesis+of+1-substituted+cyclopropylsulfonamides&doi=10.1055%2Fs-2006-933130"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1055%2Fs-2006-933130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2006-933130%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DH.%2BS.%26aulast%3DCampbell%26aufirst%3DJ.%2BA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DScola%26aufirst%3DP.%2BM.%26atitle%3DA%2520facile%2520synthesis%2520of%25201-substituted%2520cyclopropylsulfonamides%26jtitle%3DSynlett%26date%3D2006%26spage%3D725%26epage%3D728%26doi%3D10.1055%2Fs-2006-933130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Navia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P. R.</span><span> </span><span class="NLM_article-title">Design principles for orally bioavailable drugs</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span><span class="refDoi"> DOI: 10.1016/1359-6446(96)10020-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2F1359-6446%2896%2910020-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK28XlvVajurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1996&pages=179-189&author=M.+Naviaauthor=P.+R.+Chaturvedi&title=Design+principles+for+orally+bioavailable+drugs&doi=10.1016%2F1359-6446%2896%2910020-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51aR"><div class="casContent"><span class="casTitleNuber">51a</span><div class="casTitle"><span class="NLM_cas:atitle">Design principles for orally bioavailable drugs</span></div><div class="casAuthors">Navia, Manuel A.; Chaturvedi, Pravin R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">179-189</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 57 refs.  Compd. design is the hallmark of modern pharmaceutical research and development.  Unfortunately, comprehensive and reliable guidelines for the introduction of favorable bioavailability properties into designed compds. remain elusive.  Here, the authors discuss the limited set of design principles that address the problem of bioavailability, based on a retrospective anal. of orally bioavailable drugs.  The roles of partition coeff., mol. wt., carrier-mediated transport and conformational flexibility are evaluated.  These properties are discussed as guiding principles only, and cannot be considered all-encompassing determinants of oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomGbb2CkH99bVg90H21EOLACvtfcHk0lgFpZ4DW7LsDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlvVajurk%253D&md5=76cf28a4da6132c71427edc45c916717</span></div><a href="/servlet/linkout?suffix=cit51a&amp;dbid=16384&amp;doi=10.1016%2F1359-6446%2896%2910020-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F1359-6446%252896%252910020-9%26sid%3Dliteratum%253Aachs%26aulast%3DNavia%26aufirst%3DM.%26aulast%3DChaturvedi%26aufirst%3DP.%2BR.%26atitle%3DDesign%2520principles%2520for%2520orally%2520bioavailable%2520drugs%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D1996%26volume%3D1%26spage%3D179%26epage%3D189%26doi%3D10.1016%2F1359-6446%2896%2910020-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit51b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lipinski, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominy, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, P. J.</span><span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51bR"><div class="casContent"><span class="casTitleNuber">51b</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0lizF8rJRd2-8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit51b&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit51c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Egan, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merz, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, J. J.</span><span> </span><span class="NLM_article-title">Prediction of drug absorption using multivariate statistics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3867</span><span class="NLM_x">–</span> <span class="NLM_lpage">3877</span><span class="refDoi"> DOI: 10.1021/jm000292e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000292e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3867-3877&author=W.+J.+Eganauthor=K.+M.+Merzauthor=J.+J.+Baldwin&title=Prediction+of+drug+absorption+using+multivariate+statistics&doi=10.1021%2Fjm000292e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51cR"><div class="casContent"><span class="casTitleNuber">51c</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Drug Absorption Using Multivariate Statistics</span></div><div class="casAuthors">Egan, William J.; Merz, Kenneth M. Jr.; Baldwin, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3867-3877</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Literature data on compds. both well- and poorly-absorbed in humans were used to build a statistical pattern recognition model of passive intestinal absorption.  Robust outlier detection was utilized to analyze the well-absorbed compds., some of which were intermingled with the poorly-absorbed compds. in the model space.  Outliers were identified as being actively transported.  The descriptors chosen for inclusion in the model were PSA and AlogP98, based on consideration of the phys. processes involved in membrane permeability and the interrelationships and redundancies between available descriptors.  These descriptors are quite straightforward for a medicinal chemist to interpret, enhancing the utility of the model.  Mol. wt., while often used in passive absorption models, was shown to be superfluous, as it is already a component of both PSA and AlogP98.  Extensive validation of the model on hundreds of known orally delivered drugs, "drug-like" mols., and Pharmacopeia, Inc. compds., which had been assayed for Caco-2 cell permeability, demonstrated a good rate of successful predictions (74-92%, depending on the dataset and exact criterion used).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbZF9e_GNz8LVg90H21EOLACvtfcHk0lik74AVlf6I0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitLk%253D&md5=44f909ad1fd6187840921e7f07497b4e</span></div><a href="/servlet/linkout?suffix=cit51c&amp;dbid=16384&amp;doi=10.1021%2Fjm000292e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000292e%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DW.%2BJ.%26aulast%3DMerz%26aufirst%3DK.%2BM.%26aulast%3DBaldwin%26aufirst%3DJ.%2BJ.%26atitle%3DPrediction%2520of%2520drug%2520absorption%2520using%2520multivariate%2520statistics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3867%26epage%3D3877%26doi%3D10.1021%2Fjm000292e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit51d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Daina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoete, V.</span><span> </span><span class="NLM_article-title">A BOILED-egg to predict gastrointestinal absorption and brain penetration of small molecules</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">–</span> <span class="NLM_lpage">1121</span><span class="refDoi"> DOI: 10.1002/cmdc.201600182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fcmdc.201600182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=27218427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1117-1121&author=A.+Dainaauthor=V.+Zoete&title=A+BOILED-egg+to+predict+gastrointestinal+absorption+and+brain+penetration+of+small+molecules&doi=10.1002%2Fcmdc.201600182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51dR"><div class="casContent"><span class="casTitleNuber">51d</span><div class="casTitle"><span class="NLM_cas:atitle">A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules</span></div><div class="casAuthors">Daina, Antoine; Zoete, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1117-1121</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Apart from efficacy and toxicity, many drug development failures are imputable to poor pharmacokinetics and bioavailability.  Gastrointestinal absorption and brain access are two pharmacokinetic behaviors crucial to est. at various stages of the drug discovery processes.  To this end, the Brain Or IntestinaL Estd. permeation method (BOILED-Egg) is proposed as an accurate predictive model that works by computing the lipophilicity and polarity of small mols.  Concomitant predictions for both brain and intestinal permeation are obtained from the same two physicochem. descriptors and straightforwardly translated into mol. design, owing to the speed, accuracy, conceptual simplicity and clear graphical output of the model.  The BOILED-Egg can be applied in a variety of settings, from the filtering of chem. libraries at the early steps of drug discovery, to the evaluation of drug candidates for development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr3-QrxWyZcbVg90H21EOLACvtfcHk0liJd0WD3xvsPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWit78%253D&md5=2cf19e6fe089ef1c0d8f38f0fdb528cc</span></div><a href="/servlet/linkout?suffix=cit51d&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600182%26sid%3Dliteratum%253Aachs%26aulast%3DDaina%26aufirst%3DA.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DA%2520BOILED-egg%2520to%2520predict%2520gastrointestinal%2520absorption%2520and%2520brain%2520penetration%2520of%2520small%2520molecules%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1117%26epage%3D1121%26doi%3D10.1002%2Fcmdc.201600182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1420</span><span class="NLM_x">–</span> <span class="NLM_lpage">1456</span><span class="refDoi"> DOI: 10.1021/tx200211v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200211v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlCitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1420-1456&author=N.+A.+Meanwell&title=Improving+drug+candidates+by+design%3A+a+focus+on+physicochemical+properties+as+a+means+of+improving+compound+disposition+and+safety&doi=10.1021%2Ftx200211v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52aR"><div class="casContent"><span class="casTitleNuber">52a</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1420-1456</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of small mol. drug candidates from the discovery phase to a marketed product continues to be a challenging enterprise with very low success rates that have fostered the perception of poor productivity by the pharmaceutical industry.  Although there have been significant advances in preclin. profiling that have improved compd. triaging and altered the underlying reasons for compd. attrition, the failure rates have not appreciably changed.  As part of an effort to more deeply understand the reasons for candidate failure, there has been considerable interest in analyzing the physicochem. properties of marketed drugs for the purpose of comparing with drugs in discovery and development as a means capturing recent trends in drug design.  The scenario that has emerged is one in which contemporary drug discovery is thought to be focused too heavily on advancing candidates with profiles that are most easily satisfied by mols. with increased mol. wt. and higher overall lipophilicity.  The preponderance of mols. expressing these properties is frequently a function of increased arom. ring count when compared with that of the drugs launched in the latter half of the 20th century and may reflect a preoccupation with maximizing target affinity rather than taking a more holistic approach to drug design.  These attributes not only present challenges for formulation and absorption but also may influence the manifestation of toxicity during development.  By providing some definition around the optimal physicochem. properties assocd. with marketed drugs, guidelines for drug design have been developed that are based largely on calcd. parameters and which may readily be applied by medicinal chemists as an aid to understanding candidate quality.  The physicochem. properties of a mol. that are consistent with the potential for good oral absorption were initially defined by Lipinski, with addnl. insights allowing further refinement, while deeper analyses have explored the correlation with metabolic stability and toxicity.  These insights have been augmented by careful analyses of physicochem. aspects of drug-target interactions, with thermodn. profiling indicating that the signature of best-in-class drugs is a dependence on enthalpy to drive binding energetics rather than entropy, which is dependent on lipophilicity.  Optimization of the entropic contribution to the binding energy of a ligand to its target is generally much easier than refining the enthalpic element.  Consequently, in the absence of a fundamental understanding of the thermodn. complexion of an interaction, the design of mols. with increased lipophilicity becomes almost inevitable.  The application of ligand efficiency, a measure of affinity per heavy atom, group efficiency, which assesses affinity in the context of structural changes, and lipophilic ligand efficiency, which relates potency to lipophilicity, offer less sophisticated but practically useful anal. algorithms to assess the quality of drug-target interactions.  These parameters are readily calcd. and can be applied to lead optimization programs in a fashion that helps to maximize potency while minimizing the kind of lipophilic burden that has been dubbed "mol. obesity".  Several recently described lead optimization campaigns provide illustrative, informative, and productive examples of the effect of paying close attention to carefully controlling physicochem. properties by monitoring ligand efficiency and lipophilic ligand efficiency.  However, to be successful during the lead optimization phase, drug candidate identification programs will need to adopt a holistic approach that integrates multiple parameters, many of which will have unique dependencies on both the drug target and the specific chemotype under prosecution.  Nevertheless, there are many important drug targets that necessitate working in space beyond that which has been defined by the retrospective analyses of marketed drugs and which will require adaptation of some of the guideposts that are useful in directing lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQrUfIwZiIR7Vg90H21EOLACvtfcHk0liJd0WD3xvsPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlCitLs%253D&md5=9ddcf6dc81bf8ab0441df5037979ff4e</span></div><a href="/servlet/linkout?suffix=cit52a&amp;dbid=16384&amp;doi=10.1021%2Ftx200211v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200211v%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DImproving%2520drug%2520candidates%2520by%2520design%253A%2520a%2520focus%2520on%2520physicochemical%2520properties%2520as%2520a%2520means%2520of%2520improving%2520compound%2520disposition%2520and%2520safety%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1420%26epage%3D1456%26doi%3D10.1021%2Ftx200211v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit52b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Improving drug design: an update on recent applications of efficiency metrics, strategies for replacing problematic elements and compounds in non-traditional drug space</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">564</span><span class="NLM_x">–</span> <span class="NLM_lpage">616</span><span class="refDoi"> DOI: 10.1021/acs.chemrestox.6b00043</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.6b00043" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=564-616&author=N.+A.+Meanwell&title=Improving+drug+design%3A+an+update+on+recent+applications+of+efficiency+metrics%2C+strategies+for+replacing+problematic+elements+and+compounds+in+non-traditional+drug+space&doi=10.1021%2Facs.chemrestox.6b00043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52b&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.6b00043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.6b00043%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DImproving%2520drug%2520design%253A%2520an%2520update%2520on%2520recent%2520applications%2520of%2520efficiency%2520metrics%252C%2520strategies%2520for%2520replacing%2520problematic%2520elements%2520and%2520compounds%2520in%2520non-traditional%2520drug%2520space%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26spage%3D564%26epage%3D616%26doi%3D10.1021%2Facs.chemrestox.6b00043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit52c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Gibson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuire, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span> </span><span class="NLM_article-title">Principal components describing biological activities and molecular diversity of heterocyclic aromatic ring fragments</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">4065</span><span class="NLM_x">–</span> <span class="NLM_lpage">4072</span><span class="refDoi"> DOI: 10.1021/jm960058h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960058h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK28XlsVeqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=4065-4072&author=S.+Gibsonauthor=R.+McGuireauthor=D.+C.+Rees&title=Principal+components+describing+biological+activities+and+molecular+diversity+of+heterocyclic+aromatic+ring+fragments&doi=10.1021%2Fjm960058h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52cR"><div class="casContent"><span class="casTitleNuber">52c</span><div class="casTitle"><span class="NLM_cas:atitle">Principal Components Describing Biological Activities and Molecular Diversity of Heterocyclic Aromatic Ring Fragments</span></div><div class="casAuthors">Gibson, Samuel; McGuire, Ross; Rees, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4065-4072</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ten physicochem. variables have been calcd. for each of 100 different arom. rings.  These variables were selected because of their potential involvement in the mol. recognition of drug-receptor binding interactions, and they include size, lipophilicity, dipole magnitude and orientation, HOMO and LUMO energies, and electronic point charges.  A total of 59 different arom. ring systems were studied including monocyclics and [5.5]-, [6.5]- and [6.6]-fused bicyclics.  A principal components anal. of these results generated four principal components which account for 84% of the total variance in the data.  These principal components provide a quant. measure of mol. diversity, and their relevance for structure-activity relationships is discussed.  The principal components correlate with the in vitro biol. activity of heterocyclic arom. fragments within a series of previously reported HIV-1 reverse transcriptase inhibitors (Saari, W. S.; et al. J. Med. Chem. 1992, 35, 3792-3802).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI1MqV39kUdLVg90H21EOLACvtfcHk0liJd0WD3xvsPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlsVeqtLw%253D&md5=d46c4b9fa14b9cec869e83b7ac2b1980</span></div><a href="/servlet/linkout?suffix=cit52c&amp;dbid=16384&amp;doi=10.1021%2Fjm960058h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960058h%26sid%3Dliteratum%253Aachs%26aulast%3DGibson%26aufirst%3DS.%26aulast%3DMcGuire%26aufirst%3DR.%26aulast%3DRees%26aufirst%3DD.%2BC.%26atitle%3DPrincipal%2520components%2520describing%2520biological%2520activities%2520and%2520molecular%2520diversity%2520of%2520heterocyclic%2520aromatic%2520ring%2520fragments%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D4065%26epage%3D4072%26doi%3D10.1021%2Fjm960058h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Liverton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudd, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butcher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiMuzio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fandozzi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahlhut, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, B.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, J. P.</span><span> </span><span class="NLM_article-title">Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">4607</span><span class="NLM_x">–</span> <span class="NLM_lpage">4609</span><span class="refDoi"> DOI: 10.1021/ja711120r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja711120r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtFygur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=4607-4609&author=N.+J.+Livertonauthor=M.+K.+Hollowayauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=J.+W.+Butcherauthor=S.+S.+Carrollauthor=J.+DiMuzioauthor=C.+Fandozziauthor=K.+F.+Gilbertauthor=S.-S.+Maoauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=J.+J.+Romanoauthor=M.+Stahlhutauthor=B.-L.+Wanauthor=D.+B.+Olsenauthor=J.+P.+Vacca&title=Molecular+modeling+based+approach+to+potent+P2-P4+macrocyclic+inhibitors+of+hepatitis+C+NS3%2F4A+protease&doi=10.1021%2Fja711120r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Modeling Based Approach to Potent P2-P4 Macrocyclic Inhibitors of Hepatitis C NS3/4A Protease</span></div><div class="casAuthors">Liverton, Nigel J.; Holloway, M. Katharine; McCauley, John A.; Rudd, Michael T.; Butcher, John W.; Carroll, Steven S.; DiMuzio, Jillian; Fandozzi, Christine; Gilbert, Kevin F.; Mao, Shi-Shan; McIntyre, Charles J.; Nguyen, Kevin T.; Romano, Joseph J.; Stahlhut, Mark; Wan, Bang-Lin; Olsen, David B.; Vacca, Joseph P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4607-4609</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. modeling of inhibitor bound full length HCV NS3/4A protease structures proved to be a valuable tool in the design of a new series of potent NS3 protease inhibitors.  Optimization of initial compds. provided 25a.  The in vitro activity and selectivity as well as the rat pharmacokinetic profile of 25a compare favorably with the data for other NS3/4A protease inhibitors currently in clin. development for the treatment of HCV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppYenMBNqdeLVg90H21EOLACvtfcHk0lh4WdgUXZjdaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtFygur8%253D&md5=5e7bb98bdb19c30bebb30f03a702838d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fja711120r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja711120r%26sid%3Dliteratum%253Aachs%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DDiMuzio%26aufirst%3DJ.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMao%26aufirst%3DS.-S.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DStahlhut%26aufirst%3DM.%26aulast%3DWan%26aufirst%3DB.-L.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26atitle%3DMolecular%2520modeling%2520based%2520approach%2520to%2520potent%2520P2-P4%2520macrocyclic%2520inhibitors%2520of%2520hepatitis%2520C%2520NS3%252F4A%2520protease%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D4607%26epage%3D4609%26doi%3D10.1021%2Fja711120r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Jenkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcphee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gesenberg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arora, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilcher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K.</span><span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and <i>in vitro</i> metabolism of BMS-605339: a novel HCV NS3 protease inhibitor</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">1891</span><span class="NLM_x">–</span> <span class="NLM_lpage">1902</span><span class="refDoi"> DOI: 10.1002/jps.23959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fjps.23959" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2014&pages=1891-1902&author=S.+Jenkinsauthor=P.+Scolaauthor=F.+Mcpheeauthor=J.+Knipeauthor=C.+Gesenbergauthor=M.+Sinzauthor=V.+Aroraauthor=G.+Pilcherauthor=K.+Santone&title=Preclinical+pharmacokinetics+and+in+vitro+metabolism+of+BMS-605339%3A+a+novel+HCV+NS3+protease+inhibitor&doi=10.1002%2Fjps.23959"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fjps.23959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23959%26sid%3Dliteratum%253Aachs%26aulast%3DJenkins%26aufirst%3DS.%26aulast%3DScola%26aufirst%3DP.%26aulast%3DMcphee%26aufirst%3DF.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DGesenberg%26aufirst%3DC.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DArora%26aufirst%3DV.%26aulast%3DPilcher%26aufirst%3DG.%26aulast%3DSantone%26aufirst%3DK.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520in%2520vitro%2520metabolism%2520of%2520BMS-605339%253A%2520a%2520novel%2520HCV%2520NS3%2520protease%2520inhibitor%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2014%26volume%3D103%26spage%3D1891%26epage%3D1902%26doi%3D10.1002%2Fjps.23959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Scola, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venables, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sit, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cocuzza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilder, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schartman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donoso, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvyaga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajamani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tredup, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span> </span><span class="NLM_article-title">The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1730</span><span class="NLM_x">–</span> <span class="NLM_lpage">1752</span><span class="refDoi"> DOI: 10.1021/jm500297k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500297k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1730-1752&author=P.+M.+Scolaauthor=L.-Q.+Sunauthor=A.+X.+Wangauthor=J.+Chenauthor=N.+Sinauthor=B.+L.+Venablesauthor=S.-Y.+Sitauthor=Y.+Chenauthor=A.+Cocuzzaauthor=D.+M.+Bilderauthor=S.+V.+D%E2%80%99Andreaauthor=B.+Zhengauthor=P.+Hewawasamauthor=Y.+Tuauthor=J.+Friborgauthor=P.+Falkauthor=D.+Hernandezauthor=S.+Levineauthor=C.+Chenauthor=F.+Yuauthor=A.+K.+Sheafferauthor=G.+Zhaiauthor=D.+Barryauthor=J.+O.+Knipeauthor=Y.-H.+Hanauthor=R.+Schartmanauthor=M.+Donosoauthor=K.+Mosureauthor=M.+W.+Sinzauthor=T.+Zvyagaauthor=A.+C.+Goodauthor=R.+Rajamaniauthor=K.+Kishauthor=J.+Tredupauthor=H.+E.+Kleiauthor=Q.+Gaoauthor=L.+Muellerauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=S.+P.+Adamsauthor=J.+Loyauthor=P.+C.+Levesqueauthor=H.+Sunauthor=H.+Shiauthor=L.+Sunauthor=W.+Warnerauthor=D.+Liauthor=J.+Zhuauthor=N.+A.+Meanwellauthor=F.+McPhee&title=The+discovery+of+asunaprevir+%28BMS-650032%29%2C+an+orally+efficacious+NS3+protease+inhibitor+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1021%2Fjm500297k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection</span></div><div class="casAuthors">Scola, Paul M.; Sun, Li-Qiang; Wang, Alan Xiangdong; Chen, Jie; Sin, Ny; Venables, Brian L.; Sit, Sing-Yuen; Chen, Yan; Cocuzza, Anthony; Bilder, Donna M.; D'Andrea, Stanley V.; Zheng, Barbara; Hewawasam, Piyasena; Tu, Yong; Friborg, Jacques; Falk, Paul; Hernandez, Dennis; Levine, Steven; Chen, Chaoqun; Yu, Fei; Sheaffer, Amy K.; Zhai, Guangzhi; Barry, Diana; Knipe, Jay O.; Han, Yong-Hae; Schartman, Richard; Donoso, Maria; Mosure, Kathy; Sinz, Michael W.; Zvyaga, Tatyana; Good, Andrew C.; Rajamani, Ramkumar; Kish, Kevin; Tredup, Jeffrey; Klei, Herbert E.; Gao, Qi; Mueller, Luciano; Colonno, Richard J.; Grasela, Dennis M.; Adams, Stephen P.; Loy, James; Levesque, Paul C.; Sun, Huabin; Shi, Hong; Sun, Lucy; Warner, William; Li, Danshi; Zhu, Jialong; Meanwell, Nicholas A.; McPhee, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1730-1752</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of asunaprevir (BMS-650032) is described.  This tripeptidic acylsulfonamide inhibitor of the NS3/4A enzyme is currently in phase III clin. trials for the treatment of hepatitis C virus infection.  The discovery of Asunaprevir was enabled by employing an isolated rabbit heart model to screen for the cardiovascular (CV) liabilities (changes to HR and SNRT) that were responsible for the discontinuation of an earlier lead from this chem. series, BMS-605339, from clin. trials.  The structure-activity relationships (SARs) developed with respect to CV effects established that small structural changes to the P2* subsite of the mol. had a significant impact on the CV profile of a given compd.  The antiviral activity, preclin. PK profile, and toxicol. studies in rat and dog supported clin. development of BMS-650032.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCzMFiXs8YO7Vg90H21EOLACvtfcHk0lh4WdgUXZjdaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVeqsLc%253D&md5=e8015d3874b80be645a9b80b5bd05865</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm500297k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500297k%26sid%3Dliteratum%253Aachs%26aulast%3DScola%26aufirst%3DP.%2BM.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DWang%26aufirst%3DA.%2BX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSin%26aufirst%3DN.%26aulast%3DVenables%26aufirst%3DB.%2BL.%26aulast%3DSit%26aufirst%3DS.-Y.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DCocuzza%26aufirst%3DA.%26aulast%3DBilder%26aufirst%3DD.%2BM.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DS.%2BV.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DFriborg%26aufirst%3DJ.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DLevine%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DHan%26aufirst%3DY.-H.%26aulast%3DSchartman%26aufirst%3DR.%26aulast%3DDonoso%26aufirst%3DM.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSinz%26aufirst%3DM.%2BW.%26aulast%3DZvyaga%26aufirst%3DT.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DRajamani%26aufirst%3DR.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DMueller%26aufirst%3DL.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DAdams%26aufirst%3DS.%2BP.%26aulast%3DLoy%26aufirst%3DJ.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DWarner%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DMcPhee%26aufirst%3DF.%26atitle%3DThe%2520discovery%2520of%2520asunaprevir%2520%2528BMS-650032%2529%252C%2520an%2520orally%2520efficacious%2520NS3%2520protease%2520inhibitor%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1730%26epage%3D1752%26doi%3D10.1021%2Fjm500297k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friborg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaniewski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P.</span><span> </span><span class="NLM_article-title">Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5387</span><span class="NLM_x">–</span> <span class="NLM_lpage">5396</span><span class="refDoi"> DOI: 10.1128/AAC.01186-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FAAC.01186-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=22869577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKiu7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=5387-5396&author=F.+McPheeauthor=A.+K.+Sheafferauthor=J.+Friborgauthor=D.+Hernandezauthor=P.+Falkauthor=G.+Zhaiauthor=S.+Levineauthor=S.+Chaniewskiauthor=F.+Yuauthor=D.+Barryauthor=C.+Chenauthor=M.+S.+Leeauthor=K.+Mosureauthor=L.-Q.+Sunauthor=M.+Sinzauthor=N.+A.+Meanwellauthor=R.+J.+Colonnoauthor=J.+Knipeauthor=P.+Scola&title=Preclinical+profile+and+characterization+of+the+hepatitis+C+virus+NS3+protease+inhibitor+asunaprevir+%28BMS-650032%29&doi=10.1128%2FAAC.01186-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)</span></div><div class="casAuthors">McPhee, Fiona; Sheaffer, Amy K.; Friborg, Jacques; Hernandez, Dennis; Falk, Paul; Zhai, Guangzhi; Levine, Steven; Chaniewski, Susan; Yu, Fei; Barry, Diana; Chen, Chaoqun; Lee, Min S.; Mosure, Kathy; Sun, Li-Qiang; Sinz, Michael; Meanwell, Nicholas A.; Colonno, Richard J.; Knipe, Jay; Scola, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5387-5396</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Asunaprevir (ASV; BMS-650032) is a hepatitis C virus (HCV) NS3 protease inhibitor that has demonstrated efficacy in patients chronically infected with HCV genotype 1 when combined with alfa interferon and/or the NS5A replication complex inhibitor daclatasvir.  ASV competitively binds to the NS3/4A protease complex, with Ki values of 0.4 and 0.24 nM against recombinant enzymes representing genotypes 1a (H77) and 1b (J4L6S), resp.  Selectivity was demonstrated by the absence of any significant activity against the closely related GB virus-B NS3 protease and a panel of human serine or cysteine proteases.  In cell culture, ASV inhibited replication of HCV replicons representing genotypes 1 and 4, with 50% effective concns. (EC50s) ranging from 1 to 4 nM, and had weaker activity against genotypes 2 and 3 (EC50, 67 to 1,162 nM).  Selectivity was again demonstrated by the absence of activity (EC50, >12 μM) against a panel of other RNA viruses.  ASV exhibited additive or synergistic activity in combination studies with alfa interferon, ribavirin, and/or inhibitors specifically targeting NS5A or NS5B.  Plasma and tissue exposures in vivo in several animal species indicated that ASV displayed a hepatotropic disposition (liver-to-plasma ratios ranging from 40- to 359-fold across species).  Twenty-four hours postdose, liver exposures across all species tested were ≥110-fold above the inhibitor EC50s obsd. with HCV genotype-1 replicons.  Based on these virol. and exposure properties, ASV holds promise for future utility in a combination with other anti-HCV agents in the treatment of HCV-infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXvSH5FRWqFbVg90H21EOLACvtfcHk0ljkZuxEGzJ4tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKiu7fL&md5=9bbf4ea33b5c4ef48850ade4af9cfd1d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1128%2FAAC.01186-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01186-12%26sid%3Dliteratum%253Aachs%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DFriborg%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DFalk%26aufirst%3DP.%26aulast%3DZhai%26aufirst%3DG.%26aulast%3DLevine%26aufirst%3DS.%26aulast%3DChaniewski%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DBarry%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DScola%26aufirst%3DP.%26atitle%3DPreclinical%2520profile%2520and%2520characterization%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitor%2520asunaprevir%2520%2528BMS-650032%2529%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D5387%26epage%3D5396%26doi%3D10.1128%2FAAC.01186-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Mosure, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browning, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arora, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, Y.-Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillip, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mcphee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balakrishnan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soars, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinz, M.</span><span> </span><span class="NLM_article-title">Preclinical pharmacokinetics and in vitro metabolism of asunaprevir (BMS-650032), a potent hepatitis C virus NS3 protease inhibitor</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">2813</span><span class="NLM_x">–</span> <span class="NLM_lpage">2823</span><span class="refDoi"> DOI: 10.1002/jps.24356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fjps.24356" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2015&pages=2813-2823&author=K.+W.+Mosureauthor=J.+O.+Knipeauthor=M.+Browningauthor=V.+Aroraauthor=Y.-Z.+Shuauthor=T.+Phillipauthor=F.+Mcpheeauthor=P.+Scolaauthor=A.+Balakrishnanauthor=M.+G.+Soarsauthor=K.+Santoneauthor=M.+Sinz&title=Preclinical+pharmacokinetics+and+in+vitro+metabolism+of+asunaprevir+%28BMS-650032%29%2C+a+potent+hepatitis+C+virus+NS3+protease+inhibitor&doi=10.1002%2Fjps.24356"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fjps.24356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.24356%26sid%3Dliteratum%253Aachs%26aulast%3DMosure%26aufirst%3DK.%2BW.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DBrowning%26aufirst%3DM.%26aulast%3DArora%26aufirst%3DV.%26aulast%3DShu%26aufirst%3DY.-Z.%26aulast%3DPhillip%26aufirst%3DT.%26aulast%3DMcphee%26aufirst%3DF.%26aulast%3DScola%26aufirst%3DP.%26aulast%3DBalakrishnan%26aufirst%3DA.%26aulast%3DSoars%26aufirst%3DM.%2BG.%26aulast%3DSantone%26aufirst%3DK.%26aulast%3DSinz%26aufirst%3DM.%26atitle%3DPreclinical%2520pharmacokinetics%2520and%2520in%2520vitro%2520metabolism%2520of%2520asunaprevir%2520%2528BMS-650032%2529%252C%2520a%2520potent%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520inhibitor%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2015%26volume%3D104%26spage%3D2813%26epage%3D2823%26doi%3D10.1002%2Fjps.24356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Pasquinelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villegas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheridan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheaffer, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scola, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marbury, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldwater, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demicco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraft, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Talavera, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span> </span><span class="NLM_article-title">Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1838</span><span class="NLM_x">–</span> <span class="NLM_lpage">1844</span><span class="refDoi"> DOI: 10.1128/AAC.05854-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FAAC.05854-11" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=1838-1844&author=C.+Pasquinelliauthor=F.+McPheeauthor=T.+Eleyauthor=C.+Villegasauthor=K.+Sandyauthor=P.+Sheridanauthor=A.+Perssonauthor=S.+P.+Huangauthor=D.+Hernandezauthor=A.+K.+Sheafferauthor=P.+Scolaauthor=T.+Marburyauthor=E.+Lawitzauthor=R.+Goldwaterauthor=M.+Rodriguez-Torresauthor=M.+Demiccoauthor=D.+Wrightauthor=M.+Charltonauthor=W.+K.+Kraftauthor=J.+C.+Lopez-Talaveraauthor=D.+M.+Grasela&title=Single-+and+multiple-ascending-dose+studies+of+the+NS3+protease+inhibitor+asunaprevir+in+subjects+with+or+without+chronic+hepatitis+C&doi=10.1128%2FAAC.05854-11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1128%2FAAC.05854-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.05854-11%26sid%3Dliteratum%253Aachs%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DVillegas%26aufirst%3DC.%26aulast%3DSandy%26aufirst%3DK.%26aulast%3DSheridan%26aufirst%3DP.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DS.%2BP.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DSheaffer%26aufirst%3DA.%2BK.%26aulast%3DScola%26aufirst%3DP.%26aulast%3DMarbury%26aufirst%3DT.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DGoldwater%26aufirst%3DR.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DDemicco%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DD.%26aulast%3DCharlton%26aufirst%3DM.%26aulast%3DKraft%26aufirst%3DW.%2BK.%26aulast%3DLopez-Talavera%26aufirst%3DJ.%2BC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26atitle%3DSingle-%2520and%2520multiple-ascending-dose%2520studies%2520of%2520the%2520NS3%2520protease%2520inhibitor%2520asunaprevir%2520in%2520subjects%2520with%2520or%2520without%2520chronic%2520hepatitis%2520C%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D1838%26epage%3D1844%26doi%3D10.1128%2FAAC.05854-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Swinney, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, J.</span><span> </span><span class="NLM_article-title">How were new medicines discovered?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span><span class="refDoi"> DOI: 10.1038/nrd3480</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrd3480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=21701501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlCmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=507-519&author=D.+C.+Swinneyauthor=J.+Anthony&title=How+were+new+medicines+discovered%3F&doi=10.1038%2Fnrd3480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59aR"><div class="casContent"><span class="casTitleNuber">59a</span><div class="casTitle"><span class="NLM_cas:atitle">How were new medicines discovered?</span></div><div class="casAuthors">Swinney, David C.; Anthony, Jason</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">507-519</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Preclin. strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biol.-based approaches.  To investigate whether some strategies have been more successful than others in the discovery of new drugs, we analyzed the discovery strategies and the mol. mechanism of action (MMOA) for new mol. entities and new biologics that were approved by the US Food and Drug Administration between 1999 and 2008.  Out of the 259 agents that were approved, 75 were first-in-class drugs with new MMOAs, and out of these, 50 (67%) were small mols. and 25 (33%) were biologics.  The results also show that the contribution of phenotypic screening to the discovery of first-in-class small-mol. drugs exceeded that of target-based approaches - with 28 and 17 of these drugs coming from the two approaches, resp. - in an era in which the major focus was on target-based approaches.  We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE8Ah1iNz76bVg90H21EOLACvtfcHk0ljkZuxEGzJ4tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlCmsbs%253D&md5=7503620f8fbadb0a829f6ea2029936a2</span></div><a href="/servlet/linkout?suffix=cit59a&amp;dbid=16384&amp;doi=10.1038%2Fnrd3480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3480%26sid%3Dliteratum%253Aachs%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26aulast%3DAnthony%26aufirst%3DJ.%26atitle%3DHow%2520were%2520new%2520medicines%2520discovered%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D507%26epage%3D519%26doi%3D10.1038%2Fnrd3480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit59b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Macarron, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banks, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bojanic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirovic, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garyantes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D. V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hertzberg, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzen, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paslay, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schopfer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sittampalam, G. S.</span><span> </span><span class="NLM_article-title">Impact of high-throughput screening on biomedical research</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span><span class="refDoi"> DOI: 10.1038/nrd3368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrd3368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=21358738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFensbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=188-195&author=R.+Macarronauthor=M.+N.+Banksauthor=D.+Bojanicauthor=D.+J.+Burnsauthor=D.+A.+Cirovicauthor=T.+Garyantesauthor=D.+V.+S.+Greenauthor=R.+P.+Hertzbergauthor=W.+P.+Janzenauthor=J.+W.+Paslayauthor=U.+Schopferauthor=G.+S.+Sittampalam&title=Impact+of+high-throughput+screening+on+biomedical+research&doi=10.1038%2Fnrd3368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59bR"><div class="casContent"><span class="casTitleNuber">59b</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of high-throughput screening in biomedical research</span></div><div class="casAuthors">Macarron, Ricardo; Banks, Martyn N.; Bojanic, Dejan; Burns, David J.; Cirovic, Dragan A.; Garyantes, Tina; Green, Darren V. S.; Hertzberg, Robert P.; Janzen, William P.; Paslay, Jeff W.; Schopfer, Ulrich; Sittampalam, G. Sitta</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">188-195</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  High-throughput screening (HTS) has been postulated in several quarters to be a contributory factor to the decline in productivity in the pharmaceutical industry.  Moreover, it has been blamed for stifling the creativity that drug discovery demands.  In this article, we aim to dispel these myths and present the case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLnrSVehADbLVg90H21EOLACvtfcHk0liHIfpkIh0vsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFensbY%253D&md5=cb9853227506f3a3d774791cff9fd79d</span></div><a href="/servlet/linkout?suffix=cit59b&amp;dbid=16384&amp;doi=10.1038%2Fnrd3368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3368%26sid%3Dliteratum%253Aachs%26aulast%3DMacarron%26aufirst%3DR.%26aulast%3DBanks%26aufirst%3DM.%2BN.%26aulast%3DBojanic%26aufirst%3DD.%26aulast%3DBurns%26aufirst%3DD.%2BJ.%26aulast%3DCirovic%26aufirst%3DD.%2BA.%26aulast%3DGaryantes%26aufirst%3DT.%26aulast%3DGreen%26aufirst%3DD.%2BV.%2BS.%26aulast%3DHertzberg%26aufirst%3DR.%2BP.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DPaslay%26aufirst%3DJ.%2BW.%26aulast%3DSchopfer%26aufirst%3DU.%26aulast%3DSittampalam%26aufirst%3DG.%2BS.%26atitle%3DImpact%2520of%2520high-throughput%2520screening%2520on%2520biomedical%2520research%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D188%26epage%3D195%26doi%3D10.1038%2Fnrd3368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit59c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Green, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacs, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span> </span><span class="NLM_article-title">Cell-based assays to identify inhibitors of viral disease</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">–</span> <span class="NLM_lpage">676</span><span class="refDoi"> DOI: 10.1517/17460441.3.6.671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1517%2F17460441.3.6.671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=19750206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVyrtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=671-676&author=N.+Greenauthor=R.+D.+Ottauthor=R.+J.+Isaacsauthor=H.+Fang&title=Cell-based+assays+to+identify+inhibitors+of+viral+disease&doi=10.1517%2F17460441.3.6.671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59cR"><div class="casContent"><span class="casTitleNuber">59c</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-based assays to identify inhibitors of viral disease</span></div><div class="casAuthors">Green, Neil; Ott, Robert D.; Isaacs, Richard J.; Fang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">671-676</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Antagonizing the prodn. of infectious viruses inside cells requires drugs that can cross the cell membrane without harming the host cells.  Objective: It is therefore advantageous to establish the intracellular potency of antiviral drug candidates early in the drug discovery pipeline.  Methods: To this end, cell-based assays are being developed and used in high-throughput drug screening, ranging from assays that monitor replication of intact viruses to those that monitor activity of specific viral proteins.  Although numerous cell-based assays have been developed and investigated, rapid counter screens are also needed to define the specific viral targets of identified inhibitors and to eliminate non-specific screening hits.  Results/conclusions: Here, we describe the types of cell-based assays being used in antiviral drug screens and evaluate the equally important counter screens that are being used to reach the full potential of cell-based high-throughput screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBo6AqBISdKLVg90H21EOLACvtfcHk0liHIfpkIh0vsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVyrtLw%253D&md5=380dca38ab2261c84ef6993d565b9622</span></div><a href="/servlet/linkout?suffix=cit59c&amp;dbid=16384&amp;doi=10.1517%2F17460441.3.6.671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.3.6.671%26sid%3Dliteratum%253Aachs%26aulast%3DGreen%26aufirst%3DN.%26aulast%3DOtt%26aufirst%3DR.%2BD.%26aulast%3DIsaacs%26aufirst%3DR.%2BJ.%26aulast%3DFang%26aufirst%3DH.%26atitle%3DCell-based%2520assays%2520to%2520identify%2520inhibitors%2520of%2520viral%2520disease%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D671%26epage%3D676%26doi%3D10.1517%2F17460441.3.6.671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit59d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Keller, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.-Y.</span><span> </span><span class="NLM_article-title">Anti-infectives: can cellular screening deliver?</span> <span class="citation_source-journal">Curr. Opin. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span><span class="refDoi"> DOI: 10.1016/j.cbpa.2011.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.cbpa.2011.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=21723774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFClt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=529-533&author=T.+H.+Kellerauthor=P.-Y.+Shiauthor=Q.-Y.+Wang&title=Anti-infectives%3A+can+cellular+screening+deliver%3F&doi=10.1016%2Fj.cbpa.2011.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59dR"><div class="casContent"><span class="casTitleNuber">59d</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-infectives: Can cellular screening deliver?</span></div><div class="casAuthors">Keller, Thomas H.; Shi, Pei-Yong; Wang, Qing-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-533</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In an era of emerging and reemerging infectious diseases, and increasing multidrug resistance, the need to identify novel therapy is imperative.  Unfortunately, the recent shift of the drug discovery paradigm from cellular screening to target-based approaches has not delivered the anticipated benefits.  A recent renaissance of the traditional cell-based approach, on the other hand, has yielded several clin. candidates.  Three successful examples are illustrated in this review, namely spiroindolone, thiazolidinone, and diarylquinoline for the treatment of malaria, hepatitis C virus, and tuberculosis, resp.  We describe in detail their identification, mechanism of action (MoA), and common features in the chem. structures.  The challenges of the cell-based approach for anti-infective drug discovery are also discussed.  We propose a shift from std. libraries to synthetic natural-product-like compd. collections to improve the success of phenotypic lead finding and to facilitate the validation of hits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovjXnq-69ZQLVg90H21EOLACvtfcHk0liHIfpkIh0vsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFClt78%253D&md5=0313e255dec7bf47b39b23f6d354987f</span></div><a href="/servlet/linkout?suffix=cit59d&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2011.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2011.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DShi%26aufirst%3DP.-Y.%26aulast%3DWang%26aufirst%3DQ.-Y.%26atitle%3DAnti-infectives%253A%2520can%2520cellular%2520screening%2520deliver%253F%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D15%26spage%3D529%26epage%3D533%26doi%3D10.1016%2Fj.cbpa.2011.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit59e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Prior, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiruta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currais, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dargusch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maher, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schubert, D.</span><span> </span><span class="NLM_article-title">Back to the future with phenotypic screening</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">–</span> <span class="NLM_lpage">513</span><span class="refDoi"> DOI: 10.1021/cn500051h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn500051h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVWjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=503-513&author=M.+Priorauthor=C.+Chirutaauthor=A.+Curraisauthor=J.+Goldbergauthor=J.+Ramseyauthor=R.+Darguschauthor=P.+A.+Maherauthor=D.+Schubert&title=Back+to+the+future+with+phenotypic+screening&doi=10.1021%2Fcn500051h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59eR"><div class="casContent"><span class="casTitleNuber">59e</span><div class="casTitle"><span class="NLM_cas:atitle">Back to the Future with Phenotypic Screening</span></div><div class="casAuthors">Prior, Marguerite; Chiruta, Chandramouli; Currais, Antonio; Goldberg, Josh; Ramsey, Justin; Dargusch, Richard; Maher, Pamela A.; Schubert, David</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">503-513</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  There are no disease-modifying drugs for any old age assocd. neurodegenerative disease or stroke.  This is at least in part due to the failure of drug developers to recognize that the vast majority of neurodegenerative diseases arise from a confluence of multiple toxic insults that accumulate during normal aging and interact with genetic and environmental risk factors.  Thus, it is unlikely that the current single target approach based upon rare dominant mutations or even a few preselected targets is going to yield useful drugs for these conditions.  Therefore, the identification of drug candidates for neurodegeneration should be based upon their efficacy in phenotypic screening assays that reflect the biol. of the aging brain, not a single, preselected target.  It is argued here that this approach to drug discovery is the most likely to produce safe and effective drugs for neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsURT-h5gF77Vg90H21EOLACvtfcHk0lh9-LUezk5WxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVWjtbY%253D&md5=9d00b537d71aa7bef15fc73d784aba95</span></div><a href="/servlet/linkout?suffix=cit59e&amp;dbid=16384&amp;doi=10.1021%2Fcn500051h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn500051h%26sid%3Dliteratum%253Aachs%26aulast%3DPrior%26aufirst%3DM.%26aulast%3DChiruta%26aufirst%3DC.%26aulast%3DCurrais%26aufirst%3DA.%26aulast%3DGoldberg%26aufirst%3DJ.%26aulast%3DRamsey%26aufirst%3DJ.%26aulast%3DDargusch%26aufirst%3DR.%26aulast%3DMaher%26aufirst%3DP.%2BA.%26aulast%3DSchubert%26aufirst%3DD.%26atitle%3DBack%2520to%2520the%2520future%2520with%2520phenotypic%2520screening%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2014%26volume%3D5%26spage%3D503%26epage%3D513%26doi%3D10.1021%2Fcn500051h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Körner, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herian, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theilmann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">285</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">113</span><span class="refDoi"> DOI: 10.1126/science.285.5424.110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1126%2Fscience.285.5424.110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10390360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK1MXksVCqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1999&pages=110-113&author=V.+Lohmannauthor=F.+K%C3%B6rnerauthor=J.+O.+Kochauthor=U.+Herianauthor=L.+Theilmannauthor=R.+Bartenschlager&title=Replication+of+subgenomic+hepatitis+C+virus+RNAs+in+a+hepatoma+cell+line&doi=10.1126%2Fscience.285.5424.110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line</span></div><div class="casAuthors">Lohmann, V.; Korner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">5424</span>),
    <span class="NLM_cas:pages">110-113</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">An estd. 170 million persons worldwide are infected with hepatitis C virus (HCV), a major cause of chronic liver disease.  Despite increasing knowledge of genome structure and individual viral proteins, studies on virus replication and pathogenesis have been hampered by the lack of reliable and efficient cell culture systems.  A full-length consensus genome was cloned from viral RNA isolated from an infected human liver and used to construct subgenomic selectable replicons.  Upon transfection into a human hepatoma cell line, these RNAs replicated to high levels, permitting metabolic radiolabeling of viral RNA and proteins.  This work defines the structure of HCV replicons functional in cell culture and provides the basis for a long-sought cellular system that should allow detailed mol. studies of HCV and the development of antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7X754RT8y1LVg90H21EOLACvtfcHk0lh9-LUezk5WxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksVCqurk%253D&md5=b075621b316209ecf4498c9b5b33e4b5</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1126%2Fscience.285.5424.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.285.5424.110%26sid%3Dliteratum%253Aachs%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DK%25C3%25B6rner%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DJ.%2BO.%26aulast%3DHerian%26aufirst%3DU.%26aulast%3DTheilmann%26aufirst%3DL.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DReplication%2520of%2520subgenomic%2520hepatitis%2520C%2520virus%2520RNAs%2520in%2520a%2520hepatoma%2520cell%2520line%26jtitle%3DScience%26date%3D1999%26volume%3D285%26spage%3D110%26epage%3D113%26doi%3D10.1126%2Fscience.285.5424.110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1346</span><span class="NLM_x">–</span> <span class="NLM_lpage">1353</span><span class="refDoi"> DOI: 10.1128/AAC.49.4.1346-1353.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FAAC.49.4.1346-1353.2005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=1346-1353&author=D.+R.+O%E2%80%99Boyleauthor=P.+T.+Nowerauthor=J.+A.+Lemmauthor=L.+Valeraauthor=J.-H.+Sunauthor=K.+Rigatauthor=R.+Colonnoauthor=M.+Gao&title=Development+of+a+cell-based+high-throughput+specificity+screen+using+a+hepatitis+C+virus-bovine+viral+diarrhea+virus+dual+replicon+assay&doi=10.1128%2FAAC.49.4.1346-1353.2005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.4.1346-1353.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.4.1346-1353.2005%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DRigat%26aufirst%3DK.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DDevelopment%2520of%2520a%2520cell-based%2520high-throughput%2520specificity%2520screen%2520using%2520a%2520hepatitis%2520C%2520virus-bovine%2520viral%2520diarrhea%2520virus%2520dual%2520replicon%2520assay%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D1346%26epage%3D1353%26doi%3D10.1128%2FAAC.49.4.1346-1353.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, L. G.</span><span> </span><span class="NLM_article-title">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">465</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span><span class="refDoi"> DOI: 10.1038/nature08960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnature08960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=20410884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=96-100&author=M.+Gaoauthor=R.+E.+Nettlesauthor=M.+Belemaauthor=L.+B.+Snyderauthor=V.+N.+Nguyenauthor=R.+A.+Fridellauthor=M.+H.+Serrano-Wuauthor=D.+R.+Langleyauthor=J.-H.+Sunauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=C.+Wangauthor=J.+O.+Knipeauthor=C.+Chienauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=N.+A.+Meanwellauthor=L.+G.+Hamann&title=Chemical+genetics+strategy+identifies+an+HCV+NS5A+inhibitor+with+a+potent+clinical+effect&doi=10.1038%2Fnature08960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span></div><div class="casAuthors">Gao, Min; Nettles, Richard E.; Belema, Makonen; Snyder, Lawrence B.; Nguyen, Van N.; Fridell, Robert A.; Serrano-Wu, Michael H.; Langley, David R.; Sun, Jin-Hua; O'Boyle, Donald R., II; Lemm, Julie A.; Wang, Chunfu; Knipe, Jay O.; Chien, Caly; Colonno, Richard J.; Grasela, Dennis M.; Meanwell, Nicholas A.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7294</span>),
    <span class="NLM_cas:pages">96-100</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estd. to be approaching 200 million people.  Current therapy relies upon a combination of pegylated interferon-α and ribavirin, a poorly tolerated regimen typically assocd. with less than 50% sustained virol. response rate in those infected with genotype 1 virus.  The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B.  Here we describe the profile of BMS-790052, a small mol. inhibitor of the HCV NS5A protein that exhibits picomolar half-max. effective concns. (EC50) towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture.  In a phase I clin. trial in patients chronically infected with HCV, administration of a single 100-mg dose of BMS-790052 was assocd. with a 3.3 log10 redn. in mean viral load measured 24 h post-dose that was sustained for an addnl. 120 h in two patients infected with genotype 1b virus.  Genotypic anal. of samples taken at baseline, 24 and 144 h post-dose revealed that the major HCV variants obsd. had substitutions at amino-acid positions identified using the in vitro replicon system.  These results provide the first clin. validation of an inhibitor of HCV NS5A, a protein with no known enzymic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations of HCV inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAY7Lig0xT9LVg90H21EOLACvtfcHk0ljBMxb4hAMvAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D&md5=620427e987f2bccd153270cde2ef5027</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnature08960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08960%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DChemical%2520genetics%2520strategy%2520identifies%2520an%2520HCV%2520NS5A%2520inhibitor%2520with%2520a%2520potent%2520clinical%2520effect%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D96%26epage%3D100%26doi%3D10.1038%2Fnature08960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bhatti, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suresh</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandhu, J. S.</span><span> </span><span class="NLM_article-title">Recent pharmacological developments on rhodanines and 2,4-thiazolidinediones</span> <span class="citation_source-journal">Int. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2013</span><span class="NLM_x">, </span> <span class="NLM_fpage">793260</span><span class="refDoi"> DOI: 10.1155/2013/793260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1155%2F2013%2F793260" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&pages=793260&author=R.+S.+Bhattiauthor=S.+Shahauthor=+Sureshauthor=P.+Krishanauthor=J.+S.+Sandhu&title=Recent+pharmacological+developments+on+rhodanines+and+2%2C4-thiazolidinediones&doi=10.1155%2F2013%2F793260"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63a&amp;dbid=16384&amp;doi=10.1155%2F2013%2F793260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F793260%26sid%3Dliteratum%253Aachs%26aulast%3DBhatti%26aufirst%3DR.%2BS.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DSuresh%26aulast%3DKrishan%26aufirst%3DP.%26aulast%3DSandhu%26aufirst%3DJ.%2BS.%26atitle%3DRecent%2520pharmacological%2520developments%2520on%2520rhodanines%2520and%25202%252C4-thiazolidinediones%26jtitle%3DInt.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D2013%26spage%3D793260%26doi%3D10.1155%2F2013%2F793260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit63b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tripathi, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fatima, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonar, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saraf, S. K.</span><span> </span><span class="NLM_article-title">4-Thiazolidinones: the advances continue</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">52</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2013.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.ejmech.2013.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24355348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2014&pages=52-77&author=A.+C.+Tripathiauthor=S.+J.+Guptaauthor=G.+N.+Fatimaauthor=P.+K.+Sonarauthor=A.+Vermaauthor=S.+K.+Saraf&title=4-Thiazolidinones%3A+the+advances+continue&doi=10.1016%2Fj.ejmech.2013.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63bR"><div class="casContent"><span class="casTitleNuber">63b</span><div class="casTitle"><span class="NLM_cas:atitle">4-Thiazolidinones: The advances continue...</span></div><div class="casAuthors">Tripathi, Avinash C.; Gupta, Shiv Ji; Fatima, Gul Naz; Sonar, Pankaj Kumar; Verma, Amit; Saraf, Shailendra K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">52-77</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The diversity in the biol. response of 4-thiazolidinones has attracted the attention of many researchers to explore this framework for its potential.  It is, therefore, of prime importance that the study of this topic and the development of new synthetic strategies should be based on the most recent knowledge, emerging from the latest research.  This review is an endeavor to highlight the progress in the chem. and biol. activity of the 4-thiazolidinones, predominantly after 2006.  The last section of the review encompasses the various patents granted on 4-thiazolidinone analogs/derivs. with World Intellectual Proprietary Organization (WIPO) and United State Patent Trademark Office (USPTO), particularly in the duration of the year 2000 to the year 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIWsGW07DjorVg90H21EOLACvtfcHk0ljBMxb4hAMvAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yktb4%253D&md5=77a5960d66392440998a3c62628cb3ad</span></div><a href="/servlet/linkout?suffix=cit63b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DTripathi%26aufirst%3DA.%2BC.%26aulast%3DGupta%26aufirst%3DS.%2BJ.%26aulast%3DFatima%26aufirst%3DG.%2BN.%26aulast%3DSonar%26aufirst%3DP.%2BK.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DSaraf%26aufirst%3DS.%2BK.%26atitle%3D4-Thiazolidinones%253A%2520the%2520advances%2520continue%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D72%26spage%3D52%26epage%3D77%26doi%3D10.1016%2Fj.ejmech.2013.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit63c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bolli, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abele, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binkert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatfield, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangold, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathys, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menyhart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sippel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strasser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, T.</span><span> </span><span class="NLM_article-title">2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4198</span><span class="NLM_x">–</span> <span class="NLM_lpage">4211</span><span class="refDoi"> DOI: 10.1021/jm100181s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100181s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4198-4211&author=M.+H.+Bolliauthor=S.+Abeleauthor=C.+Binkertauthor=R.+Bravoauthor=S.+Buchmannauthor=D.+Burauthor=J.+Gatfieldauthor=P.+Hessauthor=C.+Kohlauthor=C.+Mangoldauthor=B.+Mathysauthor=K.+Menyhartauthor=C.+M%C3%BCllerauthor=O.+Naylerauthor=M.+Scherzauthor=G.+Schmidtauthor=V.+Sippelauthor=B.+Steinerauthor=D.+Strasserauthor=A.+Treiberauthor=T.+Weller&title=2-Imino-thiazolidin-4-one+derivatives+as+potent%2C+orally+active+S1P1+receptor+agonists&doi=10.1021%2Fjm100181s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63c&amp;dbid=16384&amp;doi=10.1021%2Fjm100181s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100181s%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DAbele%26aufirst%3DS.%26aulast%3DBinkert%26aufirst%3DC.%26aulast%3DBravo%26aufirst%3DR.%26aulast%3DBuchmann%26aufirst%3DS.%26aulast%3DBur%26aufirst%3DD.%26aulast%3DGatfield%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DKohl%26aufirst%3DC.%26aulast%3DMangold%26aufirst%3DC.%26aulast%3DMathys%26aufirst%3DB.%26aulast%3DMenyhart%26aufirst%3DK.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3DScherz%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DG.%26aulast%3DSippel%26aufirst%3DV.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DStrasser%26aufirst%3DD.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DWeller%26aufirst%3DT.%26atitle%3D2-Imino-thiazolidin-4-one%2520derivatives%2520as%2520potent%252C%2520orally%2520active%2520S1P1%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4198%26epage%3D4211%26doi%3D10.1021%2Fjm100181s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshpande, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Identification of hepatitis C virus NS5A inhibitors</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">482</span><span class="NLM_x">–</span> <span class="NLM_lpage">491</span><span class="refDoi"> DOI: 10.1128/JVI.01360-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FJVI.01360-09" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=482-491&author=J.+A.+Lemmauthor=D.+R.+O%E2%80%99Boyleauthor=M.+Liuauthor=P.+T.+Nowerauthor=R.+Colonnoauthor=M.+S.+Deshpandeauthor=L.+B.+Snyderauthor=S.+W.+Martinauthor=D.+R.+St.+Laurentauthor=M.+H.+Serrano-Wuauthor=J.+L.+Romineauthor=N.+A.+Meanwellauthor=M.+Gao&title=Identification+of+hepatitis+C+virus+NS5A+inhibitors&doi=10.1128%2FJVI.01360-09"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1128%2FJVI.01360-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01360-09%26sid%3Dliteratum%253Aachs%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DDeshpande%26aufirst%3DM.%2BS.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitors%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D482%26epage%3D491%26doi%3D10.1128%2FJVI.01360-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pawlotsky, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germanidis, G.</span><span> </span><span class="NLM_article-title">The non-structural 5A protein of hepatitis C virus</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">343</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span><span class="refDoi"> DOI: 10.1046/j.1365-2893.1999.00185.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1046%2Fj.1365-2893.1999.00185.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=343-356&author=J.-M.+Pawlotskyauthor=G.+Germanidis&title=The+non-structural+5A+protein+of+hepatitis+C+virus&doi=10.1046%2Fj.1365-2893.1999.00185.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65a&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2893.1999.00185.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2893.1999.00185.x%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.-M.%26aulast%3DGermanidis%26aufirst%3DG.%26atitle%3DThe%2520non-structural%25205A%2520protein%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D1999%26volume%3D6%26spage%3D343%26epage%3D356%26doi%3D10.1046%2Fj.1365-2893.1999.00185.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit65b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neddermann, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinkühler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallinari, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folgori, A.</span><span> </span><span class="NLM_article-title">Biochemical and immunologic properties of the nonstructural proteins of the hepatitis C virus: implications for development of antiviral agents and vaccines</span> <span class="citation_source-journal">Semin. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1055/s-2000-9504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1055%2Fs-2000-9504" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=69-84&author=R.+De+Francescoauthor=P.+Neddermannauthor=L.+Tomeiauthor=C.+Steink%C3%BChlerauthor=P.+Gallinariauthor=A.+Folgori&title=Biochemical+and+immunologic+properties+of+the+nonstructural+proteins+of+the+hepatitis+C+virus%3A+implications+for+development+of+antiviral+agents+and+vaccines&doi=10.1055%2Fs-2000-9504"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65b&amp;dbid=16384&amp;doi=10.1055%2Fs-2000-9504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2000-9504%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DNeddermann%26aufirst%3DP.%26aulast%3DTomei%26aufirst%3DL.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DGallinari%26aufirst%3DP.%26aulast%3DFolgori%26aufirst%3DA.%26atitle%3DBiochemical%2520and%2520immunologic%2520properties%2520of%2520the%2520nonstructural%2520proteins%2520of%2520the%2520hepatitis%2520C%2520virus%253A%2520implications%2520for%2520development%2520of%2520antiviral%2520agents%2520and%2520vaccines%26jtitle%3DSemin.%2520Liver%2520Dis.%26date%3D2000%26volume%3D20%26spage%3D69%26epage%3D84%26doi%3D10.1055%2Fs-2000-9504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Macdonald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, M.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A: tales of a promiscuous protein</span> <span class="citation_source-journal">J. Gen. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">2485</span><span class="NLM_x">–</span> <span class="NLM_lpage">2502</span><span class="refDoi"> DOI: 10.1099/vir.0.80204-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1099%2Fvir.0.80204-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2004&pages=2485-2502&author=A.+Macdonaldauthor=M.+Harris&title=Hepatitis+C+virus+NS5A%3A+tales+of+a+promiscuous+protein&doi=10.1099%2Fvir.0.80204-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66a&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.80204-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.80204-0%26sid%3Dliteratum%253Aachs%26aulast%3DMacdonald%26aufirst%3DA.%26aulast%3DHarris%26aufirst%3DM.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%253A%2520tales%2520of%2520a%2520promiscuous%2520protein%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2004%26volume%3D85%26spage%3D2485%26epage%3D2502%26doi%3D10.1099%2Fvir.0.80204-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit66b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ross-Thriepland, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, M.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A: enigmatic but still promiscuous 10 years on!</span> <span class="citation_source-journal">J. Gen. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">727</span><span class="NLM_x">–</span> <span class="NLM_lpage">738</span><span class="refDoi"> DOI: 10.1099/jgv.0.000009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1099%2Fjgv.0.000009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25481754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotVaktL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2015&pages=727-738&author=D.+Ross-Thrieplandauthor=M.+Harris&title=Hepatitis+C+virus+NS5A%3A+enigmatic+but+still+promiscuous+10+years+on%21&doi=10.1099%2Fjgv.0.000009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66bR"><div class="casContent"><span class="casTitleNuber">66b</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus NS5A: enigmatic but still promiscuous 10 years on!</span></div><div class="casAuthors">Ross-Thriepland, Douglas; Harris, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">727-738</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">A review.  Since 1 of us co-authored a review on NS5A a decade ago, the hepatitis C virus (HCV) field has changed dramatically, primarily due to the advent of the JFH-1 cell culture infectious clone, which allowed the study of all aspects of the virus life cycle from entry to exit.  We describe advances in our understanding of NS5A biol. over the past decade, highlighting how the JFH-1 system has allowed us to det. that NS5A is essential not only in genome replication but also in the assembly of infectious virions.  We shall review the recent structural insights: NS5A is predicted to comprise 3 domains; X-ray crystallog. has revealed the structure of domain I but there is a lack of detailed structural information about the other 2 domains, which are predicted to be largely unstructured.  Recent insights into the phosphorylation of NS5A will be discussed, and we shall highlight a few pertinent examples from the ever-expanding list of NS5A-binding partners identified over the past decade.  Lastly, we shall review the literature showing that NS5A is a potential target for a new class of highly potent small mols. that function to inhibit virus replication.  These direct-acting antivirals (DAAs) are now either licensed, or in the late stages of approval for clin. use both in the USA and in the UK/Europe.  In combination with other DAAs targeting the viral protease (NS3) and polymerase (NS5B), they are revolutionizing treatment for HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqIagaCVblebVg90H21EOLACvtfcHk0lhLPB3UwWNEzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotVaktL8%253D&md5=a57512232b774a2635cc9b61be9ca982</span></div><a href="/servlet/linkout?suffix=cit66b&amp;dbid=16384&amp;doi=10.1099%2Fjgv.0.000009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fjgv.0.000009%26sid%3Dliteratum%253Aachs%26aulast%3DRoss-Thriepland%26aufirst%3DD.%26aulast%3DHarris%26aufirst%3DM.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%253A%2520enigmatic%2520but%2520still%2520promiscuous%252010%2520years%2520on%2521%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2015%26volume%3D96%26spage%3D727%26epage%3D738%26doi%3D10.1099%2Fjgv.0.000009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Bukh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietschmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieger, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faulk, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engle, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govindarajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Claire, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">14416</span><span class="NLM_x">–</span> <span class="NLM_lpage">14421</span><span class="refDoi"> DOI: 10.1073/pnas.212532699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1073%2Fpnas.212532699" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=14416-14421&author=J.+Bukhauthor=T.+Pietschmannauthor=V.+Lohmannauthor=N.+Kriegerauthor=K.+Faulkauthor=R.+E.+Engleauthor=S.+Govindarajanauthor=M.+Shapiroauthor=M.+St.+Claireauthor=R.+Bartenschlager&title=Mutations+that+permit+efficient+replication+of+hepatitis+C+virus+RNA+in+Huh-7+cells+prevent+productive+replication+in+chimpanzees&doi=10.1073%2Fpnas.212532699"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1073%2Fpnas.212532699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.212532699%26sid%3Dliteratum%253Aachs%26aulast%3DBukh%26aufirst%3DJ.%26aulast%3DPietschmann%26aufirst%3DT.%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DKrieger%26aufirst%3DN.%26aulast%3DFaulk%26aufirst%3DK.%26aulast%3DEngle%26aufirst%3DR.%2BE.%26aulast%3DGovindarajan%26aufirst%3DS.%26aulast%3DShapiro%26aufirst%3DM.%26aulast%3DSt.%2BClaire%26aufirst%3DM.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DMutations%2520that%2520permit%2520efficient%2520replication%2520of%2520hepatitis%2520C%2520virus%2520RNA%2520in%2520Huh-7%2520cells%2520prevent%2520productive%2520replication%2520in%2520chimpanzees%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D14416%26epage%3D14421%26doi%3D10.1073%2Fpnas.212532699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sato, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, N.</span><span> </span><span class="NLM_article-title">Specific hepatitis C virus NS5A sequences determine the outcome of interferon treatment</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">1152</span><span class="NLM_x">–</span> <span class="NLM_lpage">1154</span><span class="refDoi"> DOI: 10.1016/S0016-5085(96)70089-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0016-5085%2896%2970089-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1996&pages=1152-1154&author=C.+Satoauthor=N.+Enomoto&title=Specific+hepatitis+C+virus+NS5A+sequences+determine+the+outcome+of+interferon+treatment&doi=10.1016%2FS0016-5085%2896%2970089-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68a&amp;dbid=16384&amp;doi=10.1016%2FS0016-5085%2896%2970089-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0016-5085%252896%252970089-6%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DC.%26aulast%3DEnomoto%26aufirst%3DN.%26atitle%3DSpecific%2520hepatitis%2520C%2520virus%2520NS5A%2520sequences%2520determine%2520the%2520outcome%2520of%2520interferon%2520treatment%26jtitle%3DGastroenterology%26date%3D1996%26volume%3D111%26spage%3D1152%26epage%3D1154%26doi%3D10.1016%2FS0016-5085%2896%2970089-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit68b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pawlotsky, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germanidis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellerin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frainais, P.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhumeaux, D.</span><span> </span><span class="NLM_article-title">Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">2795</span><span class="NLM_x">–</span> <span class="NLM_lpage">2805</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1998&pages=2795-2805&author=J.-M.+Pawlotskyauthor=G.+Germanidisauthor=A.+U.+Neumannauthor=M.+Pellerinauthor=P.-O.+Frainaisauthor=D.+Dhumeaux&title=Interferon+resistance+of+hepatitis+C+virus+genotype+1b%3A+relationship+to+nonstructural+5A+gene+quasispecies+mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.-M.%26aulast%3DGermanidis%26aufirst%3DG.%26aulast%3DNeumann%26aufirst%3DA.%2BU.%26aulast%3DPellerin%26aufirst%3DM.%26aulast%3DFrainais%26aufirst%3DP.-O.%26aulast%3DDhumeaux%26aufirst%3DD.%26atitle%3DInterferon%2520resistance%2520of%2520hepatitis%2520C%2520virus%2520genotype%25201b%253A%2520relationship%2520to%2520nonstructural%25205A%2520gene%2520quasispecies%2520mutations%26jtitle%3DJ.%2520Virol.%26date%3D1998%26volume%3D72%26spage%3D2795%26epage%3D2805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit68c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Pawlotsky, J. M.</span><span> </span><span class="NLM_article-title">Hepatitis C virus (HCV) NS5A protein: role in HCV replication and resistance to interferon-alpha</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span><span class="refDoi"> DOI: 10.1046/j.1365-2893.1999.00004.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1046%2Fj.1365-2893.1999.00004.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=47-48&issue=Suppl.+1&author=J.+M.+Pawlotsky&title=Hepatitis+C+virus+%28HCV%29+NS5A+protein%3A+role+in+HCV+replication+and+resistance+to+interferon-alpha&doi=10.1046%2Fj.1365-2893.1999.00004.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68c&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2893.1999.00004.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2893.1999.00004.x%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.%2BM.%26atitle%3DHepatitis%2520C%2520virus%2520%2528HCV%2529%2520NS5A%2520protein%253A%2520role%2520in%2520HCV%2520replication%2520and%2520resistance%2520to%2520interferon-alpha%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D1999%26volume%3D6%26issue%3DSuppl.%25201%26spage%3D47%26epage%3D48%26doi%3D10.1046%2Fj.1365-2893.1999.00004.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">The discovery and development of hepatitis C virus NS5A replication complex inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1643</span><span class="NLM_x">–</span> <span class="NLM_lpage">1672</span><span class="refDoi"> DOI: 10.1021/jm401793m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401793m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslygsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1643-1672&author=M.+Belemaauthor=O.+D.+Lopezauthor=J.+A.+Benderauthor=J.+L.+Romineauthor=D.+R.+Laurentauthor=D.+R.+Langleyauthor=J.+A.+Lemmauthor=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=C.+Wangauthor=R.+A.+Fridellauthor=N.+A.+Meanwell&title=The+discovery+and+development+of+hepatitis+C+virus+NS5A+replication+complex+inhibitors&doi=10.1021%2Fjm401793m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors</span></div><div class="casAuthors">Belema, Makonen; Lopez, Omar D.; Bender, John A.; Romine, Jeffrey L.; St. Laurent, Denis R.; Langley, David R.; Lemm, Julie A.; O'Boyle, Donald R., II; Sun, Jin-Hua; Wang, Chunfu; Fridell, Robert A.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1643-1672</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Lead inhibitors that target the function of the hepatitis C virus (HCV) nonstructural 5A (NS5A) protein have been identified by phenotypic screening campaigns using HCV subgenomic replicons.  The demonstration of antiviral activity in HCV-infected subjects by the HCV NS5A replication complex inhibitor (RCI) daclatasvir (1) spawned considerable interest in this mechanistic approach.  In this Perspective, we summarize the medicinal chem. studies that led to the discovery of 1 and other chemotypes for which resistance maps to the NS5A protein and provide synopses of the profiles of many of the compds. currently in clin. trials.  We also summarize what is currently known about the NS5A protein and the studies using NS5A RCIs and labeled analogs that are helping to illuminate aspects of both protein function and inhibitor interaction.  We conclude with a synopsis of the results of notable clin. trials with HCV NS5A RCIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIeKUL517UmLVg90H21EOLACvtfcHk0ljBXH7VUU7FoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslygsbk%253D&md5=cc92046f9edcb633b433a0e6a4ac3fec</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm401793m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401793m%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DLaurent%26aufirst%3DD.%2BR.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DThe%2520discovery%2520and%2520development%2520of%2520hepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1643%26epage%3D1672%26doi%3D10.1021%2Fjm401793m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Romine, J. L.; Martin, S. W.; Snyder, L. B.; Serrano-Wu, M.; Deshpande, M.; Whitehouse, D.; Lemm, J.; O’Boyle, D. R.; Gao, M.; Colonno, R.</span><span> </span><span class="NLM_article-title">Iminothiazolidinones as inhibitors of HCV replication</span>. World Patent Application WO 2004/014852. February 19,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=J.+L.+Romine&author=S.+W.+Martin&author=L.+B.+Snyder&author=M.+Serrano-Wu&author=M.+Deshpande&author=D.+Whitehouse&author=J.+Lemm&author=D.+R.+O%E2%80%99Boyle&author=M.+Gao&author=R.+Colonno&title=Iminothiazolidinones+as+inhibitors+of+HCV+replication"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26atitle%3DIminothiazolidinones%2520as%2520inhibitors%2520of%2520HCV%2520replication%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit70b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshpande, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">Inhibitors of HCV NS5A: from iminothiazolidinones to symmetrical stilbenes</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">224</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span><span class="refDoi"> DOI: 10.1021/ml1002647</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1002647" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=224-229&author=J.+L.+Romineauthor=D.+R.+St.+Laurentauthor=J.+E.+Leetauthor=S.+W.+Martinauthor=M.+H.+Serrano-Wuauthor=F.+Yangauthor=M.+Gaoauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=J.-H.+Sunauthor=P.+T.+Nowerauthor=X.+Huangauthor=M.+S.+Deshpandeauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=Inhibitors+of+HCV+NS5A%3A+from+iminothiazolidinones+to+symmetrical+stilbenes&doi=10.1021%2Fml1002647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70bR"><div class="casContent"><span class="casTitleNuber">70b</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes</span></div><div class="casAuthors">Romine, Jeffrey L.; St. Laurent, Denis R.; Leet, John E.; Martin, Scott W.; Serrano-Wu, Michael H.; Yang, Fukang; Gao, Min; O'Boyle, Donald R.; Lemm, Julie A.; Sun, Jin-Hua; Nower, Peter T.; Huang, Xiaohua; Deshpande, Milind S.; Meanwell, Nicholas A.; Snyder, Lawrence B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">224-229</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The iminothiazolidinone BMS-858 (2) was identified as a specific inhibitor of HCV replication in a genotype 1b replicon assay via a high-throughput screening campaign.  A more potent analog, BMS-824 (18), was used in resistance mapping studies, which revealed that inhibitory activity was related to disrupting the function of the HCV nonstructural protein 5A.  Despite the development of coherent and interpretable SAR, it was subsequently discovered that in DMSO 18 underwent an oxidn. and structural rearrangement to afford the thiohydantoin 47, a compd. with reduced HCV inhibitory activity.  However, HPLC bioassay fractionation studies performed after incubation of 18 in assay media led to the identification of fractions contg. a dimeric species 48 that exhibited potent antiviral activity.  Excision of the key elements hypothesized to be responsible for antiviral activity based on SAR observations reduced 48 to a simplified, sym., pharmacophore realized most effectively with the stilbene 55, a compd. that demonstrated potent inhibition of HCV in a genotype 1b replicon with an EC50 = 86 pM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj8qij0fE1q7Vg90H21EOLACvtfcHk0ljBXH7VUU7FoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFCmsg%253D%253D&md5=466b1f5dc09b9e2ecc6b581069506169</span></div><a href="/servlet/linkout?suffix=cit70b&amp;dbid=16384&amp;doi=10.1021%2Fml1002647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1002647%26sid%3Dliteratum%253Aachs%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DDeshpande%26aufirst%3DM.%2BS.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DInhibitors%2520of%2520HCV%2520NS5A%253A%2520from%2520iminothiazolidinones%2520to%2520symmetrical%2520stilbenes%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D224%26epage%3D229%26doi%3D10.1021%2Fml1002647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alberts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantone, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3795</span><span class="NLM_x">–</span> <span class="NLM_lpage">3802</span><span class="refDoi"> DOI: 10.1128/AAC.00146-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FAAC.00146-11" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=3795-3802&author=J.+A.+Lemmauthor=J.+E.+Leetauthor=D.+R.+O%E2%80%99Boyleauthor=J.+L.+Romineauthor=X.+S.+Huangauthor=D.+R.+Schroederauthor=J.+Albertsauthor=J.+L.+Cantoneauthor=J.-H.+Sunauthor=P.+T.+Nowerauthor=S.+W.+Martinauthor=M.+H.+Serrano-Wuauthor=N.+A.+Meanwellauthor=L.+B.+Snyderauthor=M.+Gao&title=Discovery+of+potent+hepatitis+C+virus+NS5A+inhibitors+with+dimeric+structures&doi=10.1128%2FAAC.00146-11"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1128%2FAAC.00146-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00146-11%26sid%3Dliteratum%253Aachs%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DHuang%26aufirst%3DX.%2BS.%26aulast%3DSchroeder%26aufirst%3DD.%2BR.%26aulast%3DAlberts%26aufirst%3DJ.%26aulast%3DCantone%26aufirst%3DJ.%2BL.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520potent%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitors%2520with%2520dimeric%2520structures%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D3795%26epage%3D3802%26doi%3D10.1128%2FAAC.00146-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Leet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belcastro, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowling, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemeth, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, H. N.</span><span> </span><span class="NLM_article-title">HPLC biogram analysis: a powerful tool used for hit confirmation in early drug discovery</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">681</span><span class="NLM_x">–</span> <span class="NLM_lpage">687</span><span class="refDoi"> DOI: 10.1177/1087057115569160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1177%2F1087057115569160" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=681-687&author=J.+E.+Leetauthor=J.+V.+Belcastroauthor=C.+J.+Dowlingauthor=G.+A.+Nemethauthor=H.+N.+Weller&title=HPLC+biogram+analysis%3A+a+powerful+tool+used+for+hit+confirmation+in+early+drug+discovery&doi=10.1177%2F1087057115569160"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1177%2F1087057115569160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057115569160%26sid%3Dliteratum%253Aachs%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DBelcastro%26aufirst%3DJ.%2BV.%26aulast%3DDowling%26aufirst%3DC.%2BJ.%26aulast%3DNemeth%26aufirst%3DG.%2BA.%26aulast%3DWeller%26aufirst%3DH.%2BN.%26atitle%3DHPLC%2520biogram%2520analysis%253A%2520a%2520powerful%2520tool%2520used%2520for%2520hit%2520confirmation%2520in%2520early%2520drug%2520discovery%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2015%26volume%3D20%26spage%3D681%26epage%3D687%26doi%3D10.1177%2F1087057115569160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Giese, B.</span> <span class="citation_source-book">Radicals in Organic Synthesis: Formation of Carbon-Carbon Bonds</span>; <span class="NLM_publisher-name">Pergamon Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1986</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1986&author=B.+Giese&title=Radicals+in+Organic+Synthesis%3A+Formation+of+Carbon-Carbon+Bonds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGiese%26aufirst%3DB.%26btitle%3DRadicals%2520in%2520Organic%2520Synthesis%253A%2520Formation%2520of%2520Carbon-Carbon%2520Bonds%26pub%3DPergamon%2520Press%26date%3D1986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit73b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Viehe, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janousek, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merenyi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stella, L.</span><span> </span><span class="NLM_article-title">The captodative effect</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">148</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span><span class="refDoi"> DOI: 10.1021/ar00113a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar00113a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaL2MXktlKrs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1985&pages=148-154&author=H.+G.+Vieheauthor=Z.+Janousekauthor=R.+Merenyiauthor=L.+Stella&title=The+captodative+effect&doi=10.1021%2Far00113a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73bR"><div class="casContent"><span class="casTitleNuber">73b</span><div class="casTitle"><span class="NLM_cas:atitle">The captodative effect</span></div><div class="casAuthors">Viehe, Heinz G.; Janousek, Zdenek; Merenyi, Robert; Stella, Lucien</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">148-54</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    </div><div class="casAbstract">The genesis of the captodative effect is reviewed with ∼60 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGont4FOPBPrxLVg90H21EOLACvtfcHk0ljv8LdyLDFuWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXktlKrs7c%253D&md5=58e437aa46c25ef758cb2a2d44ec09cc</span></div><a href="/servlet/linkout?suffix=cit73b&amp;dbid=16384&amp;doi=10.1021%2Far00113a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far00113a004%26sid%3Dliteratum%253Aachs%26aulast%3DViehe%26aufirst%3DH.%2BG.%26aulast%3DJanousek%26aufirst%3DZ.%26aulast%3DMerenyi%26aufirst%3DR.%26aulast%3DStella%26aufirst%3DL.%26atitle%3DThe%2520captodative%2520effect%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1985%26volume%3D18%26spage%3D148%26epage%3D154%26doi%3D10.1021%2Far00113a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Ingold, K. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratt, D. A.</span><span> </span><span class="NLM_article-title">Advances in radical-trapping antioxidant chemistry in the 21st century: a kinetics and mechanisms perspective</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">9022</span><span class="NLM_x">–</span> <span class="NLM_lpage">9046</span><span class="refDoi"> DOI: 10.1021/cr500226n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr500226n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=9022-9046&author=K.+U.+Ingoldauthor=D.+A.+Pratt&title=Advances+in+radical-trapping+antioxidant+chemistry+in+the+21st+century%3A+a+kinetics+and+mechanisms+perspective&doi=10.1021%2Fcr500226n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in Radical-Trapping Antioxidant Chemistry in the 21st Century: A Kinetics and Mechanisms Perspective</span></div><div class="casAuthors">Ingold, Keith U.; Pratt, Derek A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">9022-9046</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozeP_96otNHLVg90H21EOLACvtfcHk0ljuQEpp7XmoBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtLzO&md5=ea5b97ad5071ae648de3e4bea3de7425</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fcr500226n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr500226n%26sid%3Dliteratum%253Aachs%26aulast%3DIngold%26aufirst%3DK.%2BU.%26aulast%3DPratt%26aufirst%3DD.%2BA.%26atitle%3DAdvances%2520in%2520radical-trapping%2520antioxidant%2520chemistry%2520in%2520the%252021st%2520century%253A%2520a%2520kinetics%2520and%2520mechanisms%2520perspective%26jtitle%3DChem.%2520Rev.%26date%3D2014%26volume%3D114%26spage%3D9022%26epage%3D9046%26doi%3D10.1021%2Fcr500226n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75a"><span><span class="NLM_contrib-group">Kates, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dombroski, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snider, B. B.</span><span> </span><span class="NLM_article-title">Manganese(III)-based oxidative free-radical cyclization of unsaturated β-keto esters, 1,3-diketones, and malonate diesters</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2427</span><span class="NLM_x">–</span> <span class="NLM_lpage">2436</span><span class="refDoi"> DOI: 10.1021/jo00295a035</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00295a035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1990&pages=2427-2436&author=S.+A.+Katesauthor=M.+A.+Dombroskiauthor=B.+B.+Snider&title=Manganese%28III%29-based+oxidative+free-radical+cyclization+of+unsaturated+%CE%B2-keto+esters%2C+1%2C3-diketones%2C+and+malonate+diesters&doi=10.1021%2Fjo00295a035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75a&amp;dbid=16384&amp;doi=10.1021%2Fjo00295a035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00295a035%26sid%3Dliteratum%253Aachs%26aulast%3DKates%26aufirst%3DS.%2BA.%26aulast%3DDombroski%26aufirst%3DM.%2BA.%26aulast%3DSnider%26aufirst%3DB.%2BB.%26atitle%3DManganese%2528III%2529-based%2520oxidative%2520free-radical%2520cyclization%2520of%2520unsaturated%2520%25CE%25B2-keto%2520esters%252C%25201%252C3-diketones%252C%2520and%2520malonate%2520diesters%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1990%26volume%3D55%26spage%3D2427%26epage%3D2436%26doi%3D10.1021%2Fjo00295a035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit75b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Snider, B. B.</span><span> </span><span class="NLM_article-title">Manganese(III)-based oxidative free-radical cyclizations</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">339</span><span class="NLM_x">–</span> <span class="NLM_lpage">363</span><span class="refDoi"> DOI: 10.1021/cr950026m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr950026m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK28XjsVKluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1996&pages=339-363&author=B.+B.+Snider&title=Manganese%28III%29-based+oxidative+free-radical+cyclizations&doi=10.1021%2Fcr950026m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75bR"><div class="casContent"><span class="casTitleNuber">75b</span><div class="casTitle"><span class="NLM_cas:atitle">Manganese(III)-Based Oxidative Free-Radical Cyclizations</span></div><div class="casAuthors">Snider, Barry B.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">339-63</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 171 refs.  Mn(OAc)3 and other oxidants have been used in oxidative cyclizations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZGDd7A7jakLVg90H21EOLACvtfcHk0ljiZK4Z7GB-vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjsVKluw%253D%253D&md5=b5e51e70470d149c53a53701c4a7b767</span></div><a href="/servlet/linkout?suffix=cit75b&amp;dbid=16384&amp;doi=10.1021%2Fcr950026m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr950026m%26sid%3Dliteratum%253Aachs%26aulast%3DSnider%26aufirst%3DB.%2BB.%26atitle%3DManganese%2528III%2529-based%2520oxidative%2520free-radical%2520cyclizations%26jtitle%3DChem.%2520Rev.%26date%3D1996%26volume%3D96%26spage%3D339%26epage%3D363%26doi%3D10.1021%2Fcr950026m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Irie, M.</span><span> </span><span class="NLM_article-title">Diarylethenes for memories and switches</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1685</span><span class="NLM_x">–</span> <span class="NLM_lpage">1716</span><span class="refDoi"> DOI: 10.1021/cr980069d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr980069d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFGitLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=1685-1716&author=M.+Irie&title=Diarylethenes+for+memories+and+switches&doi=10.1021%2Fcr980069d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76aR"><div class="casContent"><span class="casTitleNuber">76a</span><div class="casTitle"><span class="NLM_cas:atitle">Diarylethenes for Memories and Switches</span></div><div class="casAuthors">Irie, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1685-1716</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diarylethenes with heterocyclic aryl groups are thermally reversible photochromic compds. with high resistance to fatigue.  These properties are indispensable for applications in optoelectronic devices.  Fundamental properties of these compds. and their applications to optical memory devices and switches are described.  A review with 130 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraGHEiJ_0jY7Vg90H21EOLACvtfcHk0lh89fB1BzWvPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFGitLc%253D&md5=c83c651b39092361b7d52849973cd002</span></div><a href="/servlet/linkout?suffix=cit76a&amp;dbid=16384&amp;doi=10.1021%2Fcr980069d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr980069d%26sid%3Dliteratum%253Aachs%26aulast%3DIrie%26aufirst%3DM.%26atitle%3DDiarylethenes%2520for%2520memories%2520and%2520switches%26jtitle%3DChem.%2520Rev.%26date%3D2000%26volume%3D100%26spage%3D1685%26epage%3D1716%26doi%3D10.1021%2Fcr980069d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit76b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fuss, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trushin, S. A.</span><span> </span><span class="NLM_article-title">The photochemical cis-trans isomerization of free stilbene molecules follows a hula-twist pathway</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">4178</span><span class="NLM_x">–</span> <span class="NLM_lpage">4182</span><span class="refDoi"> DOI: 10.1002/anie.200454221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fanie.200454221" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=4178-4182&author=W.+Fussauthor=C.+Kosmidisauthor=W.+E.+Schmidauthor=S.+A.+Trushin&title=The+photochemical+cis-trans+isomerization+of+free+stilbene+molecules+follows+a+hula-twist+pathway&doi=10.1002%2Fanie.200454221"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76b&amp;dbid=16384&amp;doi=10.1002%2Fanie.200454221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200454221%26sid%3Dliteratum%253Aachs%26aulast%3DFuss%26aufirst%3DW.%26aulast%3DKosmidis%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DW.%2BE.%26aulast%3DTrushin%26aufirst%3DS.%2BA.%26atitle%3DThe%2520photochemical%2520cis-trans%2520isomerization%2520of%2520free%2520stilbene%2520molecules%2520follows%2520a%2520hula-twist%2520pathway%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2004%26volume%3D43%26spage%3D4178%26epage%3D4182%26doi%3D10.1002%2Fanie.200454221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit76c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Takeuchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruhman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuneda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taketsugu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahara, T.</span><span> </span><span class="NLM_article-title">Spectroscopic tracking of structural evolution in ultrafast stilbene photoisomerization</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">322</span><span class="NLM_x">, </span> <span class="NLM_fpage">1073</span><span class="NLM_x">–</span> <span class="NLM_lpage">1077</span><span class="refDoi"> DOI: 10.1126/science.1160902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1126%2Fscience.1160902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=19008439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlGhu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2008&pages=1073-1077&author=S.+Takeuchiauthor=S.+Ruhmanauthor=T.+Tsunedaauthor=M.+Chibaauthor=T.+Taketsuguauthor=T.+Tahara&title=Spectroscopic+tracking+of+structural+evolution+in+ultrafast+stilbene+photoisomerization&doi=10.1126%2Fscience.1160902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76cR"><div class="casContent"><span class="casTitleNuber">76c</span><div class="casTitle"><span class="NLM_cas:atitle">Spectroscopic tracking of structural evolution in ultrafast stilbene photoisomerization</span></div><div class="casAuthors">Takeuchi, Satoshi; Ruhman, Sanford; Tsuneda, Takao; Chiba, Mahito; Taketsugu, Tetsuya; Tahara, Tahei</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">5904</span>),
    <span class="NLM_cas:pages">1073-1077</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Understanding a chem. reaction ultimately requires the knowledge of how each atom in the reactants moves during product formation.  Such knowledge is seldom complete and is often limited to an oversimplified reaction coordinate that neglects global motions across the mol. framework.  To overcome this limit, we recorded transient impulsive Raman spectra during ultrafast photoisomerization of cis-stilbene in soln.  The results demonstrate a gradual frequency shift of a low-frequency spectator vibration, reflecting changes in the restoring force along this coordinate throughout the isomerization.  A high-level quantum-chem. calcn. reproduces this feature and assocs. it with a continuous structural change leading to the twisted configuration.  This combined spectroscopic and computational approach should be amenable to detailed reaction visualization in other photoisomerizing systems as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV4pF4Yg5RXbVg90H21EOLACvtfcHk0ljEE1DxqCcwuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlGhu7fP&md5=0defa842e4cfd2e304a051ec55ab12db</span></div><a href="/servlet/linkout?suffix=cit76c&amp;dbid=16384&amp;doi=10.1126%2Fscience.1160902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1160902%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DS.%26aulast%3DRuhman%26aufirst%3DS.%26aulast%3DTsuneda%26aufirst%3DT.%26aulast%3DChiba%26aufirst%3DM.%26aulast%3DTaketsugu%26aufirst%3DT.%26aulast%3DTahara%26aufirst%3DT.%26atitle%3DSpectroscopic%2520tracking%2520of%2520structural%2520evolution%2520in%2520ultrafast%2520stilbene%2520photoisomerization%26jtitle%3DScience%26date%3D2008%26volume%3D322%26spage%3D1073%26epage%3D1077%26doi%3D10.1126%2Fscience.1160902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Benigni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruska, A.</span><span> </span><span class="NLM_article-title">Quantitative structure-activity relationships of mutagenic and carcinogenic aromatic amines</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">3697</span><span class="NLM_x">–</span> <span class="NLM_lpage">3714</span><span class="refDoi"> DOI: 10.1021/cr9901079</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr9901079" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlslSku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2000&pages=3697-3714&author=R.+Benigniauthor=A.+Giulianiauthor=R.+Frankeauthor=A.+Gruska&title=Quantitative+structure-activity+relationships+of+mutagenic+and+carcinogenic+aromatic+amines&doi=10.1021%2Fcr9901079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77aR"><div class="casContent"><span class="casTitleNuber">77a</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative Structure-Activity Relationships of Mutagenic and Carcinogenic Aromatic Amines</span></div><div class="casAuthors">Benigni, Romualdo; Giuliani, Alessandro; Franke, Rainer; Gruska, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3697-3714</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 76 refs. discusses the value of QSAR models in predicting carcinogenicity of well-defined chem. classes such as the arom. amines detailed in the review. In vivo data were successfully incorporated into a statistically reliable and informative model of arom. amine carcinogenic potential. TD50's as endpoints were used to measure carcinogenic potency and were a reliable basis for modeling even when data came from different labs. It was detd. from the QSAR models reviewed that arom. amines require metabolic activation to yield the ultimate carcinogen or mutagen. The principal pathway(s) of bioactivation involves the formation of a hydroxylamine, which decomps. to a reactive nitrenium ion intermediate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohUfWQFGPvGLVg90H21EOLACvtfcHk0lgUURoA6PQvFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlslSku7g%253D&md5=8e17bc92f38af39517f904dcdcec7bc4</span></div><a href="/servlet/linkout?suffix=cit77a&amp;dbid=16384&amp;doi=10.1021%2Fcr9901079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9901079%26sid%3Dliteratum%253Aachs%26aulast%3DBenigni%26aufirst%3DR.%26aulast%3DGiuliani%26aufirst%3DA.%26aulast%3DFranke%26aufirst%3DR.%26aulast%3DGruska%26aufirst%3DA.%26atitle%3DQuantitative%2520structure-activity%2520relationships%2520of%2520mutagenic%2520and%2520carcinogenic%2520aromatic%2520amines%26jtitle%3DChem.%2520Rev.%26date%3D2000%26volume%3D100%26spage%3D3697%26epage%3D3714%26doi%3D10.1021%2Fcr9901079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit77b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kugler-Steigmeier, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friederich, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graf, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlatter, C.</span><span> </span><span class="NLM_article-title">Genotoxicity of aniline derivatives in various short-term tests</span> <span class="citation_source-journal">Mutat. Res., Fundam. Mol. Mech. Mutagen.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">211</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">289</span><span class="refDoi"> DOI: 10.1016/0027-5107(89)90011-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2F0027-5107%2889%2990011-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=2494442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaL1MXitVOmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=1989&pages=279-289&author=M.+E.+Kugler-Steigmeierauthor=U.+Friederichauthor=U.+Grafauthor=W.+K.+Lutzauthor=P.+Maierauthor=C.+Schlatter&title=Genotoxicity+of+aniline+derivatives+in+various+short-term+tests&doi=10.1016%2F0027-5107%2889%2990011-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77bR"><div class="casContent"><span class="casTitleNuber">77b</span><div class="casTitle"><span class="NLM_cas:atitle">Genotoxicity of aniline derivatives in various short-term tests</span></div><div class="casAuthors">Kugler-Steigmeier, M. E.; Friederich, U.; Graf, U.; Lutz, W. K.; Maier, P.; Schlatter, C.</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, Fundamental and Molecular Mechanisms of Mutagenesis</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-89</span>CODEN:
                <span class="NLM_cas:coden">MUREAV</span>;
        ISSN:<span class="NLM_cas:issn">0027-5107</span>.
    </div><div class="casAbstract">Various substituted aniline derivs. were tested for genotoxicity in several short-term tests to examine the hypothesis that a substitution at both ortho positions (2,6-disubstitution) could prevent genotoxicity due to steric hindrance of an enzymic activation to electrophilic intermediates.  In the Salmonella/microsome assay, 2,6-dialkylsubstituted anilines and 2,4,6-trimethylaniline (2,4,6-TMA) were weakly mutagenic in strain TA100 when 20% S9 mix was used, although effects were small compared to those of 2,4-dimethylaniline and 2,4,5-trimethylaniline (2,4,5-TMA).  In Drosophila melanogaster, however, 2,4,6-TMA and 2,4,6-trichloroaniline were mutagenic in the wing spot test at 2-3 times lower doses than 2,4,5-TMA.  In the 6-thioguanine resistance test in cultured fibroblasts, 2,4,6-TMA was again mutagenic at lower doses than 2,4,5-TMA.  Two methylene-bis-aniline derivs. were also tested with the above methods: 4,4'-methylene-bis-[(2-chloroaniline)] (MOCA) was moderately genotoxic in all 3 tests systems whereas 4,4'-methylene-bis-[(2-ethyl-6-methylaniline)] (MMEA) showed no genotoxicity at all.  DNA binding studies in rats, however, revealed that MOCA and MMEA produced DNA adducts in the liver at levels typically found for moderately strong genotoxic carcinogens.  Thus, the predictive value of the in vitro test systems and particularly the Salmonella/microsome assay is inadequate to detect genotoxicity in arom. amines.  Genotoxicity seems to be a general property of aniline derivs. and does not seem to be greatly influenced by substitution at both ortho positions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7X8K383lt8bVg90H21EOLACvtfcHk0liVKpg3YNl_3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXitVOmtbg%253D&md5=f362df1cf93da42f697b7ca4d19ff59f</span></div><a href="/servlet/linkout?suffix=cit77b&amp;dbid=16384&amp;doi=10.1016%2F0027-5107%2889%2990011-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0027-5107%252889%252990011-0%26sid%3Dliteratum%253Aachs%26aulast%3DKugler-Steigmeier%26aufirst%3DM.%2BE.%26aulast%3DFriederich%26aufirst%3DU.%26aulast%3DGraf%26aufirst%3DU.%26aulast%3DLutz%26aufirst%3DW.%2BK.%26aulast%3DMaier%26aufirst%3DP.%26aulast%3DSchlatter%26aufirst%3DC.%26atitle%3DGenotoxicity%2520of%2520aniline%2520derivatives%2520in%2520various%2520short-term%2520tests%26jtitle%3DMutat.%2520Res.%252C%2520Fundam.%2520Mol.%2520Mech.%2520Mutagen.%26date%3D1989%26volume%3D211%26spage%3D279%26epage%3D289%26doi%3D10.1016%2F0027-5107%2889%2990011-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit77c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Shamovsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Börjesson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordén, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasselgren, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjö, P.</span><span> </span><span class="NLM_article-title">Explanation for main features of structure-genotoxicity relationships of aromatic amines by theoretical studies of their activation pathways in CYP1A2</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">133</span><span class="NLM_x">, </span> <span class="NLM_fpage">16168</span><span class="NLM_x">–</span> <span class="NLM_lpage">16185</span><span class="refDoi"> DOI: 10.1021/ja206427u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja206427u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2011&pages=16168-16185&author=I.+Shamovskyauthor=L.+Ripaauthor=L.+B%C3%B6rjessonauthor=C.+Meeauthor=B.+Nord%C3%A9nauthor=P.+Hansenauthor=C.+Hasselgrenauthor=M.+O%E2%80%99Donovanauthor=P.+Sj%C3%B6&title=Explanation+for+main+features+of+structure-genotoxicity+relationships+of+aromatic+amines+by+theoretical+studies+of+their+activation+pathways+in+CYP1A2&doi=10.1021%2Fja206427u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77cR"><div class="casContent"><span class="casTitleNuber">77c</span><div class="casTitle"><span class="NLM_cas:atitle">Explanation for Main Features of Structure-Genotoxicity Relationships of Aromatic Amines by Theoretical Studies of Their Activation Pathways in CYP1A2</span></div><div class="casAuthors">Shamovsky, Igor; Ripa, Lena; Borjesson, Lena; Mee, Christine; Norden, Bo; Hansen, Peter; Hasselgren, Catrin; O'Donovan, Mike; Sjo, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">16168-16185</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Arom. and heteroarom. amines (ArNH2) represent a class of potential mutagens that after being metabolically activated covalently modify DNA.  Activation of ArNH2 in many cases starts with N-hydroxylation by P 450 enzymes, primarily CYP1A2.  Poor understanding of structure-mutagenicity relationships of ArNH2 limits their use in drug discovery programs.  Key factors that facilitate activation of ArNH2 are revealed by exploring their reaction intermediates in CYP1A2 using DFT calcns.  On the basis of these calcns. and extensive anal. of structure-mutagenicity data, we suggest that mutagenic metabolites are generated by ferric peroxo intermediate, (CYP1A2)FeIII-OO-, in a three-step heterolytic mechanism.  First, the distal oxygen of the oxidant abstrs. proton from H-bonded ArNH2.  The subsequent proximal protonation of the resulting (CYP1A2)FeIII-OOH weakens both the O-O and the O-H bonds of the oxidant.  Heterolytic cleavage of the O-O bond leads to N-hydroxylation of ArNH- via SN2 mechanism, whereas cleavage of the O-H bond results in release of hydroperoxy radical.  Thus, our proposed reaction offers a mechanistic explanation for previous observations that metab. of arom. amines could cause oxidative stress.  The primary drivers for mutagenic potency of ArNH2 are (i) binding affinity of ArNH2 in the productive binding mode within the CYP1A2 substrate cavity, (ii) resonance stabilization of the anionic forms of ArNH2, and (iii) exothermicity of proton-assisted heterolytic cleavage of N-O bonds of hydroxylamines and their bioconjugates.  This leads to a strategy for designing mutagenicity free ArNH2: Structural alterations in ArNH2, which disrupt geometric compatibility with CYP1A2, hinder proton abstraction, or strongly destabilize the nitrenium ion, in this order of priority, prevent genotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrctr81IIN2trVg90H21EOLACvtfcHk0lhQmFFEF-m44w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1SrsrvI&md5=9447ee2144a899b65e9350b712ca2a46</span></div><a href="/servlet/linkout?suffix=cit77c&amp;dbid=16384&amp;doi=10.1021%2Fja206427u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja206427u%26sid%3Dliteratum%253Aachs%26aulast%3DShamovsky%26aufirst%3DI.%26aulast%3DRipa%26aufirst%3DL.%26aulast%3DB%25C3%25B6rjesson%26aufirst%3DL.%26aulast%3DMee%26aufirst%3DC.%26aulast%3DNord%25C3%25A9n%26aufirst%3DB.%26aulast%3DHansen%26aufirst%3DP.%26aulast%3DHasselgren%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%26aulast%3DSj%25C3%25B6%26aufirst%3DP.%26atitle%3DExplanation%2520for%2520main%2520features%2520of%2520structure-genotoxicity%2520relationships%2520of%2520aromatic%2520amines%2520by%2520theoretical%2520studies%2520of%2520their%2520activation%2520pathways%2520in%2520CYP1A2%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2011%26volume%3D133%26spage%3D16168%26epage%3D16185%26doi%3D10.1021%2Fja206427u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit77d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Sinsheimer, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooberman, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brezzell, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, Z.</span><span> </span><span class="NLM_article-title">The in vivo and in vitro genotoxicity of aromatic amines in relationship to the genotoxicity of benzidine</span> <span class="citation_source-journal">Mutat. Res., Fundam. Mol. Mech. Mutagen.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1016/0027-5107(92)90232-Q</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2F0027-5107%2892%2990232-Q" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1992&pages=255-262&author=J.+E.+Sinsheimerauthor=B.+H.+Hoobermanauthor=S.+K.+Dasauthor=M.+D.+Brezzellauthor=Z.+You&title=The+in+vivo+and+in+vitro+genotoxicity+of+aromatic+amines+in+relationship+to+the+genotoxicity+of+benzidine&doi=10.1016%2F0027-5107%2892%2990232-Q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77d&amp;dbid=16384&amp;doi=10.1016%2F0027-5107%2892%2990232-Q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0027-5107%252892%252990232-Q%26sid%3Dliteratum%253Aachs%26aulast%3DSinsheimer%26aufirst%3DJ.%2BE.%26aulast%3DHooberman%26aufirst%3DB.%2BH.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DBrezzell%26aufirst%3DM.%2BD.%26aulast%3DYou%26aufirst%3DZ.%26atitle%3DThe%2520in%2520vivo%2520and%2520in%2520vitro%2520genotoxicity%2520of%2520aromatic%2520amines%2520in%2520relationship%2520to%2520the%2520genotoxicity%2520of%2520benzidine%26jtitle%3DMutat.%2520Res.%252C%2520Fundam.%2520Mol.%2520Mech.%2520Mutagen.%26date%3D1992%26volume%3D268%26spage%3D255%26epage%3D262%26doi%3D10.1016%2F0027-5107%2892%2990232-Q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit77e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">You, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brezzell, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooberman, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinsheimer, J. E.</span><span> </span><span class="NLM_article-title">Substituent effects on the in vitro and in vivo genotoxicity of 4-aminobiphenyl and 4-aminostilbene derivatives</span> <span class="citation_source-journal">Mutat. Res., Genet. Toxicol. Test.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">320</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span><span class="refDoi"> DOI: 10.1016/0165-1218(94)90058-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2F0165-1218%2894%2990058-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=1994&pages=45-58&author=Z.+Youauthor=M.+D.+Brezzellauthor=S.+K.+Dasauthor=B.+H.+Hoobermanauthor=J.+E.+Sinsheimer&title=Substituent+effects+on+the+in+vitro+and+in+vivo+genotoxicity+of+4-aminobiphenyl+and+4-aminostilbene+derivatives&doi=10.1016%2F0165-1218%2894%2990058-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77e&amp;dbid=16384&amp;doi=10.1016%2F0165-1218%2894%2990058-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-1218%252894%252990058-2%26sid%3Dliteratum%253Aachs%26aulast%3DYou%26aufirst%3DZ.%26aulast%3DBrezzell%26aufirst%3DM.%2BD.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DHooberman%26aufirst%3DB.%2BH.%26aulast%3DSinsheimer%26aufirst%3DJ.%2BE.%26atitle%3DSubstituent%2520effects%2520on%2520the%2520in%2520vitro%2520and%2520in%2520vivo%2520genotoxicity%2520of%25204-aminobiphenyl%2520and%25204-aminostilbene%2520derivatives%26jtitle%3DMutat.%2520Res.%252C%2520Genet.%2520Toxicol.%2520Test.%26date%3D1994%26volume%3D320%26spage%3D45%26epage%3D58%26doi%3D10.1016%2F0165-1218%2894%2990058-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit77f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Garcia, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pye, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galbreath, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isovitsch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fradinger, E. A.</span><span> </span><span class="NLM_article-title">The functional group on (<i>E</i>)-4,4′-disubstituted stilbenes influences toxicity and antioxidative activity in differentiated PC-12 cells</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">6355</span><span class="NLM_x">–</span> <span class="NLM_lpage">6359</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.09.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmcl.2013.09.073" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=6355-6359&author=G.+X.+Garciaauthor=S.+W.+Larsenauthor=C.+Pyeauthor=M.+Galbreathauthor=R.+Isovitschauthor=E.+A.+Fradinger&title=The+functional+group+on+%28E%29-4%2C4%E2%80%B2-disubstituted+stilbenes+influences+toxicity+and+antioxidative+activity+in+differentiated+PC-12+cells&doi=10.1016%2Fj.bmcl.2013.09.073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77f&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.09.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.09.073%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DG.%2BX.%26aulast%3DLarsen%26aufirst%3DS.%2BW.%26aulast%3DPye%26aufirst%3DC.%26aulast%3DGalbreath%26aufirst%3DM.%26aulast%3DIsovitsch%26aufirst%3DR.%26aulast%3DFradinger%26aufirst%3DE.%2BA.%26atitle%3DThe%2520functional%2520group%2520on%2520%2528E%2529-4%252C4%25E2%2580%25B2-disubstituted%2520stilbenes%2520influences%2520toxicity%2520and%2520antioxidative%2520activity%2520in%2520differentiated%2520PC-12%2520cells%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D6355%26epage%3D6359%26doi%3D10.1016%2Fj.bmcl.2013.09.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit77g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Cunningham, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, E.</span><span> </span><span class="NLM_article-title">Hydrolysis of oleylanilide in the rat</span> <span class="citation_source-journal">Arch. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span><span class="refDoi"> DOI: 10.1007/BF01261384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1007%2FBF01261384" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1983&pages=157-162&author=V.+J.+Cunninghamauthor=S.+P.+Tuckerauthor=E.+Bailey&title=Hydrolysis+of+oleylanilide+in+the+rat&doi=10.1007%2FBF01261384"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77g&amp;dbid=16384&amp;doi=10.1007%2FBF01261384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01261384%26sid%3Dliteratum%253Aachs%26aulast%3DCunningham%26aufirst%3DV.%2BJ.%26aulast%3DTucker%26aufirst%3DS.%2BP.%26aulast%3DBailey%26aufirst%3DE.%26atitle%3DHydrolysis%2520of%2520oleylanilide%2520in%2520the%2520rat%26jtitle%3DArch.%2520Toxicol.%26date%3D1983%26volume%3D54%26spage%3D157%26epage%3D162%26doi%3D10.1007%2FBF01261384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mondelli, M. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silini, E.</span><span> </span><span class="NLM_article-title">Clinical significance of hepatitis C virus genotypes</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span><span class="refDoi"> DOI: 10.1016/S0168-8278(99)80377-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0168-8278%2899%2980377-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1999&pages=65-70&issue=Suppl.+1&author=M.+U.+Mondelliauthor=E.+Silini&title=Clinical+significance+of+hepatitis+C+virus+genotypes&doi=10.1016%2FS0168-8278%2899%2980377-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78a&amp;dbid=16384&amp;doi=10.1016%2FS0168-8278%2899%2980377-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-8278%252899%252980377-8%26sid%3Dliteratum%253Aachs%26aulast%3DMondelli%26aufirst%3DM.%2BU.%26aulast%3DSilini%26aufirst%3DE.%26atitle%3DClinical%2520significance%2520of%2520hepatitis%2520C%2520virus%2520genotypes%26jtitle%3DJ.%2520Hepatol.%26date%3D1999%26volume%3D31%26issue%3DSuppl.%25201%26spage%3D65%26epage%3D70%26doi%3D10.1016%2FS0168-8278%2899%2980377-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit78b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zein, N. N.</span><span> </span><span class="NLM_article-title">Clinical significance of hepatitis C virus genotypes</span> <span class="citation_source-journal">Clin. Microbiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">235</span><span class="refDoi"> DOI: 10.1128/CMR.13.2.223-235.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FCMR.13.2.223-235.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10755999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtVOqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2000&pages=223-235&author=N.+N.+Zein&title=Clinical+significance+of+hepatitis+C+virus+genotypes&doi=10.1128%2FCMR.13.2.223-235.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78bR"><div class="casContent"><span class="casTitleNuber">78b</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of hepatitis C virus genotypes</span></div><div class="casAuthors">Zein, Nizar N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">223-235</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">0893-8512</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review with 149 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIyz_GrutS8LVg90H21EOLACvtfcHk0lilU_68c4SekQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtVOqs7k%253D&md5=c3dbf9e23541db288f77cfabdf5c2e45</span></div><a href="/servlet/linkout?suffix=cit78b&amp;dbid=16384&amp;doi=10.1128%2FCMR.13.2.223-235.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.13.2.223-235.2000%26sid%3Dliteratum%253Aachs%26aulast%3DZein%26aufirst%3DN.%2BN.%26atitle%3DClinical%2520significance%2520of%2520hepatitis%2520C%2520virus%2520genotypes%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2000%26volume%3D13%26spage%3D223%26epage%3D235%26doi%3D10.1128%2FCMR.13.2.223-235.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit78c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Simmonds, P.</span><span> </span><span class="NLM_article-title">Genetic diversity and evolution of hepatitis C virus 15 years on</span> <span class="citation_source-journal">J. Gen. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">3173</span><span class="NLM_x">–</span> <span class="NLM_lpage">3188</span><span class="refDoi"> DOI: 10.1099/vir.0.80401-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1099%2Fvir.0.80401-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2004&pages=3173-3188&author=P.+Simmonds&title=Genetic+diversity+and+evolution+of+hepatitis+C+virus+15+years+on&doi=10.1099%2Fvir.0.80401-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78c&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.80401-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.80401-0%26sid%3Dliteratum%253Aachs%26aulast%3DSimmonds%26aufirst%3DP.%26atitle%3DGenetic%2520diversity%2520and%2520evolution%2520of%2520hepatitis%2520C%2520virus%252015%2520years%2520on%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2004%26volume%3D85%26spage%3D3173%26epage%3D3188%26doi%3D10.1099%2Fvir.0.80401-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit78d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Nainan, O. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alter, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruszon-Moran, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, F.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuillan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolis, H. S.</span><span> </span><span class="NLM_article-title">Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">478</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span><span class="refDoi"> DOI: 10.1053/j.gastro.2006.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1053%2Fj.gastro.2006.06.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2006&pages=478-484&author=O.+V.+Nainanauthor=M.+J.+Alterauthor=D.+Kruszon-Moranauthor=F.-X.+Gaoauthor=G.+Xiaauthor=G.+McQuillanauthor=H.+S.+Margolis&title=Hepatitis+C+virus+genotypes+and+viral+concentrations+in+participants+of+a+general+population+survey+in+the+United+States&doi=10.1053%2Fj.gastro.2006.06.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78d&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2006.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2006.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DNainan%26aufirst%3DO.%2BV.%26aulast%3DAlter%26aufirst%3DM.%2BJ.%26aulast%3DKruszon-Moran%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DF.-X.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DMcQuillan%26aufirst%3DG.%26aulast%3DMargolis%26aufirst%3DH.%2BS.%26atitle%3DHepatitis%2520C%2520virus%2520genotypes%2520and%2520viral%2520concentrations%2520in%2520participants%2520of%2520a%2520general%2520population%2520survey%2520in%2520the%2520United%2520States%26jtitle%3DGastroenterology%26date%3D2006%26volume%3D131%26spage%3D478%26epage%3D484%26doi%3D10.1053%2Fj.gastro.2006.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5057</span><span class="NLM_x">–</span> <span class="NLM_lpage">5071</span><span class="refDoi"> DOI: 10.1021/jm500335h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500335h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsFWgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5057-5071&author=M.+Belemaauthor=N.+A.+Meanwell&title=Discovery+of+daclatasvir%2C+a+pan-genotypic+hepatitis+C+virus+NS5A+replication+complex+inhibitor+with+potent+clinical+effect&doi=10.1021%2Fjm500335h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect</span></div><div class="casAuthors">Belema, Makonen; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5057-5071</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review. The discovery and development of the first-in-class hepatitis C virus (HCV) NS5A replication complex inhibitor daclatasvir provides a compelling example of the power of phenotypic screening to identify leads engaging novel targets in mechanistically unique ways.  HCV NS5A replication complex inhibitors are pan-genotypic in spectrum, and this mechanistic class provides the most potent HCV inhibitors in vitro that have been described to date.  Clin. trials with daclatasvir demonstrated a potent effect on reducing plasma viral load and, in combination with mechanistically orthogonal HCV inhibitors, established the ability to cure even the most difficult infections without the need for immune stimulation.  In this Drug Annotation, the authors describe the discovery of the original high-throughput screening lead BMS-858 and the chem. conundrum and challenges resolved in optimizing to daclatasvir as a clin. candidate and finally the authors summarize the results of select clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiU5qkfNyqXLVg90H21EOLACvtfcHk0ljQhB6UCCqA4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsFWgurs%253D&md5=1428746b49ba356ce6993a58b143e5dc</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fjm500335h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500335h%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DDiscovery%2520of%2520daclatasvir%252C%2520a%2520pan-genotypic%2520hepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitor%2520with%2520potent%2520clinical%2520effect%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5057%26epage%3D5071%26doi%3D10.1021%2Fjm500335h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Belema, M.; Schnittman, S. M.; Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Case history: the discovery of the first hepatitis C virus NS5A replication complex inhibitor daclatasvir (Daklinza)</span>. Med. Chem. Rev.<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">, </span>manuscript in press</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+Belema&author=S.+M.+Schnittman&author=N.+A.+Meanwell&title=Case+history%3A+the+discovery+of+the+first+hepatitis+C+virus+NS5A+replication+complex+inhibitor+daclatasvir+%28Daklinza%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26atitle%3DCase%2520history%253A%2520the%2520discovery%2520of%2520the%2520first%2520hepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitor%2520daclatasvir%2520%2528Daklinza%2529%26jtitle%3DMed.%2520Chem.%2520Rev.%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripka, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">779</span><span class="NLM_x">–</span> <span class="NLM_lpage">784</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmcl.2012.11.086" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=779-784&author=O.+D.+Lopezauthor=V.+N.+Nguyenauthor=D.+R.+St.+Laurentauthor=M.+Belemaauthor=M.+H.+Serrano-Wuauthor=J.+T.+Goodrichauthor=F.+Yangauthor=Y.+Qiuauthor=A.+S.+Ripkaauthor=P.+T.+Nowerauthor=L.+Valeraauthor=M.+Liuauthor=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=R.+A.+Fridellauthor=J.+A.+Lemmauthor=M.+Gaoauthor=A.+C.+Goodauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+3%3A+discovery+of+potent+analogs+with+distinct+core+topologies&doi=10.1016%2Fj.bmcl.2012.11.086"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.086%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DGoodrich%26aufirst%3DJ.%2BT.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DRipka%26aufirst%3DA.%2BS.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25203%253A%2520discovery%2520of%2520potent%2520analogs%2520with%2520distinct%2520core%2520topologies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D779%26epage%3D784%26doi%3D10.1016%2Fj.bmcl.2012.11.086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakarla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamides</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6063</span><span class="NLM_x">–</span> <span class="NLM_lpage">6066</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmcl.2012.08.049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6063-6066&author=D.+R.+St.+Laurentauthor=M.+Belemaauthor=M.+Gaoauthor=J.+Goodrichauthor=R.+Kakarlaauthor=J.+O.+Knipeauthor=J.+A.+Lemmauthor=M.+Liuauthor=O.+D.+Lopezauthor=V.+N.+Nguyenauthor=P.+T.+Nowerauthor=D.+O%E2%80%99Boyleauthor=Y.+Qiuauthor=J.+L.+Romineauthor=M.+H.+Serrano-Wuauthor=J.-H.+Sunauthor=L.+Valeraauthor=F.+Yangauthor=X.+Yangauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+2%3A+investigation+of+stilbene+prolinamides&doi=10.1016%2Fj.bmcl.2012.08.049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.049%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGoodrich%26aufirst%3DJ.%26aulast%3DKakarla%26aufirst%3DR.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25202%253A%2520investigation%2520of%2520stilbene%2520prolinamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6063%26epage%3D6066%26doi%3D10.1016%2Fj.bmcl.2012.08.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Wu, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 4: optimization for genotype 1a replicon inhibitory activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1976</span><span class="NLM_x">–</span> <span class="NLM_lpage">1994</span><span class="refDoi"> DOI: 10.1021/jm301796k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301796k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1976-1994&author=D.+R.+St.+Laurentauthor=M.+H.+Serrano-Wuauthor=M.+Belemaauthor=M.+Dingauthor=H.+Fangauthor=M.+Gaoauthor=J.+T.+Goodrichauthor=R.+G.+Krauseauthor=J.+A.+Lemmauthor=M.+Liuauthor=O.+D.+Lopezauthor=V.+N.+Nguyenauthor=P.+T.+Nowerauthor=D.+R.+O%E2%80%99Boyleauthor=B.+C.+Pearceauthor=J.+L.+Romineauthor=L.+Valeraauthor=J.-H.+Sunauthor=Y.-K.+Wangauthor=F.+Yangauthor=X.+Yangauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+4%3A+optimization+for+genotype+1a+replicon+inhibitory+activity&doi=10.1021%2Fjm301796k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fjm301796k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301796k%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGoodrich%26aufirst%3DJ.%2BT.%26aulast%3DKrause%26aufirst%3DR.%2BG.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DPearce%26aufirst%3DB.%2BC.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25204%253A%2520optimization%2520for%2520genotype%25201a%2520replicon%2520inhibitory%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1976%26epage%3D1994%26doi%3D10.1021%2Fjm301796k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4428</span><span class="NLM_x">–</span> <span class="NLM_lpage">4435</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmcl.2013.05.040" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4428-4435&author=M.+Belemaauthor=V.+N.+Nguyenauthor=D.+R.+St.+Laurentauthor=O.+D.+Lopezauthor=Y.+Qiuauthor=A.+C.+Goodauthor=P.+T.+Nowerauthor=L.+Valeraauthor=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=R.+A.+Fridellauthor=J.+A.+Lemmauthor=M.+Gaoauthor=J.+O.+Knipeauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+5%3A+discovery+of+potent+and+pan-genotypic+glycinamide+cap+derivatives&doi=10.1016%2Fj.bmcl.2013.05.040"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.040%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25205%253A%2520discovery%2520of%2520potent%2520and%2520pan-genotypic%2520glycinamide%2520cap%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4428%26epage%3D4435%26doi%3D10.1016%2Fj.bmcl.2013.05.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A replication complex inhibitors. Part 6: the discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotype 1a and 1b replicons</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1995</span><span class="NLM_x">–</span> <span class="NLM_lpage">2012</span><span class="refDoi"> DOI: 10.1021/jm4016203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1995-2012&author=M.+Belemaauthor=V.+N.+Nguyenauthor=J.+L.+Romineauthor=D.+R.+St.+Laurentauthor=O.+D.+Lopezauthor=J.+Goodrichauthor=P.+T.+Nowerauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=R.+A.+Fridellauthor=M.+Gaoauthor=H.+Fangauthor=R.+G.+Krauseauthor=Y.-K.+Wangauthor=A.+J.+Oliverauthor=A.+C.+Goodauthor=J.+O.+Knipeauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=Hepatitis+C+virus+NS5A+replication+complex+inhibitors.+Part+6%3A+the+discovery+of+a+novel+and+highly+potent+biarylimidazole+chemotype+with+inhibitory+activity+toward+genotype+1a+and+1b+replicons&doi=10.1021%2Fjm4016203"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fjm4016203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016203%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DGoodrich%26aufirst%3DJ.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DKrause%26aufirst%3DR.%2BG.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DOliver%26aufirst%3DA.%2BJ.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25206%253A%2520the%2520discovery%2520of%2520a%2520novel%2520and%2520highly%2520potent%2520biarylimidazole%2520chemotype%2520with%2520inhibitory%2520activity%2520toward%2520genotype%25201a%2520and%25201b%2520replicons%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1995%26epage%3D2012%26doi%3D10.1021%2Fjm4016203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachand, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deon, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodrich, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavoie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, O. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruediger, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Laurent, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chimalakonda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, L. G.</span><span> </span><span class="NLM_article-title">Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2013</span><span class="NLM_x">–</span> <span class="NLM_lpage">2032</span><span class="refDoi"> DOI: 10.1021/jm401836p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401836p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVWhsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2013-2032&author=M.+Belemaauthor=V.+N.+Nguyenauthor=C.+Bachandauthor=D.+H.+Deonauthor=J.+T.+Goodrichauthor=R.+Lavoieauthor=C.+A.+Jamesauthor=O.+D.+Lopezauthor=A.+Martelauthor=J.+L.+Romineauthor=E.+H.+Ruedigerauthor=L.+B.+Snyderauthor=D.+R.+St.+Laurentauthor=A.+C.+Goodauthor=D.+R.+Langleyauthor=A.+Chimalakondaauthor=A.+Furaauthor=J.+O.+Knipeauthor=P.+T.+Nowerauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=R.+A.+Fridellauthor=M.+Gaoauthor=N.+A.+Meanwellauthor=L.+G.+Hamann&title=Hepatitis+C+virus+NS5A+replication+complex+inhibitors%3A+the+discovery+of+daclatasvir&doi=10.1021%2Fjm401836p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir</span></div><div class="casAuthors">Belema, Makonen; Nguyen, Van N.; Bachand, Carol; Deon, Dan H.; Goodrich, Jason T.; James, Clint A.; Lavoie, Rico; Lopez, Omar D.; Martel, Alain; Romine, Jeffrey L.; Ruediger, Edward H.; Snyder, Lawrence B.; St. Laurent, Denis R.; Yang, Fukang; Zhu, Juliang; Wong, Henry S.; Langley, David R.; Adams, Stephen P.; Cantor, Glenn H.; Chimalakonda, Anjaneya; Fura, Aberra; Johnson, Benjamin M.; Knipe, Jay O.; Parker, Dawn D.; Santone, Kenneth S.; Fridell, Robert A.; Lemm, Julie A.; O'Boyle, Donald R., II; Colonno, Richard J.; Gao, Min; Meanwell, Nicholas A.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2013-2032</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The biphenyl derivs. I (R = NHCO2Me, NMe2) are prototypes of a novel class of NS5A replication complex inhibitors that demonstrate high inhibitory potency toward a panel of clin. relevant HCV strains encompassing genotypes 1-6.  However, these compds. exhibit poor systemic exposure in rat pharmacokinetic studies after oral dosing.  The structure-activity relationship investigations that improved the exposure properties of the parent bis-phenylimidazole chemotype, culminating in the identification of the highly potent NS5A replication complex inhibitor daclatasvir (II, X = 4,4'-biphenylene) are described.  An element crit. to success was the realization that the arylglycine cap of I (R = NHCO2Me) could be replaced with an alkylglycine deriv. and still maintain the high inhibitory potency of the series if accompanied with a stereoinversion, a finding that enabled a rapid optimization of exposure properties.  Compd. II had EC50 values of 50 and 9 pM toward genotype-1a and -1b replicons, resp., and oral bioavailabilities of 38-108% in preclin. species.  Compd. II provided clin. proof-of-concept for the NS5A replication complex inhibitor class, and regulatory approval to market it with the NS3/4A protease inhibitor asunaprevir for the treatment of HCV genotype-1b infection has recently been sought in Japan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYnJILm4L3mbVg90H21EOLACvtfcHk0lhxSgtbrFDNHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVWhsr8%253D&md5=ca5c44e9b15fda7cb4632066ef2a673a</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fjm401836p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401836p%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DBachand%26aufirst%3DC.%26aulast%3DDeon%26aufirst%3DD.%2BH.%26aulast%3DGoodrich%26aufirst%3DJ.%2BT.%26aulast%3DLavoie%26aufirst%3DR.%26aulast%3DJames%26aufirst%3DC.%2BA.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DMartel%26aufirst%3DA.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DRuediger%26aufirst%3DE.%2BH.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DHepatitis%2520C%2520virus%2520NS5A%2520replication%2520complex%2520inhibitors%253A%2520the%2520discovery%2520of%2520daclatasvir%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2013%26epage%3D2032%26doi%3D10.1021%2Fjm401836p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Wakita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietschmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Date, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murthy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habermann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraeusslich, H.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizokami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, T. J.</span><span> </span><span class="NLM_article-title">Production of infectious hepatitis C virus in tissue culture from a cloned viral genome</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">791</span><span class="NLM_x">–</span> <span class="NLM_lpage">796</span><span class="refDoi"> DOI: 10.1038/nm1268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnm1268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=15951748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1aju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=791-796&author=T.+Wakitaauthor=T.+Pietschmannauthor=T.+Katoauthor=T.+Dateauthor=M.+Miyamotoauthor=Z.+Zhaoauthor=K.+Murthyauthor=A.+Habermannauthor=H.-G.+Kraeusslichauthor=M.+Mizokamiauthor=R.+Bartenschlagerauthor=T.+J.+Liang&title=Production+of+infectious+hepatitis+C+virus+in+tissue+culture+from+a+cloned+viral+genome&doi=10.1038%2Fnm1268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Production of infectious hepatitis C virus in tissue culture from a cloned viral genome</span></div><div class="casAuthors">Wakita, Takaji; Pietschmann, Thomas; Kato, Takanobu; Date, Tomoko; Miyamoto, Michiko; Zhao, Zijiang; Murthy, Krishna; Habermann, Anja; Kraeusslich, Hans-Georg; Mizokami, Masashi; Bartenschlager, Ralf; Liang, T. Jake</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">791-796</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection causes chronic liver diseases and is a global public health problem.  Detailed analyses of HCV have been hampered by the lack of viral culture systems.  Subgenomic replicons of the JFH1 genotype 2a strain cloned from an individual with fulminant hepatitis replicate efficiently in cell culture.  Here we show that the JFH1 genome replicates efficiently and supports secretion of viral particles after transfection into a human hepatoma cell line (Huh7).  Particles have a d. of about 1.15-1.17 g/mL and a spherical morphol. with an av. diam. of about 55 nm.  Secreted virus is infectious for Huh7 cells and infectivity can be neutralized by CD81-specific antibodies and by Igs from chronically infected individuals.  The cell culture-generated HCV is infectious for chimpanzee.  This system provides a powerful tool for studying the viral life cycle and developing antiviral strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqra8QhVAEyJ7Vg90H21EOLACvtfcHk0lia2IOPttp7TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1aju7c%253D&md5=91235eedec98d1b3d6a4bc4bc68f6d11</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fnm1268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1268%26sid%3Dliteratum%253Aachs%26aulast%3DWakita%26aufirst%3DT.%26aulast%3DPietschmann%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DT.%26aulast%3DDate%26aufirst%3DT.%26aulast%3DMiyamoto%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DMurthy%26aufirst%3DK.%26aulast%3DHabermann%26aufirst%3DA.%26aulast%3DKraeusslich%26aufirst%3DH.-G.%26aulast%3DMizokami%26aufirst%3DM.%26aulast%3DBartenschlager%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DT.%2BJ.%26atitle%3DProduction%2520of%2520infectious%2520hepatitis%2520C%2520virus%2520in%2520tissue%2520culture%2520from%2520a%2520cloned%2520viral%2520genome%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D791%26epage%3D796%26doi%3D10.1038%2Fnm1268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ascher, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wielens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nero, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doughty, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M. W.</span><span> </span><span class="NLM_article-title">Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_elocation-id">4765</span><span class="refDoi"> DOI: 10.1038/srep04765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fsrep04765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24755925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC2cnlvFOktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&author=D.+B.+Ascherauthor=J.+Wielensauthor=T.+L.+Neroauthor=L.+Doughtyauthor=C.+J.+Mortonauthor=M.+W.+Parker&title=Potent+hepatitis+C+inhibitors+bind+directly+to+NS5A+and+reduce+its+affinity+for+RNA&doi=10.1038%2Fsrep04765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88aR"><div class="casContent"><span class="casTitleNuber">88a</span><div class="casTitle"><span class="NLM_cas:atitle">Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA</span></div><div class="casAuthors">Ascher David B; Nero Tracy L; Doughty Larissa; Morton Craig J; Wielens Jerome; Parker Michael W</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4765</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hepatitis C virus (HCV) infection affects more than 170 million people.  The high genetic variability of HCV and the rapid development of drug-resistant strains are driving the urgent search for new direct-acting antiviral agents.  A new class of agents has recently been developed that are believed to target the HCV protein NS5A although precisely where they interact and how they affect function is unknown.  Here we describe an in vitro assay based on microscale thermophoresis and demonstrate that two clinically relevant inhibitors bind tightly to NS5A domain 1 and inhibit RNA binding.  Conversely, RNA binding inhibits compound binding.  The compounds bind more weakly to known resistance mutants L31V and Y93H.  The compounds do not affect NS5A dimerisation.  We propose that current NS5A inhibitors act by favouring a dimeric structure of NS5A that does not bind RNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxEeB9BnDI1kloaUqgkFHkfW6udTcc2eZPlVfO6yqHp7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnlvFOktw%253D%253D&md5=2496f9f19e614aa099e18509e86c9e02</span></div><a href="/servlet/linkout?suffix=cit88a&amp;dbid=16384&amp;doi=10.1038%2Fsrep04765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep04765%26sid%3Dliteratum%253Aachs%26aulast%3DAscher%26aufirst%3DD.%2BB.%26aulast%3DWielens%26aufirst%3DJ.%26aulast%3DNero%26aufirst%3DT.%2BL.%26aulast%3DDoughty%26aufirst%3DL.%26aulast%3DMorton%26aufirst%3DC.%2BJ.%26aulast%3DParker%26aufirst%3DM.%2BW.%26atitle%3DPotent%2520hepatitis%2520C%2520inhibitors%2520bind%2520directly%2520to%2520NS5A%2520and%2520reduce%2520its%2520affinity%2520for%2520RNA%26jtitle%3DSci.%2520Rep.%26date%3D2014%26volume%3D4%26doi%3D10.1038%2Fsrep04765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit88b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kwon, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niedziela-Majka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brendza, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Link, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakowicz, R.</span><span> </span><span class="NLM_article-title">Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">e0122844</span><span class="refDoi"> DOI: 10.1371/journal.pone.0122844</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1371%2Fjournal.pone.0122844" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0122844&issue=4&author=H.+J.+Kwonauthor=W.+Xingauthor=K.+Chanauthor=A.+Niedziela-Majkaauthor=K.+M.+Brendzaauthor=T.+Kirschbergauthor=D.+Katoauthor=J.+O.+Linkauthor=G.+Chengauthor=X.+Liuauthor=R.+Sakowicz&title=Direct+binding+of+ledipasvir+to+HCV+NS5A%3A+mechanism+of+resistance+to+an+HCV+antiviral+agent&doi=10.1371%2Fjournal.pone.0122844"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0122844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0122844%26sid%3Dliteratum%253Aachs%26aulast%3DKwon%26aufirst%3DH.%2BJ.%26aulast%3DXing%26aufirst%3DW.%26aulast%3DChan%26aufirst%3DK.%26aulast%3DNiedziela-Majka%26aufirst%3DA.%26aulast%3DBrendza%26aufirst%3DK.%2BM.%26aulast%3DKirschberg%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DD.%26aulast%3DLink%26aufirst%3DJ.%2BO.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSakowicz%26aufirst%3DR.%26atitle%3DDirect%2520binding%2520of%2520ledipasvir%2520to%2520HCV%2520NS5A%253A%2520mechanism%2520of%2520resistance%2520to%2520an%2520HCV%2520antiviral%2520agent%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26issue%3D4%26spage%3De0122844%26doi%3D10.1371%2Fjournal.pone.0122844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Tellinghuisen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotrigiano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">435</span><span class="NLM_x">, </span> <span class="NLM_fpage">374</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span><span class="refDoi"> DOI: 10.1038/nature03580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnature03580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=15902263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkt1Wkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=435&publication_year=2005&pages=374-379&author=T.+L.+Tellinghuisenauthor=J.+Marcotrigianoauthor=C.+M.+Rice&title=Structure+of+the+zinc-binding+domain+of+an+essential+component+of+the+hepatitis+C+virus+replicase&doi=10.1038%2Fnature03580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase</span></div><div class="casAuthors">Tellinghuisen, Timothy L.; Marcotrigiano, Joseph; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">435</span>
        (<span class="NLM_cas:issue">7040</span>),
    <span class="NLM_cas:pages">374-379</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a human pathogen affecting nearly 3% of the world's population.  Chronic infections can lead to cirrhosis and liver cancer.  The RNA replication machine of HCV is a multi-subunit membrane-assocd. complex.  The non-structural protein NS5A is an active component of HCV replicase, as well as a pivotal regulator of replication and a modulator of cellular processes ranging from innate immunity to dysregulated cell growth.  NS5A is a large phosphoprotein (56-58 kDa) with an amphipathic α-helix at its amino terminus that promotes membrane assocn.  After this helix region, NS5A is organized into three domains.  The N-terminal domain (domain I) coordinates a single zinc atom per protein mol.  Mutations disrupting either the membrane anchor or zinc binding of NS5A are lethal for RNA replication.  However, probing the role of NS5A in replication has been hampered by a lack of structural information about this multifunctional protein.  Here we report the structure of NS5A domain I at 2.5-Å resoln., which contains a novel fold, a new zinc-coordination motif and a disulfide bond.  We use mol. surface anal. to suggest the location of protein-, RNA- and membrane-interaction sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe6tBo4Nrq7rVg90H21EOLACvtfcHk0lhf2znUyws8jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkt1Wkt7Y%253D&md5=0f74b457e5921d4aa1993df8e9a08d46</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fnature03580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03580%26sid%3Dliteratum%253Aachs%26aulast%3DTellinghuisen%26aufirst%3DT.%2BL.%26aulast%3DMarcotrigiano%26aufirst%3DJ.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DStructure%2520of%2520the%2520zinc-binding%2520domain%2520of%2520an%2520essential%2520component%2520of%2520the%2520hepatitis%2520C%2520virus%2520replicase%26jtitle%3DNature%26date%3D2005%26volume%3D435%26spage%3D374%26epage%3D379%26doi%3D10.1038%2Fnature03580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Love, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodsky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, C. N.</span><span> </span><span class="NLM_article-title">Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">4395</span><span class="NLM_x">–</span> <span class="NLM_lpage">4403</span><span class="refDoi"> DOI: 10.1128/JVI.02352-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FJVI.02352-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=19244328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlt1Kqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2009&pages=4395-4403&author=R.+A.+Loveauthor=O.+Brodskyauthor=M.+J.+Hickeyauthor=P.+A.+Wellsauthor=C.+N.+Cronin&title=Crystal+structure+of+a+novel+dimeric+form+of+NS5A+domain+I+protein+from+hepatitis+C+virus&doi=10.1128%2FJVI.02352-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90aR"><div class="casContent"><span class="casTitleNuber">90a</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus</span></div><div class="casAuthors">Love, Robert A.; Brodsky, Oleg; Hickey, Michael J.; Wells, Peter A.; Cronin, Ciaran N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4395-4403</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A new protein expression vector design utilizing an N-terminal six-histidine tag and tobacco etch virus protease cleavage site upstream of the hepatitis C virus NS5A sequence has resulted in a more straightforward purifn. method and improved yields of purified NS5A domain I protein.  High-resoln. diffracting crystals of NS5A domain I (amino acids 33 to 202) [NS5A(33-202)] were obtained by using detergent additive crystn. screens, leading to the structure of a homodimer which is organized differently from that published previously, yet is consistent with a membrane assocn. model for NS5A.  The monomer-monomer interface of NS5A(33-202) features an extensive buried surface area involving the most-highly conserved face of each monomer.  The two alternate structural forms of domain I now available may be indicative of the multiple roles emerging for NS5A in viral RNA replication and viral particle assembly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNYc2eJlR_hLVg90H21EOLACvtfcHk0lj2FYOfq76cPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlt1Kqu7s%253D&md5=70ea61461a99afb962e76a4c3f5495db</span></div><a href="/servlet/linkout?suffix=cit90a&amp;dbid=16384&amp;doi=10.1128%2FJVI.02352-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02352-08%26sid%3Dliteratum%253Aachs%26aulast%3DLove%26aufirst%3DR.%2BA.%26aulast%3DBrodsky%26aufirst%3DO.%26aulast%3DHickey%26aufirst%3DM.%2BJ.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DCronin%26aufirst%3DC.%2BN.%26atitle%3DCrystal%2520structure%2520of%2520a%2520novel%2520dimeric%2520form%2520of%2520NS5A%2520domain%2520I%2520protein%2520from%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Virol.%26date%3D2009%26volume%3D83%26spage%3D4395%26epage%3D4403%26doi%3D10.1128%2FJVI.02352-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit90b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lambert, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedgethorne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, S. J.</span><span> </span><span class="NLM_article-title">The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">723</span><span class="NLM_x">–</span> <span class="NLM_lpage">734</span><span class="refDoi"> DOI: 10.1002/pro.2456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fpro.2456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24639329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXot1ynsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=723-734&author=S.+M.+Lambertauthor=D.+R.+Langleyauthor=J.+A.+Garnettauthor=K.+Hedgethorneauthor=N.+A.+Meanwellauthor=S.+J.+Matthews&title=The+crystal+structure+of+NS5A+domain+1+from+genotype+1a+reveals+new+clues+to+the+mechanism+of+action+for+dimeric+HCV+inhibitors&doi=10.1002%2Fpro.2456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90bR"><div class="casContent"><span class="casTitleNuber">90b</span><div class="casTitle"><span class="NLM_cas:atitle">The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors</span></div><div class="casAuthors">Lambert, Sebastian M.; Langley, David R.; Garnett, James A.; Angell, Richard; Hedgethorne, Katy; Meanwell, Nicholas A.; Matthews, Steve J.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">723-734</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">New direct acting antivirals (DAAs) such as daclatasvir (DCV; BMS-790052), which target NS5A function with picomolar potency, are showing promise in clin. trials.  The exact nature of how these compds. have an inhibitory effect on HCV is unknown; however, major resistance mutations appear in the N-terminal region of NS5A that include the amphipathic helix and domain 1.  The dimeric symmetry of these compds. suggests that they act on a dimer of NS5A, which is also consistent with the presence of dimers in crystals of NS5A domain 1 from genotype 1b.  Genotype 1a HCV is less potently affected by these compds. and resistance mutations have a greater effect than in the 1b genotypes.  We have obtained crystals of domain 1 of the important 1a NS5A homolog and intriguingly, our X-ray crystal structure reveals two new dimeric forms of this domain.  Furthermore, the high solvent content (75%) makes it ideal for ligand-soaking.  Daclatasvir (DCV) shows twofold symmetry suggesting NS5A dimers may be of physiol. importance and serve as potential binding sites for DCV.  These dimers also allow for new conformations of a NS5A expansive network which could explain its operation on the membranous web.  Addnl., sulfates bound in the crystal structure may provide evidence for the previously proposed RNA binding groove, or explain regulation of NS5A domain 2 and 3 function and phosphorylation, by domain 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxWMcrYirNTLVg90H21EOLACvtfcHk0lj2FYOfq76cPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXot1ynsLo%253D&md5=726ec7c39e3be54c1924dacd16f20263</span></div><a href="/servlet/linkout?suffix=cit90b&amp;dbid=16384&amp;doi=10.1002%2Fpro.2456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.2456%26sid%3Dliteratum%253Aachs%26aulast%3DLambert%26aufirst%3DS.%2BM.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DGarnett%26aufirst%3DJ.%2BA.%26aulast%3DHedgethorne%26aufirst%3DK.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DMatthews%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520crystal%2520structure%2520of%2520NS5A%2520domain%25201%2520from%2520genotype%25201a%2520reveals%2520new%2520clues%2520to%2520the%2520mechanism%2520of%2520action%2520for%2520dimeric%2520HCV%2520inhibitors%26jtitle%3DProtein%2520Sci.%26date%3D2014%26volume%3D23%26spage%3D723%26epage%3D734%26doi%3D10.1002%2Fpro.2456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Appel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">From structure to function: new insights into hepatitis C virus RNA replication</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">9833</span><span class="NLM_x">–</span> <span class="NLM_lpage">9836</span><span class="refDoi"> DOI: 10.1074/jbc.R500026200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1074%2Fjbc.R500026200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=9833-9836&author=N.+Appelauthor=T.+Schallerauthor=F.+Peninauthor=R.+Bartenschlager&title=From+structure+to+function%3A+new+insights+into+hepatitis+C+virus+RNA+replication&doi=10.1074%2Fjbc.R500026200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R500026200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R500026200%26sid%3Dliteratum%253Aachs%26aulast%3DAppel%26aufirst%3DN.%26aulast%3DSchaller%26aufirst%3DT.%26aulast%3DPenin%26aufirst%3DF.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DFrom%2520structure%2520to%2520function%253A%2520new%2520insights%2520into%2520hepatitis%2520C%2520virus%2520RNA%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D9833%26epage%3D9836%26doi%3D10.1074%2Fjbc.R500026200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Boyle, D. R.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moulin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nophsker, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belema, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">527</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">258</span><span class="refDoi"> DOI: 10.1038/nature15711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnature15711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26536115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOrtLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=527&publication_year=2015&pages=245-258&author=J.-H.+Sunauthor=D.+R.+O%E2%80%99Boyleauthor=R.+A.+Fridellauthor=D.+R.+Langleyauthor=C.+Wangauthor=S.+B.+Robertsauthor=P.+Nowerauthor=B.+M.+Johnsonauthor=F.+Moulinauthor=M.+J.+Nophskerauthor=Y.-K.+Wangauthor=M.+Liuauthor=K.+Rigatauthor=Y.+Tuauthor=P.+Hewawasamauthor=J.+Kadowauthor=N.+A.+Meanwellauthor=M.+Cockettauthor=J.+A.+Lemmauthor=M.+Kramerauthor=M.+Belemaauthor=M.+Gao&title=Resensitizing+daclatasvir-resistant+hepatitis+C+variants+by+allosteric+modulation+of+NS5A&doi=10.1038%2Fnature15711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A</span></div><div class="casAuthors">Sun, Jin-Hua; O'Boyle, Donald R., II; Fridell, Robert A.; Langley, David R.; Wang, Chunfu; Roberts, Susan B.; Nower, Peter; Johnson, Benjamin M.; Moulin, Frederic; Nophsker, Michelle J.; Wang, Ying-Kai; Liu, Mengping; Rigat, Karen; Tu, Yong; Hewawasam, Piyasena; Kadow, John; Meanwell, Nicholas A.; Cockett, Mark; Lemm, Julie A.; Kramer, Melissa; Belema, Makonen; Gao, Min</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">527</span>
        (<span class="NLM_cas:issue">7577</span>),
    <span class="NLM_cas:pages">245-248</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">It is estd. that more than 170 million people are infected with hepatitis C virus (HCV) worldwide.  Clin. trials have demonstrated that, for the first time in human history, the potential exists to eradicate a chronic viral disease using combination therapies that contain only direct-acting antiviral agents.  HCV non-structural protein 5A (NS5A) is a multifunctional protein required for several stages of the virus replication cycle.  NS5A replication complex inhibitors, exemplified by daclatasvir (DCV; also known as BMS-790052 and Daklinza), belong to the most potent class of direct-acting anti-HCV agents described so far, with in vitro activity in the picomolar (pM) to low nanomolar (nM) range.  The potency obsd. in vitro has translated into clin. efficacy, with HCV RNA declining by ∼3-4 log10 in infected patients after administration of single oral doses of DCV.  Understanding the exceptional potency of DCV was a key objective of this study.  Although DCV and an NS5A inhibitor analog (Syn-395) are inactive against certain NS5A resistance variants, combinations of the pair enhance DCV potency by >1000-fold, restoring activity to the pM range.  This synergistic effect was validated in vivo using an HCV-infected chimeric mouse model.  The cooperative interaction of a pair of compds. suggests that NS5A protein mols. communicate with each other: one inhibitor binds to resistant NS5A, causing a conformational change that is transmitted to adjacent NS5As, resensitizing resistant NS5A so that the second inhibitor can act to restore inhibition.  This unprecedented synergistic anti-HCV activity also enhances the resistance barrier of DCV, providing addnl. options for HCV combination therapy and new insight into the role of NS5A in the HCV replication cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz6u8iN4_EYbVg90H21EOLACvtfcHk0lg2Zu3zYlsylw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOrtLbN&md5=b5eb912480b1c321b17701cc5ef30204</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fnature15711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature15711%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DNower%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DB.%2BM.%26aulast%3DMoulin%26aufirst%3DF.%26aulast%3DNophsker%26aufirst%3DM.%2BJ.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DRigat%26aufirst%3DK.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DKadow%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DCockett%26aufirst%3DM.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DKramer%26aufirst%3DM.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DResensitizing%2520daclatasvir-resistant%2520hepatitis%2520C%2520variants%2520by%2520allosteric%2520modulation%2520of%2520NS5A%26jtitle%3DNature%26date%3D2015%26volume%3D527%26spage%3D245%26epage%3D258%26doi%3D10.1038%2Fnature15711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargittai, M. R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raney, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span> </span><span class="NLM_article-title">Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">36417</span><span class="NLM_x">–</span> <span class="NLM_lpage">36428</span><span class="refDoi"> DOI: 10.1074/jbc.M508175200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1074%2Fjbc.M508175200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=36417-36428&author=L.+Huangauthor=J.+Hwangauthor=S.+D.+Sharmaauthor=M.+R.+S.+Hargittaiauthor=Y.+Chenauthor=J.+J.+Arnoldauthor=K.+D.+Raneyauthor=C.+E.+Cameron&title=Hepatitis+C+virus+nonstructural+protein+5A+%28NS5A%29+is+an+RNA-binding+protein&doi=10.1074%2Fjbc.M508175200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93a&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M508175200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M508175200%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DHwang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BD.%26aulast%3DHargittai%26aufirst%3DM.%2BR.%2BS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DArnold%26aufirst%3DJ.%2BJ.%26aulast%3DRaney%26aufirst%3DK.%2BD.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26atitle%3DHepatitis%2520C%2520virus%2520nonstructural%2520protein%25205A%2520%2528NS5A%2529%2520is%2520an%2520RNA-binding%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D36417%26epage%3D36428%26doi%3D10.1074%2Fjbc.M508175200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit93b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hwang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordek, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kihara, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raney, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span> </span><span class="NLM_article-title">Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">12480</span><span class="NLM_x">–</span> <span class="NLM_lpage">12491</span><span class="refDoi"> DOI: 10.1128/JVI.01319-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FJVI.01319-10" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=12480-12491&author=J.+Hwangauthor=L.+Huangauthor=D.+G.+Cordekauthor=R.+Vaughanauthor=S.+L.+Reynoldsauthor=G.+Kiharaauthor=K.+D.+Raneyauthor=C.+C.+Kaoauthor=C.+E.+Cameron&title=Hepatitis+C+virus+nonstructural+protein+5A%3A+biochemical+characterization+of+a+novel+structural+class+of+RNA-binding+proteins&doi=10.1128%2FJVI.01319-10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93b&amp;dbid=16384&amp;doi=10.1128%2FJVI.01319-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01319-10%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DCordek%26aufirst%3DD.%2BG.%26aulast%3DVaughan%26aufirst%3DR.%26aulast%3DReynolds%26aufirst%3DS.%2BL.%26aulast%3DKihara%26aufirst%3DG.%26aulast%3DRaney%26aufirst%3DK.%2BD.%26aulast%3DKao%26aufirst%3DC.%2BC.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26atitle%3DHepatitis%2520C%2520virus%2520nonstructural%2520protein%25205A%253A%2520biochemical%2520characterization%2520of%2520a%2520novel%2520structural%2520class%2520of%2520RNA-binding%2520proteins%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D12480%26epage%3D12491%26doi%3D10.1128%2FJVI.01319-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Lim, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterju, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordek, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Rivera, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Targett-Adams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallay, P. A.</span><span> </span><span class="NLM_article-title">Correlation between NS5A dimerization and HCV replication</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">30861</span><span class="NLM_x">–</span> <span class="NLM_lpage">30873</span><span class="refDoi"> DOI: 10.1074/jbc.M112.376822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1074%2Fjbc.M112.376822" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=30861-30873&author=P.+J.+Limauthor=U.+Chatterjuauthor=D.+Cordekauthor=S.+D.+Sharmaauthor=J.+A.+Garcia-Riveraauthor=C.+E.+Cameronauthor=K.+Linauthor=P.+Targett-Adamsauthor=P.+A.+Gallay&title=Correlation+between+NS5A+dimerization+and+HCV+replication&doi=10.1074%2Fjbc.M112.376822"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.376822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.376822%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DP.%2BJ.%26aulast%3DChatterju%26aufirst%3DU.%26aulast%3DCordek%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DS.%2BD.%26aulast%3DGarcia-Rivera%26aufirst%3DJ.%2BA.%26aulast%3DCameron%26aufirst%3DC.%2BE.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DTargett-Adams%26aufirst%3DP.%26aulast%3DGallay%26aufirst%3DP.%2BA.%26atitle%3DCorrelation%2520between%2520NS5A%2520dimerization%2520and%2520HCV%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D30861%26epage%3D30873%26doi%3D10.1074%2Fjbc.M112.376822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Guedj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansone, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotler, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Layden, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uprichard, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">3991</span><span class="NLM_x">–</span> <span class="NLM_lpage">3996</span><span class="refDoi"> DOI: 10.1073/pnas.1203110110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1073%2Fpnas.1203110110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=23431163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVWms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=3991-3996&author=J.+Guedjauthor=H.+Dahariauthor=L.+Rongauthor=N.+D.+Sansoneauthor=R.+E.+Nettlesauthor=S.+J.+Cotlerauthor=T.+J.+Laydenauthor=S.+L.+Uprichardauthor=A.+S.+Perelson&title=Modeling+shows+that+the+NS5A+inhibitor+daclatasvir+has+two+modes+of+action+and+yields+a+shorter+estimate+of+the+hepatitis+C+virus+half-life&doi=10.1073%2Fpnas.1203110110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life</span></div><div class="casAuthors">Guedj, Jeremie; Dahari, Harel; Rong, Libin; Sansone, Natasha D.; Nettles, Richard E.; Cotler, Scott J.; Layden, Thomas J.; Uprichard, Susan L.; Perelson, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3991-3996, S3991/1-S3991/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The nonstructural 5A (NS5A) protein is a target for drug development against hepatitis C virus (HCV).  Interestingly, the NS5A inhibitor daclatasvir (BMS-790052) caused a decrease in serum HCV RNA levels by about two orders of magnitude within 6 h of administration.  However, NS5A has no known enzymic functions, making it difficult to understand daclatasvir's mode of action (MOA) and to est. its antiviral effectiveness.  Modeling viral kinetics during therapy has provided important insights into the MOA and effectiveness of a variety of anti-HCV agents.  Here, we show that understanding the effects of daclatasvir in vivo requires a multiscale model that incorporates drug effects on the HCV intracellular lifecycle, and we validated this approach with in vitro HCV infection expts.  The model predicts that daclatasvir efficiently blocks two distinct stages of the viral lifecycle, namely viral RNA synthesis and virion assembly/secretion with mean effectiveness of 99% and 99.8%, resp., and yields a more precise est. of the serum HCV half-life, 45 min, i.e., around four times shorter than previous ests.  Intracellular HCV RNA in HCV-infected cells treated with daclatasvir and the HCV polymerase inhibitor NM107 showed a similar pattern of decline.  However, daclatasvir treatment led to an immediate and rapid decline of extracellular HCV titers compared to a delayed (6-9 h) and slower decline with NM107, confirming an effect of daclatasvir on both viral replication and assembly/secretion.  The multiscale modeling approach, validated with in vitro kinetic expts., brings a unique conceptual framework for understanding the mechanism of action of a variety of agents in development for the treatment of HCV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSYdT4WQUN7LVg90H21EOLACvtfcHk0liRGTpcewWJ_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVWms7g%253D&md5=81f3b8c49b97120f70b440211b4bf979</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1203110110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1203110110%26sid%3Dliteratum%253Aachs%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DRong%26aufirst%3DL.%26aulast%3DSansone%26aufirst%3DN.%2BD.%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DCotler%26aufirst%3DS.%2BJ.%26aulast%3DLayden%26aufirst%3DT.%2BJ.%26aulast%3DUprichard%26aufirst%3DS.%2BL.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DModeling%2520shows%2520that%2520the%2520NS5A%2520inhibitor%2520daclatasvir%2520has%2520two%2520modes%2520of%2520action%2520and%2520yields%2520a%2520shorter%2520estimate%2520of%2520the%2520hepatitis%2520C%2520virus%2520half-life%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D3991%26epage%3D3996%26doi%3D10.1073%2Fpnas.1203110110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Appel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zayas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krijnse-Locker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friebe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartenschlager, R.</span><span> </span><span class="NLM_article-title">Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1000035</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1000035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1371%2Fjournal.ppat.1000035" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=e1000035&author=N.+Appelauthor=M.+Zayasauthor=S.+Millerauthor=J.+Krijnse-Lockerauthor=T.+Schallerauthor=P.+Friebeauthor=S.+Kallisauthor=U.+Engelauthor=R.+Bartenschlager&title=Essential+role+of+domain+III+of+nonstructural+protein+5A+for+hepatitis+C+virus+infectious+particle+assembly&doi=10.1371%2Fjournal.ppat.1000035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96a&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1000035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1000035%26sid%3Dliteratum%253Aachs%26aulast%3DAppel%26aufirst%3DN.%26aulast%3DZayas%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DS.%26aulast%3DKrijnse-Locker%26aufirst%3DJ.%26aulast%3DSchaller%26aufirst%3DT.%26aulast%3DFriebe%26aufirst%3DP.%26aulast%3DKallis%26aufirst%3DS.%26aulast%3DEngel%26aufirst%3DU.%26aulast%3DBartenschlager%26aufirst%3DR.%26atitle%3DEssential%2520role%2520of%2520domain%2520III%2520of%2520nonstructural%2520protein%25205A%2520for%2520hepatitis%2520C%2520virus%2520infectious%2520particle%2520assembly%26jtitle%3DPLoS%2520Pathog.%26date%3D2008%26volume%3D4%26spage%3De1000035%26doi%3D10.1371%2Fjournal.ppat.1000035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit96b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tellinghuisen, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foss, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treadaway, J.</span><span> </span><span class="NLM_article-title">Regulation of hepatitis C virion production via phosphorylation of the NS5A protein</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1000032</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1000032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1371%2Fjournal.ppat.1000032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=e1000032&author=T.+L.+Tellinghuisenauthor=K.+L.+Fossauthor=J.+Treadaway&title=Regulation+of+hepatitis+C+virion+production+via+phosphorylation+of+the+NS5A+protein&doi=10.1371%2Fjournal.ppat.1000032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1000032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1000032%26sid%3Dliteratum%253Aachs%26aulast%3DTellinghuisen%26aufirst%3DT.%2BL.%26aulast%3DFoss%26aufirst%3DK.%2BL.%26aulast%3DTreadaway%26aufirst%3DJ.%26atitle%3DRegulation%2520of%2520hepatitis%2520C%2520virion%2520production%2520via%2520phosphorylation%2520of%2520the%2520NS5A%2520protein%26jtitle%3DPLoS%2520Pathog.%26date%3D2008%26volume%3D4%26spage%3De1000032%26doi%3D10.1371%2Fjournal.ppat.1000032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit96c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hughes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, M.</span><span> </span><span class="NLM_article-title">Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles</span> <span class="citation_source-journal">J. Gen. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">1329</span><span class="NLM_x">–</span> <span class="NLM_lpage">1334</span><span class="refDoi"> DOI: 10.1099/vir.0.009332-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1099%2Fvir.0.009332-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=19264615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmvFCls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2009&pages=1329-1334&author=M.+Hughesauthor=S.+Griffinauthor=M.+Harris&title=Domain+III+of+NS5A+contributes+to+both+RNA+replication+and+assembly+of+hepatitis+C+virus+particles&doi=10.1099%2Fvir.0.009332-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96cR"><div class="casContent"><span class="casTitleNuber">96c</span><div class="casTitle"><span class="NLM_cas:atitle">Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles</span></div><div class="casAuthors">Hughes, Mair; Griffin, Stephen; Harris, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1329-1334</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) NS5A protein plays a crit. role in viral RNA replication and has recently been shown to play a role in particle prodn. in the infectious genotype 2a HCV clone (JFH-1).  Here, we show that alanine substitutions of serines 2428/2430 within the C-terminal domain III of NS5A do not affect subgenomic replicon RNA replication but do reduce particle prodn.  In contrast, substitution of serines 2390/2391 had no effect on either RNA replication or particle prodn.  Relative to genotype 1, all genotype 2 HCV isolates contain a 19 residue insertion near the C terminus of domain III which, when deleted (Δ2408-2426), resulted in a delay to both RNA replication and particle prodn.  None of these mutations affected the ratio of basal to hyperphosphorylated NS5A, suggesting that serines between residues 2390 and 2430 are not phosphorylated.  We propose that although domain III is dispensable for RNA replication, it nevertheless influences this process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJlH2lNItkx7Vg90H21EOLACvtfcHk0lhgGYoPp60G6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmvFCls7s%253D&md5=efda79b2a76a7c4b1a76980d22b91904</span></div><a href="/servlet/linkout?suffix=cit96c&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.009332-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.009332-0%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DM.%26atitle%3DDomain%2520III%2520of%2520NS5A%2520contributes%2520to%2520both%2520RNA%2520replication%2520and%2520assembly%2520of%2520hepatitis%2520C%2520virus%2520particles%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2009%26volume%3D90%26spage%3D1329%26epage%3D1334%26doi%3D10.1099%2Fvir.0.009332-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit96d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Lindenbach, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, C. M.</span><span> </span><span class="NLM_article-title">The ins and outs of hepatitis C virus entry and assembly</span> <span class="citation_source-journal">Nat. Rev. Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">688</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span><span class="refDoi"> DOI: 10.1038/nrmicro3098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrmicro3098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24018384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSku7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=688-700&author=B.+D.+Lindenbachauthor=C.+M.+Rice&title=The+ins+and+outs+of+hepatitis+C+virus+entry+and+assembly&doi=10.1038%2Fnrmicro3098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96dR"><div class="casContent"><span class="casTitleNuber">96d</span><div class="casTitle"><span class="NLM_cas:atitle">The ins and outs of Hepatitis C virus entry and assembly</span></div><div class="casAuthors">Lindenbach, Brett D.; Rice, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">688-700</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus, a major human pathogen, produces infectious virus particles with several unique features, such as an ability to interact with serum lipoproteins, a dizzyingly complicated process of virus entry, and a pathway of virus assembly and release that is closely linked to lipoprotein secretion.  Here, we review these unique features, with an emphasis on recent discoveries concerning virus particle structure, virus entry and virus particle assembly and release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ9p4sl_7FALVg90H21EOLACvtfcHk0lhgGYoPp60G6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSku7rE&md5=1153290b9a49d66f837935f0de45be7f</span></div><a href="/servlet/linkout?suffix=cit96d&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro3098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro3098%26sid%3Dliteratum%253Aachs%26aulast%3DLindenbach%26aufirst%3DB.%2BD.%26aulast%3DRice%26aufirst%3DC.%2BM.%26atitle%3DThe%2520ins%2520and%2520outs%2520of%2520hepatitis%2520C%2520virus%2520entry%2520and%2520assembly%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2013%26volume%3D11%26spage%3D688%26epage%3D700%26doi%3D10.1038%2Fnrmicro3098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hashimoto, H.; Mizutani, K.; Yoshida, A.</span><span> </span><span class="NLM_article-title">Preparation of heterocyclic compounds as remedies for hepatitis C</span>. World Patent Application WO 2001/047883, May 7,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=H.+Hashimoto&author=K.+Mizutani&author=A.+Yoshida&title=Preparation+of+heterocyclic+compounds+as+remedies+for+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DH.%26atitle%3DPreparation%2520of%2520heterocyclic%2520compounds%2520as%2520remedies%2520for%2520hepatitis%2520C%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit97b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Harper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avolio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Filippo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Migliaccio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Francesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narjes, F.</span><span> </span><span class="NLM_article-title">Development and preliminary optimization of indole-<i>N</i>-acetamide inhibitors of hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1314</span><span class="NLM_x">–</span> <span class="NLM_lpage">1317</span><span class="refDoi"> DOI: 10.1021/jm049122i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049122i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1314-1317&author=S.+Harperauthor=B.+Paciniauthor=S.+Avolioauthor=M.+Di+Filippoauthor=G.+Migliaccioauthor=R.+Lauferauthor=R.+De+Francescoauthor=M.+Rowleyauthor=F.+Narjes&title=Development+and+preliminary+optimization+of+indole-N-acetamide+inhibitors+of+hepatitis+C+virus+NS5B+polymerase&doi=10.1021%2Fjm049122i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97b&amp;dbid=16384&amp;doi=10.1021%2Fjm049122i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049122i%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DPacini%26aufirst%3DB.%26aulast%3DAvolio%26aufirst%3DS.%26aulast%3DDi%2BFilippo%26aufirst%3DM.%26aulast%3DMigliaccio%26aufirst%3DG.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DNarjes%26aufirst%3DF.%26atitle%3DDevelopment%2520and%2520preliminary%2520optimization%2520of%2520indole-N-acetamide%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1314%26epage%3D1317%26doi%3D10.1021%2Fjm049122i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit97c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bykowski, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dansereau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duceppe, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haché, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakalian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagacé, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKercher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreault, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thauvette, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span> </span><span class="NLM_article-title">Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4987</span><span class="NLM_x">–</span> <span class="NLM_lpage">4993</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2006.07.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmcl.2006.07.074" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4987-4993&author=P.+L.+Beaulieuauthor=J.+Gillardauthor=D.+Bykowskiauthor=C.+Brochuauthor=N.+Dansereauauthor=J.+S.+Duceppeauthor=B.+Hach%C3%A9author=A.+Jakalianauthor=L.+Lagac%C3%A9author=S.+LaPlanteauthor=G.+McKercherauthor=E.+Moreauauthor=S.+Perreaultauthor=T.+Stammersauthor=L.+Thauvetteauthor=J.+Warringtonauthor=G.+Kukolj&title=Improved+replicon+cellular+activity+of+non-nucleoside+allosteric+inhibitors+of+HCV+NS5B+polymerase%3A+from+benzimidazole+to+indole+scaffolds&doi=10.1016%2Fj.bmcl.2006.07.074"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.07.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.07.074%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DGillard%26aufirst%3DJ.%26aulast%3DBykowski%26aufirst%3DD.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DDansereau%26aufirst%3DN.%26aulast%3DDuceppe%26aufirst%3DJ.%2BS.%26aulast%3DHach%25C3%25A9%26aufirst%3DB.%26aulast%3DJakalian%26aufirst%3DA.%26aulast%3DLagac%25C3%25A9%26aufirst%3DL.%26aulast%3DLaPlante%26aufirst%3DS.%26aulast%3DMcKercher%26aufirst%3DG.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DStammers%26aufirst%3DT.%26aulast%3DThauvette%26aufirst%3DL.%26aulast%3DWarrington%26aufirst%3DJ.%26aulast%3DKukolj%26aufirst%3DG.%26atitle%3DImproved%2520replicon%2520cellular%2520activity%2520of%2520non-nucleoside%2520allosteric%2520inhibitors%2520of%2520HCV%2520NS5B%2520polymerase%253A%2520from%2520benzimidazole%2520to%2520indole%2520scaffolds%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4987%26epage%3D4993%26doi%3D10.1016%2Fj.bmcl.2006.07.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit97d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Beaulieu, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolicoeur, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garneau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poupart, M. A.</span><span> </span><span class="NLM_article-title">From benzimidazole to indole-5-carboxamide thumb pocket I inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">3658</span><span class="NLM_x">–</span> <span class="NLM_lpage">3663</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.04.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmcl.2011.04.059" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=3658-3663&author=P.+L.+Beaulieuauthor=J.+Gillardauthor=E.+Jolicoeurauthor=J.+Duanauthor=M.+Garneauauthor=G.+Kukoljauthor=M.+A.+Poupart&title=From+benzimidazole+to+indole-5-carboxamide+thumb+pocket+I+inhibitors+of+HCV+NS5B+polymerase.+Part+1%3A+indole+C-2+SAR+and+discovery+of+diamide+derivatives+with+nanomolar+potency+in+cell-based+subgenomic+replicons&doi=10.1016%2Fj.bmcl.2011.04.059"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.04.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.04.059%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DP.%2BL.%26aulast%3DGillard%26aufirst%3DJ.%26aulast%3DJolicoeur%26aufirst%3DE.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DPoupart%26aufirst%3DM.%2BA.%26atitle%3DFrom%2520benzimidazole%2520to%2520indole-5-carboxamide%2520thumb%2520pocket%2520I%2520inhibitors%2520of%2520HCV%2520NS5B%2520polymerase.%2520Part%25201%253A%2520indole%2520C-2%2520SAR%2520and%2520discovery%2520of%2520diamide%2520derivatives%2520with%2520nanomolar%2520potency%2520in%2520cell-based%2520subgenomic%2520replicons%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D3658%26epage%3D3663%26doi%3D10.1016%2Fj.bmcl.2011.04.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudyma, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witmer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camac, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheriff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beno, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelosi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentles, R. G.</span><span> </span><span class="NLM_article-title">Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2925</span><span class="NLM_x">–</span> <span class="NLM_lpage">2929</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.03.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmcl.2011.03.067" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2925-2929&author=X.+Zhengauthor=T.+W.+Hudymaauthor=S.+W.+Martinauthor=C.+Bergstromauthor=M.+Dingauthor=F.+Heauthor=J.+Romineauthor=M.+A.+Possauthor=J.+F.+Kadowauthor=C.+H.+Changauthor=J.+Wanauthor=M.+R.+Witmerauthor=P.+Morinauthor=D.+M.+Camacauthor=S.+Sheriffauthor=B.+R.+Benoauthor=K.+L.+Rigatauthor=Y.+K.+Wangauthor=R.+Fridellauthor=J.+Lemmauthor=D.+Qiuauthor=M.+Liuauthor=S.+Vossauthor=L.+Pelosiauthor=S.+B.+Robertsauthor=M.+Gaoauthor=J.+Knipeauthor=R.+G.+Gentles&title=Syntheses+and+initial+evaluation+of+a+series+of+indolo-fused+heterocyclic+inhibitors+of+the+polymerase+enzyme+%28NS5B%29+of+the+hepatitis+C+virus&doi=10.1016%2Fj.bmcl.2011.03.067"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.03.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.03.067%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DHudyma%26aufirst%3DT.%2BW.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DBergstrom%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DRomine%26aufirst%3DJ.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DChang%26aufirst%3DC.%2BH.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DMorin%26aufirst%3DP.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DRigat%26aufirst%3DK.%2BL.%26aulast%3DWang%26aufirst%3DY.%2BK.%26aulast%3DFridell%26aufirst%3DR.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DPelosi%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26atitle%3DSyntheses%2520and%2520initial%2520evaluation%2520of%2520a%2520series%2520of%2520indolo-fused%2520heterocyclic%2520inhibitors%2520of%2520the%2520polymerase%2520enzyme%2520%2528NS5B%2529%2520of%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2925%26epage%3D2929%26doi%3D10.1016%2Fj.bmcl.2011.03.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">te Velthuis, A. J. W.</span><span> </span><span class="NLM_article-title">Common and unique features of viral RNA-dependent polymerase</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">4403</span><span class="NLM_x">–</span> <span class="NLM_lpage">442</span><span class="refDoi"> DOI: 10.1007/s00018-014-1695-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1007%2Fs00018-014-1695-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2014&pages=4403-442&author=A.+J.+W.+te+Velthuis&title=Common+and+unique+features+of+viral+RNA-dependent+polymerase&doi=10.1007%2Fs00018-014-1695-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99a&amp;dbid=16384&amp;doi=10.1007%2Fs00018-014-1695-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-014-1695-z%26sid%3Dliteratum%253Aachs%26aulast%3Dte%2BVelthuis%26aufirst%3DA.%2BJ.%2BW.%26atitle%3DCommon%2520and%2520unique%2520features%2520of%2520viral%2520RNA-dependent%2520polymerase%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2014%26volume%3D71%26spage%3D4403%26epage%3D442%26doi%3D10.1007%2Fs00018-014-1695-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit99b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Choi, K. H.</span><span> </span><span class="NLM_article-title">Viral polymerases</span> <span class="citation_source-journal">Adv. Exp. Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">726</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">304</span><span class="refDoi"> DOI: 10.1007/978-1-4614-0980-9_12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1007%2F978-1-4614-0980-9_12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=726&publication_year=2012&pages=267-304&author=K.+H.+Choi&title=Viral+polymerases&doi=10.1007%2F978-1-4614-0980-9_12"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99b&amp;dbid=16384&amp;doi=10.1007%2F978-1-4614-0980-9_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4614-0980-9_12%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DK.%2BH.%26atitle%3DViral%2520polymerases%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2012%26volume%3D726%26spage%3D267%26epage%3D304%26doi%3D10.1007%2F978-1-4614-0980-9_12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentles, R. G.</span><span> </span><span class="NLM_article-title">The synthesis of novel heteroaryl-fused 7,8,9,10-tetrahydro-6<i>H</i>-azepino[1,2-<i>a</i>]indoles, 4-oxo-2,3-dihydro-1<i>H</i>-[1,4]diazepino[1,7-<i>a</i>]indoles and 1,2,4,5-tetrahydro-[1,4]oxazepino[4,5-<i>a</i>]indoles. Effective inhibitors of HCV NS5B polymerase</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">6654</span><span class="NLM_x">–</span> <span class="NLM_lpage">6662</span><span class="refDoi"> DOI: 10.1039/c1ob05525a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1039%2Fc1ob05525a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=21800000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCrtL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=6654-6662&author=M.+Dingauthor=F.+Heauthor=M.+A.+Possauthor=K.+L.+Rigatauthor=Y.-K.+Wangauthor=S.+B.+Robertsauthor=D.+Qiuauthor=R.+A.+Fridellauthor=M.+Gaoauthor=R.+G.+Gentles&title=The+synthesis+of+novel+heteroaryl-fused+7%2C8%2C9%2C10-tetrahydro-6H-azepino%5B1%2C2-a%5Dindoles%2C+4-oxo-2%2C3-dihydro-1H-%5B1%2C4%5Ddiazepino%5B1%2C7-a%5Dindoles+and+1%2C2%2C4%2C5-tetrahydro-%5B1%2C4%5Doxazepino%5B4%2C5-a%5Dindoles.+Effective+inhibitors+of+HCV+NS5B+polymerase&doi=10.1039%2Fc1ob05525a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100aR"><div class="casContent"><span class="casTitleNuber">100a</span><div class="casTitle"><span class="NLM_cas:atitle">The synthesis of novel heteroaryl-fused 7,8,9,10-tetrahydro-6H-azepino[1,2-a]indoles, 4-oxo-2,3-dihydro-1H-[1,4]diazepino[1,7-a]indoles and 1,2,4,5-tetrahydro-[1,4]oxazepino[4,5-a]indoles. Effective inhibitors of HCV NS5B polymerase</span></div><div class="casAuthors">Ding, Min; He, Feng; Poss, Michael A.; Rigat, Karen L.; Wang, Ying-Kai; Roberts, Susan B.; Qiu, Dike; Fridell, Robert A.; Gao, Min; Gentles, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6654-6662</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Three synthetic approaches have been developed that allow efficient access to novel heteroaryl fused indole ring systems, including: 7,8,9,10-tetrahydro-6H-azepino[1,2-a]indoles, 4-oxo-2,3-dihydro-1H-[1,4]diazepino[1,7-a]indoles, and 1,2,4,5-tetrahydro[1,4]oxazepino[4,5-a]indoles.  Each strategy is fully exemplified and the relative merits and limitations of the approaches are discussed.  The hepatitis C virus (HCV) non-structural 5B (NS5B) polymerase inhibitory activities of select examples from each mol. class are briefly presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJOYGwyYtw97Vg90H21EOLACvtfcHk0ljQk9PyGdTMsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCrtL7L&md5=32a10811ab2d90f8672ff47937f7d9b6</span></div><a href="/servlet/linkout?suffix=cit100a&amp;dbid=16384&amp;doi=10.1039%2Fc1ob05525a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1ob05525a%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DRigat%26aufirst%3DK.%2BL.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DQiu%26aufirst%3DD.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26atitle%3DThe%2520synthesis%2520of%2520novel%2520heteroaryl-fused%25207%252C8%252C9%252C10-tetrahydro-6H-azepino%255B1%252C2-a%255Dindoles%252C%25204-oxo-2%252C3-dihydro-1H-%255B1%252C4%255Ddiazepino%255B1%252C7-a%255Dindoles%2520and%25201%252C2%252C4%252C5-tetrahydro-%255B1%252C4%255Doxazepino%255B4%252C5-a%255Dindoles.%2520Effective%2520inhibitors%2520of%2520HCV%2520NS5B%2520polymerase%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2011%26volume%3D9%26spage%3D6654%26epage%3D6662%26doi%3D10.1039%2Fc1ob05525a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit100b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudyma, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beno, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelosi, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentles, R. G.</span><span> </span><span class="NLM_article-title">Synthesis and SAR studies of novel heteroaryl fused tetracyclic indole-diamide compounds: potent allosteric inhibitors of the hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2866</span><span class="NLM_x">–</span> <span class="NLM_lpage">2871</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.02.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.bmcl.2012.02.063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2866-2871&author=M.+Dingauthor=F.+Heauthor=T.+W.+Hudymaauthor=X.+Zhengauthor=M.+A.+Possauthor=J.+F.+Kadowauthor=B.+R.+Benoauthor=K.+L.+Rigatauthor=Y.+K.+Wangauthor=R.+A.+Fridellauthor=J.+A.+Lemmauthor=D.+Qiuauthor=M.+Liuauthor=S.+Vossauthor=L.+A.+Pelosiauthor=S.+B.+Robertsauthor=M.+Gaoauthor=J.+Knipeauthor=R.+G.+Gentles&title=Synthesis+and+SAR+studies+of+novel+heteroaryl+fused+tetracyclic+indole-diamide+compounds%3A+potent+allosteric+inhibitors+of+the+hepatitis+C+virus+NS5B+polymerase&doi=10.1016%2Fj.bmcl.2012.02.063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.02.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.02.063%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DHudyma%26aufirst%3DT.%2BW.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DRigat%26aufirst%3DK.%2BL.%26aulast%3DWang%26aufirst%3DY.%2BK.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DQiu%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DPelosi%26aufirst%3DL.%2BA.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26atitle%3DSynthesis%2520and%2520SAR%2520studies%2520of%2520novel%2520heteroaryl%2520fused%2520tetracyclic%2520indole-diamide%2520compounds%253A%2520potent%2520allosteric%2520inhibitors%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2866%26epage%3D2871%26doi%3D10.1016%2Fj.bmcl.2012.02.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Gentles, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant-Young, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudyma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regueiro-Ren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, K.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beno, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camac, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheriff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tredup, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witmer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanumegowda, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelosi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span> </span><span class="NLM_article-title">Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1855</span><span class="NLM_x">–</span> <span class="NLM_lpage">1879</span><span class="refDoi"> DOI: 10.1021/jm4016894</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016894" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1855-1879&author=R.+G.+Gentlesauthor=M.+Dingauthor=J.+A.+Benderauthor=C.+P.+Bergstromauthor=K.+Grant-Youngauthor=P.+Hewawasamauthor=T.+Hudymaauthor=S.+Martinauthor=A.+Nickelauthor=A.+Regueiro-Renauthor=Y.+Tuauthor=Z.+Yangauthor=K.-S.+Yeungauthor=X.+Zhengauthor=S.+Chaoauthor=J.-H.+Sunauthor=B.+R.+Benoauthor=D.+M.+Camacauthor=C.-H.+Changauthor=M.+Gaoauthor=P.+E.+Morinauthor=S.+Sheriffauthor=J.+Tredupauthor=J.+Wanauthor=M.+R.+Witmerauthor=D.+Xieauthor=U.+Hanumegowdaauthor=J.+Knipeauthor=K.+Mosureauthor=K.+S.+Santoneauthor=D.+D.+Parkerauthor=X.+Zhuoauthor=J.+Lemmauthor=M.+Liuauthor=L.+Pelosiauthor=K.+Rigatauthor=S.+Vossauthor=Y.+Wangauthor=Y.-K.+Wangauthor=R.+J.+Colonnoauthor=M.+Gaoauthor=S.+B.+Robertsauthor=Q.+Gaoauthor=A.+Ngauthor=N.+A.+Meanwellauthor=J.+F.+Kadow&title=Discovery+and+preclinical+characterization+of+the+cyclopropylindolobenzazepine+BMS-791325%2C+a+potent+allosteric+inhibitor+of+the+hepatitis+C+virus+NS5B+polymerase&doi=10.1021%2Fjm4016894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase</span></div><div class="casAuthors">Gentles, Robert G.; Ding, Min; Bender, John A.; Bergstrom, Carl P.; Grant-Young, Katharine; Hewawasam, Piyasena; Hudyma, Thomas; Martin, Scott; Nickel, Andrew; Regueiro-Ren, Alicia; Tu, Yong; Yang, Zhong; Yeung, Kap-Sun; Zheng, Xiaofan; Beno, Brett R.; Camac, Daniel M.; Chang, Chong-Hwan; Gao, Mian; Morin, Paul E.; Sheriff, Steven; Tredup, Jeff; Wan, John; Witmer, Mark R.; Xie, Dianlin; Hanumegowda, Umesh; Knipe, Jay; Mosure, Kathy; Santone, Kenneth S.; Parker, Dawn D.; Zhuo, Xiaoliang; Lemm, Julie; Liu, Mengping; Pelosi, Lenore; Rigat, Karen; Voss, Stacey; Wang, Yi; Wang, Ying-Kai; Colonno, Richard C.; Gao, Min; Roberts, Susan B.; Gao, Qi; Ng, Alicia; Meanwell, Nicholas A.; Kadow, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1855-1879</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Described herein are structure-activity relationship studies that resulted in the optimization of the activity of members of a class of cyclopropyl-fused indolobenzazepine HCV NS5B polymerase inhibitors.  Subsequent iterations of analog design and syntheses successfully addressed off-target activities, most notably human pregnane X receptor (hPXR) transactivation, and led to significant improvements in the physicochem. properties of lead compds.  Those analogs exhibiting improved soly. and membrane permeability were shown to have notably enhanced pharmacokinetic profiles.  Addnl., a series of alkyl bridged piperazine carboxamides was identified as being of particular interest, and from which the compd. BMS-791325 (I) was found to have distinguishing antiviral, safety, and pharmacokinetic properties that resulted in its selection for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn4YKQoSYkS7Vg90H21EOLACvtfcHk0lhShMc_WtB6BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKkuw%253D%253D&md5=f13f5d86a1c17737784e905c7843ff72</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjm4016894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016894%26sid%3Dliteratum%253Aachs%26aulast%3DGentles%26aufirst%3DR.%2BG.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DBergstrom%26aufirst%3DC.%2BP.%26aulast%3DGrant-Young%26aufirst%3DK.%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DHudyma%26aufirst%3DT.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DNickel%26aufirst%3DA.%26aulast%3DRegueiro-Ren%26aufirst%3DA.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYeung%26aufirst%3DK.-S.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DChao%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DCamac%26aufirst%3DD.%2BM.%26aulast%3DChang%26aufirst%3DC.-H.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DMorin%26aufirst%3DP.%2BE.%26aulast%3DSheriff%26aufirst%3DS.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DHanumegowda%26aufirst%3DU.%26aulast%3DKnipe%26aufirst%3DJ.%26aulast%3DMosure%26aufirst%3DK.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DParker%26aufirst%3DD.%2BD.%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DPelosi%26aufirst%3DL.%26aulast%3DRigat%26aufirst%3DK.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.-K.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DNg%26aufirst%3DA.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26atitle%3DDiscovery%2520and%2520preclinical%2520characterization%2520of%2520the%2520cyclopropylindolobenzazepine%2520BMS-791325%252C%2520a%2520potent%2520allosteric%2520inhibitor%2520of%2520the%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1855%26epage%3D1879%26doi%3D10.1021%2Fjm4016894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Hewawasam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudyma, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentles, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">A practical and efficient synthesis of 6-carboalkoxy-13-cycloalkyl-5<i>H</i>-indolo[2,1-<i>a</i>][2] benzazepine-10-carboxylic acid derivatives</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1148</span><span class="NLM_x">–</span> <span class="NLM_lpage">1153</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2013.12.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.tetlet.2013.12.085" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1148-1153&author=P.+Hewawasamauthor=Y.+Tuauthor=T.+W.+Hudymaauthor=X.+Zhangauthor=R.+G.+Gentlesauthor=J.+F.+Kadowauthor=N.+A.+Meanwell&title=A+practical+and+efficient+synthesis+of+6-carboalkoxy-13-cycloalkyl-5H-indolo%5B2%2C1-a%5D%5B2%5D+benzazepine-10-carboxylic+acid+derivatives&doi=10.1016%2Fj.tetlet.2013.12.085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2013.12.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2013.12.085%26sid%3Dliteratum%253Aachs%26aulast%3DHewawasam%26aufirst%3DP.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DHudyma%26aufirst%3DT.%2BW.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DA%2520practical%2520and%2520efficient%2520synthesis%2520of%25206-carboalkoxy-13-cycloalkyl-5H-indolo%255B2%252C1-a%255D%255B2%255D%2520benzazepine-10-carboxylic%2520acid%2520derivatives%26jtitle%3DTetrahedron%2520Lett.%26date%3D2014%26volume%3D55%26spage%3D1148%26epage%3D1153%26doi%3D10.1016%2Fj.tetlet.2013.12.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Sinz, M. W.</span><span> </span><span class="NLM_article-title">Pregnane X receptor: prediction and attenuation of human CYP3A4 enzyme induction and drug-drug interactions</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">418</span><span class="refDoi"> DOI: 10.1016/S0065-7743(08)00023-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0065-7743%2808%2900023-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2008&pages=405-418&author=M.+W.+Sinz&title=Pregnane+X+receptor%3A+prediction+and+attenuation+of+human+CYP3A4+enzyme+induction+and+drug-drug+interactions&doi=10.1016%2FS0065-7743%2808%2900023-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2808%2900023-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252808%252900023-7%26sid%3Dliteratum%253Aachs%26aulast%3DSinz%26aufirst%3DM.%2BW.%26atitle%3DPregnane%2520X%2520receptor%253A%2520prediction%2520and%2520attenuation%2520of%2520human%2520CYP3A4%2520enzyme%2520induction%2520and%2520drug-drug%2520interactions%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2008%26volume%3D43%26spage%3D405%26epage%3D418%26doi%3D10.1016%2FS0065-7743%2808%2900023-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Lemm, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentles, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelosi, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigat, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosure, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knipe, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colonno, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santone, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3485</span><span class="NLM_x">–</span> <span class="NLM_lpage">3495</span><span class="refDoi"> DOI: 10.1128/AAC.02495-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FAAC.02495-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24733465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCntLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=3485-3495&author=J.+A.+Lemmauthor=M.+Liuauthor=R.+G.+Gentlesauthor=M.+Dingauthor=S.+Vossauthor=L.+A.+Pelosiauthor=Y.+K.+Wangauthor=K.+L.+Rigatauthor=K.+W.+Mosureauthor=J.+A.+Benderauthor=J.+O.+Knipeauthor=R.+Colonnoauthor=N.+A.+Meanwellauthor=J.+F.+Kadowauthor=K.+S.+Santoneauthor=S.+B.+Robertsauthor=M.+Gao&title=Preclinical+characterization+of+BMS-791325%2C+an+allosteric+inhibitor+of+hepatitis+C+Virus+NS5B+polymerase&doi=10.1128%2FAAC.02495-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C virus NS5B polymerase</span></div><div class="casAuthors">Lemm, Julie A.; Liu, Mengping; Gentles, Robert G.; Ding, Min; Voss, Stacey; Pelosi, Lenore A.; Wang, Ying-Kai; Rigat, Karen L.; Mosure, Kathleen W.; Bender, John A.; Knipe, Jay O.; Colonno, Richard; Meanwell, Nicholas A.; Kadow, John F.; Santone, Kenneth S.; Roberts, Susan B.; Gao, Min</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3485-3495, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">BMS-791325 is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase.  BMS-791325 inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4 and 5 at 50 % inhibitory concns. (IC50) below 28 nM.  In cell culture, BMS-791325 inhibited replication of HCV subgenomic replicons representing genotypes 1a and 1b at 50% effective concns. (EC50s) of 3 nM and 6 nM, resp., with similar (3 to 18 nM) values for genotypes 3a, 4a and 5a.  Potency against genotype 6a showed more variability (9 to 125 nM) and activity was weaker against genotype 2 (EC50, 87 to 925 nM).  Specificity was demonstrated by the absence of activity (EC50s of >4 μM) against a panel of mammalian viruses and cytotoxic concns. (50%) were >3,000-fold above the HCV EC50.  Resistance substitutions selected by BMS-791325 in genotype 1 replicons mostly mapped to a single site, NS5B amino acid 495 (P495A/S/L/T).  Additive or synergistic activity was obsd. in combination studies using BMS-791325 with alfa interferon plus ribavirin, inhibitors of NS3 protease or NS5A and other classes of NS5B inhibitor (palm site 2-binding or nucleoside analogs).  Plasma and liver exposuresin vivo in several animal species indicated that BMS-791325 has a hepatotropic disposition (liver-to-plasma ratios ranging from 1.6- to 60-fold across species).  Twenty-four hours postdose, liver exposures across all species tested were ≥10-fold above the inhibitor EC50s obsd. with HCV genotype 1 replicons.  These findings support the evaluation of BMS-791325 in combination regimens for the treatment of HCV.  Phase 3 studies are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEqRFEKxGsgbVg90H21EOLACvtfcHk0lifiSSVGRPztg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCntLjF&md5=d3f934398d420d4ef91f9eb7b71b5059</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1128%2FAAC.02495-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02495-13%26sid%3Dliteratum%253Aachs%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DVoss%26aufirst%3DS.%26aulast%3DPelosi%26aufirst%3DL.%2BA.%26aulast%3DWang%26aufirst%3DY.%2BK.%26aulast%3DRigat%26aufirst%3DK.%2BL.%26aulast%3DMosure%26aufirst%3DK.%2BW.%26aulast%3DBender%26aufirst%3DJ.%2BA.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DPreclinical%2520characterization%2520of%2520BMS-791325%252C%2520an%2520allosteric%2520inhibitor%2520of%2520hepatitis%2520C%2520Virus%2520NS5B%2520polymerase%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D3485%26epage%3D3495%26doi%3D10.1128%2FAAC.02495-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Gentile, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zappulo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonomo, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maraolo, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, G.</span><span> </span><span class="NLM_article-title">Beclabuvir for the treatment of hepatitis C</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1111</span><span class="NLM_x">–</span> <span class="NLM_lpage">1121</span><span class="refDoi"> DOI: 10.1517/13543784.2015.1059820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1517%2F13543784.2015.1059820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26156630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCksb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1111-1121&author=I.+Gentileauthor=E.+Zappuloauthor=A.+R.+Buonomoauthor=A.+E.+Maraoloauthor=G.+Borgia&title=Beclabuvir+for+the+treatment+of+hepatitis+C&doi=10.1517%2F13543784.2015.1059820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Beclabuvir for the treatment of hepatitis C</span></div><div class="casAuthors">Gentile, Ivan; Zappulo, Emanuela; Buonomo, Antonio Riccardo; Maraolo, Alberto Enrico; Borgia, Guglielmo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1111-1121</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: About 185,000,000 people worldwide are chronically infected with hepatitis C virus (HCV).  Currently, the most successful HCV infection antiviral therapies reduce the chance of progression towards the advanced phases of the hepatopathy (liver cirrhosis, hepatocellular carcinoma and death).  Recently, however, several new direct-acting antivirals against HCV are available or are in an advanced phase of clin. development.  Areas covered: This review focuses on beclabuvir, an allosteric non-nucleotide inhibitor of HCV polymerase.  The article covers its pharmacokinetics, mechanism of action, in addn. to its tolerability and safety profile as well as its resistance pattern.  Expert opinion: The pharmacokinetic, efficacy and tolerability profile of beclabuvir, as well as its barrier to resistance, are very favorable.  In particular, the combination of beclabuvir with asunaprevir and daclatasvir achieves very high rates of viral eradication (about 90%) in patients infected with HCV genotype 1, which is the most common genotype worldwide.  Therefore, beclabuvir represents a powerful weapon against HCV infection and has to be considered an optimal option in tailored IFN-free combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomjiRJtkTLmrVg90H21EOLACvtfcHk0lifiSSVGRPztg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCksb3N&md5=c0781930e17ca4764d7da0e80ac2dc7a</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1059820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1059820%26sid%3Dliteratum%253Aachs%26aulast%3DGentile%26aufirst%3DI.%26aulast%3DZappulo%26aufirst%3DE.%26aulast%3DBuonomo%26aufirst%3DA.%2BR.%26aulast%3DMaraolo%26aufirst%3DA.%2BE.%26aulast%3DBorgia%26aufirst%3DG.%26atitle%3DBeclabuvir%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1111%26epage%3D1121%26doi%3D10.1517%2F13543784.2015.1059820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuttle, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J. A.</span><span> </span><span class="NLM_article-title">Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">7416</span><span class="NLM_x">–</span> <span class="NLM_lpage">7423</span><span class="refDoi"> DOI: 10.1128/AAC.03851-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FAAC.03851-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25267677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVymsLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=7416-7423&author=M.+Liuauthor=M.+Tuttleauthor=M.+Gaoauthor=J.+A.+Lemm&title=Potency+and+resistance+analysis+of+hepatitis+C+virus+NS5B+polymerase+inhibitor+BMS-791325+on+all+major+genotypes&doi=10.1128%2FAAC.03851-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes</span></div><div class="casAuthors">Liu, Mengping; Tuttle, Maria; Gao, Min; Lemm, Julie A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">7416-7423, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">BMS-791325 is a hepatitis C virus (HCV) inhibitor binding to the thumb domain of the NS5B RNA-dependent RNA polymerase.  BMS-791325 is well characterized in genotype 1 (GT1) and exhibits good inhibitory activity (50% effective concn. [EC50], <10 nM) against hybrid replicons contg. patient NS5B sequences from GT3a, -4a, and -5a while potency against GT2 is significantly reduced.  BMS-791325 potency against GT6a hybrid replicons is more variable, with two of three hybrid clones having EC50s similar to that for GT1 while a third patient clone was ∼10 times less susceptible to BMS-791325.  To characterize the resistance profile of BMS-791325 beyond GT1, curing studies were performed across GT1a and -3a to -6a and demonstrated that GT1a has the highest resistance barrier vs. BMS-791325 while GT6a has the lowest.  Selection of GT3 to -6 NS5B chimeric replicon cells at different concns. of BMS-791325 revealed substitutions in the thumb domain of NS5B at residues 494 and 495 that conferred different levels of resistance to BMS-791325 but remained susceptible to NS5A or NS3 protease inhibitors.  In addn., we demonstrate that the reduced potency of BMS-791325 against one GT6a patient is due to an A494 polymorphism present in ∼21% of sequences in the European HCV database.  The results from this report suggest that BMS-791325 is a candidate for combination treatment of HCV GT3 to -6 chronic infections, and the resistance profiles identified will provide useful information for future clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5_mdXydNNWLVg90H21EOLACvtfcHk0lgLVejUkE64SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVymsLzL&md5=8c28943f5323ac850671503c57974cb0</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1128%2FAAC.03851-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03851-14%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DTuttle%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26atitle%3DPotency%2520and%2520resistance%2520analysis%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%2520inhibitor%2520BMS-791325%2520on%2520all%2520major%2520genotypes%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D7416%26epage%3D7423%26doi%3D10.1128%2FAAC.03851-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Rigat, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Argyrou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanslau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcinkeviciene, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gentles, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abell, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. B.</span><span> </span><span class="NLM_article-title">Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">33456</span><span class="NLM_x">–</span> <span class="NLM_lpage">33468</span><span class="refDoi"> DOI: 10.1074/jbc.M114.613653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1074%2Fjbc.M114.613653" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=33456-33468&author=K.+L.+Rigatauthor=H.+Luauthor=Y.+K.+Wangauthor=A.+Argyrouauthor=C.+Fanslauauthor=B.+Benoauthor=Y.+Wangauthor=J.+Marcinkevicieneauthor=M.+Dingauthor=R.+G.+Gentlesauthor=M.+Gaoauthor=L.+M.+Abellauthor=S.+B.+Roberts&title=Mechanism+of+inhibition+for+BMS-791325%2C+a+novel+non-nucleoside+inhibitor+of+hepatitis+C+virus+NS5B+polymerase&doi=10.1074%2Fjbc.M114.613653"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.613653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.613653%26sid%3Dliteratum%253Aachs%26aulast%3DRigat%26aufirst%3DK.%2BL.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DY.%2BK.%26aulast%3DArgyrou%26aufirst%3DA.%26aulast%3DFanslau%26aufirst%3DC.%26aulast%3DBeno%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMarcinkeviciene%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DM.%26aulast%3DGentles%26aufirst%3DR.%2BG.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DAbell%26aufirst%3DL.%2BM.%26aulast%3DRoberts%26aufirst%3DS.%2BB.%26atitle%3DMechanism%2520of%2520inhibition%2520for%2520BMS-791325%252C%2520a%2520novel%2520non-nucleoside%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520NS5B%2520polymerase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26spage%3D33456%26epage%3D33468%26doi%3D10.1074%2Fjbc.M114.613653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yuan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouyang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinsanya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moehlenkamp, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubry, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, M. E.</span><span> </span><span class="NLM_article-title">A validated LC-MS/MS method for the simultaneous determination of BMS-791325, a hepatitis C virus NS5B RNA polymerase inhibitor, and its metabolite in plasma</span> <span class="citation_source-journal">J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">973</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.1016/j.jchromb.2014.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jchromb.2014.10.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=973&publication_year=2014&pages=1-8&author=L.+Yuanauthor=H.+Jiangauthor=N.+Zhengauthor=Y.+Q.+Xiaauthor=Z.+Ouyangauthor=J.+Zengauthor=B.+Akinsanyaauthor=J.+L.+Valentineauthor=J.+D.+Moehlenkampauthor=Y.+Dengauthor=A.+F.+Aubryauthor=M.+E.+Arnold&title=A+validated+LC-MS%2FMS+method+for+the+simultaneous+determination+of+BMS-791325%2C+a+hepatitis+C+virus+NS5B+RNA+polymerase+inhibitor%2C+and+its+metabolite+in+plasma&doi=10.1016%2Fj.jchromb.2014.10.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108a&amp;dbid=16384&amp;doi=10.1016%2Fj.jchromb.2014.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jchromb.2014.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DXia%26aufirst%3DY.%2BQ.%26aulast%3DOuyang%26aufirst%3DZ.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DAkinsanya%26aufirst%3DB.%26aulast%3DValentine%26aufirst%3DJ.%2BL.%26aulast%3DMoehlenkamp%26aufirst%3DJ.%2BD.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DAubry%26aufirst%3DA.%2BF.%26aulast%3DArnold%26aufirst%3DM.%2BE.%26atitle%3DA%2520validated%2520LC-MS%252FMS%2520method%2520for%2520the%2520simultaneous%2520determination%2520of%2520BMS-791325%252C%2520a%2520hepatitis%2520C%2520virus%2520NS5B%2520RNA%2520polymerase%2520inhibitor%252C%2520and%2520its%2520metabolite%2520in%2520plasma%26jtitle%3DJ.%2520Chromatogr.%2520B%253A%2520Anal.%2520Technol.%2520Biomed.%2520Life%2520Sci.%26date%3D2014%26volume%3D973%26spage%3D1%26epage%3D8%26doi%3D10.1016%2Fj.jchromb.2014.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit108b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kandoussi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadiyala, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cojocaru, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubry, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, J.</span><span> </span><span class="NLM_article-title">Sensitive and accurate liquid chromatography-tandem mass spectrometry methods for quantitative determination of a novel hepatitis C NS5B inhibitor BMS-791325 and its active metabolite in human plasma and urine</span> <span class="citation_source-journal">J. Pharm. Biomed. Anal.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1016/j.jpba.2014.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jpba.2014.12.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2015&pages=17-23&author=H.+Jiangauthor=R.+Demersauthor=H.+Kandoussiauthor=R.+Burrellauthor=T.+Eleyauthor=P.+Kadiyalaauthor=L.+Cojocaruauthor=C.+Bakerauthor=J.+Ryanauthor=A.+F.+Aubryauthor=M.+E.+Arnoldauthor=J.+Zeng&title=Sensitive+and+accurate+liquid+chromatography-tandem+mass+spectrometry+methods+for+quantitative+determination+of+a+novel+hepatitis+C+NS5B+inhibitor+BMS-791325+and+its+active+metabolite+in+human+plasma+and+urine&doi=10.1016%2Fj.jpba.2014.12.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108b&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2014.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2014.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DDemers%26aufirst%3DR.%26aulast%3DKandoussi%26aufirst%3DH.%26aulast%3DBurrell%26aufirst%3DR.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DKadiyala%26aufirst%3DP.%26aulast%3DCojocaru%26aufirst%3DL.%26aulast%3DBaker%26aufirst%3DC.%26aulast%3DRyan%26aufirst%3DJ.%26aulast%3DAubry%26aufirst%3DA.%2BF.%26aulast%3DArnold%26aufirst%3DM.%2BE.%26aulast%3DZeng%26aufirst%3DJ.%26atitle%3DSensitive%2520and%2520accurate%2520liquid%2520chromatography-tandem%2520mass%2520spectrometry%2520methods%2520for%2520quantitative%2520determination%2520of%2520a%2520novel%2520hepatitis%2520C%2520NS5B%2520inhibitor%2520BMS-791325%2520and%2520its%2520active%2520metabolite%2520in%2520human%2520plasma%2520and%2520urine%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2015%26volume%3D107%26spage%3D17%26epage%3D23%26doi%3D10.1016%2Fj.jpba.2014.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Sims, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berglind, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vutikullird, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span> </span><span class="NLM_article-title">Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3496</span><span class="NLM_x">–</span> <span class="NLM_lpage">3503</span><span class="refDoi"> DOI: 10.1128/AAC.02579-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FAAC.02579-13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=3496-3503&author=K.+D.+Simsauthor=J.+Lemmauthor=T.+Eleyauthor=M.+Liuauthor=A.+Berglindauthor=D.+Shermanauthor=E.+Lawitzauthor=A.+B.+Vutikullirdauthor=P.+Tebasauthor=M.+Gaoauthor=C.+Pasquinelliauthor=D.+M.+Grasela&title=Randomized%2C+placebo-controlled%2C+single-ascending-dose+study+of+BMS-791325%2C+a+hepatitis+C+virus+%28HCV%29+NS5B+polymerase+inhibitor%2C+in+HCV+genotype+1+infection&doi=10.1128%2FAAC.02579-13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1128%2FAAC.02579-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02579-13%26sid%3Dliteratum%253Aachs%26aulast%3DSims%26aufirst%3DK.%2BD.%26aulast%3DLemm%26aufirst%3DJ.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DBerglind%26aufirst%3DA.%26aulast%3DSherman%26aufirst%3DD.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DVutikullird%26aufirst%3DA.%2BB.%26aulast%3DTebas%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26atitle%3DRandomized%252C%2520placebo-controlled%252C%2520single-ascending-dose%2520study%2520of%2520BMS-791325%252C%2520a%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%2520NS5B%2520polymerase%2520inhibitor%252C%2520in%2520HCV%2520genotype%25201%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D3496%26epage%3D3503%26doi%3D10.1128%2FAAC.02579-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Nettles, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marbury, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldwater, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMicco, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vutikullird, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Talavera, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span> </span><span class="NLM_article-title">Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1956</span><span class="NLM_x">–</span> <span class="NLM_lpage">1965</span><span class="refDoi"> DOI: 10.1002/hep.24609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.24609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=21837752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1956-1965&author=R.+E.+Nettlesauthor=M.+Gaoauthor=M.+Bifanoauthor=E.+Chungauthor=A.+Perssonauthor=T.+C.+Marburyauthor=R.+Goldwaterauthor=M.+P.+DeMiccoauthor=M.+Rodriguez-Torresauthor=A.+Vutikullirdauthor=E.+Fuentesauthor=E.+Lawitzauthor=J.+C.+Lopez-Talaveraauthor=D.+M.+Grasela&title=Multiple+ascending+dose+study+of+BMS-790052%2C+a+nonstructural+protein+5A+replication+complex+inhibitor%2C+in+patients+infected+with+hepatitis+C+virus+genotype+1&doi=10.1002%2Fhep.24609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1</span></div><div class="casAuthors">Nettles, Richard E.; Gao, Min; Bifano, Marc; Chung, Ellen; Persson, Anna; Marbury, Thomas C.; Goldwater, Ronald; DeMicco, Michael P.; Rodriguez-Torres, Maribel; Vutikullird, Apinya; Fuentes, Ernesto; Lawitz, Eric; Lopez-Talavera, Juan Carlos; Grasela, Dennis M.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1956-1965</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The antiviral activity, resistance profile, pharmacokinetics (PK), safety, and tolerability of BMS-790052, a nonstructural protein 5A (NS5A) replication complex inhibitor, were evaluated in a double-blind, placebo-controlled, sequential panel, multiple ascending dose study.  Thirty patients with chronic hepatitis C virus (HCV) genotype 1 infection were randomized to receive a 14-day course of BMS-790052 (1, 10, 30, 60, or 100 mg once daily or 30 mg twice daily) or placebo in a ratio of 4:1.  The mean max. decline from baseline in HCV RNA ranged from 2.8 to 4.1 log10 IU/mL; the placebo group showed no evidence of antiviral activity.  Most patients experienced viral rebound on or before day 7 of treatment with BMS-790052 monotherapy; viral rebound was assocd. with viral variants that had been previously implicated in resistance development in the in vitro replicon system.  The PK profile was supportive of once-daily dosing with median peak plasma concns. at 1-2 h postdose and mean terminal half-life of 12-15 h.  Steady state was achieved following 3-4 days of daily dosing.  BMS-790052 was well tolerated in all dose groups, with adverse events occurring with a similar frequency in BMS-790052- and placebo-treated groups.  There were no clin. relevant changes in vital signs, lab., or ECG parameters.  Conclusion: BMS-7590052 is the first NS5A replication complex inhibitor with multiple dose proof-of-concept in clinic.  At doses of 1-100 mg daily, BMS-790052 was well tolerated, had a PK profile supportive of once-daily dosing, and produced a rapid and substantial decrease in HCV-RNA levels in patients chronically infected with HCV genotype 1. (HEPATOl.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjY1mjsJbg-LVg90H21EOLACvtfcHk0lisn4kSwfHDdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsLrJ&md5=080f30aec3629e68b832fe6491c54d16</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1002%2Fhep.24609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24609%26sid%3Dliteratum%253Aachs%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DBifano%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DMarbury%26aufirst%3DT.%2BC.%26aulast%3DGoldwater%26aufirst%3DR.%26aulast%3DDeMicco%26aufirst%3DM.%2BP.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DVutikullird%26aufirst%3DA.%26aulast%3DFuentes%26aufirst%3DE.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DLopez-Talavera%26aufirst%3DJ.%2BC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26atitle%3DMultiple%2520ascending%2520dose%2520study%2520of%2520BMS-790052%252C%2520a%2520nonstructural%2520protein%25205A%2520replication%2520complex%2520inhibitor%252C%2520in%2520patients%2520infected%2520with%2520hepatitis%2520C%2520virus%2520genotype%25201%26jtitle%3DHepatology%26date%3D2011%26volume%3D54%26spage%3D1956%26epage%3D1965%26doi%3D10.1002%2Fhep.24609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Liu-Young, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozal, M. J.</span><span> </span><span class="NLM_article-title">Hepatitis C protease and polymerase inhibitors in development</span> <span class="citation_source-journal">AIDS Patient Care STDS</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">457</span><span class="refDoi"> DOI: 10.1089/apc.2007.0199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1089%2Fapc.2007.0199" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=449-457&author=G.+Liu-Youngauthor=M.+J.+Kozal&title=Hepatitis+C+protease+and+polymerase+inhibitors+in+development&doi=10.1089%2Fapc.2007.0199"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1089%2Fapc.2007.0199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fapc.2007.0199%26sid%3Dliteratum%253Aachs%26aulast%3DLiu-Young%26aufirst%3DG.%26aulast%3DKozal%26aufirst%3DM.%2BJ.%26atitle%3DHepatitis%2520C%2520protease%2520and%2520polymerase%2520inhibitors%2520in%2520development%26jtitle%3DAIDS%2520Patient%2520Care%2520STDS%26date%3D2008%26volume%3D22%26spage%3D449%26epage%3D457%26doi%3D10.1089%2Fapc.2007.0199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Marks, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span> </span><span class="NLM_article-title">The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1119</span><span class="NLM_x">–</span> <span class="NLM_lpage">1121</span><span class="refDoi"> DOI: 10.3851/IMP2424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.3851%2FIMP2424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=23188750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVCks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1119-1121&author=K.+M.+Marksauthor=I.+M.+Jacobson&title=The+first+wave%3A+HCV+NS3+protease+inhibitors+telaprevir+and+boceprevir&doi=10.3851%2FIMP2424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir</span></div><div class="casAuthors">Marks, Kristen M.; Jacobson, Ira M.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Therapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6, Pt. B</span>),
    <span class="NLM_cas:pages">1119-1131</span>CODEN:
                <span class="NLM_cas:coden">ANTHFA</span>;
        ISSN:<span class="NLM_cas:issn">1359-6535</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press</span>)
        </div><div class="casAbstract">A review.  Boceprevir and telaprevir are peptidomimetic serine protease inhibitors that have been recently approved for the treatment of HCV chronic infection.  The addn. of these drugs to the prior std. of care, pegylated interferon and ribavirin, improves sustained virol. response rates for treatment-naive and treatment-experienced patients and shortens the duration of treatment for over half of treatment-naive patients.  This review describes the clin. data supporting the approval and use of telaprevir and boceprevir, the algorithm for the use of these drugs, their adverse effects, as well as their important drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZHoeJhY2iNbVg90H21EOLACvtfcHk0lgkj-Co9y-P3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVCks7Y%253D&md5=6e1aaf842302212cb85b4eb68d7355d5</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.3851%2FIMP2424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2424%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DK.%2BM.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26atitle%3DThe%2520first%2520wave%253A%2520HCV%2520NS3%2520protease%2520inhibitors%2520telaprevir%2520and%2520boceprevir%26jtitle%3DAntiviral%2520Ther.%26date%3D2012%26volume%3D17%26spage%3D1119%26epage%3D1121%26doi%3D10.3851%2FIMP2424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113a"><span><span class="NLM_contrib-group">Butt, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanwal, F.</span><span> </span><span class="NLM_article-title">Boceprevir and telaprevir in the management of hepatitis c virus-infected patients</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span><span class="refDoi"> DOI: 10.1093/cid/cir774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1093%2Fcid%2Fcir774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=22156853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs12gsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2012&pages=96-104&author=A.+A.+Buttauthor=F.+Kanwal&title=Boceprevir+and+telaprevir+in+the+management+of+hepatitis+c+virus-infected+patients&doi=10.1093%2Fcid%2Fcir774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113aR"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Boceprevir and Telaprevir in the Management of Hepatitis C Virus-Infected Patients</span></div><div class="casAuthors">Saravolatz, Louis D.; Butt, Adeel A.; Kanwal, Fasiha</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">96-104</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Recent approval of direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) offers a major advance in the management of HCV infection.  These DAAs, boceprevir and telaprevir, when given with pegylated interferon alpha (Peg-IFN) and ribavirin (RBV), result in a much higher sustained virol. response rate compared with Peg-IFN and RBV.  The DAA-contg. regimens are approved for HCV genotype 1 infection in HCV treatment-naive and HCV treatment-experienced patients.  In this review, we present an overview of pharmacol., efficacy, adverse events, and emergence of resistance-assocd. variants with the use of these agents.  As with all drugs, esp. newly approved drugs, clinicians must consult the package insert for detailed prescribing information, list of all reported adverse events, contraindications, and drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojATMQ3wLXdrVg90H21EOLACvtfcHk0lgkj-Co9y-P3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs12gsr7F&md5=d650f9930f42fa11521a8682df53ae80</span></div><a href="/servlet/linkout?suffix=cit113a&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcir774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcir774%26sid%3Dliteratum%253Aachs%26aulast%3DButt%26aufirst%3DA.%2BA.%26aulast%3DKanwal%26aufirst%3DF.%26atitle%3DBoceprevir%2520and%2520telaprevir%2520in%2520the%2520management%2520of%2520hepatitis%2520c%2520virus-infected%2520patients%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2012%26volume%3D54%26spage%3D96%26epage%3D104%26doi%3D10.1093%2Fcid%2Fcir774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit113b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Park, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawson, K. A.</span><span> </span><span class="NLM_article-title">Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis</span> <span class="citation_source-journal">J. Clin. Pharm. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span><span class="refDoi"> DOI: 10.1111/jcpt.12106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fjcpt.12106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=14-24&author=C.+Parkauthor=S.+Jiangauthor=K.+A.+Lawson&title=Efficacy+and+safety+of+telaprevir+and+boceprevir+in+patients+with+hepatitis+C+genotype+1%3A+a+meta-analysis&doi=10.1111%2Fjcpt.12106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113b&amp;dbid=16384&amp;doi=10.1111%2Fjcpt.12106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcpt.12106%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DLawson%26aufirst%3DK.%2BA.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520telaprevir%2520and%2520boceprevir%2520in%2520patients%2520with%2520hepatitis%2520C%2520genotype%25201%253A%2520a%2520meta-analysis%26jtitle%3DJ.%2520Clin.%2520Pharm.%2520Ther.%26date%3D2014%26volume%3D39%26spage%3D14%26epage%3D24%26doi%3D10.1111%2Fjcpt.12106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Keating, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curran, M. P.</span><span> </span><span class="NLM_article-title">Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">701</span><span class="NLM_x">–</span> <span class="NLM_lpage">730</span><span class="refDoi"> DOI: 10.2165/00003495-200363070-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.2165%2F00003495-200363070-00008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=701-730&author=G.+M.+Keatingauthor=M.+P.+Curran&title=Peginterferon-alpha-2a+%2840kD%29+plus+ribavirin%3A+a+review+of+its+use+in+the+management+of+chronic+hepatitis+C&doi=10.2165%2F00003495-200363070-00008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114a&amp;dbid=16384&amp;doi=10.2165%2F00003495-200363070-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200363070-00008%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26aulast%3DCurran%26aufirst%3DM.%2BP.%26atitle%3DPeginterferon-alpha-2a%2520%252840kD%2529%2520plus%2520ribavirin%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520management%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DDrugs%26date%3D2003%26volume%3D63%26spage%3D701%26epage%3D730%26doi%3D10.2165%2F00003495-200363070-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit114b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Keam, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cvetković, R. S.</span><span> </span><span class="NLM_article-title">Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">1273</span><span class="NLM_x">–</span> <span class="NLM_lpage">1317</span><span class="refDoi"> DOI: 10.2165/00003495-200868090-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.2165%2F00003495-200868090-00006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=1273-1317&author=S.+J.+Keamauthor=R.+S.+Cvetkovi%C4%87&title=Peginterferon-alpha-2a+%2840+kD%29+plus+ribavirin%3A+a+review+of+its+use+in+the+management+of+chronic+hepatitis+C+mono-infection&doi=10.2165%2F00003495-200868090-00006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114b&amp;dbid=16384&amp;doi=10.2165%2F00003495-200868090-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200868090-00006%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26aulast%3DCvetkovi%25C4%2587%26aufirst%3DR.%2BS.%26atitle%3DPeginterferon-alpha-2a%2520%252840%2520kD%2529%2520plus%2520ribavirin%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520management%2520of%2520chronic%2520hepatitis%2520C%2520mono-infection%26jtitle%3DDrugs%26date%3D2008%26volume%3D68%26spage%3D1273%26epage%3D1317%26doi%3D10.2165%2F00003495-200868090-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit114c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Aghemo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grazia Rumi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, M.</span><span> </span><span class="NLM_article-title">Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">494</span><span class="refDoi"> DOI: 10.1038/nrgastro.2010.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrgastro.2010.101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=485-494&author=A.+Aghemoauthor=M.+Grazia+Rumiauthor=M.+Colombo&title=Pegylated+interferons+%CE%B12a+and+%CE%B12b+in+the+treatment+of+chronic+hepatitis+C&doi=10.1038%2Fnrgastro.2010.101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114c&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2010.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2010.101%26sid%3Dliteratum%253Aachs%26aulast%3DAghemo%26aufirst%3DA.%26aulast%3DGrazia%2BRumi%26aufirst%3DM.%26aulast%3DColombo%26aufirst%3DM.%26atitle%3DPegylated%2520interferons%2520%25CE%25B12a%2520and%2520%25CE%25B12b%2520in%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2010%26volume%3D7%26spage%3D485%26epage%3D494%26doi%3D10.1038%2Fnrgastro.2010.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Gish, R. G.</span><span> </span><span class="NLM_article-title">Treating HCV with ribavirin analogues and ribavirin-like molecules</span> <span class="citation_source-journal">J. Antimicrob. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span><span class="refDoi"> DOI: 10.1093/jac/dki405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1093%2Fjac%2Fdki405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=16293677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFyruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2006&pages=8-13&author=R.+G.+Gish&title=Treating+HCV+with+ribavirin+analogues+and+ribavirin-like+molecules&doi=10.1093%2Fjac%2Fdki405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Treating HCV with ribavirin analogues and ribavirin-like molecules</span></div><div class="casAuthors">Gish, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-13</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Nucleos(t)ide analogs have proven useful in the treatment of viral infections.  Ribavirin is a nucleoside, guanosine analog, whose mechanisms of action include inhibition of inosine monophosphate dehydrogenase (IMPDH), which is the key step in de novo guanine synthesis, a requirement for viral replication.  In combination with pegylated interferon alfa, ribavirin is the std. of care for the treatment of chronic hepatitis C today.  However, the medication is assocd. with significant hemolytic anemia, which may require dose redn., discontinuation or treatment with recombinant human erythropoietin.  Dose redn. also appears to decrease sustained viral clearance rates.  Newer IMPDH inhibitors are in various stages of development.  Viramidine, a liver-targeting prodrug of ribavirin, has demonstrated significant antiviral activity and erythrocyte-sparing properties.  It is currently in Phase 3 trials.  Clin. trials of merimepodib, another investigational IMPDH inhibitor, have completed enrollment for a Phase 2b study as a third medication for administration with pegylated interferon plus ribavirin.  Although other IMDPH inhibitors also have antiviral activity, these medications appear best suited as immunosuppressive medications at this time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrduaZ9nO9-ULVg90H21EOLACvtfcHk0lgsk6c_BiKcAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFyruw%253D%253D&md5=f8793466b8e56e5ed2fc7428f544d7b6</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdki405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdki405%26sid%3Dliteratum%253Aachs%26aulast%3DGish%26aufirst%3DR.%2BG.%26atitle%3DTreating%2520HCV%2520with%2520ribavirin%2520analogues%2520and%2520ribavirin-like%2520molecules%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2006%26volume%3D57%26spage%3D8%26epage%3D13%26doi%3D10.1093%2Fjac%2Fdki405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ara, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span> </span><span class="NLM_article-title">New direct-acting antiviral therapies for treatment of chronic hepatitis C virus infection</span> <span class="citation_source-journal">Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">458</span><span class="NLM_x">–</span> <span class="NLM_lpage">466</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=458-466&author=A.+K.+Araauthor=P.+J.+Pockros&title=New+direct-acting+antiviral+therapies+for+treatment+of+chronic+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAra%26aufirst%3DA.%2BK.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26atitle%3DNew%2520direct-acting%2520antiviral%2520therapies%2520for%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DGastroenterol.%2520Hepatol.%26date%3D2015%26volume%3D11%26spage%3D458%26epage%3D466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit116b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Price, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shvachko, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauly, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manos, M. M.</span><span> </span><span class="NLM_article-title">Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting</span> <span class="citation_source-journal">Dig. Dis. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3043</span><span class="NLM_x">–</span> <span class="NLM_lpage">3052</span><span class="refDoi"> DOI: 10.1007/s10620-014-3294-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1007%2Fs10620-014-3294-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=3043-3052&author=J.+C.+Priceauthor=R.+C.+Murphyauthor=V.+A.+Shvachkoauthor=M.+P.+Paulyauthor=M.+M.+Manos&title=Effectiveness+of+telaprevir+and+boceprevir+triple+therapy+for+patients+with+hepatitis+C+virus+infection+in+a+large+integrated+care+setting&doi=10.1007%2Fs10620-014-3294-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116b&amp;dbid=16384&amp;doi=10.1007%2Fs10620-014-3294-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10620-014-3294-0%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DJ.%2BC.%26aulast%3DMurphy%26aufirst%3DR.%2BC.%26aulast%3DShvachko%26aufirst%3DV.%2BA.%26aulast%3DPauly%26aufirst%3DM.%2BP.%26aulast%3DManos%26aufirst%3DM.%2BM.%26atitle%3DEffectiveness%2520of%2520telaprevir%2520and%2520boceprevir%2520triple%2520therapy%2520for%2520patients%2520with%2520hepatitis%2520C%2520virus%2520infection%2520in%2520a%2520large%2520integrated%2520care%2520setting%26jtitle%3DDig.%2520Dis.%2520Sci.%26date%3D2014%26volume%3D59%26spage%3D3043%26epage%3D3052%26doi%3D10.1007%2Fs10620-014-3294-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit116c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Backus, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belperio, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahoumian, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mole, L. A.</span><span> </span><span class="NLM_article-title">Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort</span> <span class="citation_source-journal">Aliment. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">93</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span><span class="refDoi"> DOI: 10.1111/apt.12546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fapt.12546" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=93-103&author=L.+I.+Backusauthor=P.+S.+Belperioauthor=T.+A.+Shahoumianauthor=R.+Cheungauthor=L.+A.+Mole&title=Comparative+effectiveness+of+the+hepatitis+C+virus+protease+inhibitors+boceprevir+and+telaprevir+in+a+large+U.S.+cohort&doi=10.1111%2Fapt.12546"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116c&amp;dbid=16384&amp;doi=10.1111%2Fapt.12546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fapt.12546%26sid%3Dliteratum%253Aachs%26aulast%3DBackus%26aufirst%3DL.%2BI.%26aulast%3DBelperio%26aufirst%3DP.%2BS.%26aulast%3DShahoumian%26aufirst%3DT.%2BA.%26aulast%3DCheung%26aufirst%3DR.%26aulast%3DMole%26aufirst%3DL.%2BA.%26atitle%3DComparative%2520effectiveness%2520of%2520the%2520hepatitis%2520C%2520virus%2520protease%2520inhibitors%2520boceprevir%2520and%2520telaprevir%2520in%2520a%2520large%2520U.S.%2520cohort%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D39%26spage%3D93%26epage%3D103%26doi%3D10.1111%2Fapt.12546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit116d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearlman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Argo, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maliakkal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alam, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vainorius, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">HCV-TARGET Study Group.</span><span> </span><span class="NLM_article-title">Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">286</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span><span class="refDoi"> DOI: 10.1016/j.jhep.2014.08.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2014.08.052" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=286-293&author=S.+C.+Gordonauthor=A.+J.+Muirauthor=J.+K.+Limauthor=B.+Pearlmanauthor=C.+K.+Argoauthor=A.+Ramaniauthor=B.+Maliakkalauthor=I.+Alamauthor=T.+G.+Stewartauthor=M.+Vainoriusauthor=J.+Peterauthor=D.+R.+Nelsonauthor=M.+W.+Friedauthor=K.+R.+Reddyauthor=HCV-TARGET+Study+Group.&title=Safety+profile+of+boceprevir+and+telaprevir+in+chronic+hepatitis+C%3A+real+world+experience+from+HCV-TARGET&doi=10.1016%2Fj.jhep.2014.08.052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116d&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.08.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.08.052%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DPearlman%26aufirst%3DB.%26aulast%3DArgo%26aufirst%3DC.%2BK.%26aulast%3DRamani%26aufirst%3DA.%26aulast%3DMaliakkal%26aufirst%3DB.%26aulast%3DAlam%26aufirst%3DI.%26aulast%3DStewart%26aufirst%3DT.%2BG.%26aulast%3DVainorius%26aufirst%3DM.%26aulast%3DPeter%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DFried%26aufirst%3DM.%2BW.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3D%26atitle%3DSafety%2520profile%2520of%2520boceprevir%2520and%2520telaprevir%2520in%2520chronic%2520hepatitis%2520C%253A%2520real%2520world%2520experience%2520from%2520HCV-TARGET%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26spage%3D286%26epage%3D293%26doi%3D10.1016%2Fj.jhep.2014.08.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit116e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Smith, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Love, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammad, R. A.</span><span> </span><span class="NLM_article-title">The changing landscape of adverse drug events associated with chronic hepatitis C virus therapy</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1649</span><span class="NLM_x">–</span> <span class="NLM_lpage">1652</span><span class="refDoi"> DOI: 10.1517/14740338.2015.1088002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1517%2F14740338.2015.1088002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26365685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWhsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1649-1652&author=M.+A.+Smithauthor=B.+L.+Loveauthor=R.+A.+Mohammad&title=The+changing+landscape+of+adverse+drug+events+associated+with+chronic+hepatitis+C+virus+therapy&doi=10.1517%2F14740338.2015.1088002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116eR"><div class="casContent"><span class="casTitleNuber">116e</span><div class="casTitle"><span class="NLM_cas:atitle">The changing landscape of adverse drug events associated with chronic hepatitis C virus therapy</span></div><div class="casAuthors">Smith, Michael A.; Love, Bryan L.; Mohammad, Rima A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1649-1652</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Treatment of chronic hepatitis C virus (HCV) therapy has rapidly changed since the approval of IFN in the 1990s.  Early treatment brought about significant and therapy limiting adverse drug events (ADEs) such as anemia.  Since the direct-acting antivirals were first approved in 2011 and then advanced in 2013, treatment-related ADEs and therapy discontinuations have rapidly decreased, while sustained virol. response rates have significantly increased.  As the market for treating chronic HCV therapy has changed, so too has the ADE profile clinicians may need to manage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpunv_cYC0DILVg90H21EOLACvtfcHk0lhrxfBVMaNTaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWhsbzP&md5=7ffa79c393a587077c724434c6152b48</span></div><a href="/servlet/linkout?suffix=cit116e&amp;dbid=16384&amp;doi=10.1517%2F14740338.2015.1088002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2015.1088002%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DM.%2BA.%26aulast%3DLove%26aufirst%3DB.%2BL.%26aulast%3DMohammad%26aufirst%3DR.%2BA.%26atitle%3DThe%2520changing%2520landscape%2520of%2520adverse%2520drug%2520events%2520associated%2520with%2520chronic%2520hepatitis%2520C%2520virus%2520therapy%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2015%26volume%3D14%26spage%3D1649%26epage%3D1652%26doi%3D10.1517%2F14740338.2015.1088002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit116f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">De Clercq, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span> </span><span class="NLM_article-title">Approved antiviral drugs over the past 50 years</span> <span class="citation_source-journal">Clin. Microbiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span><span class="refDoi"> DOI: 10.1128/CMR.00102-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FCMR.00102-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=27281742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252Fos12htA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=695-747&author=E.+De+Clercqauthor=G.+Li&title=Approved+antiviral+drugs+over+the+past+50+years&doi=10.1128%2FCMR.00102-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116fR"><div class="casContent"><span class="casTitleNuber">116f</span><div class="casTitle"><span class="NLM_cas:atitle">Approved Antiviral Drugs over the Past 50 Years</span></div><div class="casAuthors">De Clercq Erik; Li Guangdi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical microbiology reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">695-747</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs categorized into 13 functional groups have been formally approved for the treatment of the following 9 human infectious diseases: (i) HIV infections (protease inhibitors, integrase inhibitors, entry inhibitors, nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and acyclic nucleoside phosphonate analogues), (ii) hepatitis B virus (HBV) infections (lamivudine, interferons, nucleoside analogues, and acyclic nucleoside phosphonate analogues), (iii) hepatitis C virus (HCV) infections (ribavirin, interferons, NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors), (iv) herpesvirus infections (5-substituted 2'-deoxyuridine analogues, entry inhibitors, nucleoside analogues, pyrophosphate analogues, and acyclic guanosine analogues), (v) influenza virus infections (ribavirin, matrix 2 protein inhibitors, RNA polymerase inhibitors, and neuraminidase inhibitors), (vi) human cytomegalovirus infections (acyclic guanosine analogues, acyclic nucleoside phosphonate analogues, pyrophosphate analogues, and oligonucleotides), (vii) varicella-zoster virus infections (acyclic guanosine analogues, nucleoside analogues, 5-substituted 2'-deoxyuridine analogues, and antibodies), (viii) respiratory syncytial virus infections (ribavirin and antibodies), and (ix) external anogenital warts caused by human papillomavirus infections (imiquimod, sinecatechins, and podofilox).  Here, we present for the first time a comprehensive overview of antiviral drugs approved over the past 50 years, shedding light on the development of effective antiviral treatments against current and emerging infectious diseases worldwide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbPpNpCY_qYTEC-75aqa5AfW6udTcc2eZUJ5HxurxSHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252Fos12htA%253D%253D&md5=1d25d961c1c6a72d6bc4634041bbb6fe</span></div><a href="/servlet/linkout?suffix=cit116f&amp;dbid=16384&amp;doi=10.1128%2FCMR.00102-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00102-15%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DG.%26atitle%3DApproved%2520antiviral%2520drugs%2520over%2520the%2520past%252050%2520years%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2016%26volume%3D29%26spage%3D695%26epage%3D747%26doi%3D10.1128%2FCMR.00102-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Melnikova, I.</span><span> </span><span class="NLM_article-title">Hepatitis C therapies</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">799</span><span class="NLM_x">–</span> <span class="NLM_lpage">800</span><span class="refDoi"> DOI: 10.1038/nrd2661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrd2661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFOlu7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=799-800&author=I.+Melnikova&title=Hepatitis+C+therapies&doi=10.1038%2Fnrd2661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C therapies</span></div><div class="casAuthors">Melnikova, Irena</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">799-800</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwmcuz35JAU7Vg90H21EOLACvtfcHk0lgu30z1xpSP8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFOlu7vI&md5=13eaab781a0fdbc9eb174db07603bf8a</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fnrd2661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2661%26sid%3Dliteratum%253Aachs%26aulast%3DMelnikova%26aufirst%3DI.%26atitle%3DHepatitis%2520C%2520therapies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D799%26epage%3D800%26doi%3D10.1038%2Fnrd2661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sarrazin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartels, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanzelka, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müh, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wincheringer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weegink, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reesink, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, A. D.</span><span> </span><span class="NLM_article-title">Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">1767</span><span class="NLM_x">–</span> <span class="NLM_lpage">1777</span><span class="refDoi"> DOI: 10.1053/j.gastro.2007.02.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1053%2Fj.gastro.2007.02.037" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2007&pages=1767-1777&author=C.+Sarrazinauthor=T.+L.+Kiefferauthor=D.+Bartelsauthor=B.+Hanzelkaauthor=U.+M%C3%BChauthor=M.+Welkerauthor=D.+Wincheringerauthor=Y.+Zhouauthor=H.+M.+Chuauthor=C.+Linauthor=C.+Weeginkauthor=H.+Reesinkauthor=S.+Zeuzemauthor=A.+D.+Kwong&title=Dynamic+hepatitis+C+virus+genotypic+and+phenotypic+changes+in+patients+treated+with+the+protease+inhibitor+telaprevir&doi=10.1053%2Fj.gastro.2007.02.037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118a&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2007.02.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2007.02.037%26sid%3Dliteratum%253Aachs%26aulast%3DSarrazin%26aufirst%3DC.%26aulast%3DKieffer%26aufirst%3DT.%2BL.%26aulast%3DBartels%26aufirst%3DD.%26aulast%3DHanzelka%26aufirst%3DB.%26aulast%3DM%25C3%25BCh%26aufirst%3DU.%26aulast%3DWelker%26aufirst%3DM.%26aulast%3DWincheringer%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DChu%26aufirst%3DH.%2BM.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DWeegink%26aufirst%3DC.%26aulast%3DReesink%26aufirst%3DH.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DKwong%26aufirst%3DA.%2BD.%26atitle%3DDynamic%2520hepatitis%2520C%2520virus%2520genotypic%2520and%2520phenotypic%2520changes%2520in%2520patients%2520treated%2520with%2520the%2520protease%2520inhibitor%2520telaprevir%26jtitle%3DGastroenterology%26date%3D2007%26volume%3D132%26spage%3D1767%26epage%3D1777%26doi%3D10.1053%2Fj.gastro.2007.02.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit118b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Susser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermehren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forestier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welker, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grigorian, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Füller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarrazin, C.</span><span> </span><span class="NLM_article-title">Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir</span> <span class="citation_source-journal">J. Clin. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span><span class="refDoi"> DOI: 10.1016/j.jcv.2011.08.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jcv.2011.08.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=321-327&author=S.+Susserauthor=J.+Vermehrenauthor=N.+Forestierauthor=M.+W.+Welkerauthor=N.+Grigorianauthor=C.+F%C3%BCllerauthor=D.+Pernerauthor=S.+Zeuzemauthor=C.+Sarrazin&title=Analysis+of+long-term+persistence+of+resistance+mutations+within+the+hepatitis+C+virus+NS3+protease+after+treatment+with+telaprevir+or+boceprevir&doi=10.1016%2Fj.jcv.2011.08.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118b&amp;dbid=16384&amp;doi=10.1016%2Fj.jcv.2011.08.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcv.2011.08.015%26sid%3Dliteratum%253Aachs%26aulast%3DSusser%26aufirst%3DS.%26aulast%3DVermehren%26aufirst%3DJ.%26aulast%3DForestier%26aufirst%3DN.%26aulast%3DWelker%26aufirst%3DM.%2BW.%26aulast%3DGrigorian%26aufirst%3DN.%26aulast%3DF%25C3%25BCller%26aufirst%3DC.%26aulast%3DPerner%26aufirst%3DD.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DSarrazin%26aufirst%3DC.%26atitle%3DAnalysis%2520of%2520long-term%2520persistence%2520of%2520resistance%2520mutations%2520within%2520the%2520hepatitis%2520C%2520virus%2520NS3%2520protease%2520after%2520treatment%2520with%2520telaprevir%2520or%2520boceprevir%26jtitle%3DJ.%2520Clin.%2520Virol.%26date%3D2011%26volume%3D52%26spage%3D321%26epage%3D327%26doi%3D10.1016%2Fj.jcv.2011.08.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit118c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bartels, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, E. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcial, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrn, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeiffer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tigges, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adiwijaya, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, T. L.</span><span> </span><span class="NLM_article-title">Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects</span> <span class="citation_source-journal">J. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">198</span><span class="NLM_x">, </span> <span class="NLM_fpage">800</span><span class="NLM_x">–</span> <span class="NLM_lpage">807</span><span class="refDoi"> DOI: 10.1086/591141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1086%2F591141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2008&pages=800-807&author=D.+J.+Bartelsauthor=Y.+Zhouauthor=E.+Z.+Zhangauthor=M.+Marcialauthor=R.+A.+Byrnauthor=T.+Pfeifferauthor=A.+M.+Tiggesauthor=B.+S.+Adiwijayaauthor=C.+Linauthor=A.+D.+Kwongauthor=T.+L.+Kieffer&title=Natural+prevalence+of+hepatitis+C+virus+variants+with+decreased+sensitivity+to+NS3.4A+protease+inhibitors+in+treatment-naive+subjects&doi=10.1086%2F591141"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118c&amp;dbid=16384&amp;doi=10.1086%2F591141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F591141%26sid%3Dliteratum%253Aachs%26aulast%3DBartels%26aufirst%3DD.%2BJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DE.%2BZ.%26aulast%3DMarcial%26aufirst%3DM.%26aulast%3DByrn%26aufirst%3DR.%2BA.%26aulast%3DPfeiffer%26aufirst%3DT.%26aulast%3DTigges%26aufirst%3DA.%2BM.%26aulast%3DAdiwijaya%26aufirst%3DB.%2BS.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DKwong%26aufirst%3DA.%2BD.%26aulast%3DKieffer%26aufirst%3DT.%2BL.%26atitle%3DNatural%2520prevalence%2520of%2520hepatitis%2520C%2520virus%2520variants%2520with%2520decreased%2520sensitivity%2520to%2520NS3.4A%2520protease%2520inhibitors%2520in%2520treatment-naive%2520subjects%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2008%26volume%3D198%26spage%3D800%26epage%3D807%26doi%3D10.1086%2F591141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Boyle, D. R.,  2nd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kienzle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1924</span><span class="NLM_x">–</span> <span class="NLM_lpage">1935</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1924-1935&author=R.+A.+Fridellauthor=C.+Wangauthor=J.-H.+Sunauthor=D.+R.+O%27Boyleauthor=P.+Nowerauthor=L.+Valeraauthor=D.+Qiuauthor=S.+Robertsauthor=X.+Huangauthor=B.+Kienzleauthor=M.+Bifanoauthor=R.+E.+Nettlesauthor=M.+Gao&title=Genotypic+and+phenotypic+analysis+of+variants+resistant+to+hepatitis+C+virus+nonstructural+protein+5A+replication+complex+inhibitor+BMS-790052+in+humans%3A+in+vitro+and+in+vivo+correlations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DO%2527Boyle%26aufirst%3DD.%2BR.%26aulast%3DNower%26aufirst%3DP.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DQiu%26aufirst%3DD.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DKienzle%26aufirst%3DB.%26aulast%3DBifano%26aufirst%3DM.%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DGenotypic%2520and%2520phenotypic%2520analysis%2520of%2520variants%2520resistant%2520to%2520hepatitis%2520C%2520virus%2520nonstructural%2520protein%25205A%2520replication%2520complex%2520inhibitor%2520BMS-790052%2520in%2520humans%253A%2520in%2520vitro%2520and%2520in%2520vivo%2520correlations%26jtitle%3DHepatology%26date%3D2011%26volume%3D54%26spage%3D1924%26epage%3D1935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit119b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Boyle, D. R.,  2nd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nower, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valera, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span> </span><span class="NLM_article-title">Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2054</span><span class="NLM_x">–</span> <span class="NLM_lpage">2065</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=2054-2065&author=C.+Wangauthor=J.-H.+Sunauthor=D.+R.+O%27Boyleauthor=P.+Nowerauthor=L.+Valeraauthor=S.+Robertsauthor=R.+A.+Fridellauthor=M.+Gao&title=Persistence+of+resistant+variants+in+hepatitis+C+virus-infected+patients+treated+with+the+NS5A+replication+complex+inhibitor+daclatasvir"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DO%2527Boyle%26aufirst%3DD.%2BR.%26aulast%3DNower%26aufirst%3DP.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DPersistence%2520of%2520resistant%2520variants%2520in%2520hepatitis%2520C%2520virus-infected%2520patients%2520treated%2520with%2520the%2520NS5A%2520replication%2520complex%2520inhibitor%2520daclatasvir%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D2054%26epage%3D2065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Powdrill, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchesnokov, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozak, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svarovskaia, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouyos, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Götte, M.</span><span> </span><span class="NLM_article-title">Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">20509</span><span class="NLM_x">–</span> <span class="NLM_lpage">20513</span><span class="refDoi"> DOI: 10.1073/pnas.1105797108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1073%2Fpnas.1105797108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=20509-20513&author=M.+H.+Powdrillauthor=E.+P.+Tchesnokovauthor=R.+A.+Kozakauthor=R.+S.+Russellauthor=R.+Martinauthor=E.+S.+Svarovskaiaauthor=H.+Moauthor=R.+D.+Kouyosauthor=M.+G%C3%B6tte&title=Contribution+of+a+mutational+bias+in+hepatitis+C+virus+replication+to+the+genetic+barrier+in+the+development+of+drug+resistance&doi=10.1073%2Fpnas.1105797108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1105797108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1105797108%26sid%3Dliteratum%253Aachs%26aulast%3DPowdrill%26aufirst%3DM.%2BH.%26aulast%3DTchesnokov%26aufirst%3DE.%2BP.%26aulast%3DKozak%26aufirst%3DR.%2BA.%26aulast%3DRussell%26aufirst%3DR.%2BS.%26aulast%3DMartin%26aufirst%3DR.%26aulast%3DSvarovskaia%26aufirst%3DE.%2BS.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DKouyos%26aufirst%3DR.%2BD.%26aulast%3DG%25C3%25B6tte%26aufirst%3DM.%26atitle%3DContribution%2520of%2520a%2520mutational%2520bias%2520in%2520hepatitis%2520C%2520virus%2520replication%2520to%2520the%2520genetic%2520barrier%2520in%2520the%2520development%2520of%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D20509%26epage%3D20513%26doi%3D10.1073%2Fpnas.1105797108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit120b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wyles, D. L.</span><span> </span><span class="NLM_article-title">Antiviral resistance and the future landscape of hepatitis C virus infection therapy</span> <span class="citation_source-journal">J. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">207</span><span class="NLM_x"> (</span><span class="NLM_issue">S1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S33</span><span class="NLM_x">–</span> <span class="NLM_lpage">S39</span><span class="refDoi"> DOI: 10.1093/infdis/jis761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1093%2Finfdis%2Fjis761" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=2013&pages=S33-S39&issue=S1&author=D.+L.+Wyles&title=Antiviral+resistance+and+the+future+landscape+of+hepatitis+C+virus+infection+therapy&doi=10.1093%2Finfdis%2Fjis761"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120b&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjis761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjis761%26sid%3Dliteratum%253Aachs%26aulast%3DWyles%26aufirst%3DD.%2BL.%26atitle%3DAntiviral%2520resistance%2520and%2520the%2520future%2520landscape%2520of%2520hepatitis%2520C%2520virus%2520infection%2520therapy%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2013%26volume%3D207%26issue%3DS1%26spage%3DS33%26epage%3DS39%26doi%3D10.1093%2Finfdis%2Fjis761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit120c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wyles, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, J. A.</span><span> </span><span class="NLM_article-title">Importance of HCV genotype 1 subtypes for drug resistance and response to therapy</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">240</span><span class="refDoi"> DOI: 10.1111/jvh.12230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fjvh.12230" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=229-240&author=D.+L.+Wylesauthor=J.+A.+Gutierrez&title=Importance+of+HCV+genotype+1+subtypes+for+drug+resistance+and+response+to+therapy&doi=10.1111%2Fjvh.12230"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120c&amp;dbid=16384&amp;doi=10.1111%2Fjvh.12230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.12230%26sid%3Dliteratum%253Aachs%26aulast%3DWyles%26aufirst%3DD.%2BL.%26aulast%3DGutierrez%26aufirst%3DJ.%2BA.%26atitle%3DImportance%2520of%2520HCV%2520genotype%25201%2520subtypes%2520for%2520drug%2520resistance%2520and%2520response%2520to%2520therapy%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2014%26volume%3D21%26spage%3D229%26epage%3D240%26doi%3D10.1111%2Fjvh.12230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirschfield, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghesquiere, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sievert, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafran, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatum, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waked, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esmat, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serfaty, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vierling, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiland, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunetto, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwo, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bräu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noviello, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnittman, S.</span><span> </span><span class="NLM_article-title">Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study</span> <span class="citation_source-journal">Gut</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">948</span><span class="NLM_x">–</span> <span class="NLM_lpage">956</span><span class="refDoi"> DOI: 10.1136/gutjnl-2014-307498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1136%2Fgutjnl-2014-307498" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=948-956&author=C.+H%C3%A9zodeauthor=G.+M.+Hirschfieldauthor=W.+Ghesquiereauthor=W.+Sievertauthor=M.+Rodriguez-Torresauthor=S.+D.+Shafranauthor=P.+J.+Thuluvathauthor=H.+A.+Tatumauthor=I.+Wakedauthor=G.+E.+Esmatauthor=E.+J.+Lawitzauthor=V.+K.+Rustgiauthor=S.+Polauthor=N.+Weisauthor=P.+J.+Pockrosauthor=M.+Bourli%C3%A8reauthor=L.+Serfatyauthor=J.+M.+Vierlingauthor=M.+W.+Friedauthor=O.+Weilandauthor=M.+R.+Brunettoauthor=G.+T.+Eversonauthor=S.+Zeuzemauthor=P.+Y.+Kwoauthor=M.+Sulkowskiauthor=N.+Br%C3%A4uauthor=D.+Hernandezauthor=F.+McPheeauthor=M.+Wind-Rotoloauthor=Z.+Liuauthor=S.+Novielloauthor=E.+A.+Hughesauthor=P.+D.+Yinauthor=S.+Schnittman&title=Daclatasvir+plus+peginterferon+alfa+and+ribavirin+for+treatment-naive+chronic+hepatitis+C+genotype+1+or+4+infection%3A+a+randomised+study&doi=10.1136%2Fgutjnl-2014-307498"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121a&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2014-307498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2014-307498%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DHirschfield%26aufirst%3DG.%2BM.%26aulast%3DGhesquiere%26aufirst%3DW.%26aulast%3DSievert%26aufirst%3DW.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DShafran%26aufirst%3DS.%2BD.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DTatum%26aufirst%3DH.%2BA.%26aulast%3DWaked%26aufirst%3DI.%26aulast%3DEsmat%26aufirst%3DG.%2BE.%26aulast%3DLawitz%26aufirst%3DE.%2BJ.%26aulast%3DRustgi%26aufirst%3DV.%2BK.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DWeis%26aufirst%3DN.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DSerfaty%26aufirst%3DL.%26aulast%3DVierling%26aufirst%3DJ.%2BM.%26aulast%3DFried%26aufirst%3DM.%2BW.%26aulast%3DWeiland%26aufirst%3DO.%26aulast%3DBrunetto%26aufirst%3DM.%2BR.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DKwo%26aufirst%3DP.%2BY.%26aulast%3DSulkowski%26aufirst%3DM.%26aulast%3DBr%25C3%25A4u%26aufirst%3DN.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DNoviello%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DYin%26aufirst%3DP.%2BD.%26aulast%3DSchnittman%26aufirst%3DS.%26atitle%3DDaclatasvir%2520plus%2520peginterferon%2520alfa%2520and%2520ribavirin%2520for%2520treatment-naive%2520chronic%2520hepatitis%2520C%2520genotype%25201%2520or%25204%2520infection%253A%2520a%2520randomised%2520study%26jtitle%3DGut%26date%3D2015%26volume%3D64%26spage%3D948%26epage%3D956%26doi%3D10.1136%2Fgutjnl-2014-307498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit121b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dore, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafran, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramji, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tatum, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taliani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunetto, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaltron, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strasser, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghesquiere, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harley, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fung, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Lédinghen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooney, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noviello, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span> </span><span class="NLM_article-title">Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">148</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">366</span><span class="refDoi"> DOI: 10.1053/j.gastro.2014.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1053%2Fj.gastro.2014.10.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2015&pages=355-366&author=G.+J.+Doreauthor=E.+Lawitzauthor=C.+H%C3%A9zodeauthor=S.+D.+Shafranauthor=A.+Ramjiauthor=H.+A.+Tatumauthor=G.+Talianiauthor=A.+Tranauthor=M.+R.+Brunettoauthor=S.+Zaltronauthor=S.+I.+Strasserauthor=N.+Weisauthor=W.+Ghesquiereauthor=S.+S.+Leeauthor=D.+Larreyauthor=S.+Polauthor=H.+Harleyauthor=J.+Georgeauthor=S.+K.+Fungauthor=V.+de+L%C3%A9dinghenauthor=P.+Hagensauthor=F.+McPheeauthor=D.+Hernandezauthor=D.+Cohenauthor=E.+Cooneyauthor=S.+Novielloauthor=E.+Hughes&title=Daclatasvir+plus+peginterferon+and+ribavirin+is+noninferior+to+peginterferon+and+ribavirin+alone%2C+and+reduces+the+duration+of+treatment+for+HCV+genotype+2+or+3+infection&doi=10.1053%2Fj.gastro.2014.10.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121b&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2014.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2014.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DDore%26aufirst%3DG.%2BJ.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DShafran%26aufirst%3DS.%2BD.%26aulast%3DRamji%26aufirst%3DA.%26aulast%3DTatum%26aufirst%3DH.%2BA.%26aulast%3DTaliani%26aufirst%3DG.%26aulast%3DTran%26aufirst%3DA.%26aulast%3DBrunetto%26aufirst%3DM.%2BR.%26aulast%3DZaltron%26aufirst%3DS.%26aulast%3DStrasser%26aufirst%3DS.%2BI.%26aulast%3DWeis%26aufirst%3DN.%26aulast%3DGhesquiere%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DS.%2BS.%26aulast%3DLarrey%26aufirst%3DD.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DHarley%26aufirst%3DH.%26aulast%3DGeorge%26aufirst%3DJ.%26aulast%3DFung%26aufirst%3DS.%2BK.%26aulast%3Dde%2BL%25C3%25A9dinghen%26aufirst%3DV.%26aulast%3DHagens%26aufirst%3DP.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DCohen%26aufirst%3DD.%26aulast%3DCooney%26aufirst%3DE.%26aulast%3DNoviello%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DE.%26atitle%3DDaclatasvir%2520plus%2520peginterferon%2520and%2520ribavirin%2520is%2520noninferior%2520to%2520peginterferon%2520and%2520ribavirin%2520alone%252C%2520and%2520reduces%2520the%2520duration%2520of%2520treatment%2520for%2520HCV%2520genotype%25202%2520or%25203%2520infection%26jtitle%3DGastroenterology%26date%3D2015%26volume%3D148%26spage%3D355%26epage%3D366%26doi%3D10.1053%2Fj.gastro.2014.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Bronowicki, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratziu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bessone, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martorell, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span> </span><span class="NLM_article-title">Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1220</span><span class="NLM_x">–</span> <span class="NLM_lpage">1227</span><span class="refDoi"> DOI: 10.1016/j.jhep.2014.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2014.07.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=1220-1227&author=J.+P.+Bronowickiauthor=V.+Ratziuauthor=A.+Gadanoauthor=P.+J.+Thuluvathauthor=F.+Bessoneauthor=C.+T.+Martorellauthor=S.+Polauthor=R.+Tergauthor=Z.+Younesauthor=B.+Heauthor=T.+Eleyauthor=D.+Cohenauthor=F.+Yuauthor=D.+Hernandezauthor=F.+McPheeauthor=P.+Mendezauthor=E.+Hughes&title=Randomized+trial+of+asunaprevir+plus+peginterferon+alfa+and+ribavirin+for+previously+untreated+genotype+1+or+4+chronic+hepatitis+C&doi=10.1016%2Fj.jhep.2014.07.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DBronowicki%26aufirst%3DJ.%2BP.%26aulast%3DRatziu%26aufirst%3DV.%26aulast%3DGadano%26aufirst%3DA.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DBessone%26aufirst%3DF.%26aulast%3DMartorell%26aufirst%3DC.%2BT.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DTerg%26aufirst%3DR.%26aulast%3DYounes%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DCohen%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DMendez%26aufirst%3DP.%26aulast%3DHughes%26aufirst%3DE.%26atitle%3DRandomized%2520trial%2520of%2520asunaprevir%2520plus%2520peginterferon%2520alfa%2520and%2520ribavirin%2520for%2520previously%2520untreated%2520genotype%25201%2520or%25204%2520chronic%2520hepatitis%2520C%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D61%26spage%3D1220%26epage%3D1227%26doi%3D10.1016%2Fj.jhep.2014.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lok, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martorell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reindollar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrova, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span> </span><span class="NLM_article-title">Preliminary study of two antiviral agents for hepatitis C genotype 1</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">216</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span><span class="refDoi"> DOI: 10.1056/NEJMoa1104430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1104430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=22256805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=216-224&author=A.+S.+Lokauthor=D.+F.+Gardinerauthor=E.+Lawitzauthor=C.+Martorellauthor=G.+T.+Eversonauthor=R.+Ghalibauthor=R.+Reindollarauthor=V.+Rustgiauthor=F.+McPheeauthor=M.+Wind-Rotoloauthor=A.+Perssonauthor=K.+Zhuauthor=D.+I.+Dimitrovaauthor=T.+Eleyauthor=T.+Guoauthor=D.+M.+Graselaauthor=C.+Pasquinelli&title=Preliminary+study+of+two+antiviral+agents+for+hepatitis+C+genotype+1&doi=10.1056%2FNEJMoa1104430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123aR"><div class="casContent"><span class="casTitleNuber">123a</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary study of two antiviral agents for hepatitis C genotype 1</span></div><div class="casAuthors">Lok, Anna S.; Gardiner, David F.; Lawitz, Eric; Martorell, Claudia; Everson, Gregory T.; Ghalib, Reem; Reindollar, Robert; Rustgi, Vinod; McPhee, Fiona; Wind-Rotolo, Megan; Persson, Anna; Zhu, Kurt; Dimitrova, Dessislava I.; Eley, Timothy; Guo, Tong; Grasela, Dennis M.; Pasquinelli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">216-224</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addn. of multiple direct-acting antiviral agents to their treatment regimen.  METHODS: This open-label, phase 2a study included an exploratory cohort of 21 patients with chronic HCV genotype 1 infection who had not had a response to previous therapy (i.e., had not had ≥2 log10 decline in HCV RNA after ≥12 wk of treatment with peginterferon and ribavirin).  We randomly assigned patients to receive the NS5A replication complex inhibitor daclatasvir (60 mg once daily) and the NS3 protease inhibitor asunaprevir (600 mg twice daily) alone (group A, 11 patients) or in combination with peginterferon alfa-2a and ribavirin (group B, 10 patients) for 24 wk.  The primary end point was the percentage of patients with a sustained virol. response 12 wk after the end of the treatment period.  RESULTS: A total of 4 patients in group A (36%; 2 of 9 with HCV genotype la and 2 of 2 with genotype lb) had a sustained virol. response at 12 wk after treatment and also at 24 wk after treatment.  Six patients (all with HCV genotype la) had viral breakthrough while receiving therapy, and resistance mutations to both antiviral agents were found in all cases; 1 patient had a viral response at the end of treatment but had a relapse after the treatment period.  All 10 patients in group B had a sustained virol. response at 12 wk after treatment, and 9 had a sustained virol. response at 24 wk after treatment Diarrhea was the most common adverse event in both groups.  Six patients had transient elevations of alanine aminotransferase levels to more than 3 times the upper limit of the normal range.  CONCLUSIONS: This preliminary study involving patients with HCV genotype 1 infection who had not had a response to prior therapy showed that a sustained virol. response can be achieved with two direct-acting antiviral agents only.  In addn., a high rate of sustained virol. response was achieved when the two direct-acting antiviral agents were combined with peginterferon alfa-2a and ribavirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiY7QiDziiRbVg90H21EOLACvtfcHk0lg9Qdwi_nTDZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yltrw%253D&md5=5b986bac6ea53144898c91e8e2eaf5bc</span></div><a href="/servlet/linkout?suffix=cit123a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1104430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1104430%26sid%3Dliteratum%253Aachs%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DMartorell%26aufirst%3DC.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DReindollar%26aufirst%3DR.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DDimitrova%26aufirst%3DD.%2BI.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DPasquinelli%26aufirst%3DC.%26atitle%3DPreliminary%2520study%2520of%2520two%2520antiviral%2520agents%2520for%2520hepatitis%2520C%2520genotype%25201%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D216%26epage%3D224%26doi%3D10.1056%2FNEJMoa1104430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit123b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lok, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serfaty, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span> </span><span class="NLM_article-title">Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">490</span><span class="NLM_x">–</span> <span class="NLM_lpage">499</span><span class="refDoi"> DOI: 10.1016/j.jhep.2013.10.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2013.10.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24444658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=490-499&author=A.+S.+Lokauthor=D.+F.+Gardinerauthor=C.+H%C3%A9zodeauthor=E.+J.+Lawitzauthor=M.+Bourli%C3%A8reauthor=G.+T.+Eversonauthor=P.+Marcellinauthor=M.+Rodriguez-Torresauthor=S.+Polauthor=L.+Serfatyauthor=T.+Eleyauthor=S.-P.+Huangauthor=J.+Liauthor=M.+Wind-Rotoloauthor=F.+Yuauthor=F.+McPheeauthor=D.+M.+Graselaauthor=C.+Pasquinelli&title=Randomized+trial+of+daclatasvir+and+asunaprevir+with+or+without+PegIFN%2FRBV+for+hepatitis+C+virus+genotype+1+null+responders&doi=10.1016%2Fj.jhep.2013.10.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123bR"><div class="casContent"><span class="casTitleNuber">123b</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders</span></div><div class="casAuthors">Lok, Anna S.; Gardiner, David F.; Hezode, Christophe; Lawitz, Eric J.; Bourliere, Marc; Everson, Gregory T.; Marcellin, Patrick; Rodriguez-Torres, Maribel; Pol, Stanislas; Serfaty, Lawrence; Eley, Timothy; Huang, Shu-Pang; Li, Jianling; Wind-Rotolo, Megan; Yu, Fei; McPhee, Fiona; Grasela, Dennis M.; Pasquinelli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">490-499</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Patients with chronic hepatitis C virus (HCV) infection and prior null response (<2 log HCV RNA decline after ≥12 wk of PegIFN/RBV) have limited options.  We evaluated daclatasvir plus once- or twice-daily asunaprevir in non-cirrhotic genotype 1 null responders.  In this randomized, phase 2a, open-label, 24-wk treatment study, 101 patients received daclatasvir (60 mg) once-daily.  In addn., 38 genotype 1b patients received asunaprevir (200 mg) twice- (DUAL A1) or once-daily (DUAL A2); 36 genotype 1a and 5 genotype 1b patients received asunaprevir twice- (QUAD B1) or once-daily (QUAD B2) plus PegIFN/RBV; and 18 genotype 1a and 4 genotype 1b patients received asunaprevir twice-daily plus ribavirin (TRIPLE B3).  The primary endpoint was undetectable HCV RNA 12 wk post-treatment (sustained virol. response, SVR12).  Across all groups, mean HCV RNA was ≥6 log IU/mL, and 99% of patients had a non-CC IL28B genotype.  SVR12 rates were 78% (A1), 65% (A2), 95% (B1), and 95% (B2).  In B3, most genotype 1a patients experienced virol. breakthrough.  The most common adverse events were headache, diarrhea, and asthenia.  Grade 3-4 aminotransferase elevations were infrequent and not treatment-limiting.  In genotype 1 null responders, daclatasvir plus twice-daily asunaprevir DUAL therapy is effective for most genotype 1b patients, and daclatasvir, asunaprevir, and PegIFN/RBV QUAD therapy is effective for nearly all genotype 1a and 1b patients; but neither DUAL nor TRIPLE therapy is effective for genotype 1a patients.  Interferon-free regimens including daclatasvir and twice-daily asunaprevir for genotype 1 null responders should be tailored to subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmaQLpKkbNoLVg90H21EOLACvtfcHk0li-KYpV1ojC8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlartw%253D%253D&md5=d216b31a62adc838c4f2215fcfff4838</span></div><a href="/servlet/linkout?suffix=cit123b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2013.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2013.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DLawitz%26aufirst%3DE.%2BJ.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DSerfaty%26aufirst%3DL.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DPasquinelli%26aufirst%3DC.%26atitle%3DRandomized%2520trial%2520of%2520daclatasvir%2520and%2520asunaprevir%2520with%2520or%2520without%2520PegIFN%252FRBV%2520for%2520hepatitis%2520C%2520virus%2520genotype%25201%2520null%2520responders%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D60%26spage%3D490%26epage%3D499%26doi%3D10.1016%2Fj.jhep.2013.10.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Gane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stedman, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angus, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritchie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ipe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcos, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Najera, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopatin, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berrey, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laughlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shulman, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. F.</span><span> </span><span class="NLM_article-title">Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">376</span><span class="NLM_x">, </span> <span class="NLM_fpage">1467</span><span class="NLM_x">–</span> <span class="NLM_lpage">1475</span><span class="refDoi"> DOI: 10.1016/S0140-6736(10)61384-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0140-6736%2810%2961384-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2010&pages=1467-1475&author=E.+J.+Ganeauthor=S.+K.+Robertsauthor=C.+A.+Stedmanauthor=P.+W.+Angusauthor=B.+Ritchieauthor=R.+Elstonauthor=D.+Ipeauthor=P.+N.+Morcosauthor=L.+Baherauthor=I.+Najeraauthor=T.+Chuauthor=U.+Lopatinauthor=M.+M.+Berreyauthor=W.+Bradfordauthor=M.+Laughlinauthor=N.+S.+Shulmanauthor=P.+F.+Smith&title=Oral+combination+therapy+with+a+nucleoside+polymerase+inhibitor+%28RG7128%29+and+danoprevir+for+chronic+hepatitis+C+genotype+1+infection+%28INFORM-1%29%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+dose-escalation+trial&doi=10.1016%2FS0140-6736%2810%2961384-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2810%2961384-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252810%252961384-0%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DRoberts%26aufirst%3DS.%2BK.%26aulast%3DStedman%26aufirst%3DC.%2BA.%26aulast%3DAngus%26aufirst%3DP.%2BW.%26aulast%3DRitchie%26aufirst%3DB.%26aulast%3DElston%26aufirst%3DR.%26aulast%3DIpe%26aufirst%3DD.%26aulast%3DMorcos%26aufirst%3DP.%2BN.%26aulast%3DBaher%26aufirst%3DL.%26aulast%3DNajera%26aufirst%3DI.%26aulast%3DChu%26aufirst%3DT.%26aulast%3DLopatin%26aufirst%3DU.%26aulast%3DBerrey%26aufirst%3DM.%2BM.%26aulast%3DBradford%26aufirst%3DW.%26aulast%3DLaughlin%26aufirst%3DM.%26aulast%3DShulman%26aufirst%3DN.%2BS.%26aulast%3DSmith%26aufirst%3DP.%2BF.%26atitle%3DOral%2520combination%2520therapy%2520with%2520a%2520nucleoside%2520polymerase%2520inhibitor%2520%2528RG7128%2529%2520and%2520danoprevir%2520for%2520chronic%2520hepatitis%2520C%2520genotype%25201%2520infection%2520%2528INFORM-1%2529%253A%2520a%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%252C%2520dose-escalation%2520trial%26jtitle%3DLancet%26date%3D2010%26volume%3D376%26spage%3D1467%26epage%3D1475%26doi%3D10.1016%2FS0140-6736%2810%2961384-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lange, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span> </span><span class="NLM_article-title">IL28B single nucleotide polymorphisms in the treatment of hepatitis C</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">692</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span><span class="refDoi"> DOI: 10.1016/j.jhep.2011.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2011.03.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=692-701&author=C.+M.+Langeauthor=S.+Zeuzem&title=IL28B+single+nucleotide+polymorphisms+in+the+treatment+of+hepatitis+C&doi=10.1016%2Fj.jhep.2011.03.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125a&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2011.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2011.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DC.%2BM.%26aulast%3DZeuzem%26aufirst%3DS.%26atitle%3DIL28B%2520single%2520nucleotide%2520polymorphisms%2520in%2520the%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DJ.%2520Hepatol.%26date%3D2011%26volume%3D55%26spage%3D692%26epage%3D701%26doi%3D10.1016%2Fj.jhep.2011.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit125b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hayes, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aikata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span> </span><span class="NLM_article-title">Genetics of IL28B and HCV - response to infection and treatment</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">406</span><span class="NLM_x">–</span> <span class="NLM_lpage">417</span><span class="refDoi"> DOI: 10.1038/nrgastro.2012.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrgastro.2012.101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=406-417&author=C.+N.+Hayesauthor=M.+Imamuraauthor=H.+Aikataauthor=K.+Chayama&title=Genetics+of+IL28B+and+HCV+-+response+to+infection+and+treatment&doi=10.1038%2Fnrgastro.2012.101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125b&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2012.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2012.101%26sid%3Dliteratum%253Aachs%26aulast%3DHayes%26aufirst%3DC.%2BN.%26aulast%3DImamura%26aufirst%3DM.%26aulast%3DAikata%26aufirst%3DH.%26aulast%3DChayama%26aufirst%3DK.%26atitle%3DGenetics%2520of%2520IL28B%2520and%2520HCV%2520-%2520response%2520to%2520infection%2520and%2520treatment%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2012%26volume%3D9%26spage%3D406%26epage%3D417%26doi%3D10.1038%2Fnrgastro.2012.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit125c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cariani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Missale, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trenti, T.</span><span> </span><span class="NLM_article-title">Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis</span> <span class="citation_source-journal">Pharmacogenomics J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">18</span><span class="NLM_x">–</span> <span class="NLM_lpage">29</span><span class="refDoi"> DOI: 10.1038/tpj.2015.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Ftpj.2015.28" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=18-29&author=E.+Carianiauthor=L.+Roliauthor=G.+Missaleauthor=E.+Villaauthor=C.+Ferrariauthor=T.+Trenti&title=Interleukin+28B+polymorphisms+as+predictors+of+sustained+virological+response+in+chronic+hepatitis+C%3A+systematic+review+and+meta-analysis&doi=10.1038%2Ftpj.2015.28"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125c&amp;dbid=16384&amp;doi=10.1038%2Ftpj.2015.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ftpj.2015.28%26sid%3Dliteratum%253Aachs%26aulast%3DCariani%26aufirst%3DE.%26aulast%3DRoli%26aufirst%3DL.%26aulast%3DMissale%26aufirst%3DG.%26aulast%3DVilla%26aufirst%3DE.%26aulast%3DFerrari%26aufirst%3DC.%26aulast%3DTrenti%26aufirst%3DT.%26atitle%3DInterleukin%252028B%2520polymorphisms%2520as%2520predictors%2520of%2520sustained%2520virological%2520response%2520in%2520chronic%2520hepatitis%2520C%253A%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DPharmacogenomics%2520J.%26date%3D2016%26volume%3D16%26spage%3D18%26epage%3D29%26doi%3D10.1038%2Ftpj.2015.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Neumann, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gretch, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiley, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Layden, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1126/science.282.5386.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1126%2Fscience.282.5386.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=9756471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADyaK1cXmsFOjsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=1998&pages=103-107&author=A.+U.+Neumannauthor=N.+P.+Lamauthor=H.+Dahariauthor=D.+R.+Gretchauthor=T.+E.+Wileyauthor=T.+J.+Laydenauthor=A.+S.+Perelson&title=Hepatitis+C+viral+dynamics+in+vivo+and+the+antiviral+efficacy+of+interferon-%CE%B1+therapy&doi=10.1126%2Fscience.282.5386.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126aR"><div class="casContent"><span class="casTitleNuber">126a</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy</span></div><div class="casAuthors">Neumann, Avidan U.; Lam, Nancy P.; Dahari, Harel; Gretch, David R.; Wiley, Thelma E.; Layden, Thomas J.; Perelson, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">5386</span>),
    <span class="NLM_cas:pages">103-107</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">To better understand the dynamics of hepatitis C virus and the antiviral effect of interferon-α-2b (IFN), viral decline in 23 patients during therapy was analyzed with a math. model.  The anal. indicates that the major initial effect of IFN is to block virion prodn. or release, with blocking efficacies of 81, 95, and 96% for daily doses of 5, 10, and 15 million IU, resp.  The estd. virion half-life (t1/2) was, on av., 2.7 h, with pretreatment prodn. and clearance of 1012 virions per day.  The estd. infected cell death rate exhibited large inter-patient variation (corresponding t1/2=1.7 to 70 days), was inversely correlated with baseline viral load, and was pos. correlated with alanine aminotransferase levels.  Fast death rates were predictive of virus being undetectable by polymerase chain reaction at 3 mo.  These findings show that infection with hepatitis C virus is highly dynamic and that early monitoring of viral load can help guide therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQOathmcXps7Vg90H21EOLACvtfcHk0lhBpD1IO2mWZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsFOjsLc%253D&md5=d349eda98ccf4883a81211b02ed553e8</span></div><a href="/servlet/linkout?suffix=cit126a&amp;dbid=16384&amp;doi=10.1126%2Fscience.282.5386.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.282.5386.103%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DA.%2BU.%26aulast%3DLam%26aufirst%3DN.%2BP.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DGretch%26aufirst%3DD.%2BR.%26aulast%3DWiley%26aufirst%3DT.%2BE.%26aulast%3DLayden%26aufirst%3DT.%2BJ.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DHepatitis%2520C%2520viral%2520dynamics%2520in%2520vivo%2520and%2520the%2520antiviral%2520efficacy%2520of%2520interferon-%25CE%25B1%2520therapy%26jtitle%3DScience%26date%3D1998%26volume%3D282%26spage%3D103%26epage%3D107%26doi%3D10.1126%2Fscience.282.5386.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit126b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Perelson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micol, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span> </span><span class="NLM_article-title">New kinetic models for the hepatitis C virus</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">749</span><span class="NLM_x">–</span> <span class="NLM_lpage">754</span><span class="refDoi"> DOI: 10.1002/hep.20882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.20882" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2005&pages=749-754&author=A.+S.+Perelsonauthor=E.+Herrmannauthor=F.+Micolauthor=S.+Zeuzem&title=New+kinetic+models+for+the+hepatitis+C+virus&doi=10.1002%2Fhep.20882"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126b&amp;dbid=16384&amp;doi=10.1002%2Fhep.20882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.20882%26sid%3Dliteratum%253Aachs%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26aulast%3DHerrmann%26aufirst%3DE.%26aulast%3DMicol%26aufirst%3DF.%26aulast%3DZeuzem%26aufirst%3DS.%26atitle%3DNew%2520kinetic%2520models%2520for%2520the%2520hepatitis%2520C%2520virus%26jtitle%3DHepatology%26date%3D2005%26volume%3D42%26spage%3D749%26epage%3D754%26doi%3D10.1002%2Fhep.20882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit126c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Rapid emergence of protease inhibitor resistance in hepatitis C virus</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">30ra32</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3000544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1126%2Fscitranslmed.3000544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=20445200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC3czhsVCksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=30ra32&author=L.+Rongauthor=H.+Dahariauthor=R.+M.+Ribeiroauthor=A.+S.+Perelson&title=Rapid+emergence+of+protease+inhibitor+resistance+in+hepatitis+C+virus&doi=10.1126%2Fscitranslmed.3000544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126cR"><div class="casContent"><span class="casTitleNuber">126c</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid emergence of protease inhibitor resistance in hepatitis C virus</span></div><div class="casAuthors">Rong Libin; Dahari Harel; Ribeiro Ruy M; Perelson Alan S</div><div class="citationInfo"><span class="NLM_cas:title">Science translational medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">30ra32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">About 170 million people worldwide are infected with hepatitis C virus (HCV).  The current standard therapy leads to sustained viral elimination in only approximately 50% of the treated patients.  Telaprevir, an HCV protease inhibitor, has substantial antiviral activity in patients with chronic HCV infection.  However, in clinical trials, drug-resistant variants emerge at frequencies of 5 to 20% of the total virus population as early as the second day after the beginning of treatment.  Here, using probabilistic and viral dynamic models, we show that such rapid emergence of drug resistance is expected.  We calculate that all possible single- and double-mutant viruses preexist before treatment and that one additional mutation is expected to arise during therapy.  Examining data from a clinical trial of telaprevir therapy for HCV infection in detail, we show that our model fits the observed dynamics of both drug-sensitive and drug-resistant viruses and argue that therapy with only direct antivirals will require drug combinations that have a genetic barrier of four or more mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSA6aX3zCRlexsqfvU0ziafW6udTcc2eYII10NpJKEzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czhsVCksw%253D%253D&md5=6ca2fe0702a2cc59599e7658c278895f</span></div><a href="/servlet/linkout?suffix=cit126c&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3000544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3000544%26sid%3Dliteratum%253Aachs%26aulast%3DRong%26aufirst%3DL.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DRibeiro%26aufirst%3DR.%2BM.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DRapid%2520emergence%2520of%2520protease%2520inhibitor%2520resistance%2520in%2520hepatitis%2520C%2520virus%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2010%26volume%3D2%26spage%3D30ra32%26doi%3D10.1126%2Fscitranslmed.3000544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit126d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Guedj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1030</span><span class="NLM_x">–</span> <span class="NLM_lpage">1037</span><span class="refDoi"> DOI: 10.1002/hep.24788</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.24788" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1030-1037&author=J.+Guedjauthor=H.+Dahariauthor=E.+Shudoauthor=P.+Smithauthor=A.+S.+Perelson&title=Hepatitis+C+viral+kinetics+with+the+nucleoside+polymerase+inhibitor+mericitabine+%28RG7128%29&doi=10.1002%2Fhep.24788"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126d&amp;dbid=16384&amp;doi=10.1002%2Fhep.24788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24788%26sid%3Dliteratum%253Aachs%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DShudo%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DHepatitis%2520C%2520viral%2520kinetics%2520with%2520the%2520nucleoside%2520polymerase%2520inhibitor%2520mericitabine%2520%2528RG7128%2529%26jtitle%3DHepatology%26date%3D2012%26volume%3D55%26spage%3D1030%26epage%3D1037%26doi%3D10.1002%2Fhep.24788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit126e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Rong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahari, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffield, D. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model</span> <span class="citation_source-journal">PLoS Comput. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">e1002959</span><span class="refDoi"> DOI: 10.1371/journal.pcbi.1002959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1371%2Fjournal.pcbi.1002959" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=e1002959&issue=3&author=L.+Rongauthor=J.+Guedjauthor=H.+Dahariauthor=D.+J.+Coffieldauthor=M.+Leviauthor=P.+Smithauthor=A.+S.+Perelson&title=Analysis+of+hepatitis+C+virus+decline+during+treatment+with+the+protease+inhibitor+danoprevir+using+a+multiscale+model&doi=10.1371%2Fjournal.pcbi.1002959"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126e&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1002959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1002959%26sid%3Dliteratum%253Aachs%26aulast%3DRong%26aufirst%3DL.%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DCoffield%26aufirst%3DD.%2BJ.%26aulast%3DLevi%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DAnalysis%2520of%2520hepatitis%2520C%2520virus%2520decline%2520during%2520treatment%2520with%2520the%2520protease%2520inhibitor%2520danoprevir%2520using%2520a%2520multiscale%2520model%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2013%26volume%3D9%26issue%3D3%26spage%3De1002959%26doi%3D10.1371%2Fjournal.pcbi.1002959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit126f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Shudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Modeling HCV kinetics under therapy using PK and PD information</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">332</span><span class="refDoi"> DOI: 10.1517/17425250902787616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1517%2F17425250902787616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=19331594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkt1SmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=321-332&author=E.+Shudoauthor=R.+M.+Ribeiroauthor=A.+S.+Perelson&title=Modeling+HCV+kinetics+under+therapy+using+PK+and+PD+information&doi=10.1517%2F17425250902787616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126fR"><div class="casContent"><span class="casTitleNuber">126f</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling HCV kinetics under therapy using PK and PD information</span></div><div class="casAuthors">Shudo, Emi; Ribeiro, Ruy M.; Perelson, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">321-332</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Math. models have proven helpful in analyzing the virol. response to antiviral therapy in hepatitis C virus (HCV) infected subjects.  Objective: To summarize the uses and limitations of different models for analyzing HCV kinetic data under pegylated IFN therapy.  Methods: We formulate math. models and fit them by nonlinear least square regression to patient data to est. model parameters.  We compare the goodness of fit and parameter values estd. by different models statistically.  Results/conclusion: The best model for parameter estn. depends on the availability and the quality of data as well as the therapy used.  We also discuss the math. models that will be needed to analyze HCV kinetic data from clin. trials with new antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7kS3YsFzpdrVg90H21EOLACvtfcHk0lhDmKSFaYl47A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkt1SmtL8%253D&md5=eb7d5f818c186ce3e2f80bf6e29a5b4a</span></div><a href="/servlet/linkout?suffix=cit126f&amp;dbid=16384&amp;doi=10.1517%2F17425250902787616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250902787616%26sid%3Dliteratum%253Aachs%26aulast%3DShudo%26aufirst%3DE.%26aulast%3DRibeiro%26aufirst%3DR.%2BM.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DModeling%2520HCV%2520kinetics%2520under%2520therapy%2520using%2520PK%2520and%2520PD%2520information%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26spage%3D321%26epage%3D332%26doi%3D10.1517%2F17425250902787616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit126g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Rong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling</span> <span class="citation_source-journal">Crit. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1615/CritRevImmunol.v30.i2.30</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1615%2FCritRevImmunol.v30.i2.30" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=20370626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntValsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=131-148&author=L.+Rongauthor=A.+S.+Perelson&title=Treatment+of+hepatitis+C+virus+infection+with+interferon+and+small+molecule+direct+antivirals%3A+viral+kinetics+and+modeling&doi=10.1615%2FCritRevImmunol.v30.i2.30"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126gR"><div class="casContent"><span class="casTitleNuber">126g</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling</span></div><div class="casAuthors">Rong, Libin; Perelson, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Reviews in Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-148</span>CODEN:
                <span class="NLM_cas:coden">CCRIDE</span>;
        ISSN:<span class="NLM_cas:issn">1040-8401</span>.
    
            (<span class="NLM_cas:orgname">Begell House, Inc.</span>)
        </div><div class="casAbstract">A review.  Hepatitis C virus (HCV) infection remains a threat to global public health.  Treatment with pegylated interferon (IFN) plus ribavirin leads to a sustained virol. response in about 50% of patients.  New therapies using direct antiviral agents have the potential to cure patients unresponsive to IFN-based therapies.  Math. modeling has played an important role in studying HCV kinetics.  Using models, one can evaluate the effectiveness of new treatment agents, est. important parameters that govern virus-host interactions, explore possible mechanisms of drug action against HCV, investigate the development of drug resistance, and study quasispecies dynamics during therapy.  Here we review our current knowledge of HCV kinetics under IFN-based therapy and newly developed antiviral agents specifically targeted to attack HCV, and show how math. models have helped to improve our understanding of HCV infection and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRdLbw3w12frVg90H21EOLACvtfcHk0lhDmKSFaYl47A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntValsr4%253D&md5=ee1f9e95d0f1670f51739b4fa377e840</span></div><a href="/servlet/linkout?suffix=cit126g&amp;dbid=16384&amp;doi=10.1615%2FCritRevImmunol.v30.i2.30&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1615%252FCritRevImmunol.v30.i2.30%26sid%3Dliteratum%253Aachs%26aulast%3DRong%26aufirst%3DL.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DTreatment%2520of%2520hepatitis%2520C%2520virus%2520infection%2520with%2520interferon%2520and%2520small%2520molecule%2520direct%2520antivirals%253A%2520viral%2520kinetics%2520and%2520modeling%26jtitle%3DCrit.%2520Rev.%2520Immunol.%26date%3D2010%26volume%3D30%26spage%3D131%26epage%3D148%26doi%3D10.1615%2FCritRevImmunol.v30.i2.30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit126h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Ribeiro, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoddard, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Learn, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korber, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrish, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">e1002881</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1002881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1371%2Fjournal.ppat.1002881" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=e1002881&issue=8&author=R.+M.+Ribeiroauthor=H.+Liauthor=S.+Wangauthor=M.+B.+Stoddardauthor=G.+H.+Learnauthor=B.+T.+Korberauthor=T.+Bhattacharyaauthor=J.+Guedjauthor=E.+H.+Parrishauthor=B.+H.+Hahnauthor=G.+M.+Shawauthor=A.+S.+Perelson&title=Quantifying+the+diversification+of+hepatitis+C+virus+%28HCV%29+during+primary+infection%3A+estimates+of+the+in+vivo+mutation+rate&doi=10.1371%2Fjournal.ppat.1002881"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126h&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1002881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1002881%26sid%3Dliteratum%253Aachs%26aulast%3DRibeiro%26aufirst%3DR.%2BM.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DStoddard%26aufirst%3DM.%2BB.%26aulast%3DLearn%26aufirst%3DG.%2BH.%26aulast%3DKorber%26aufirst%3DB.%2BT.%26aulast%3DBhattacharya%26aufirst%3DT.%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DParrish%26aufirst%3DE.%2BH.%26aulast%3DHahn%26aufirst%3DB.%2BH.%26aulast%3DShaw%26aufirst%3DG.%2BM.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DQuantifying%2520the%2520diversification%2520of%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%2520during%2520primary%2520infection%253A%2520estimates%2520of%2520the%2520in%2520vivo%2520mutation%2520rate%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26issue%3D8%26spage%3De1002881%26doi%3D10.1371%2Fjournal.ppat.1002881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit126i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Chatterjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perelson, A. S.</span><span> </span><span class="NLM_article-title">Mathematical modeling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1171</span><span class="NLM_x">–</span> <span class="NLM_lpage">1182</span><span class="refDoi"> DOI: 10.3851/IMP2428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.3851%2FIMP2428" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1171-1182&author=A.+Chatterjeeauthor=J.+Guedjauthor=A.+S.+Perelson&title=Mathematical+modeling+of+HCV+infection%3A+what+can+it+teach+us+in+the+era+of+direct-acting+antiviral+agents%3F&doi=10.3851%2FIMP2428"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126i&amp;dbid=16384&amp;doi=10.3851%2FIMP2428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2428%26sid%3Dliteratum%253Aachs%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DMathematical%2520modeling%2520of%2520HCV%2520infection%253A%2520what%2520can%2520it%2520teach%2520us%2520in%2520the%2520era%2520of%2520direct-acting%2520antiviral%2520agents%253F%26jtitle%3DAntiviral%2520Ther.%26date%3D2012%26volume%3D17%26spage%3D1171%26epage%3D1182%26doi%3D10.3851%2FIMP2428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit126j"><span><span class="NLM_label">(j) </span><span class="NLM_contrib-group">Perelson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guedj, J.</span><span> </span><span class="NLM_article-title">Modelling hepatitis C therapy--predicting effects of treatment</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">445</span><span class="refDoi"> DOI: 10.1038/nrgastro.2015.97</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrgastro.2015.97" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=437-445&author=A.+S.+Perelsonauthor=J.+Guedj&title=Modelling+hepatitis+C+therapy%2D%2Dpredicting+effects+of+treatment&doi=10.1038%2Fnrgastro.2015.97"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126j&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2015.97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2015.97%26sid%3Dliteratum%253Aachs%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26aulast%3DGuedj%26aufirst%3DJ.%26atitle%3DModelling%2520hepatitis%2520C%2520therapy--predicting%2520effects%2520of%2520treatment%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2015%26volume%3D12%26spage%3D437%26epage%3D445%26doi%3D10.1038%2Fnrgastro.2015.97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Chung, R. T.</span><span> </span><span class="NLM_article-title">A watershed moment in the treatment of hepatitis C</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span><span class="refDoi"> DOI: 10.1056/NEJMe1113272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMe1113272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=22256811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Gns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=273-275&author=R.+T.+Chung&title=A+watershed+moment+in+the+treatment+of+hepatitis+C&doi=10.1056%2FNEJMe1113272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">A watershed moment in the treatment of hepatitis C</span></div><div class="casAuthors">Chung, Raymond T.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-275</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv3ffT6ZbaILVg90H21EOLACvtfcHk0lg1JZuBZYt2wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Gns7s%253D&md5=a0a82b76f878d91ed04bb09ed6a6339e</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1056%2FNEJMe1113272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe1113272%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DR.%2BT.%26atitle%3DA%2520watershed%2520moment%2520in%2520the%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D273%26epage%3D275%26doi%3D10.1056%2FNEJMe1113272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lee, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, M.</span><span> </span><span class="NLM_article-title">New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials</span> <span class="citation_source-journal">Int. J. Clin. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">355</span><span class="refDoi"> DOI: 10.1111/j.1742-1241.2012.02895.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fj.1742-1241.2012.02895.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=22420497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKhsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2012&pages=342-355&author=L.+Y.+Leeauthor=C.+Y.+Tongauthor=T.+Wongauthor=M.+Wilkinson&title=New+therapies+for+chronic+hepatitis+C+infection%3A+a+systematic+review+of+evidence+from+clinical+trials&doi=10.1111%2Fj.1742-1241.2012.02895.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128aR"><div class="casContent"><span class="casTitleNuber">128a</span><div class="casTitle"><span class="NLM_cas:atitle">New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials</span></div><div class="casAuthors">Lee, L. Y.; Tong, C. Y. W.; Wong, T.; Wilkinson, M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Practice</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">342-355</span>CODEN:
                <span class="NLM_cas:coden">IJCPF9</span>;
        ISSN:<span class="NLM_cas:issn">1742-1241</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Introduction: Hepatitis C virus (HCV) affects approx. 3% of the world population.  The current std. of care for treatment of HCV is a combination of pegylated interferon and ribavirin.  Approx. 10% of patients will stop treatment and 30% of patients require dose redn. because of side effects.  For genotype 1 HCV-infected patients, only 40% of patients will achieve undetectable viral load 26 wk posttreatment.  Aims: The objectives of this review were to identify new treatments that are in clin. trials.  These include boceprevir and telaprevir which are in routine clin. use and form part of the American Assocn. for the Study of Liver Diseases (AASLD) 2011 guidelines as well as drugs based on observational studies, improving/modifying ribavirin or interferon-based therapies, modifying the host response and finally the use of direct-acting antiviral agents (DAA).  Materials and methods: MEDLINE and EMBASE databases were searched from 2008 to 2011 for treatments for hepatitis C.  Furthermore, abstrs. and poster presentations for the annual European Assocn. Study of the Liver, AASLD, Digestive Disease Week and Asian Pacific Assocn. for the study of the Liver were searched for relevant material.  Results: All four classes of DAA; NS3/NS4a serine protease inhibitors, cyclophilin inhibitors, NS5b polymerase inhibitors and NS5a inhibitors, show good success rates.  Trials have been performed without ribavirin or interferon and demonstrate good antiviral activity with a decreased side effect profile.  Combinations of DAA are a promising area of research with a high success rate.  Conclusions: Clin. trials show that future HCV therapy could be personalised, achieve higher success rates with decreased adverse incidents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcnWdjumn__7Vg90H21EOLACvtfcHk0lg1JZuBZYt2wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKhsr8%253D&md5=9620ce54c3ed4bb62e1bdc134725facd</span></div><a href="/servlet/linkout?suffix=cit128a&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-1241.2012.02895.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-1241.2012.02895.x%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DL.%2BY.%26aulast%3DTong%26aufirst%3DC.%2BY.%26aulast%3DWong%26aufirst%3DT.%26aulast%3DWilkinson%26aufirst%3DM.%26atitle%3DNew%2520therapies%2520for%2520chronic%2520hepatitis%2520C%2520infection%253A%2520a%2520systematic%2520review%2520of%2520evidence%2520from%2520clinical%2520trials%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2012%26volume%3D66%26spage%3D342%26epage%3D355%26doi%3D10.1111%2Fj.1742-1241.2012.02895.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit128b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Liang, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghany, M. G.</span><span> </span><span class="NLM_article-title">Current and future therapies for hepatitis C virus infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">1907</span><span class="NLM_x">–</span> <span class="NLM_lpage">1917</span><span class="refDoi"> DOI: 10.1056/NEJMra1213651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMra1213651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=23675659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsl2gs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=1907-1917&author=T.+J.+Liangauthor=M.+G.+Ghany&title=Current+and+future+therapies+for+hepatitis+C+virus+infection&doi=10.1056%2FNEJMra1213651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128bR"><div class="casContent"><span class="casTitleNuber">128b</span><div class="casTitle"><span class="NLM_cas:atitle">Current and future therapies for hepatitis C virus infection</span></div><div class="casAuthors">Liang, T. Jake; Ghany, Marc G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1907-1917</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The recent approval of two direct-acting antiviral agents for hepatitis C viral (HCV) infection that specifically inhibit viral replication has dramatically increased the viral clearance rate.  It is anticipated that in the course of such a screening process, a large no. of persons will be found to be infected with HCV; this article reviews the current therapy for HCV infection and the landscape of drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4zjjmKeKrZrVg90H21EOLACvtfcHk0lhh1o-IlXCdLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsl2gs78%253D&md5=6be058d0298a4441a180ac076d7293aa</span></div><a href="/servlet/linkout?suffix=cit128b&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1213651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1213651%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DT.%2BJ.%26aulast%3DGhany%26aufirst%3DM.%2BG.%26atitle%3DCurrent%2520and%2520future%2520therapies%2520for%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D1907%26epage%3D1917%26doi%3D10.1056%2FNEJMra1213651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit128c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kohli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottilil, S.</span><span> </span><span class="NLM_article-title">Treatment of hepatitis C: a systematic review. <i>JAMA</i></span> <span class="citation_source-journal">J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">631</span><span class="NLM_x">–</span> <span class="NLM_lpage">640</span><span class="refDoi"> DOI: 10.1001/jama.2014.7085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1001%2Fjama.2014.7085" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2014&pages=631-640&author=A.+Kohliauthor=A.+Shafferauthor=A.+Shermanauthor=S.+Kottilil&title=Treatment+of+hepatitis+C%3A+a+systematic+review.+JAMA&doi=10.1001%2Fjama.2014.7085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit128c&amp;dbid=16384&amp;doi=10.1001%2Fjama.2014.7085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2014.7085%26sid%3Dliteratum%253Aachs%26aulast%3DKohli%26aufirst%3DA.%26aulast%3DShaffer%26aufirst%3DA.%26aulast%3DSherman%26aufirst%3DA.%26aulast%3DKottilil%26aufirst%3DS.%26atitle%3DTreatment%2520of%2520hepatitis%2520C%253A%2520a%2520systematic%2520review.%2520JAMA%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2014%26volume%3D312%26spage%3D631%26epage%3D640%26doi%3D10.1001%2Fjama.2014.7085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Toyoda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, J.</span><span> </span><span class="NLM_article-title">Changes in hepatitis C virus genotype distribution in Japan</span> <span class="citation_source-journal">Epidemiol. Infect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">142</span><span class="NLM_x">, </span> <span class="NLM_fpage">2624</span><span class="NLM_x">–</span> <span class="NLM_lpage">2628</span><span class="refDoi"> DOI: 10.1017/S0950268814000478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1017%2FS0950268814000478" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2014&pages=2624-2628&author=H.+Toyodaauthor=T.+Kumadaauthor=K.+Takaguchiauthor=N.+Shimadaauthor=J.+Tanaka&title=Changes+in+hepatitis+C+virus+genotype+distribution+in+Japan&doi=10.1017%2FS0950268814000478"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1017%2FS0950268814000478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0950268814000478%26sid%3Dliteratum%253Aachs%26aulast%3DToyoda%26aufirst%3DH.%26aulast%3DKumada%26aufirst%3DT.%26aulast%3DTakaguchi%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DJ.%26atitle%3DChanges%2520in%2520hepatitis%2520C%2520virus%2520genotype%2520distribution%2520in%2520Japan%26jtitle%3DEpidemiol.%2520Infect.%26date%3D2014%26volume%3D142%26spage%3D2624%26epage%3D2628%26doi%3D10.1017%2FS0950268814000478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span><span class="refDoi"> DOI: 10.1002/hep.24724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.24724" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=742-748&author=K.+Chayamaauthor=S.+Takahashiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Ikedaauthor=H.+Ishikawaauthor=H.+Watanabeauthor=F.+McPheeauthor=E.+Hughesauthor=H.+Kumada&title=Dual+therapy+with+the+nonstructural+protein+5A+inhibitor%2C+daclatasvir%2C+and+the+nonstructural+protein+3+protease+inhibitor%2C+asunaprevir%2C+in+hepatitis+C+virus+genotype+1b-infected+null+responders&doi=10.1002%2Fhep.24724"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130a&amp;dbid=16384&amp;doi=10.1002%2Fhep.24724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24724%26sid%3Dliteratum%253Aachs%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DDual%2520therapy%2520with%2520the%2520nonstructural%2520protein%25205A%2520inhibitor%252C%2520daclatasvir%252C%2520and%2520the%2520nonstructural%2520protein%25203%2520protease%2520inhibitor%252C%2520asunaprevir%252C%2520in%2520hepatitis%2520C%2520virus%2520genotype%25201b-infected%2520null%2520responders%26jtitle%3DHepatology%26date%3D2012%26volume%3D55%26spage%3D742%26epage%3D748%26doi%3D10.1002%2Fhep.24724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit130b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">646</span><span class="NLM_x">–</span> <span class="NLM_lpage">654</span><span class="refDoi"> DOI: 10.1016/j.jhep.2012.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2012.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=23178977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvFeksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=646-654&author=Y.+Karinoauthor=J.+Toyotaauthor=K.+Ikedaauthor=F.+Suzukiauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=H.+Ishikawaauthor=H.+Watanabeauthor=D.+Hernandezauthor=F.+Yuauthor=F.+McPheeauthor=H.+Kumada&title=Characterization+of+virologic+escape+in+hepatitis+C+virus+genotype+1b+patients+treated+with+the+direct-acting+antivirals+daclatasvir+and+asunaprevir&doi=10.1016%2Fj.jhep.2012.11.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130bR"><div class="casContent"><span class="casTitleNuber">130b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir</span></div><div class="casAuthors">Karino, Yoshiyasu; Toyota, Joji; Ikeda, Kenji; Suzuki, Fumitaka; Chayama, Kazuaki; Kawakami, Yoshiiku; Ishikawa, Hiroki; Watanabe, Hideaki; Hernandez, Dennis; Yu, Fei; McPhee, Fiona; Kumada, Hiromitsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">646-654</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Daclatasvir and asunaprevir are NS5A and NS3 protease-targeted antivirals currently under development for treatment of chronic hepatitis C virus infection.  Clin. data on baseline and on-treatment correlates of drug resistance and response to these agents are currently limited.Hepatitis C virus genotype 1b Japanese patients (prior null responders to PegIFN-α/RBV [n = 21] or PegIFN-α/RBV ineligible or intolerant [n = 22]) were administered daclatasvir/asunaprevir for 24 wk during a phase 2a open-label study.  Genotypic and phenotypic analyses of NS3 and NS5A substitutions were performed at baseline, after virol. failure, and post-treatment through follow-up week 36.There were three viral breakthroughs and four relapsers.  Baseline NS3 polymorphisms (T54S, Q80L, V170M) at amino acid positions previously assocd. with low-level resistance (<9-fold) to select NS3 protease inhibitors were detected in four null responders and three ineligibles, but were not assocd. with virol. failure.  Baseline NS5A polymorphisms (L28M, L31M, Y93H) assocd. with daclatasvir resistance (<25-fold) were detected in five null responders and six ineligibles.  All three viral breakthroughs and 2/4 relapsers carried a baseline NS5A-Y93H polymorphism.  NS3 and NS5A resistance-assocd. variants were detected together (NS3-D168A/V, NS5A-L31M/V-Y93H) after virol. failure.  Generally, daclatasvir-resistant substitutions persisted through 48 wk post-treatment, whereas asunaprevir-resistant substitutions were no longer detectable.  Overall, 5/10 patients with baseline NS5A-Y93H experienced virol. failure, while 5/10 achieved a sustained virol. response.The potential assocn. of a pre-existing NS5A-Y93H polymorphism with virol. failure on daclatasvir/asunaprevir combination treatment will be examd. in larger studies.  The persistence of treatment-emergent daclatasvir- and asunaprevir-resistant substitutions will require assessment in longer-term follow-up studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6FdD0algZ2rVg90H21EOLACvtfcHk0lj7-GmnHEpHPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvFeksQ%253D%253D&md5=be5c769092743c85ce74039cb262b6ac</span></div><a href="/servlet/linkout?suffix=cit130b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DF.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DCharacterization%2520of%2520virologic%2520escape%2520in%2520hepatitis%2520C%2520virus%2520genotype%25201b%2520patients%2520treated%2520with%2520the%2520direct-acting%2520antivirals%2520daclatasvir%2520and%2520asunaprevir%26jtitle%3DJ.%2520Hepatol.%26date%3D2013%26volume%3D58%26spage%3D646%26epage%3D654%26doi%3D10.1016%2Fj.jhep.2012.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit130c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span><span class="refDoi"> DOI: 10.1016/j.jhep.2012.09.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2012.09.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=23183526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2jtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=655-662&author=Y.+Suzukiauthor=K.+Ikedaauthor=F.+Suzukiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=H.+Ishikawaauthor=J.+Watanabeauthor=W.+Huauthor=T.+Eleyauthor=F.+McPheeauthor=E.+Hughesauthor=H.+Kumada&title=Dual+oral+therapy+with+daclatasvir+and+asunaprevir+for+patients+with+HCV+genotype+1b+infection+and+limited+treatment+options&doi=10.1016%2Fj.jhep.2012.09.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130cR"><div class="casContent"><span class="casTitleNuber">130c</span><div class="casTitle"><span class="NLM_cas:atitle">Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options</span></div><div class="casAuthors">Suzuki, Yoshiyuki; Ikeda, Kenji; Suzuki, Fumitaka; Toyota, Joji; Karino, Yoshiyasu; Chayama, Kazuaki; Kawakami, Yoshiiku; Ishikawa, Hiroki; Watanabe, Hideaki; Hu, Wenhua; Eley, Timothy; McPhee, Fiona; Hughes, Eric; Kumada, Hiromitsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">655-662</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Improved therapeutic options for chronic hepatitis C virus (HCV) infection are needed for patients who are poor candidates for treatment with current regimens due to anticipated intolerability or low likelihood of response.  In this open-label, phase 2a study of Japanese patients with chronic HCV genotype 1b infection, 21 null responders (<2 log10 HCV RNA redn. after 12 wk of peginterferon/ribavirin) and 22 patients intolerant to or medically ineligible for peginterferon/ribavirin therapy received dual oral treatment for 24 wk with the NS5A replication complex inhibitor daclatasvir (DCV) and the NS3 protease inhibitor asunaprevir (ASV).  The primary efficacy end point was sustained virol. response at 12 wk post-treatment (SVR12).  Thirty-six of 43 enrolled patients completed 24 wk of therapy.  Serum HCV RNA levels declined rapidly, becoming undetectable in all patients on therapy by week 8.  Overall, 76.7% of patients achieved SVR12 and SVR24, including 90.5% of null responders and 63.6% of ineligible/intolerant patients.  There were no virol. failures among null responders.  Three ineligible/intolerant patients experienced viral breakthrough and four relapsed post-treatment.  Diarrhea, nasopharyngitis, headache, and ALT/AST increases, generally mild, were the most common adverse events; three discontinuations before week 24 were due to adverse events that included hyperbilirubinemia and transaminase elevations (two patients).  Dual therapy with daclatasvir and asunaprevir, without peginterferon/ribavirin, was well tolerated and achieved high SVR rates in two groups of difficult-to-treat patients with hepatitis C virus genotype 1b infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq1ZlrHtPRHLVg90H21EOLACvtfcHk0lj7-GmnHEpHPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2jtbw%253D&md5=48caec88fbfc444ea629aac577c2ed95</span></div><a href="/servlet/linkout?suffix=cit130c&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.09.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.09.037%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DF.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DDual%2520oral%2520therapy%2520with%2520daclatasvir%2520and%2520asunaprevir%2520for%2520patients%2520with%2520HCV%2520genotype%25201b%2520infection%2520and%2520limited%2520treatment%2520options%26jtitle%3DJ.%2520Hepatol.%26date%3D2013%26volume%3D58%26spage%3D655%26epage%3D662%26doi%3D10.1016%2Fj.jhep.2012.09.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit130c1"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Kumada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ido, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izumi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koike, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takehara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagoshi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damokosh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span> </span><span class="NLM_article-title">Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">2083</span><span class="NLM_x">–</span> <span class="NLM_lpage">2091</span><span class="refDoi"> DOI: 10.1002/hep.27113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130c1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.27113" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=2083-2091&author=H.+Kumadaauthor=Y.+Suzukiauthor=K.+Ikedaauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=A.+Idoauthor=K.+Yamamotoauthor=K.+Takaguchiauthor=N.+Izumiauthor=K.+Koikeauthor=T.+Takeharaauthor=N.+Kawadaauthor=M.+Sataauthor=H.+Miyagoshiauthor=T.+Eleyauthor=F.+McPheeauthor=A.+Damokoshauthor=H.+Ishikawaauthor=E.+Hughes&title=Daclatasvir+plus+asunaprevir+for+chronic+HCV+genotype+1b+infection&doi=10.1002%2Fhep.27113"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130c1&amp;dbid=16384&amp;doi=10.1002%2Fhep.27113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27113%26sid%3Dliteratum%253Aachs%26aulast%3DKumada%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIdo%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DTakaguchi%26aufirst%3DK.%26aulast%3DIzumi%26aufirst%3DN.%26aulast%3DKoike%26aufirst%3DK.%26aulast%3DTakehara%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DN.%26aulast%3DSata%26aufirst%3DM.%26aulast%3DMiyagoshi%26aufirst%3DH.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DDamokosh%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DHughes%26aufirst%3DE.%26atitle%3DDaclatasvir%2520plus%2520asunaprevir%2520for%2520chronic%2520HCV%2520genotype%25201b%2520infection%26jtitle%3DHepatology%26date%3D2014%26volume%3D59%26spage%3D2083%26epage%3D2091%26doi%3D10.1002%2Fhep.27113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit130d"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karino, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhore, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumada, H.</span><span> </span><span class="NLM_article-title">High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms</span> <span class="citation_source-journal">Adv. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">637</span><span class="NLM_x">–</span> <span class="NLM_lpage">649</span><span class="refDoi"> DOI: 10.1007/s12325-015-0221-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1007%2Fs12325-015-0221-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=637-649&author=F.+McPheeauthor=Y.+Suzukiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=M.+L.+Yuauthor=S.+H.+Ahnauthor=H.+Ishikawaauthor=R.+Bhoreauthor=N.+Zhouauthor=D.+Hernandezauthor=P.+Mendezauthor=H.+Kumada&title=High+sustained+virologic+response+to+daclatasvir+plus+asunaprevir+in+elderly+and+cirrhotic+patients+with+hepatitis+C+virus+genotype+1b+without+baseline+NS5A+polymorphisms&doi=10.1007%2Fs12325-015-0221-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130d&amp;dbid=16384&amp;doi=10.1007%2Fs12325-015-0221-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-015-0221-5%26sid%3Dliteratum%253Aachs%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DM.%2BL.%26aulast%3DAhn%26aufirst%3DS.%2BH.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DBhore%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DN.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DMendez%26aufirst%3DP.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DHigh%2520sustained%2520virologic%2520response%2520to%2520daclatasvir%2520plus%2520asunaprevir%2520in%2520elderly%2520and%2520cirrhotic%2520patients%2520with%2520hepatitis%2520C%2520virus%2520genotype%25201b%2520without%2520baseline%2520NS5A%2520polymorphisms%26jtitle%3DAdv.%2520Ther.%26date%3D2015%26volume%3D32%26spage%3D637%26epage%3D649%26doi%3D10.1007%2Fs12325-015-0221-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit130e"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Kanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasui, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haga, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imazeki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokosuka, O.</span><span> </span><span class="NLM_article-title">Daclatasvir plus asunaprevir treatment for real-world HCV genotype 1-infected patients in Japan</span> <span class="citation_source-journal">Int. J. Med. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">418</span><span class="NLM_x">–</span> <span class="NLM_lpage">423</span><span class="refDoi"> DOI: 10.7150/ijms.15519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.7150%2Fijms.15519" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=418-423&author=T.+Kandaauthor=S.+Yasuiauthor=M.+Nakamuraauthor=E.+Suzukiauthor=M.+Araiauthor=Y.+Hagaauthor=R.+Sasakiauthor=S.+Wuauthor=S.+Nakamotoauthor=F.+Imazekiauthor=O.+Yokosuka&title=Daclatasvir+plus+asunaprevir+treatment+for+real-world+HCV+genotype+1-infected+patients+in+Japan&doi=10.7150%2Fijms.15519"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130e&amp;dbid=16384&amp;doi=10.7150%2Fijms.15519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fijms.15519%26sid%3Dliteratum%253Aachs%26aulast%3DKanda%26aufirst%3DT.%26aulast%3DYasui%26aufirst%3DS.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DE.%26aulast%3DArai%26aufirst%3DM.%26aulast%3DHaga%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DNakamoto%26aufirst%3DS.%26aulast%3DImazeki%26aufirst%3DF.%26aulast%3DYokosuka%26aufirst%3DO.%26atitle%3DDaclatasvir%2520plus%2520asunaprevir%2520treatment%2520for%2520real-world%2520HCV%2520genotype%25201-infected%2520patients%2520in%2520Japan%26jtitle%3DInt.%2520J.%2520Med.%2520Sci.%26date%3D2016%26volume%3D13%26spage%3D418%26epage%3D423%26doi%3D10.7150%2Fijms.15519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Poole, R. M.</span><span> </span><span class="NLM_article-title">Daclatasvir + asunaprevir: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1559</span><span class="NLM_x">–</span> <span class="NLM_lpage">1571</span><span class="refDoi"> DOI: 10.1007/s40265-014-0279-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1007%2Fs40265-014-0279-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25117197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtl2gu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1559-1571&author=R.+M.+Poole&title=Daclatasvir+%2B+asunaprevir%3A+first+global+approval&doi=10.1007%2Fs40265-014-0279-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir + Asunaprevir: First Global Approval</span></div><div class="casAuthors">Poole, Raewyn M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1559-1571</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  The combination of daclatasvir + asunaprevir [Daklinza + Sunvepra (Japan)], two direct-acting antiviral agents, has been developed by Bristol-Myers Squibb for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infections, including those with compensated cirrhosis.  Daclatasvir + asunaprevir has received its first global approval in this indication in Japan.  Daclatasvir + asunaprevir is the first all-oral, interferon- and ribavirin-free regimen for this indication.  This article summarizes the milestones in the development of daclatasvir + asunaprevir leading to this first approval for the treatment of chronic HCV genotype 1 infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF9-lXzdKBdbVg90H21EOLACvtfcHk0lhvbkVTI8OcQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtl2gu77M&md5=efde97ee214598388e1db80bb303d1c6</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0279-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0279-4%26sid%3Dliteratum%253Aachs%26aulast%3DPoole%26aufirst%3DR.%2BM.%26atitle%3DDaclatasvir%2520%252B%2520asunaprevir%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D1559%26epage%3D1571%26doi%3D10.1007%2Fs40265-014-0279-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sievert, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mollison, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angus, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronowicki, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz-Lasanta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Ledinghen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boparai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">UNITY-1 Study Group.</span><span> </span><span class="NLM_article-title">Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">1728</span><span class="NLM_x">–</span> <span class="NLM_lpage">1735</span><span class="refDoi"> DOI: 10.1001/jama.2015.3860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1001%2Fjama.2015.3860" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2015&pages=1728-1735&author=F.+Poordadauthor=W.+Sievertauthor=L.+Mollisonauthor=M.+Bennettauthor=E.+Tseauthor=N.+Brauauthor=J.+Levinauthor=T.+Sepeauthor=S.+S.+Leeauthor=P.+Angusauthor=B.+Conwayauthor=S.+Polauthor=N.+Boyerauthor=J.-P.+Bronowickiauthor=I.+Jacobsonauthor=A.+J.+Muirauthor=K.+R.+Reddyauthor=E.+Tamauthor=G.+Ortiz-Lasantaauthor=V.+de+Ledinghenauthor=M.+Sulkowskiauthor=N.+Boparaiauthor=F.+McPheeauthor=E.+Hughesauthor=E.+S.+Swensonauthor=P.+D.+Yinauthor=UNITY-1+Study+Group.&title=Fixed-dose+combination+therapy+with+daclatasvir%2C+asunaprevir%2C+and+beclabuvir+for+noncirrhotic+patients+with+HCV+genotype+1+infection&doi=10.1001%2Fjama.2015.3860"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132a&amp;dbid=16384&amp;doi=10.1001%2Fjama.2015.3860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2015.3860%26sid%3Dliteratum%253Aachs%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DSievert%26aufirst%3DW.%26aulast%3DMollison%26aufirst%3DL.%26aulast%3DBennett%26aufirst%3DM.%26aulast%3DTse%26aufirst%3DE.%26aulast%3DBrau%26aufirst%3DN.%26aulast%3DLevin%26aufirst%3DJ.%26aulast%3DSepe%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DS.%2BS.%26aulast%3DAngus%26aufirst%3DP.%26aulast%3DConway%26aufirst%3DB.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DBoyer%26aufirst%3DN.%26aulast%3DBronowicki%26aufirst%3DJ.-P.%26aulast%3DJacobson%26aufirst%3DI.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DTam%26aufirst%3DE.%26aulast%3DOrtiz-Lasanta%26aufirst%3DG.%26aulast%3Dde%2BLedinghen%26aufirst%3DV.%26aulast%3DSulkowski%26aufirst%3DM.%26aulast%3DBoparai%26aufirst%3DN.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DSwenson%26aufirst%3DE.%2BS.%26aulast%3DYin%26aufirst%3DP.%2BD.%26aulast%3D%26atitle%3DFixed-dose%2520combination%2520therapy%2520with%2520daclatasvir%252C%2520asunaprevir%252C%2520and%2520beclabuvir%2520for%2520noncirrhotic%2520patients%2520with%2520HCV%2520genotype%25201%2520infection%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2015%26volume%3D313%26spage%3D1728%26epage%3D1735%26doi%3D10.1001%2Fjama.2015.3860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit132b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herring, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheikh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yozviak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramji, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vierling, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghesquiere, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, P. D.</span><span> </span><span class="NLM_article-title">Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">1736</span><span class="NLM_x">–</span> <span class="NLM_lpage">1744</span><span class="refDoi"> DOI: 10.1001/jama.2015.3868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1001%2Fjama.2015.3868" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2015&pages=1736-1744&author=A.+J.+Muirauthor=F.+Poordadauthor=J.+Lalezariauthor=G.+Eversonauthor=G.+J.+Doreauthor=R.+Herringauthor=A.+Sheikhauthor=P.+Kwoauthor=C.+H%C3%A9zodeauthor=P.+J.+Pockrosauthor=A.+Tranauthor=J.+Yozviakauthor=N.+Reauauthor=A.+Ramjiauthor=K.+Stuartauthor=A.+J.+Thompsonauthor=J.+Vierlingauthor=B.+Freilichauthor=J.+Cooperauthor=W.+Ghesquiereauthor=R.+Yangauthor=F.+McPheeauthor=E.+A.+Hughesauthor=E.+S.+Swensonauthor=P.+D.+Yin&title=Daclatasvir+in+combination+with+asunaprevir+and+beclabuvir+for+hepatitis+C+virus+genotype+1+infection+with+compensated+cirrhosis&doi=10.1001%2Fjama.2015.3868"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132b&amp;dbid=16384&amp;doi=10.1001%2Fjama.2015.3868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2015.3868%26sid%3Dliteratum%253Aachs%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DEverson%26aufirst%3DG.%26aulast%3DDore%26aufirst%3DG.%2BJ.%26aulast%3DHerring%26aufirst%3DR.%26aulast%3DSheikh%26aufirst%3DA.%26aulast%3DKwo%26aufirst%3DP.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DTran%26aufirst%3DA.%26aulast%3DYozviak%26aufirst%3DJ.%26aulast%3DReau%26aufirst%3DN.%26aulast%3DRamji%26aufirst%3DA.%26aulast%3DStuart%26aufirst%3DK.%26aulast%3DThompson%26aufirst%3DA.%2BJ.%26aulast%3DVierling%26aufirst%3DJ.%26aulast%3DFreilich%26aufirst%3DB.%26aulast%3DCooper%26aufirst%3DJ.%26aulast%3DGhesquiere%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DSwenson%26aufirst%3DE.%2BS.%26aulast%3DYin%26aufirst%3DP.%2BD.%26atitle%3DDaclatasvir%2520in%2520combination%2520with%2520asunaprevir%2520and%2520beclabuvir%2520for%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%2520with%2520compensated%2520cirrhosis%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2015%26volume%3D313%26spage%3D1736%26epage%3D1744%26doi%3D10.1001%2Fjama.2015.3868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Conjeevaram, H.</span><span> </span><span class="NLM_article-title">Continued progress against hepatitis C infection</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">1716</span><span class="NLM_x">–</span> <span class="NLM_lpage">1717</span><span class="refDoi"> DOI: 10.1001/jama.2015.4368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1001%2Fjama.2015.4368" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2015&pages=1716-1717&author=H.+Conjeevaram&title=Continued+progress+against+hepatitis+C+infection&doi=10.1001%2Fjama.2015.4368"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1001%2Fjama.2015.4368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2015.4368%26sid%3Dliteratum%253Aachs%26aulast%3DConjeevaram%26aufirst%3DH.%26atitle%3DContinued%2520progress%2520against%2520hepatitis%2520C%2520infection%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2015%26volume%3D313%26spage%3D1716%26epage%3D1717%26doi%3D10.1001%2Fjama.2015.4368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fontana, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appelman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hindes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifano, M.</span><span> </span><span class="NLM_article-title">Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation</span> <span class="citation_source-journal">Liver Transpl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1053</span><span class="NLM_x">–</span> <span class="NLM_lpage">1059</span><span class="refDoi"> DOI: 10.1002/lt.23482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Flt.23482" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1053-1059&author=R.+J.+Fontanaauthor=E.+A.+Hughesauthor=H.+Appelmanauthor=R.+Hindesauthor=D.+Dimitrovaauthor=M.+Bifano&title=Case+report+of+successful+peginterferon%2C+ribavirin%2C+and+daclatasvir+therapy+for+recurrent+cholestatic+hepatitis+C+after+liver+retransplantation&doi=10.1002%2Flt.23482"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134a&amp;dbid=16384&amp;doi=10.1002%2Flt.23482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Flt.23482%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DAppelman%26aufirst%3DH.%26aulast%3DHindes%26aufirst%3DR.%26aulast%3DDimitrova%26aufirst%3DD.%26aulast%3DBifano%26aufirst%3DM.%26atitle%3DCase%2520report%2520of%2520successful%2520peginterferon%252C%2520ribavirin%252C%2520and%2520daclatasvir%2520therapy%2520for%2520recurrent%2520cholestatic%2520hepatitis%2520C%2520after%2520liver%2520retransplantation%26jtitle%3DLiver%2520Transpl.%26date%3D2012%26volume%3D18%26spage%3D1053%26epage%3D1059%26doi%3D10.1002%2Flt.23482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit134b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fontana, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appelman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hindes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span> </span><span class="NLM_article-title">Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C</span> <span class="citation_source-journal">Am. J. Transplant.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1601</span><span class="NLM_x">–</span> <span class="NLM_lpage">1605</span><span class="refDoi"> DOI: 10.1111/ajt.12209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fajt.12209" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1601-1605&author=R.+J.+Fontanaauthor=E.+A.+Hughesauthor=M.+Bifanoauthor=H.+Appelmanauthor=D.+Dimitrovaauthor=R.+Hindesauthor=W.+T.+Symonds&title=Sofosbuvir+and+daclatasvir+combination+therapy+in+a+liver+transplant+recipient+with+severe+recurrent+cholestatic+hepatitis+C&doi=10.1111%2Fajt.12209"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134b&amp;dbid=16384&amp;doi=10.1111%2Fajt.12209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fajt.12209%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DBifano%26aufirst%3DM.%26aulast%3DAppelman%26aufirst%3DH.%26aulast%3DDimitrova%26aufirst%3DD.%26aulast%3DHindes%26aufirst%3DR.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26atitle%3DSofosbuvir%2520and%2520daclatasvir%2520combination%2520therapy%2520in%2520a%2520liver%2520transplant%2520recipient%2520with%2520severe%2520recurrent%2520cholestatic%2520hepatitis%2520C%26jtitle%3DAm.%2520J.%2520Transplant.%26date%3D2013%26volume%3D13%26spage%3D1601%26epage%3D1605%26doi%3D10.1111%2Fajt.12209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit134c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Leroy, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumortier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coilly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebagh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fougerou-Leurent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radenne, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durand, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvain, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebray, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houssel-Debry, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">d’Alteroche, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov-Sanchez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diallo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pageaux, G.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duclos-Vallee, J.-C.</span><span> </span><span class="NLM_article-title">Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation</span> <span class="citation_source-journal">Clin. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1993</span><span class="NLM_x">–</span> <span class="NLM_lpage">2001</span><span class="refDoi"> DOI: 10.1016/j.cgh.2015.05.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.cgh.2015.05.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=1993-2001&author=V.+Leroyauthor=J.+Dumortierauthor=A.+Coillyauthor=M.+Sebaghauthor=C.+Fougerou-Leurentauthor=S.+Radenneauthor=D.+Bottaauthor=F.+Durandauthor=C.+Silvainauthor=P.+Lebrayauthor=P.+Houssel-Debryauthor=N.+Kamarauthor=L.+d%E2%80%99Alterocheauthor=V.+Petrov-Sanchezauthor=A.+Dialloauthor=G.-P.+Pageauxauthor=J.-C.+Duclos-Vallee&title=Efficacy+of+sofosbuvir+and+daclatasvir+in+patients+with+fibrosing+cholestatic+hepatitis+C+after+liver+transplantation&doi=10.1016%2Fj.cgh.2015.05.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134c&amp;dbid=16384&amp;doi=10.1016%2Fj.cgh.2015.05.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cgh.2015.05.030%26sid%3Dliteratum%253Aachs%26aulast%3DLeroy%26aufirst%3DV.%26aulast%3DDumortier%26aufirst%3DJ.%26aulast%3DCoilly%26aufirst%3DA.%26aulast%3DSebagh%26aufirst%3DM.%26aulast%3DFougerou-Leurent%26aufirst%3DC.%26aulast%3DRadenne%26aufirst%3DS.%26aulast%3DBotta%26aufirst%3DD.%26aulast%3DDurand%26aufirst%3DF.%26aulast%3DSilvain%26aufirst%3DC.%26aulast%3DLebray%26aufirst%3DP.%26aulast%3DHoussel-Debry%26aufirst%3DP.%26aulast%3DKamar%26aufirst%3DN.%26aulast%3Dd%25E2%2580%2599Alteroche%26aufirst%3DL.%26aulast%3DPetrov-Sanchez%26aufirst%3DV.%26aulast%3DDiallo%26aufirst%3DA.%26aulast%3DPageaux%26aufirst%3DG.-P.%26aulast%3DDuclos-Vallee%26aufirst%3DJ.-C.%26atitle%3DEfficacy%2520of%2520sofosbuvir%2520and%2520daclatasvir%2520in%2520patients%2520with%2520fibrosing%2520cholestatic%2520hepatitis%2520C%2520after%2520liver%2520transplantation%26jtitle%3DClin.%2520Gastroenterol.%2520Hepatol.%26date%3D2015%26volume%3D13%26spage%3D1993%26epage%3D2001%26doi%3D10.1016%2Fj.cgh.2015.05.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit134d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akamatsu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasegawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kokudo, N.</span><span> </span><span class="NLM_article-title">Daclatasvir and asunaprevir for recurrent hepatitis C following living-donor liver transplantation with human immunodeficiency virus coinfection</span> <span class="citation_source-journal">Hepatol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">829</span><span class="NLM_x">–</span> <span class="NLM_lpage">832</span><span class="refDoi"> DOI: 10.1111/hepr.12614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fhepr.12614" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2016&pages=829-832&author=T.+Tanakaauthor=N.+Akamatsuauthor=J.+Kanekoauthor=J.+Aritaauthor=S.+Tamuraauthor=K.+Hasegawaauthor=Y.+Sakamotoauthor=N.+Kokudo&title=Daclatasvir+and+asunaprevir+for+recurrent+hepatitis+C+following+living-donor+liver+transplantation+with+human+immunodeficiency+virus+coinfection&doi=10.1111%2Fhepr.12614"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134d&amp;dbid=16384&amp;doi=10.1111%2Fhepr.12614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fhepr.12614%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DAkamatsu%26aufirst%3DN.%26aulast%3DKaneko%26aufirst%3DJ.%26aulast%3DArita%26aufirst%3DJ.%26aulast%3DTamura%26aufirst%3DS.%26aulast%3DHasegawa%26aufirst%3DK.%26aulast%3DSakamoto%26aufirst%3DY.%26aulast%3DKokudo%26aufirst%3DN.%26atitle%3DDaclatasvir%2520and%2520asunaprevir%2520for%2520recurrent%2520hepatitis%2520C%2520following%2520living-donor%2520liver%2520transplantation%2520with%2520human%2520immunodeficiency%2520virus%2520coinfection%26jtitle%3DHepatol.%2520Res.%26date%3D2016%26volume%3D46%26spage%3D829%26epage%3D832%26doi%3D10.1111%2Fhepr.12614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit134e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Herzer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos-Köhn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Achterfeld, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paul, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canbay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerken, G.</span><span> </span><span class="NLM_article-title">Daclatasvir, simeprevir and ribavirin as a promising interferon-free triple regimen for HCV recurrence after liver transplant</span> <span class="citation_source-journal">Digestion</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">326</span><span class="NLM_x">–</span> <span class="NLM_lpage">333</span><span class="refDoi"> DOI: 10.1159/000382075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1159%2F000382075" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2015&pages=326-333&author=K.+Herzerauthor=A.+Papadopoulos-K%C3%B6hnauthor=A.+Walkerauthor=A.+Achterfeldauthor=A.+Paulauthor=A.+Canbayauthor=J.+Timmauthor=G.+Gerken&title=Daclatasvir%2C+simeprevir+and+ribavirin+as+a+promising+interferon-free+triple+regimen+for+HCV+recurrence+after+liver+transplant&doi=10.1159%2F000382075"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134e&amp;dbid=16384&amp;doi=10.1159%2F000382075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000382075%26sid%3Dliteratum%253Aachs%26aulast%3DHerzer%26aufirst%3DK.%26aulast%3DPapadopoulos-K%25C3%25B6hn%26aufirst%3DA.%26aulast%3DWalker%26aufirst%3DA.%26aulast%3DAchterfeld%26aufirst%3DA.%26aulast%3DPaul%26aufirst%3DA.%26aulast%3DCanbay%26aufirst%3DA.%26aulast%3DTimm%26aufirst%3DJ.%26aulast%3DGerken%26aufirst%3DG.%26atitle%3DDaclatasvir%252C%2520simeprevir%2520and%2520ribavirin%2520as%2520a%2520promising%2520interferon-free%2520triple%2520regimen%2520for%2520HCV%2520recurrence%2520after%2520liver%2520transplant%26jtitle%3DDigestion%26date%3D2015%26volume%3D91%26spage%3D326%26epage%3D333%26doi%3D10.1159%2F000382075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit134f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Coilly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duclos-Vallée, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuel, D.</span><span> </span><span class="NLM_article-title">Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">44</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span><span class="refDoi"> DOI: 10.1111/liv.12728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fliv.12728" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=44-50&issue=Suppl.+1&author=A.+Coillyauthor=B.+Rocheauthor=J.+C.+Duclos-Vall%C3%A9eauthor=D.+Samuel&title=Optimal+therapy+in+hepatitis+C+virus+liver+transplant+patients+with+direct+acting+antivirals&doi=10.1111%2Fliv.12728"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134f&amp;dbid=16384&amp;doi=10.1111%2Fliv.12728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fliv.12728%26sid%3Dliteratum%253Aachs%26aulast%3DCoilly%26aufirst%3DA.%26aulast%3DRoche%26aufirst%3DB.%26aulast%3DDuclos-Vall%25C3%25A9e%26aufirst%3DJ.%2BC.%26aulast%3DSamuel%26aufirst%3DD.%26atitle%3DOptimal%2520therapy%2520in%2520hepatitis%2520C%2520virus%2520liver%2520transplant%2520patients%2520with%2520direct%2520acting%2520antivirals%26jtitle%3DLiver%2520Int.%26date%3D2015%26volume%3D35%26issue%3DSuppl.%25201%26spage%3D44%26epage%3D50%26doi%3D10.1111%2Fliv.12728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit134g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Righi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Londero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnelutti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassetti, M.</span><span> </span><span class="NLM_article-title">Impact of new treatment options for hepatitis C virus infection in liver transplantation</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">10760</span><span class="NLM_x">–</span> <span class="NLM_lpage">10775</span><span class="refDoi"> DOI: 10.3748/wjg.v21.i38.10760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.3748%2Fwjg.v21.i38.10760" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=10760-10775&author=E.+Righiauthor=A.+Londeroauthor=A.+Carneluttiauthor=U.+Baccaraniauthor=M.+Bassetti&title=Impact+of+new+treatment+options+for+hepatitis+C+virus+infection+in+liver+transplantation&doi=10.3748%2Fwjg.v21.i38.10760"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134g&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v21.i38.10760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v21.i38.10760%26sid%3Dliteratum%253Aachs%26aulast%3DRighi%26aufirst%3DE.%26aulast%3DLondero%26aufirst%3DA.%26aulast%3DCarnelutti%26aufirst%3DA.%26aulast%3DBaccarani%26aufirst%3DU.%26aulast%3DBassetti%26aufirst%3DM.%26atitle%3DImpact%2520of%2520new%2520treatment%2520options%2520for%2520hepatitis%2520C%2520virus%2520infection%2520in%2520liver%2520transplantation%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2015%26volume%3D21%26spage%3D10760%26epage%3D10775%26doi%3D10.3748%2Fwjg.v21.i38.10760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassanein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lok, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinestrosa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P.J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind-Rotolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hindes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquinelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grasela, D. M.</span><span> </span><span class="NLM_article-title">for the AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span><span class="refDoi"> DOI: 10.1056/NEJMoa1306218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1306218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24428467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFymtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=211-221&author=M.+S.+Sulkowskiauthor=D.+F.+Gardinerauthor=M.+Rodriguez-Torresauthor=K.+R.+Reddyauthor=T.+Hassaneinauthor=I.+Jacobsonauthor=E.+Lawitzauthor=A.+S.+Lokauthor=F.+Hinestrosaauthor=P.J.+Thuluvathauthor=H.+Schwartzauthor=D.+R.+Nelsonauthor=G.+T.+Eversonauthor=T.+Eleyauthor=M.+Wind-Rotoloauthor=S.-P.+Huangauthor=M.+Gaoauthor=D.+Hernandezauthor=F.+McPheeauthor=D.+Shermanauthor=R.+Hindesauthor=W.+Symondsauthor=C.+Pasquinelliauthor=D.+M.+Grasela&title=for+the+AI444040+Study+Group.+Daclatasvir+plus+sofosbuvir+for+previously+treated+or+untreated+chronic+HCV+infection&doi=10.1056%2FNEJMoa1306218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135aR"><div class="casContent"><span class="casTitleNuber">135a</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection</span></div><div class="casAuthors">Sulkowski, Mark S.; Gardiner, David F.; Rodriguez-Torres, Maribel; Reddy, K. Rajender; Hassanein, Tarek; Jacobson, Ira; Lawitz, Eric; Lok, Anna S.; Hinestrosa, Federico; Thuluvath, Paul J.; Schwartz, Howard; Nelson, David R.; Everson, Gregory T.; Eley, Timothy; Wind-Rotolo, Megan; Huang, Shu-Pang; Gao, Min; Hernandez, Dennis; McPhee, Fiona; Sherman, Diane; Hindes, Robert; Symonds, William; Pasquinelli, Claudio; Grasela, Dennis M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211-221</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection.  We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analog HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3.  METHODS In this open-label study, we initially randomly assigned 44 previously untreated patients with HCV genotype 1 infection and 44 patients infected with HCV genotype 2 or 3 to daclatasvir at a dose of 60 mg orally once daily plus sofosbuvir at a dose of 400 mg orally once daily, with or without ribavirin, for 24 wk.  The study was expanded to include 123 addnl. patients with genotype 1 infection who were randomly assigned to daclatasvir plus sofosbuvir, with or without ribavirin, for 12 wk (82 previously untreated patients) or 24 wk (41 patients who had previous virol. failure with telaprevir or boceprevir plus peginterferon alfa ribavirin).  The primary end point was a sustained virol. response (an HCV RNA level of <25 IU per mL) at week 12 after the end of therapy.  RESULTS Overall, 211 patients received treatment.  Among patients with genotype 1 infection, 98% of 126 previously untreated patients and 98% of 41 patients who did not have a sustained virol. response with HCV protease inhibitors had a sustained virol. response at week 12 after the end of therapy.  A total of 92% of 26 patients with genotype 2 infection and 89% of 18 patients with genotype 3 infection had a sustained virol. response at week 12.  High rates of sustained virol. response at week 12 were obsd. among patients with HCV subtypes 1a and 1b (98% and 100%, resp.) and those with CC and non-CC IL28B genotypes (93% and 98%, resp.), as well as among patients who received ribavirin and those who did not (94% and 98%, resp.).  The most common adverse events were fatigue, headache, and nausea.  CONCLUSIONS Once-daily oral daclatasvir plus sofosbuvir was assocd. with high rates of sustained virol. response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMiCkoKS-KUrVg90H21EOLACvtfcHk0lgTEiu0DH2WAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFymtb0%253D&md5=bc9eff52401d2f1e00505d30fcffd2c5</span></div><a href="/servlet/linkout?suffix=cit135a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306218%26sid%3Dliteratum%253Aachs%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DI.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DHinestrosa%26aufirst%3DF.%26aulast%3DThuluvath%26aufirst%3DP.J.%26aulast%3DSchwartz%26aufirst%3DH.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DS.-P.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DSherman%26aufirst%3DD.%26aulast%3DHindes%26aufirst%3DR.%26aulast%3DSymonds%26aufirst%3DW.%26aulast%3DPasquinelli%26aufirst%3DC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26atitle%3Dfor%2520the%2520AI444040%2520Study%2520Group.%2520Daclatasvir%2520plus%2520sofosbuvir%2520for%2520previously%2520treated%2520or%2520untreated%2520chronic%2520HCV%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D211%26epage%3D221%26doi%3D10.1056%2FNEJMoa1306218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit135b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wyles, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruane, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dieterich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luetkemeyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dretler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fishbein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gathe, J. C.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinestrosa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huynh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overton, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramgopal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rashbaum, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarsella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yozviak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noviello, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ackerman, P.</span><span> </span><span class="NLM_article-title">for the ALLY-2 Investigators. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">714</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span><span class="refDoi"> DOI: 10.1056/NEJMoa1503153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1503153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26196502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC28XpslOltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=714-725&author=D.+L.+Wylesauthor=P.+J.+Ruaneauthor=M.+S.+Sulkowskiauthor=D.+Dieterichauthor=A.+Luetkemeyerauthor=T.+R.+Morganauthor=K.+E.+Shermanauthor=R.+Dretlerauthor=D.+Fishbeinauthor=J.+C.+Gatheauthor=S.+Hennauthor=F.+Hinestrosaauthor=C.+Huynhauthor=C.+McDonaldauthor=A.+Millsauthor=E.+T.+Overtonauthor=M.+Ramgopalauthor=B.+Rashbaumauthor=G.+Rayauthor=A.+Scarsellaauthor=J.+Yozviakauthor=F.+McPheeauthor=Z.+Liuauthor=E.+Hughesauthor=P.+D.+Yinauthor=S.+Novielloauthor=P.+Ackerman&title=for+the+ALLY-2+Investigators.+Daclatasvir+plus+sofosbuvir+for+HCV+in+patients+coinfected+with+HIV-1&doi=10.1056%2FNEJMoa1503153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135bR"><div class="casContent"><span class="casTitleNuber">135b</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1</span></div><div class="casAuthors">Wyles, D. L.; Ruane, P. J.; Sulkowski, M. S.; Dieterich, D.; Luetkemeyer, A.; Morgan, T. R.; Sherman, K. E.; Dretler, R.; Fishbein, D.; Gathe, J. C., Jr.; Henn, S.; Hinestrosa, F.; Huynh, C.; McDonald, C.; Mills, A.; Overton, E. T.; Ramgopal, M.; Rashbaum, B.; Ray, G.; Scarsella, A.; Yozviak, J.; McPhee, F.; Liu, Z.; Hughes, E.; Yin, P. D.; Noviello, S.; Ackerman, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">714-725</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The combination of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor sofosbuvir has shown efficacy in patients with HCV monoinfection.  Data are lacking on the efficacy and safety of this combination in patients coinfected with human immunodeficiency virus type 1 (HIV-1).  Methods: This was an open-label study involving 151 patients who had not received HCV treatment and 52 previously treated patients, all of whom were coinfected with HIV-1.  Previously untreated patients were randomly assigned in a 2:1 ratio to receive either 12 wk or 8 wk of daclatasvir at a std. dose of 60 mg daily (with dose adjustment for concomitant antiretroviral medications) plus 400 mg of sofosbuvir daily.  Previously treated patients were assigned to undergo 12 wk of therapy at the same doses.  The primary end point was a sustained virol. response at week 12 after the end of therapy among previously untreated patients with HCV genotype 1 who were treated for 12 wk.  Results: Patients had HCV genotypes 1 through 4 (83% with genotype 1), and 14% had compensated cirrhosis; 98% were receiving antiretroviral therapy.  Among patients with genotype 1, a sustained virol. response was reported in 96.4% (95% confidence interval [CI], 89.8 to 99.2) who were treated for 12 wk and in 75.6% (95% CI, 59.7 to 87.6) who were treated for 8 wk among previously untreated patients and in 97.7% (95% CI, 88.0 to 99.9) who were treated for 12 wk among previously treated patients.  Rates of sustained virol. response across all genotypes were 97.0% (95% CI, 91.6 to 99.4), 76.0% (95% CI, 61.8 to 86.9), and 98.1% (95% CI, 89.7 to 100), resp.  The most common adverse events were fatigue, nausea, and headache.  There were no study-drug discontinuations because of adverse events.  HIV-1 suppression was not compromised.  Conclusions: Among previously untreated HIV-HCV coinfected patients receiving daclatasvir plus sofosbuvir for HCV infection, the rate of sustained virol. response across all genotypes was 97.0% after 12 wk of treatment and 76.0% after 8 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1QHYpFV8ML7Vg90H21EOLACvtfcHk0lgTEiu0DH2WAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpslOltA%253D%253D&md5=f514ea5a2ce454efd22e2d4ed172aaa5</span></div><a href="/servlet/linkout?suffix=cit135b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1503153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1503153%26sid%3Dliteratum%253Aachs%26aulast%3DWyles%26aufirst%3DD.%2BL.%26aulast%3DRuane%26aufirst%3DP.%2BJ.%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DDieterich%26aufirst%3DD.%26aulast%3DLuetkemeyer%26aufirst%3DA.%26aulast%3DMorgan%26aufirst%3DT.%2BR.%26aulast%3DSherman%26aufirst%3DK.%2BE.%26aulast%3DDretler%26aufirst%3DR.%26aulast%3DFishbein%26aufirst%3DD.%26aulast%3DGathe%26aufirst%3DJ.%2BC.%26aulast%3DHenn%26aufirst%3DS.%26aulast%3DHinestrosa%26aufirst%3DF.%26aulast%3DHuynh%26aufirst%3DC.%26aulast%3DMcDonald%26aufirst%3DC.%26aulast%3DMills%26aufirst%3DA.%26aulast%3DOverton%26aufirst%3DE.%2BT.%26aulast%3DRamgopal%26aufirst%3DM.%26aulast%3DRashbaum%26aufirst%3DB.%26aulast%3DRay%26aufirst%3DG.%26aulast%3DScarsella%26aufirst%3DA.%26aulast%3DYozviak%26aufirst%3DJ.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DYin%26aufirst%3DP.%2BD.%26aulast%3DNoviello%26aufirst%3DS.%26aulast%3DAckerman%26aufirst%3DP.%26atitle%3Dfor%2520the%2520ALLY-2%2520Investigators.%2520Daclatasvir%2520plus%2520sofosbuvir%2520for%2520HCV%2520in%2520patients%2520coinfected%2520with%2520HIV-1%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D714%26epage%3D725%26doi%3D10.1056%2FNEJMoa1503153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit135c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nelson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harlan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oguchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz-Lasanta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinovitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravendhran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheikh, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varunok, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennicken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rana, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span> </span><span class="NLM_article-title">ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1127</span><span class="NLM_x">–</span> <span class="NLM_lpage">1135</span><span class="refDoi"> DOI: 10.1002/hep.27726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.27726" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25614962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlt1WktLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2015&pages=1127-1135&author=D.+R.+Nelsonauthor=J.+N.+Cooperauthor=J.+P.+Lalezariauthor=E.+Lawitzauthor=P.+J.+Pockrosauthor=N.+Gitlinauthor=B.+F.+Freilichauthor=Z.+H.+Younesauthor=W.+Harlanauthor=R.+Ghalibauthor=G.+Oguchiauthor=P.+J.+Thuluvathauthor=G.+Ortiz-Lasantaauthor=M.+Rabinovitzauthor=D.+Bernsteinauthor=M.+Bennettauthor=T.+Hawkinsauthor=N.+Ravendhranauthor=A.+M.+Sheikhauthor=P.+Varunokauthor=K.+V.+Kowdleyauthor=D.+Hennickenauthor=F.+McPheeauthor=K.+Ranaauthor=E.+A.+Hughes&title=ALLY-3+Study+Team.+All-oral+12-week+treatment+with+daclatasvir+plus+sofosbuvir+in+patients+with+hepatitis+C+virus+genotype+3+infection%3A+ALLY-3+phase+III+study&doi=10.1002%2Fhep.27726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135cR"><div class="casContent"><span class="casTitleNuber">135c</span><div class="casTitle"><span class="NLM_cas:atitle">All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study</span></div><div class="casAuthors">Nelson, David R.; Cooper, James N.; Lalezari, Jacob P.; Lawitz, Eric; Pockros, Paul J.; Gitlin, Norman; Freilich, Bradley F.; Younes, Ziad H.; Harlan, William; Ghalib, Reem; Oguchi, Godson; Thuluvath, Paul J.; Ortiz-Lasanta, Grisell; Rabinovitz, Mordechai; Bernstein, David; Bennett, Michael; Hawkins, Trevor; Ravendhran, Natarajan; Sheikh, Aasim M.; Varunok, Peter; Kowdley, Kris V.; Hennicken, Delphine; McPhee, Fiona; Rana, Khurram; Hughes, Eric A.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1127-1135</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are limited, with the currently approved all-oral regimens requiring 24-wk treatment and the addn. of ribavirin (RBV).  This phase III study (ALLY-3; : NCT02032901) evaluated the 12-wk regimen of daclatasvir (DCV; pangenotypic nonstructural protein [NS]5A inhibitor) plus sofosbuvir (SOF; pangenotypic NS5B inhibitor) in patients infected with genotype 3.  Patients were either treatment naive (n = 101) or treatment experienced (n = 51) and received DCV 60 mg plus SOF 400 mg once-daily for 12 wk.  Coprimary endpoints were the proportions of treatment-naive and treatment-experienced patients achieving a sustained virol. response (SVR) at post-treatment week 12 (SVR12).  SVR12 rates were 90% (91 of 101) and 86% (44 of 51) in treatment-naive and treatment-experienced patients, resp.; no virol. breakthrough was obsd., and ≥99% of patients had a virol. response (VR) at the end of treatment.  SVR12 rates were higher in patients without cirrhosis (96%; 105 of 109) than in those with cirrhosis (63%; 20 of 32).  Five of seven patients who previously failed treatment with an SOF-contg. regimen and 2 of 2 who previously failed treatment with an alisporivir-contg. regimen achieved SVR12.  Baseline characteristics, including gender, age, HCV-RNA levels, and interleukin-28B genotype, did not impact virol. outcome.  DCV plus SOF was well tolerated; there were no adverse events (AEs) leading to discontinuation and only 1 serious AE on-treatment, which was unrelated to study medications.  The few treatment-emergent grade 3/4 lab. abnormalities that were obsd. were transient.  Conclusion: A 12-wk regimen of DCV plus SOF achieved SVR12 in 96% of patients with genotype 3 infection without cirrhosis and was well tolerated.  Addnl. evaluation to optimize efficacy in genotype 3-infected patients with cirrhosis is underway. (Hepatol. 2015;61:1127-1135).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqACqGC7OGEIrVg90H21EOLACvtfcHk0lhx3YTX2WS1-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlt1WktLw%253D&md5=477b15de820348180ad3bcd6694e2170</span></div><a href="/servlet/linkout?suffix=cit135c&amp;dbid=16384&amp;doi=10.1002%2Fhep.27726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27726%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DCooper%26aufirst%3DJ.%2BN.%26aulast%3DLalezari%26aufirst%3DJ.%2BP.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DGitlin%26aufirst%3DN.%26aulast%3DFreilich%26aufirst%3DB.%2BF.%26aulast%3DYounes%26aufirst%3DZ.%2BH.%26aulast%3DHarlan%26aufirst%3DW.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DOguchi%26aufirst%3DG.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DOrtiz-Lasanta%26aufirst%3DG.%26aulast%3DRabinovitz%26aufirst%3DM.%26aulast%3DBernstein%26aufirst%3DD.%26aulast%3DBennett%26aufirst%3DM.%26aulast%3DHawkins%26aufirst%3DT.%26aulast%3DRavendhran%26aufirst%3DN.%26aulast%3DSheikh%26aufirst%3DA.%2BM.%26aulast%3DVarunok%26aufirst%3DP.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DHennicken%26aufirst%3DD.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DRana%26aufirst%3DK.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26atitle%3DALLY-3%2520Study%2520Team.%2520All-oral%252012-week%2520treatment%2520with%2520daclatasvir%2520plus%2520sofosbuvir%2520in%2520patients%2520with%2520hepatitis%2520C%2520virus%2520genotype%25203%2520infection%253A%2520ALLY-3%2520phase%2520III%2520study%26jtitle%3DHepatology%26date%3D2015%26volume%3D61%26spage%3D1127%26epage%3D1135%26doi%3D10.1002%2Fhep.27726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vierling, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noviello, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, E. S.</span><span> </span><span class="NLM_article-title">Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1493</span><span class="NLM_x">–</span> <span class="NLM_lpage">1505</span><span class="refDoi"> DOI: 10.1002/hep.28446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.28446" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2016&pages=1493-1505&author=F.+Poordadauthor=E.+R.+Schiffauthor=J.+M.+Vierlingauthor=C.+Landisauthor=R.+J.+Fontanaauthor=R.+Yangauthor=F.+McPheeauthor=E.+A.+Hughesauthor=S.+Novielloauthor=E.+S.+Swenson&title=Daclatasvir+with+sofosbuvir+and+ribavirin+for+hepatitis+C+virus+infection+with+advanced+cirrhosis+or+post-liver+transplantation+recurrence&doi=10.1002%2Fhep.28446"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2Fhep.28446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.28446%26sid%3Dliteratum%253Aachs%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DSchiff%26aufirst%3DE.%2BR.%26aulast%3DVierling%26aufirst%3DJ.%2BM.%26aulast%3DLandis%26aufirst%3DC.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DNoviello%26aufirst%3DS.%26aulast%3DSwenson%26aufirst%3DE.%2BS.%26atitle%3DDaclatasvir%2520with%2520sofosbuvir%2520and%2520ribavirin%2520for%2520hepatitis%2520C%2520virus%2520infection%2520with%2520advanced%2520cirrhosis%2520or%2520post-liver%2520transplantation%2520recurrence%26jtitle%3DHepatology%26date%3D2016%26volume%3D63%26spage%3D1493%26epage%3D1505%26doi%3D10.1002%2Fhep.28446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronowicki, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loustaud-Ratti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gea, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olveira, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banyai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Assi, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thabut, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pruitt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beumont-Mauviel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouwerkerk-Mahadevan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picchio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bifano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPhee, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boparai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noviello, S.</span><span> </span><span class="NLM_article-title">LEAGUE-1 Study Team. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">292</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span><span class="refDoi"> DOI: 10.1016/j.jhep.2015.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2015.09.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=292-300&author=S.+Zeuzemauthor=C.+H%C3%A9zodeauthor=J.+P.+Bronowickiauthor=V.+Loustaud-Rattiauthor=F.+Geaauthor=M.+Butiauthor=A.+Olveiraauthor=T.+Banyaiauthor=M.+T.+Al-Assiauthor=J.+Petersenauthor=D.+Thabutauthor=A.+Gadanoauthor=R.+Pruittauthor=M.+Makaraauthor=M.+Bourli%C3%A8reauthor=S.+Polauthor=M.+Beumont-Mauvielauthor=S.+Ouwerkerk-Mahadevanauthor=G.+Picchioauthor=M.+Bifanoauthor=F.+McPheeauthor=N.+Boparaiauthor=K.+Cheungauthor=E.+A.+Hughesauthor=S.+Noviello&title=LEAGUE-1+Study+Team.+Daclatasvir+plus+simeprevir+with+or+without+ribavirin+for+the+treatment+of+chronic+hepatitis+C+virus+genotype+1+infection&doi=10.1016%2Fj.jhep.2015.09.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2015.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2015.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DBronowicki%26aufirst%3DJ.%2BP.%26aulast%3DLoustaud-Ratti%26aufirst%3DV.%26aulast%3DGea%26aufirst%3DF.%26aulast%3DButi%26aufirst%3DM.%26aulast%3DOlveira%26aufirst%3DA.%26aulast%3DBanyai%26aufirst%3DT.%26aulast%3DAl-Assi%26aufirst%3DM.%2BT.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DThabut%26aufirst%3DD.%26aulast%3DGadano%26aufirst%3DA.%26aulast%3DPruitt%26aufirst%3DR.%26aulast%3DMakara%26aufirst%3DM.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DPol%26aufirst%3DS.%26aulast%3DBeumont-Mauviel%26aufirst%3DM.%26aulast%3DOuwerkerk-Mahadevan%26aufirst%3DS.%26aulast%3DPicchio%26aufirst%3DG.%26aulast%3DBifano%26aufirst%3DM.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DBoparai%26aufirst%3DN.%26aulast%3DCheung%26aufirst%3DK.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DNoviello%26aufirst%3DS.%26atitle%3DLEAGUE-1%2520Study%2520Team.%2520Daclatasvir%2520plus%2520simeprevir%2520with%2520or%2520without%2520ribavirin%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D64%26spage%3D292%26epage%3D300%26doi%3D10.1016%2Fj.jhep.2015.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Afdhal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chojkier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puoti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero-Gomez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarski, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggisch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bräu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span> </span><span class="NLM_article-title">for the ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1889</span><span class="NLM_x">–</span> <span class="NLM_lpage">1898</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1402454" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1889-1898&author=N.+Afdhalauthor=S.+Zeuzemauthor=P.+Kwoauthor=M.+Chojkierauthor=N.+Gitlinauthor=M.+Puotiauthor=M.+Romero-Gomezauthor=J.-P.+Zarskiauthor=K.+Agarwalauthor=P.+Buggischauthor=G.+R.+Fosterauthor=N.+Br%C3%A4uauthor=M.+Butiauthor=I.+M.+Jacobsonauthor=G.+M.+Subramanianauthor=X.+Dingauthor=H.+Moauthor=J.+C.+Yangauthor=P.+S.+Pangauthor=W.+T.+Symondsauthor=J.+G.+McHutchisonauthor=A.+J.+Muirauthor=A.+Mangiaauthor=P.+Marcellin&title=for+the+ION-1+Investigators.+Ledipasvir+and+sofosbuvir+for+untreated+HCV+genotype+1+infection&doi=10.1056%2FNEJMoa1402454"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402454%26sid%3Dliteratum%253Aachs%26aulast%3DAfdhal%26aufirst%3DN.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DKwo%26aufirst%3DP.%26aulast%3DChojkier%26aufirst%3DM.%26aulast%3DGitlin%26aufirst%3DN.%26aulast%3DPuoti%26aufirst%3DM.%26aulast%3DRomero-Gomez%26aufirst%3DM.%26aulast%3DZarski%26aufirst%3DJ.-P.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DBuggisch%26aufirst%3DP.%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DBr%25C3%25A4u%26aufirst%3DN.%26aulast%3DButi%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DMarcellin%26aufirst%3DP.%26atitle%3Dfor%2520the%2520ION-1%2520Investigators.%2520Ledipasvir%2520and%2520sofosbuvir%2520for%2520untreated%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1889%26epage%3D1898%26doi%3D10.1056%2FNEJMoa1402454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit138b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Afdhal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahass, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitlin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herring, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bisceglie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arora, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvory-Sobol, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwo, P.</span><span> </span><span class="NLM_article-title">for the ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1483</span><span class="NLM_x">–</span> <span class="NLM_lpage">1493</span><span class="refDoi"> DOI: 10.1056/NEJMoa1316366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1316366" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1483-1493&author=N.+Afdhalauthor=K.+R.+Reddyauthor=D.+R.+Nelsonauthor=E.+Lawitzauthor=S.+C.+Gordonauthor=E.+Schiffauthor=R.+Nahassauthor=R.+Ghalibauthor=N.+Gitlinauthor=R.+Herringauthor=J.+Lalezariauthor=Z.+H.+Younesauthor=P.+J.+Pockrosauthor=A.+M.+Di+Bisceglieauthor=S.+Aroraauthor=G.+M.+Subramanianauthor=Y.+Zhuauthor=H.+Dvory-Sobolauthor=J.+C.+Yangauthor=P.+S.+Pangauthor=W.+T.+Symondsauthor=J.+G.+McHutchisonauthor=A.+J.+Muirauthor=M.+Sulkowskiauthor=P.+Kwo&title=for+the+ION-2+Investigators.+Ledipasvir+and+sofosbuvir+for+previously+treated+HCV+genotype+1+infection&doi=10.1056%2FNEJMoa1316366"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1316366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1316366%26sid%3Dliteratum%253Aachs%26aulast%3DAfdhal%26aufirst%3DN.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DSchiff%26aufirst%3DE.%26aulast%3DNahass%26aufirst%3DR.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DGitlin%26aufirst%3DN.%26aulast%3DHerring%26aufirst%3DR.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DYounes%26aufirst%3DZ.%2BH.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DDi%2BBisceglie%26aufirst%3DA.%2BM.%26aulast%3DArora%26aufirst%3DS.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DDvory-Sobol%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DSulkowski%26aufirst%3DM.%26aulast%3DKwo%26aufirst%3DP.%26atitle%3Dfor%2520the%2520ION-2%2520Investigators.%2520Ledipasvir%2520and%2520sofosbuvir%2520for%2520previously%2520treated%2520HCV%2520genotype%25201%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1483%26epage%3D1493%26doi%3D10.1056%2FNEJMoa1316366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit138c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossaro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiffman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chojkier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herring, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bisceglie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svarovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pound, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ION-3 Investigators.</span><span> </span><span class="NLM_article-title">Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1879</span><span class="NLM_x">–</span> <span class="NLM_lpage">1888</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1402355" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1879-1888&author=K.+V.+Kowdleyauthor=S.+C.+Gordonauthor=K.+R.+Reddyauthor=L.+Rossaroauthor=D.+E.+Bernsteinauthor=E.+Lawitzauthor=M.+L.+Shiffmanauthor=E.+Schiffauthor=R.+Ghalibauthor=M.+Ryanauthor=V.+Rustgiauthor=M.+Chojkierauthor=R.+Herringauthor=A.+M.+Di+Bisceglieauthor=P.+J.+Pockrosauthor=G.+M.+Subramanianauthor=D.+Anauthor=E.+Svarovskaiaauthor=R.+H.+Hylandauthor=P.+S.+Pangauthor=W.+T.+Symondsauthor=J.+G.+McHutchisonauthor=A.+J.+Muirauthor=D.+Poundauthor=M.+W.+Friedauthor=ION-3+Investigators.&title=Ledipasvir+and+sofosbuvir+for+8+or+12+weeks+for+chronic+HCV+without+cirrhosis&doi=10.1056%2FNEJMoa1402355"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402355%26sid%3Dliteratum%253Aachs%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DRossaro%26aufirst%3DL.%26aulast%3DBernstein%26aufirst%3DD.%2BE.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DShiffman%26aufirst%3DM.%2BL.%26aulast%3DSchiff%26aufirst%3DE.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DRyan%26aufirst%3DM.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DChojkier%26aufirst%3DM.%26aulast%3DHerring%26aufirst%3DR.%26aulast%3DDi%2BBisceglie%26aufirst%3DA.%2BM.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DAn%26aufirst%3DD.%26aulast%3DSvarovskaia%26aufirst%3DE.%26aulast%3DHyland%26aufirst%3DR.%2BH.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DPound%26aufirst%3DD.%26aulast%3DFried%26aufirst%3DM.%2BW.%26aulast%3D%26atitle%3DLedipasvir%2520and%2520sofosbuvir%2520for%25208%2520or%252012%2520weeks%2520for%2520chronic%2520HCV%2520without%2520cirrhosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1879%26epage%3D1888%26doi%3D10.1056%2FNEJMoa1402355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit138d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Alqahtani, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afdhal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pound, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M.</span><span> </span><span class="NLM_article-title">Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span><span class="refDoi"> DOI: 10.1002/hep.27890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.27890" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=25-30&author=S.+A.+Alqahtaniauthor=N.+Afdhalauthor=S.+Zeuzemauthor=S.+C.+Gordonauthor=A.+Mangiaauthor=P.+Kwoauthor=M.+Friedauthor=J.+C.+Yangauthor=X.+Dingauthor=P.+S.+Pangauthor=J.+G.+McHutchisonauthor=D.+Poundauthor=K.+R.+Reddyauthor=P.+Marcellinauthor=K.+V.+Kowdleyauthor=M.+Sulkowski&title=Safety+and+tolerability+of+ledipasvir%2Fsofosbuvir+with+and+without+ribavirin+in+patients+with+chronic+hepatitis+C+virus+genotype+1+infection%3A+analysis+of+phase+III+ION+trials&doi=10.1002%2Fhep.27890"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138d&amp;dbid=16384&amp;doi=10.1002%2Fhep.27890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27890%26sid%3Dliteratum%253Aachs%26aulast%3DAlqahtani%26aufirst%3DS.%2BA.%26aulast%3DAfdhal%26aufirst%3DN.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DKwo%26aufirst%3DP.%26aulast%3DFried%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DPound%26aufirst%3DD.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DSulkowski%26aufirst%3DM.%26atitle%3DSafety%2520and%2520tolerability%2520of%2520ledipasvir%252Fsofosbuvir%2520with%2520and%2520without%2520ribavirin%2520in%2520patients%2520with%2520chronic%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%253A%2520analysis%2520of%2520phase%2520III%2520ION%2520trials%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D25%26epage%3D30%26doi%3D10.1002%2Fhep.27890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit138e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Naggie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saag, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workowski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruane, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towner, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luetkemeyer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baden, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sax, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santana-Bagur, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">German, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvory-Sobol, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J.G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stedman, C. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales-Ramirez, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bräu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaweera, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colson, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tebas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dieterich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M.</span><span> </span><span class="NLM_article-title">for the ION-4 Investigators. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">705</span><span class="NLM_x">–</span> <span class="NLM_lpage">713</span><span class="refDoi"> DOI: 10.1056/NEJMoa1501315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1501315" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=705-713&author=S.+Naggieauthor=C.+Cooperauthor=M.+Saagauthor=K.+Workowskiauthor=P.+Ruaneauthor=W.+J.+Townerauthor=K.+Marksauthor=A.+Luetkemeyerauthor=R.+P.+Badenauthor=P.+E.+Saxauthor=E.+Ganeauthor=J.+Santana-Bagurauthor=L.+M.+Stammauthor=J.+C.+Yangauthor=P.+Germanauthor=M.+Dvory-Sobolauthor=L.+Niauthor=P.+S.+Pangauthor=J.G.+McHutchisonauthor=C.+A.+M.+Stedmanauthor=J.+O.+Morales-Ramirezauthor=N.+Br%C3%A4uauthor=D.+Jayaweeraauthor=A.+E.+Colsonauthor=P.+Tebasauthor=D.+K.+Wongauthor=D.+Dieterichauthor=M.+Sulkowski&title=for+the+ION-4+Investigators.+Ledipasvir+and+sofosbuvir+for+HCV+in+patients+coinfected+with+HIV-1&doi=10.1056%2FNEJMoa1501315"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138e&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1501315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1501315%26sid%3Dliteratum%253Aachs%26aulast%3DNaggie%26aufirst%3DS.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DSaag%26aufirst%3DM.%26aulast%3DWorkowski%26aufirst%3DK.%26aulast%3DRuane%26aufirst%3DP.%26aulast%3DTowner%26aufirst%3DW.%2BJ.%26aulast%3DMarks%26aufirst%3DK.%26aulast%3DLuetkemeyer%26aufirst%3DA.%26aulast%3DBaden%26aufirst%3DR.%2BP.%26aulast%3DSax%26aufirst%3DP.%2BE.%26aulast%3DGane%26aufirst%3DE.%26aulast%3DSantana-Bagur%26aufirst%3DJ.%26aulast%3DStamm%26aufirst%3DL.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DGerman%26aufirst%3DP.%26aulast%3DDvory-Sobol%26aufirst%3DM.%26aulast%3DNi%26aufirst%3DL.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DMcHutchison%26aufirst%3DJ.G.%26aulast%3DStedman%26aufirst%3DC.%2BA.%2BM.%26aulast%3DMorales-Ramirez%26aufirst%3DJ.%2BO.%26aulast%3DBr%25C3%25A4u%26aufirst%3DN.%26aulast%3DJayaweera%26aufirst%3DD.%26aulast%3DColson%26aufirst%3DA.%2BE.%26aulast%3DTebas%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DD.%2BK.%26aulast%3DDieterich%26aufirst%3DD.%26aulast%3DSulkowski%26aufirst%3DM.%26atitle%3Dfor%2520the%2520ION-4%2520Investigators.%2520Ledipasvir%2520and%2520sofosbuvir%2520for%2520HCV%2520in%2520patients%2520coinfected%2520with%2520HIV-1%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D705%26epage%3D713%26doi%3D10.1056%2FNEJMoa1501315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit138f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Kohli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osinusi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meissner, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marti, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotb, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolley, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidharthan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Townsend, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egerson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapoor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spurlin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sneller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proschan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teferi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talwani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleiner, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbott, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symonds, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polis, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fauci, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masur, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottilil, S.</span><span> </span><span class="NLM_article-title">Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2a cohort study</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">385</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1113</span><span class="refDoi"> DOI: 10.1016/S0140-6736(14)61228-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0140-6736%2814%2961228-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=1107-1113&author=A.+Kohliauthor=A.+Osinusiauthor=Z.+Simsauthor=A.+Nelsonauthor=E.+G.+Meissnerauthor=L.+L.+Barrettauthor=D.+Bonauthor=M.+M.+Martiauthor=R.+Silkauthor=C.+Kotbauthor=C.+Grossauthor=T.+A.+Jolleyauthor=S.+Sidharthanauthor=T.+Petersenauthor=K.+Townsendauthor=D.+Egersonauthor=R.+Kapoorauthor=E.+Spurlinauthor=M.+Snellerauthor=M.+Proschanauthor=E.+Herrmannauthor=R.+Kwanauthor=G.+Teferiauthor=R.+Talwaniauthor=G.+Diazauthor=D.+E.+Kleinerauthor=B.+J.+Woodauthor=J.+Chavezauthor=S.+Abbottauthor=W.+T.+Symondsauthor=G.+M.+Subramanianauthor=P.+S.+Pangauthor=J.+McHutchisonauthor=M.+A.+Polisauthor=A.+S.+Fauciauthor=H.+Masurauthor=S.+Kottilil&title=Virological+response+after+6+week+triple-drug+regimens+for+hepatitis+C%3A+a+proof-of-concept+phase+2a+cohort+study&doi=10.1016%2FS0140-6736%2814%2961228-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138f&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2961228-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252961228-9%26sid%3Dliteratum%253Aachs%26aulast%3DKohli%26aufirst%3DA.%26aulast%3DOsinusi%26aufirst%3DA.%26aulast%3DSims%26aufirst%3DZ.%26aulast%3DNelson%26aufirst%3DA.%26aulast%3DMeissner%26aufirst%3DE.%2BG.%26aulast%3DBarrett%26aufirst%3DL.%2BL.%26aulast%3DBon%26aufirst%3DD.%26aulast%3DMarti%26aufirst%3DM.%2BM.%26aulast%3DSilk%26aufirst%3DR.%26aulast%3DKotb%26aufirst%3DC.%26aulast%3DGross%26aufirst%3DC.%26aulast%3DJolley%26aufirst%3DT.%2BA.%26aulast%3DSidharthan%26aufirst%3DS.%26aulast%3DPetersen%26aufirst%3DT.%26aulast%3DTownsend%26aufirst%3DK.%26aulast%3DEgerson%26aufirst%3DD.%26aulast%3DKapoor%26aufirst%3DR.%26aulast%3DSpurlin%26aufirst%3DE.%26aulast%3DSneller%26aufirst%3DM.%26aulast%3DProschan%26aufirst%3DM.%26aulast%3DHerrmann%26aufirst%3DE.%26aulast%3DKwan%26aufirst%3DR.%26aulast%3DTeferi%26aufirst%3DG.%26aulast%3DTalwani%26aufirst%3DR.%26aulast%3DDiaz%26aufirst%3DG.%26aulast%3DKleiner%26aufirst%3DD.%2BE.%26aulast%3DWood%26aufirst%3DB.%2BJ.%26aulast%3DChavez%26aufirst%3DJ.%26aulast%3DAbbott%26aufirst%3DS.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DMcHutchison%26aufirst%3DJ.%26aulast%3DPolis%26aufirst%3DM.%2BA.%26aulast%3DFauci%26aufirst%3DA.%2BS.%26aulast%3DMasur%26aufirst%3DH.%26aulast%3DKottilil%26aufirst%3DS.%26atitle%3DVirological%2520response%2520after%25206%2520week%2520triple-drug%2520regimens%2520for%2520hepatitis%2520C%253A%2520a%2520proof-of-concept%2520phase%25202a%2520cohort%2520study%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D1107%26epage%3D1113%26doi%3D10.1016%2FS0140-6736%2814%2961228-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit138g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Kohli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapoor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sims, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidharthan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotb, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teferi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugarman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osinusi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polis, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masur, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottilil, S.</span><span> </span><span class="NLM_article-title">Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study</span> <span class="citation_source-journal">Lancet Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1049</span><span class="NLM_x">–</span> <span class="NLM_lpage">1054</span><span class="refDoi"> DOI: 10.1016/S1473-3099(15)00157-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS1473-3099%2815%2900157-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=1049-1054&author=A.+Kohliauthor=R.+Kapoorauthor=Z.+Simsauthor=A.+Nelsonauthor=S.+Sidharthanauthor=B.+Lamauthor=R.+Silkauthor=C.+Kotbauthor=C.+Grossauthor=G.+Teferiauthor=K.+Sugarmanauthor=P.+S.+Pangauthor=A.+Osinusiauthor=M.+A.+Polisauthor=V.+Rustgiauthor=H.+Masurauthor=S.+Kottilil&title=Ledipasvir+and+sofosbuvir+for+hepatitis+C+genotype+4%3A+a+proof-of-concept%2C+single-centre%2C+open-label+phase+2a+cohort+study&doi=10.1016%2FS1473-3099%2815%2900157-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138g&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2815%2900157-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252815%252900157-7%26sid%3Dliteratum%253Aachs%26aulast%3DKohli%26aufirst%3DA.%26aulast%3DKapoor%26aufirst%3DR.%26aulast%3DSims%26aufirst%3DZ.%26aulast%3DNelson%26aufirst%3DA.%26aulast%3DSidharthan%26aufirst%3DS.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DSilk%26aufirst%3DR.%26aulast%3DKotb%26aufirst%3DC.%26aulast%3DGross%26aufirst%3DC.%26aulast%3DTeferi%26aufirst%3DG.%26aulast%3DSugarman%26aufirst%3DK.%26aulast%3DPang%26aufirst%3DP.%2BS.%26aulast%3DOsinusi%26aufirst%3DA.%26aulast%3DPolis%26aufirst%3DM.%2BA.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DMasur%26aufirst%3DH.%26aulast%3DKottilil%26aufirst%3DS.%26atitle%3DLedipasvir%2520and%2520sofosbuvir%2520for%2520hepatitis%2520C%2520genotype%25204%253A%2520a%2520proof-of-concept%252C%2520single-centre%252C%2520open-label%2520phase%25202a%2520cohort%2520study%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2015%26volume%3D15%26spage%3D1049%26epage%3D1054%26doi%3D10.1016%2FS1473-3099%2815%2900157-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Kumari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, M. H.</span><span> </span><span class="NLM_article-title">Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span><span class="refDoi"> DOI: 10.1517/14656566.2015.1013938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1517%2F14656566.2015.1013938" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=739-748&author=R.+Kumariauthor=M.+H.+Nguyen&title=Fixed-dose+combination+of+sofosbuvir+and+ledipasvir+for+the+treatment+of+chronic+hepatitis+C+genotype+1&doi=10.1517%2F14656566.2015.1013938"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1517%2F14656566.2015.1013938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2015.1013938%26sid%3Dliteratum%253Aachs%26aulast%3DKumari%26aufirst%3DR.%26aulast%3DNguyen%26aufirst%3DM.%2BH.%26atitle%3DFixed-dose%2520combination%2520of%2520sofosbuvir%2520and%2520ledipasvir%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520genotype%25201%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26volume%3D16%26spage%3D739%26epage%3D748%26doi%3D10.1517%2F14656566.2015.1013938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Deeks, E. D.</span><span> </span><span class="NLM_article-title">Ombitasvir/paritaprevir/ritonavir plus dasabuvir: a review in chronic HCV genotype 1 infection</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">1027</span><span class="NLM_x">–</span> <span class="NLM_lpage">1038</span><span class="refDoi"> DOI: 10.1007/s40265-015-0412-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1007%2Fs40265-015-0412-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26059288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKlsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1027-1038&author=E.+D.+Deeks&title=Ombitasvir%2Fparitaprevir%2Fritonavir+plus+dasabuvir%3A+a+review+in+chronic+HCV+genotype+1+infection&doi=10.1007%2Fs40265-015-0412-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1027-1038</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A fixed-dose tablet comprising ombitasvir (an NS5A replication complex inhibitor), paritaprevir (an NS3/4A protease inhibitor) and ritonavir (a cytochrome P 450 inhibitor) taken in combination with dasabuvir (an NS5B polymerase inhibitor) is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in several countries, including the USA (copackaged as Viekira Pak) and those of the EU (Viekirax and Exviera).  In phase II and III trials, this interferon-free regimen, taken ± ribavirin, provided high rates of sustained virol. response 12 wk post-treatment in adults with chronic HCV genotype 1a or 1b infection, including those with compensated cirrhosis, liver transplants or HIV-1 co-infection.  The regimen was generally well tolerated, with nausea, insomnia, asthenia, pruritus, other skin reactions and fatigue being among the most common tolerability issues.  Thus, ombitasvir/paritaprevir/ritonavir plus dasabuvir is an effective interferon-free, direct-acting antiviral regimen for use ± ribavirin in a broad range of adults chronically infected with HCV genotype 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW5HI8UPXjAbVg90H21EOLACvtfcHk0lilDjH6-2Huow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKlsr3K&md5=d15144247ccea647d11855b4b087c3fa</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0412-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0412-z%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DOmbitasvir%252Fparitaprevir%252Fritonavir%2520plus%2520dasabuvir%253A%2520a%2520review%2520in%2520chronic%2520HCV%2520genotype%25201%2520infection%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1027%26epage%3D1038%26doi%3D10.1007%2Fs40265-015-0412-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ferenci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marinho, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younes, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enayati, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baruch, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhandari, B.R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexandru Caruntu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sepe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chulanov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janczewska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzardini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gervain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassanein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podsadecki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span> </span><span class="NLM_article-title">ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1983</span><span class="NLM_x">–</span> <span class="NLM_lpage">1992</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1402338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24795200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1983-1992&author=P.+Ferenciauthor=D.+Bernsteinauthor=J.+Lalezariauthor=D.+Cohenauthor=Y.+Luoauthor=C.+Cooperauthor=E.+Tamauthor=R.+T.+Marinhoauthor=N.+Tsaiauthor=A.+Nybergauthor=T.+D.+Boxauthor=Z.+Younesauthor=P.+Enayatiauthor=S.+Greenauthor=Y.+Baruchauthor=B.R.+Bhandariauthor=F.+Alexandru+Caruntuauthor=T.+Sepeauthor=V.+Chulanovauthor=E.+Janczewskaauthor=G.+Rizzardiniauthor=J.+Gervainauthor=R.+Planasauthor=C.+Morenoauthor=T.+Hassaneinauthor=W.+Xieauthor=M.+Kingauthor=T.+Podsadeckiauthor=K.+R.+Reddy&title=ABT-450%2Fr-ombitasvir+and+dasabuvir+with+or+without+ribavirin+for+HCV&doi=10.1056%2FNEJMoa1402338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141aR"><div class="casContent"><span class="casTitleNuber">141a</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-450/r-mbitasvir and dasabuvir with or without ribavirin for HCV</span></div><div class="casAuthors">Ferenci, Peter; Bernstein, David; Lalezari, Jacob; Cohen, Daniel; Luo, Yan; Cooper, Curtis; Tam, Edward; Marinho, Rui T.; Tsai, Naoky; Nyberg, Anders; Box, Terry D.; Younes, Ziad; Enayati, Pedram; Green, Sinikka; Baruch, Yaacov; Bhandari, Bal Raj; Caruntu, Florin Alexandru; Sepe, Thomas; Chulanov, Vladimir; Janczewska, Ewa; Rizzardini, Giuliano; Gervain, Judit; Planas, Ramon; Moreno, Christophe; Hassanein, Tarek; Xie, Wangang; King, Martin; Podsadecki, Thomas; Reddy, K. Rajender</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1983-1992, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir, and dasabuvir with or without ribavirin has shown efficacy in inducing a sustained virol. response in a phase 2 study involving patients with hepatitis C virus (HCV) genotype 1 infection.  We conducted two phase 3 trials to examine the efficacy and safety of this regimen in previously untreated patients with HCV genotype 1 infection and no cirrhosis.  Methods: We randomly assigned 419 patients with HCV genotype 1b infection (PEARL-III study) and 305 patients with genotype 1a infection (PEARL-IV study) to 12 wk of ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir), dasabuvir (250 mg twice daily), and ribavirin administered according to body wt. or to matching placebo for ribavirin.  The primary efficacy end point was a sustained virol. response (an HCV RNA level of <25 IU per mL) 12 wk after the end of treatment.  Results: The study regimen resulted in high rates of sustained virol. response among patients with HCV genotype 1b infection (99.5% with ribavirin and 99.0% without ribavirin) and among those with genotype 1a infection (97.0% and 90.2%, resp.).  Of patients with genotype 1b infection, 1 had virol. failure, and 2 did not have data available at post-treatment week 12.  Among patients with genotype 1a infection, the rate of virol. failure was higher in the ribavirin-free group than in the ribavirin group (7.8% vs. 2.0%).  In both studies, decreases in the Hb level were significantly more common in patients receiving ribavirin.  Two patients (0.3%) discontinued the study drugs owing to adverse events.  The most common adverse events were fatigue, headache, and nausea.  Conclusions: Twelve weeks of treatment with ABT-450/r-ombitasvir and dasabuvir without ribavirin was assocd. with high rates of sustained virol. response among previously untreated patients with HCV genotype 1 infection.  Rates of virol. failure were higher without ribavirin than with ribavirin among patients with genotype 1a infection but not among those with genotype 1b infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru0b7jyqCe37Vg90H21EOLACvtfcHk0lhc5ctNO33eOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbnN&md5=b08a13aba3156a82bdcdd71203269b28</span></div><a href="/servlet/linkout?suffix=cit141a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402338%26sid%3Dliteratum%253Aachs%26aulast%3DFerenci%26aufirst%3DP.%26aulast%3DBernstein%26aufirst%3DD.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DE.%26aulast%3DMarinho%26aufirst%3DR.%2BT.%26aulast%3DTsai%26aufirst%3DN.%26aulast%3DNyberg%26aufirst%3DA.%26aulast%3DBox%26aufirst%3DT.%2BD.%26aulast%3DYounes%26aufirst%3DZ.%26aulast%3DEnayati%26aufirst%3DP.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DBaruch%26aufirst%3DY.%26aulast%3DBhandari%26aufirst%3DB.R.%26aulast%3DAlexandru%2BCaruntu%26aufirst%3DF.%26aulast%3DSepe%26aufirst%3DT.%26aulast%3DChulanov%26aufirst%3DV.%26aulast%3DJanczewska%26aufirst%3DE.%26aulast%3DRizzardini%26aufirst%3DG.%26aulast%3DGervain%26aufirst%3DJ.%26aulast%3DPlanas%26aufirst%3DR.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DKing%26aufirst%3DM.%26aulast%3DPodsadecki%26aufirst%3DT.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26atitle%3DABT-450%252Fr-ombitasvir%2520and%2520dasabuvir%2520with%2520or%2520without%2520ribavirin%2520for%2520HCV%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1983%26epage%3D1992%26doi%3D10.1056%2FNEJMoa1402338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit141b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hezode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trinh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowdley, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiffman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedemeyer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forns, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Silva-Tillmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podsadecki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, B.</span><span> </span><span class="NLM_article-title">ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1973</span><span class="NLM_x">–</span> <span class="NLM_lpage">1982</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402869</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1402869" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1973-1982&author=F.+Poordadauthor=C.+Hezodeauthor=R.+Trinhauthor=K.+V.+Kowdleyauthor=S.+Zeuzemauthor=K.+Agarwalauthor=M.+L.+Shiffmanauthor=H.+Wedemeyerauthor=T.+Bergauthor=E.+M.+Yoshidaauthor=X.+Fornsauthor=S.+S.+Lovellauthor=B.+Da+Silva-Tillmannauthor=C.+A.+Collinsauthor=A.+L.+Campbellauthor=T.+Podsadeckiauthor=B.+Bernstein&title=ABT-450%2Fr-ombitasvir+and+dasabuvir+with+ribavirin+for+hepatitis+C+with+cirrhosis&doi=10.1056%2FNEJMoa1402869"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402869%26sid%3Dliteratum%253Aachs%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DHezode%26aufirst%3DC.%26aulast%3DTrinh%26aufirst%3DR.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DShiffman%26aufirst%3DM.%2BL.%26aulast%3DWedemeyer%26aufirst%3DH.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DE.%2BM.%26aulast%3DForns%26aufirst%3DX.%26aulast%3DLovell%26aufirst%3DS.%2BS.%26aulast%3DDa%2BSilva-Tillmann%26aufirst%3DB.%26aulast%3DCollins%26aufirst%3DC.%2BA.%26aulast%3DCampbell%26aufirst%3DA.%2BL.%26aulast%3DPodsadecki%26aufirst%3DT.%26aulast%3DBernstein%26aufirst%3DB.%26atitle%3DABT-450%252Fr-ombitasvir%2520and%2520dasabuvir%2520with%2520ribavirin%2520for%2520hepatitis%2520C%2520with%2520cirrhosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1973%26epage%3D1982%26doi%3D10.1056%2FNEJMoa1402869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit141c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baykal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marinho, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poordad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedemeyer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desmond, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bisceglie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varunok, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassanein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilot-Matias, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DaSilva-Tillmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podsadecki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, B.</span><span> </span><span class="NLM_article-title">Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1604</span><span class="NLM_x">–</span> <span class="NLM_lpage">1614</span><span class="refDoi"> DOI: 10.1056/NEJMoa1401561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1401561" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1604-1614&author=S.+Zeuzemauthor=I.+M.+Jacobsonauthor=T.+Baykalauthor=R.+T.+Marinhoauthor=F.+Poordadauthor=M.+Bourli%C3%A8reauthor=M.+S.+Sulkowskiauthor=H.+Wedemeyerauthor=E.+Tamauthor=P.+Desmondauthor=D.+M.+Jensenauthor=A.+M.+Di+Bisceglieauthor=P.+Varunokauthor=T.+Hassaneinauthor=J.+Xiongauthor=T.+Pilot-Matiasauthor=B.+DaSilva-Tillmannauthor=L.+Larsenauthor=T.+Podsadeckiauthor=B.+Bernstein&title=Retreatment+of+HCV+with+ABT-450%2Fr-ombitasvir+and+dasabuvir+with+ribavirin&doi=10.1056%2FNEJMoa1401561"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1401561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1401561%26sid%3Dliteratum%253Aachs%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DBaykal%26aufirst%3DT.%26aulast%3DMarinho%26aufirst%3DR.%2BT.%26aulast%3DPoordad%26aufirst%3DF.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DWedemeyer%26aufirst%3DH.%26aulast%3DTam%26aufirst%3DE.%26aulast%3DDesmond%26aufirst%3DP.%26aulast%3DJensen%26aufirst%3DD.%2BM.%26aulast%3DDi%2BBisceglie%26aufirst%3DA.%2BM.%26aulast%3DVarunok%26aufirst%3DP.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DXiong%26aufirst%3DJ.%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DDaSilva-Tillmann%26aufirst%3DB.%26aulast%3DLarsen%26aufirst%3DL.%26aulast%3DPodsadecki%26aufirst%3DT.%26aulast%3DBernstein%26aufirst%3DB.%26atitle%3DRetreatment%2520of%2520HCV%2520with%2520ABT-450%252Fr-ombitasvir%2520and%2520dasabuvir%2520with%2520ribavirin%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1604%26epage%3D1614%26doi%3D10.1056%2FNEJMoa1401561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit141d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Sulkowski, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eron, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trinh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalezari, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gathe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruane, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elion, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bredeek, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blick, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khatri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredrick, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilot-Matias, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Silva-Tillmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGovern, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podsadecki, T.</span><span> </span><span class="NLM_article-title">Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1. A Randomized Trial</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">1223</span><span class="NLM_x">–</span> <span class="NLM_lpage">1231</span><span class="refDoi"> DOI: 10.1001/jama.2015.1328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1001%2Fjama.2015.1328" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2015&pages=1223-1231&author=M.+S.+Sulkowskiauthor=J.+J.+Eronauthor=D.+Wylesauthor=R.+Trinhauthor=J.+Lalezariauthor=C.+Wangauthor=J.+Slimauthor=L.+Bhattiauthor=J.+Gatheauthor=P.+J.+Ruaneauthor=R.+Elionauthor=F.+Bredeekauthor=R.+Brennanauthor=G.+Blickauthor=A.+Khatriauthor=K.+Gibbonsauthor=Y.+B.+Huauthor=L.+Fredrickauthor=G.+Schnellauthor=T.+Pilot-Matiasauthor=R.+Tripathiauthor=B.+Da+Silva-Tillmannauthor=B.+McGovernauthor=A.+L.+Campbellauthor=T.+Podsadecki&title=Ombitasvir%2C+paritaprevir+co-dosed+with+ritonavir%2C+dasabuvir%2C+and+ribavirin+for+hepatitis+C+in+patients+co-infected+with+HIV-1.+A+Randomized+Trial&doi=10.1001%2Fjama.2015.1328"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141d&amp;dbid=16384&amp;doi=10.1001%2Fjama.2015.1328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2015.1328%26sid%3Dliteratum%253Aachs%26aulast%3DSulkowski%26aufirst%3DM.%2BS.%26aulast%3DEron%26aufirst%3DJ.%2BJ.%26aulast%3DWyles%26aufirst%3DD.%26aulast%3DTrinh%26aufirst%3DR.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSlim%26aufirst%3DJ.%26aulast%3DBhatti%26aufirst%3DL.%26aulast%3DGathe%26aufirst%3DJ.%26aulast%3DRuane%26aufirst%3DP.%2BJ.%26aulast%3DElion%26aufirst%3DR.%26aulast%3DBredeek%26aufirst%3DF.%26aulast%3DBrennan%26aufirst%3DR.%26aulast%3DBlick%26aufirst%3DG.%26aulast%3DKhatri%26aufirst%3DA.%26aulast%3DGibbons%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DY.%2BB.%26aulast%3DFredrick%26aufirst%3DL.%26aulast%3DSchnell%26aufirst%3DG.%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DTripathi%26aufirst%3DR.%26aulast%3DDa%2BSilva-Tillmann%26aufirst%3DB.%26aulast%3DMcGovern%26aufirst%3DB.%26aulast%3DCampbell%26aufirst%3DA.%2BL.%26aulast%3DPodsadecki%26aufirst%3DT.%26atitle%3DOmbitasvir%252C%2520paritaprevir%2520co-dosed%2520with%2520ritonavir%252C%2520dasabuvir%252C%2520and%2520ribavirin%2520for%2520hepatitis%2520C%2520in%2520patients%2520co-infected%2520with%2520HIV-1.%2520A%2520Randomized%2520Trial%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2015%26volume%3D313%26spage%3D1223%26epage%3D1231%26doi%3D10.1001%2Fjama.2015.1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit141e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asselah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassanein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berenguer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleischer-Stepniewska, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilot-Matias, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mobashery, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilchez, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, S.</span><span> </span><span class="NLM_article-title">Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">385</span><span class="NLM_x">, </span> <span class="NLM_fpage">2502</span><span class="NLM_x">–</span> <span class="NLM_lpage">2509</span><span class="refDoi"> DOI: 10.1016/S0140-6736(15)60159-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0140-6736%2815%2960159-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=2502-2509&author=C.+H%C3%A9zodeauthor=T.+Asselahauthor=K.+R.+Reddyauthor=T.+Hassaneinauthor=M.+Berenguerauthor=K.+Fleischer-Stepniewskaauthor=P.+Marcellinauthor=C.+Hallauthor=G.+Schnellauthor=T.+Pilot-Matiasauthor=N.+Mobasheryauthor=R.+Redmanauthor=R.+A.+Vilchezauthor=S.+Pol&title=Ombitasvir+plus+paritaprevir+plus+ritonavir+with+or+without+ribavirin+in+treatment-naive+and+treatment-experienced+patients+with+genotype+4+chronic+hepatitis+C+virus+infection+%28PEARL-I%29%3A+a+randomised%2C+open-label+trial&doi=10.1016%2FS0140-6736%2815%2960159-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141e&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2960159-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252960159-3%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DBerenguer%26aufirst%3DM.%26aulast%3DFleischer-Stepniewska%26aufirst%3DK.%26aulast%3DMarcellin%26aufirst%3DP.%26aulast%3DHall%26aufirst%3DC.%26aulast%3DSchnell%26aufirst%3DG.%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DMobashery%26aufirst%3DN.%26aulast%3DRedman%26aufirst%3DR.%26aulast%3DVilchez%26aufirst%3DR.%2BA.%26aulast%3DPol%26aufirst%3DS.%26atitle%3DOmbitasvir%2520plus%2520paritaprevir%2520plus%2520ritonavir%2520with%2520or%2520without%2520ribavirin%2520in%2520treatment-naive%2520and%2520treatment-experienced%2520patients%2520with%2520genotype%25204%2520chronic%2520hepatitis%2520C%2520virus%2520infection%2520%2528PEARL-I%2529%253A%2520a%2520randomised%252C%2520open-label%2520trial%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D2502%26epage%3D2509%26doi%3D10.1016%2FS0140-6736%2815%2960159-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Kwo, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantry, P.S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coakley, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Te, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitsky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terrault, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, J. R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setze, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilot-Matias, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilchez, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forns, X.</span><span> </span><span class="NLM_article-title">An interferon-free antiviral regimen for HCV after liver transplantation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">2375</span><span class="NLM_x">–</span> <span class="NLM_lpage">2382</span><span class="refDoi"> DOI: 10.1056/NEJMoa1408921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1408921" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=2375-2382&author=P.+Y.+Kwoauthor=P.S.+Mantryauthor=E.+Coakleyauthor=H.+S.+Teauthor=H.+E.+Vargasauthor=R.+Brownauthor=F.+Gordonauthor=J.+Levitskyauthor=N.+A.+Terraultauthor=J.+R.+Burtonauthor=W.+Xieauthor=C.+Setzeauthor=P.+Badriauthor=T.+Pilot-Matiasauthor=R.+A.+Vilchezauthor=X.+Forns&title=An+interferon-free+antiviral+regimen+for+HCV+after+liver+transplantation&doi=10.1056%2FNEJMoa1408921"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1408921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1408921%26sid%3Dliteratum%253Aachs%26aulast%3DKwo%26aufirst%3DP.%2BY.%26aulast%3DMantry%26aufirst%3DP.S.%26aulast%3DCoakley%26aufirst%3DE.%26aulast%3DTe%26aufirst%3DH.%2BS.%26aulast%3DVargas%26aufirst%3DH.%2BE.%26aulast%3DBrown%26aufirst%3DR.%26aulast%3DGordon%26aufirst%3DF.%26aulast%3DLevitsky%26aufirst%3DJ.%26aulast%3DTerrault%26aufirst%3DN.%2BA.%26aulast%3DBurton%26aufirst%3DJ.%2BR.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DSetze%26aufirst%3DC.%26aulast%3DBadri%26aufirst%3DP.%26aulast%3DPilot-Matias%26aufirst%3DT.%26aulast%3DVilchez%26aufirst%3DR.%2BA.%26aulast%3DForns%26aufirst%3DX.%26atitle%3DAn%2520interferon-free%2520antiviral%2520regimen%2520for%2520HCV%2520after%2520liver%2520transplantation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D2375%26epage%3D2382%26doi%3D10.1056%2FNEJMoa1408921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Keating, G. M.</span><span> </span><span class="NLM_article-title">Elbasvir/grazoprevir: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span><span class="refDoi"> DOI: 10.1007/s40265-016-0558-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1007%2Fs40265-016-0558-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=617-624&author=G.+M.+Keating&title=Elbasvir%2Fgrazoprevir%3A+first+global+approval&doi=10.1007%2Fs40265-016-0558-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0558-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0558-3%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DElbasvir%252Fgrazoprevir%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D617%26epage%3D624%26doi%3D10.1007%2Fs40265-016-0558-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Carrion, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, P.</span><span> </span><span class="NLM_article-title">Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">883</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span><span class="refDoi"> DOI: 10.1080/14740338.2016.1179278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1080%2F14740338.2016.1179278" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=883-890&author=A.+F.+Carrionauthor=P.+Martin&title=Safety+and+efficacy+of+elbasvir+and+grazoprevir+for+treatment+of+hepatitis+C&doi=10.1080%2F14740338.2016.1179278"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144a&amp;dbid=16384&amp;doi=10.1080%2F14740338.2016.1179278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14740338.2016.1179278%26sid%3Dliteratum%253Aachs%26aulast%3DCarrion%26aufirst%3DA.%2BF.%26aulast%3DMartin%26aufirst%3DP.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520elbasvir%2520and%2520grazoprevir%2520for%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2016%26volume%3D15%26spage%3D883%26epage%3D890%26doi%3D10.1080%2F14740338.2016.1179278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit144b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Alric, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnet, D.</span><span> </span><span class="NLM_article-title">Grazoprevir + elbasvir for the treatment of hepatitis C virus infection</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">735</span><span class="NLM_x">–</span> <span class="NLM_lpage">742</span><span class="refDoi"> DOI: 10.1517/14656566.2016.1161028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1517%2F14656566.2016.1161028" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=735-742&author=L.+Alricauthor=D.+Bonnet&title=Grazoprevir+%2B+elbasvir+for+the+treatment+of+hepatitis+C+virus+infection&doi=10.1517%2F14656566.2016.1161028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144b&amp;dbid=16384&amp;doi=10.1517%2F14656566.2016.1161028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2016.1161028%26sid%3Dliteratum%253Aachs%26aulast%3DAlric%26aufirst%3DL.%26aulast%3DBonnet%26aufirst%3DD.%26atitle%3DGrazoprevir%2520%252B%2520elbasvir%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2016%26volume%3D17%26spage%3D735%26epage%3D742%26doi%3D10.1517%2F14656566.2016.1161028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit144c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Landaverde, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, J. L.</span><span> </span><span class="NLM_article-title">Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection</span> <span class="citation_source-journal">Expert Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">419</span><span class="NLM_x">–</span> <span class="NLM_lpage">429</span><span class="refDoi"> DOI: 10.1586/17474124.2016.1147346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1586%2F17474124.2016.1147346" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=419-429&author=C.+Landaverdeauthor=J.+Wellsauthor=R.+Hamnerauthor=J.+L.+Goldstein&title=Dual+therapy+of+grazoprevir+and+elbasvir+for+the+treatment+of+hepatitis+C+infection&doi=10.1586%2F17474124.2016.1147346"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144c&amp;dbid=16384&amp;doi=10.1586%2F17474124.2016.1147346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F17474124.2016.1147346%26sid%3Dliteratum%253Aachs%26aulast%3DLandaverde%26aufirst%3DC.%26aulast%3DWells%26aufirst%3DJ.%26aulast%3DHamner%26aufirst%3DR.%26aulast%3DGoldstein%26aufirst%3DJ.%2BL.%26atitle%3DDual%2520therapy%2520of%2520grazoprevir%2520and%2520elbasvir%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520infection%26jtitle%3DExpert%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2016%26volume%3D10%26spage%3D419%26epage%3D429%26doi%3D10.1586%2F17474124.2016.1147346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit144d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Roensholt, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerstoft, J.</span><span> </span><span class="NLM_article-title">Grazoprevir and elbasvir: a second-generation protease inhibitor and a second-generation NS5A inhibitor in a combination regimen for treatment of chronic hepatitis C</span> <span class="citation_source-journal">Future Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">691</span><span class="NLM_x">–</span> <span class="NLM_lpage">698</span><span class="refDoi"> DOI: 10.2217/fvl.15.40</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.2217%2Ffvl.15.40" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=691-698&author=F.+F.+Roensholtauthor=J.+Gerstoft&title=Grazoprevir+and+elbasvir%3A+a+second-generation+protease+inhibitor+and+a+second-generation+NS5A+inhibitor+in+a+combination+regimen+for+treatment+of+chronic+hepatitis+C&doi=10.2217%2Ffvl.15.40"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144d&amp;dbid=16384&amp;doi=10.2217%2Ffvl.15.40&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffvl.15.40%26sid%3Dliteratum%253Aachs%26aulast%3DRoensholt%26aufirst%3DF.%2BF.%26aulast%3DGerstoft%26aufirst%3DJ.%26atitle%3DGrazoprevir%2520and%2520elbasvir%253A%2520a%2520second-generation%2520protease%2520inhibitor%2520and%2520a%2520second-generation%2520NS5A%2520inhibitor%2520in%2520a%2520combination%2520regimen%2520for%2520treatment%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DFuture%2520Virol.%26date%3D2015%26volume%3D10%26spage%3D691%26epage%3D698%26doi%3D10.2217%2Ffvl.15.40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghalib, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pockros, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ari, Z. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNubile, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barr, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterton, J. R.</span><span> </span><span class="NLM_article-title">Grazoprevir-elbasvir combination therapy for treatment-naïve cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span><span class="refDoi"> DOI: 10.7326/M15-0785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.7326%2FM15-0785" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2015&pages=1-13&author=S.+Zeuzemauthor=R.+Ghalibauthor=K.+R.+Reddyauthor=P.+J.+Pockrosauthor=Z.+B.+Ariauthor=Y.+Zhaoauthor=D.+D.+Brownauthor=S.+Wanauthor=M.+J.+DiNubileauthor=B.-Y.+Nguyenauthor=M.+N.+Robertsonauthor=J.+Wahlauthor=E.+Barrauthor=J.+R.+Butterton&title=Grazoprevir-elbasvir+combination+therapy+for+treatment-na%C3%AFve+cirrhotic+and+noncirrhotic+patients+with+chronic+HCV+genotype+1%2C+4%2C+or+6+infection%3A+a+randomized+trial&doi=10.7326%2FM15-0785"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.7326%2FM15-0785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252FM15-0785%26sid%3Dliteratum%253Aachs%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DPockros%26aufirst%3DP.%2BJ.%26aulast%3DAri%26aufirst%3DZ.%2BB.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DD.%2BD.%26aulast%3DWan%26aufirst%3DS.%26aulast%3DDiNubile%26aufirst%3DM.%2BJ.%26aulast%3DNguyen%26aufirst%3DB.-Y.%26aulast%3DRobertson%26aufirst%3DM.%2BN.%26aulast%3DWahl%26aufirst%3DJ.%26aulast%3DBarr%26aufirst%3DE.%26aulast%3DButterton%26aufirst%3DJ.%2BR.%26atitle%3DGrazoprevir-elbasvir%2520combination%2520therapy%2520for%2520treatment-na%25C3%25AFve%2520cirrhotic%2520and%2520noncirrhotic%2520patients%2520with%2520chronic%2520HCV%2520genotype%25201%252C%25204%252C%2520or%25206%2520infection%253A%2520a%2520randomized%2520trial%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2015%26volume%3D163%26spage%3D1%26epage%3D13%26doi%3D10.7326%2FM15-0785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Feld, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asselah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruane, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruener, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abergel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzotta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafran, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towner, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNally, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osinusi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svarovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span> </span><span class="NLM_article-title">for the ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">2599</span><span class="NLM_x">–</span> <span class="NLM_lpage">2607</span><span class="refDoi"> DOI: 10.1056/NEJMoa1512610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1512610" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2599-2607&author=J.+J.+Feldauthor=I.+M.+Jacobsonauthor=C.+H%C3%A9zodeauthor=T.+Asselahauthor=P.+J.+Ruaneauthor=N.+Gruenerauthor=A.+Abergelauthor=A.+Mangiaauthor=C.+L.+Laiauthor=H.+L.+Chanauthor=F.+Mazzottaauthor=C.+Morenoauthor=E.+Yoshidaauthor=S.+D.+Shafranauthor=W.+J.+Townerauthor=T.+T.+Tranauthor=J.+McNallyauthor=A.+Osinusiauthor=E.+Svarovskaiaauthor=Y.+Zhuauthor=D.+M.+Brainardauthor=J.+G.+McHutchisonauthor=K.+Agarwalauthor=S.+Zeuzem&title=for+the+ASTRAL-1+Investigators.+Sofosbuvir+and+velpatasvir+for+HCV+genotype+1%2C+2%2C+4%2C+5%2C+and+6+infection&doi=10.1056%2FNEJMoa1512610"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1512610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1512610%26sid%3Dliteratum%253Aachs%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DRuane%26aufirst%3DP.%2BJ.%26aulast%3DGruener%26aufirst%3DN.%26aulast%3DAbergel%26aufirst%3DA.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DC.%2BL.%26aulast%3DChan%26aufirst%3DH.%2BL.%26aulast%3DMazzotta%26aufirst%3DF.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DYoshida%26aufirst%3DE.%26aulast%3DShafran%26aufirst%3DS.%2BD.%26aulast%3DTowner%26aufirst%3DW.%2BJ.%26aulast%3DTran%26aufirst%3DT.%2BT.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DOsinusi%26aufirst%3DA.%26aulast%3DSvarovskaia%26aufirst%3DE.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DZeuzem%26aufirst%3DS.%26atitle%3Dfor%2520the%2520ASTRAL-1%2520Investigators.%2520Sofosbuvir%2520and%2520velpatasvir%2520for%2520HCV%2520genotype%25201%252C%25202%252C%25204%252C%25205%252C%2520and%25206%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2599%26epage%3D2607%26doi%3D10.1056%2FNEJMoa1512610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit146b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Foster, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afdhal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bräu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pianko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiffman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towner, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruane, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourlière, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asselah, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agarwal, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stedman, C. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvory-Sobol, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNally, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osinusi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzotta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulkowski, M.</span><span> </span><span class="NLM_article-title">for the ASTRAL-2 and ASTRAL-3 Investigators. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">2608</span><span class="NLM_x">–</span> <span class="NLM_lpage">2617</span><span class="refDoi"> DOI: 10.1056/NEJMoa1512612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1512612" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2608-2617&author=G.+R.+Fosterauthor=N.+Afdhalauthor=S.+K.+Robertsauthor=N.+Br%C3%A4uauthor=E.+J.+Ganeauthor=S.+Piankoauthor=E.+Lawitzauthor=A.+Thompsonauthor=M.+L.+Shiffmanauthor=C.+Cooperauthor=W.+J.+Townerauthor=B.+Conwayauthor=P.+Ruaneauthor=M.+Bourli%C3%A8reauthor=T.+Asselahauthor=T.+Bergauthor=S.+Zeuzemauthor=W.+Rosenbergauthor=K.+Agarwalauthor=C.+A.+M.+Stedmanauthor=H.+Moauthor=H.+Dvory-Sobolauthor=L.+Hanauthor=J.+Wangauthor=J.+McNallyauthor=A.+Osinusiauthor=D.+M.+Brainardauthor=J.+G.+McHutchisonauthor=F.+Mazzottaauthor=T.+T.+Tranauthor=S.+C.+Gordonauthor=K.+Patelauthor=N.+Reauauthor=A.+Mangiaauthor=M.+Sulkowski&title=for+the+ASTRAL-2+and+ASTRAL-3+Investigators.+Sofosbuvir+and+velpatasvir+for+HCV+genotype+2+and+3+infection&doi=10.1056%2FNEJMoa1512612"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1512612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1512612%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DG.%2BR.%26aulast%3DAfdhal%26aufirst%3DN.%26aulast%3DRoberts%26aufirst%3DS.%2BK.%26aulast%3DBr%25C3%25A4u%26aufirst%3DN.%26aulast%3DGane%26aufirst%3DE.%2BJ.%26aulast%3DPianko%26aufirst%3DS.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DShiffman%26aufirst%3DM.%2BL.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DTowner%26aufirst%3DW.%2BJ.%26aulast%3DConway%26aufirst%3DB.%26aulast%3DRuane%26aufirst%3DP.%26aulast%3DBourli%25C3%25A8re%26aufirst%3DM.%26aulast%3DAsselah%26aufirst%3DT.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DRosenberg%26aufirst%3DW.%26aulast%3DAgarwal%26aufirst%3DK.%26aulast%3DStedman%26aufirst%3DC.%2BA.%2BM.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DDvory-Sobol%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DOsinusi%26aufirst%3DA.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMazzotta%26aufirst%3DF.%26aulast%3DTran%26aufirst%3DT.%2BT.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DReau%26aufirst%3DN.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DSulkowski%26aufirst%3DM.%26atitle%3Dfor%2520the%2520ASTRAL-2%2520and%2520ASTRAL-3%2520Investigators.%2520Sofosbuvir%2520and%2520velpatasvir%2520for%2520HCV%2520genotype%25202%2520and%25203%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2608%26epage%3D2617%26doi%3D10.1056%2FNEJMoa1512612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit146c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Curry, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Leary, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bzowej, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korenblat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenkel, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flamm, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiano, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teperman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fried, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doehle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNally, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osinusi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R. S.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, M.</span><span> </span><span class="NLM_article-title">for the ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">2618</span><span class="NLM_x">–</span> <span class="NLM_lpage">2628</span><span class="refDoi"> DOI: 10.1056/NEJMoa1512614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMoa1512614" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2618-2628&author=M.+P.+Curryauthor=J.+G.+O%E2%80%99Learyauthor=N.+Bzowejauthor=A.+J.+Muirauthor=K.+M.+Korenblatauthor=J.+M.+Fenkelauthor=K.+R.+Reddyauthor=E.+Lawitzauthor=S.+L.+Flammauthor=T.+Schianoauthor=L.+Tepermanauthor=R.+Fontanaauthor=E.+Schiffauthor=M.+Friedauthor=B.+Doehleauthor=D.+Anauthor=J.+McNallyauthor=A.+Osinusiauthor=D.+M.+Brainardauthor=J.+G.+McHutchisonauthor=R.+S.+Brownauthor=M.+Charlton&title=for+the+ASTRAL-4+Investigators.+Sofosbuvir+and+velpatasvir+for+HCV+in+patients+with+decompensated+cirrhosis&doi=10.1056%2FNEJMoa1512614"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1512614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1512614%26sid%3Dliteratum%253Aachs%26aulast%3DCurry%26aufirst%3DM.%2BP.%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DJ.%2BG.%26aulast%3DBzowej%26aufirst%3DN.%26aulast%3DMuir%26aufirst%3DA.%2BJ.%26aulast%3DKorenblat%26aufirst%3DK.%2BM.%26aulast%3DFenkel%26aufirst%3DJ.%2BM.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DFlamm%26aufirst%3DS.%2BL.%26aulast%3DSchiano%26aufirst%3DT.%26aulast%3DTeperman%26aufirst%3DL.%26aulast%3DFontana%26aufirst%3DR.%26aulast%3DSchiff%26aufirst%3DE.%26aulast%3DFried%26aufirst%3DM.%26aulast%3DDoehle%26aufirst%3DB.%26aulast%3DAn%26aufirst%3DD.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DOsinusi%26aufirst%3DA.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DBrown%26aufirst%3DR.%2BS.%26aulast%3DCharlton%26aufirst%3DM.%26atitle%3Dfor%2520the%2520ASTRAL-4%2520Investigators.%2520Sofosbuvir%2520and%2520velpatasvir%2520for%2520HCV%2520in%2520patients%2520with%2520decompensated%2520cirrhosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2618%26epage%3D2628%26doi%3D10.1056%2FNEJMoa1512614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit146d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Everson, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towner, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyles, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahass, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thuluvath, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etzkorn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinestrosa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinovitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNally, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doehle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. T.</span><span> </span><span class="NLM_article-title">Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">818</span><span class="NLM_x">–</span> <span class="NLM_lpage">826</span><span class="refDoi"> DOI: 10.7326/M15-1000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.7326%2FM15-1000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26551051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC28vgt1agtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2015&pages=818-826&author=G.+T.+Eversonauthor=W.+J.+Townerauthor=M.+N.+Davisauthor=D.+L.+Wylesauthor=R.+G.+Nahassauthor=P.+J.+Thuluvathauthor=K.+Etzkornauthor=F.+Hinestrosaauthor=M.+Tongauthor=M.+Rabinovitzauthor=J.+McNallyauthor=D.+M.+Brainardauthor=L.+Hanauthor=B.+Doehleauthor=J.+G.+McHutchisonauthor=T.+Morganauthor=R.+T.+Chungauthor=T.+T.+Tran&title=Sofosbuvir+with+velpatasvir+in+treatment-naive+noncirrhotic+patients+with+genotype+1+to+6+hepatitis+C+virus+infection%3A+a+randomized+trial&doi=10.7326%2FM15-1000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146dR"><div class="casContent"><span class="casTitleNuber">146d</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial</span></div><div class="casAuthors">Everson Gregory T; Towner William J; Davis Mitchell N; Wyles David L; Nahass Ronald G; Thuluvath Paul J; Etzkorn Kyle; Hinestrosa Federico; Tong Myron; Rabinovitz Mordechai; McNally John; Brainard Diana M; Han Lingling; Doehle Brian; McHutchison John G; Morgan Timothy; Chung Raymond T; Tran Tram T</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">818-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Effective, pangenotypic treatments for hepatitis C virus (HCV) infection are needed.  OBJECTIVE:  To assess the safety and efficacy of sofosbuvir with velpatasvir in patients infected with HCV genotypes 1 to 6.  DESIGN:  Randomized, phase 2, open-label study. (ClinicalTrials.gov: NCT01858766).  SETTING:  48 U.S. sites.  PATIENTS:  377 treatment-naive noncirrhotic patients.  In part A, patients infected with HCV genotypes 1 to 6 were randomly assigned to sofosbuvir, 400 mg, with velpatasvir, 25 or 100 mg, for 12 weeks.  In part B, patients with genotype 1 or 2 HCV infection were randomly assigned to sofosbuvir, 400 mg, and velpatasvir, 25 or 100 mg, with or without ribavirin for 8 weeks.  MEASUREMENTS:  Sustained virologic response at 12 weeks (SVR12).  RESULTS:  In part A, SVR12 rates were 96% (26 of 27) with velpatasvir, 25 mg, and 100% (28 of 28) with velpatasvir, 100 mg, for genotype 1; 93% (25 of 27) in both groups for genotype 3; and 96% (22 of 23) with velpatasvir, 25 mg, and 95% (21 of 22) with velpatasvir, 100 mg, for genotypes 2, 4, 5, and 6.  In part B, for genotype 1, SVR12 rates were 87% (26 of 30) with velpatasvir, 25 mg; 83% (25 of 30) with velpatasvir, 25 mg, plus ribavirin; 90% (26 of 29) with velpatasvir, 100 mg; and 81% (25 of 31) with velpatasvir, 100 mg, plus ribavirin.  For genotype 2, SVR12 rates were 77% (20 of 26) with velpatasvir, 25 mg; 88% (22 of 25) with velpatasvir, 25 mg, plus ribavirin; 88% (23 of 26) with velpatasvir, 100 mg; and 88% (23 of 26) with velpatasvir, 100 mg, plus ribavirin.  Adverse events included fatigue (21%), headache (20%), and nausea (12%).  One patient committed suicide.  LIMITATION:  The study was open-label, no inferential statistics were planned, and sample sizes were small.  CONCLUSION:  Twelve weeks of sofosbuvir, 400 mg, and velpatasvir, 100 mg, was well-tolerated and resulted in high SVR in patients infected with HCV genotypes 1 to 6.  PRIMARY FUNDING SOURCE:  Gilead Sciences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSe_4IC_iyrYa2q3xNe7a7QfW6udTcc2eZAHgmSJXMMArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vgt1agtg%253D%253D&md5=d849efe4192fca8ae7921dd1e2bebfcb</span></div><a href="/servlet/linkout?suffix=cit146d&amp;dbid=16384&amp;doi=10.7326%2FM15-1000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252FM15-1000%26sid%3Dliteratum%253Aachs%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DTowner%26aufirst%3DW.%2BJ.%26aulast%3DDavis%26aufirst%3DM.%2BN.%26aulast%3DWyles%26aufirst%3DD.%2BL.%26aulast%3DNahass%26aufirst%3DR.%2BG.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DEtzkorn%26aufirst%3DK.%26aulast%3DHinestrosa%26aufirst%3DF.%26aulast%3DTong%26aufirst%3DM.%26aulast%3DRabinovitz%26aufirst%3DM.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DHan%26aufirst%3DL.%26aulast%3DDoehle%26aufirst%3DB.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DMorgan%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DR.%2BT.%26aulast%3DTran%26aufirst%3DT.%2BT.%26atitle%3DSofosbuvir%2520with%2520velpatasvir%2520in%2520treatment-naive%2520noncirrhotic%2520patients%2520with%2520genotype%25201%2520to%25206%2520hepatitis%2520C%2520virus%2520infection%253A%2520a%2520randomized%2520trial%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2015%26volume%3D163%26spage%3D818%26epage%3D826%26doi%3D10.7326%2FM15-1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Lawitz, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Riordan, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asatryan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overcash, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kort, J.</span><span> </span><span class="NLM_article-title">Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1546</span><span class="NLM_x">–</span> <span class="NLM_lpage">1555</span><span class="refDoi"> DOI: 10.1128/AAC.02264-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1128%2FAAC.02264-15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=1546-1555&author=E.+J.+Lawitzauthor=W.+D.+O%E2%80%99Riordanauthor=A.+Asatryanauthor=B.+L.+Freilichauthor=T.+D.+Boxauthor=J.+S.+Overcashauthor=S.+Lovellauthor=T.+I.+Ngauthor=W.+Liuauthor=A.+Campbellauthor=C.+W.+Linauthor=B.+Yaoauthor=J.+Kort&title=Potent+antiviral+activities+of+the+direct-acting+antivirals+ABT-493+and+ABT-530+with+three-day+monotherapy+for+hepatitis+C+virus+genotype+1+infection&doi=10.1128%2FAAC.02264-15"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1128%2FAAC.02264-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02264-15%26sid%3Dliteratum%253Aachs%26aulast%3DLawitz%26aufirst%3DE.%2BJ.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DW.%2BD.%26aulast%3DAsatryan%26aufirst%3DA.%26aulast%3DFreilich%26aufirst%3DB.%2BL.%26aulast%3DBox%26aufirst%3DT.%2BD.%26aulast%3DOvercash%26aufirst%3DJ.%2BS.%26aulast%3DLovell%26aufirst%3DS.%26aulast%3DNg%26aufirst%3DT.%2BI.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DC.%2BW.%26aulast%3DYao%26aufirst%3DB.%26aulast%3DKort%26aufirst%3DJ.%26atitle%3DPotent%2520antiviral%2520activities%2520of%2520the%2520direct-acting%2520antivirals%2520ABT-493%2520and%2520ABT-530%2520with%2520three-day%2520monotherapy%2520for%2520hepatitis%2520C%2520virus%2520genotype%25201%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D1546%26epage%3D1555%26doi%3D10.1128%2FAAC.02264-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Rodriguez-Torres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glass, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freilich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Bisceglie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvory-Sobol, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krefetz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marbury, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawitz, E.</span><span> </span><span class="NLM_article-title">GS-9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double-blind, dose-ranging phase 1 study</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">614</span><span class="refDoi"> DOI: 10.1111/jvh.12527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fjvh.12527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26957110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOkurbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=614&author=M.+Rodriguez-Torresauthor=S.+Glassauthor=J.+Hillauthor=B.+Freilichauthor=D.+Hassmanauthor=A.+M.+Di+Bisceglieauthor=J.+G.+Taylorauthor=B.+J.+Kirbyauthor=H.+Dvory-Sobolauthor=J.+C.+Yangauthor=D.+Anauthor=L.+M.+Stammauthor=D.+M.+Brainardauthor=S.+Kimauthor=D.+Krefetzauthor=W.+Smithauthor=T.+Marburyauthor=E.+Lawitz&title=GS-9857+in+patients+with+chronic+hepatitis+C+virus+genotype+1%E2%80%934+infection%3A+a+randomized%2C+double-blind%2C+dose-ranging+phase+1+study&doi=10.1111%2Fjvh.12527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study</span></div><div class="casAuthors">Rodriguez-Torres, M.; Glass, S.; Hill, J.; Freilich, B.; Hassman, D.; Di Bisceglie, A. M.; Taylor, J. G.; Kirby, B. J.; Dvory-Sobol, H.; Yang, J. C.; An, D.; Stamm, L. M.; Brainard, D. M.; Kim, S.; Krefetz, D.; Smith, W.; Marbury, T.; Lawitz, E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Viral Hepatitis</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">614-622</span>CODEN:
                <span class="NLM_cas:coden">JVHEER</span>;
        ISSN:<span class="NLM_cas:issn">1365-2893</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Summary : GS-9857, an inhibitor of the hepatitis C virus (HCV) nonstructural protein (NS) 3/4A, demonstrates potent activity against HCV genotypes 1-6 and improved coverage against commonly encountered NS3 resistance-assocd. variants (RAVs).  In this study, the safety, tolerability, antiviral activity and pharmacokinetics (PK) of GS-9857 were evaluated in patients with chronic HCV genotype 1-4 infection.  Patients with genotype 1-4 infection received placebo or once-daily GS-9857 at doses ranging from 50 to 300 mg for 3 days under fasting conditions.  GS-9857 was well tolerated; all reported adverse events (AEs) were mild or moderate in severity.  Diarrhoea and headache were the most commonly reported AEs.  Grade 3 or 4 lab. abnormalities were obsd. in 17% of patients receiving GS-9857; there were no Grade 3 or 4 abnormalities in alanine aminotransferase, aspartate aminotransferase or alk. phosphatase levels.  GS-9857 demonstrated potent antiviral activity in patients with chronic HCV infection, achieving mean and median max. redns. in HCV RNA of ≥3 log10 IU/mL following administration of a 100-mg dose in patients with HCV genotype 1a, 1b, 2, 3 or 4 infection.  The antiviral activity of GS-9857 was unaffected by the presence of pretreatment NS3 RAVs.  In patients with genotype 1-4 infection, GS-9857 exhibited linear PK and was assocd. with a median half-life of 29-42 h, supporting once-daily dosing.  Thus, the tolerability, efficacy and pharmacokinetic profile of GS-9857 support its further evaluation for treatment of patients with chronic HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8oJDwl-bOdbVg90H21EOLACvtfcHk0ljSLPoFn0wU5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOkurbK&md5=257769b545cb4289b8f9fc5298454f91</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1111%2Fjvh.12527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.12527%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DGlass%26aufirst%3DS.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DFreilich%26aufirst%3DB.%26aulast%3DHassman%26aufirst%3DD.%26aulast%3DDi%2BBisceglie%26aufirst%3DA.%2BM.%26aulast%3DTaylor%26aufirst%3DJ.%2BG.%26aulast%3DKirby%26aufirst%3DB.%2BJ.%26aulast%3DDvory-Sobol%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DAn%26aufirst%3DD.%26aulast%3DStamm%26aufirst%3DL.%2BM.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DKrefetz%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DW.%26aulast%3DMarbury%26aufirst%3DT.%26aulast%3DLawitz%26aufirst%3DE.%26atitle%3DGS-9857%2520in%2520patients%2520with%2520chronic%2520hepatitis%2520C%2520virus%2520genotype%25201%25E2%2580%25934%2520infection%253A%2520a%2520randomized%252C%2520double-blind%252C%2520dose-ranging%2520phase%25201%2520study%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2016%26volume%3D23%26spage%3D614%26doi%3D10.1111%2Fjvh.12527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Gane, E.J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwabe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svarovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamm, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brainard, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stedman, C. A.</span><span> </span><span class="NLM_article-title">Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naïve or previously treated patients with HCV genotype 1 or 3 infections</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1053/j.gastro.2016.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1053%2Fj.gastro.2016.05.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=E.J.+Ganeauthor=C.+Schwabeauthor=R.+H.+Hylandauthor=Y.+Yangauthor=E.+Svarovskaiaauthor=L.+M.+Stammauthor=D.+M.+Brainardauthor=J.+G.+McHutchisonauthor=C.+A.+Stedman&title=Efficacy+of+the+combination+of+sofosbuvir%2C+velpatasvir%2C+and+the+NS3%2F4A+protease+inhibitor+GS-9857+in+treatment-na%C3%AFve+or+previously+treated+patients+with+HCV+genotype+1+or+3+infections&doi=10.1053%2Fj.gastro.2016.05.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2016.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2016.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.J.%26aulast%3DSchwabe%26aufirst%3DC.%26aulast%3DHyland%26aufirst%3DR.%2BH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DSvarovskaia%26aufirst%3DE.%26aulast%3DStamm%26aufirst%3DL.%2BM.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DStedman%26aufirst%3DC.%2BA.%26atitle%3DEfficacy%2520of%2520the%2520combination%2520of%2520sofosbuvir%252C%2520velpatasvir%252C%2520and%2520the%2520NS3%252F4A%2520protease%2520inhibitor%2520GS-9857%2520in%2520treatment-na%25C3%25AFve%2520or%2520previously%2520treated%2520patients%2520with%2520HCV%2520genotype%25201%2520or%25203%2520infections%26jtitle%3DGastroenterology%26date%3D2016%26doi%3D10.1053%2Fj.gastro.2016.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Kwong, A. D.</span><span> </span><span class="NLM_article-title">The HCV revolution did not happen overnight</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span><span class="refDoi"> DOI: 10.1021/ml500070q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500070q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjt1yltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=214-220&author=A.+D.+Kwong&title=The+HCV+revolution+did+not+happen+overnight&doi=10.1021%2Fml500070q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">The HCV Revolution Did Not Happen Overnight</span></div><div class="casAuthors">Kwong, Ann D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">214-220</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The progress in HCV therapy in the last three years is similar to the progress that took HIV therapy ∼14 years.  We are at the brink of approval for an all-oral drug combination that is dosed once daily as a single pill, has >95% efficacy, and is well tolerated.  This article summarizes the path to this success and the challenges still ahead.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg5BynQvE32rVg90H21EOLACvtfcHk0lhB7RiuJPVE4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjt1yltr0%253D&md5=719af45391278d0c65f0e35f579a0c83</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Fml500070q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500070q%26sid%3Dliteratum%253Aachs%26aulast%3DKwong%26aufirst%3DA.%2BD.%26atitle%3DThe%2520HCV%2520revolution%2520did%2520not%2520happen%2520overnight%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D214%26epage%3D220%26doi%3D10.1021%2Fml500070q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koszalka, G. W.</span><span> </span><span class="NLM_article-title">2007: a difficult year for HCV drug development</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">128</span><span class="NLM_x">–</span> <span class="NLM_lpage">131</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=18246515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FovVahuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=128-131&author=N.+A.+Meanwellauthor=G.+W.+Koszalka&title=2007%3A+a+difficult+year+for+HCV+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">2007: a difficult year for HCV drug development</span></div><div class="casAuthors">Meanwell Nicholas A; Koszalka George W</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in investigational drugs (London, England : 2000)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">128-31</span>
        ISSN:<span class="NLM_cas:issn">1472-4472</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbNRSEMlKlqjC850By6mxpfW6udTcc2eYUB4mjo5RMQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FovVahuw%253D%253D&md5=40fbf1852de9cb2914e88c69d55d8d8b</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKoszalka%26aufirst%3DG.%2BW.%26atitle%3D2007%253A%2520a%2520difficult%2520year%2520for%2520HCV%2520drug%2520development%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D9%26spage%3D128%26epage%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Williams, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pico, A. R.</span><span> </span><span class="NLM_article-title">From scientific discovery to cures: bright stars within a galaxy</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1016/j.cell.2015.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.cell.2015.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26406364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKqtrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2015&pages=21-23&author=R.+S.+Williamsauthor=S.+Lotiaauthor=A.+K.+Hollowayauthor=A.+R.+Pico&title=From+scientific+discovery+to+cures%3A+bright+stars+within+a+galaxy&doi=10.1016%2Fj.cell.2015.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">From Scientific Discovery to Cures: Bright Stars within a Galaxy</span></div><div class="casAuthors">Williams, R. Sanders; Lotia, Samad; Holloway, Alisha K.; Pico, Alexander R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-23</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We propose that data mining and network anal. utilizing public databases can identify and quantify relationships between scientific discoveries and major advances in medicine (cures).  Further development of such approaches could help to increase public understanding and governmental support for life science research and could enhance decision making in the quest for cures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptIzvc7ZBDRLVg90H21EOLACvtfcHk0lhB7RiuJPVE4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKqtrvN&md5=17df22c69780c25df589f4ff8227c337</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DR.%2BS.%26aulast%3DLotia%26aufirst%3DS.%26aulast%3DHolloway%26aufirst%3DA.%2BK.%26aulast%3DPico%26aufirst%3DA.%2BR.%26atitle%3DFrom%2520scientific%2520discovery%2520to%2520cures%253A%2520bright%2520stars%2520within%2520a%2520galaxy%26jtitle%3DCell%26date%3D2015%26volume%3D163%26spage%3D21%26epage%3D23%26doi%3D10.1016%2Fj.cell.2015.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Calcoen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elias, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span> </span><span class="NLM_article-title">What does it take to produce a breakthrough drug?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span><span class="refDoi"> DOI: 10.1038/nrd4570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrd4570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25722234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC2Mrpt1yquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=161-162&author=D.+Calcoenauthor=L.+Eliasauthor=X.+Yu&title=What+does+it+take+to+produce+a+breakthrough+drug%3F&doi=10.1038%2Fnrd4570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">What does it take to produce a breakthrough drug?</span></div><div class="casAuthors">Calcoen Dirk; Elias Laura; Yu Xiaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQynMISMHL85z69zv1FsJFMfW6udTcc2ead1viUolPZ_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mrpt1yquw%253D%253D&md5=aa00201a6a9fe7a72032eb4bf3bd1e74</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1038%2Fnrd4570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4570%26sid%3Dliteratum%253Aachs%26aulast%3DCalcoen%26aufirst%3DD.%26aulast%3DElias%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DX.%26atitle%3DWhat%2520does%2520it%2520take%2520to%2520produce%2520a%2520breakthrough%2520drug%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D161%26epage%3D162%26doi%3D10.1038%2Fnrd4570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kola, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, J.</span><span> </span><span class="NLM_article-title">Can the pharmaceutical industry reduce attrition rates?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">711</span><span class="NLM_x">–</span> <span class="NLM_lpage">715</span><span class="refDoi"> DOI: 10.1038/nrd1470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrd1470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=15286737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=711-715&author=I.+Kolaauthor=J.+Landis&title=Can+the+pharmaceutical+industry+reduce+attrition+rates%3F&doi=10.1038%2Fnrd1470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154aR"><div class="casContent"><span class="casTitleNuber">154a</span><div class="casTitle"><span class="NLM_cas:atitle">Opinion: Can the pharmaceutical industry reduce attrition rates?</span></div><div class="casAuthors">Kola, Ismail; Landis, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-716</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry faces considerable challenges, both politically and fiscally.  Politically, governments around the world are trying to contain costs and, as health care budgets constitute a very significant part of governmental spending, these costs are the subject of intense scrutiny.  In the United States, drug costs are also the subject of intense political discourse.  This article deals with the fiscal pressures that face the industry from the perspective of R&D.  What impinges on productivity How can we improve current reduced R&D productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruAlrpFPFmiLVg90H21EOLACvtfcHk0ljmfqMTctBL7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtLs%253D&md5=f9025c13a1506f607aaf68415570ed01</span></div><a href="/servlet/linkout?suffix=cit154a&amp;dbid=16384&amp;doi=10.1038%2Fnrd1470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1470%26sid%3Dliteratum%253Aachs%26aulast%3DKola%26aufirst%3DI.%26aulast%3DLandis%26aufirst%3DJ.%26atitle%3DCan%2520the%2520pharmaceutical%2520industry%2520reduce%2520attrition%2520rates%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D711%26epage%3D715%26doi%3D10.1038%2Fnrd1470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit154b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Waring, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrowsmith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandrell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennie, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, A.</span><span> </span><span class="NLM_article-title">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">–</span> <span class="NLM_lpage">486</span><span class="refDoi"> DOI: 10.1038/nrd4609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrd4609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26091267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=475-486&author=M.+J.+Waringauthor=J.+Arrowsmithauthor=A.+R.+Leachauthor=P.+D.+Leesonauthor=S.+Mandrellauthor=R.+M.+Owenauthor=G.+Pairaudeauauthor=W.+D.+Pennieauthor=S.+D.+Pickettauthor=J.+Wangauthor=O.+Wallaceauthor=A.+Weir&title=An+analysis+of+the+attrition+of+drug+candidates+from+four+major+pharmaceutical+companies&doi=10.1038%2Fnrd4609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154bR"><div class="casContent"><span class="casTitleNuber">154b</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span></div><div class="casAuthors">Waring, Michael J.; Arrowsmith, John; Leach, Andrew R.; Leeson, Paul D.; Mandrell, Sam; Owen, Robert M.; Pairaudeau, Garry; Pennie, William D.; Pickett, Stephen D.; Wang, Jibo; Wallace, Owen; Weir, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-486</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development.  Attempts to reduce the no. of efficacy- and safety-related failures by analyzing possible links to the physicochem. properties of small-mol. drug candidates have been inconclusive because of the limited size of data sets from individual companies.  Here, we describe the compilation and anal. of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer.  The anal. reaffirms that control of physicochem. properties during compd. optimization is beneficial in identifying compds. of candidate drug quality and indicates for the first time a link between the physicochem. properties of compds. and clin. failure due to safety issues.  The results also suggest that further control of physicochem. properties is unlikely to have a significant effect on attrition rates and that addnl. work is required to address safety-related failures.  Further cross-company collaborations will be crucial to future progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLfBWrLC3ZLVg90H21EOLACvtfcHk0ljmfqMTctBL7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM&md5=1fdc374d32816b1e91438152299dd1b1</span></div><a href="/servlet/linkout?suffix=cit154b&amp;dbid=16384&amp;doi=10.1038%2Fnrd4609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4609%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DMandrell%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPennie%26aufirst%3DW.%2BD.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DWeir%26aufirst%3DA.%26atitle%3DAn%2520analysis%2520of%2520the%2520attrition%2520of%2520drug%2520candidates%2520from%2520four%2520major%2520pharmaceutical%2520companies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D475%26epage%3D486%26doi%3D10.1038%2Fnrd4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit154c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craighead, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Economides, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenthal, J.</span><span> </span><span class="NLM_article-title">Clinical development success rates for investigational drugs</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">40</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1038/nbt.2786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnbt.2786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24406927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFyjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=40-51&author=M.+Hayauthor=D.+W.+Thomasauthor=J.+L.+Craigheadauthor=C.+Economidesauthor=J.+Rosenthal&title=Clinical+development+success+rates+for+investigational+drugs&doi=10.1038%2Fnbt.2786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154cR"><div class="casContent"><span class="casTitleNuber">154c</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical development success rates for investigational drugs</span></div><div class="casAuthors">Hay, Michael; Thomas, David W.; Craighead, John L.; Economides, Celia; Rosenthal, Jesse</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-51</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The most comprehensive survey of clin. success rates across the drug industry to date shows productivity may be even lower than previous ests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdqyRgsoFYDbVg90H21EOLACvtfcHk0lgUkr9C3ea9tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFyjsA%253D%253D&md5=87a63ec8d8bb213b3d42519395725038</span></div><a href="/servlet/linkout?suffix=cit154c&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2786%26sid%3Dliteratum%253Aachs%26aulast%3DHay%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DD.%2BW.%26aulast%3DCraighead%26aufirst%3DJ.%2BL.%26aulast%3DEconomides%26aufirst%3DC.%26aulast%3DRosenthal%26aufirst%3DJ.%26atitle%3DClinical%2520development%2520success%2520rates%2520for%2520investigational%2520drugs%26jtitle%3DNat.%2520Biotechnol.%26date%3D2014%26volume%3D32%26spage%3D40%26epage%3D51%26doi%3D10.1038%2Fnbt.2786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit154d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Arrowsmith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, P.</span><span> </span><span class="NLM_article-title">Phase II and Phase III attrition rates 2011–2012</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">569</span><span class="refDoi"> DOI: 10.1038/nrd4090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnrd4090" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=569&author=J.+Arrowsmithauthor=P.+Miller&title=Phase+II+and+Phase+III+attrition+rates+2011%E2%80%932012&doi=10.1038%2Fnrd4090"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154d&amp;dbid=16384&amp;doi=10.1038%2Fnrd4090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4090%26sid%3Dliteratum%253Aachs%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DP.%26atitle%3DPhase%2520II%2520and%2520Phase%2520III%2520attrition%2520rates%25202011%25E2%2580%25932012%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D569%26doi%3D10.1038%2Fnrd4090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Lam, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffers, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younoszai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazel, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Younossi, Z. M.</span><span> </span><span class="NLM_article-title">The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment</span> <span class="citation_source-journal">Ther. Adv. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">298</span><span class="NLM_x">–</span> <span class="NLM_lpage">312</span><span class="refDoi"> DOI: 10.1177/1756283X15587481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1177%2F1756283X15587481" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=298-312&author=B.+P.+Lamauthor=T.+Jeffersauthor=Z.+Younoszaiauthor=Y.+Fazelauthor=Z.+M.+Younossi&title=The+changing+landscape+of+hepatitis+C+virus+therapy%3A+focus+on+interferon-free+treatment&doi=10.1177%2F1756283X15587481"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1177%2F1756283X15587481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1756283X15587481%26sid%3Dliteratum%253Aachs%26aulast%3DLam%26aufirst%3DB.%2BP.%26aulast%3DJeffers%26aufirst%3DT.%26aulast%3DYounoszai%26aufirst%3DZ.%26aulast%3DFazel%26aufirst%3DY.%26aulast%3DYounossi%26aufirst%3DZ.%2BM.%26atitle%3DThe%2520changing%2520landscape%2520of%2520hepatitis%2520C%2520virus%2520therapy%253A%2520focus%2520on%2520interferon-free%2520treatment%26jtitle%3DTher.%2520Adv.%2520Gastroenterol.%26date%3D2015%26volume%3D8%26spage%3D298%26epage%3D312%26doi%3D10.1177%2F1756283X15587481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Azvolinsky, A.</span><span> </span><span class="NLM_article-title">Industry chases pan-genotypic and shorter HCV treatments</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">575</span><span class="NLM_x">–</span> <span class="NLM_lpage">576</span><span class="refDoi"> DOI: 10.1038/nbt0615-575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnbt0615-575" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=575-576&author=A.+Azvolinsky&title=Industry+chases+pan-genotypic+and+shorter+HCV+treatments&doi=10.1038%2Fnbt0615-575"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1038%2Fnbt0615-575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt0615-575%26sid%3Dliteratum%253Aachs%26aulast%3DAzvolinsky%26aufirst%3DA.%26atitle%3DIndustry%2520chases%2520pan-genotypic%2520and%2520shorter%2520HCV%2520treatments%26jtitle%3DNat.%2520Biotechnol.%26date%3D2015%26volume%3D33%26spage%3D575%26epage%3D576%26doi%3D10.1038%2Fnbt0615-575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Horner, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naggie, S.</span><span> </span><span class="NLM_article-title">Successes and challenges on the road to cure hepatitis C</span> <span class="citation_source-journal">PLoS Pathog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">e1004854</span><span class="refDoi"> DOI: 10.1371/journal.ppat.1004854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1371%2Fjournal.ppat.1004854" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=e1004854&issue=6&author=S.+M.+Hornerauthor=S.+Naggie&title=Successes+and+challenges+on+the+road+to+cure+hepatitis+C&doi=10.1371%2Fjournal.ppat.1004854"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1004854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1004854%26sid%3Dliteratum%253Aachs%26aulast%3DHorner%26aufirst%3DS.%2BM.%26aulast%3DNaggie%26aufirst%3DS.%26atitle%3DSuccesses%2520and%2520challenges%2520on%2520the%2520road%2520to%2520cure%2520hepatitis%2520C%26jtitle%3DPLoS%2520Pathog.%26date%3D2015%26volume%3D11%26issue%3D6%26spage%3De1004854%26doi%3D10.1371%2Fjournal.ppat.1004854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dore, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feld, J. J.</span><span> </span><span class="NLM_article-title">Hepatitis C virus therapeutic development: in pursuit of "perfectovir"</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1829</span><span class="NLM_x">–</span> <span class="NLM_lpage">1836</span><span class="refDoi"> DOI: 10.1093/cid/civ197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1093%2Fcid%2Fciv197" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2015&pages=1829-1836&author=G.+J.+Doreauthor=J.+J.+Feld&title=Hepatitis+C+virus+therapeutic+development%3A+in+pursuit+of+%22perfectovir%22&doi=10.1093%2Fcid%2Fciv197"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158a&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciv197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciv197%26sid%3Dliteratum%253Aachs%26aulast%3DDore%26aufirst%3DG.%2BJ.%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26atitle%3DHepatitis%2520C%2520virus%2520therapeutic%2520development%253A%2520in%2520pursuit%2520of%2520%2522perfectovir%2522%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2015%26volume%3D60%26spage%3D1829%26epage%3D1836%26doi%3D10.1093%2Fcid%2Fciv197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit158b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">De Clercq, E.</span><span> </span><span class="NLM_article-title">Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace</span> <span class="citation_source-journal">Rev. Med. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">254</span><span class="NLM_x">–</span> <span class="NLM_lpage">267</span><span class="refDoi"> DOI: 10.1002/rmv.1842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Frmv.1842" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=254-267&author=E.+De+Clercq&title=Development+of+antiviral+drugs+for+the+treatment+of+hepatitis+C+at+an+accelerating+pace&doi=10.1002%2Frmv.1842"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158b&amp;dbid=16384&amp;doi=10.1002%2Frmv.1842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frmv.1842%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DDevelopment%2520of%2520antiviral%2520drugs%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520at%2520an%2520accelerating%2520pace%26jtitle%3DRev.%2520Med.%2520Virol.%26date%3D2015%26volume%3D25%26spage%3D254%26epage%3D267%26doi%3D10.1002%2Frmv.1842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit158c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nyalakonda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Utay, N. S.</span><span> </span><span class="NLM_article-title">A new era of therapy for hepatitis C virus infection</span> <span class="citation_source-journal">Curr. Opin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">478</span><span class="refDoi"> DOI: 10.1097/QCO.0000000000000190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1097%2FQCO.0000000000000190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=26203851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVeqtrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=471-478&author=H.+Nyalakondaauthor=N.+S.+Utay&title=A+new+era+of+therapy+for+hepatitis+C+virus+infection&doi=10.1097%2FQCO.0000000000000190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158cR"><div class="casContent"><span class="casTitleNuber">158c</span><div class="casTitle"><span class="NLM_cas:atitle">A new era of therapy for hepatitis C virus infection</span></div><div class="casAuthors">Nyalakonda, Harita; Utay, Netanya S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Infectious Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">471-478</span>CODEN:
                <span class="NLM_cas:coden">COIDE5</span>;
        ISSN:<span class="NLM_cas:issn">0951-7375</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Previous treatments with pegylated interferon (PEG-IFN) and ribavirin for hepatitis C virus (HCV) infection resulted in significant adverse events and low cure rates, even with the addn. of first-generation protease inhibitors.  The std. of care for chronic HCV infection changed dramatically in 2013 with the approval of second-generation direct-acting antivirals, which led the way for IFN-free combination regimens.  Recent findings: All-oral combinations of direct-acting antivirals, with or without ribavirin, have shown high efficacy and are well tolerated in patients with the predominant genotypes, advanced fibrosis stages, and HIV co-infection.  New fixed-dose co-formulations of direct-acting antivirals have allowed simpler regimens with shorter treatment durations and low rates of discontinuation, but are assocd. with substantial costs.  Summary: Since 2013, all-oral, IFN-free regimens with direct-acting antivirals have quickly become the mainstay of treatment for HCV infection as they provide high rates of sustained virol. response with a relatively short duration of treatment and low side-effect profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocUgZvQ9EvB7Vg90H21EOLACvtfcHk0liSyEmOFw3lqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVeqtrvJ&md5=7fc449f6c3bd851ac1f0e057cc868cbd</span></div><a href="/servlet/linkout?suffix=cit158c&amp;dbid=16384&amp;doi=10.1097%2FQCO.0000000000000190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQCO.0000000000000190%26sid%3Dliteratum%253Aachs%26aulast%3DNyalakonda%26aufirst%3DH.%26aulast%3DUtay%26aufirst%3DN.%2BS.%26atitle%3DA%2520new%2520era%2520of%2520therapy%2520for%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DCurr.%2520Opin.%2520Infect.%2520Dis.%26date%3D2015%26volume%3D28%26spage%3D471%26epage%3D478%26doi%3D10.1097%2FQCO.0000000000000190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit158d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">McConachie, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kale-Pradhan, P. B.</span><span> </span><span class="NLM_article-title">New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir</span> <span class="citation_source-journal">Expert Rev. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span><span class="refDoi"> DOI: 10.1586/17512433.2016.1129272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1586%2F17512433.2016.1129272" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=287-302&author=S.+M.+McConachieauthor=S.+M.+Wilhelmauthor=P.+B.+Kale-Pradhan&title=New+direct-acting+antivirals+in+hepatitis+C+therapy%3A+a+review+of+sofosbuvir%2C+ledipasvir%2C+daclatasvir%2C+simeprevir%2C+paritaprevir%2C+ombitasvir+and+dasabuvir&doi=10.1586%2F17512433.2016.1129272"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158d&amp;dbid=16384&amp;doi=10.1586%2F17512433.2016.1129272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F17512433.2016.1129272%26sid%3Dliteratum%253Aachs%26aulast%3DMcConachie%26aufirst%3DS.%2BM.%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DKale-Pradhan%26aufirst%3DP.%2BB.%26atitle%3DNew%2520direct-acting%2520antivirals%2520in%2520hepatitis%2520C%2520therapy%253A%2520a%2520review%2520of%2520sofosbuvir%252C%2520ledipasvir%252C%2520daclatasvir%252C%2520simeprevir%252C%2520paritaprevir%252C%2520ombitasvir%2520and%2520dasabuvir%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2016%26volume%3D9%26spage%3D287%26epage%3D302%26doi%3D10.1586%2F17512433.2016.1129272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizokami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, A. E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, J. W.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gojobori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alter, H. J.</span><span> </span><span class="NLM_article-title">A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">15584</span><span class="NLM_x">–</span> <span class="NLM_lpage">15589</span><span class="refDoi"> DOI: 10.1073/pnas.242608099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1073%2Fpnas.242608099" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=15584-15589&author=Y.+Tanakaauthor=K.+Hanadaauthor=M.+Mizokamiauthor=A.+E.+T.+Yeoauthor=J.+W.-K.+Shihauthor=T.+Gojoboriauthor=H.+J.+Alter&title=A+comparison+of+the+molecular+clock+of+hepatitis+C+virus+in+the+United+States+and+Japan+predicts+that+hepatocellular+carcinoma+incidence+in+the+United+States+will+increase+over+the+next+two+decades&doi=10.1073%2Fpnas.242608099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1073%2Fpnas.242608099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.242608099%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DHanada%26aufirst%3DK.%26aulast%3DMizokami%26aufirst%3DM.%26aulast%3DYeo%26aufirst%3DA.%2BE.%2BT.%26aulast%3DShih%26aufirst%3DJ.%2BW.-K.%26aulast%3DGojobori%26aufirst%3DT.%26aulast%3DAlter%26aufirst%3DH.%2BJ.%26atitle%3DA%2520comparison%2520of%2520the%2520molecular%2520clock%2520of%2520hepatitis%2520C%2520virus%2520in%2520the%2520United%2520States%2520and%2520Japan%2520predicts%2520that%2520hepatocellular%2520carcinoma%2520incidence%2520in%2520the%2520United%2520States%2520will%2520increase%2520over%2520the%2520next%2520two%2520decades%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D15584%26epage%3D15589%26doi%3D10.1073%2Fpnas.242608099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wong, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQuillan, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHutchison, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poynard, T.</span><span> </span><span class="NLM_article-title">Estimating future hepatitis C morbidity, mortality, and costs in the United States</span> <span class="citation_source-journal">Am. J. Public Health</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">1562</span><span class="NLM_x">–</span> <span class="NLM_lpage">1569</span><span class="refDoi"> DOI: 10.2105/AJPH.90.10.1562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.2105%2FAJPH.90.10.1562" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2000&pages=1562-1569&author=J.+B.+Wongauthor=G.+M.+McQuillanauthor=J.+G.+McHutchisonauthor=T.+Poynard&title=Estimating+future+hepatitis+C+morbidity%2C+mortality%2C+and+costs+in+the+United+States&doi=10.2105%2FAJPH.90.10.1562"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160a&amp;dbid=16384&amp;doi=10.2105%2FAJPH.90.10.1562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2105%252FAJPH.90.10.1562%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DJ.%2BB.%26aulast%3DMcQuillan%26aufirst%3DG.%2BM.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DPoynard%26aufirst%3DT.%26atitle%3DEstimating%2520future%2520hepatitis%2520C%2520morbidity%252C%2520mortality%252C%2520and%2520costs%2520in%2520the%2520United%2520States%26jtitle%3DAm.%2520J.%2520Public%2520Health%26date%3D2000%26volume%3D90%26spage%3D1562%26epage%3D1569%26doi%3D10.2105%2FAJPH.90.10.1562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit160b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Volk, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tocco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lok, A. S.</span><span> </span><span class="NLM_article-title">Public health impact of antiviral therapy for hepatitis C in the United States</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1750</span><span class="NLM_x">–</span> <span class="NLM_lpage">1755</span><span class="refDoi"> DOI: 10.1002/hep.23220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.23220" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=1750-1755&author=M.+L.+Volkauthor=R.+Toccoauthor=S.+Sainiauthor=A.+S.+Lok&title=Public+health+impact+of+antiviral+therapy+for+hepatitis+C+in+the+United+States&doi=10.1002%2Fhep.23220"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160b&amp;dbid=16384&amp;doi=10.1002%2Fhep.23220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.23220%26sid%3Dliteratum%253Aachs%26aulast%3DVolk%26aufirst%3DM.%2BL.%26aulast%3DTocco%26aufirst%3DR.%26aulast%3DSaini%26aufirst%3DS.%26aulast%3DLok%26aufirst%3DA.%2BS.%26atitle%3DPublic%2520health%2520impact%2520of%2520antiviral%2520therapy%2520for%2520hepatitis%2520C%2520in%2520the%2520United%2520States%26jtitle%3DHepatology%26date%3D2009%26volume%3D50%26spage%3D1750%26epage%3D1755%26doi%3D10.1002%2Fhep.23220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit160c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rein, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittenborn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinbaum, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesesne, S. B.</span><span> </span><span class="NLM_article-title">Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States</span> <span class="citation_source-journal">Dig. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">66</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span><span class="refDoi"> DOI: 10.1016/j.dld.2010.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.dld.2010.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=20739252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FivFantA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2011&pages=66-72&author=D.+B.+Reinauthor=J.+S.+Wittenbornauthor=C.+M.+Weinbaumauthor=M.+Sabinauthor=B.+D.+Smithauthor=S.+B.+Lesesne&title=Forecasting+the+morbidity+and+mortality+associated+with+prevalent+cases+of+pre-cirrhotic+chronic+hepatitis+C+in+the+United+States&doi=10.1016%2Fj.dld.2010.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160cR"><div class="casContent"><span class="casTitleNuber">160c</span><div class="casTitle"><span class="NLM_cas:atitle">Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States</span></div><div class="casAuthors">Rein David B; Wittenborn John S; Weinbaum Cindy M; Sabin Miriam; Smith Bryce D; Lesesne Sarah B</div><div class="citationInfo"><span class="NLM_cas:title">Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66-72</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Without diagnosis and antiviral therapy, many patients with chronic hepatitis C infections will develop end-stage liver disease and die from complications.  AIMS:  To evaluate the future impacts of preventive interventions and treatment advances, this paper forecasts a baseline estimate of the future morbidity and mortality of prevalent hepatitis C when left untreated.  METHODS:  We simulated the future disease progression and death for all Americans with prevalent hepatitis C in 2005.  To validate the model, we used past seroprevalence to forecast contemporary outcomes.  We used the validated model to forecast future cases of end-stage liver disease, transplants, and deaths from 2010 to 2060, and we estimated credible intervals using Monte Carlo simulation.  RESULTS:  When programmed with past data, our model predicted current levels of hepatitis C outcomes with accuracy between ±1% and 13%.  Morbidity and mortality from hepatitis C will rise from 2010 to a peak between the years 2030 and 2035.  We forecasted a peak of 38,600 incident cases of end-stage liver disease; 3200 referrals for transplant; and 36,100 deaths.  CONCLUSIONS:  Because current rates of screening and treatment are low, future morbidity and mortality from hepatitis C are likely to increase substantially without public health interventions to increase treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_cA6-nOPYw__I8Jvzw4xCfW6udTcc2eaMdRYANpu06rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FivFantA%253D%253D&md5=f7eeeddbc5d78e9182d8c1da09d34fe2</span></div><a href="/servlet/linkout?suffix=cit160c&amp;dbid=16384&amp;doi=10.1016%2Fj.dld.2010.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dld.2010.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DRein%26aufirst%3DD.%2BB.%26aulast%3DWittenborn%26aufirst%3DJ.%2BS.%26aulast%3DWeinbaum%26aufirst%3DC.%2BM.%26aulast%3DSabin%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DLesesne%26aufirst%3DS.%2BB.%26atitle%3DForecasting%2520the%2520morbidity%2520and%2520mortality%2520associated%2520with%2520prevalent%2520cases%2520of%2520pre-cirrhotic%2520chronic%2520hepatitis%2520C%2520in%2520the%2520United%2520States%26jtitle%3DDig.%2520Liver%2520Dis.%26date%3D2011%26volume%3D43%26spage%3D66%26epage%3D72%26doi%3D10.1016%2Fj.dld.2010.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit160d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ly, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klevens, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiles, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmberg, S. D.</span><span> </span><span class="NLM_article-title">The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">278</span><span class="refDoi"> DOI: 10.7326/0003-4819-156-4-201202210-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.7326%2F0003-4819-156-4-201202210-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=22351712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A280%3ADC%252BC383kvFCkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2012&pages=271-278&author=K.+N.+Lyauthor=J.+Xingauthor=R.+M.+Klevensauthor=R.+B.+Jilesauthor=J.+W.+Wardauthor=S.+D.+Holmberg&title=The+increasing+burden+of+mortality+from+viral+hepatitis+in+the+United+States+between+1999+and+2007&doi=10.7326%2F0003-4819-156-4-201202210-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160dR"><div class="casContent"><span class="casTitleNuber">160d</span><div class="casTitle"><span class="NLM_cas:atitle">The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007</span></div><div class="casAuthors">Ly Kathleen N; Xing Jian; Klevens R Monina; Jiles Ruth B; Ward John W; Holmberg Scott D</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">271-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The increasing health burden and mortality from hepatitis B virus (HBV) and hepatitis C virus (HCV) in the United States are underappreciated.  OBJECTIVE:  To examine mortality from HBV; HCV; and, for comparison, HIV.  DESIGN:  Analysis of U.S. multiple-cause mortality data from 1999 to 2007 from the National Center for Health Statistics.  SETTING:  All U.S. states and the District of Columbia.  PARTICIPANTS:  Approximately 22 million decedents.  MEASUREMENTS:  Age-adjusted mortality rates from HBV, HCV, and HIV.  Logistic regression analyses of 2007 data generated 4 independent models per outcome (HCV- or HBV-related deaths) that each included 1 of 4 comorbid conditions and all sociodemographic characteristics.  RESULTS:  Between 1999 and 2007, recorded deaths from HCV [corrected] increased significantly to 15,106, whereas deaths from HIV declined to 12,734 by 2007.  Factors associated with HCV-related deaths included chronic liver disease, HBV co-infection, alcohol-related conditions, minority status, and HIV co-infection.  Factors that increased odds of HBV-related death included chronic liver disease, HCV co-infection, Asian or Pacific Islander descent, HIV co-infection, and alcohol-related conditions.  Most deaths from HBV and HCV occurred in middle-aged persons.  LIMITATION:  A person other than the primary physician of the decedent frequently completed the death certificate, and HCV and HBV often were not detected and thus not reported as causes of death.  CONCLUSION:  By 2007, HCV had superseded HIV as a cause of death in the United States, and deaths from HCV and HBV disproportionately occurred in middle-aged persons.  To achieve decreases in mortality similar to those seen with HIV requires new policy initiatives to detect patients with chronic hepatitis and link them to care and treatment.  PRIMARY FUNDING SOURCE:  Centers for Disease Control and Prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4NjyWh_C-GsrRqEXsZufAfW6udTcc2eaMdRYANpu06rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383kvFCkuw%253D%253D&md5=365f7666e37e4aefd608b4e3cd2a8d8c</span></div><a href="/servlet/linkout?suffix=cit160d&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-156-4-201202210-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-156-4-201202210-00004%26sid%3Dliteratum%253Aachs%26aulast%3DLy%26aufirst%3DK.%2BN.%26aulast%3DXing%26aufirst%3DJ.%26aulast%3DKlevens%26aufirst%3DR.%2BM.%26aulast%3DJiles%26aufirst%3DR.%2BB.%26aulast%3DWard%26aufirst%3DJ.%2BW.%26aulast%3DHolmberg%26aufirst%3DS.%2BD.%26atitle%3DThe%2520increasing%2520burden%2520of%2520mortality%2520from%2520viral%2520hepatitis%2520in%2520the%2520United%2520States%2520between%25201999%2520and%25202007%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2012%26volume%3D156%26spage%3D271%26epage%3D278%26doi%3D10.7326%2F0003-4819-156-4-201202210-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit160e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Klevens, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiles, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmberg, S. D.</span><span> </span><span class="NLM_article-title">Evolving epidemiology of hepatitis C virus in the United States</span> <span class="citation_source-journal">Clin. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">S3</span><span class="NLM_x">–</span> <span class="NLM_lpage">S9</span><span class="refDoi"> DOI: 10.1093/cid/cis393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1093%2Fcid%2Fcis393" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=S3-S9&author=R.+M.+Klevensauthor=D.+J.+Huauthor=R.+Jilesauthor=S.+D.+Holmberg&title=Evolving+epidemiology+of+hepatitis+C+virus+in+the+United+States&doi=10.1093%2Fcid%2Fcis393"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160e&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fcis393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fcis393%26sid%3Dliteratum%253Aachs%26aulast%3DKlevens%26aufirst%3DR.%2BM.%26aulast%3DHu%26aufirst%3DD.%2BJ.%26aulast%3DJiles%26aufirst%3DR.%26aulast%3DHolmberg%26aufirst%3DS.%2BD.%26atitle%3DEvolving%2520epidemiology%2520of%2520hepatitis%2520C%2520virus%2520in%2520the%2520United%2520States%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2012%26volume%3D55%26spage%3DS3%26epage%3DS9%26doi%3D10.1093%2Fcid%2Fcis393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit160f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Razavi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkhoury, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elbasha, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasini, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poynard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span> </span><span class="NLM_article-title">Chronic hepatitis C virus (HCV) disease burden and cost in the United States</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">2164</span><span class="NLM_x">–</span> <span class="NLM_lpage">2170</span><span class="refDoi"> DOI: 10.1002/hep.26218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.26218" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=2164-2170&author=H.+Razaviauthor=A.+C.+Elkhouryauthor=E.+Elbashaauthor=C.+Estesauthor=K.+Pasiniauthor=T.+Poynardauthor=R.+Kumar&title=Chronic+hepatitis+C+virus+%28HCV%29+disease+burden+and+cost+in+the+United+States&doi=10.1002%2Fhep.26218"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160f&amp;dbid=16384&amp;doi=10.1002%2Fhep.26218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26218%26sid%3Dliteratum%253Aachs%26aulast%3DRazavi%26aufirst%3DH.%26aulast%3DElkhoury%26aufirst%3DA.%2BC.%26aulast%3DElbasha%26aufirst%3DE.%26aulast%3DEstes%26aufirst%3DC.%26aulast%3DPasini%26aufirst%3DK.%26aulast%3DPoynard%26aufirst%3DT.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DChronic%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%2520disease%2520burden%2520and%2520cost%2520in%2520the%2520United%2520States%26jtitle%3DHepatology%26date%3D2013%26volume%3D57%26spage%3D2164%26epage%3D2170%26doi%3D10.1002%2Fhep.26218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit160g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Razavi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waked, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarrazin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Idilman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calinas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendes Correa, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lázaro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akarca, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aleman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balık, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bihl, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilodeau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blasco, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandão Mello, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggmann, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calleja, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheinquer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coelho, H. S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramp, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doss, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duberg, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Sayed, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ergör, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esmat, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falconer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Félix, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferraz, M. L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferreira, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Samaniego, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerstoft, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giria, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonçales, F. L.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gower, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gschwantler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guimarães Pessôa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hindman, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kåberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaita, K. D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kautz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaymakoglu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krajden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krarup, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laleman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavanchy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marinho, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marotta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauss, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negro, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemecek, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Örmeci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Øvrehus, A. L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasini, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltekian, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramji, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roudot-Thoraval, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarmento-Castro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semela, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiha, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sievert, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stärkel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauber, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbanek, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Damme, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Thiel, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Vlierberghe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandijck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedemeyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiegand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yosry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zekry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müllhaupt, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estes, C.</span><span> </span><span class="NLM_article-title">The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl.. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">59</span><span class="refDoi"> DOI: 10.1111/jvh.12248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fjvh.12248" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=34-59&issue=Suppl..+1&author=H.+Razaviauthor=I.+Wakedauthor=C.+Sarrazinauthor=R.+P.+Myersauthor=R.+Idilmanauthor=F.+Calinasauthor=W.+Vogelauthor=M.+C.+Mendes+Correaauthor=C.+H%C3%A9zodeauthor=P.+L%C3%A1zaroauthor=U.+Akarcaauthor=S.+Alemanauthor=I.+Bal%C4%B1kauthor=T.+Bergauthor=F.+Bihlauthor=M.+Bilodeauauthor=A.+J.+Blascoauthor=C.+E.+Brand%C3%A3o+Melloauthor=P.+Bruggmannauthor=M.+Butiauthor=J.+L.+Callejaauthor=H.+Cheinquerauthor=P.+B.+Christensenauthor=M.+Clausenauthor=H.+S.+M.+Coelhoauthor=M.+E.+Crampauthor=G.+J.+Doreauthor=W.+Dossauthor=A.+S.+Dubergauthor=M.+H.+El-Sayedauthor=G.+Erg%C3%B6rauthor=G.+Esmatauthor=K.+Falconerauthor=J.+F%C3%A9lixauthor=M.+L.+G.+Ferrazauthor=P.+R.+Ferreiraauthor=S.+Frankovaauthor=J.+Garc%C3%ADa-Samaniegoauthor=J.+Gerstoftauthor=J.+A.+Giriaauthor=F.+L.+Gon%C3%A7alesauthor=E.+Gowerauthor=M.+Gschwantlerauthor=M.+Guimar%C3%A3es+Pess%C3%B4aauthor=S.+J.+Hindmanauthor=H.+Hoferauthor=P.+Husaauthor=M.+K%C3%A5bergauthor=K.+D.+E.+Kaitaauthor=A.+Kautzauthor=S.+Kaymakogluauthor=M.+Krajdenauthor=H.+Krarupauthor=W.+Lalemanauthor=D.+Lavanchyauthor=R.+T.+Marinhoauthor=P.+Marottaauthor=S.+Maussauthor=C.+Morenoauthor=K.+Murphyauthor=F.+Negroauthor=V.+Nemecekauthor=V.+%C3%96rmeciauthor=A.+L.+H.+%C3%98vrehusauthor=J.+Parkesauthor=K.+Pasiniauthor=K.+M.+Peltekianauthor=A.+Ramjiauthor=N.+Reisauthor=S.+K.+Robertsauthor=W.+M.+Rosenbergauthor=F.+Roudot-Thoravalauthor=S.+D.+Ryderauthor=R.+Sarmento-Castroauthor=D.+Semelaauthor=M.+Shermanauthor=G.+E.+Shihaauthor=W.+Sievertauthor=J.+Sperlauthor=P.+St%C3%A4rkelauthor=R.+E.+Stauberauthor=A.+J.+Thompsonauthor=P.+Urbanekauthor=P.+Van+Dammeauthor=I.+van+Thielauthor=H.+Van+Vlierbergheauthor=D.+Vandijckauthor=D.+Wedemeyerauthor=N.+Weisauthor=J.+Wiegandauthor=A.+Yosryauthor=A.+Zekryauthor=M.+Cornbergauthor=B.+M%C3%BCllhauptauthor=C.+Estes&title=The+present+and+future+disease+burden+of+hepatitis+C+virus+%28HCV%29+infection+with+today%E2%80%99s+treatment+paradigm&doi=10.1111%2Fjvh.12248"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160g&amp;dbid=16384&amp;doi=10.1111%2Fjvh.12248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.12248%26sid%3Dliteratum%253Aachs%26aulast%3DRazavi%26aufirst%3DH.%26aulast%3DWaked%26aufirst%3DI.%26aulast%3DSarrazin%26aufirst%3DC.%26aulast%3DMyers%26aufirst%3DR.%2BP.%26aulast%3DIdilman%26aufirst%3DR.%26aulast%3DCalinas%26aufirst%3DF.%26aulast%3DVogel%26aufirst%3DW.%26aulast%3DMendes%2BCorrea%26aufirst%3DM.%2BC.%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DL%25C3%25A1zaro%26aufirst%3DP.%26aulast%3DAkarca%26aufirst%3DU.%26aulast%3DAleman%26aufirst%3DS.%26aulast%3DBal%25C4%25B1k%26aufirst%3DI.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DBihl%26aufirst%3DF.%26aulast%3DBilodeau%26aufirst%3DM.%26aulast%3DBlasco%26aufirst%3DA.%2BJ.%26aulast%3DBrand%25C3%25A3o%2BMello%26aufirst%3DC.%2BE.%26aulast%3DBruggmann%26aufirst%3DP.%26aulast%3DButi%26aufirst%3DM.%26aulast%3DCalleja%26aufirst%3DJ.%2BL.%26aulast%3DCheinquer%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DP.%2BB.%26aulast%3DClausen%26aufirst%3DM.%26aulast%3DCoelho%26aufirst%3DH.%2BS.%2BM.%26aulast%3DCramp%26aufirst%3DM.%2BE.%26aulast%3DDore%26aufirst%3DG.%2BJ.%26aulast%3DDoss%26aufirst%3DW.%26aulast%3DDuberg%26aufirst%3DA.%2BS.%26aulast%3DEl-Sayed%26aufirst%3DM.%2BH.%26aulast%3DErg%25C3%25B6r%26aufirst%3DG.%26aulast%3DEsmat%26aufirst%3DG.%26aulast%3DFalconer%26aufirst%3DK.%26aulast%3DF%25C3%25A9lix%26aufirst%3DJ.%26aulast%3DFerraz%26aufirst%3DM.%2BL.%2BG.%26aulast%3DFerreira%26aufirst%3DP.%2BR.%26aulast%3DFrankova%26aufirst%3DS.%26aulast%3DGarc%25C3%25ADa-Samaniego%26aufirst%3DJ.%26aulast%3DGerstoft%26aufirst%3DJ.%26aulast%3DGiria%26aufirst%3DJ.%2BA.%26aulast%3DGon%25C3%25A7ales%26aufirst%3DF.%2BL.%26aulast%3DGower%26aufirst%3DE.%26aulast%3DGschwantler%26aufirst%3DM.%26aulast%3DGuimar%25C3%25A3es%2BPess%25C3%25B4a%26aufirst%3DM.%26aulast%3DHindman%26aufirst%3DS.%2BJ.%26aulast%3DHofer%26aufirst%3DH.%26aulast%3DHusa%26aufirst%3DP.%26aulast%3DK%25C3%25A5berg%26aufirst%3DM.%26aulast%3DKaita%26aufirst%3DK.%2BD.%2BE.%26aulast%3DKautz%26aufirst%3DA.%26aulast%3DKaymakoglu%26aufirst%3DS.%26aulast%3DKrajden%26aufirst%3DM.%26aulast%3DKrarup%26aufirst%3DH.%26aulast%3DLaleman%26aufirst%3DW.%26aulast%3DLavanchy%26aufirst%3DD.%26aulast%3DMarinho%26aufirst%3DR.%2BT.%26aulast%3DMarotta%26aufirst%3DP.%26aulast%3DMauss%26aufirst%3DS.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DMurphy%26aufirst%3DK.%26aulast%3DNegro%26aufirst%3DF.%26aulast%3DNemecek%26aufirst%3DV.%26aulast%3D%25C3%2596rmeci%26aufirst%3DV.%26aulast%3D%25C3%2598vrehus%26aufirst%3DA.%2BL.%2BH.%26aulast%3DParkes%26aufirst%3DJ.%26aulast%3DPasini%26aufirst%3DK.%26aulast%3DPeltekian%26aufirst%3DK.%2BM.%26aulast%3DRamji%26aufirst%3DA.%26aulast%3DReis%26aufirst%3DN.%26aulast%3DRoberts%26aufirst%3DS.%2BK.%26aulast%3DRosenberg%26aufirst%3DW.%2BM.%26aulast%3DRoudot-Thoraval%26aufirst%3DF.%26aulast%3DRyder%26aufirst%3DS.%2BD.%26aulast%3DSarmento-Castro%26aufirst%3DR.%26aulast%3DSemela%26aufirst%3DD.%26aulast%3DSherman%26aufirst%3DM.%26aulast%3DShiha%26aufirst%3DG.%2BE.%26aulast%3DSievert%26aufirst%3DW.%26aulast%3DSperl%26aufirst%3DJ.%26aulast%3DSt%25C3%25A4rkel%26aufirst%3DP.%26aulast%3DStauber%26aufirst%3DR.%2BE.%26aulast%3DThompson%26aufirst%3DA.%2BJ.%26aulast%3DUrbanek%26aufirst%3DP.%26aulast%3DVan%2BDamme%26aufirst%3DP.%26aulast%3Dvan%2BThiel%26aufirst%3DI.%26aulast%3DVan%2BVlierberghe%26aufirst%3DH.%26aulast%3DVandijck%26aufirst%3DD.%26aulast%3DWedemeyer%26aufirst%3DD.%26aulast%3DWeis%26aufirst%3DN.%26aulast%3DWiegand%26aufirst%3DJ.%26aulast%3DYosry%26aufirst%3DA.%26aulast%3DZekry%26aufirst%3DA.%26aulast%3DCornberg%26aufirst%3DM.%26aulast%3DM%25C3%25BCllhaupt%26aufirst%3DB.%26aulast%3DEstes%26aufirst%3DC.%26atitle%3DThe%2520present%2520and%2520future%2520disease%2520burden%2520of%2520hepatitis%2520C%2520virus%2520%2528HCV%2529%2520infection%2520with%2520today%25E2%2580%2599s%2520treatment%2520paradigm%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2014%26volume%3D21%26issue%3DSuppl..%25201%26spage%3D34%26epage%3D59%26doi%3D10.1111%2Fjvh.12248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Basnayake, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Easterbrook, P. J.</span><span> </span><span class="NLM_article-title">Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature</span> <span class="citation_source-journal">J. Viral Hepatitis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">549</span><span class="refDoi"> DOI: 10.1111/jvh.12519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fjvh.12519" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=545-549&author=S.+K.+Basnayakeauthor=P.+J.+Easterbrook&title=Wide+variation+in+estimates+of+global+prevalence+and+burden+of+chronic+hepatitis+B+and+C+infection+cited+in+published+literature&doi=10.1111%2Fjvh.12519"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161a&amp;dbid=16384&amp;doi=10.1111%2Fjvh.12519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjvh.12519%26sid%3Dliteratum%253Aachs%26aulast%3DBasnayake%26aufirst%3DS.%2BK.%26aulast%3DEasterbrook%26aufirst%3DP.%2BJ.%26atitle%3DWide%2520variation%2520in%2520estimates%2520of%2520global%2520prevalence%2520and%2520burden%2520of%2520chronic%2520hepatitis%2520B%2520and%2520C%2520infection%2520cited%2520in%2520published%2520literature%26jtitle%3DJ.%2520Viral%2520Hepatitis%26date%3D2016%26volume%3D23%26spage%3D545%26epage%3D549%26doi%3D10.1111%2Fjvh.12519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit161b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chhatwal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabiri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donohue, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanwal, F.</span><span> </span><span class="NLM_article-title">Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1002/hep.28571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.28571" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+Chhatwalauthor=X.+Wangauthor=T.+Ayerauthor=M.+Kabiriauthor=R.+T.+Chungauthor=C.+Hurauthor=J.+M.+Donohueauthor=M.+S.+Robertsauthor=F.+Kanwal&title=Hepatitis+C+disease+burden+in+the+United+States+in+the+era+of+oral+direct-acting+antivirals&doi=10.1002%2Fhep.28571"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161b&amp;dbid=16384&amp;doi=10.1002%2Fhep.28571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.28571%26sid%3Dliteratum%253Aachs%26aulast%3DChhatwal%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DAyer%26aufirst%3DT.%26aulast%3DKabiri%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DR.%2BT.%26aulast%3DHur%26aufirst%3DC.%26aulast%3DDonohue%26aufirst%3DJ.%2BM.%26aulast%3DRoberts%26aufirst%3DM.%2BS.%26aulast%3DKanwal%26aufirst%3DF.%26atitle%3DHepatitis%2520C%2520disease%2520burden%2520in%2520the%2520United%2520States%2520in%2520the%2520era%2520of%2520oral%2520direct-acting%2520antivirals%26jtitle%3DHepatology%26date%3D2016%26doi%3D10.1002%2Fhep.28571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit161c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ward, J. W.</span><span> </span><span class="NLM_article-title">The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease</span> <span class="citation_source-journal">Top. Antiviral Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=15-19&author=J.+W.+Ward&title=The+hidden+epidemic+of+hepatitis+C+virus+infection+in+the+United+States%3A+occult+transmission+and+burden+of+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DJ.%2BW.%26atitle%3DThe%2520hidden%2520epidemic%2520of%2520hepatitis%2520C%2520virus%2520infection%2520in%2520the%2520United%2520States%253A%2520occult%2520transmission%2520and%2520burden%2520of%2520disease%26jtitle%3DTop.%2520Antiviral%2520Med.%26date%3D2013%26volume%3D21%26spage%3D15%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit161d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Edlin, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckhardt, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmberg, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swan, T.</span><span> </span><span class="NLM_article-title">Toward a more accurate estimate of the prevalence of hepatitis C in the United States</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">1353</span><span class="NLM_x">–</span> <span class="NLM_lpage">1363</span><span class="refDoi"> DOI: 10.1002/hep.27978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.27978" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=1353-1363&author=B.+R.+Edlinauthor=B.+J.+Eckhardtauthor=M.+A.+Shuauthor=S.+D.+Holmbergauthor=T.+Swan&title=Toward+a+more+accurate+estimate+of+the+prevalence+of+hepatitis+C+in+the+United+States&doi=10.1002%2Fhep.27978"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161d&amp;dbid=16384&amp;doi=10.1002%2Fhep.27978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27978%26sid%3Dliteratum%253Aachs%26aulast%3DEdlin%26aufirst%3DB.%2BR.%26aulast%3DEckhardt%26aufirst%3DB.%2BJ.%26aulast%3DShu%26aufirst%3DM.%2BA.%26aulast%3DHolmberg%26aufirst%3DS.%2BD.%26aulast%3DSwan%26aufirst%3DT.%26atitle%3DToward%2520a%2520more%2520accurate%2520estimate%2520of%2520the%2520prevalence%2520of%2520hepatitis%2520C%2520in%2520the%2520United%2520States%26jtitle%3DHepatology%26date%3D2015%26volume%3D62%26spage%3D1353%26epage%3D1363%26doi%3D10.1002%2Fhep.27978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mühlberger, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lettmeier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sroczynski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siebert, U.</span><span> </span><span class="NLM_article-title">HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality</span> <span class="citation_source-journal">BMC Public Health</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="refDoi"> DOI: 10.1186/1471-2458-9-34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1186%2F1471-2458-9-34" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=34&author=N.+M%C3%BChlbergerauthor=R.+Schwarzerauthor=B.+Lettmeierauthor=G.+Sroczynskiauthor=S.+Zeuzemauthor=U.+Siebert&title=HCV-related+burden+of+disease+in+Europe%3A+a+systematic+assessment+of+incidence%2C+prevalence%2C+morbidity%2C+and+mortality&doi=10.1186%2F1471-2458-9-34"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162a&amp;dbid=16384&amp;doi=10.1186%2F1471-2458-9-34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2458-9-34%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BChlberger%26aufirst%3DN.%26aulast%3DSchwarzer%26aufirst%3DR.%26aulast%3DLettmeier%26aufirst%3DB.%26aulast%3DSroczynski%26aufirst%3DG.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DSiebert%26aufirst%3DU.%26atitle%3DHCV-related%2520burden%2520of%2520disease%2520in%2520Europe%253A%2520a%2520systematic%2520assessment%2520of%2520incidence%252C%2520prevalence%252C%2520morbidity%252C%2520and%2520mortality%26jtitle%3DBMC%2520Public%2520Health%26date%3D2009%26volume%3D9%26spage%3D34%26doi%3D10.1186%2F1471-2458-9-34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit162b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Harris, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Angelis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, H. E.</span><span> </span><span class="NLM_article-title">Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">530</span><span class="NLM_x">–</span> <span class="NLM_lpage">537</span><span class="refDoi"> DOI: 10.1016/j.jhep.2014.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2014.05.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=530-537&author=R.+J.+Harrisauthor=B.+Thomasauthor=J.+Griffithsauthor=A.+Costellaauthor=R.+Chapmanauthor=M.+Ramsayauthor=D.+De+Angelisauthor=H.+E.+Harris&title=Increased+uptake+and+new+therapies+are+needed+to+avert+rising+hepatitis+C-related+end+stage+liver+disease+in+England%3A+modelling+the+predicted+impact+of+treatment+under+different+scenarios&doi=10.1016%2Fj.jhep.2014.05.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162b&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2014.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2014.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DR.%2BJ.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DGriffiths%26aufirst%3DJ.%26aulast%3DCostella%26aufirst%3DA.%26aulast%3DChapman%26aufirst%3DR.%26aulast%3DRamsay%26aufirst%3DM.%26aulast%3DDe%2BAngelis%26aufirst%3DD.%26aulast%3DHarris%26aufirst%3DH.%2BE.%26atitle%3DIncreased%2520uptake%2520and%2520new%2520therapies%2520are%2520needed%2520to%2520avert%2520rising%2520hepatitis%2520C-related%2520end%2520stage%2520liver%2520disease%2520in%2520England%253A%2520modelling%2520the%2520predicted%2520impact%2520of%2520treatment%2520under%2520different%2520scenarios%26jtitle%3DJ.%2520Hepatol.%26date%3D2014%26volume%3D61%26spage%3D530%26epage%3D537%26doi%3D10.1016%2Fj.jhep.2014.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Edlin, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkelstein, E. R.</span><span> </span><span class="NLM_article-title">Can hepatitis C be eradicated in the United States?</span> <span class="citation_source-journal">Antiviral Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">79</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span><span class="refDoi"> DOI: 10.1016/j.antiviral.2014.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.antiviral.2014.07.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2014&pages=79-93&author=B.+R.+Edlinauthor=E.+R.+Winkelstein&title=Can+hepatitis+C+be+eradicated+in+the+United+States%3F&doi=10.1016%2Fj.antiviral.2014.07.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163a&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DEdlin%26aufirst%3DB.%2BR.%26aulast%3DWinkelstein%26aufirst%3DE.%2BR.%26atitle%3DCan%2520hepatitis%2520C%2520be%2520eradicated%2520in%2520the%2520United%2520States%253F%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D110%26spage%3D79%26epage%3D93%26doi%3D10.1016%2Fj.antiviral.2014.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit163b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ippolito, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capobianchi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonelli, G.</span><span> </span><span class="NLM_article-title">Is hepatitis C virus eradication around the corner only 25 years after its discovery?</span> <span class="citation_source-journal">Int. J. Antimicrob. Agents</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1016/j.ijantimicag.2014.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.ijantimicag.2014.09.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=111-112&author=G.+Ippolitoauthor=M.+R.+Capobianchiauthor=S.+Laniniauthor=G.+Antonelli&title=Is+hepatitis+C+virus+eradication+around+the+corner+only+25+years+after+its+discovery%3F&doi=10.1016%2Fj.ijantimicag.2014.09.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163b&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2014.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2014.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DIppolito%26aufirst%3DG.%26aulast%3DCapobianchi%26aufirst%3DM.%2BR.%26aulast%3DLanini%26aufirst%3DS.%26aulast%3DAntonelli%26aufirst%3DG.%26atitle%3DIs%2520hepatitis%2520C%2520virus%2520eradication%2520around%2520the%2520corner%2520only%252025%2520years%2520after%2520its%2520discovery%253F%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2015%26volume%3D45%26spage%3D111%26epage%3D112%26doi%3D10.1016%2Fj.ijantimicag.2014.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit163c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Pawlotsky, J.-M.</span><span> </span><span class="NLM_article-title">Hepatitis C virus: from discovery to eradication in 40 years?</span> <span class="citation_source-journal">Clin. Microbiol. Infect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">105</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span><span class="refDoi"> DOI: 10.1111/j.1469-0691.2010.03435.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fj.1469-0691.2010.03435.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=105-106&author=J.-M.+Pawlotsky&title=Hepatitis+C+virus%3A+from+discovery+to+eradication+in+40+years%3F&doi=10.1111%2Fj.1469-0691.2010.03435.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163c&amp;dbid=16384&amp;doi=10.1111%2Fj.1469-0691.2010.03435.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1469-0691.2010.03435.x%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.-M.%26atitle%3DHepatitis%2520C%2520virus%253A%2520from%2520discovery%2520to%2520eradication%2520in%252040%2520years%253F%26jtitle%3DClin.%2520Microbiol.%2520Infect.%26date%3D2011%26volume%3D17%26spage%3D105%26epage%3D106%26doi%3D10.1111%2Fj.1469-0691.2010.03435.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit163d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Gane, E.</span><span> </span><span class="NLM_article-title">Hepatitis C beware - the end is nigh</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">384</span><span class="NLM_x">, </span> <span class="NLM_fpage">1557</span><span class="NLM_x">–</span> <span class="NLM_lpage">1560</span><span class="refDoi"> DOI: 10.1016/S0140-6736(14)61225-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2FS0140-6736%2814%2961225-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2014&pages=1557-1560&author=E.+Gane&title=Hepatitis+C+beware+-+the+end+is+nigh&doi=10.1016%2FS0140-6736%2814%2961225-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163d&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2961225-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252961225-3%26sid%3Dliteratum%253Aachs%26aulast%3DGane%26aufirst%3DE.%26atitle%3DHepatitis%2520C%2520beware%2520-%2520the%2520end%2520is%2520nigh%26jtitle%3DLancet%26date%3D2014%26volume%3D384%26spage%3D1557%26epage%3D1560%26doi%3D10.1016%2FS0140-6736%2814%2961225-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Linthicum, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchez Gonzalez, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulligan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreyfus, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juday, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marx, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakdawalla, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edlin, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brookmeyer, R.</span><span> </span><span class="NLM_article-title">Value of expanding HCV screening and treatment policies in the United States</span> <span class="citation_source-journal">Am. J. Manag. Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">Spec. Issue No. 6</span><span class="NLM_x">) </span> <span class="NLM_fpage">SP227</span><span class="NLM_x">–</span> <span class="NLM_lpage">SP235</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=SP227-SP235&issue=Spec.+Issue+No.+6&author=M.+T.+Linthicumauthor=Y.+Sanchez+Gonzalezauthor=K.+Mulliganauthor=G.+A.+Morenoauthor=D.+Dreyfusauthor=T.+Judayauthor=S.+E.+Marxauthor=D.+N.+Lakdawallaauthor=B.+R.+Edlinauthor=R.+Brookmeyer&title=Value+of+expanding+HCV+screening+and+treatment+policies+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLinthicum%26aufirst%3DM.%2BT.%26aulast%3DSanchez%2BGonzalez%26aufirst%3DY.%26aulast%3DMulligan%26aufirst%3DK.%26aulast%3DMoreno%26aufirst%3DG.%2BA.%26aulast%3DDreyfus%26aufirst%3DD.%26aulast%3DJuday%26aufirst%3DT.%26aulast%3DMarx%26aufirst%3DS.%2BE.%26aulast%3DLakdawalla%26aufirst%3DD.%2BN.%26aulast%3DEdlin%26aufirst%3DB.%2BR.%26aulast%3DBrookmeyer%26aufirst%3DR.%26atitle%3DValue%2520of%2520expanding%2520HCV%2520screening%2520and%2520treatment%2520policies%2520in%2520the%2520United%2520States%26jtitle%3DAm.%2520J.%2520Manag.%2520Care%26date%3D2016%26volume%3D22%26issue%3DSpec.%2520Issue%2520No.%25206%26spage%3DSP227%26epage%3DSP235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit164b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chahal, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marseille, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tice, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ollendorf, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, J. G.</span><span> </span><span class="NLM_article-title">Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population</span> <span class="citation_source-journal">JAMA Int. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">176</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span><span class="refDoi"> DOI: 10.1001/jamainternmed.2015.6011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1001%2Fjamainternmed.2015.6011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2016&pages=65-73&author=H.+S.+Chahalauthor=E.+A.+Marseilleauthor=J.+A.+Ticeauthor=S.+D.+Pearsonauthor=D.+A.+Ollendorfauthor=R.+K.+Foxauthor=J.+G.+Kahn&title=Cost-effectiveness+of+early+treatment+of+hepatitis+C+virus+genotype+1+by+stage+of+liver+fibrosis+in+a+US+treatment-naive+population&doi=10.1001%2Fjamainternmed.2015.6011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164b&amp;dbid=16384&amp;doi=10.1001%2Fjamainternmed.2015.6011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamainternmed.2015.6011%26sid%3Dliteratum%253Aachs%26aulast%3DChahal%26aufirst%3DH.%2BS.%26aulast%3DMarseille%26aufirst%3DE.%2BA.%26aulast%3DTice%26aufirst%3DJ.%2BA.%26aulast%3DPearson%26aufirst%3DS.%2BD.%26aulast%3DOllendorf%26aufirst%3DD.%2BA.%26aulast%3DFox%26aufirst%3DR.%2BK.%26aulast%3DKahn%26aufirst%3DJ.%2BG.%26atitle%3DCost-effectiveness%2520of%2520early%2520treatment%2520of%2520hepatitis%2520C%2520virus%2520genotype%25201%2520by%2520stage%2520of%2520liver%2520fibrosis%2520in%2520a%2520US%2520treatment-naive%2520population%26jtitle%3DJAMA%2520Int.%2520Med.%26date%3D2016%26volume%3D176%26spage%3D65%26epage%3D73%26doi%3D10.1001%2Fjamainternmed.2015.6011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Heim, M. H.</span><span> </span><span class="NLM_article-title">25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">535</span><span class="NLM_x">–</span> <span class="NLM_lpage">542</span><span class="refDoi"> DOI: 10.1038/nri3463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnri3463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=23743475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovFamurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=535-542&author=M.+H.+Heim&title=25+years+of+interferon-based+treatment+of+chronic+hepatitis+C%3A+an+epoch+coming+to+an+end&doi=10.1038%2Fnri3463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165aR"><div class="casContent"><span class="casTitleNuber">165a</span><div class="casTitle"><span class="NLM_cas:atitle">25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end</span></div><div class="casAuthors">Heim, Markus H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">535-542</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chronic hepatitis caused by infection with hepatitis C virus C (HCV) (therefore known as chronic hepatitis C (CHC)) is a leading cause of liver disease worldwide.  For the past 25 years, recombinant interferon-α (IFNα) has been the main component of treatments for HCV infection.  Treatment efficacy has shown a stepwise improvement following the pegylation of IFNα and its use in combination with other antiviral drugs.  However, viral escape mechanisms, refractory IFNα signalling in the liver and substantial drug toxicity still limit the efficacy of this treatment.  A new generation of HCV-specific antiviral drugs will probably improve response rates and might replace IFNs in CHC treatment in the next few years.  This Timeline article summarizes the history of CHC treatment using recombinant IFNα with an emphasis on the mechanisms of action and the causes of non-response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKQQMKuR1xXLVg90H21EOLACvtfcHk0lgq12Co_9A-wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovFamurc%253D&md5=29af7191c765714e2020f354979e0e50</span></div><a href="/servlet/linkout?suffix=cit165a&amp;dbid=16384&amp;doi=10.1038%2Fnri3463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3463%26sid%3Dliteratum%253Aachs%26aulast%3DHeim%26aufirst%3DM.%2BH.%26atitle%3D25%2520years%2520of%2520interferon-based%2520treatment%2520of%2520chronic%2520hepatitis%2520C%253A%2520an%2520epoch%2520coming%2520to%2520an%2520end%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D13%26spage%3D535%26epage%3D542%26doi%3D10.1038%2Fnri3463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit165b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sheridan, C.</span><span> </span><span class="NLM_article-title">FDA approvals usher in the post-interferon era in HCV</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span><span class="refDoi"> DOI: 10.1038/nbt0114-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1038%2Fnbt0114-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24406908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltVOjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=3-5&author=C.+Sheridan&title=FDA+approvals+usher+in+the+post-interferon+era+in+HCV&doi=10.1038%2Fnbt0114-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165bR"><div class="casContent"><span class="casTitleNuber">165b</span><div class="casTitle"><span class="NLM_cas:atitle">FDA approvals usher in the post-interferon era in HCV</span></div><div class="casAuthors">Sheridan, Cormac</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-5</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPpDya1nSFUbVg90H21EOLACvtfcHk0lgq12Co_9A-wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltVOjsw%253D%253D&md5=4c9a6b443360f6dc44fd62fb78e92d04</span></div><a href="/servlet/linkout?suffix=cit165b&amp;dbid=16384&amp;doi=10.1038%2Fnbt0114-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt0114-3%26sid%3Dliteratum%253Aachs%26aulast%3DSheridan%26aufirst%3DC.%26atitle%3DFDA%2520approvals%2520usher%2520in%2520the%2520post-interferon%2520era%2520in%2520HCV%26jtitle%3DNat.%2520Biotechnol.%26date%3D2014%26volume%3D32%26spage%3D3%26epage%3D5%26doi%3D10.1038%2Fnbt0114-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Thomas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghany, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, T. J.</span><span> </span><span class="NLM_article-title">The application and mechanism of action of ribavirin in therapy of hepatitis C</span> <span class="citation_source-journal">Antiviral Chem. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.3851/IMP2125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.3851%2FIMP2125" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=1-12&author=E.+Thomasauthor=M.+G.+Ghanyauthor=T.+J.+Liang&title=The+application+and+mechanism+of+action+of+ribavirin+in+therapy+of+hepatitis+C&doi=10.3851%2FIMP2125"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166a&amp;dbid=16384&amp;doi=10.3851%2FIMP2125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2125%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DE.%26aulast%3DGhany%26aufirst%3DM.%2BG.%26aulast%3DLiang%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520application%2520and%2520mechanism%2520of%2520action%2520of%2520ribavirin%2520in%2520therapy%2520of%2520hepatitis%2520C%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D2012%26volume%3D23%26spage%3D1%26epage%3D12%26doi%3D10.3851%2FIMP2125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit166b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Clark, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, D. R.</span><span> </span><span class="NLM_article-title">The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1111/j.1478-3231.2011.02711.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fj.1478-3231.2011.02711.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=103-107&author=V.+Clarkauthor=D.+R.+Nelson&title=The+role+of+ribavirin+in+direct+acting+antiviral+drug+regimens+for+chronic+hepatitis+C&doi=10.1111%2Fj.1478-3231.2011.02711.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166b&amp;dbid=16384&amp;doi=10.1111%2Fj.1478-3231.2011.02711.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1478-3231.2011.02711.x%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DV.%26aulast%3DNelson%26aufirst%3DD.%2BR.%26atitle%3DThe%2520role%2520of%2520ribavirin%2520in%2520direct%2520acting%2520antiviral%2520drug%2520regimens%2520for%2520chronic%2520hepatitis%2520C%26jtitle%3DLiver%2520Int.%26date%3D2012%26volume%3D32%26spage%3D103%26epage%3D107%26doi%3D10.1111%2Fj.1478-3231.2011.02711.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit166c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Brillanti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roda, E.</span><span> </span><span class="NLM_article-title">Ribavirin for chronic hepatitis C: and the mystery goes on</span> <span class="citation_source-journal">Dig. Liver Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span><span class="refDoi"> DOI: 10.1016/j.dld.2010.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.dld.2010.10.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2011&pages=425-430&author=S.+Brillantiauthor=G.+Mazzellaauthor=E.+Roda&title=Ribavirin+for+chronic+hepatitis+C%3A+and+the+mystery+goes+on&doi=10.1016%2Fj.dld.2010.10.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166c&amp;dbid=16384&amp;doi=10.1016%2Fj.dld.2010.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dld.2010.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DBrillanti%26aufirst%3DS.%26aulast%3DMazzella%26aufirst%3DG.%26aulast%3DRoda%26aufirst%3DE.%26atitle%3DRibavirin%2520for%2520chronic%2520hepatitis%2520C%253A%2520and%2520the%2520mystery%2520goes%2520on%26jtitle%3DDig.%2520Liver%2520Dis.%26date%3D2011%26volume%3D43%26spage%3D425%26epage%3D430%26doi%3D10.1016%2Fj.dld.2010.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit166d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Jain, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoellner, C.</span><span> </span><span class="NLM_article-title">Role of ribavirin in HCV treatment response: now and in the future</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">673</span><span class="NLM_x">–</span> <span class="NLM_lpage">683</span><span class="refDoi"> DOI: 10.1517/14656560903580001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1517%2F14656560903580001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=673-683&author=M.+K.+Jainauthor=C.+Zoellner&title=Role+of+ribavirin+in+HCV+treatment+response%3A+now+and+in+the+future&doi=10.1517%2F14656560903580001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166d&amp;dbid=16384&amp;doi=10.1517%2F14656560903580001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656560903580001%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DM.%2BK.%26aulast%3DZoellner%26aufirst%3DC.%26atitle%3DRole%2520of%2520ribavirin%2520in%2520HCV%2520treatment%2520response%253A%2520now%2520and%2520in%2520the%2520future%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2010%26volume%3D11%26spage%3D673%26epage%3D683%26doi%3D10.1517%2F14656560903580001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit166e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Hézode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronowicki, J. P.</span><span> </span><span class="NLM_article-title">Ideal oral combinations to eradicate HCV: the role of ribavirin</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span><span class="refDoi"> DOI: 10.1016/j.jhep.2015.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2015.09.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=215-225&author=C.+H%C3%A9zodeauthor=J.+P.+Bronowicki&title=Ideal+oral+combinations+to+eradicate+HCV%3A+the+role+of+ribavirin&doi=10.1016%2Fj.jhep.2015.09.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166e&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2015.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2015.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25A9zode%26aufirst%3DC.%26aulast%3DBronowicki%26aufirst%3DJ.%2BP.%26atitle%3DIdeal%2520oral%2520combinations%2520to%2520eradicate%2520HCV%253A%2520the%2520role%2520of%2520ribavirin%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D64%26spage%3D215%26epage%3D225%26doi%3D10.1016%2Fj.jhep.2015.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit166f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Shiffman, M. L.</span><span> </span><span class="NLM_article-title">What future for ribavirin?</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">68</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span><span class="refDoi"> DOI: 10.1111/j.1478-3231.2008.01936.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1111%2Fj.1478-3231.2008.01936.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=68-73&issue=Suppl.+1&author=M.+L.+Shiffman&title=What+future+for+ribavirin%3F&doi=10.1111%2Fj.1478-3231.2008.01936.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166f&amp;dbid=16384&amp;doi=10.1111%2Fj.1478-3231.2008.01936.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1478-3231.2008.01936.x%26sid%3Dliteratum%253Aachs%26aulast%3DShiffman%26aufirst%3DM.%2BL.%26atitle%3DWhat%2520future%2520for%2520ribavirin%253F%26jtitle%3DLiver%2520Int.%26date%3D2009%26volume%3D29%26issue%3DSuppl.%25201%26spage%3D68%26epage%3D73%26doi%3D10.1111%2Fj.1478-3231.2008.01936.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">Alonso-Zaldivar, R.</span> $1,000 per pill drug overtaken by pricier successor. <a href="https://www.yahoo.com/news/1-000-per-pill-drug-overtaken-pricier-successor-121337557--finance.html" class="extLink">https://www.yahoo.com/news/1-000-per-pill-drug-overtaken-pricier-successor-121337557--finance.html</a> (accessed on June 4,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Alonso-Zaldivar%2C+R.+%241%2C000+per+pill+drug+overtaken+by+pricier+successor.+https%3A%2F%2Fwww.yahoo.com%2Fnews%2F1-000-per-pill-drug-overtaken-pricier-successor-121337557%2D%2Dfinance.html+%28accessed+on+June+4%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso-Zaldivar%26aufirst%3DR.%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pawlotsky, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feld, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeuzem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoofnagle, J. H.</span><span> </span><span class="NLM_article-title">From non-A, non-B hepatitis to hepatitis C virus cure</span> <span class="citation_source-journal">J. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">S87</span><span class="NLM_x">–</span> <span class="NLM_lpage">S89</span><span class="refDoi"> DOI: 10.1016/j.jhep.2015.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1016%2Fj.jhep.2015.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=25920094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFChur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=S87-S89&author=J.-M.+Pawlotskyauthor=J.+J.+Feldauthor=S.+Zeuzemauthor=J.+H.+Hoofnagle&title=From+non-A%2C+non-B+hepatitis+to+hepatitis+C+virus+cure&doi=10.1016%2Fj.jhep.2015.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168aR"><div class="casContent"><span class="casTitleNuber">168a</span><div class="casTitle"><span class="NLM_cas:atitle">From non-A, non-B hepatitis to hepatitis C virus cure</span></div><div class="casAuthors">Pawlotsky, Jean-Michel; Feld, Jordan J.; Zeuzem, Stefan; Hoofnagle, Jay H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1_Suppl.</span>),
    <span class="NLM_cas:pages">S87-S99</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) was discovered in the late 1980s.  Interferon (IFN)-α was proposed as an antiviral treatment for chronic hepatitis C at about the same time.  Successive improvements in IFN-α-based therapy (dose finding, pegylation, addn. of ribavirin) increased the rates of sustained virol. response, i.e. the rates of curing HCV infection.  These rates were further improved by adding the first available direct-acting antiviral (DAA) drugs to the combination of pegylated IFN-α and ribavirin.  An IFN-free era finally started in 2014, yielding rates of sustained virol. response over 90% in patients treated for 8 to 24 wk with all-oral regimens.  Major challenges however remain in implementation of these new treatment strategies, not only in low- to middle-income countries, but also in high-income countries where the price of these therapies is still prohibitive.  Elimination of HCV infection through treatment in certain areas is possible but raises major public health issues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6T_7lvdy2bbVg90H21EOLACvtfcHk0lj_m2kA7f9SnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFChur4%253D&md5=da525df1d2b9303f5afea1c8f0538952</span></div><a href="/servlet/linkout?suffix=cit168a&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2015.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2015.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DPawlotsky%26aufirst%3DJ.-M.%26aulast%3DFeld%26aufirst%3DJ.%2BJ.%26aulast%3DZeuzem%26aufirst%3DS.%26aulast%3DHoofnagle%26aufirst%3DJ.%2BH.%26atitle%3DFrom%2520non-A%252C%2520non-B%2520hepatitis%2520to%2520hepatitis%2520C%2520virus%2520cure%26jtitle%3DJ.%2520Hepatol.%26date%3D2015%26volume%3D62%26spage%3DS87%26epage%3DS89%26doi%3D10.1016%2Fj.jhep.2015.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit168b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ward, J. W.</span><span> </span><span class="NLM_article-title">Hepatitis C virus: the 25-year journey from discovery to cure</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1479</span><span class="NLM_x">–</span> <span class="NLM_lpage">1482</span><span class="refDoi"> DOI: 10.1002/hep.27377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1002%2Fhep.27377" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2014&pages=1479-1482&author=J.+W.+Ward&title=Hepatitis+C+virus%3A+the+25-year+journey+from+discovery+to+cure&doi=10.1002%2Fhep.27377"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168b&amp;dbid=16384&amp;doi=10.1002%2Fhep.27377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.27377%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DJ.%2BW.%26atitle%3DHepatitis%2520C%2520virus%253A%2520the%252025-year%2520journey%2520from%2520discovery%2520to%2520cure%26jtitle%3DHepatology%26date%3D2014%26volume%3D60%26spage%3D1479%26epage%3D1482%26doi%3D10.1002%2Fhep.27377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group">Chung, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumert, T. F.</span><span> </span><span class="NLM_article-title">Curing chronic hepatitis C - the arc of a medical triumph</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">1576</span><span class="NLM_x">–</span> <span class="NLM_lpage">1578</span><span class="refDoi"> DOI: 10.1056/NEJMp1400986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=10.1056%2FNEJMp1400986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=24720678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnt1Grsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=1576-1578&author=R.+T.+Chungauthor=T.+F.+Baumert&title=Curing+chronic+hepatitis+C+-+the+arc+of+a+medical+triumph&doi=10.1056%2FNEJMp1400986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: curing chronic hepatitis C - the arc of a medical triumph</span></div><div class="casAuthors">Chung, Raymond T.; Baumert, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1576-1578</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgQ-Eau5Mvq7Vg90H21EOLACvtfcHk0liI5v1Wj1eqfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnt1Grsrw%253D&md5=7690e941509eac54c37f1339df6c555e</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1056%2FNEJMp1400986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp1400986%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DR.%2BT.%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26atitle%3DCuring%2520chronic%2520hepatitis%2520C%2520-%2520the%2520arc%2520of%2520a%2520medical%2520triumph%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D1576%26epage%3D1578%26doi%3D10.1056%2FNEJMp1400986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00915&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-16%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00915%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00915" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679aaaa33c963cb8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
